Clustering O 0 0.00017130983178503811
of O 0 5.246026375971269e-06
missense O 0 0.0015374200884252787
mutations O 0 0.00010953459423035383
in O 0 1.0869099241972435e-05
the O 0 0.0007934935856610537
ataxia B-Disease 1 0.9994655251502991
- I-Disease 1 0.9962601661682129
telangiectasia I-Disease 1 0.9968996047973633
gene O 0 4.128847649553791e-05
in O 0 2.6364991754235234e-06
a O 0 0.00010231605847366154
sporadic B-Disease 0 0.23227496445178986
T I-Disease 1 0.9980588555335999
- I-Disease 1 0.9883440732955933
cell I-Disease 1 0.7303247451782227
leukaemia I-Disease 1 0.9954197406768799
. O 0 0.00019563086971174926

Ataxia B-Disease 1 0.9939461350440979
- I-Disease 1 0.9920177459716797
telangiectasia I-Disease 1 0.9954798221588135
( O 0 0.002862211549654603
A B-Disease 1 0.5408935546875
- I-Disease 1 0.9948550462722778
T I-Disease 1 0.9983406066894531
) O 0 2.8892275167891057e-06
is O 0 5.350482297217241e-07
a O 0 1.3663934623764362e-05
recessive B-Disease 1 0.8876683712005615
multi I-Disease 1 0.993514895439148
- I-Disease 1 0.9992105960845947
system I-Disease 1 0.9903168678283691
disorder I-Disease 1 0.9996991157531738
caused O 0 0.015612752176821232
by O 0 6.136838806014566e-07
mutations O 0 2.5004546841955744e-06
in O 0 3.2699166041538774e-08
the O 0 6.353744907983128e-08
ATM O 0 1.7216823835042305e-05
gene O 0 1.7113393369072583e-06
at O 0 1.339956611445814e-06
11q22 O 0 0.0008338585030287504
- O 0 0.0011694011045619845
q23 O 0 0.0006556088337674737
( O 0 8.80465995578561e-06
ref O 0 0.0014819070929661393
. O 0 1.3588811498266296e-07
3 O 0 1.6260684105873224e-06
) O 0 1.8679355662243324e-06
. O 0 4.0018635445449036e-06

The O 0 7.408407691400498e-05
risk O 0 0.020734276622533798
of O 0 0.00010111132723977789
cancer B-Disease 1 0.998613715171814
, O 0 4.488533886615187e-05
especially O 0 0.0003432690573390573
lymphoid B-Disease 1 0.7621525526046753
neoplasias I-Disease 0 0.34341520071029663
, O 0 2.201347342634108e-06
is O 0 9.277920867134526e-07
substantially O 0 0.0004259391571395099
elevated O 0 0.012741193175315857
in O 0 4.671287024393678e-05
A B-Disease 1 0.9773642420768738
- I-Disease 1 0.9994459748268127
T I-Disease 1 0.9997169375419617
patients O 1 0.579422652721405
and O 0 1.306446051785315e-06
has O 0 1.3948179002909455e-06
long O 0 1.747438909660559e-05
been O 0 4.853574750995904e-07
associated O 0 1.2492458154156338e-05
with O 0 3.572850982891396e-05
chromosomal O 1 0.9902290105819702
instability O 1 0.9877358078956604
. O 0 0.00037925198557786644

By O 0 3.945033677155152e-05
analysing O 0 0.0028358660638332367
tumour B-Disease 1 0.9949954748153687
DNA O 0 0.0003050337836612016
from O 0 4.809741585631855e-05
patients O 0 0.010524437762796879
with O 0 1.4675417332910001e-05
sporadic B-Disease 0 0.039169713854789734
T I-Disease 1 0.9965194463729858
- I-Disease 0 0.4862522780895233
cell I-Disease 0 0.08669417351484299
prolymphocytic I-Disease 1 0.984607994556427
leukaemia I-Disease 1 0.9983324408531189
( O 0 0.003971089143306017
T B-Disease 1 0.9951903820037842
- I-Disease 0 0.06903717666864395
PLL I-Disease 0 0.3869462013244629
) O 0 9.236683808921953e-07
, O 0 8.425665498634771e-08
a O 0 7.178481951086724e-07
rare O 0 0.00014537631068378687
clonal B-Disease 0 0.3278343081474304
malignancy I-Disease 1 0.8676801919937134
with O 0 3.5703035905498837e-07
similarities O 0 1.2765960946126143e-06
to O 0 9.634219111376296e-08
a O 0 8.488625098834746e-06
mature B-Disease 0 0.0351128876209259
T I-Disease 1 0.996955394744873
- I-Disease 0 0.1581861674785614
cell I-Disease 0 0.02986307442188263
leukaemia I-Disease 1 0.9902331829071045
seen O 0 7.117876975826221e-06
in O 0 2.364159172429936e-06
A B-Disease 0 0.1018303632736206
- I-Disease 1 0.9851500391960144
T I-Disease 1 0.9972525238990784
, O 0 1.287228030832921e-07
we O 0 5.383184564777821e-09
demonstrate O 0 1.543862993003131e-08
a O 0 9.09498165668765e-09
high O 0 3.852433394513355e-08
frequency O 0 1.4183668461953403e-08
of O 0 5.305210848405295e-08
ATM O 0 9.536024299450219e-05
mutations O 0 3.393664155737497e-05
in O 0 2.0743347704410553e-05
T B-Disease 1 0.986343264579773
- I-Disease 0 0.07084333151578903
PLL I-Disease 1 0.5794984698295593
. O 0 4.9004349421011284e-05

In O 0 6.58731642033672e-06
marked O 0 1.7128404579125345e-05
contrast O 0 4.630276634998154e-06
to O 0 1.0885293022511178e-07
the O 0 1.6590493601142953e-07
ATM O 0 6.575349834747612e-05
mutation O 0 1.055522898241179e-05
pattern O 0 2.5778284907573834e-05
in O 0 3.451950760791078e-06
A B-Disease 0 0.06988954544067383
- I-Disease 1 0.9948775768280029
T I-Disease 1 0.9982877373695374
, O 0 7.648235111901158e-08
the O 0 7.1652248578857325e-09
most O 0 1.0993852050944497e-08
frequent O 0 2.4502702444806346e-07
nucleotide O 0 2.4391908937104745e-07
changes O 0 5.823605988553027e-07
in O 0 1.7528570595004567e-07
this O 0 2.047387852144311e-06
leukaemia B-Disease 1 0.9858220219612122
were O 0 1.6904759831959382e-06
missense O 0 0.0021830538753420115
mutations O 0 0.0004249427292961627
. O 0 3.686722266138531e-05

These O 0 1.8423658048050129e-06
clustered O 0 8.021344001463149e-06
in O 0 1.523463595276553e-07
the O 0 6.310651912144749e-08
region O 0 1.8402710111331544e-07
corresponding O 0 4.120958863040869e-08
to O 0 7.3800641153809465e-09
the O 0 2.377402630315828e-08
kinase O 0 3.2810737593536032e-06
domain O 0 1.2567080887038173e-07
, O 0 1.2145872752000741e-08
which O 0 2.311969282686732e-09
is O 0 2.2661361676057368e-09
highly O 0 1.9720413746426857e-08
conserved O 0 9.017239221975615e-08
in O 0 1.3047124980403169e-07
ATM O 0 0.00023384134692605585
- O 0 0.00012073261314071715
related O 0 8.984943633549847e-07
proteins O 0 1.1195348292858398e-07
in O 0 1.1271065858409202e-07
mouse O 0 2.6362718926975504e-05
, O 0 1.9695647779371939e-07
yeast O 0 1.1393796739866957e-05
and O 0 7.456826551788254e-07
Drosophila O 0 2.3217678972287104e-05
. O 0 1.000351767288521e-05

The O 0 2.393804834355251e-06
resulting O 0 1.0823183401953429e-05
amino O 0 4.655017164623132e-06
- O 0 0.00025643882690928876
acid O 0 1.0144589396077208e-05
substitutions O 0 5.231425461715844e-07
are O 0 2.430005174858252e-08
predicted O 0 1.0265980563417543e-06
to O 0 1.1708765512707942e-08
interfere O 0 2.376741150555972e-07
with O 0 1.3703856893698685e-07
ATP O 0 0.00023830799909774214
binding O 0 7.052498744997138e-07
or O 0 4.695738482496381e-07
substrate O 0 2.4456796381855384e-05
recognition O 0 1.126137976825703e-05
. O 0 2.072883398795966e-05

Two O 0 5.036226298216206e-07
of O 0 8.176275514415465e-07
seventeen O 0 7.881352212280035e-05
mutated O 0 0.1462300419807434
T B-Disease 1 0.9906739592552185
- I-Disease 0 0.013177188113331795
PLL I-Disease 0 0.0624505914747715
samples O 0 7.187702522060135e-07
had O 0 1.7217230663391092e-07
a O 0 2.9765504905299167e-07
previously O 0 4.138448275625706e-06
reported O 0 0.0001231132191605866
A B-Disease 0 0.02152787521481514
- I-Disease 1 0.9606348276138306
T I-Disease 1 0.9952320456504822
allele O 0 0.0002505746961105615
. O 0 2.3513792257290334e-05

In O 0 1.9524803064996377e-05
contrast O 0 0.00013747846242040396
, O 0 2.015352038142737e-06
no O 0 1.194268179460778e-06
mutations O 0 3.153002126055071e-06
were O 0 3.029796502573845e-08
detected O 0 8.980873644759413e-07
in O 0 1.4185616237227805e-08
the O 0 5.995079277454352e-08
p53 O 0 3.567206704246928e-06
gene O 0 1.3087854995319503e-06
, O 0 2.003326216026835e-07
suggesting O 0 2.778365796984872e-06
that O 0 2.3208737331970042e-07
this O 0 8.87781243363861e-06
tumour B-Disease 1 0.9991129040718079
suppressor O 0 0.02722332626581192
is O 0 4.117549963211786e-07
not O 0 9.603471085029014e-08
frequently O 0 1.3358978776523145e-06
altered O 0 1.727438393572811e-05
in O 0 1.8118214484275086e-06
this O 0 2.3255131964106113e-05
leukaemia B-Disease 1 0.99598628282547
. O 0 0.00016555660113226622

Occasional O 0 0.0006605887319892645
missense O 0 0.0015800812980160117
mutations O 0 7.12495602783747e-05
in O 0 1.1703662039508345e-06
ATM O 0 4.176037691649981e-05
were O 0 6.165524268908484e-08
also O 0 1.038654175999909e-07
found O 0 3.6426419569579593e-07
in O 0 1.3485675935953623e-06
tumour B-Disease 1 0.9877529144287109
DNA O 0 2.381824560870882e-05
from O 0 3.889159415848553e-06
patients O 0 0.0022287003230303526
with O 0 4.513076419243589e-06
B B-Disease 0 0.018399175256490707
- I-Disease 0 0.015376021154224873
cell I-Disease 0 0.0030519335996359587
non I-Disease 0 0.0029526222497224808
- I-Disease 1 0.9928346872329712
Hodgkins I-Disease 1 0.9993894100189209
lymphomas I-Disease 1 0.9935005307197571
( O 0 1.7563137589604594e-05
B B-Disease 0 0.00022172799799591303
- I-Disease 0 3.996973828179762e-05
NHL I-Disease 0 2.175146846639109e-06
) O 0 4.37840412814694e-08
and O 0 1.5991291846262357e-08
a O 0 5.04792069477844e-07
B B-Disease 0 0.00038704625330865383
- I-Disease 0 0.0004371314134914428
NHL I-Disease 0 8.106289169518277e-05
cell O 0 7.691742939641699e-05
line O 0 1.2118403901695274e-05
. O 0 7.009798537183087e-06

The O 0 1.647864678488986e-06
evidence O 0 5.813645316266047e-07
of O 0 4.870415182267607e-08
a O 0 1.9367858783425618e-07
significant O 0 3.2853964171408734e-07
proportion O 0 9.207985272041697e-07
of O 0 2.0099592745737027e-07
loss O 0 0.009485623799264431
- O 0 0.0007032452267594635
of O 0 4.0981970528264355e-07
- O 0 0.001261429744772613
function O 0 4.5019154981673637e-07
mutations O 0 8.62316937855212e-07
and O 0 1.0768777869429869e-08
a O 0 4.1536523553986626e-08
complete O 0 4.2772029473781004e-07
absence O 0 3.1117909315980796e-07
of O 0 5.657800450364903e-09
the O 0 1.9810213913729058e-08
normal O 0 1.0968512498266136e-07
copy O 0 1.222949350676572e-07
of O 0 8.745940860421797e-09
ATM O 0 5.9029721342085395e-06
in O 0 1.0257055649276481e-08
the O 0 1.0181604004344535e-08
majority O 0 1.1121835541416658e-07
of O 0 3.592959672005236e-07
mutated O 0 0.019863242283463478
tumours B-Disease 1 0.9815235733985901
establishes O 0 0.0004883432411588728
somatic O 0 0.00025459687458351254
inactivation O 0 0.0004354580887593329
of O 0 1.7334494728515892e-08
this O 0 4.286640020723098e-08
gene O 0 3.0287336016954214e-07
in O 0 5.0374747928572106e-08
the O 0 1.5948259601827885e-07
pathogenesis O 0 0.0016287575708702207
of O 0 1.9884239463863196e-06
sporadic B-Disease 0 0.04629699885845184
T I-Disease 1 0.9977887868881226
- I-Disease 0 0.3690264821052551
PLL I-Disease 1 0.564552366733551
and O 0 4.372103603600408e-07
suggests O 0 2.3126335690903943e-06
that O 0 3.926161085132662e-08
ATM O 0 2.3192076696432196e-05
acts O 0 9.367039979224501e-07
as O 0 1.8517208673074492e-06
a O 0 0.00021305809787008911
tumour B-Disease 1 0.9958840012550354
suppressor O 0 0.16340120136737823
. O 0 6.42647355562076e-05

As O 0 2.2031599655747414e-06
constitutional O 0 3.604364565035212e-06
DNA O 0 5.229088856140152e-06
was O 0 2.369385896372478e-07
not O 0 1.862467335911333e-08
available O 0 2.4201254333888755e-08
, O 0 3.361325084938471e-08
a O 0 1.2289112873986596e-06
putative O 0 0.0010318612912669778
hereditary O 0 0.0999460443854332
predisposition O 1 0.7144221663475037
to O 0 0.00012652945588342845
T B-Disease 1 0.9982160925865173
- I-Disease 0 0.21662774682044983
PLL I-Disease 0 0.16490156948566437
will O 0 3.351230475345801e-07
require O 0 9.2674684992744e-07
further O 0 6.260526674850553e-07
investigation O 0 9.904281796480063e-06
. O 0 1.5049536159494892e-06
. O 0 9.770335964276455e-06

Myotonic B-Disease 1 0.9945645332336426
dystrophy I-Disease 1 0.995764970779419
protein O 0 0.0003540204488672316
kinase O 0 0.0004878561885561794
is O 0 3.2216300382970076e-07
involved O 0 1.3894911887746275e-07
in O 0 1.217333256420261e-08
the O 0 1.3226131301280475e-08
modulation O 0 2.11617631862282e-07
of O 0 3.413431315379967e-08
the O 0 7.831966399862722e-07
Ca2 O 0 0.0025595752522349358
+ O 0 0.008538475260138512
homeostasis O 0 0.08361528813838959
in O 0 7.119509245967492e-05
skeletal O 1 0.9940926432609558
muscle O 1 0.9812939763069153
cells O 0 0.0070718033239245415
. O 0 7.17746588634327e-05

Myotonic B-Disease 1 0.9938530921936035
dystrophy I-Disease 1 0.9982571005821228
( O 1 0.5555538535118103
DM B-Disease 1 0.9983640313148499
) O 0 3.511281465762295e-05
, O 0 1.3271663874547812e-06
the O 0 2.9506211376428837e-06
most O 0 0.00014182334416545928
prevalent O 1 0.9967213273048401
muscular B-Disease 1 0.9998431205749512
disorder I-Disease 1 0.9998359680175781
in O 0 0.0002827739517670125
adults O 0 0.007131634745746851
, O 0 5.078532467450714e-06
is O 0 8.821770620670577e-07
caused O 0 3.303757694084197e-05
by O 0 2.5207410203620384e-07
( O 0 5.00191026731045e-06
CTG O 0 0.001252201502211392
) O 0 8.349895779247163e-07
n O 0 1.6146894267876633e-05
- O 0 2.6059542506118305e-05
repeat O 0 2.5276042379118735e-06
expansion O 0 2.0351342300273245e-07
in O 0 3.967026263040907e-09
a O 0 1.0530741612058137e-08
gene O 0 2.8589566269943134e-08
encoding O 0 2.351323402649541e-08
a O 0 5.574137063035778e-08
protein O 0 6.171571840241086e-07
kinase O 0 1.852641253208276e-05
( O 0 6.196983576955972e-06
DM B-Disease 1 0.9224767684936523
protein O 0 3.0294957014120882e-06
kinase O 0 3.111149635515176e-05
; O 0 2.717872121138498e-06
DMPK O 0 0.0007842578343115747
) O 0 9.770811004727875e-08
and O 0 1.4011527937896062e-08
involves O 0 1.9421534602770407e-07
changes O 0 2.968601222619327e-07
in O 0 3.060247308894759e-07
cytoarchitecture O 0 0.0006133897113613784
and O 0 2.157993549189996e-06
ion O 0 0.0007034909212961793
homeostasis O 0 0.10074210911989212
. O 0 6.783316348446533e-05

To O 0 1.2210305158077972e-06
obtain O 0 1.1889884490301483e-06
clues O 0 2.229142637588666e-06
to O 0 4.157543997962421e-08
the O 0 8.037572030161755e-08
normal O 0 6.058889994164929e-07
biological O 0 9.569979511070414e-07
role O 0 8.059048184350104e-08
of O 0 7.146651626044331e-08
DMPK O 0 0.0009291848400607705
in O 0 2.8149233344265667e-07
cellular O 0 4.719528806162998e-05
ion O 0 0.0005253927665762603
homeostasis O 0 0.014317111112177372
, O 0 1.4703157091844332e-07
we O 0 9.68486357777465e-09
have O 0 4.717415347244014e-09
compared O 0 1.0124228566610327e-07
the O 0 6.498987659142585e-08
resting O 0 3.870312139042653e-05
[ O 0 4.742732926388271e-05
Ca2 O 0 0.0006029242067597806
+ O 0 0.00041050344589166343
] O 0 7.431210178765468e-06
i O 0 6.763113447050273e-08
, O 0 4.171283318754604e-09
the O 0 3.3059242010580192e-09
amplitude O 0 4.973651357431663e-08
and O 0 8.010250240886307e-09
shape O 0 6.17965213223215e-07
of O 0 6.079657310920084e-08
depolarization O 0 0.0011901694815605879
- O 0 0.0069607095792889595
induced O 0 0.01406901516020298
Ca2 O 0 0.0026514274068176746
+ O 0 0.000932761759031564
transients O 0 6.878635758766904e-05
, O 0 2.1918165060696992e-08
and O 0 2.8964317611013257e-09
the O 0 1.7054351264533807e-09
content O 0 4.396267794248843e-09
of O 0 1.0346715484388369e-08
ATP O 0 2.7553554900805466e-05
- O 0 5.085744305688422e-06
driven O 0 4.303290097595891e-07
ion O 0 4.136341431149049e-06
pumps O 0 8.572294973419048e-06
in O 0 3.573658773348143e-07
cultured O 0 0.00012813459034077823
skeletal O 1 0.6296675801277161
muscle O 0 0.03437552601099014
cells O 0 3.249051815146231e-06
of O 0 1.2389946846269595e-07
wild O 0 1.3887950444768649e-05
- O 0 0.0005232320982031524
type O 0 6.188645056681708e-05
and O 0 1.729688051455014e-06
DMPK O 0 0.2801467478275299
[ O 0 0.0012508310610428452
- O 0 0.04187533259391785
/ O 0 0.041923511773347855
- O 0 0.0022953269071877003
] O 0 0.0002413259499007836
knockout O 0 0.0036911657080054283
mice O 0 0.0020660373847931623
. O 0 2.4455745005980134e-05

In O 0 2.340243008802645e-05
vitro O 0 0.0002275589358760044
- O 0 0.002796067390590906
differentiated O 0 0.0010592570761218667
DMPK O 0 0.4200890362262726
[ O 0 0.0016786707565188408
- O 0 0.0574168935418129
/ O 0 0.027603095397353172
- O 0 0.0004746707563754171
] O 0 4.074769822182134e-05
myotubes O 0 6.169576954562217e-05
exhibit O 0 8.907621236176055e-07
a O 0 1.2679980443408567e-07
higher O 0 1.7047000255843159e-06
resting O 0 9.287213470088318e-05
[ O 0 4.2503164877416566e-05
Ca2 O 0 0.0003408248594496399
+ O 0 0.000201796879991889
] O 0 7.361365078395465e-06
i O 0 1.6005152758680197e-07
than O 0 1.4053547658932075e-08
do O 0 8.27716206686091e-08
wild O 0 2.740095169428969e-06
- O 0 0.0013061831705272198
type O 0 0.00032980635296553373
myotubes O 0 0.0004724536556750536
because O 0 2.9777872612157807e-08
of O 0 5.271226566350151e-09
an O 0 1.7584248723778728e-08
altered O 0 4.059028242409113e-07
open O 0 7.450572070410999e-08
probability O 0 2.7064958274536366e-08
of O 0 2.5137401493680045e-08
voltage O 0 8.725476618565153e-06
- O 0 0.00018972826364915818
dependent O 0 9.58302553044632e-06
l O 0 0.011883490718901157
- O 0 0.00031763777951709926
type O 0 5.592863817582838e-05
Ca2 O 0 0.00019839653396047652
+ O 0 8.606439951108769e-05
and O 0 1.0827784535649698e-06
Na O 0 0.0022379732690751553
+ O 0 7.627240847796202e-05
channels O 0 3.912928605132038e-06
. O 0 5.9647900343406945e-06

The O 0 1.7180509530589916e-05
mutant O 0 0.0003526316722854972
myotubes O 0 0.0018587947124615312
exhibit O 0 1.6102347217383794e-05
smaller O 0 1.251565663551446e-06
and O 0 4.1767631842049013e-07
slower O 0 4.257042382960208e-05
Ca2 O 0 0.00045181423774920404
+ O 0 9.301971294917166e-05
responses O 0 7.787695039951359e-07
upon O 0 2.52723765470364e-07
triggering O 0 4.947055276716128e-05
by O 0 5.050886784374597e-07
acetylcholine O 0 0.00033079637796618044
or O 0 6.14137036336615e-07
high O 0 1.073674502549693e-05
external O 0 9.211264841724187e-05
K O 0 0.004911936353892088
+ O 0 0.0024798312224447727
. O 0 2.016414509853348e-05

In O 0 4.895752681477461e-06
addition O 0 4.331054242356913e-06
, O 0 3.5236942608207755e-07
we O 0 4.057998026496534e-08
observed O 0 9.463242633955815e-08
that O 0 1.6621653387005608e-08
these O 0 7.63380754165155e-08
Ca2 O 0 0.0004813690029550344
+ O 0 0.0010228045284748077
transients O 0 0.0003388469631318003
partially O 0 6.661800398433115e-06
result O 0 1.3081823624361277e-07
from O 0 1.3751558114449836e-08
an O 0 1.0827557517245623e-08
influx O 0 3.1861077331996057e-07
of O 0 1.513187974921948e-08
extracellular O 0 1.8303135220776312e-06
Ca2 O 0 1.3067029613011982e-05
+ O 0 3.957807166443672e-06
through O 0 3.707252460571908e-08
the O 0 6.616861583097489e-07
l O 0 0.018832290545105934
- O 0 0.0003394570667296648
type O 0 9.713244799058884e-05
Ca2 O 0 0.0003813251678366214
+ O 0 0.00014296689187176526
channel O 0 1.4594218555430416e-05
. O 0 5.79222296437365e-06

Neither O 0 1.6239209799095988e-05
the O 0 4.031145124372415e-07
content O 0 7.079358965711435e-07
nor O 0 5.313235647008696e-07
the O 0 2.8088619430377548e-08
activity O 0 2.1160755636628892e-07
of O 0 3.073098184813716e-07
Na O 0 0.01350112073123455
+ O 0 0.0006721241516061127
/ O 0 0.0003159313928335905
K O 0 3.4491960832383484e-05
+ O 0 3.214343450963497e-05
ATPase O 0 4.564669870887883e-05
and O 0 6.616533596570662e-07
sarcoplasmic O 0 0.003256133757531643
reticulum O 0 0.0013504762900993228
Ca2 O 0 0.0010725382016971707
+ O 0 0.0013625659048557281
- O 0 0.0007273714290931821
ATPase O 0 0.0003016749396920204
are O 0 1.687758697244135e-07
affected O 0 5.481150310515659e-06
by O 0 1.8456508996678167e-06
DMPK O 0 0.06684952974319458
absence O 0 0.0002785393444355577
. O 0 4.3928816012339666e-05

In O 0 2.5791607640712755e-06
conclusion O 0 2.6028869797301013e-06
, O 0 3.784628574976523e-07
our O 0 1.0706500574997335e-07
data O 0 3.5593393477029167e-07
suggest O 0 1.212748998113966e-06
that O 0 9.656130117718931e-08
DMPK O 0 0.0010048082331195474
is O 0 3.9484124414457256e-08
involved O 0 4.022196975483894e-08
in O 0 2.7951323033903464e-08
modulating O 0 4.153655027039349e-06
the O 0 8.955240993202551e-09
initial O 0 8.65820979356613e-08
events O 0 2.919501085330012e-08
of O 0 4.7920813983637345e-08
excitation O 0 3.1816292903386056e-05
- O 0 0.0014988082693889737
contraction O 0 0.0009069722145795822
coupling O 0 0.0001211846320074983
in O 0 5.423322363640182e-05
skeletal O 1 0.9952620267868042
muscle O 1 0.9232827425003052
. O 0 2.074872827506624e-05
. O 0 3.8100195524748415e-05

Constitutional O 0 0.0016357555286958814
RB1 O 1 0.9785414338111877
- O 0 0.2153189480304718
gene O 0 0.0011983372969552875
mutations O 0 0.0022053646389395
in O 0 0.00013969201245345175
patients O 1 0.588797926902771
with O 0 0.0001261540746781975
isolated O 0 0.0478978231549263
unilateral B-Disease 0 0.1785946935415268
retinoblastoma I-Disease 1 0.9886454343795776
. O 0 0.00036903598811477423

In O 0 2.6622996301739477e-05
most O 0 2.5693512725410983e-05
patients O 0 0.014514992944896221
with O 0 1.7859609215520322e-05
isolated O 0 0.005262409336864948
unilateral B-Disease 0 0.08238189667463303
retinoblastoma I-Disease 1 0.9973559379577637
, O 0 0.0004103815299458802
tumor B-Disease 1 0.9682868719100952
development O 0 4.108193479623878e-06
is O 0 1.6791308610208944e-07
initiated O 0 1.754239519868861e-06
by O 0 1.654121888350346e-07
somatic O 0 2.9696720957872458e-05
inactivation O 0 8.463991980534047e-05
of O 0 1.5155910304542886e-08
both O 0 3.12814947278639e-08
alleles O 0 6.773969971618499e-07
of O 0 1.2332041876561561e-07
the O 0 1.5146053556236438e-05
RB1 O 1 0.9773696064949036
gene O 0 0.00036129800719209015
. O 0 3.9846963773015887e-05

However O 0 1.2901846275781281e-05
, O 0 7.147959308895224e-07
some O 0 7.58316005544657e-08
of O 0 1.7614569003399083e-07
these O 0 4.971502676198725e-06
patients O 0 0.11840862780809402
can O 0 1.4698879567731638e-05
transmit O 0 0.0039050369523465633
retinoblastoma B-Disease 1 0.9925665855407715
predisposition O 0 0.13874322175979614
to O 0 5.943729775026441e-07
their O 0 1.0310053539797082e-06
offspring O 0 0.00031643721740692854
. O 0 3.847987682092935e-05

To O 0 5.339940685189504e-07
determine O 0 2.455631715747586e-07
the O 0 4.716725499065433e-08
frequency O 0 1.1353043305462052e-07
and O 0 3.046909569093259e-08
nature O 0 2.3158681017321214e-07
of O 0 1.2188415610125958e-07
constitutional O 0 7.140028174035251e-05
RB1 O 1 0.9927045702934265
- O 0 0.07805726677179337
gene O 0 0.00021951590315438807
mutations O 0 0.00015891296789050102
in O 0 9.546120054437779e-06
patients O 0 0.04015439376235008
with O 0 1.1848550457216334e-05
isolated O 0 0.00147444405592978
unilateral B-Disease 0 0.002712099812924862
retinoblastoma I-Disease 1 0.5095311999320984
, O 0 3.6076619380764896e-07
we O 0 2.6270511099824034e-08
analyzed O 0 4.2515091536188265e-07
DNA O 0 3.264158294769004e-06
from O 0 6.561253030668013e-06
peripheral O 0 0.4102970361709595
blood O 0 0.010825635865330696
and O 0 1.2602858987520449e-05
from O 0 0.0003692852915264666
tumor B-Disease 1 0.9980395436286926
tissue O 1 0.6830305457115173
. O 0 0.00011479624663479626

The O 0 1.8103602315022727e-06
analysis O 0 3.10155382976518e-06
of O 0 3.6794378956983564e-06
tumors B-Disease 1 0.9737420082092285
from O 0 1.04674609247013e-06
54 O 0 8.941955456975847e-06
( O 0 1.38160169171897e-06
71 O 0 2.1299290438037133e-06
% O 0 9.271255407838908e-08
) O 0 3.266974246685095e-08
of O 0 3.7312009482093345e-08
76 O 0 7.602536061313003e-05
informative O 0 3.591589120333083e-05
patients O 0 0.011657255701720715
showed O 0 1.4281566109275445e-05
loss O 0 2.6234862161800265e-05
of O 0 2.4215756866396987e-07
constitutional O 0 7.049445412121713e-05
heterozygosity O 1 0.9550930261611938
( O 0 0.013274449855089188
LOH O 1 0.9976658821105957
) O 0 6.784813649574062e-06
at O 0 6.505798864964163e-06
intragenic O 0 0.0040633357129991055
loci O 0 0.00011158028792124242
. O 0 1.777960278559476e-05

Three O 0 1.8114931208401686e-06
of O 0 3.0430674087256193e-06
13 O 0 0.0007964149699546397
uninformative O 1 0.9707851409912109
patients O 0 0.21145591139793396
had O 0 9.811400559556205e-06
constitutional O 0 3.6690453271148726e-05
deletions O 0 0.0017487594159319997
. O 0 0.00011380907380953431

For O 0 4.607150913216174e-06
39 O 0 1.827614141802769e-05
randomly O 0 5.74583827983588e-06
selected O 0 3.349515827721916e-05
tumors B-Disease 1 0.9914546012878418
, O 0 7.857185664761346e-06
SSCP O 0 0.06446823477745056
, O 0 5.550373771257e-06
hetero O 0 0.011313924565911293
- O 0 0.0002611422387417406
duplex O 0 0.00016446466906927526
analysis O 0 1.4823649507889058e-07
, O 0 2.7110425904197655e-08
sequencing O 0 1.6565498128784384e-07
, O 0 3.1871891792434326e-08
and O 0 1.8247936495185968e-08
Southern O 0 3.5421069810581685e-07
blot O 0 1.4259030649554916e-05
analysis O 0 4.3334154042895534e-08
were O 0 7.75839836819614e-09
used O 0 3.2093204538341524e-08
to O 0 1.0751275425491258e-07
identify O 0 4.630324838217348e-06
mutations O 0 7.82418719609268e-05
. O 0 1.728305323922541e-05

Mutations O 0 7.535958866355941e-05
were O 0 6.096298648117227e-07
detected O 0 2.753588887571823e-06
in O 0 9.16728026822966e-08
21 O 0 1.0378397519161808e-06
( O 0 5.071487407803943e-07
91 O 0 2.4661603674758226e-06
% O 0 8.426484754409103e-08
) O 0 1.3609665927560854e-07
of O 0 3.7870185565225256e-07
23 O 0 0.0017767262179404497
tumors B-Disease 1 0.9978405237197876
with O 0 0.0021153371781110764
LOH O 1 0.9967185854911804
. O 0 0.00018265913240611553

In O 0 2.3267296000994975e-06
6 O 0 4.550004177872324e-06
( O 0 1.3517145589503343e-06
38 O 0 7.963772645780409e-07
% O 0 1.1356216589319956e-07
) O 0 1.2333288168520085e-07
of O 0 2.891979420382995e-07
16 O 0 0.0007290903595276177
tumors B-Disease 1 0.9990880489349365
without O 0 0.00016525537648703903
LOH O 1 0.9984198808670044
, O 0 2.1556638785114046e-07
one O 0 5.311346029657216e-08
mutation O 0 1.939097501235665e-06
was O 0 1.5706815759131132e-07
detected O 0 6.292418675002409e-07
, O 0 6.2089382524277426e-09
and O 0 3.1832021463173987e-09
in O 0 6.823751341755724e-09
9 O 0 1.9698427422554232e-07
( O 0 1.0309900488891799e-07
56 O 0 1.250452044132544e-07
% O 0 1.4629719657932583e-08
) O 0 1.3154303424300906e-08
of O 0 3.785472557638059e-08
the O 0 1.7331163689959794e-05
tumors B-Disease 1 0.9992104768753052
without O 0 0.00031096371822059155
LOH O 1 0.9989867806434631
, O 0 6.111491188676155e-07
both O 0 1.871223815896883e-07
mutations O 0 7.117469976947177e-06
were O 0 1.3978166180095286e-07
found O 0 2.4354260403924854e-06
. O 0 1.157389397121733e-05

Thus O 0 3.3005535442498513e-06
, O 0 2.693072076453973e-07
a O 0 7.125662904172714e-08
total O 0 2.3611429256220617e-08
of O 0 2.119835862401942e-08
45 O 0 1.05674814676604e-06
mutations O 0 2.2029246338206576e-06
were O 0 4.7180119366885265e-08
identified O 0 3.520023483361001e-06
in O 0 1.56818005052628e-05
tumors B-Disease 1 0.9960297346115112
of O 0 6.46748230792582e-06
36 O 0 0.010221733711659908
patients O 1 0.7239637970924377
. O 0 0.0001250317000085488

Thirty O 0 2.443884477543179e-05
- O 0 3.169313640682958e-05
nine O 0 2.9022297098890704e-07
of O 0 3.937507742080015e-08
the O 0 2.5918740220731706e-07
mutations O 0 1.062587762135081e-05
- O 0 1.552579487906769e-05
including O 0 1.0147679319061353e-07
34 O 0 3.810250461810938e-07
small O 0 1.618128067093494e-07
mutations O 0 6.165818717818183e-07
, O 0 3.0856195820661014e-08
2 O 0 4.786203362527885e-07
large O 0 1.6140451180035598e-06
structural O 0 0.0009200493223033845
alterations O 0 3.703240872710012e-05
, O 0 2.5450654561609554e-07
and O 0 3.769801821817964e-07
hypermethylation O 0 0.00841517373919487
in O 0 5.865879302291432e-06
3 O 0 0.007155558560043573
tumors O 1 0.999224066734314
- O 0 0.0004233175714034587
were O 0 2.2159953871891958e-08
not O 0 1.7707264987620874e-08
detected O 0 3.6412595250112645e-07
in O 0 9.324631733420574e-09
the O 0 5.8452670259612205e-08
corresponding O 0 7.306489806069294e-06
peripheral O 0 0.046206239610910416
blood O 0 0.0037488203961402178
DNA O 0 0.00013569873408414423
. O 0 2.5937632017303258e-05

In O 0 3.1177014534478076e-06
6 O 0 6.495520665339427e-06
( O 0 8.462787377538916e-07
17 O 0 3.7191938417890924e-07
% O 0 6.26438492190573e-08
) O 0 2.3276601979205225e-08
of O 0 8.18039946892668e-09
the O 0 2.489411770056904e-07
36 O 0 3.420224675210193e-05
patients O 0 0.0009300147066824138
, O 0 7.198884333092792e-08
a O 0 1.6108883471588342e-07
mutation O 0 2.7081512143922737e-06
was O 0 1.0712158626802193e-07
detected O 0 4.804849140782608e-07
in O 0 5.374074962816167e-09
constitutional O 0 8.273295293292904e-08
DNA O 0 9.01332498415286e-07
, O 0 2.226837914065527e-08
and O 0 5.147636095159669e-09
1 O 0 2.5372662193490214e-08
of O 0 4.192380220757741e-09
these O 0 2.653611197445116e-08
mutations O 0 1.9001090549863875e-06
is O 0 3.517428481814022e-08
known O 0 7.283104963562437e-08
to O 0 1.4534626835427389e-08
be O 0 1.841113217437851e-08
associated O 0 4.0238279552795575e-07
with O 0 9.960270972442231e-07
reduced O 0 0.00030904883169569075
expressivity O 0 0.1835089921951294
. O 0 4.315558908274397e-05

The O 0 1.700849793451198e-06
presence O 0 6.57780333312985e-07
of O 0 6.13703718954639e-08
a O 0 4.871005216955382e-07
constitutional O 0 2.5478782390564447e-06
mutation O 0 3.809638292295858e-05
was O 0 4.2269445543752227e-07
not O 0 3.572370488313936e-08
associated O 0 2.4608550575067056e-07
with O 0 4.007058507227157e-08
an O 0 1.0537516459407925e-07
early O 0 4.2717138057923876e-06
age O 0 0.00011680412717396393
at O 0 4.120096127735451e-05
treatment O 0 0.0290483757853508
. O 0 7.085326797096059e-05

In O 0 2.2348547645378858e-05
1 O 0 9.164400398731232e-05
patient O 0 0.003864431753754616
, O 0 9.788269380806014e-06
somatic O 0 0.0012561685871332884
mosaicism O 0 0.08806420117616653
was O 0 8.587650199842756e-07
demonstrated O 0 5.039598818257218e-07
by O 0 2.4655479435864436e-08
molecular O 0 4.5450113361766853e-07
analysis O 0 3.8218921361021785e-08
of O 0 1.2842357399733828e-08
DNA O 0 8.301746561301115e-07
and O 0 1.2157002515778004e-07
RNA O 0 9.539495295030065e-06
from O 0 1.0756792107713409e-05
peripheral O 0 0.19001291692256927
blood O 0 0.010605609975755215
. O 0 3.569809996406548e-05

In O 0 6.928121001692489e-05
2 O 0 0.0007146591087803245
patients O 0 0.00591806136071682
without O 0 7.518208349210909e-07
a O 0 4.742018973047379e-06
detectable O 0 0.0008174878894351423
mutation O 0 7.976841880008578e-05
in O 0 1.1404254109947942e-05
peripheral O 1 0.648919403553009
blood O 0 0.04604785889387131
, O 0 2.2649359380011447e-05
mosaicism O 0 0.3539687991142273
was O 0 1.4563078138962737e-06
suggested O 0 7.948430607029877e-07
because O 0 6.086166592922382e-08
1 O 0 1.1724704052085144e-07
of O 0 8.499883108470385e-08
the O 0 1.2623993825400248e-05
patients O 1 0.9480631947517395
showed O 0 0.43485212326049805
multifocal O 1 0.9995695948600769
tumors B-Disease 1 0.9995231628417969
and O 0 4.1910556092261686e-07
the O 0 1.1054308401980961e-07
other O 0 1.0130816008313559e-07
later O 0 2.331976702407701e-06
developed O 0 0.0001102819514926523
bilateral B-Disease 0 0.002069773618131876
retinoblastoma I-Disease 1 0.9706262350082397
. O 0 0.0001944026880664751

In O 0 3.9009978536341805e-06
conclusion O 0 3.4439831324561965e-06
, O 0 3.545497122559027e-07
our O 0 1.2417000050390925e-07
results O 0 3.541711919297086e-07
emphasize O 0 5.062479999651259e-07
that O 0 2.1331842958716152e-08
the O 0 5.899073229898022e-08
manifestation O 0 2.773720188997686e-05
and O 0 3.3481188665973605e-07
transmissibility O 0 0.0015626313397660851
of O 0 4.0114716171046894e-07
retinoblastoma B-Disease 0 0.05614234879612923
depend O 0 2.183407161737705e-07
on O 0 1.3883568072969865e-08
the O 0 9.350991980738854e-09
nature O 0 3.010297788819116e-08
of O 0 2.074658667083895e-09
the O 0 1.22119834244927e-08
first O 0 1.731539533977866e-08
mutation O 0 2.803579945975798e-07
, O 0 5.040509343245958e-09
its O 0 3.4649818569931767e-09
time O 0 5.550549353472434e-09
in O 0 9.124224042977858e-09
development O 0 8.417939056926116e-08
, O 0 1.079921929658667e-08
and O 0 2.4035724521809243e-09
the O 0 2.178823343967906e-09
number O 0 3.259385650267177e-09
and O 0 1.0280324147515785e-08
types O 0 1.0655204363274606e-07
of O 0 4.110455620320863e-08
cells O 0 1.1032587281079032e-05
that O 0 1.0644702541640072e-07
are O 0 7.043411898166596e-08
affected O 0 7.135874966479605e-06
. O 0 9.503123123977275e-07
. O 0 6.808621947129723e-06

Hereditary B-Disease 1 0.9918280839920044
deficiency I-Disease 1 0.9966753721237183
of I-Disease 0 7.925087857074686e-07
the I-Disease 0 6.454614549511462e-07
fifth I-Disease 0 2.5904701033141464e-06
component I-Disease 0 1.3437343113764655e-06
of I-Disease 0 7.713222061056513e-08
complement I-Disease 0 5.79056586502702e-06
in O 0 2.0378311091917567e-06
man O 0 7.1712740464136e-05
. O 0 1.6551568478462286e-05

I O 0 0.0050028301775455475
. O 0 0.0008251120452769101

Clinical O 0 0.04895668476819992
, O 0 0.00010111431765835732
immunochemical O 0 0.09971535205841064
, O 0 5.899590632907348e-06
and O 0 2.6531308776611695e-06
family O 0 3.849742279271595e-05
studies O 0 4.742832243209705e-05
. O 0 3.838839620584622e-05

The O 0 2.340612354601035e-06
first O 0 1.7583581666258397e-06
recognized O 0 1.12176576294587e-05
human O 0 5.9080393839394674e-05
kindred O 0 0.43034279346466064
with O 0 0.01755659654736519
hereditary B-Disease 1 0.9989981055259705
deficiency I-Disease 1 0.9995131492614746
of I-Disease 0 1.2146456640493852e-07
the I-Disease 0 1.6118966073008778e-07
fifth I-Disease 0 1.7783472685550805e-06
component I-Disease 0 1.2190105280751595e-06
of I-Disease 0 9.186464211552448e-08
complement I-Disease 0 1.5824851288925856e-05
( O 0 2.6319061362301e-05
C5 O 0 0.021088728681206703
) O 0 1.977847887246753e-06
is O 0 6.752440526724968e-07
described O 0 1.840453660406638e-05
. O 0 1.2090953532606363e-05

The O 0 9.532192052574828e-06
proband O 0 0.0004900817875750363
, O 0 1.2208208772790385e-06
a O 0 8.586225703766104e-07
20 O 0 4.867879852099577e-06
- O 0 0.0007029688567854464
year O 0 2.3414642782881856e-05
- O 0 0.0025912108831107616
old O 0 0.00039372534956783056
black O 0 0.004175485577434301
female O 0 0.023889318108558655
with O 1 0.9938777089118958
systemic B-Disease 1 0.9999191761016846
lupus I-Disease 1 0.9999425411224365
erythematosus I-Disease 1 0.9998725652694702
since O 0 0.0016759447753429413
age O 0 0.0012172155547887087
11 O 0 6.46923144813627e-05
, O 0 2.628993388498202e-05
lacked O 0 0.013325617648661137
serum O 1 0.9059955477714539
hemolytic O 1 0.998576283454895
complement O 0 3.114941137027927e-05
activity O 0 6.585388291568961e-06
, O 0 2.0661968846980017e-06
even O 0 3.5582572763814824e-06
during O 0 4.172255648882128e-05
remission O 0 0.21779654920101166
. O 0 5.864106788067147e-05

C5 O 0 0.12888203561306
was O 0 5.5313103075604886e-05
undetectable O 0 0.0055489069782197475
in O 0 1.4015370197739685e-06
her O 0 1.3208783457230311e-05
serum O 0 0.0008986442117020488
by O 0 7.335642067118897e-07
both O 0 4.590043317875825e-06
immunodiffusion O 0 0.27662208676338196
and O 0 0.00026763611822389066
hemolytic O 1 0.9973602890968323
assays O 0 0.0014974502846598625
. O 0 0.0001576802460476756

Other O 0 9.973891792469658e-07
complement O 0 2.202260930062039e-06
components O 0 9.593097729521105e-07
were O 0 8.89500029188639e-08
normal O 0 2.308495140823652e-06
during O 0 2.3090735339792445e-05
remission O 0 0.3959900140762329
of O 0 0.00019399124721530825
lupus O 1 0.9997578263282776
, O 0 5.882382083655102e-06
but O 0 2.0241373022145126e-06
C1 O 0 0.22501057386398315
, O 0 1.1794027159339748e-06
C4 O 0 0.001438446925021708
, O 0 2.024280092882691e-06
C2 O 0 0.06560433655977249
, O 0 7.375999757641694e-07
and O 0 1.314255086981575e-06
C3 O 0 0.08979886770248413
levels O 0 0.00011367088882252574
fell O 0 0.0007574084447696805
during O 0 0.00011689548409776762
exacerbations O 1 0.9557360410690308
. O 0 9.948799561243504e-05

A O 0 3.0203567803255282e-05
younger O 0 7.549279689555988e-05
half O 0 2.2059850380173884e-05
- O 0 0.0027104958426207304
sister O 0 7.277420081663877e-05
, O 0 1.664226488173881e-06
who O 0 3.845133505819831e-06
had O 0 1.7010272131301463e-05
no O 0 0.000618598482105881
underlying O 1 0.9953606724739075
disease O 1 0.9995786547660828
, O 0 4.469218310987344e-06
was O 0 9.69514985627029e-07
also O 0 1.3617248839636886e-07
found O 0 2.238955119082675e-07
to O 0 3.126888259430416e-07
lack O 0 9.653722372604534e-05
immunochemically O 0 0.2285359501838684
detectable O 0 0.031000399962067604
C5 O 0 0.08446989208459854
. O 0 3.9195860153995454e-05

By O 0 0.0009493731195107102
hemolytic O 1 0.9963723421096802
assay O 0 0.0003788007306866348
, O 0 3.3789140161388787e-06
she O 0 1.6161321809704532e-06
exhibited O 0 3.525540023474605e-06
1 O 0 6.967463832552312e-07
- O 0 5.39654865860939e-06
2 O 0 6.869866098213606e-08
% O 0 7.4423458507055784e-09
of O 0 1.8688397496191556e-09
the O 0 2.148467892482131e-08
normal O 0 1.6521385077794548e-06
serum O 0 0.000431100808782503
C5 O 0 0.0005251122056506574
level O 0 2.868710282655229e-07
and O 0 1.6292515780946815e-08
normal O 0 1.1700242197321131e-07
concentrations O 0 3.21331441455186e-07
of O 0 6.443861444438426e-09
other O 0 3.680844429254648e-08
complement O 0 3.255726824136218e-06
components O 0 9.719435183797032e-06
. O 0 9.76212049863534e-06

C5 O 0 0.04379331320524216
levels O 0 1.5376850569737144e-05
of O 0 2.533494978251838e-07
other O 0 1.8512832866690587e-07
family O 0 1.216590248986904e-06
members O 0 2.3327848097665083e-08
were O 0 9.98753080239112e-09
either O 0 3.401719439466433e-08
normal O 0 1.1379449205151104e-07
or O 0 4.5274301641029524e-08
approximately O 0 8.323850408942235e-08
half O 0 7.059119866426045e-07
- O 0 8.017051732167602e-05
normal O 0 5.253609174360463e-07
, O 0 9.388453037217914e-08
consistent O 0 4.631330625670671e-07
with O 0 9.582884104020195e-07
autosomal O 0 0.048302825540304184
codominant O 0 0.01085282489657402
inheritance O 0 2.887198206735775e-05
of O 0 3.6343072906674934e-07
the O 0 9.648527338868007e-06
gene O 0 0.0008986630709841847
determining O 0 0.007220693863928318
C5 B-Disease 1 0.9967166781425476
deficiency I-Disease 1 0.9984716773033142
. O 0 0.0006952192052267492

Normal O 0 0.15296240150928497
hemolytic O 1 0.9964606165885925
titers O 0 0.11608438938856125
were O 0 1.072112695510441e-06
restored O 0 4.68419511889806e-06
to O 0 1.997119056795782e-07
both O 0 1.3183827149987337e-06
homozygous O 0 0.0017954088980332017
C5 B-Disease 1 0.9976558685302734
- I-Disease 1 0.9956660270690918
deficient I-Disease 1 0.9976999163627625
( O 0 0.00011613454262260348
C5D B-Disease 1 0.8950213193893433
) O 0 5.580674496741267e-06
sera O 0 9.16369172045961e-05
by O 0 3.259176040160128e-08
addition O 0 7.514180566658979e-08
of O 0 7.745729391217537e-08
highly O 0 9.503671208221931e-06
purified O 0 0.00011354403977748007
human O 0 6.915651465533301e-05
C5 O 0 0.08733177930116653
. O 0 4.039057239424437e-05

In O 0 7.326893410208868e-06
specific O 0 2.5297209504060447e-05
C5 O 1 0.7955479621887207
titrations O 0 0.31719276309013367
, O 0 5.146572220837697e-06
however O 0 6.924030344634957e-07
, O 0 1.830326112894909e-07
it O 0 2.2088933349095896e-08
was O 0 9.475976980866108e-08
noted O 0 1.1874196559347183e-07
that O 0 3.733064080080339e-09
when O 0 9.129168532240328e-09
limited O 0 1.3542000409927368e-08
amounts O 0 2.3737142029744973e-08
of O 0 9.102253173409736e-09
C5 O 0 7.834945427021012e-05
were O 0 4.113684948237051e-09
assayed O 0 8.636207837753318e-08
in O 0 3.31067573355881e-09
the O 0 2.2662400844808417e-09
presence O 0 1.96515124173402e-08
of O 0 1.049610975911719e-08
low O 0 3.212960791643127e-06
dilutions O 0 3.002453740919009e-05
of O 0 9.71676570316049e-08
either O 0 3.7023455661255866e-06
C5D B-Disease 1 0.940201461315155
serum O 0 0.0004538289795164019
, O 0 1.3307362678460777e-07
curving O 0 4.6724344429094344e-06
rather O 0 4.433506362033768e-08
than O 0 9.220588736980062e-08
linear O 0 1.8029471902991645e-05
dose O 0 0.001872519962489605
- O 0 0.00045091650099493563
response O 0 1.8567765209809295e-06
plots O 0 2.2523315124090004e-07
were O 0 1.1587174775229414e-08
consistently O 0 1.6587804907430836e-07
obtained O 0 7.011497871189931e-08
, O 0 9.585171056869513e-08
suggesting O 0 1.088204953703098e-06
some O 0 1.0682309437015647e-07
inhibitory O 0 1.5469291611225344e-05
effect O 0 1.3135648259776644e-05
. O 0 1.0087871487485245e-05

Further O 0 1.063980016624555e-05
studies O 0 4.871168130193837e-06
suggested O 0 3.747359642147785e-06
that O 0 1.9787788119174365e-07
low O 0 9.60769466473721e-06
dilutions O 0 0.0002686605730559677
of O 0 1.8938243329102988e-06
C5D B-Disease 1 0.9958561062812805
serum O 0 0.005199088249355555
contain O 0 4.811401595361531e-06
a O 0 2.574476866357145e-06
factor O 0 1.7989934349316172e-05
( O 0 1.8293886796527659e-06
or O 0 1.9031381270906422e-07
factors O 0 2.290428966489344e-07
) O 0 6.974510569079939e-08
interfering O 0 1.3160357070773898e-07
at O 0 2.28414638314689e-08
some O 0 5.536571201503193e-09
step O 0 1.971590677385393e-07
in O 0 1.0081623713631416e-07
the O 0 3.1331856007454917e-06
hemolytic O 1 0.9986850619316101
assay O 0 1.0362581633671653e-05
of O 0 3.696274006870226e-07
C5 O 0 0.015644213184714317
, O 0 1.3691735034626618e-07
rather O 0 3.286041660999217e-08
than O 0 3.570544393483033e-08
a O 0 6.064613558010024e-07
true O 0 1.2771021829394158e-05
C5 O 0 0.052705068141222
inhibitor O 0 0.00287804938852787
or O 0 2.1609388568322174e-05
inactivator O 0 0.020440978929400444
. O 0 4.067603003932163e-05

Of O 0 6.964540716580814e-06
clinical O 0 0.000788319215644151
interest O 0 1.2983924762011156e-06
are O 0 6.146010633756305e-08
( O 0 2.8093396053918696e-07
a O 0 5.3616890482999224e-08
) O 0 2.9141490998085828e-08
the O 0 1.447873465565408e-08
documentation O 0 1.373383383906912e-06
of O 0 5.069512553745881e-06
membranous O 1 0.9984142780303955
glomerulonephritis B-Disease 1 0.9996209144592285
, O 1 0.544579803943634
vasculitis B-Disease 1 0.9997031092643738
, O 0 0.015074766241014004
and O 0 0.04789435490965843
arthritis B-Disease 1 0.9998922348022461
in O 0 1.510493802925339e-06
an O 0 6.345134124785545e-07
individual O 0 1.2373643585306127e-06
lacking O 0 0.00037999736377969384
C5 O 0 0.06796606630086899
( O 0 7.253962621689425e-07
and O 0 1.003693483880852e-08
its O 0 2.292780010293427e-08
biologic O 0 5.856909046997316e-05
functions O 0 4.8294541699078763e-08
) O 0 7.248320343933301e-08
, O 0 2.2354255335699236e-08
and O 0 2.089468154053975e-08
( O 0 4.63663383243329e-07
b O 0 2.224536501671537e-06
) O 0 4.158535560350174e-08
a O 0 1.0686976281704119e-07
remarkable O 0 5.888264240638819e-06
propensity O 0 0.000583820219617337
to O 0 2.1761969037470408e-05
bacterial B-Disease 1 0.999112069606781
infections I-Disease 1 0.9988407492637634
in O 0 8.662353252475441e-07
the O 0 1.525331526863738e-06
proband O 0 0.006298404652625322
, O 0 1.617955263100157e-07
even O 0 4.6530413300160944e-08
during O 0 1.1605515481960538e-07
periods O 0 4.534014976798062e-07
of O 0 8.584606803196948e-08
low O 0 4.35838992416393e-05
- O 0 0.00028045769431628287
dose O 0 1.74146807694342e-05
or O 0 3.3412609923288983e-07
alternate O 0 3.1732126899441937e-06
- O 0 0.0014539548428729177
day O 0 7.237460522446781e-05
corticosteroid O 1 0.715307354927063
therapy O 0 0.039163582026958466
. O 0 8.806813275441527e-05

Other O 0 1.1190036275365856e-06
observations O 0 2.5753020054253284e-06
indicate O 0 2.1544135506701423e-06
that O 0 1.257462258763553e-07
the O 0 6.68606105591607e-07
C5D B-Disease 0 0.26649588346481323
state O 0 1.990416649277904e-07
is O 0 6.540123109743945e-08
compatible O 0 4.269537328127626e-07
with O 0 1.5006999376510066e-07
normal O 0 6.771400876459666e-06
coagulation O 0 0.0018949168734252453
function O 0 2.0398482547534513e-07
and O 0 1.7462223667052967e-08
the O 0 2.991141911934392e-08
capacity O 0 3.3674700716801453e-07
to O 0 9.99860816364162e-08
mount O 0 4.752389941131696e-05
a O 0 7.91952625149861e-05
neutrophilic O 1 0.9912503957748413
leukocytosis O 1 0.9936362504959106
during O 0 0.03997153043746948
pyogenic B-Disease 1 0.995637834072113
infection I-Disease 1 0.9940961599349976
. O 0 4.025425369036384e-05
. O 0 7.642296986887231e-05

Susceptibility O 1 0.9486924409866333
to O 0 0.26492437720298767
ankylosing B-Disease 1 0.9993925094604492
spondylitis I-Disease 1 0.9994100332260132
in O 0 0.00019372269161976874
twins O 0 0.005356712266802788
: O 0 3.510034503051429e-06
the O 0 5.1500546049965124e-08
role O 0 1.1090209284247976e-07
of O 0 5.1164910530587804e-08
genes O 0 3.3601988889131462e-06
, O 0 5.3722151278634556e-06
HLA O 1 0.6768354773521423
, O 0 4.667503787914029e-07
and O 0 1.7402680896339007e-07
the O 0 1.253919208465959e-06
environment O 0 3.859210846712813e-05
. O 0 1.2266454177733976e-05

OBJECTIVE O 0 9.681654773885384e-06
To O 0 4.800887154488009e-07
determine O 0 4.2416598944328143e-07
the O 0 1.7496536486305558e-07
relative O 0 5.5976465773710515e-06
effects O 0 3.18956736009568e-05
of O 0 3.0047684163037047e-07
genetic O 0 0.000259724969509989
and O 0 3.469402599876048e-06
environmental O 0 0.0005458764499053359
factors O 0 4.483541852096096e-05
in O 0 5.518191755982116e-05
susceptibility O 1 0.9738302826881409
to O 0 0.34510666131973267
ankylosing B-Disease 1 0.999810516834259
spondylitis I-Disease 1 0.9997836947441101
( O 0 0.014459188096225262
AS B-Disease 0 0.0004070813301950693
) O 0 3.823560109594837e-05
. O 0 2.8018155717290938e-05

METHODS O 0 0.00012211775174364448
Twins O 0 0.0008088717004284263
with O 0 2.7384103304939345e-06
AS B-Disease 0 2.2927224563318305e-06
were O 0 6.008999520190628e-08
identified O 0 3.122704299585166e-07
from O 0 2.094716080591752e-07
the O 0 2.712074774535722e-06
Royal O 0 0.001806744490750134
National O 0 0.03983253985643387
Hospital O 1 0.9939324259757996
for O 0 0.4940798282623291
Rheumatic B-Disease 1 0.9997517466545105
Diseases I-Disease 1 0.9993826150894165
database O 0 0.09763626754283905
. O 0 0.000577846891246736

Clinical O 0 0.013823834247887135
and O 0 2.1212887077126652e-05
radiographic O 0 0.08845716714859009
examinations O 0 3.564367216313258e-05
were O 0 1.3739109760990686e-07
performed O 0 4.6258222141659644e-07
to O 0 7.708073326284648e-07
establish O 0 0.000261452398262918
diagnoses O 1 0.9943742752075195
, O 0 0.001401616376824677
and O 0 0.12355951964855194
disease O 1 0.9998237490653992
severity O 1 0.9855120778083801
was O 0 4.040746716782451e-06
assessed O 0 2.3200823306979146e-06
using O 0 3.5471195758418617e-08
a O 0 1.902159993960595e-07
combination O 0 1.443896167074854e-06
of O 0 9.607098405695069e-08
validated O 0 7.314312369999243e-06
scoring O 0 2.348594989598496e-06
systems O 0 0.0001541165984235704
. O 0 1.3677140486834105e-05

HLA O 0 0.08040253072977066
typing O 0 0.00025945319794118404
for O 0 2.03124091058271e-05
HLA O 1 0.8893470764160156
- O 0 0.009457793086767197
B27 O 0 0.004193061497062445
, O 0 3.425130853429437e-05
HLA O 1 0.8561664819717407
- O 0 0.001768929185345769
B60 O 0 0.00035097956424579024
, O 0 1.0297200105924276e-06
and O 0 4.957946657668799e-06
HLA O 1 0.95865398645401
- O 0 0.023480916395783424
DR1 O 0 0.01721278578042984
was O 0 7.284715763944405e-08
performed O 0 2.9154612946058478e-08
by O 0 1.9874514478601668e-08
polymerase O 0 8.628009709354956e-06
chain O 0 3.028493210877059e-06
reaction O 0 2.881160696688312e-07
with O 0 2.601873561047796e-08
sequence O 0 2.408009436294378e-07
- O 0 1.1559564882190898e-05
specific O 0 9.81010046530173e-08
primers O 0 1.0645352631399874e-05
, O 0 9.996510641485656e-08
and O 0 1.5128048858059628e-07
zygosity O 0 0.0001488235720898956
was O 0 3.88558987651777e-07
assessed O 0 2.0192208012304036e-06
using O 0 1.542492100270465e-06
microsatellite O 0 0.005336716305464506
markers O 0 0.0007423320203088224
. O 0 4.10567045037169e-05

Genetic O 0 0.0006055670091882348
and O 0 4.353224539954681e-06
environmental O 0 1.860908741946332e-05
variance O 0 1.2962125310878037e-06
components O 0 1.7931755564859486e-06
were O 0 3.8550943770587764e-08
assessed O 0 9.364306947645673e-07
with O 0 6.592210155531575e-08
the O 0 2.3759933753808582e-07
program O 0 3.846303116006311e-06
Mx O 0 0.0005653244443237782
, O 0 1.1771779107050406e-08
using O 0 3.4966236572842035e-09
data O 0 4.698163635907804e-09
from O 0 2.316051794792884e-09
this O 0 1.5730334812502633e-09
and O 0 4.326319302805359e-09
previous O 0 5.601314256864498e-08
studies O 0 8.857550426455418e-08
of O 0 7.901317644609662e-08
twins O 0 0.00011805038229795173
with O 0 4.71802150059375e-06
AS B-Disease 0 7.513076707255095e-05
. O 0 2.5565757823642343e-05

RESULTS O 0 7.987649041751865e-06
Six O 0 1.035038621921558e-06
of O 0 5.116657462167495e-07
8 O 0 3.579009717213921e-05
monozygotic O 0 0.019055653363466263
( O 0 0.0002420504461042583
MZ O 1 0.9472920894622803
) O 0 8.867708856996614e-06
twin O 0 0.0008784381789155304
pairs O 0 5.019616219215095e-05
were O 0 1.6079358829301782e-05
disease O 1 0.9985952973365784
concordant O 0 0.01196242868900299
, O 0 7.309405418709503e-07
compared O 0 7.138681326068763e-07
with O 0 2.072393279206608e-08
4 O 0 8.028011677652103e-08
of O 0 1.3042330770929311e-08
15 O 0 4.1591471244828426e-07
B27 O 0 5.343912198441103e-05
- O 0 2.1948171706753783e-05
positive O 0 6.431995416278369e-07
dizygotic O 0 0.00033619714668020606
( O 0 4.012797944596969e-06
DZ O 0 0.0019863813649863005
) O 0 1.9379757532078656e-07
twin O 0 4.500650447880616e-06
pairs O 0 2.4179709612326405e-07
( O 0 1.5726450897091127e-07
27 O 0 1.2949283245689003e-07
% O 0 2.293129952590789e-08
) O 0 8.347664781638287e-09
and O 0 2.397039233770215e-09
4 O 0 1.4530107783627955e-08
of O 0 1.0311961951003923e-08
32 O 0 1.2138980309828185e-06
DZ O 0 0.0018670335412025452
twin O 0 1.9012377379112877e-05
pairs O 0 5.661586897076631e-07
overall O 0 6.646042152169684e-07
( O 0 1.5974106304383895e-07
12 O 0 9.606291939689982e-08
. O 0 3.988285612877007e-08
5 O 0 3.4587182540235517e-07
% O 0 4.859911086896318e-07
) O 0 1.2509761972978595e-06
. O 0 2.9270536288095172e-06

Nonsignificant O 0 0.025403495877981186
increases O 0 8.047185110626742e-05
in O 0 4.815785814571427e-07
similarity O 0 1.8960543002322083e-06
with O 0 3.7142916653465363e-07
regard O 0 5.706144293071702e-06
to O 0 4.087622073711827e-06
age O 0 0.04826546832919121
at O 0 0.46163105964660645
disease O 1 0.9998136162757874
onset O 1 0.9980225563049316
and O 0 3.635988434780302e-07
all O 0 5.927359580937264e-08
of O 0 1.9610420167737175e-06
the O 0 0.0026338074821978807
disease O 1 0.9996020197868347
severity O 1 0.797305703163147
scores O 0 4.441563942236826e-05
assessed O 0 2.8036063667968847e-05
were O 0 5.351503205019981e-07
noted O 0 0.0001269701315322891
in O 0 0.0003414842358324677
disease O 1 0.9990230798721313
- O 1 0.8770509958267212
concordant O 1 0.9713398814201355
MZ O 1 0.9974005222320557
twins O 0 0.012551892548799515
compared O 0 0.00010460270277690142
with O 0 4.2869243770837784e-05
concordant O 1 0.8705183267593384
DZ O 1 0.9890053868293762
twins O 0 0.051740579307079315
. O 0 0.00019996159244328737

HLA O 1 0.967807948589325
- O 0 0.02770610898733139
B27 O 0 0.002353268675506115
and O 0 6.757543360436102e-06
B60 O 0 0.0006346142617985606
were O 0 4.7050085072442016e-07
associated O 0 1.2801444427168462e-05
with O 0 6.068818493076833e-06
the O 0 0.00017506134463474154
disease O 1 0.9986029267311096
in O 0 3.3141509447887074e-06
probands O 0 0.009607106447219849
, O 0 1.6321635598615103e-07
and O 0 2.6439058942173688e-08
the O 0 6.0701559334575e-08
rate O 0 1.7754257441993104e-06
of O 0 1.6588388689342537e-06
disease O 1 0.9884840846061707
concordance O 0 0.00016547880659345537
was O 0 1.934719648488681e-06
significantly O 0 2.4399789253948256e-05
increased O 0 2.563530188126606e-06
among O 0 9.654064569986076e-07
DZ O 0 0.06971285492181778
twin O 0 5.0240363634657115e-05
pairs O 0 4.594224662923807e-07
in O 0 4.236432360471554e-08
which O 0 5.316829643220444e-08
the O 0 4.2514969322837715e-07
co O 0 0.00037543641519732773
- O 0 0.0005886483122594655
twin O 0 6.379299884429201e-05
was O 0 1.3512359942069452e-07
positive O 0 6.343186953472468e-08
for O 0 3.704396789316888e-08
both O 0 3.6724790675179975e-07
B27 O 0 0.0008098369580693543
and O 0 9.132154445978813e-06
DR1 O 0 0.2659558951854706
. O 0 1.953068931470625e-05

Additive O 0 0.0011292396811768413
genetic O 0 0.0015797172673046589
effects O 0 0.00038093276089057326
were O 0 2.5535067038617854e-07
estimated O 0 1.2088668199794483e-06
to O 0 4.8185693657387674e-08
contribute O 0 1.034789875120623e-06
97 O 0 9.683146799943643e-07
% O 0 2.6557275489835774e-08
of O 0 1.0983288944999003e-08
the O 0 1.0980296849538718e-07
population O 0 4.4282754174673755e-07
variance O 0 3.4198681078123627e-06
. O 0 7.003383871051483e-06

CONCLUSION O 0 0.0006177515024319291
Susceptibility O 0 0.008010921068489552
to O 0 1.6833940890137455e-06
AS B-Disease 0 8.06730349722784e-06
is O 0 7.110293722689676e-07
largely O 0 1.0458899168952485e-06
genetically O 0 4.528208592091687e-06
determined O 0 8.02011243195011e-07
, O 0 8.894066638731601e-08
and O 0 4.622540927812224e-08
the O 0 5.19908724072593e-07
environmental O 0 0.0003115269064437598
trigger O 0 0.0018068116623908281
for O 0 6.066562036721734e-06
the O 0 0.0004674993106164038
disease O 1 0.9988675117492676
is O 0 2.048269016086124e-05
probably O 0 8.152693771990016e-05
ubiquitous O 0 0.001213116804137826
. O 0 3.401612411835231e-05

HLA O 1 0.9710623025894165
- O 0 0.010592164471745491
B27 O 0 0.00038793336716480553
accounts O 0 9.011030215333449e-07
for O 0 1.0258116844852339e-07
a O 0 4.2179405568276707e-07
minority O 0 5.39764243967511e-07
of O 0 3.6500971134501015e-08
the O 0 5.679768264599261e-07
overall O 0 0.0002867529110517353
genetic O 0 0.002355914330109954
susceptibility O 0 0.018917568027973175
to O 0 2.9141826871637022e-06
AS B-Disease 0 9.445243631489575e-05
. O 0 3.429473872529343e-05

Cell O 0 0.0004207456368021667
cycle O 0 0.0007197651430033147
- O 0 0.0010402818443253636
dependent O 0 1.5343655832111835e-05
colocalization O 0 0.00038716194103471935
of O 0 8.218905804824317e-07
BARD1 O 0 0.02833048813045025
and O 0 1.2812687373298104e-06
BRCA1 O 0 0.0001367868680972606
proteins O 0 2.6518611662140756e-07
in O 0 1.1317013814959864e-07
discrete O 0 3.2977220598695567e-06
nuclear O 0 0.00012073433754267171
domains O 0 5.918178794672713e-05
. O 0 1.8077817003359087e-05

Germ O 1 0.8091939687728882
- O 0 0.002642808947712183
line O 0 1.7129219486378133e-05
mutations O 0 3.952756287617376e-06
of O 0 1.5969627042977663e-07
the O 0 1.7177129620904452e-06
BRCA1 O 0 0.004658878780901432
gene O 0 4.5173303078627214e-05
predispose O 0 0.0008764684316702187
women O 0 4.483967586565996e-06
to O 0 1.4653955986432265e-06
early O 0 0.0007530904840677977
- O 1 0.9973574280738831
onset O 1 0.999496340751648
breast B-Disease 1 0.9997497200965881
and I-Disease 1 0.9955680966377258
ovarian I-Disease 1 0.9999419450759888
cancer I-Disease 1 0.9997952580451965
by O 0 1.7853035387815908e-05
compromising O 0 0.0012213931186124682
the O 0 2.7952075924986275e-06
genes O 0 3.505382846924476e-05
presumptive O 0 0.2818496823310852
function O 0 5.990083081997e-06
as O 0 6.140038294688566e-06
a O 0 0.0005114516243338585
tumor B-Disease 1 0.9957850575447083
suppressor O 0 0.49666866660118103
. O 0 6.612020661123097e-05

Although O 0 7.636779628228396e-06
the O 0 1.3750162679571076e-06
biochemical O 0 4.9247348215430975e-05
properties O 0 3.30803732140339e-06
of O 0 1.4406033415070851e-06
BRCA1 O 0 0.052039824426174164
polypeptides O 0 0.00011847259156638756
are O 0 7.066516616305307e-08
not O 0 3.699644679500125e-08
understood O 0 2.2639045482719666e-07
, O 0 1.6222713838942582e-08
their O 0 6.01216143536476e-09
expression O 0 1.0944271622292945e-07
pattern O 0 1.2959059176864685e-06
and O 0 6.516887651741854e-08
subcellular O 0 4.143870683037676e-06
localization O 0 5.828878784086555e-06
suggest O 0 5.253103267932602e-07
a O 0 1.7227019100118923e-07
role O 0 6.524959985654277e-07
in O 0 1.0950019486699603e-06
cell O 0 0.0007197153172455728
- O 0 0.002425373299047351
cycle O 0 0.00015622348291799426
regulation O 0 9.689044236438349e-05
. O 0 1.5544343114015646e-05

When O 0 0.00015726417768746614
resting O 0 0.005646117962896824
cells O 0 0.00013817539729643613
are O 0 5.941780045759515e-07
induced O 0 0.001116083818487823
to O 0 4.305815082261688e-07
proliferate O 0 6.181118078529835e-05
, O 0 4.380693141570191e-08
the O 0 3.788990454722807e-08
steady O 0 4.272365913493559e-06
- O 0 4.851783160120249e-06
state O 0 2.1930418370175175e-08
levels O 0 6.811114872107282e-08
of O 0 1.4893587696462873e-08
BRCA1 O 0 2.64798836724367e-05
increase O 0 1.8563572723451216e-07
in O 0 2.7024414706033895e-08
late O 0 1.4575069826605613e-06
G1 O 0 0.001975590828806162
and O 0 1.1401724009374448e-08
reach O 0 3.370454138007517e-08
a O 0 3.9490675618480964e-08
maximum O 0 2.6849633627534786e-07
during O 0 4.215502031001961e-06
S O 0 0.004093808121979237
phase O 0 0.0001283517776755616
. O 0 1.4779406228626613e-05

Moreover O 0 0.00012798803800251335
, O 0 4.34321054854081e-06
in O 0 2.9500356504286174e-06
S O 0 0.00746722798794508
phase O 0 0.00017398320778738707
cells O 0 6.947961810510606e-05
, O 0 1.7575433730598888e-06
BRCA1 O 0 0.00014278173330239952
polypeptides O 0 3.0473536298813997e-06
are O 0 2.5564785843812388e-08
hyperphosphorylated O 0 7.237460522446781e-05
and O 0 6.18728250856293e-08
accumulate O 0 3.071980927416007e-06
into O 0 8.49537755698293e-08
discrete O 0 2.5774786536203464e-06
subnuclear O 0 0.004150683525949717
foci O 0 0.0017716577276587486
termed O 0 0.0017002229578793049
" O 0 2.62783305515768e-05
BRCA1 O 0 0.008551749400794506
nuclear O 0 0.0005664827185682952
dots O 0 0.0010294596431776881
. O 0 3.117945379926823e-05

" O 0 0.000588924391195178
BRCA1 O 0 0.1618948131799698
associates O 0 0.005830281879752874
in O 0 4.475734840525547e-06
vivo O 0 7.920758071122691e-05
with O 0 1.4118452327238629e-06
a O 0 2.9538492526626214e-05
structurally O 0 0.005912553984671831
related O 0 0.0002052114432444796
protein O 0 0.00017598789418116212
termed O 0 0.013866855762898922
BARD1 O 1 0.7448749542236328
. O 0 0.00015167088713496923

Here O 0 3.4001250241999514e-06
we O 0 1.760388954608061e-07
show O 0 1.2394343684718478e-07
that O 0 8.189751099507703e-09
the O 0 2.277333699396422e-08
steady O 0 6.325652975647245e-06
- O 0 1.3720396054850426e-05
state O 0 4.678394915913486e-08
levels O 0 2.980424369525281e-07
of O 0 5.576210426738726e-08
BARD1 O 0 0.006433108821511269
, O 0 1.6389438428632275e-07
unlike O 0 3.520469817885896e-07
those O 0 2.3298278861716426e-08
of O 0 1.6681497072568163e-07
BRCA1 O 0 0.0036479763220995665
, O 0 2.4052278035924246e-07
remain O 0 1.6964808935426845e-07
relatively O 0 3.9035219856486947e-07
constant O 0 2.2634044398728292e-06
during O 0 8.896134204405826e-06
cell O 0 0.0010644732974469662
cycle O 0 0.0026814292650669813
progression O 0 0.10816153883934021
. O 0 9.063439210876822e-05

However O 0 2.5319801352452487e-05
, O 0 6.531174676638329e-06
immunostaining O 0 0.0038345137145370245
revealed O 0 4.318894207244739e-05
that O 0 9.665118341217749e-07
BARD1 O 0 0.016102029010653496
resides O 0 1.2156102457083762e-05
within O 0 6.813452841925027e-07
BRCA1 O 0 0.0007248672191053629
nuclear O 0 3.459381696302444e-05
dots O 0 2.3173373847384937e-05
during O 0 1.6380843135266332e-06
S O 0 0.00014231089153327048
phase O 0 8.787167757873249e-07
of O 0 1.3315203162278522e-08
the O 0 1.3027741374571633e-07
cell O 0 2.68920721282484e-05
cycle O 0 2.2856225768919103e-05
, O 0 1.0607329414824562e-07
but O 0 1.629351054077688e-08
not O 0 7.436911531044643e-09
during O 0 1.6381640932650043e-07
the O 0 5.669004394803778e-07
G1 O 0 0.050263937562704086
phase O 0 0.00025861323229037225
. O 0 2.8383961762301624e-05

Nevertheless O 0 0.00023972228518687189
, O 0 2.3958782549016178e-05
BARD1 O 0 0.04173106700181961
polypeptides O 0 4.859811087953858e-05
are O 0 7.194794449105757e-08
found O 0 4.1328370059545705e-08
exclusively O 0 1.9331388045884523e-08
in O 0 6.973603916549109e-09
the O 0 6.745487279857798e-09
nuclear O 0 1.1755527395962417e-07
fractions O 0 2.985988700743292e-08
of O 0 1.6172327477192994e-08
both O 0 2.578678675035917e-07
G1 O 0 0.18296712636947632
- O 0 0.0005866328137926757
and O 0 2.1425194063340314e-06
S O 0 0.02588915079832077
- O 0 0.000905329710803926
phase O 0 0.00011046086001442745
cells O 0 0.00013264520384836942
. O 0 8.427547982137185e-06

Therefore O 0 1.1639865078905132e-05
, O 0 4.527915280050365e-06
progression O 0 0.0011303724022582173
to O 0 3.0336793770402437e-06
S O 0 0.0088144950568676
phase O 0 1.726489790598862e-05
is O 0 9.772618625447649e-08
accompanied O 0 2.9070440632494865e-07
by O 0 1.7354510717382254e-08
the O 0 2.6162103594629116e-08
aggregation O 0 8.35696198464575e-07
of O 0 1.574601924403396e-07
nuclear O 0 4.734336835099384e-05
BARD1 O 0 0.0022092170547693968
polypeptides O 0 3.217367338947952e-05
into O 0 4.775894467456965e-06
BRCA1 O 0 0.003846802283078432
nuclear O 0 0.00041410012636333704
dots O 0 0.0009529758826829493
. O 0 4.526610064203851e-05

This O 0 7.517328867834294e-06
cell O 0 0.0002579636056907475
cycle O 0 0.0004340939049143344
- O 0 0.0005478794919326901
dependent O 0 1.3261783351481427e-05
colocalization O 0 0.00026065148995257914
of O 0 7.384410309896339e-07
BARD1 O 0 0.04929918423295021
and O 0 2.4988096356537426e-06
BRCA1 O 0 0.0017608518246561289
indicates O 0 6.726527317368891e-06
a O 0 2.023287066776902e-07
role O 0 5.502264457390993e-07
for O 0 1.1968905937465024e-06
BARD1 O 0 0.09825391322374344
in O 0 3.572547939256765e-05
BRCA1 O 0 0.49433058500289917
- O 0 0.30276405811309814
mediated O 0 0.21853294968605042
tumor B-Disease 1 0.994698166847229
suppression O 0 0.07429426908493042
. O 0 0.000240863228100352

Ethnic O 0 1.2397028513078112e-05
differences O 0 1.1706391887855716e-05
in O 0 7.341024002016638e-07
the O 0 1.3364331152843079e-06
HFE O 0 0.031762368977069855
codon O 0 5.4255517170531675e-05
282 O 0 0.0006884499453008175
( O 0 0.00038577296072617173
Cys O 1 0.9829745888710022
/ O 1 0.5678125619888306
Tyr O 0 0.27445337176322937
) O 0 1.4643905160482973e-05
polymorphism O 0 0.00011744105722755194
. O 0 2.6911646273219958e-05

Recent O 0 8.91891322680749e-05
studies O 0 1.110921675717691e-05
have O 0 1.3724118161917431e-06
shown O 0 2.4050053980317898e-05
that O 0 8.178281132131815e-05
hereditary B-Disease 1 0.9987860321998596
hemochromatosis I-Disease 1 0.9998475313186646
( O 1 0.7751383185386658
HH B-Disease 1 0.9994738698005676
) O 0 1.3083264093438629e-05
is O 0 2.599917365841975e-07
likely O 0 5.772508302470669e-07
to O 0 2.2872111316019073e-08
be O 0 2.5395756608759257e-08
caused O 0 1.167249047284713e-05
by O 0 5.320694995702979e-08
homozygosity O 0 0.00010256466339342296
for O 0 3.6020853855234236e-08
a O 0 7.165062356762064e-07
Cys282Tyr O 0 0.0010210240725427866
mutation O 0 2.6091972813446773e-06
in O 0 7.189142081642785e-08
the O 0 4.904234742753033e-07
HFE O 0 0.06869731098413467
gene O 0 9.24518553802045e-06
located O 0 1.9344927295605885e-06
4 O 0 1.0396167454018723e-05
. O 0 1.189395879919175e-05

5 O 0 0.0002011473843595013
Mb O 0 0.024817179888486862
telomeric O 0 0.02692253142595291
to O 0 5.483093627844937e-05
HLA O 1 0.9830684065818787
- O 0 0.009422571398317814
A O 0 0.00010676124657038599
. O 0 6.17055338807404e-05

Population O 0 7.786048627167474e-06
studies O 0 8.043351726882975e-07
of O 0 7.838169580054455e-08
this O 0 1.1133699473475644e-07
polymorphism O 0 2.6532370611676015e-06
are O 0 1.8843353544184538e-08
facilitated O 0 6.023136620569858e-07
by O 0 1.8217644282003675e-08
the O 0 3.0026026109908344e-08
fact O 0 6.740088309697967e-08
that O 0 1.6663776136738306e-08
the O 0 1.6363996735435649e-07
Cys282Tyr O 0 0.0012999901082366705
mutation O 0 1.0923861736955587e-05
creates O 0 1.4629458746640012e-05
a O 0 6.88648742652731e-06
Rsal O 0 0.005386411678045988
restriction O 0 3.738703890121542e-05
site O 0 2.0457233404158615e-05
. O 0 1.4657850442745257e-05

We O 0 9.909600748869707e-07
have O 0 6.318299483609735e-08
studied O 0 2.408742147963494e-07
the O 0 9.255742128289057e-08
codon O 0 4.612787506630411e-06
282 O 0 8.74631223268807e-05
( O 0 5.6107113778125495e-05
Cys O 1 0.9089446067810059
/ O 0 0.2045487016439438
Tyr O 0 0.022222789004445076
) O 0 4.1000581063599384e-07
polymorphism O 0 4.805527282769617e-07
in O 0 2.0576900183755242e-08
different O 0 1.657005732624839e-08
ethnic O 0 5.519829073818983e-07
groups O 0 2.518794872230501e-06
. O 0 1.955870357051026e-05

In O 0 2.3734414753562305e-06
agreement O 0 1.6048819588831975e-06
with O 0 2.7650571610138286e-07
previous O 0 6.509582703984051e-07
observations O 0 1.0562382612988586e-06
the O 0 2.341467506994377e-06
Tyr O 0 0.18449856340885162
allele O 0 2.5300199922639877e-05
appeared O 0 1.1120716862933477e-06
to O 0 3.9033427157164624e-08
be O 0 3.0334970091416835e-08
rare O 0 5.106807748234132e-06
or O 0 5.730782390855893e-07
absent O 0 1.453374443372013e-05
in O 0 6.493152113762335e-07
Asiatic O 0 0.0007624842110089958
( O 0 1.5680145679652924e-06
Indian O 0 9.011124575408758e-07
, O 0 1.6792655799235945e-07
Chinese O 0 1.0424782885820605e-06
) O 0 2.9671086849702988e-06
populations O 0 7.685658601985779e-06
. O 0 6.424439106922364e-06

The O 0 1.895775881166628e-06
highest O 0 4.233353138261009e-06
allele O 0 2.5773165361897554e-06
frequency O 0 4.1168667053170793e-07
( O 0 4.71448572625377e-07
7 O 0 2.1966278040963516e-07
. O 0 2.284080835579516e-08
5 O 0 1.2902182788820937e-07
% O 0 9.52995407033086e-08
) O 0 8.998014067174154e-08
was O 0 7.358379150446126e-08
found O 0 1.781166929504252e-07
in O 0 3.7324258528315113e-07
Swedes O 0 5.476802107295953e-05
. O 0 1.1642806384770665e-05

Saamis O 0 0.0023977640084922314
( O 0 1.5032803275971673e-05
2 O 0 4.380185146146687e-06
% O 0 6.918030521774199e-07
) O 0 3.423296845994628e-07
and O 0 1.2846525976328849e-07
Mordvinians O 0 7.393192208837718e-05
( O 0 1.6545179448712588e-07
1 O 0 5.135536795819462e-08
. O 0 7.626222320311626e-09
8 O 0 6.753857206831526e-08
% O 0 4.620504867602904e-08
) O 0 4.264922282004591e-08
had O 0 2.0185566995678528e-08
significantly O 0 1.8588197292501718e-07
lower O 0 4.4325595638383675e-08
frequencies O 0 6.737579383297998e-09
of O 0 1.251305725702423e-08
the O 0 9.396055133947812e-07
Tyr O 0 0.07140696793794632
allele O 0 7.97154862084426e-05
. O 0 1.1839231774501968e-05

Comparisons O 0 9.389790648128837e-06
with O 0 8.308408041557414e-07
allele O 0 3.82222788175568e-06
frequencies O 0 3.9831473941376316e-07
based O 0 3.588251331620995e-07
on O 0 9.565590062265983e-07
prevalence O 0 0.053890205919742584
estimates O 0 2.8906200896017253e-05
of O 0 4.221673862048192e-06
HH B-Disease 1 0.9979220032691956
showed O 0 3.861242930724984e-06
some O 0 2.489078632095243e-08
disagreements O 0 9.137652909885219e-07
with O 0 4.71785881472897e-08
the O 0 1.9062569833749876e-07
RFLP O 0 0.00035641039721667767
data O 0 5.155765165909543e-07
, O 0 2.3522390790731151e-07
particularly O 0 1.0854882930289023e-06
in O 0 6.923310706952179e-07
Finns O 0 9.618556214263663e-05
. O 0 1.7841055523604155e-05

The O 0 1.4828592611593194e-05
newly O 0 0.00011433805775595829
described O 0 0.0005845874547958374
HFE O 1 0.8771814107894897
marker O 0 8.037559746298939e-05
provides O 0 1.3248004506749567e-06
a O 0 1.0894473945199934e-07
new O 0 7.698567827674196e-08
approach O 0 5.338097253115848e-08
to O 0 5.883888931634829e-09
the O 0 3.6058178665143714e-08
screening O 0 2.626122750370996e-06
of O 0 7.101673418219434e-07
HH B-Disease 1 0.9937532544136047
as O 0 8.882521740360971e-08
well O 0 1.9022792230316554e-08
as O 0 7.414151070861408e-09
studies O 0 1.0465645239321475e-08
of O 0 3.809278226185597e-09
the O 0 3.7927357254829985e-08
relationship O 0 1.20896254429681e-06
between O 0 9.219338039656577e-07
the O 0 1.064599200617522e-05
HFE O 1 0.9873886108398438
Tyr O 1 0.6470093131065369
allele O 0 8.221859025070444e-05
and O 0 7.164774615375791e-06
different O 0 5.453142148326151e-05
disorders O 1 0.9984989166259766
including O 0 0.24637390673160553
cancer B-Disease 1 0.9972430467605591

Autosomal B-Disease 1 0.9839457869529724
dominant I-Disease 1 0.9875625371932983
neurohypophyseal I-Disease 1 0.9973357319831848
diabetes I-Disease 1 0.9996139407157898
insipidus I-Disease 1 0.9976441264152527
associated O 0 0.00014752289280295372
with O 0 1.8004170669883024e-06
a O 0 5.892488843528554e-06
missense O 0 0.000293706136289984
mutation O 0 2.942266655736603e-05
encoding O 0 3.301048855064437e-05
Gly23 O 0 0.4598380923271179
- O 1 0.6021196246147156
- O 0 0.26440098881721497
> O 0 0.10449280589818954
Val O 0 0.01509579923003912
in O 0 1.9746701582334936e-05
neurophysin O 0 0.10128174722194672
II O 0 0.30800315737724304
. O 0 8.608984353486449e-05

Autosomal B-Disease 1 0.9805164933204651
dominant I-Disease 1 0.9803003072738647
neurohypophyseal I-Disease 1 0.9957088232040405
diabetes I-Disease 1 0.9994440674781799
insipidus I-Disease 1 0.9978612065315247
( O 0 0.017354948446154594
ADNDI B-Disease 1 0.9721803665161133
) O 0 0.0001964501425391063
is O 0 0.00022327325132209808
an O 0 0.11128628253936768
inherited B-Disease 1 0.9997509121894836
disease I-Disease 1 0.9999020099639893
caused O 1 0.9735926985740662
by O 0 0.00020301580661907792
progressive O 1 0.8951159715652466
degeneration O 1 0.9991782307624817
of O 0 1.2573677850014064e-06
the O 0 5.1865849854948465e-06
magnocellular O 0 0.1365312784910202
neurons O 0 9.358554052596446e-06
of O 0 3.239084733763775e-08
the O 0 4.433362903455418e-07
hypothalamus O 0 7.10672393324785e-05
leading O 0 2.5329347863589646e-06
to O 0 1.566022405086187e-07
decreased O 0 1.8122729670722038e-05
ability O 0 1.3026313183672755e-07
to O 0 1.014370809571119e-08
produce O 0 8.385328698068406e-08
the O 0 2.143787583008816e-07
hormone O 0 5.450443859444931e-05
arginine O 0 5.329102714313194e-05
vasopressin O 0 0.00043865208863280714
( O 0 3.641472721938044e-05
AVP O 0 0.030588746070861816
) O 0 1.3326809494174086e-05
. O 0 1.6737696569180116e-05

Affected O 0 0.0009702991810627282
individuals O 0 5.505747139977757e-06
are O 0 3.8617110931227216e-07
not O 0 1.90135438060679e-06
symptomatic O 0 0.4347682595252991
at O 0 2.04397838388104e-05
birth O 0 0.00014987756730988622
, O 0 2.279160298712668e-06
but O 0 2.0883799152215943e-06
usually O 0 0.00010298479901393875
develop O 1 0.9290768504142761
diabetes B-Disease 1 0.9997468590736389
insipidus I-Disease 1 0.996898889541626
at O 0 1.286210408579791e-05
1 O 0 2.6659961804398336e-05
- O 0 0.0010564030380919576
6 O 0 4.5544431486632675e-05
yr O 0 0.005652822554111481
of O 0 5.788693897557096e-07
age O 0 6.0450114688137546e-05
. O 0 1.733640419843141e-05

The O 0 9.713236977404449e-06
genetic O 0 6.842150469310582e-05
locus O 0 4.017142055090517e-05
of O 0 1.9118876934953732e-06
the O 0 0.0002247579104732722
disease O 1 0.9965638518333435
is O 0 1.4948934676795034e-06
the O 0 5.010556833440205e-06
AVP O 1 0.5615110397338867
- O 0 0.06205064803361893
neurophysin O 0 0.06412889063358307
II O 0 0.07499700039625168
( O 0 2.5630251911934465e-05
NPII O 0 0.008936543948948383
) O 0 8.843343266562442e-07
gene O 0 1.10885764570412e-06
, O 0 7.19506871860176e-08
and O 0 9.42350908417211e-08
mutations O 0 8.990130481834058e-06
that O 0 5.396355504672101e-07
cause O 0 0.005659095477312803
ADNDI B-Disease 0 0.21755942702293396
have O 0 5.744249165218207e-08
been O 0 1.065918375786623e-08
found O 0 8.690319575066496e-09
in O 0 3.309608809232145e-09
both O 0 2.350725614164162e-09
the O 0 5.709663408737242e-09
signal O 0 7.253368039528141e-08
peptide O 0 1.0826137497588206e-07
of O 0 1.5147616494459726e-08
the O 0 4.907257107333862e-07
prepro O 0 0.009035667404532433
- O 0 0.014645951800048351
AVP O 0 0.21987728774547577
- O 0 0.006077757570892572
NPII O 0 0.007465825416147709
precursor O 0 1.8461842046235688e-05
and O 0 2.465651789407275e-07
within O 0 1.1578534895306802e-06
NPII O 0 0.03794712573289871
itself O 0 8.113427611533552e-05
. O 0 2.4899938580347225e-05

An O 0 3.597381873987615e-05
affected O 0 0.0004392255505081266
girl O 0 0.00030231435084715486
who O 0 1.1148962357765413e-06
presented O 0 1.4333758144857711e-06
at O 0 5.532825753107318e-07
9 O 0 1.3873305988454376e-06
months O 0 5.629003680951428e-07
of O 0 2.7962041571072405e-08
age O 0 7.704472409386653e-06
and O 0 4.7298425442932057e-07
her O 0 1.4783156075282022e-05
similarly O 0 0.000202658397029154
affected O 0 0.00012541163596324623
younger O 0 8.100594277493656e-05
brother O 0 2.377004966547247e-05
and O 0 1.519693597629157e-07
father O 0 6.023981313774129e-07
were O 0 6.47426601219081e-09
all O 0 2.872905247031099e-09
found O 0 1.4142202076072863e-08
to O 0 3.785449287363463e-09
have O 0 3.5183727042920054e-09
a O 0 3.780010970899639e-08
novel O 0 9.646306580179953e-07
missense O 0 2.7656958991428837e-05
mutation O 0 8.310687007906381e-06
( O 0 4.495901521295309e-06
G1758 O 0 0.0008920714026317
- O 0 0.014272311702370644
- O 0 0.009337770752608776
> O 0 0.003015947062522173
T O 0 0.0003758688399102539
) O 0 8.68533156506146e-09
encoding O 0 8.138411722313776e-09
the O 0 4.033311462592337e-09
amino O 0 5.1359972275122345e-08
acid O 0 1.5995203739294084e-06
substitution O 0 3.0382855129573727e-06
Gly23 O 0 0.004177742172032595
- O 0 0.007929369807243347
- O 0 0.0033306898549199104
> O 0 0.0054621645249426365
Val O 0 0.0006993995048105717
within O 0 3.3653268474154174e-06
NPII O 0 0.009708540514111519
. O 0 2.1479314455064014e-05

The O 0 1.2105419955332763e-05
mutation O 0 6.789159670006484e-05
was O 0 2.0525922082015313e-06
confirmed O 0 3.836646101262886e-06
by O 0 6.944702590772067e-07
restriction O 0 2.3112414055503905e-05
endonuclease O 0 0.0023721579927951097
analysis O 0 1.514079576736549e-05
. O 0 1.9073975636274554e-05

A O 0 0.00020565258455462754
T1 O 0 0.1660487800836563
- O 0 8.647951472084969e-05
weighted O 0 1.8473043610356399e-06
magnetic O 0 2.3485993096983293e-06
resonance O 0 6.155898518045433e-06
imaging O 0 1.2951946700923145e-05
of O 0 1.6133097346937575e-07
the O 0 2.628460379128228e-06
fathers O 0 0.0004782984033226967
pituitary O 1 0.9403732419013977
gland O 0 0.10455526411533356
demonstrates O 0 0.00017880670202430338
an O 0 1.2771521141985431e-05
attenuated O 0 0.12433846294879913
posterior O 0 0.4068531095981598
pituitary O 1 0.9581450819969177
bright O 0 0.026797320693731308
spot O 0 0.00047148388694040477
. O 0 0.00010868362005567178

This O 0 1.1746426935133059e-05
mutation O 0 0.0002471939951647073
may O 0 2.702746087379637e-06
be O 0 2.242138386066017e-08
valuable O 0 8.120675687450785e-08
for O 0 6.684244624466373e-08
developing O 0 3.584968453651527e-06
models O 0 4.20750939156278e-06
of O 0 6.943676453374792e-06
dominantly B-Disease 1 0.9947688579559326
inherited I-Disease 1 0.9991482496261597
neurodegeneration I-Disease 1 0.9995790123939514
, O 0 2.3181405595096294e-06
as O 0 6.925596096607478e-08
the O 0 5.861433649556602e-08
early O 0 7.392619636448217e-07
age O 0 9.543352462060284e-06
of O 0 1.7263809013456921e-06
onset O 1 0.9991456270217896
of O 0 0.0007969129364937544
symptoms O 1 0.9995670914649963
suggests O 0 0.0007078669150359929
that O 0 3.383375428711588e-07
this O 0 8.113923399832856e-07
mutation O 0 9.338348172605038e-05
may O 0 1.2473142305680085e-06
be O 0 2.0133274603040263e-08
particularly O 0 4.6885071469660033e-07
deleterious O 0 7.69271809986094e-06
to O 0 7.609732932678526e-08
the O 0 1.2125292414566502e-06
magnocellular O 0 0.2703230381011963
neuron O 0 0.06847575306892395
. O 0 8.752536814427003e-06
. O 0 1.7095409930334426e-05

Frequent O 0 0.0009373667999170721
inactivation O 0 0.012149447575211525
of O 0 8.144263847498223e-05
PTEN O 1 0.9880207180976868
/ O 1 0.9883125424385071
MMAC1 O 1 0.9764997959136963
in O 0 0.006289082113653421
primary O 1 0.9851367473602295
prostate B-Disease 1 0.999464213848114
cancer I-Disease 1 0.998663067817688
. O 0 0.0068930573761463165

Sporadic B-Disease 1 0.987082839012146
prostate I-Disease 1 0.9992972612380981
carcinoma I-Disease 1 0.9994483590126038
is O 0 1.33624180307379e-05
the O 0 3.1243355351762148e-06
most O 0 4.7103608267207164e-06
common O 0 0.001416725805029273
male B-Disease 0 0.08517620712518692
cancer I-Disease 1 0.9978935122489929
in O 0 1.1933710766243166e-06
the O 0 5.271913323667832e-07
Western O 0 4.440578777575865e-06
world O 0 1.9273643374617677e-06
, O 0 4.266443554001853e-08
yet O 0 1.1431775526205001e-08
many O 0 1.2712527697189557e-09
of O 0 2.686677325058895e-09
the O 0 6.274668606920386e-08
major O 0 2.441500100758276e-06
genetic O 0 5.031420187151525e-06
events O 0 7.59408820272256e-08
involved O 0 1.5814553933068964e-07
in O 0 6.735461965945433e-08
the O 0 2.336053768203783e-07
progression O 0 0.00032924683182500303
of O 0 3.7854226775380084e-07
this O 0 1.8519152945373207e-05
often O 0 0.005368118640035391
fatal O 1 0.9994552731513977
cancer B-Disease 1 0.9994741082191467
remain O 0 1.5820203770999797e-05
to O 0 9.157429872175271e-07
be O 0 1.14172496523679e-06
elucidated O 0 0.0011164048919454217
. O 0 2.9763403290417045e-05

Numerous O 0 0.00010342391033191234
cytogenetic O 0 0.015922849997878075
and O 0 1.7874619516078383e-05
allelotype O 0 0.032330222427845
studies O 0 1.432784029020695e-05
have O 0 9.58244527282659e-07
reported O 0 2.4573362679802813e-05
frequent O 0 2.4035745809669606e-05
loss O 0 0.00017187249613925815
of O 0 8.883163218342816e-07
heterozygosity O 0 0.027420267462730408
on O 0 1.4103506146057043e-05
chromosomal O 0 0.2691832482814789
arm O 1 0.6192181706428528
10q O 0 0.49327683448791504
in O 0 0.0031325938180088997
sporadic B-Disease 1 0.9941989183425903
prostate I-Disease 1 0.9996248483657837
cancer I-Disease 1 0.99885094165802
. O 0 0.00471788365393877

Deletion O 0 0.0011497818632051349
mapping O 0 8.565035386709496e-05
studies O 0 1.141296888818033e-05
have O 0 4.1578223886062915e-07
unambiguously O 0 2.4307471903739497e-05
identified O 0 6.909452849868103e-07
a O 0 2.786004813515319e-07
region O 0 4.065331040692399e-07
of O 0 7.267091461926611e-08
chromosome O 0 0.00010794306581374258
10q23 O 0 0.00011102329881396145
to O 0 2.5139893722325724e-08
be O 0 7.727781969890657e-09
the O 0 3.757554267735941e-08
minimal O 0 3.378598194103688e-06
area O 0 4.1771613723540213e-07
of O 0 8.373315836252004e-07
loss O 0 0.004182404838502407
. O 0 4.6255841880338266e-05

A O 0 6.056395795894787e-05
new O 0 0.0001824561768444255
tumor B-Disease 1 0.9577364921569824
suppressor O 0 0.018201343715190887
gene O 0 0.00016625740681774914
, O 0 9.71741319517605e-05
PTEN O 1 0.9827806949615479
/ O 1 0.7362111210823059
MMAC1 O 1 0.6001719236373901
, O 0 2.0659681467805058e-06
was O 0 8.996449878395651e-07
isolated O 0 1.2445821084838826e-05
recently O 0 1.9044103964915848e-06
at O 0 4.726668123566924e-08
this O 0 1.2687994654925205e-08
region O 0 1.0651323378851885e-07
of O 0 2.9308997895327593e-08
chromosome O 0 3.633362575783394e-05
10q23 O 0 9.526872599963099e-05
and O 0 5.0464375789260885e-08
found O 0 3.0784423898921887e-08
to O 0 6.921513140412117e-09
be O 0 1.0783678838777178e-08
inactivated O 0 2.152271690647467e-06
by O 0 6.307836031282932e-08
mutation O 0 1.1389352948754095e-05
in O 0 9.548431989969686e-06
three O 0 0.017247352749109268
prostate B-Disease 1 0.9998363256454468
cancer I-Disease 1 0.9996390342712402
cell O 0 0.4205816388130188
lines O 0 0.0017338580219075084
. O 0 0.00012495207192841917

We O 0 7.602355617564172e-05
screened O 0 0.003801222424954176
80 O 0 0.2939768135547638
prostate B-Disease 1 0.9992867112159729
tumors I-Disease 1 0.9984948635101318
by O 0 5.91186244491837e-06
microsatellite O 0 0.019185304641723633
analysis O 0 2.0132792997173965e-06
and O 0 2.5933772462849447e-07
found O 0 5.209807909523079e-07
chromosome O 0 2.8458114684326574e-05
10q23 O 0 4.858782631345093e-05
to O 0 4.404201092711446e-08
be O 0 2.347348626585699e-08
deleted O 0 2.935392103609047e-06
in O 0 3.5659923014463857e-07
23 O 0 1.4755661140952725e-05
cases O 0 4.653408905141987e-05
. O 0 1.7541393390274607e-05

We O 0 9.345446869701846e-07
then O 0 2.171311876963955e-07
proceeded O 0 2.0111825449475873e-07
with O 0 1.4458451325083388e-08
sequence O 0 3.218914557123753e-08
analysis O 0 2.6942377218119873e-08
of O 0 1.5954336518575474e-08
the O 0 3.0976025300333276e-07
entire O 0 8.632412937004119e-05
PTEN O 1 0.8993212580680847
/ O 0 0.17237946391105652
MMAC1 O 0 0.0649469867348671
coding O 0 0.0001434532750863582
region O 0 1.5351075717262574e-06
and O 0 7.794889711476571e-08
tested O 0 1.0699473023123574e-06
for O 0 3.661246594788281e-08
homozygous O 0 2.4882444904505974e-06
deletion O 0 1.7456819477956742e-05
with O 0 3.840687838874146e-07
new O 0 4.19827028963482e-06
intragenic O 0 0.006220219191163778
markers O 0 1.4044260751688853e-05
in O 0 6.16393620589406e-08
these O 0 2.921044028880715e-08
23 O 0 2.8968258902750676e-06
cases O 0 2.309173396497499e-06
with O 0 1.9370716017874656e-06
10q23 O 0 0.00987025536596775
loss O 0 0.0009508885559625924
of O 0 9.017855518322904e-06
heterozygosity O 0 0.4542425274848938
. O 0 0.00012093494297005236

The O 0 7.544927598246431e-07
identification O 0 3.119379812233092e-07
of O 0 5.760871957249947e-08
the O 0 8.95758489605214e-08
second O 0 6.327489359136962e-07
mutational O 0 0.0004518992791417986
event O 0 1.2722692872557673e-06
in O 0 9.551226298754045e-08
10 O 0 3.521517442095501e-07
( O 0 8.615943443146534e-07
43 O 0 2.338144895475125e-06
% O 0 2.4960304472188e-06
) O 0 5.156499537406489e-05
tumors B-Disease 1 0.9933280944824219
establishes O 0 0.011171998456120491
PTEN O 1 0.9767453074455261
/ O 0 0.10356582701206207
MMAC1 O 0 0.001896374742500484
as O 0 3.789893909811326e-08
a O 0 9.04243648847114e-08
main O 0 5.791808348476479e-07
inactivation O 0 0.0001108872311306186
target O 0 2.3796010850674065e-07
of O 0 4.2920643750221643e-07
10q O 0 0.010426739230751991
loss O 0 0.10439902544021606
in O 0 0.0006708420114591718
sporadic B-Disease 1 0.9964225888252258
prostate I-Disease 1 0.9997909665107727
cancer I-Disease 1 0.9994547963142395
. O 0 0.00021221995120868087
. O 0 0.00018884445307776332

Risk O 0 0.020543767139315605
reversals O 0 0.0016712092328816652
in O 0 1.8068370991386473e-05
predictive O 0 0.001833712449297309
testing O 0 0.016619522124528885
for O 0 0.07907278090715408
Huntington B-Disease 1 0.9987683892250061
disease I-Disease 1 0.9988119602203369
. O 0 0.004292774945497513

The O 0 1.5408996887344983e-06
first O 0 1.3771999647360644e-06
predictive O 0 0.00010350373486289755
testing O 0 0.0008949468610808253
for O 0 0.012073527090251446
Huntington B-Disease 1 0.9997149109840393
disease I-Disease 1 0.9997162222862244
( O 0 0.00024196068989112973
HD B-Disease 0 0.0028504233341664076
) O 0 2.445950997298496e-07
was O 0 1.2570349205986986e-08
based O 0 7.259246981305978e-09
on O 0 4.079220516928217e-09
analysis O 0 1.5141580433919444e-08
of O 0 1.5976871381440105e-08
linked O 0 9.609509106667247e-06
polymorphic O 0 6.443169695558026e-05
DNA O 0 5.796080131403869e-06
markers O 0 1.100430017686449e-05
to O 0 3.192512565419747e-08
estimate O 0 4.037809162582562e-07
the O 0 3.491807021305249e-08
likelihood O 0 1.5332597058659303e-06
of O 0 3.992349917325555e-08
inheriting O 0 0.0001427837705705315
the O 0 6.044716087671986e-07
mutation O 0 1.1699908100126777e-05
for O 0 2.0536085685307626e-06
HD B-Disease 0 0.0037537480238825083
. O 0 2.6065334168379195e-05

Limits O 0 3.4070033052557847e-06
to O 0 1.733453700580867e-07
accuracy O 0 3.19299743978263e-07
included O 0 1.284270467749593e-07
recombination O 0 8.833463880364434e-07
between O 0 7.964383286207521e-08
the O 0 1.2537979898752383e-07
DNA O 0 3.4454517390258843e-06
markers O 0 6.448944077419583e-06
and O 0 4.4280216826564356e-08
the O 0 1.7884245551158529e-07
mutation O 0 1.2087518371117767e-05
, O 0 6.668543051091547e-07
pedigree O 0 0.00031269033206626773
structure O 0 2.639422518768697e-06
, O 0 6.552259179670727e-08
and O 0 1.4448884755324798e-08
whether O 0 3.7592464252611535e-08
DNA O 0 3.49945509015015e-07
samples O 0 8.420428088129484e-08
were O 0 7.505382981776165e-09
available O 0 3.960510852607513e-08
from O 0 1.2254513137577305e-07
family O 0 1.3876945104129845e-06
members O 0 7.186702077888185e-07
. O 0 1.0015000952989794e-05

With O 0 1.6120053487611585e-06
direct O 0 1.1335737326589879e-06
tests O 0 1.2019257837891928e-06
for O 0 8.766253500880339e-08
the O 0 8.070012995631259e-07
HD B-Disease 0 0.004660313483327627
mutation O 0 1.4911452126398217e-05
, O 0 6.162819943256181e-08
we O 0 8.141733509603455e-09
have O 0 3.4131562021144646e-09
assessed O 0 5.1508600051874964e-08
the O 0 1.9978452225899446e-09
accuracy O 0 1.1643646047332368e-08
of O 0 2.8932183315788507e-09
results O 0 4.616831361659024e-08
obtained O 0 1.668082205696919e-08
by O 0 1.99916510013054e-08
linkage O 0 7.00371083439677e-06
approaches O 0 7.787836580064322e-07
when O 0 1.8360428555297403e-07
requested O 0 3.194261353201e-07
to O 0 1.3058908621133014e-08
do O 0 2.1263922178604844e-08
so O 0 9.969240544194236e-09
by O 0 1.4002096371257267e-08
the O 0 9.268214284929854e-08
test O 0 2.682309059309773e-06
individuals O 0 2.5212991658918327e-06
. O 0 1.62725082191173e-05

For O 0 4.808952326129656e-06
six O 0 3.3909841476997826e-06
such O 0 1.1332689382470562e-06
individuals O 0 1.26854376958363e-06
, O 0 4.993261200070265e-07
there O 0 1.572837078356315e-07
was O 0 3.447051426519465e-07
significant O 0 7.976938150022761e-07
disparity O 0 0.00020021706586703658
between O 0 4.904917432213551e-07
the O 0 1.770422841218533e-06
tests O 0 3.666355041787028e-05
. O 0 1.4975795238569845e-05

Three O 0 1.0176156592933694e-06
went O 0 2.5204674329870613e-06
from O 0 1.216014879901195e-06
a O 0 2.5269144316553138e-05
decreased O 0 0.01052026730030775
risk O 0 0.00020628927450161427
to O 0 6.800716789712169e-08
an O 0 6.347979137899529e-07
increased O 0 7.87767130532302e-05
risk O 0 0.00036520505091175437
, O 0 4.470060233074946e-08
while O 0 1.0122120031041959e-08
in O 0 1.0411767448204046e-08
another O 0 2.9172579019132172e-08
three O 0 5.827901006227876e-08
the O 0 2.384733761573443e-06
risk O 0 0.005028265994042158
was O 0 1.1470364370325115e-05
decreased O 0 0.0005064812139607966
. O 0 1.609569699212443e-05

Knowledge O 0 3.2497337087988853e-06
of O 0 3.6732708963427285e-07
the O 0 6.791694318053487e-07
potential O 0 8.041296496230643e-06
reasons O 0 4.593572100475285e-07
for O 0 4.963691324633146e-08
these O 0 3.087975031235146e-08
changes O 0 4.82230234410963e-07
in O 0 8.775437976282774e-08
results O 0 4.0227652675639547e-07
and O 0 4.9871978546889295e-08
impact O 0 6.340597451526264e-07
of O 0 3.7340917913297744e-08
these O 0 5.007701133763476e-07
risk O 0 0.0024360313545912504
reversals O 0 0.0003188994014635682
on O 0 6.952568583074026e-07
both O 0 1.4008340940563357e-06
patients O 0 0.003979576285928488
and O 0 1.1507164998647568e-07
the O 0 2.3102431612187502e-07
counseling O 0 5.0034428568324074e-05
team O 0 1.7057848822332744e-07
can O 0 1.414543948641267e-08
assist O 0 3.8325424611684866e-08
in O 0 5.257420276905123e-09
the O 0 5.161902016936892e-09
development O 0 4.748055459913303e-08
of O 0 1.006972372152859e-08
strategies O 0 2.364407009736169e-06
for O 0 9.133787415294137e-08
the O 0 1.378211663904949e-06
prevention O 0 0.007898097857832909
and O 0 1.7135656094069418e-07
, O 0 9.561142633174313e-08
where O 0 4.1151700713726314e-08
necessary O 0 1.2775103641615715e-07
, O 0 8.58806217252095e-08
management O 0 8.914275326787902e-07
of O 0 2.3797298354111263e-08
a O 0 3.792674533542595e-06
risk O 0 0.0008531883941031992
reversal O 0 3.70029010809958e-05
in O 0 5.329470553760984e-08
any O 0 1.0500219360665142e-07
predictive O 0 9.127225894189905e-06
testing O 0 1.470454390073428e-05
program O 0 7.161112534959102e-06
. O 0 7.489575750696531e-07
. O 0 4.564359187497757e-06

A O 0 2.5398903744644485e-05
novel O 0 2.195705019403249e-05
common O 0 1.8631071725394577e-05
missense O 0 0.00041608494939282537
mutation O 0 4.508138226810843e-05
G301C O 0 7.307002670131624e-05
in O 0 2.0264424449578655e-07
the O 0 4.276105869394087e-07
N O 0 0.00016947487893048674
- O 0 0.0004247110919095576
acetylgalactosamine O 0 0.0023186334874480963
- O 0 0.00039418143569491804
6 O 0 5.1653343689395115e-05
- O 0 0.005080489907413721
sulfate O 0 0.02670367807149887
sulfatase O 0 0.2431027889251709
gene O 0 4.368668305687606e-05
in O 0 1.3295707503857557e-05
mucopolysaccharidosis B-Disease 0 0.3919250965118408
IVA I-Disease 1 0.9809771180152893
. O 0 0.00026562027051113546

Mucopolysaccharidosis B-Disease 1 0.5950953364372253
IVA I-Disease 1 0.9753274321556091
( O 0 0.0035837609320878983
MPS B-Disease 0 0.2856132388114929
IVA I-Disease 1 0.9961870312690735
) O 0 3.64335865015164e-05
is O 0 5.200349278311478e-06
an O 0 6.393764488166198e-05
autosomal B-Disease 1 0.9953123331069946
recessive I-Disease 1 0.9988055229187012
lysosomal I-Disease 1 0.9994476437568665
storage I-Disease 1 0.9993314743041992
disorder I-Disease 1 0.9998051524162292
caused O 1 0.7988054752349854
by O 0 2.1447647668537684e-05
a O 0 0.0005286046070978045
genetic B-Disease 1 0.8836742043495178
defect I-Disease 1 0.9916298985481262
in O 0 1.8535198250901885e-05
N O 0 0.00788835622370243
- O 0 0.019638096913695335
acetylgalactosamine O 0 0.018742168322205544
- O 0 0.001486288383603096
6 O 0 0.00013862052583135664
- O 0 0.017485767602920532
sulfate O 0 0.2357833981513977
sulfatase O 1 0.8425009250640869
( O 0 6.642444350291044e-05
GALNS O 0 0.0377771332859993
) O 0 1.4385604117705952e-05
. O 0 1.0237236892862711e-05

In O 0 5.2562572818715125e-06
previous O 0 1.131079170590965e-05
studies O 0 7.312805792025756e-06
, O 0 3.879007124396594e-07
we O 0 2.492618200733432e-08
have O 0 9.382649324152226e-09
found O 0 2.014237665548535e-08
two O 0 1.1407837341437244e-08
common O 0 1.2874752428615466e-06
mutations O 0 6.615394795517204e-06
in O 0 5.141476435710501e-07
Caucasians O 0 0.00022628479928243905
and O 0 5.942596317254356e-07
Japanese O 0 2.1465879399329424e-05
, O 0 2.627002004373935e-06
respectively O 0 1.4026605640538037e-05
. O 0 1.1969640581810381e-05

To O 0 5.748792773374589e-06
characterize O 0 0.0001267370389541611
the O 0 2.108850139848073e-06
mutational O 0 0.0021278790663927794
spectrum O 0 8.238679583882913e-06
in O 0 6.741939984067358e-08
various O 0 3.044812402208663e-08
ethnic O 0 1.8099477472333092e-07
groups O 0 1.311445174678738e-07
, O 0 1.409475913760616e-07
mutations O 0 8.991406730274321e-07
in O 0 3.08167322771169e-08
the O 0 2.0379076204335433e-07
GALNS O 0 0.0010872827842831612
gene O 0 3.29379940922081e-06
in O 0 8.721489166418905e-07
Colombian O 0 0.00010726779873948544
MPS B-Disease 1 0.6325895190238953
IVA I-Disease 1 0.9994041919708252
patients O 0 0.3881590664386749
were O 0 3.890432367370522e-07
investigated O 0 2.863463305402547e-05
, O 0 3.9755042280376074e-07
and O 0 1.8854396444112353e-07
genetic O 0 1.7250644305022433e-05
backgrounds O 0 1.1725984450094984e-06
were O 0 1.8035546389683077e-08
extensively O 0 5.410557832874474e-07
analyzed O 0 2.792127702377911e-07
to O 0 1.5399486130718287e-08
identify O 0 1.8312427130240394e-07
racial O 0 7.928821901259653e-07
origin O 0 3.3856796477493845e-08
, O 0 1.0944600781215286e-08
based O 0 1.221995304945267e-08
on O 0 1.3951977351212008e-08
mitochondrial O 0 1.9632689145510085e-06
DNA O 0 3.972793820139486e-06
( O 0 2.1991022549627814e-06
mtDNA O 0 6.041481356078293e-06
) O 0 1.595270077814348e-06
lineages O 0 1.4342468602990266e-05
. O 0 1.0598430890240707e-05

Three O 0 1.085313760995632e-05
novel O 0 0.00020598933042492718
missense O 0 0.009787905029952526
mutations O 0 0.0004232503997627646
never O 0 1.2352796147752088e-05
identified O 0 3.722568408193183e-06
previously O 0 1.290216118832177e-06
in O 0 1.0834193631126254e-07
other O 0 8.912764570823128e-08
populations O 0 1.314503379035159e-06
and O 0 1.6658914248068868e-08
found O 0 1.366879232023166e-08
in O 0 9.194330630180048e-09
16 O 0 3.40044792324079e-08
out O 0 6.1644400695115564e-09
of O 0 1.1616672956904495e-08
19 O 0 1.0217981980531476e-06
Colombian O 0 4.152154360781424e-06
MPS B-Disease 0 0.0004887612885795534
IVA I-Disease 1 0.9824656248092651
unrelated O 0 8.02827489678748e-05
alleles O 0 7.081667263264535e-06
account O 0 1.1037543572456343e-06
for O 0 1.5064298395373044e-06
84 O 0 0.0003462029271759093
. O 0 2.88573373836698e-05

2 O 0 4.291141522116959e-06
% O 0 2.562796623806207e-07
of O 0 4.3355978363024406e-08
the O 0 2.6955669341077737e-07
alleles O 0 2.957494871225208e-06
in O 0 2.925472131209972e-07
this O 0 5.046197202318581e-07
study O 0 2.1499048671103083e-05
. O 0 1.92995103134308e-05

The O 0 4.278792766854167e-05
G301C O 0 0.0010657324455678463
and O 0 1.1364897545718122e-05
S162F O 0 0.0011763256043195724
mutations O 0 3.752298653125763e-05
account O 0 2.1921944153291406e-06
for O 0 2.0246548046998214e-06
68 O 0 0.0004477541951928288
. O 0 6.645054963883013e-05

4 O 0 4.393342896946706e-05
% O 0 9.908457286655903e-06
and O 0 4.342291049397318e-06
10 O 0 1.5347548469435424e-05
. O 0 3.038760223716963e-05

5 O 0 1.4960037333366927e-05
% O 0 1.4653662674390944e-06
of O 0 3.531317247507104e-07
mutations O 0 2.1997833755449392e-05
, O 0 4.4413440036805696e-07
respectively O 0 7.287738412742328e-07
, O 0 5.4902827173464175e-08
whereas O 0 1.3854263158918911e-07
the O 0 2.237455909437358e-08
remaining O 0 3.275429207860725e-07
F69V O 0 0.003057986730709672
is O 0 5.179647288855449e-08
limited O 0 6.453839063169653e-08
to O 0 1.1240382846722241e-08
a O 0 1.5790801910497976e-07
single O 0 1.3612058182843612e-06
allele O 0 3.1596322514815256e-05
. O 0 1.380484172841534e-05

The O 0 1.1711506886058487e-05
skewed O 0 0.0003599100455176085
prevalence O 0 0.0034730250481516123
of O 0 4.947792717757693e-07
G301C O 0 0.00046578189358115196
in O 0 4.067716190547799e-07
only O 0 2.2731380511231691e-07
Colombian O 0 2.759651943051722e-05
patients O 0 0.0005382810486480594
and O 0 1.438040442280908e-07
haplotype O 0 7.384870696114376e-05
analysis O 0 8.220506941825079e-08
by O 0 3.391968661503597e-08
restriction O 0 7.578387339890469e-07
fragment O 0 2.871066271836753e-06
length O 0 8.746911248636025e-07
polymorphisms O 0 1.4149156868370483e-06
in O 0 3.800875703063866e-08
the O 0 1.7287948139710352e-07
GALNS O 0 0.010273134335875511
gene O 0 6.492820830317214e-06
suggest O 0 9.552115898259217e-07
that O 0 1.3456060798944236e-07
G301C O 0 7.163018017308787e-05
originated O 0 1.0158278200833593e-06
from O 0 1.5378506645902235e-07
a O 0 1.4265939398683258e-06
common O 0 1.0170308087253943e-05
ancestor O 0 7.323074532905594e-05
. O 0 3.5389581171330065e-05

Investigation O 0 1.56965234054951e-05
of O 0 4.7423219484699075e-07
the O 0 8.25893835099123e-07
genetic O 0 2.151205080735963e-05
background O 0 1.2869473948740051e-06
by O 0 5.042666018084674e-08
means O 0 7.193202833377654e-08
of O 0 2.1595441879185273e-08
mtDNA O 0 3.981828740506899e-06
lineages O 0 4.115337560506305e-06
indicate O 0 1.2790333130396903e-06
that O 0 4.622770077844507e-08
all O 0 5.858315077489351e-08
our O 0 2.3423408492817543e-06
patients O 0 0.0006784470751881599
are O 0 2.265510801180426e-08
probably O 0 1.5837585465305892e-07
of O 0 3.9645165372803604e-08
native O 0 2.2248334516916657e-06
American O 0 1.2448669622244779e-05
descent O 0 0.00042162270983681083

Low O 0 1.974954648176208e-05
frequency O 0 2.800426500471076e-06
of O 0 2.80259587270848e-06
BRCA1 O 0 0.011483803391456604
germline O 0 0.006445872597396374
mutations O 0 0.00013770925579592586
in O 0 1.0220106560154818e-05
45 O 0 0.009072857908904552
German O 1 0.9941410422325134
breast B-Disease 1 0.9993922710418701
/ I-Disease 1 0.9993391633033752
ovarian I-Disease 1 0.9997739195823669
cancer I-Disease 1 0.9993663430213928
families O 0 0.007978836074471474
. O 0 0.000899661099538207

In O 0 2.346320343349362e-06
this O 0 4.516751914707129e-07
study O 0 1.4393536957868491e-06
we O 0 6.897648177073279e-07
investigated O 0 6.680699152639136e-05
45 O 0 0.0005868492880836129
German O 1 0.9651144742965698
breast B-Disease 1 0.999535083770752
/ I-Disease 1 0.9996308088302612
ovarian I-Disease 1 0.999919056892395
cancer I-Disease 1 0.9997385144233704
families O 0 4.669607733376324e-05
for O 0 8.305655683216173e-06
germline O 0 0.09792903810739517
mutations O 0 3.110683974227868e-05
in O 0 7.968649811118667e-07
the O 0 7.341749096667627e-06
BRCA1 O 0 0.14867064356803894
gene O 0 0.0003840252757072449
. O 0 5.689500176231377e-05

We O 0 1.6046891460064217e-06
identified O 0 1.170101768366294e-06
four O 0 7.07509343556012e-07
germline O 0 0.00146958336699754
mutations O 0 4.38218739873264e-05
in O 0 1.0715561074903235e-05
three O 0 0.002743635792285204
breast B-Disease 1 0.9997407793998718
cancer I-Disease 1 0.999496579170227
families O 0 3.6766283301403746e-05
and O 0 4.1724265429365914e-06
in O 0 7.100836228346452e-05
one O 0 0.032649096101522446
breast B-Disease 1 0.9997846484184265
- I-Disease 1 0.9998326301574707
ovarian I-Disease 1 0.9999634027481079
cancer I-Disease 1 0.9999266862869263
family O 0 0.0011971056228503585
. O 0 8.06071398073982e-07
among O 0 7.276245383991409e-08
these O 0 5.729583474334277e-09
were O 0 7.679089364387437e-09
one O 0 8.47511500978726e-08
frameshift O 0 0.0011875603813678026
mutation O 0 2.875938662327826e-06
, O 0 3.223055244916395e-08
one O 0 3.8227597087825416e-08
nonsense O 0 1.4070295037527103e-05
mutation O 0 1.0232844260826823e-06
, O 0 1.2595885223731784e-08
one O 0 1.1262530463795883e-08
novel O 0 4.021480322080606e-07
splice O 0 1.5779944078531116e-05
site O 0 1.602114139132027e-06
mutation O 0 3.0573733056371566e-06
, O 0 1.0800459193660572e-07
and O 0 1.1695981072534778e-07
one O 0 6.93394895279198e-07
missense O 0 0.0003525715146679431
mutation O 0 0.00013996948837302625
. O 0 4.22701814386528e-05

The O 0 1.9589111616369337e-05
missense O 0 0.002373108407482505
mutation O 0 0.00021755149646196514
was O 0 2.989487484228448e-06
also O 0 4.73604416129092e-07
found O 0 5.020755793339049e-07
in O 0 8.488216849400487e-07
2 O 0 2.4016409952309914e-05
. O 0 1.8663968148757704e-05

8 O 0 7.764766451145988e-06
% O 0 5.251740731182508e-07
of O 0 7.523243539253599e-08
the O 0 2.8324592449280317e-07
general O 0 4.383937721286202e-06
population O 0 1.1129394579256768e-06
, O 0 3.908692747245368e-07
suggesting O 0 5.050413165008649e-06
that O 0 1.4352974631037796e-07
it O 0 2.7506649757924606e-07
is O 0 5.5471718951594085e-06
not O 0 2.7266336473985575e-05
disease O 1 0.9978025555610657
associated O 0 0.0005221157916821539
. O 0 6.913910328876227e-05

The O 0 1.1587213521124795e-05
average O 0 0.0002319910126971081
age O 0 0.005334362853318453
of O 0 0.006576789543032646
disease O 1 0.9996943473815918
onset O 1 0.9991938471794128
in O 0 1.8380804249318317e-05
those O 0 1.086633164959494e-05
families O 0 0.0002055372897302732
harbouring O 1 0.9518285989761353
causative O 0 0.07834146916866302
mutations O 0 0.00012732416507788002
was O 0 1.8549180822446942e-06
between O 0 4.240533144184155e-06
32 O 0 5.614602196146734e-05
. O 0 2.2570506189367734e-05

3 O 0 8.179474389180541e-05
and O 0 1.2257076377863996e-05
37 O 0 0.00015389600594062358
. O 0 6.701589882140979e-05

4 O 0 1.690241515461821e-05
years O 0 4.431508386915084e-06
, O 0 6.269010555115528e-07
whereas O 0 1.4092059927861555e-06
the O 0 2.8661369810834003e-07
family O 0 6.014680820953799e-06
harbouring O 0 0.0010854849824681878
the O 0 7.896208558122453e-07
missense O 0 0.00019906731904484332
mutation O 0 8.04067440185463e-06
had O 0 8.399911877177146e-08
an O 0 6.203246982749988e-08
average O 0 2.7615360522759147e-06
age O 0 3.352705562065239e-06
of O 0 4.080841904396948e-07
onset O 1 0.780558168888092
of O 0 2.7130110993311973e-06
51 O 0 0.0004099612415302545
. O 0 2.6743486159830354e-05

2 O 0 0.0005033950437791646
years O 0 0.00047222382272593677
. O 0 0.00017919584934134036

These O 0 3.068306341447169e-06
findings O 0 1.0101415682584047e-05
show O 0 1.737417051117518e-06
that O 0 7.992868518158502e-07
BRCA1 O 0 0.0010432970011606812
is O 0 2.2652433528946858e-07
implicated O 0 6.4649543674022425e-06
in O 0 3.198119813418998e-08
a O 0 1.2195741305731644e-07
small O 0 6.798920253459073e-07
fraction O 0 2.6219353458145633e-05
of O 0 0.001986872870475054
breast B-Disease 1 0.9997445940971375
/ I-Disease 1 0.9997473359107971
ovarian I-Disease 1 0.9999421834945679
cancer I-Disease 1 0.9998334646224976
families O 0 9.048931678989902e-05
suggesting O 0 3.203938467777334e-05
the O 0 2.412926392025838e-07
involvement O 0 3.6993137655372266e-06
of O 0 2.806616237194248e-07
another O 0 2.178431168431416e-05
susceptibility O 0 0.039449501782655716
gene O 0 0.00032909243600443006
( O 0 0.0001498095371061936
s O 0 0.02382068708539009
) O 0 0.00016023199714254588

Paternal O 0 0.14678287506103516
transmission O 1 0.7474104166030884
of O 1 0.5834326148033142
congenital B-Disease 1 0.9988954067230225
myotonic I-Disease 1 0.9991286396980286
dystrophy I-Disease 1 0.9989197254180908
. O 0 0.42499715089797974

We O 0 1.5410483683808707e-05
report O 0 2.1620582629111595e-05
a O 0 6.428472261177376e-06
rare O 0 0.00019797569257207215
case O 0 8.503990829922259e-05
of O 0 0.00011318611359456554
paternally O 1 0.9930725693702698
transmitted O 1 0.9952327609062195
congenital B-Disease 1 0.9995065927505493
myotonic I-Disease 1 0.9992928504943848
dystrophy I-Disease 1 0.999616265296936
( O 1 0.9922780990600586
DM B-Disease 1 0.9988859295845032
) O 0 0.0018968268996104598
. O 0 0.00026883784448727965

The O 0 1.701105065876618e-05
proband O 0 0.0008013455662876368
is O 0 7.459814241883578e-07
a O 0 1.63142408382555e-06
23 O 0 1.4931929399608634e-05
year O 0 6.083717744331807e-05
old O 0 0.007330071646720171
, O 0 0.001988290809094906
mentally B-Disease 1 0.9974395036697388
retarded I-Disease 1 0.9962266683578491
male O 1 0.6426932215690613
who O 1 0.9281438589096069
suffers O 1 0.9992369413375854
severe O 1 0.9990635514259338
muscular B-Disease 1 0.9989392161369324
weakness I-Disease 1 0.9960177540779114
. O 0 0.014256661757826805

He O 0 0.0001176451551145874
presented O 0 0.0005896970396861434
with O 0 0.023762794211506844
respiratory O 1 0.9994351267814636
and O 0 0.00017525663133710623
feeding O 0 0.026875503361225128
difficulties O 0 0.060114335268735886
at O 0 0.00013807188952341676
birth O 0 0.004262926056981087
. O 0 0.00021009892225265503

His O 0 0.00013527327973861247
two O 0 0.0003419806307647377
sibs O 1 0.993556559085846
suffer O 1 0.9936226010322571
from O 0 0.009021729230880737
childhood O 1 0.9930834770202637
onset O 1 0.9980632662773132
DM B-Disease 1 0.9977053999900818
. O 0 0.010530228726565838

Their O 0 4.12505096392124e-06
late O 0 2.080837293760851e-05
father O 0 6.0057968767068814e-06
had O 0 3.427194030791725e-07
the O 0 1.9792882710589765e-07
adult O 0 5.52179517399054e-06
type O 0 0.00015495828120037913
of O 0 1.328887628915254e-05
DM B-Disease 1 0.9992929697036743
, O 0 6.970242338866228e-06
with O 0 1.055765551427612e-05
onset O 1 0.8915148377418518
around O 0 2.467658987370669e-06
30 O 0 6.442575795517769e-06
years O 0 1.4007476238475647e-05
. O 0 1.560738201078493e-05

Only O 0 8.567167810724641e-07
six O 0 1.1500662822072627e-06
other O 0 1.7117918105213903e-07
cases O 0 1.5140315099415602e-06
of O 0 2.670061292064929e-07
paternal O 0 0.0016398255247622728
transmission O 0 0.04816046729683876
of O 0 0.008040817454457283
congenital B-Disease 1 0.9998362064361572
DM I-Disease 1 0.9997137188911438
have O 0 2.392638270976022e-05
been O 0 6.3580282585462555e-06
reported O 0 0.00018626285600475967
recently O 0 0.00022154519683681428
. O 0 3.585838931030594e-05

We O 0 3.1060058063303586e-06
review O 0 4.334724053478567e-06
the O 0 1.3429951195575995e-06
sex O 0 2.9019471185165457e-05
related O 0 0.00013351444795262069
effects O 0 0.00047156683285720646
on O 0 8.989624802779872e-06
transmission O 0 0.11573602259159088
of O 0 0.00463875150308013
congenital B-Disease 1 0.9993852376937866
DM I-Disease 1 0.9986565113067627
. O 0 0.007458715699613094

Decreased O 0 0.006473961286246777
fertility O 0 0.000796297681517899
of O 0 7.321559110096132e-07
males O 0 2.9902896130806766e-05
with O 0 4.1287141357315704e-05
adult O 0 0.15040166676044464
onset O 1 0.9995461106300354
DM B-Disease 1 0.9996269941329956
and O 0 1.1158143024658784e-05
contraction O 0 0.001127514406107366
of O 0 7.215821540285106e-08
the O 0 4.6893478611309547e-07
repeat O 0 0.00017919568927027285
upon O 0 5.076849447505083e-07
male O 0 4.58222302768263e-06
transmission O 0 1.132582747231936e-05
contribute O 0 4.1800547023740364e-07
to O 0 1.008313876837974e-08
the O 0 2.069932136805619e-08
almost O 0 1.8485911823518109e-07
absent O 0 4.692041784437606e-06
occurrence O 0 2.967575710499659e-06
of O 0 2.2945305033772456e-07
paternal O 0 0.0006356753874570131
transmission O 0 0.02380773425102234
of O 0 0.0020263870246708393
congenital B-Disease 1 0.9992917776107788
DM I-Disease 1 0.9986306428909302
. O 0 0.005814471282064915

Also O 0 2.418216581645538e-06
the O 0 4.379494100703596e-07
fathers O 0 1.4559676628778107e-06
of O 0 2.9576600013569987e-07
the O 0 5.773053999291733e-06
reported O 0 0.0028821276500821114
congenitally O 1 0.6689189672470093
affected O 0 0.0001888642436824739
children O 0 4.439829808688955e-06
showed O 0 2.178052909584949e-06
, O 0 4.543061038475571e-08
on O 0 3.010918092627435e-08
average O 0 8.883425834937952e-07
, O 0 1.8939601886813762e-07
shorter O 0 3.8199777918634936e-05
CTG O 0 0.013499559834599495
repeat O 0 0.00017729100363794714
lengths O 0 8.217838330892846e-05
and O 0 2.81423558590177e-06
hence O 0 0.0002613901160657406
less O 0 0.015679148957133293
severe O 1 0.9995653033256531
clinical O 1 0.9989595413208008
symptoms O 1 0.9991795420646667
than O 0 3.972729700763011e-06
the O 0 8.068373062997125e-06
mothers O 0 0.00032945408020168543
of O 0 3.1606787160853855e-06
children O 0 0.0038396248128265142
with O 0 0.3709561824798584
congenital B-Disease 1 0.9995695948600769
DM I-Disease 1 0.999038815498352
. O 0 0.006850681267678738

We O 0 6.130081146693556e-06
conclude O 0 2.1979802113492042e-05
that O 0 1.0927996072496171e-06
paternal O 0 0.00031578412745147943
transmission O 0 0.007147812284529209
of O 0 0.005307858809828758
congenital B-Disease 1 0.9998637437820435
DM I-Disease 1 0.9998326301574707
is O 0 7.51308398321271e-05
rare O 0 0.00023117578530218452
and O 0 8.68385086505441e-07
preferentially O 0 1.4143735825200565e-05
occurs O 0 4.487064416025532e-06
with O 0 4.5268529902386945e-06
onset O 1 0.9265962243080139
of O 0 1.3329745343071409e-05
DM B-Disease 1 0.9987574815750122
past O 0 2.5334036308777286e-06
30 O 0 1.1603428902162705e-06
years O 0 7.689527024012932e-07
in O 0 1.815394767845646e-07
the O 0 4.951007213094272e-07
father O 0 1.257416806765832e-05
. O 0 1.8571980717752012e-06
. O 0 1.6330479411408305e-05

The O 0 0.00010439514880999923
RB1 O 1 0.888428270816803
gene O 0 0.00014139828272163868
mutation O 0 7.178499799920246e-05
in O 0 1.995878847083077e-06
a O 0 2.6435574909555726e-05
child O 0 0.005893825087696314
with O 0 0.005836592987179756
ectopic B-Disease 1 0.9940375089645386
intracranial I-Disease 1 0.9974167346954346
retinoblastoma I-Disease 1 0.9945958256721497
. O 0 0.002294049598276615

The O 0 9.927136125043035e-05
RB1 O 1 0.7952193021774292
gene O 0 0.00013719494745600969
mutation O 0 0.00016734177188482136
was O 0 2.5126432774413843e-06
investigated O 0 8.339919986610767e-06
in O 0 2.892657846587099e-07
a O 0 4.125798568566097e-06
child O 0 0.000495928165037185
with O 0 0.00022929148690309376
ectopic B-Disease 1 0.9977654218673706
intracranial I-Disease 1 0.9989864230155945
retinoblastoma I-Disease 0 0.15541495382785797
using O 0 2.961859593142435e-07
DNA O 0 1.247596173925558e-06
obtained O 0 8.187895872424633e-08
from O 0 5.757104304393579e-08
both O 0 1.0683184825666103e-07
the O 0 2.462616293996689e-06
pineal B-Disease 0 0.08722800016403198
and I-Disease 0 9.445172327104956e-05
retinal I-Disease 1 0.9983474016189575
tumours I-Disease 1 0.9976320266723633
of O 0 7.373210792138707e-06
the O 0 0.0001187381349154748
patient O 0 0.19329658150672913
. O 0 0.00010994143667630851

A O 0 2.79845353361452e-05
nonsense O 0 0.00012023915769532323
mutation O 0 7.557893241028069e-06
in O 0 3.3389804343642027e-07
exon O 0 3.333108907099813e-05
17 O 0 1.2870848422608105e-06
( O 0 4.5540099335994455e-07
codon O 0 9.254184760720818e-07
556 O 0 3.173563754899078e-06
) O 0 3.841266149606781e-08
of O 0 1.8972714954657022e-08
the O 0 8.75356988672138e-07
RB1 O 1 0.7006217837333679
gene O 0 4.711200745077804e-06
was O 0 1.2346657740636147e-07
found O 0 2.2708841029839277e-08
to O 0 4.622776828000497e-09
be O 0 3.7789993356796e-09
present O 0 8.128640871518655e-08
homozygously O 0 7.185566937550902e-05
in O 0 3.233510526001737e-08
both O 0 4.291335642392369e-08
the O 0 9.34318279632862e-07
retinal B-Disease 1 0.5801311135292053
and I-Disease 0 4.8342371883336455e-06
the I-Disease 0 8.387421985389665e-05
pineal I-Disease 1 0.9742491841316223
tumours I-Disease 1 0.9955602884292603
. O 0 0.0001615595247130841

The O 0 1.5290031569747953e-06
same O 0 9.351178960059769e-07
mutation O 0 1.0435552212584298e-05
was O 0 2.627395190302195e-07
present O 0 6.484723371613654e-07
heterozygously O 0 0.00013782513269688934
in O 0 2.6614831227789182e-08
the O 0 1.668947824384759e-08
DNA O 0 1.8561625836355233e-07
from O 0 1.1718798376136874e-08
the O 0 1.4081989796466132e-08
constitutional O 0 1.8703654802720848e-07
cells O 0 1.2498552450779243e-06
of O 0 2.526154929682889e-08
the O 0 1.538978835924354e-06
patient O 0 0.011616475880146027
, O 0 5.326056111698563e-07
proving O 0 4.077553057868499e-06
it O 0 5.612176057212537e-09
to O 0 3.5541611875800072e-09
be O 0 4.0196947992399146e-09
of O 0 7.35738296953059e-08
germline O 0 0.0003629403654485941
origin O 0 2.8674926397798117e-06
. O 0 1.9852932382491417e-05

The O 0 8.386787158087827e-06
initial O 0 5.0004142394755036e-05
mutation O 0 0.00010844468488357961
was O 0 1.2872076240455499e-06
shown O 0 2.9653784849870135e-07
to O 0 3.5595832059698296e-08
have O 0 2.111059949072569e-08
occurred O 0 2.855126695067156e-07
in O 0 5.110609890834894e-08
the O 0 3.445457252837514e-07
paternally O 0 0.0006417682743631303
derived O 0 3.4327102184761316e-05
RB1 O 1 0.6999735236167908
allele O 0 0.0001811449765227735
. O 0 2.969244451378472e-05

The O 0 1.0889850273088086e-05
mutation O 0 5.093668369227089e-05
is O 0 2.2387095555131964e-07
in O 0 6.06456680429801e-08
an O 0 2.2263707322167647e-08
area O 0 2.753362338125953e-08
of O 0 2.4386959118771756e-09
the O 0 9.097584907635792e-09
gene O 0 5.444004713694994e-08
that O 0 1.8548550473340697e-09
encodes O 0 2.385997355247582e-08
the O 0 8.81159500920603e-09
protein O 0 4.3778322833532e-07
- O 0 1.2751172107527964e-05
binding O 0 2.4125444042510935e-07
region O 0 5.172904593564454e-07
known O 0 1.2044647235143202e-07
as O 0 2.4090720529557075e-08
the O 0 1.2118768211166753e-07
pocket O 0 0.0005540746496990323
region O 0 7.191583222265763e-07
and O 0 4.695586142133834e-08
has O 0 1.2266919213743677e-07
been O 0 5.699655503121903e-08
detected O 0 1.5181188928181655e-06
in O 0 3.2993806797776415e-08
other O 0 5.975967809490612e-08
cases O 0 3.367728368175449e-06
of O 0 2.7114722342957975e-06
retinoblastoma B-Disease 1 0.9606913328170776
. O 0 1.485351640440058e-05
. O 0 2.2902549972059205e-05

Low O 0 5.325638267095201e-05
levels O 0 4.337287464295514e-06
of O 0 4.6532454689440783e-07
beta O 0 0.00019021262414753437
hexosaminidase O 0 0.0040939562022686005
A O 0 8.459451237285975e-06
in O 0 2.539007709856378e-06
healthy O 0 0.0008755557355470955
individuals O 0 6.693565410387237e-06
with O 0 0.0002725958183873445
apparent O 1 0.9830619096755981
deficiency O 1 0.9995070695877075
of O 0 2.7685978238878306e-06
this O 0 9.466974006500095e-06
enzyme O 0 0.0006522135226987302
. O 0 4.280490611563437e-05

Appreciable O 0 0.0007264331798069179
beta O 0 0.0003169492701999843
hexosaminidase O 0 0.002156487898901105
A O 0 1.1158100278407801e-05
( O 0 5.19114746566629e-06
hex O 0 1.9150636944686994e-05
A O 0 7.906697874204838e-07
) O 0 2.2457683712673315e-07
activity O 0 1.9644062376755755e-07
has O 0 7.768070275915306e-08
been O 0 3.9677239271895814e-08
detected O 0 3.982413545600139e-06
in O 0 1.5333035889852908e-06
cultured O 0 0.0034434227272868156
skin O 1 0.9948062300682068
fibroblasts O 0 0.27659568190574646
and O 0 0.005812120623886585
melanoma B-Disease 1 0.9997528195381165
tissue O 1 0.7306528091430664
from O 0 3.3633528801146895e-05
healthy O 0 0.0011094824876636267
individuals O 0 2.812403181451373e-06
previously O 0 9.906398190651089e-06
reported O 0 5.606994091067463e-05
as O 0 3.097250328210066e-06
having O 0 0.00015677233750466257
deficiency B-Disease 1 0.9957783222198486
of I-Disease 0 4.0975319137714905e-08
hex I-Disease 0 1.422441073373193e-05
A I-Disease 0 3.45224606235206e-07
activity O 0 1.6155422599695157e-07
indistinguishable O 0 1.4779398043174297e-06
from O 0 7.742494290141622e-08
that O 0 6.671164243243766e-08
of O 0 2.0847248833888443e-06
patients O 1 0.8858833312988281
with O 1 0.5851923227310181
Tay B-Disease 1 0.9995560050010681
- I-Disease 1 0.9993674159049988
Sachs I-Disease 1 0.9994353652000427
disease I-Disease 1 0.9992218017578125
( O 0 0.008215518668293953
TSD B-Disease 1 0.9912930130958557
) O 0 9.51589536271058e-05
. O 0 3.910715167876333e-05

Identification O 0 5.499219696503133e-06
and O 0 9.496437769485055e-07
quantitation O 0 9.396598034072667e-05
of O 0 3.495285909593804e-07
hex O 0 7.817638106644154e-05
A O 0 2.563366479080287e-06
, O 0 4.813829264094238e-07
amounting O 0 6.3267266341426875e-06
to O 0 4.1784403492783895e-07
3 O 0 1.2673909623117652e-05
. O 0 1.12216594061465e-05

5 O 0 8.571040962124243e-05
% O 0 8.047937444644049e-05
- O 0 0.005703970789909363
6 O 0 0.00019549251010175794
. O 0 5.817553756060079e-05

9 O 0 5.700248038920108e-06
% O 0 3.969715578477917e-07
of O 0 6.09269434903581e-08
total O 0 5.99638269704883e-07
beta O 0 4.992271715309471e-05
hexosaminidase O 0 0.0007152730249799788
activity O 0 8.157738307090767e-07
, O 0 7.331383500286393e-08
has O 0 1.6448982620431707e-08
been O 0 3.666100978350073e-09
obtained O 0 1.2955430506167431e-08
by O 0 4.194750502506395e-08
cellulose O 0 8.9618559286464e-05
acetate O 0 0.00014940439723432064
gel O 0 0.00026573045761324465
electrophoresis O 0 2.5322262445115484e-05
, O 0 3.7580852563223743e-07
DEAE O 0 0.0004350968811195344
- O 0 3.1099927582545206e-05
cellulose O 0 4.90401143906638e-05
ion O 0 1.2271368177607656e-05
- O 0 2.1336831196094863e-05
exchange O 0 9.039019346346322e-07
chromatography O 0 0.00013933230366092175
, O 0 1.336935383733362e-06
radial O 0 0.0005725595983676612
immunodiffusion O 0 0.002424076898023486
, O 0 1.351454102405114e-06
and O 0 1.3348549146030564e-06
radioimmunoassay O 0 0.004122617654502392
. O 0 1.932465056597721e-05

Previous O 0 0.0001298363204114139
family O 0 0.00010090010619023815
studies O 0 1.7827278497861698e-05
suggested O 0 1.4702089174534194e-05
that O 0 1.7408191865797562e-07
these O 0 8.955979069469322e-08
individuals O 0 6.405276167242846e-07
may O 0 1.1245806490478572e-06
be O 0 3.8460608919876904e-08
compound O 0 5.804614829685306e-06
heterozygotes O 0 4.246071694069542e-05
for O 0 2.9666251677440414e-08
the O 0 1.3268382303976978e-07
common O 0 4.594081019604346e-06
mutant O 0 0.0012328457087278366
TSD B-Disease 1 0.9671152830123901
gene O 0 7.428935077768983e-06
and O 0 1.3162805601041327e-07
a O 0 1.6397145827795612e-06
rare O 0 3.6095225368626416e-05
( O 0 1.0723289960878901e-05
allelic O 0 0.0006549094105139375
) O 0 4.986093699699268e-06
mutant O 0 0.00019790777878370136
gene O 0 7.92893479228951e-05
. O 0 2.350888098590076e-05

Thus O 0 4.454036570677999e-06
, O 0 5.381523919822939e-07
the O 0 2.958376228434645e-07
postulated O 0 1.9849203454214148e-05
rate O 0 7.278615612449357e-06
mutant O 0 6.421835860237479e-05
gene O 0 5.569201675825752e-06
appears O 0 8.595179679105058e-07
to O 0 6.5738006149729244e-09
code O 0 1.5696297595013675e-08
for O 0 2.3955357697502677e-09
the O 0 3.1499414188118635e-09
expression O 0 1.023155693502531e-08
of O 0 4.840407186179618e-09
low O 0 6.032967689861835e-07
amounts O 0 1.057577350138672e-07
of O 0 5.7625641147751594e-08
hex O 0 5.5064112530089915e-05
A O 0 1.0443338396726176e-05
. O 0 1.3425324141280726e-05

Heterozygotes O 0 0.0018145432695746422
for O 0 2.986999561471748e-06
the O 0 4.272463684173999e-06
rare O 0 0.0010466844541952014
mutant O 0 0.00209849257953465
may O 0 6.458521056629252e-06
be O 0 5.43287441701068e-08
indistinguishable O 0 7.623470537510002e-06
from O 0 6.955526714591542e-07
heterozygotes O 0 0.00015618551697116345
for O 0 1.720232774005126e-07
the O 0 1.0644899930412066e-06
common O 0 0.00018954981351271272
TSD B-Disease 1 0.991178572177887
mutant O 0 0.0043355547823011875
. O 0 6.902270251885056e-05

However O 0 4.6609789023932535e-06
, O 0 3.8549549685740203e-07
direct O 0 2.3017236117084394e-07
visualization O 0 1.1556588106031995e-05
and O 0 1.914134060143624e-07
quantitation O 0 5.02491275256034e-05
of O 0 6.82792062889348e-08
hex O 0 7.003130122029688e-06
A O 0 1.641426337073426e-07
by O 0 1.8975791604702863e-08
the O 0 2.2608055871842225e-08
methods O 0 2.014267010963522e-07
described O 0 8.713202078070026e-06
may O 0 5.217990292294417e-06
prevent O 0 5.083502037450671e-05
false O 0 2.074047915812116e-05
- O 0 0.006642263848334551
positive O 0 2.568513446021825e-05
prenatal O 0 0.27643439173698425
diagnosis O 0 0.22085195779800415
of O 0 2.5182375793519896e-06
TSD B-Disease 1 0.9931700229644775
in O 0 2.2911158339411486e-06
fetuses O 0 0.00013782945461571217
having O 0 4.222883092097618e-07
the O 0 1.6734398400330974e-07
incomplete O 0 3.5379660403123125e-05
hex B-Disease 0 0.014963971450924873
A I-Disease 0 0.004817167297005653
deficiency I-Disease 1 0.9989544153213501
of O 0 1.0730112620649379e-07
the O 0 8.216460400944925e-07
type O 0 0.0003243319224566221
described O 0 4.284872375137638e-06
in O 0 1.798567268451734e-07
the O 0 3.806549955243099e-07
four O 0 4.1250391404901166e-06
healthy O 0 0.0010251578642055392
individuals O 0 8.461401739623398e-05

The O 0 0.00027875369414687157
tumor B-Disease 1 0.942380428314209
suppressor O 0 0.05604986473917961
gene O 0 0.0011972100473940372
Smad4 O 1 0.8876506686210632
/ O 1 0.5711819529533386
Dpc4 O 0 0.00347567955031991
is O 0 1.9133931061787735e-07
required O 0 1.2697853435383877e-07
for O 0 1.5925157015317382e-07
gastrulation O 0 0.007671440951526165
and O 0 1.7842577904048085e-07
later O 0 2.3271415727776912e-07
for O 0 2.8584503297679476e-07
anterior O 0 0.0010909328702837229
development O 0 8.16629267319513e-07
of O 0 1.303697558796557e-07
the O 0 3.091716735070804e-06
mouse O 0 0.0011594494571909308
embryo O 0 0.0006474729161709547
. O 0 2.766957004496362e-05

Mutations O 0 9.902346937451512e-05
in O 0 3.329874289192958e-06
the O 0 3.1728093745186925e-05
SMAD4 O 1 0.9919062852859497
/ O 1 0.9929671287536621
DPC4 O 1 0.9932349324226379
tumor B-Disease 1 0.9939952492713928
suppressor O 0 0.005627868231385946
gene O 0 3.94338076148415e-06
, O 0 8.321120503751445e-08
a O 0 6.257017304278634e-08
key O 0 2.0422346835857752e-07
signal O 0 5.150654374119767e-07
transducer O 0 1.8962471585837193e-05
in O 0 2.0072181428076874e-07
most O 0 7.692402164138912e-07
TGFbeta O 0 0.10139352828264236
- O 0 0.00698829535394907
related O 0 1.6019115719245747e-05
pathways O 0 8.246406650869176e-06
, O 0 5.83711248225427e-08
are O 0 3.788207969535051e-09
involved O 0 2.5583565488318527e-08
in O 0 2.2657397735770246e-08
50 O 0 3.923826170648681e-07
% O 0 2.1800062768306816e-06
of O 0 3.785313674598001e-05
pancreatic B-Disease 1 0.9986748695373535
cancers I-Disease 1 0.9974536299705505
. O 0 0.0005393667379394174

Homozygous O 0 0.008563202805817127
Smad4 O 1 0.8059521317481995
mutant O 1 0.5721530914306641
mice O 1 0.7762893438339233
die O 0 0.07208161801099777
before O 0 7.201787866506493e-06
day O 0 1.2367660019663163e-05
7 O 0 6.56807460472919e-05
. O 0 2.298909384990111e-05

5 O 0 4.9388487241230905e-05
of O 0 1.062101455318043e-05
embryogenesis O 0 0.006788915488868952
. O 0 0.00024823646526783705

Mutant O 0 0.00030785135459154844
embryos O 0 2.018074519583024e-05
have O 0 5.689043405254779e-07
reduced O 0 1.9229752069804817e-05
size O 0 1.3176046195439994e-05
, O 0 1.1833640201075468e-06
fail O 0 2.1200488845352083e-05
to O 0 1.4125897962458112e-07
gastrulate O 0 0.0006194633315317333
or O 0 3.137286057608435e-07
express O 0 1.3804677791995346e-06
a O 0 1.1399308732507052e-06
mesodermal O 0 0.002637868747115135
marker O 0 0.00010077923798235133
, O 0 4.509598738877685e-07
and O 0 3.897618228165811e-07
show O 0 5.587992291111732e-06
abnormal O 0 0.002130890730768442
visceral O 0 0.008507858030498028
endoderm O 0 0.23344440758228302
development O 0 0.0003424729220569134
. O 0 8.471444016322494e-05

Growth B-Disease 1 0.954701840877533
retardation I-Disease 1 0.9925354719161987
of O 0 3.5615846627479186e-06
the O 0 9.459809371037409e-05
Smad4 O 1 0.9804282784461975
- O 1 0.8709340691566467
deficient O 0 0.42528262734413147
embryos O 0 7.633655513927806e-06
results O 0 1.8549039850768168e-06
from O 0 1.1754804063457414e-06
reduced O 0 0.00020050840976182371
cell O 0 0.0009427969926036894
proliferation O 0 0.0013479064218699932
rather O 0 2.536163776767353e-07
than O 0 3.163345638768078e-07
increased O 0 1.0250053492200095e-05
apoptosis O 0 0.0007583339465782046
. O 0 1.8525548512116075e-05

Aggregation O 0 6.866439071018249e-05
of O 0 6.741708602930885e-06
mutant O 0 0.0015459175920113921
Smad4 O 0 0.19989164173603058
ES O 0 0.0062414249405264854
cells O 0 1.9549381249817088e-05
with O 0 1.2416103345458396e-06
wild O 0 5.0876773457275704e-05
- O 0 0.0048217615112662315
type O 0 0.0005350767751224339
tetraploid O 0 0.0017496536020189524
morulae O 0 0.026760270819067955
rescues O 0 0.003915281035006046
the O 0 6.647532427450642e-05
gastrulation B-Disease 1 0.9788416028022766
defect I-Disease 1 0.9477876424789429
. O 0 0.00026586122112348676

These O 0 3.7193819935055217e-06
results O 0 8.376211553695612e-06
indicate O 0 8.697030352777801e-06
that O 0 5.307913397700759e-07
Smad4 O 0 0.0025382060557603836
is O 0 1.3555249722685403e-07
initially O 0 1.4596515995890513e-07
required O 0 1.819135952985107e-08
for O 0 4.165622513596645e-09
the O 0 8.870158829665797e-09
differentiation O 0 4.442758836376015e-07
of O 0 1.6211208375693786e-08
the O 0 1.7387584705375048e-07
visceral O 0 0.00028430423117242754
endoderm O 0 0.0017638725694268942
and O 0 8.829398723264603e-08
that O 0 3.534841042096559e-08
the O 0 5.870853669875942e-07
gastrulation B-Disease 0 0.494928777217865
defect I-Disease 0 0.024433249607682228
in O 0 3.040579201751825e-07
the O 0 7.727563797743642e-07
epiblast O 0 0.04995196312665939
is O 0 3.1430897706741234e-07
secondary O 0 2.143484152838937e-06
and O 0 3.072105130286218e-07
non O 0 3.088879748247564e-05
- O 0 0.000964803621172905
cell O 0 7.691889913985506e-05
autonomous O 0 5.874046564713353e-06
. O 0 1.3213343663665e-05

Rescued O 0 0.007143005728721619
embryos O 0 0.0021804131101816893
show O 0 0.006867597810924053
severe O 1 0.9978413581848145
anterior O 1 0.9855844378471375
truncations O 0 0.2150319367647171
, O 0 5.800613962492207e-06
indicating O 0 8.297896783915348e-06
a O 0 1.9218859392822196e-07
second O 0 1.4061194519854325e-07
important O 0 4.3430883778228235e-08
role O 0 2.8081234404453426e-07
for O 0 9.905301112667075e-07
Smad4 O 0 0.021134009584784508
in O 0 7.507392183470074e-06
anterior O 0 0.19410420954227448
patterning O 0 0.044319991022348404
during O 0 0.00033066864125430584
embryogenesis O 0 0.053586266934871674
. O 0 0.0001783129555406049

Prevalence O 0 0.0071727074682712555
of O 0 3.90278773920727e-06
p16 O 0 0.0010885793017223477
and O 0 1.4696145626658108e-05
CDK4 O 0 0.304757684469223
germline O 0 0.05186079069972038
mutations O 0 0.0003381927963346243
in O 0 6.0870483139296994e-05
48 O 0 0.4963882565498352
melanoma B-Disease 1 0.9996837377548218
- O 1 0.995719850063324
prone O 1 0.7232809662818909
families O 0 3.289123924332671e-05
in O 0 9.477216735831462e-06
France O 0 0.00022160119260661304
. O 0 2.6651727239368483e-05

The O 0 0.0004501567455008626
French O 0 0.16029410064220428
Familial B-Disease 1 0.9919435977935791
Melanoma I-Disease 1 0.9979861974716187
Study O 0 0.0029002204537391663
Group O 0 0.001117559615522623
. O 0 0.00024627582752145827

Germline O 0 0.01499178260564804
mutations O 0 4.872577483183704e-05
in O 0 8.634014534436574e-07
the O 0 1.0827619689735002e-06
p16 O 0 0.0005012454348616302
and O 0 2.157318476747605e-06
CDK4 O 0 0.01430294569581747
genes O 0 8.650085305816901e-07
have O 0 2.4286382682703334e-08
been O 0 1.5325616331551828e-08
reported O 0 2.0517884991022584e-07
in O 0 2.0902694686242285e-08
a O 0 2.195534563043111e-07
subset O 0 1.7952503185370006e-05
of O 0 2.2373304091161117e-05
melanoma B-Disease 1 0.9996733665466309
pedigrees O 0 0.011081509292125702
, O 0 2.4147043404809665e-06
but O 0 2.1262708571612166e-07
their O 0 3.7555989251814026e-07
prevalence O 0 0.07939181476831436
is O 0 1.9855498578635888e-07
not O 0 4.789029617313645e-08
well O 0 4.070335819505999e-07
known O 0 3.9866317820269614e-06
. O 0 7.030056167423027e-06

We O 0 2.083997287627426e-06
searched O 0 3.459266508798464e-06
for O 0 1.78904542735836e-07
such O 0 3.406888708923361e-07
germline O 0 0.0007347514037974179
mutations O 0 8.351731594302692e-06
in O 0 1.345073997072177e-06
48 O 0 0.00033670460106804967
French O 0 0.3254527151584625
melanoma B-Disease 1 0.9997674822807312
- O 1 0.9045661091804504
prone O 0 0.05655617639422417
families O 0 8.637399560029735e-07
selected O 0 3.2620057766052923e-08
according O 0 2.638888041417431e-08
to O 0 5.705580452541881e-09
two O 0 1.5620884141753777e-08
major O 0 1.533484805804619e-06
criteria O 0 9.965553999791155e-07
families O 0 1.203135298055713e-07
with O 0 3.483505039980628e-08
at O 0 4.092814265277411e-08
least O 0 7.997701167994364e-09
three O 0 9.853810212234748e-09
affected O 0 2.7857285544996557e-07
members O 0 1.843242358745556e-08
( O 0 2.0805289580039243e-07
n O 0 3.0087767299846746e-06
= O 0 5.217666966927936e-06
20 O 0 4.664201824766678e-08
) O 0 2.3912685165328185e-08
or O 0 9.878762696757803e-09
families O 0 1.4305358675414936e-08
with O 0 1.1943755318100102e-08
two O 0 2.624081574253978e-08
affected O 0 1.0895321338466601e-06
members O 0 9.008966905810212e-09
, O 0 6.252923068217342e-09
one O 0 1.0927303506491626e-09
of O 0 2.509236152192784e-09
them O 0 1.1105382391463081e-08
affected O 0 2.5262471581299906e-07
before O 0 6.48540199321701e-09
the O 0 2.2946424760306172e-09
age O 0 2.6419852972026092e-08
of O 0 3.470557619067449e-09
50 O 0 6.639466931801508e-08
( O 0 1.9226412462103326e-07
n O 0 2.6154802981182e-06
= O 0 7.435690349666402e-06
28 O 0 1.533287417032625e-07
) O 0 2.5407334902638468e-08
, O 0 3.8962371107231775e-09
and O 0 3.0385567395541102e-09
one O 0 1.395463833375743e-08
additional O 0 3.3549017075529264e-07
minor O 0 0.0002455426729284227
criterion O 0 0.001019127550534904
. O 0 2.8258453312446363e-05

Sixteen O 0 1.4779547200305387e-05
different O 0 2.8572885639732704e-06
p16 O 0 0.007069691084325314
germline O 0 0.022172512486577034
mutations O 0 2.3512715415563434e-05
were O 0 5.016763537923907e-08
found O 0 1.5489250415612332e-07
in O 0 8.054438893623228e-08
21 O 0 7.580353553748864e-07
families O 0 1.3377473351283697e-07
, O 0 3.6038098727431134e-08
while O 0 2.714571323281234e-08
one O 0 1.4167464712500077e-07
germline O 0 0.001228789915330708
mutation O 0 1.782323124643881e-05
, O 0 8.173273613465426e-07
Arg24His O 0 0.0014898848021402955
, O 0 3.1824393431634235e-07
was O 0 2.4075339410956076e-07
detected O 0 1.2223761132190702e-06
in O 0 9.312620363743918e-08
the O 0 5.867842673978885e-07
CDK4 O 0 0.009794076904654503
gene O 0 0.00011402295058360323
. O 0 2.5431674657738768e-05

The O 0 4.914488158647146e-07
frequency O 0 5.249447667665663e-07
of O 0 1.591926519495246e-07
p16 O 0 0.00014794268645346165
gene O 0 3.2667835512256715e-06
mutation O 0 9.919471040120698e-07
in O 0 1.4925550573252622e-08
our O 0 8.976292598106284e-09
sample O 0 1.7690993558971968e-08
( O 0 8.492931868886444e-08
44 O 0 1.5396012997825892e-07
% O 0 4.132040842819151e-08
) O 0 3.587959795936513e-08
is O 0 4.481121251842524e-09
among O 0 3.831641670615227e-09
the O 0 9.917560106487144e-09
highest O 0 6.75148783102486e-07
rates O 0 1.6336646240233677e-06
yet O 0 8.42679028778548e-08
reported O 0 1.9084689029114088e-07
and O 0 9.910544385149933e-09
the O 0 6.835947630179362e-08
CDK4 O 0 0.002243669470772147
mutation O 0 4.1129109717985557e-07
is O 0 3.6479235188124903e-09
the O 0 5.9377445182917654e-09
second O 0 2.0522034560599423e-07
mutation O 0 6.6277143560000695e-06
detected O 0 2.5093340809689835e-06
in O 0 3.775774004566301e-08
this O 0 1.7368260785133316e-07
gene O 0 2.0373692677821964e-05
worldwide O 0 4.2913299694191664e-05
. O 0 1.4161782019073144e-05

In O 0 4.951322353008436e-06
summary O 0 1.3166903045203071e-05
, O 0 8.424458428635262e-07
our O 0 2.3961200668054516e-07
results O 0 6.410935498024628e-07
show O 0 2.0836465353113454e-07
frequent O 0 5.370562234929821e-07
involvement O 0 3.0121074701128236e-07
of O 0 2.4830756117921737e-08
the O 0 4.297470752590016e-07
p16 O 0 0.000590879877563566
gene O 0 9.226658585248515e-05
in O 0 0.00011143078154418617
familial B-Disease 1 0.9993459582328796
melanoma I-Disease 1 0.9997949004173279
and O 0 1.6797119997136178e-06
confirm O 0 9.155342581834702e-07
the O 0 1.8907076793084343e-08
role O 0 3.328614894826387e-08
of O 0 1.1230503638159917e-08
the O 0 2.517651296329859e-07
CDK4 O 0 0.0038734532427042723
gene O 0 4.9587461035116576e-06
as O 0 1.4066400808587787e-06
a O 0 0.001255515613593161
melanoma B-Disease 1 0.9996281862258911
- O 1 0.8007845282554626
predisposing O 0 0.024344876408576965
gene O 0 0.0001034848828567192
. O 0 4.518244168139063e-06
. O 0 1.988783697015606e-05

Progression O 0 0.00100318540353328
of O 0 5.5082678045437206e-06
somatic O 0 0.001448685536161065
CTG O 0 0.26363620162010193
repeat O 0 0.001351944636553526
length O 0 4.459576302906498e-05
heterogeneity O 0 0.00020648133067879826
in O 0 1.242847133653413e-06
the O 0 8.836826964397915e-06
blood O 0 0.1743251234292984
cells O 0 0.019837895408272743
of O 0 0.019852811470627785
myotonic B-Disease 1 0.9995216131210327
dystrophy I-Disease 1 0.9997153878211975
patients O 1 0.9970479607582092
. O 0 0.0035451536532491446

The O 0 5.924018751102267e-06
genetic O 0 4.997516225557774e-05
basis O 0 1.0608411685097963e-05
of O 0 0.0026563561987131834
myotonic B-Disease 1 0.9993765950202942
dystrophy I-Disease 1 0.9996939897537231
( O 1 0.9225903749465942
DM B-Disease 1 0.9993324875831604
) O 0 3.988300704804715e-06
is O 0 4.384680707403277e-08
the O 0 1.9740509671350992e-08
expansion O 0 4.691861761330074e-07
of O 0 2.8939483698309232e-08
an O 0 4.5116289015822986e-07
unstable O 0 0.010397672653198242
CTG O 0 0.018999960273504257
repeat O 0 1.1693961823766585e-05
in O 0 1.4407331327959128e-08
the O 0 1.2058871234899016e-08
34 O 0 1.7278388497743435e-07
UTR O 0 6.515311270050006e-06
of O 0 1.5640411632489304e-08
the O 0 5.791797548226896e-07
DM B-Disease 1 0.977988600730896
protein O 0 2.288765927005443e-06
kinase O 0 2.050260445685126e-05
gene O 0 1.3210647011874244e-06
on O 0 2.5487719312877744e-07
chromosome O 0 5.844946645083837e-05
19 O 0 1.9231403712183237e-05
. O 0 1.0160602869291324e-05

One O 0 4.251107554864575e-07
of O 0 1.1683004430551591e-07
the O 0 1.6853829265528475e-07
principal O 0 4.946971330355154e-07
features O 0 2.5874038556139567e-07
of O 0 1.7370579996622837e-07
the O 0 2.1614130673697218e-05
DM B-Disease 1 0.9992913007736206
mutation O 0 3.863239544443786e-05
is O 0 7.341066066146595e-08
an O 0 7.076767616354118e-08
extraordinarily O 0 1.0892654245253652e-05
high O 0 8.692177289049141e-07
level O 0 2.229116233820605e-07
of O 0 5.4624564427285804e-08
somatic O 0 0.00021327254944480956
mosaicism O 0 0.1210566833615303
, O 0 4.529200623437646e-07
due O 0 6.61472938645602e-07
to O 0 2.738352122833021e-08
an O 0 5.5116345265560085e-08
extremely O 0 1.6037849945860216e-06
high O 0 1.4720851595484419e-06
degree O 0 3.7883552295170375e-07
of O 0 1.3921545871653507e-07
somatic O 0 0.00016530595894437283
instability O 0 0.0001783741608960554
both O 0 3.476568721794138e-08
within O 0 6.776917160777884e-08
and O 0 7.855366845888057e-08
between O 0 4.596113853949646e-07
different O 0 7.225474973893142e-07
tissues O 0 0.0012365992879495025
. O 0 2.902270898630377e-05

This O 0 2.6126430384465493e-05
instability O 0 0.009040920063853264
appears O 0 9.895888979372103e-06
to O 0 4.2691379320558553e-08
be O 0 1.2584238540114256e-08
biased O 0 9.59830686042551e-08
towards O 0 2.8784574723772494e-08
further O 0 4.8219067849686326e-08
expansion O 0 3.4235191037623736e-07
and O 0 9.549766311067742e-09
continuous O 0 1.45865669765044e-07
throughout O 0 2.260904885531545e-08
the O 0 7.784293210022497e-09
life O 0 3.506810841713559e-08
of O 0 5.984189144214724e-09
an O 0 3.0041721998941284e-08
individual O 0 5.4963074092029274e-08
, O 0 1.1185551329617738e-07
features O 0 4.968238158653548e-07
that O 0 1.8792960077007592e-08
could O 0 5.639466138518401e-08
be O 0 8.902617310013738e-09
associated O 0 1.428396103619889e-07
with O 0 4.928145713734011e-08
the O 0 2.536338001846161e-07
progressive O 0 8.311964484164491e-05
nature O 0 6.290760211413726e-06
of O 0 4.752151198772481e-06
the O 0 0.00109037384390831
disease O 1 0.9983983635902405
. O 0 0.00042344146640971303

Although O 0 1.152736513176933e-05
increasing O 0 7.393433861579979e-06
measured O 0 1.040381448547123e-05
allele O 0 5.03549053973984e-05
size O 0 8.275433356175199e-05
between O 0 4.650916162063368e-05
patients O 0 0.052896056324243546
clearly O 0 2.8632950943574542e-06
correlates O 0 7.834581083443481e-06
with O 0 2.2282576139787125e-07
an O 0 1.7606520259505487e-06
increased O 0 0.0008118133409880102
severity O 1 0.7911165952682495
of O 0 2.0691522877314128e-05
symptoms O 1 0.9921459555625916
and O 0 1.582587003667868e-07
an O 0 1.5697142430326494e-07
earlier O 0 4.6675399971718434e-06
age O 0 2.466812657075934e-05
of O 0 1.9799463188974187e-06
onset O 1 0.9906909465789795
, O 0 2.2530169019319146e-07
this O 0 1.641156366360974e-08
correlation O 0 1.5023610444586666e-07
is O 0 8.448528987514692e-09
not O 0 1.991727227590445e-09
precise O 0 2.0807505052289343e-08
and O 0 1.5205365855308628e-08
measured O 0 2.61459462080893e-07
allele O 0 1.2082986131645157e-06
length O 0 6.606213105442293e-07
cannot O 0 4.989015067735636e-08
be O 0 1.2994003650845798e-09
used O 0 2.6625934790303063e-09
as O 0 2.1044859188634746e-09
an O 0 3.883017019035151e-09
accurate O 0 1.5504946304645273e-07
predictor O 0 1.462220461689867e-05
of O 0 1.1916590381133574e-07
age O 0 3.182239379384555e-05
of O 0 9.106142897508107e-06
onset O 1 0.994408905506134
. O 0 0.0003378504188731313

In O 0 1.0652566970748012e-06
order O 0 1.9146233398714685e-07
to O 0 6.691783482892788e-08
further O 0 1.8078034713653324e-07
characterize O 0 7.037636351014953e-06
the O 0 1.9375102056073956e-07
dynamics O 0 0.00010285622556693852
of O 0 7.90975354902912e-06
DM B-Disease 1 0.9989855885505676
CTG O 1 0.9774051308631897
repeat O 0 0.047979701310396194
somatic O 0 0.003569136606529355
instability O 0 0.004557714331895113
, O 0 2.7987445605504035e-07
we O 0 1.615835998336479e-08
have O 0 5.41458167191422e-09
studied O 0 9.374549847507296e-08
repeat O 0 3.668716090032831e-06
length O 0 1.7400093099695368e-07
changes O 0 6.52682601298693e-08
over O 0 8.583035082665447e-08
time O 0 3.280612475009548e-07
in O 0 1.7700631360639818e-05
111 O 1 0.9418673515319824
myotonic B-Disease 1 0.9997366070747375
dystrophy I-Disease 1 0.9998643398284912
patients O 1 0.9526966214179993
with O 0 3.695899431477301e-05
varying O 0 0.00750983040779829
clinical O 1 0.8557837605476379
severity O 1 0.914076030254364
and O 0 1.2248078746779356e-05
CTG O 0 0.21390904486179352
repeat O 0 5.685339783667587e-05
size O 0 2.560417442509788e-07
over O 0 1.5798176988823798e-08
time O 0 7.638362831130507e-09
intervals O 0 5.3645738518071084e-08
of O 0 2.3470578369710893e-08
1 O 0 2.705515726120211e-06
- O 0 0.00010827584628714249
7 O 0 3.908516191586386e-06
years O 0 4.729671218228759e-06
. O 0 6.893268619023729e-06

We O 0 2.3585000690218294e-06
have O 0 1.697152498536525e-07
found O 0 1.5249112550463906e-07
a O 0 8.925540129212095e-08
direct O 0 1.1904913321814092e-07
progression O 0 5.52736091776751e-05
of O 0 1.677664052124328e-08
the O 0 9.628341501866089e-08
size O 0 2.266143155793543e-06
heterogeneity O 0 1.0581192327663302e-05
over O 0 1.1730140414556445e-07
time O 0 5.347003551037233e-08
related O 0 5.813689654132759e-07
to O 0 4.050898994023555e-08
initial O 0 7.488506525987759e-06
CTG O 0 0.015875117853283882
repeat O 0 5.589824650087394e-05
size O 0 3.7046942225060775e-07
and O 0 9.278928736478065e-09
the O 0 6.4986260817079256e-09
time O 0 1.1033407076865842e-08
interval O 0 2.2490496576210717e-07
and O 0 2.023691436647823e-08
always O 0 7.390350731384387e-08
biased O 0 4.053844691043196e-07
towards O 0 2.836898147506872e-07
further O 0 1.8743811551757972e-06
expansion O 0 6.6245804191567e-05
. O 0 1.6551741282455623e-05

Attempts O 0 9.914166184898932e-06
to O 0 7.241119988066202e-07
mathematically O 0 3.1501228932029335e-06
model O 0 3.1199497243505903e-06
the O 0 5.015548936171399e-07
dynamics O 0 9.312691690865904e-05
have O 0 1.2282605155178317e-07
proved O 0 1.7617236380829127e-06
only O 0 4.9926036638225924e-08
partially O 0 5.7554361774236895e-06
successful O 0 7.508792805310804e-07
suggesting O 0 1.4046762544239755e-06
that O 0 1.278382644187559e-08
individual O 0 3.198558928829698e-08
specific O 0 2.0561645897032577e-07
genetic O 0 0.00013292768562678248
and O 0 1.0920444765361026e-05
/ O 0 0.2063886672258377
or O 0 3.5426885460765334e-06
environmental O 0 1.279734442505287e-05
factors O 0 1.3269078635858023e-07
also O 0 6.209707859028413e-09
play O 0 3.98934885126323e-09
a O 0 6.291926979429263e-08
role O 0 3.0601540856878273e-07
in O 0 8.208972417378391e-07
somatic O 0 0.0009258284699171782
mosaicism O 0 0.3305681645870209
. O 0 5.43805981578771e-06
. O 0 1.532113856228534e-05

Aspartylglucosaminuria B-Disease 1 0.698433518409729
among O 0 0.00010268238838762045
Palestinian O 0 0.0003782071580644697
Arabs O 0 0.0005751807475462556
. O 0 0.00013702445721719414

Aspartylglucosaminuria B-Disease 1 0.9693573117256165
( O 0 0.02382184937596321
AGU B-Disease 1 0.9929062128067017
) O 0 2.0786757886526175e-05
is O 0 2.131536575689097e-06
a O 0 4.892342985840514e-05
rare O 0 0.08546417206525803
disorder B-Disease 1 0.9977013468742371
of I-Disease 0 1.951257581822574e-05
glycoprotein I-Disease 1 0.9846704006195068
metabolism I-Disease 0 0.43812400102615356
caused O 0 0.03193017095327377
by O 0 3.8435973692685366e-06
the O 0 3.1239280360750854e-05
deficiency B-Disease 1 0.9984241724014282
of I-Disease 0 3.704669495618873e-07
the I-Disease 0 1.0644448593666311e-05
lysosomal I-Disease 1 0.9017173647880554
enzyme I-Disease 0 0.001301866490393877
aspartylglucosaminidase I-Disease 0 0.1910618245601654
( O 0 0.00020049902377650142
AGA O 0 0.04609302803874016
) O 0 2.3529360987595282e-05
. O 0 1.7653328541200608e-05

AGU B-Disease 1 0.9913401007652283
is O 0 0.0004824363568332046
inherited O 1 0.7282329797744751
as O 0 2.6037683710455894e-05
an O 0 0.0003157627652399242
autosomal O 1 0.9983503818511963
recessive O 1 0.9987109899520874
trait O 0 0.18985553085803986
and O 0 4.617492322722683e-06
occurs O 0 5.624004643323133e-06
with O 0 1.9598142841914523e-07
a O 0 3.523701082031039e-07
high O 0 1.3797160818285192e-06
frequency O 0 8.400007800446474e-08
in O 0 3.36569421222066e-08
Finland O 0 7.27455130800081e-07
because O 0 7.88375018601073e-08
of O 0 4.357392668907778e-08
a O 0 2.463104692651541e-06
founder O 0 0.00020598284027073532
effect O 0 6.085747736506164e-05
. O 0 2.1156763978069648e-05

While O 0 4.193284621578641e-05
very O 0 2.5126886612270027e-05
few O 0 0.00015040926518850029
patients O 0 0.4339768588542938
with O 0 0.00023690050875302404
AGU B-Disease 1 0.9986175298690796
have O 0 2.6399004582344787e-07
been O 0 1.0564886565589404e-07
reported O 0 9.515638907942048e-07
from O 0 1.8548071523127874e-07
non O 0 5.37455161975231e-06
- O 0 0.00016875793517101556
Finnish O 0 2.2276773961493745e-05
origin O 0 9.368058044856298e-07
, O 0 5.554307790589519e-06
we O 0 2.922944440797437e-05
diagnosed O 1 0.9990580677986145
the O 0 0.00019122223602607846
disorder O 1 0.999413013458252
in O 0 2.4250237402156927e-05
8 O 0 0.002036269987002015
patients O 0 0.01687672734260559
originating O 0 1.874590338957205e-06
from O 0 4.4058904791199893e-07
3 O 0 6.757427854608977e-06
unrelated O 0 3.7579244235530496e-05
families O 0 4.252583494235296e-07
, O 0 3.197095210794032e-08
all O 0 5.6466316067371736e-09
Palestinian O 0 5.475077387018246e-07
Arabs O 0 4.981560550731956e-07
from O 0 4.7781810508240596e-08
the O 0 1.2420682082847634e-07
region O 0 9.746053137860144e-07
of O 0 2.3559096007375047e-07
Jerusalem O 0 4.1177550883730873e-05
. O 0 2.4042004952207208e-05

The O 0 0.0005034267669543624
clinical O 1 0.8380253911018372
diagnosis O 1 0.9940240979194641
of O 0 0.0010212414199486375
AGU B-Disease 1 0.9990276098251343
is O 0 2.8163618480903096e-05
often O 0 3.4793329177773558e-06
difficult O 0 2.7860203317686683e-06
, O 0 9.678201706719847e-08
in O 0 1.925356407639356e-08
particular O 0 2.4179522384315533e-08
early O 0 6.491170978506489e-08
in O 0 1.7130973972712127e-08
the O 0 3.152226923930357e-08
course O 0 1.8611821133163176e-06
of O 0 3.117613118774898e-07
the O 0 0.00011702440679073334
disease O 1 0.9973151087760925
, O 0 1.0073031120327869e-07
and O 0 1.4521935653988294e-08
most O 0 1.1588390691485984e-08
of O 0 1.3525432507321966e-07
the O 0 2.342350853723474e-05
patients O 1 0.9251046180725098
are O 0 8.055872058321256e-06
diagnosed O 1 0.9970372915267944
after O 0 2.1456255581142614e-06
the O 0 1.656617740763977e-07
age O 0 2.26189399654686e-06
of O 0 1.0248044901572939e-07
5 O 0 1.0702151485020295e-05
years O 0 1.7255448256037198e-05
. O 0 1.8790447938954458e-05

However O 0 2.462544034642633e-05
, O 0 6.526218385261018e-06
since O 0 1.561686622153502e-05
these O 0 2.719819349294994e-06
patients O 0 0.01185926515609026
excrete O 0 0.0002030395990004763
early O 0 4.67170764295588e-07
large O 0 1.643707037146669e-07
amounts O 0 1.9959577457484556e-07
of O 0 1.229505102173789e-07
aspartylglucosamine O 0 0.000756052671931684
in O 0 2.706904353999562e-07
urine O 0 1.3042093996773474e-05
, O 0 3.318048698019993e-07
biochemical O 0 2.7174961360287853e-05
screening O 0 3.802039827860426e-06
is O 0 4.917620088917829e-08
easy O 0 5.202777515478374e-07
by O 0 3.044621053049923e-07
urine O 0 3.408252450753935e-05
chromatography O 0 0.001958038192242384
. O 0 2.8167542041046545e-06
. O 0 9.998940186051186e-06

Detection O 0 6.519768066937104e-05
of O 0 1.6404433154093567e-06
heterozygous O 0 4.830089892493561e-05
carriers O 0 4.9868522182805464e-05
of O 0 1.3362827075980022e-06
the O 0 0.00033414378412999213
ataxia B-Disease 1 0.9993057250976562
- I-Disease 1 0.9966478943824768
telangiectasia I-Disease 1 0.997073769569397
( O 0 3.2727224606787786e-05
ATM O 0 0.0001081219088518992
) O 0 7.119413112377515e-07
gene O 0 1.128911208070349e-06
by O 0 5.939808147559233e-07
G2 O 0 0.3319561779499054
phase O 0 0.00043764320435002446
chromosomal O 0 0.01596996746957302
radiosensitivity O 0 0.0458088219165802
of O 0 3.748797098523937e-05
peripheral O 1 0.9890276193618774
blood O 1 0.9596431255340576
lymphocytes O 1 0.9516008496284485
. O 0 0.0002016154903685674

In O 0 0.008057622238993645
ataxia B-Disease 1 0.9954674243927002
- I-Disease 1 0.992347240447998
telangiectasia I-Disease 1 0.9966722726821899
( O 0 0.009274004958570004
A B-Disease 1 0.9333505034446716
- I-Disease 1 0.9984899759292603
T I-Disease 1 0.9995123147964478
) O 0 0.0014982004649937153
patients O 0 0.021923327818512917
, O 0 2.486488597241987e-07
mutations O 0 4.875703893958416e-07
in O 0 8.086946223784253e-09
a O 0 3.462783482177656e-08
single O 0 6.473823788155642e-08
gene O 0 6.907601459715806e-07
, O 0 1.2902884805043868e-07
ATM O 0 5.3710300562670454e-05
, O 0 4.08369146498444e-07
result O 0 2.3647273792448686e-06
in O 0 8.666272151458543e-06
an O 0 0.009167283773422241
autosomal B-Disease 1 0.9997656941413879
recessive I-Disease 1 0.9998582601547241
syndrome I-Disease 1 0.9999537467956543
that O 0 1.773563963070046e-05
embraces O 0 0.0005217207944951952
a O 0 4.6142126848280896e-06
variety O 0 2.1516846118174726e-06
of O 0 4.49924613121766e-07
clinical O 0 0.012730994261801243
features O 0 4.8100348067237064e-05
and O 0 4.9835311983770225e-06
manifests O 0 0.007600196171551943
extreme O 0 0.0013303711311891675
radiosensitivity O 0 0.012981532141566277
and O 0 4.2098588437511353e-07
a O 0 1.5589386066494626e-06
strong O 0 2.33952232520096e-05
pre O 0 0.014242347329854965
- O 0 0.03808336332440376
disposition O 0 0.001113796723075211
to O 0 1.9711105778696947e-05
malignancy B-Disease 1 0.9735779762268066
. O 0 6.080115417717025e-05

Heterozygotes O 0 0.0005589011707343161
for O 0 1.2655675618589157e-06
the O 0 1.1168319815624272e-06
ATM O 0 0.00023002480156719685
gene O 0 5.147539013705682e-06
have O 0 6.068304259088109e-08
no O 0 1.4542757753588376e-07
clinical O 0 8.73218505148543e-06
expression O 0 2.4339857418453903e-07
of O 0 4.703016713847319e-07
A B-Disease 0 0.4848169982433319
- I-Disease 1 0.9984768033027649
T I-Disease 1 0.9995173215866089
but O 0 1.3810134987579659e-05
may O 0 9.187965042656288e-05
be O 0 8.674425771459937e-06
cancer B-Disease 1 0.9976614713668823
prone O 0 0.003777514211833477
with O 0 4.7349016085718176e-07
a O 0 3.128351863779244e-06
moderate O 0 0.00013451874838210642
increase O 0 5.406965101428796e-06
in O 0 4.783807980857091e-07
in O 0 1.942992184922332e-06
vitro O 0 0.0003278729855082929
radiosensitivity O 0 0.01918318308889866
. O 0 3.328249658807181e-05

We O 0 2.475031124049565e-06
performed O 0 1.6771031141615822e-06
a O 0 1.0659192639650428e-06
blind O 0 4.309020732762292e-05
chromosomal O 0 7.419133180519566e-05
analysis O 0 1.3237206530902768e-06
on O 0 2.161274551326642e-06
G2 O 1 0.893905520439148
- O 0 0.000986109720543027
phase O 0 5.114051964483224e-05
lymphocytes O 0 0.0005583627498708665
from O 0 3.3135648891402525e-07
7 O 0 8.880386303644627e-06
unrelated O 0 0.00031027692602947354
A B-Disease 0 0.19998179376125336
- I-Disease 1 0.9981776475906372
T I-Disease 1 0.999394416809082
patients O 0 0.01027575321495533
, O 0 3.991688117821468e-07
13 O 0 3.249990641052136e-06
obligate O 0 9.748180309543386e-05
A B-Disease 0 0.009720771573483944
- I-Disease 1 0.9778429865837097
T I-Disease 1 0.9987128973007202
heterozygotes O 0 0.0066721634939312935
( O 0 1.96411360775528e-06
parents O 0 2.2294308621439995e-07
of O 0 6.049340584013407e-08
the O 0 3.449084488238441e-06
patients O 0 0.006933862343430519
) O 0 4.2017168766506074e-07
, O 0 2.558249434514437e-08
and O 0 7.4032140418012204e-09
14 O 0 3.730461273221408e-08
normal O 0 8.13936225085854e-08
controls O 0 4.108771065602923e-07
following O 0 3.452074679444195e-07
X O 0 0.00010160338570130989
- O 0 1.5428320693899877e-05
irradiation O 0 1.2911183375763358e-06
with O 0 7.624988995758031e-08
1 O 0 1.45486694691499e-06
Gy O 0 0.0010345411719754338
in O 0 8.971705156568532e-09
order O 0 5.645985456936842e-09
to O 0 3.862157704759284e-09
evaluate O 0 1.1088178553109174e-07
this O 0 8.262552420035263e-09
cytogenetic O 0 8.90891988092335e-06
method O 0 1.2130638715746045e-08
as O 0 6.0420157765861404e-09
a O 0 3.978613705157841e-08
tool O 0 5.837557068844035e-07
for O 0 6.665567298114183e-08
detection O 0 5.387601504480699e-06
of O 0 5.028883265367767e-07
ATM O 0 0.0015199388144537807
carriers O 0 0.0005875519127584994
. O 0 1.576766953803599e-05

Both O 0 9.725515701575205e-05
A B-Disease 0 0.16313299536705017
- I-Disease 1 0.9937792420387268
T I-Disease 1 0.99806147813797
homozygotes O 0 0.2613459825515747
and O 0 8.813019121589605e-06
heterozygotes O 0 0.005906766280531883
showed O 0 3.385479794815183e-05
significantly O 0 2.2364942196873017e-05
increased O 0 1.9615210931078764e-06
levels O 0 2.738274588409695e-06
of O 0 1.2238575664014206e-06
radiation O 1 0.8651033639907837
- O 1 0.682536244392395
induced O 1 0.9185159802436829
chromatid O 1 0.980412483215332
damage O 0 0.03508863225579262
relative O 0 2.266117007820867e-06
to O 0 2.854690173137442e-08
that O 0 1.3682930344316446e-08
of O 0 5.025095717314798e-08
normal O 0 6.297453182924073e-06
controls O 0 5.6276283430634066e-05
. O 0 1.4223203834262677e-05

These O 0 1.2642743740798323e-06
results O 0 1.7881583289636183e-06
show O 0 3.687928824547271e-07
that O 0 8.242455606932708e-08
the O 0 5.49767548818636e-07
G2 O 1 0.6990780830383301
- O 0 0.0007263487204909325
phase O 0 0.0001173035052488558
chromosomal O 0 0.005013065878301859
radiosensitivity O 0 0.007035473361611366
assay O 0 5.108620371174766e-06
can O 0 1.2792289005858493e-08
be O 0 5.842419326107517e-10
used O 0 1.64896218901589e-09
for O 0 1.9325481215304308e-09
the O 0 1.0478627743282232e-08
detection O 0 2.7741482426790753e-06
of O 0 5.701068062080594e-07
A B-Disease 0 0.04270670935511589
- I-Disease 1 0.9921675324440002
T I-Disease 1 0.997355580329895
heterozygotes O 0 0.04035832732915878
. O 0 4.3775267840828747e-05

In O 0 4.290453944122419e-06
combination O 0 3.967701195506379e-05
with O 0 2.068328058157931e-06
molecular O 0 0.0001291384396608919
genetic O 0 0.00019357127894181758
analyses O 0 1.3173759725759737e-05
, O 0 4.0473858575751365e-07
this O 0 9.728078254056527e-08
test O 0 1.3361004675971344e-06
may O 0 7.355446030032908e-08
be O 0 6.345007852459617e-10
of O 0 9.114810017862851e-10
value O 0 4.4677399557713215e-09
in O 0 6.2789649035721595e-09
studies O 0 4.0860751227000947e-08
of O 0 5.5923681685499105e-08
familial B-Disease 0 0.05068554729223251
and I-Disease 0 6.356760422931984e-06
sporadic I-Disease 0 0.011652367189526558
cancers I-Disease 1 0.9350827932357788
aimed O 0 4.400277703098254e-06
at O 0 6.59574368455651e-07
determination O 0 3.671946728900366e-07
of O 0 1.1926409193563359e-08
the O 0 5.8600136298991856e-08
potential O 0 5.838197694174596e-07
involvement O 0 1.1924461205126136e-06
of O 0 3.008312603469676e-07
ATM O 0 0.004252488724887371
mutations O 0 0.0008697431767359376
in O 0 0.00022172842000145465
tumor B-Disease 1 0.9991782307624817
risk O 0 0.055545058101415634
or O 0 4.406791049405001e-06
development O 0 1.5430703570018522e-05
. O 0 4.331107902544318e-06
. O 0 2.0553761714836583e-05

Ataxia B-Disease 1 0.996069073677063
- I-Disease 1 0.9937347769737244
telangiectasia I-Disease 1 0.996174693107605
: O 0 5.744530790252611e-05
identification O 0 2.8466974981711246e-06
and O 0 4.1199618294740503e-07
detection O 0 9.4868291853345e-06
of O 0 3.33603310309627e-07
founder O 0 0.00022305449238047004
- O 0 0.00037108035758137703
effect O 0 2.2338542748912005e-06
mutations O 0 1.2692323707597097e-06
in O 0 4.0787867305880354e-08
the O 0 9.147002089093803e-08
ATM O 0 3.6093126254854724e-05
gene O 0 2.5605593236832647e-06
in O 0 1.9899289327440783e-07
ethnic O 0 2.9956522666907404e-06
populations O 0 6.41098667983897e-05
. O 0 3.421999645070173e-05

To O 0 9.554102007314214e-07
facilitate O 0 9.145568924395775e-07
the O 0 1.4602629505588993e-07
evaluation O 0 8.972296541287506e-07
of O 0 1.879466822174436e-07
ATM O 0 0.0004939377540722489
heterozygotes O 0 0.0005796722252853215
for O 0 1.1437400644354057e-06
susceptibility O 0 0.00641958462074399
to O 0 2.5256358640035614e-06
other O 0 4.3535546865314245e-05
diseases O 1 0.9996799230575562
, O 0 1.5554900528513826e-05
such O 0 6.536446016980335e-05
as O 0 0.13569718599319458
breast B-Disease 1 0.9998968839645386
cancer I-Disease 1 0.9997817873954773
, O 0 2.0254310584277846e-06
we O 0 3.091215816652948e-08
have O 0 6.30914520627357e-09
attempted O 0 9.495806096992965e-08
to O 0 1.1502069519053748e-08
define O 0 3.3760395012905065e-07
the O 0 3.4460743592035215e-08
most O 0 6.718013167983372e-08
common O 0 5.819392185912875e-07
mutations O 0 4.236376014432608e-07
and O 0 5.9588356471351744e-09
their O 0 1.1202200056459333e-08
frequencies O 0 3.209856629382557e-07
in O 0 1.583779157954268e-05
ataxia B-Disease 1 0.9986780285835266
- I-Disease 1 0.9883240461349487
telangiectasia I-Disease 1 0.9986646175384521
( O 0 0.0002215665444964543
A B-Disease 0 0.06767971068620682
- I-Disease 1 0.9250405430793762
T I-Disease 1 0.9961571097373962
) O 0 4.402195827424293e-06
homozygotes O 0 0.00029146953602321446
from O 0 2.4192144110202207e-07
10 O 0 4.941718998452416e-07
ethnic O 0 1.9783533389272634e-06
populations O 0 2.5852928956737742e-05
. O 0 1.676880128798075e-05

Both O 0 8.358034392585978e-06
genomic O 0 0.00014577053661923856
mutations O 0 2.015036079683341e-05
and O 0 1.6082543652373715e-07
their O 0 8.87463045273762e-08
effects O 0 2.4926241167122498e-05
on O 0 1.8053312089705287e-07
cDNA O 0 1.1277725207037292e-05
were O 0 9.165136134470231e-07
characterized O 0 0.001346068107523024
. O 0 4.531637750915252e-05

Protein O 0 9.034204413183033e-05
- O 0 0.0004574541817419231
truncation O 0 3.631657818914391e-05
testing O 0 7.911842203611741e-07
of O 0 2.7786434486642975e-08
the O 0 4.810112130826383e-08
entire O 0 7.578821623610565e-07
ATM O 0 9.247865818906575e-06
cDNA O 0 4.379934580356348e-06
detected O 0 3.8995958675513975e-06
92 O 0 3.2120722153194947e-06
( O 0 4.2798430399670906e-07
66 O 0 1.6085901961560012e-06
% O 0 1.2487276990214013e-07
) O 0 1.853283038144582e-07
truncating O 0 2.8885036954306997e-05
mutations O 0 1.718643716230872e-06
in O 0 9.546199919441278e-08
140 O 0 5.6256358220707625e-06
mutant O 0 0.00012353244528640062
alleles O 0 5.207636422710493e-05
screened O 0 0.00016405651695095003
. O 0 2.3876760678831488e-05

The O 0 2.8769440177711658e-05
haplotyping O 0 0.04897001385688782
of O 0 2.3527027224190533e-05
patients O 0 0.17516149580478668
with O 0 7.090513463481329e-06
identical O 0 0.00023070152383297682
mutations O 0 0.0005438564112409949
indicates O 0 2.4148670490831137e-05
that O 0 2.024826706303884e-08
almost O 0 1.515180692024387e-08
all O 0 1.644041125459239e-09
of O 0 4.0558529867951165e-09
these O 0 8.985765020952385e-09
represent O 0 4.885273341415086e-08
common O 0 1.0242011967420694e-06
ancestry O 0 2.1290720724209677e-06
and O 0 8.375705817798007e-08
that O 0 3.305515861029562e-08
very O 0 1.6072118569354643e-07
few O 0 1.1493119700389798e-06
spontaneously O 0 9.16393764782697e-05
recurring O 0 0.0028340017888695
ATM O 0 0.009197691455483437
mutations O 0 0.0003407273907214403
exist O 0 7.489692507078871e-06
. O 0 1.7811984434956685e-05

Assays O 0 5.989164128550328e-05
requiring O 0 2.3225496988743544e-05
minimal O 0 1.1230288691876922e-05
amounts O 0 7.126545256141981e-07
of O 0 7.582682570728139e-08
genomic O 0 9.176801540888846e-06
DNA O 0 1.935140289788251e-06
were O 0 2.1965666618939395e-08
designed O 0 7.183454044934479e-07
to O 0 3.875161169730745e-08
allow O 0 2.6964053745359706e-07
rapid O 0 0.0001371813559671864
screening O 0 8.73763292474905e-06
for O 0 1.7624280701511452e-07
common O 0 4.402728791319532e-06
ethnic O 0 1.3229962860350497e-05
mutations O 0 0.000477783934911713
. O 0 3.4181248338427395e-05

These O 0 4.221536983095575e-06
rapid O 0 0.00021710575674660504
assays O 0 2.407591455266811e-05
detected O 0 3.264717452111654e-05
mutations O 0 3.0632950256404e-06
in O 0 1.0409091544261173e-07
76 O 0 3.7345766941143665e-06
% O 0 7.428762671679578e-08
of O 0 4.8886754200339055e-08
Costa O 0 1.842826350184623e-05
Rican O 0 1.9340894141350873e-05
patients O 0 0.000357409764546901
( O 0 4.4362641915540735e-07
3 O 0 1.5202472525288613e-07
) O 0 1.882460232138783e-08
, O 0 2.241187901930175e-09
50 O 0 5.663393309873754e-09
% O 0 4.996097313636483e-09
of O 0 1.0751496581917763e-08
Norwegian O 0 1.0061440661957022e-05
patients O 0 0.00019018015882465988
( O 0 2.2498069540688448e-07
1 O 0 6.74383002774448e-08
) O 0 1.0668540717517772e-08
, O 0 3.6633607258806933e-09
25 O 0 9.96120075313911e-09
% O 0 1.623713963283535e-08
of O 0 4.545271181655153e-08
Polish O 0 0.00038986263098195195
patients O 0 0.0009006586042232811
( O 0 4.5356412670116697e-07
4 O 0 1.621421432673742e-07
) O 0 2.8084013337092983e-08
, O 0 4.9597801421441545e-09
and O 0 2.9567941428609856e-09
14 O 0 2.044365743358867e-08
% O 0 1.943331362497247e-08
of O 0 6.239938699081904e-08
Italian O 0 0.00020497952937148511
patients O 0 0.004731635097414255
( O 0 1.2929173180964426e-06
1 O 0 5.88533964673843e-07
) O 0 1.0360049174096275e-07
, O 0 1.1278308065243436e-08
as O 0 4.0194878536681244e-09
well O 0 6.251563267056781e-09
as O 0 2.3179179464705157e-08
in O 0 1.0673002037719925e-07
patients O 0 6.09787784924265e-05
of O 0 2.0046756787905906e-07
Amish O 0 0.0006581725319847465
/ O 0 0.004804403055459261
Mennonite O 0 6.750644388375804e-05
and O 0 4.6164527134351374e-07
Irish O 0 7.210165222204523e-06
English O 0 4.3681461647793185e-06
backgrounds O 0 4.620020627044141e-05
. O 0 2.7056783437728882e-05

Additional O 0 1.3312481314642355e-05
mutations O 0 2.030930954788346e-05
were O 0 1.600376293708905e-07
observed O 0 2.8399298912518134e-07
in O 0 1.229204968922204e-07
Japanese O 0 3.82006328436546e-06
, O 0 2.335472260028837e-07
Utah O 0 4.161418473813683e-06
Mormon O 0 2.07113089345512e-06
, O 0 4.845369971917535e-07
and O 0 6.373408041326911e-07
African O 0 4.0010309021454304e-05
American O 0 0.00023940432583913207
patients O 0 0.2976113557815552
. O 0 9.573098213877529e-05

These O 0 1.2105904261261458e-06
assays O 0 2.528711092963931e-06
should O 0 2.2254754128425702e-07
facilitate O 0 7.036255169623473e-07
screening O 0 7.528815331170335e-06
for O 0 2.5554390958859585e-06
A B-Disease 0 0.08596701174974442
- I-Disease 1 0.994170069694519
T I-Disease 1 0.9988364577293396
heterozygotes O 0 0.001897830399684608
in O 0 4.9666937229631e-07
the O 0 6.402881922440429e-07
populations O 0 7.209683644759934e-06
studied O 0 2.4006085368455388e-06
. O 0 1.5023797459434718e-06
. O 0 9.250106813851744e-06

The O 0 0.00047095282934606075
von B-Disease 1 0.9493622183799744
Hippel I-Disease 1 0.9864044189453125
- I-Disease 1 0.9901482462882996
Lindau I-Disease 1 0.9951487183570862
tumor I-Disease 1 0.9964119791984558
suppressor O 0 0.06506896764039993
gene O 0 2.138058334821835e-05
is O 0 1.9197902645373688e-07
required O 0 2.3131178750190884e-07
for O 0 2.395437093127839e-07
cell O 0 8.910572796594352e-05
cycle O 0 7.947759877424687e-05
exit O 0 9.569200483383611e-05
upon O 0 1.3507401490642224e-05
serum O 0 0.004760316573083401
withdrawal O 0 0.0004163930716458708
. O 0 4.3438263674033806e-05

The O 0 8.604049071436748e-06
inactivation O 0 0.00038015301106497645
of O 0 1.35040545501397e-06
the O 0 2.6449495635461062e-05
von B-Disease 1 0.7476294636726379
Hippel I-Disease 1 0.9881261587142944
- I-Disease 1 0.915218710899353
Lindau I-Disease 1 0.9876992702484131
( I-Disease 0 0.004459526855498552
VHL I-Disease 1 0.9929612278938293
) I-Disease 0 0.0010816662106662989
tumor I-Disease 1 0.9922060370445251
suppressor O 0 0.42479172348976135
gene O 0 0.0033498744014650583
predisposes O 1 0.6796550154685974
affected O 0 0.00013014829892199486
individuals O 0 1.8667763015400851e-06
to O 0 2.5629440187913133e-06
the O 0 0.00023787058307789266
human O 1 0.9902003407478333
VHL B-Disease 1 0.9997677206993103
cancer I-Disease 1 0.9999338388442993
syndrome I-Disease 1 0.9998841285705566
and O 0 2.6438499844516627e-05
is O 0 6.5852941588673275e-06
associated O 0 3.761524203582667e-05
with O 0 0.0001021113566821441
sporadic B-Disease 1 0.9819754958152771
renal I-Disease 1 0.9997841715812683
cell I-Disease 1 0.998207688331604
carcinomas I-Disease 1 0.9993419051170349
( O 0 0.4765634536743164
RCC B-Disease 1 0.996959924697876
) O 0 0.0001417631865479052
and O 0 0.00010428112000226974
brain B-Disease 1 0.8056480884552002
hemangioblastomas I-Disease 0 0.3857607841491699
. O 0 9.033791138790548e-05

VHL O 1 0.9287940859794617
- O 0 0.00767682958394289
negative O 0 0.00040492633706890047
786 O 0 0.03849754482507706
- O 0 0.0701252669095993
0 O 0 0.0009028848726302385
RCC B-Disease 1 0.9920897483825684
cells O 0 3.1878465961199254e-05
are O 0 1.4668955827801256e-07
tumorigenic O 0 0.0009754628408700228
in O 0 1.691446755103243e-06
nude O 0 0.002876206999644637
mice O 0 0.00016303117445204407
which O 0 4.848152812542139e-08
is O 0 5.825744864296212e-08
suppressed O 0 1.7445864841647563e-06
by O 0 4.929236041562035e-08
the O 0 3.4920006442007434e-07
reintroduction O 0 0.000171462437720038
of O 0 1.1861890925501939e-05
VHL B-Disease 1 0.9787830114364624
. O 0 0.00010242948337690905

Remarkably O 0 0.001409983728080988
, O 0 3.6869337236566935e-06
this O 0 3.0036827070034633e-07
occurs O 0 2.777314193735947e-06
without O 0 3.1136733014136553e-07
affecting O 0 3.305747895865352e-06
the O 0 1.239542939401872e-07
growth O 0 1.4139865925244521e-05
rate O 0 1.4552457514582784e-06
and O 0 1.2780003544321517e-07
cell O 0 1.09809134301031e-05
cycle O 0 7.928557351988275e-06
profile O 0 1.4625028370574e-06
of O 0 1.8660943013060205e-08
these O 0 7.872615270798633e-08
cells O 0 7.421535428875359e-06
in O 0 5.949037813479663e-07
culture O 0 1.1334570444887504e-05
. O 0 8.498426723235752e-06

The O 0 3.440969521761872e-05
786 O 0 0.004546363838016987
- O 0 0.0009764968999661505
0 O 0 2.3786216843291186e-05
cell O 0 5.0479524361435324e-05
line O 0 9.086720638151746e-06
, O 0 1.7785440604711766e-06
like O 0 1.6656756997690536e-05
many O 0 3.1371324439533055e-05
cancer B-Disease 1 0.9982427358627319
cells O 0 7.177021325333044e-05
, O 0 4.057348519381776e-07
fails O 0 8.323171641677618e-06
to O 0 1.814630934404704e-08
exit O 0 2.3904399313323665e-06
the O 0 8.130160722430446e-08
cell O 0 1.2170695299573708e-05
cycle O 0 2.6504390916670673e-05
upon O 0 5.114382020110497e-06
serum O 0 0.004655076656490564
withdrawal O 0 0.00031903808121569455
. O 0 2.5107674446189776e-05

Here O 0 1.0725487300078385e-05
, O 0 6.850120826129569e-07
it O 0 6.769669624873131e-08
is O 0 2.453702130367219e-08
shown O 0 3.45811059787593e-08
that O 0 4.7754360466001344e-09
reintroduction O 0 5.952488209004514e-07
of O 0 7.860713857610335e-09
the O 0 1.1874208638573691e-07
wild O 0 1.631998566153925e-05
- O 0 0.006024940870702267
type O 0 0.0006793570937588811
VHL B-Disease 0 0.40179356932640076
gene O 0 3.425168870307971e-06
restores O 0 1.2014756975986529e-05
the O 0 8.839542431360314e-08
ability O 0 7.712712886132067e-07
of O 0 4.659445494326064e-06
VHL O 1 0.996841311454773
- O 1 0.9832985997200012
negative O 0 0.35316213965415955
RCC B-Disease 1 0.9993122816085815
cancer I-Disease 1 0.9985748529434204
cells O 0 1.4854295841359999e-05
to O 0 6.639808702857408e-08
exit O 0 2.1838311567989876e-06
the O 0 5.21082128557282e-08
cell O 0 6.625085461564595e-06
cycle O 0 5.029515250498662e-06
and O 0 2.2072218541779876e-07
enter O 0 9.602125828678254e-06
G0 O 1 0.8091743588447571
/ O 0 0.01280675083398819
quiescence O 0 0.002545563969761133
in O 0 4.755619102070341e-06
low O 0 0.00035087636206299067
serum O 0 0.005854124668985605
. O 0 2.8483991627581418e-05

Both O 0 0.00012119849998271093
VHL O 1 0.9747387766838074
- O 0 0.0072016180492937565
positive O 0 1.7357198885292746e-05
and O 0 3.4029588277917355e-05
VHL O 1 0.9929266571998596
- O 0 0.32481178641319275
negative O 0 0.0016486381646245718
RCC B-Disease 1 0.9953126907348633
cells O 0 5.623781544272788e-05
exit O 0 2.1705365725210868e-05
the O 0 3.623536883878842e-07
cell O 0 3.210835711797699e-05
cycle O 0 2.082070022879634e-05
by O 0 4.3520444137357117e-07
contact O 0 1.5185565644060262e-05
inhibition O 0 0.00019972510926891118
. O 0 2.8402102543623187e-05

The O 0 2.833595499396324e-05
cyclin O 0 0.005803236272186041
- O 0 0.0003816384414676577
dependent O 0 1.7756354282028042e-05
kinase O 0 0.00015579297905787826
inhibitor O 0 0.00025801206356845796
, O 0 1.9391418391023763e-06
p27 O 0 0.0003993817081209272
, O 0 3.5766387895819207e-07
accumulates O 0 2.9008180717937648e-05
upon O 0 7.033886504359543e-07
serum O 0 0.0007921563228592277
withdrawal O 0 7.224328328447882e-06
, O 0 2.4099362505580757e-08
only O 0 2.366312923385294e-09
in O 0 3.5210918625239174e-09
the O 0 9.044123672197202e-09
presence O 0 1.310863666503792e-07
of O 0 2.8793422757189546e-07
VHL B-Disease 1 0.9034109711647034
, O 0 1.4865666742025496e-07
as O 0 1.169046726090528e-08
a O 0 3.212909405192477e-08
result O 0 8.624832759096535e-08
of O 0 6.586966527777349e-09
the O 0 4.859734659135029e-08
stabilization O 0 7.64465585234575e-06
of O 0 3.568325013247886e-08
the O 0 3.6587684348887706e-07
protein O 0 1.5873614756856114e-05
. O 0 8.932196578825824e-06

We O 0 2.974125891341828e-06
propose O 0 1.1211711353098508e-05
that O 0 1.1768371166454017e-07
the O 0 2.0313530058047036e-07
loss O 0 2.4713406673981808e-05
of O 0 3.232049721191288e-07
wild O 0 0.00011761463974835351
- O 0 0.10086674988269806
type O 0 0.008181004785001278
VHL B-Disease 1 0.8937139511108398
gene O 0 5.946660621702904e-06
results O 0 4.489893115078303e-07
in O 0 5.050780771398422e-08
a O 0 2.4438105583612924e-07
specific O 0 1.1802624158008257e-06
cellular O 0 0.0007150991004891694
defect O 0 0.08155776560306549
in O 0 8.418695870204829e-06
serum O 0 0.1529448926448822
- O 0 0.002835867227986455
dependent O 0 9.030128239828628e-06
growth O 0 1.9898234313586727e-05
control O 0 1.7073764411179582e-06
, O 0 2.710738158384629e-07
which O 0 2.7632222554530017e-07
may O 0 1.3049895642325282e-05
initiate O 0 0.0009421377908438444
tumor B-Disease 1 0.9740067720413208
formation O 0 0.0015835176454856992
. O 0 6.903475150465965e-05

This O 0 4.430426997714676e-06
is O 0 2.2110045847512083e-06
corrected O 0 6.025478069204837e-05
by O 0 6.195561041977271e-08
the O 0 1.1025396418062883e-07
reintroduction O 0 1.4844269571767654e-05
of O 0 3.895006273069157e-07
wild O 0 0.00017663411563262343
- O 0 0.2865546643733978
type O 0 0.12169299274682999
VHL B-Disease 1 0.9950127005577087
, O 0 1.923530908243265e-05
implicating O 0 0.07907278090715408
VHL B-Disease 1 0.6339089274406433
as O 0 1.040567667587311e-07
the O 0 2.2307771985197178e-07
first O 0 8.995361895358656e-06
tumor B-Disease 1 0.9271903038024902
suppressor O 0 0.000280446169199422
involved O 0 5.631039812215022e-08
in O 0 8.344448687580552e-09
the O 0 1.0110813519759176e-08
regulation O 0 3.386713558484189e-07
of O 0 5.0840291976328444e-08
cell O 0 4.992733374820091e-05
cycle O 0 4.1751372918952256e-05
exit O 0 2.43404592765728e-05
, O 0 8.166481535454295e-08
which O 0 6.807267638464509e-09
is O 0 7.839571658507793e-09
consistent O 0 3.306676532588426e-08
with O 0 2.4089526817760998e-08
its O 0 1.637904745166452e-07
gatekeeper O 0 0.00011566119792405516
function O 0 5.558698603636003e-07
in O 0 9.263853826269042e-07
the O 0 3.7400091969175264e-05
kidney O 1 0.9982755184173584
. O 0 1.720202089927625e-05
. O 0 3.667366036097519e-05

Piebaldism B-Disease 1 0.9799442291259766
with O 0 0.03207261487841606
deafness B-Disease 1 0.9987937211990356
: O 0 0.00030671231797896326
molecular O 0 0.0001206851884489879
evidence O 0 1.1747682037821505e-05
for O 0 7.48976390241296e-06
an O 0 0.00023026378767099231
expanded O 1 0.7341929078102112
syndrome O 1 0.999143123626709
. O 0 0.0008238180889748037

In O 0 2.4292603484354913e-06
a O 0 2.4547284738218877e-06
South O 0 1.0827333426277619e-05
African O 0 1.0915364327956922e-05
girl O 0 0.00010135817137779668
of O 0 4.746104423247743e-06
Xhosa O 1 0.7096070051193237
stock O 0 0.003963866271078587
with O 0 0.0006852169753983617
severe O 1 0.997923731803894
piebaldism B-Disease 1 0.9926367998123169
and O 0 0.023921139538288116
profound O 1 0.9973925352096558
congenital O 1 0.9998810291290283
sensorineural B-Disease 1 0.9997718930244446
deafness I-Disease 1 0.999800980091095
we O 0 1.2657374099944718e-05
identified O 0 2.4385471988352947e-06
a O 0 3.1518968057753227e-07
novel O 0 2.3440547920472454e-06
missense O 0 1.155668815044919e-05
substitution O 0 4.828422675018373e-07
at O 0 7.311916760954773e-08
a O 0 5.567665795069843e-08
highly O 0 1.0881743861546056e-07
conserved O 0 6.92807944346896e-08
residue O 0 2.0153143509560323e-07
in O 0 5.240670564177208e-09
the O 0 1.1639117225570317e-08
intracellular O 0 9.058668979378126e-07
kinase O 0 5.282794290906168e-07
domain O 0 2.318373404364138e-08
of O 0 1.4454617947023962e-08
the O 0 7.820502219146874e-07
KIT O 0 0.0634005069732666
proto O 0 0.07976234704256058
- O 0 0.018470318987965584
oncogene O 0 0.005301075056195259
, O 0 4.327490842115367e-06
R796G O 0 0.0007079289644025266
. O 0 1.3666397535416763e-05

Though O 0 0.0006595347658731043
auditory B-Disease 0 0.1410081535577774
anomalies I-Disease 0 0.0149233378469944
have O 0 3.41039310569613e-07
been O 0 1.3811258270379767e-07
observed O 0 5.53397626390506e-07
in O 0 5.222602226240269e-07
mice O 0 7.704488234594464e-05
with O 0 1.0642656889103819e-06
dominant O 0 0.00043396188993938267
white O 0 0.048467736691236496
spotting O 0 0.3225882947444916
( O 0 0.00043284945422783494
W O 1 0.9449129104614258
) O 0 1.4650071307187318e-06
due O 0 2.99989460472716e-06
to O 0 1.8014166016655508e-06
KIT O 1 0.9346246123313904
mutations O 0 0.013714984990656376
, O 0 0.00043690603342838585
deafness B-Disease 1 0.9993751645088196
is O 0 4.5152529537517694e-07
not O 0 8.288647990184472e-08
typical O 0 1.896844150905963e-05
in O 0 2.280101625729003e-06
human O 0 8.104627340799198e-05
piebaldism B-Disease 0 0.13380971550941467
. O 0 9.662434604251757e-05

Thus O 0 9.39129495236557e-06
, O 0 1.0309856861567823e-06
the O 0 6.506641057058005e-07
occurrence O 0 0.00013101329386699945
of O 0 0.00011972546781180426
sensorineural B-Disease 1 0.9994029998779297
deafness I-Disease 1 0.9997320771217346
in O 0 2.6474228434381075e-05
this O 0 8.606068149674684e-06
patient O 0 0.0103797297924757
extends O 0 5.400109148467891e-05
considerably O 0 3.600475565690431e-06
the O 0 3.431565787082036e-08
phenotypic O 0 6.406107218026591e-07
range O 0 2.2345032846260438e-07
of O 0 1.0526026272827949e-07
piebaldism B-Disease 0 0.0008303397335112095
due O 0 2.3242637325893156e-06
to O 0 3.3378725561306055e-07
KIT O 0 0.01608433946967125
gene O 0 1.2305553354963195e-05
mutation O 0 6.192877663124818e-06
in O 0 1.6293363103159209e-07
humans O 0 2.920601218647789e-06
and O 0 1.0013644669015775e-06
tightens O 0 0.009447243064641953
the O 0 2.7999300300507457e-07
clinical O 0 6.762074190191925e-05
similarity O 0 2.9620621262438362e-06
between O 0 1.5584330412821146e-06
piebaldism B-Disease 0 0.0015910539077594876
and O 0 9.562309344346431e-08
the O 0 6.383810102761345e-08
various O 0 2.1052221654827008e-07
forms O 0 0.00014805050159338862
of O 0 0.014366991817951202
Waardenburg B-Disease 1 0.999393105506897
syndrome I-Disease 1 0.9995189905166626
. O 0 0.0002566416223999113
. O 0 0.00017514901992399246

Cycloheximide O 0 0.0027653842698782682
facilitates O 0 2.4403070710832253e-05
the O 0 3.880516885601537e-07
identification O 0 3.269212811574107e-07
of O 0 1.6364776911359513e-07
aberrant O 0 0.00010686238965718076
transcripts O 0 2.779884425763157e-06
resulting O 0 2.152602064597886e-06
from O 0 1.0008950113160608e-07
a O 0 2.646217183155386e-07
novel O 0 2.800725496854284e-06
splice O 0 7.157965592341498e-05
- O 0 0.00016477829194627702
site O 0 1.6367772559533478e-06
mutation O 0 3.2989235023705987e-06
in O 0 3.926034253254329e-07
COL17A1 O 0 0.008056098595261574
in O 0 9.666418918641284e-07
a O 0 3.019657015101984e-05
patient O 0 0.03703932836651802
with O 0 0.000926507986150682
generalized O 1 0.9915026426315308
atrophic B-Disease 1 0.9981550574302673
benign I-Disease 1 0.9977598190307617
epidermolysis I-Disease 1 0.9956242442131042
bullosa I-Disease 1 0.9908870458602905
. O 0 0.006149153225123882

Patients O 1 0.9541268348693848
with O 0 0.009022803977131844
generalized O 1 0.9869352579116821
atrophic B-Disease 1 0.9971049427986145
benign I-Disease 1 0.9980936646461487
epidermolysis I-Disease 1 0.9975388050079346
bullosa I-Disease 1 0.99566650390625
often O 0 0.000103241422038991
show O 0 1.9268887626822107e-05
decreased O 0 8.97624995559454e-05
expression O 0 1.6838902183735627e-06
of O 0 2.879341764128185e-06
type O 1 0.7942259907722473
XVII O 1 0.9989495873451233
collagen O 0 0.4762698709964752
, O 0 3.842204705506447e-07
a O 0 1.2084265108569525e-06
transmembrane O 0 0.00030576344579458237
hemidesmosomal O 0 0.0003261007950641215
protein O 0 1.311279220317374e-06
encoded O 0 6.038032438482333e-07
by O 0 2.5920937787304865e-06
COL17A1 O 0 0.025359440594911575
. O 0 2.3442122255801223e-05

This O 0 3.064533757424215e-06
report O 0 2.73667660621868e-06
documents O 0 5.98241172156122e-07
a O 0 4.3213071876380127e-07
novel O 0 6.2842782426741906e-06
splice O 0 0.00011497173545649275
- O 0 0.00017597227997612208
site O 0 1.5382305491584702e-06
mutation O 0 4.962956609233515e-06
in O 0 4.99930308706098e-07
COL17A1 O 0 0.008320176042616367
in O 0 5.776076932306751e-07
a O 0 6.963610758248251e-06
patient O 0 0.00584727106615901
with O 0 0.00012869368947576731
generalized O 1 0.992443859577179
atrophic B-Disease 1 0.9992648959159851
benign I-Disease 1 0.9991482496261597
epidermolysis I-Disease 1 0.9991365075111389
bullosa I-Disease 1 0.9985040426254272
, O 0 1.5334264389821328e-05
and O 0 6.813667141614133e-07
applies O 0 1.0500534699531272e-06
a O 0 2.6613136583364394e-07
new O 0 3.339923182466009e-07
methodology O 0 3.975216031903983e-07
to O 0 2.3291079287446337e-08
define O 0 5.163731771062885e-07
and O 0 5.799513758120156e-08
characterize O 0 7.886261300882325e-06
the O 0 1.0990061127813533e-07
resulting O 0 4.619817900675116e-06
mRNA O 0 3.1017816581879742e-06
splice O 0 0.00011883147817570716
variants O 0 6.305018905550241e-05
. O 0 1.8581706171971746e-05

Mutational O 0 0.001311743981204927
analysis O 0 4.888232069788501e-06
of O 0 2.2319634354062146e-06
COL17A1 O 0 0.02784169651567936
identified O 0 8.149673703883309e-06
a O 0 1.2031222468067426e-05
maternally O 0 0.017736956477165222
inherited O 1 0.6745762228965759
G O 0 0.0987607017159462
- O 0 0.002418831456452608
to O 0 2.849905513357953e-06
- O 0 0.026817485690116882
T O 0 0.47556596994400024
transversion O 0 0.00010075241880258545
at O 0 1.0338177958146844e-07
the O 0 3.415508942339329e-08
- O 0 2.056048060694593e-06
1 O 0 4.526385311010017e-08
position O 0 1.3838940660093613e-08
of O 0 5.043935757953477e-08
exon O 0 8.950581832323223e-05
32 O 0 1.3962639059172943e-05
. O 0 1.020210129354382e-05

This O 0 5.447480816656025e-06
acceptor O 0 0.0005468839081004262
splice O 0 0.0008395295008085668
- O 0 0.0005760031053796411
site O 0 2.117217036357033e-06
mutation O 0 2.784989646897884e-06
led O 0 1.7641804106460768e-07
to O 0 1.2595861242914452e-08
the O 0 3.2118617099285984e-08
formation O 0 7.035597491267254e-07
of O 0 3.86380989425561e-08
aberrant O 0 2.5639885279815644e-05
transcripts O 0 1.8976678575199912e-06
present O 0 7.227556579891825e-07
at O 0 2.897773583754315e-06
extremely O 0 4.166871804045513e-05
low O 0 0.00012699193030130118
levels O 0 6.983287312323228e-05
. O 0 1.0347097486373968e-05

Based O 0 4.310595159040531e-06
on O 0 6.263919090088166e-07
our O 0 4.1225166569347493e-07
recent O 0 1.7896476265377714e-06
finding O 0 1.1261519148320076e-06
that O 0 4.973519480699906e-07
cycloheximide O 0 0.004886353854089975
stabilized O 0 0.0025595850311219692
mutant O 0 5.28180789842736e-05
COL17A1 O 0 0.0013444332871586084
transcripts O 0 2.7287333068670705e-06
in O 0 2.40362481918055e-07
keratinocytes O 0 5.621888703899458e-05
homozygous O 0 1.0430470638311817e-06
for O 0 7.266273627237751e-08
a O 0 2.258931999676861e-06
frameshift O 0 0.037635430693626404
mutation O 0 5.01331942359684e-06
, O 0 3.353109789827613e-08
the O 0 9.855501303945857e-09
effects O 0 6.373456358232943e-07
of O 0 7.72922614800109e-09
the O 0 7.24145294839218e-08
splice O 0 3.140170520055108e-05
- O 0 3.144056609016843e-05
site O 0 1.8146488400816452e-07
mutation O 0 9.262682709731962e-08
on O 0 7.139645763487579e-09
splicing O 0 1.4999386621639132e-07
of O 0 3.6250920487646e-08
COL17A1 O 0 0.00026717109722085297
transcripts O 0 3.470447609288385e-07
were O 0 8.087594594030634e-09
determined O 0 3.971865680796327e-08
using O 0 4.562269140251374e-08
reverse O 0 1.5139034076128155e-05
transcriptase O 0 0.00017198118439409882
polymerase O 0 1.6720992789487354e-05
chain O 0 1.997067101910943e-06
reaction O 0 1.2616038702617516e-07
of O 0 5.60538282456946e-09
total O 0 3.80983244951949e-08
RNA O 0 4.028424029911548e-07
from O 0 1.5069096548359084e-07
keratinocytes O 0 3.5967095755040646e-05
incubated O 0 2.8958977509319084e-06
for O 0 3.7537228081419016e-07
2 O 0 1.3519735148292966e-05
. O 0 8.564425115764607e-06

5 O 0 6.14245655015111e-05
h O 0 0.0002043558342847973
in O 0 3.8275430824796786e-07
the O 0 1.5666603303543525e-07
presence O 0 6.55754774925299e-07
or O 0 1.3984873703520861e-07
absence O 0 7.913351396382495e-07
of O 0 7.283326652895994e-08
10 O 0 3.3680560136417625e-06
microg O 0 0.0034024720080196857
cycloheximide O 0 0.0013783519389107823
per O 0 4.549639925244264e-06
ml O 0 0.011925552040338516
. O 0 2.617765676404815e-05

Using O 0 1.204021941703104e-06
this O 0 2.8966442755518074e-07
approach O 0 1.0343123904021922e-06
, O 0 3.3402159260731423e-07
an O 0 2.743601896781911e-07
abnormally O 0 0.0011567191686481237
spliced O 0 5.2850882639177144e-05
transcript O 0 1.9258324755355716e-05
was O 0 1.8553342329141742e-07
identified O 0 3.8909291788513656e-08
that O 0 1.9919628169162706e-09
contains O 0 4.253789764874227e-09
an O 0 1.8387958933274717e-09
extra O 0 1.4164095674118471e-08
264 O 0 1.3040381929840805e-07
bases O 0 1.015662220993363e-08
upstream O 0 4.4693695855357873e-08
from O 0 1.2001484250845351e-08
exon O 0 3.850285338558024e-06
32 O 0 3.3863420867419336e-07
, O 0 3.806636428294041e-08
resulting O 0 2.885978744870954e-07
in O 0 2.099992002513318e-08
a O 0 3.3142222832793777e-07
premature O 0 0.000192692328710109
termination O 0 2.8809219656977803e-05
codon O 0 1.6779541738287662e-06
27 O 0 2.124224920407869e-06
bp O 0 7.876685231167357e-06
downstream O 0 8.944965088630852e-07
from O 0 1.0487029555861227e-07
the O 0 4.1735140143828175e-07
cryptic O 0 0.00011836746125482023
splice O 0 0.00026218031416647136
site O 0 3.977156666223891e-05
. O 0 2.3768465325701982e-05

Three O 0 1.0747939995781053e-06
other O 0 5.517913450603373e-07
splice O 0 7.824216299923137e-05
variants O 0 8.963402251538355e-06
, O 0 9.886400675895857e-08
including O 0 1.6043840034285495e-08
one O 0 6.1214397995001946e-09
derived O 0 1.6172819528037508e-08
from O 0 5.862011764889985e-09
the O 0 8.018290920119853e-09
skipping O 0 6.137084369584045e-07
of O 0 2.4974056600512995e-08
exon O 0 3.753350756596774e-05
32 O 0 2.1689804725610884e-06
, O 0 1.2527222281732975e-07
were O 0 3.522195157756869e-08
also O 0 2.1981638553825178e-07
identified O 0 3.555567445800989e-06
. O 0 7.670193554076832e-06

These O 0 9.369389317726018e-07
results O 0 2.9459984034474473e-06
indicate O 0 2.3698294171481393e-06
the O 0 3.0496022418446955e-07
usefulness O 0 2.581744956842158e-05
of O 0 2.4066303012659773e-06
cycloheximide O 1 0.6876168847084045
treatment O 0 0.0012297040084376931
in O 0 1.1019278645107988e-07
evaluating O 0 1.332878127868753e-06
the O 0 8.678429708197655e-08
abnormal O 0 5.6579069678264204e-06
processing O 0 5.103557398911107e-08
of O 0 4.916763884921238e-09
mRNA O 0 6.939705343711466e-08
due O 0 8.86972344460446e-08
to O 0 3.390642433487301e-08
splice O 0 3.5020751965930685e-05
- O 0 0.0002535607200115919
site O 0 2.443871608193149e-06
mutations O 0 4.245494437782327e-06
, O 0 1.5909765238575346e-07
because O 0 2.5871224806905957e-07
( O 0 5.457977181322349e-07
i O 0 9.38515896109493e-08
) O 0 2.857468395234264e-08
aberrant O 0 7.857357218199468e-07
splicing O 0 2.2414290867800446e-07
often O 0 4.432812872323666e-08
generates O 0 1.9105902993032942e-07
a O 0 2.671118295438646e-07
premature O 0 0.00014712492702528834
termination O 0 4.299202555557713e-05
codon O 0 2.776170276774792e-06
, O 0 4.2618322027010436e-07
( O 0 1.179312789645337e-06
ii O 0 2.124306956829969e-05
) O 0 8.059094369627928e-08
transcripts O 0 3.906747281234857e-07
with O 0 4.159206525855552e-07
premature O 0 0.002610956784337759
termination O 0 0.00021430499327834696
codons O 0 8.829599210002925e-06
can O 0 1.516583552074735e-07
occur O 0 2.6744243086795905e-07
at O 0 4.073314130437211e-07
low O 0 1.6211421097978018e-05
or O 0 1.9465737750579137e-06
undetectable O 0 0.0016374399419873953
levels O 0 9.427164400221955e-07
due O 0 1.5172953737874195e-07
to O 0 2.4254118713429307e-08
nonsense O 0 3.7786883240187308e-06
- O 0 1.7455583929404384e-06
mediated O 0 7.05058255334734e-07
mRNA O 0 2.287582532289889e-07
decay O 0 4.912726126349298e-06
, O 0 5.4995055620565836e-08
and O 0 4.760833149930477e-08
( O 0 1.1015008567483164e-06
iii O 0 0.00017459510127082467
) O 0 3.317789065704346e-08
the O 0 4.0149057412008915e-09
levels O 0 4.254497909528254e-08
of O 0 1.322456033570063e-09
these O 0 4.376924156446194e-09
transcripts O 0 1.8745924990071217e-07
can O 0 1.7841072619262377e-08
be O 0 1.53011114889523e-08
increased O 0 4.6123864194669295e-07
by O 0 7.804810593370348e-07
cycloheximide O 0 0.002029452007263899
. O 0 1.577717557665892e-05

A O 0 7.547594577772543e-05
deletion O 0 0.0013387658400461078
mutation O 0 0.00011564476153580472
in O 0 3.957697572332108e-06
COL17A1 O 0 0.010395144112408161
in O 0 6.090597253205488e-07
five O 0 1.7858133105619345e-06
Austrian O 0 0.0007847845554351807
families O 0 3.247475251555443e-05
with O 0 0.00032455529435537755
generalized O 1 0.9929189085960388
atrophic B-Disease 1 0.9987457990646362
benign I-Disease 1 0.9982700347900391
epidermolysis I-Disease 1 0.997771143913269
bullosa I-Disease 1 0.9952789545059204
represents O 0 8.530702325515449e-05
propagation O 0 8.360003448615316e-06
of O 0 5.831336125083908e-07
an O 0 3.06219976664579e-06
ancestral O 0 0.0006024080794304609
allele O 0 0.0006165398517623544
. O 0 7.42521951906383e-05

Patients O 1 0.9438660740852356
with O 0 0.0059024677611887455
generalized O 1 0.9908587336540222
atrophic B-Disease 1 0.9979290962219238
benign I-Disease 1 0.9985479712486267
epidermolysis I-Disease 1 0.9982853531837463
bullosa I-Disease 1 0.9971327781677246
, O 0 1.9007029550266452e-05
a O 0 3.4963102280016756e-06
usually O 0 1.9897402125934605e-06
nonlethal O 0 0.0001155789359472692
form O 0 7.481439752154984e-06
of O 0 3.702153480844572e-05
junctional B-Disease 1 0.9975457787513733
epidermolysis I-Disease 1 0.9978883862495422
bullosa I-Disease 1 0.9969906806945801
, O 0 1.640689151827246e-05
have O 0 3.140320359307225e-06
generalized O 0 0.006773211527615786
blistering B-Disease 1 0.9103720784187317
, O 0 0.018819238990545273
nail B-Disease 1 0.9983587861061096
dystrophy I-Disease 1 0.9991499185562134
, O 0 0.34923768043518066
patchy B-Disease 1 0.9987456798553467
alopecia I-Disease 1 0.9995002746582031
, O 0 0.0019881564658135176
and O 0 0.004124775528907776
dental B-Disease 1 0.9977787137031555
abnormalities I-Disease 1 0.9960184693336487
. O 0 0.0013143152464181185

Skin B-Disease 1 0.9957014918327332
fragility I-Disease 1 0.9857733845710754
in O 0 2.4531591407139786e-05
most O 0 5.237868208496366e-06
cases O 0 1.7173531887237914e-05
is O 0 4.1781814275054785e-07
due O 0 1.871196673164377e-06
to O 0 5.726166918407216e-08
mutations O 0 5.742101620853646e-07
in O 0 1.0327984689695313e-08
the O 0 3.647501145565002e-08
gene O 0 1.8103687580151018e-06
encoding O 0 1.3618222510558553e-05
type O 0 0.15251542627811432
XVII O 1 0.9974519610404968
collagen O 1 0.9590970277786255
( O 0 0.00015391524357255548
COL17A1 O 0 0.17465147376060486
) O 0 1.7898519217851572e-05
. O 0 9.802880413189996e-06

Recently O 0 0.00016133028839249164
, O 0 2.8150409434601897e-06
we O 0 4.084174349827663e-07
reported O 0 2.044207803919562e-06
five O 0 5.386730208556401e-07
Austrian O 0 0.0001643013529246673
families O 0 1.592753324075602e-05
with O 0 0.00036683690268546343
generalized O 1 0.9929087162017822
atrophic B-Disease 1 0.9987382292747498
benign I-Disease 1 0.998975396156311
epidermolysis I-Disease 1 0.9988054037094116
bullosa I-Disease 1 0.9973486661911011
who O 0 3.5838053008774295e-05
share O 0 3.452895498412545e-06
the O 0 1.59169428570749e-06
same O 0 1.463310036342591e-05
COL17A1 O 0 0.3375610113143921
mutation O 0 0.0014077069936320186
. O 0 6.064752597012557e-05

Affected O 0 0.0002868612064048648
individuals O 0 1.9754950244532665e-06
in O 0 1.8612320218380773e-07
three O 0 9.095835906691718e-08
families O 0 4.1027175257113413e-07
are O 0 2.5893433175383507e-08
homozygous O 0 2.98747249871667e-06
for O 0 6.878938734189433e-07
4003delTC O 0 0.014167570509016514
, O 0 7.546086635557003e-07
whereas O 0 7.618503445883107e-07
those O 0 1.717373443455017e-08
in O 0 1.691999607089656e-08
two O 0 2.025842604780337e-08
others O 0 2.6151533916163316e-07
are O 0 1.1253365528318682e-07
compound O 0 9.2578302428592e-05
heterozygotes O 0 0.011043199338018894
. O 0 4.1794231947278604e-05

To O 0 2.417049927316839e-06
determine O 0 1.3052468830210273e-06
if O 0 2.1478825829035486e-07
the O 0 7.136081592307164e-08
occurrence O 0 1.9917526969948085e-06
of O 0 1.1991261317234603e-07
4003delTC O 0 0.0006238106288947165
in O 0 1.5434574152095593e-07
these O 0 6.98370925533709e-08
unrelated O 0 2.2552327209268697e-05
families O 0 1.1737855629689875e-06
signifies O 0 1.3401367141341325e-05
propagation O 0 2.2407580502203928e-07
of O 0 1.25134391737447e-08
an O 0 6.774732952408158e-08
ancestral O 0 5.504597538674716e-06
allele O 0 2.3013951704342617e-06
or O 0 1.3719942160150822e-07
a O 0 8.11816505574825e-07
mutational O 0 0.0037388447672128677
hot O 0 4.784630800713785e-05
spot O 0 2.816286723827943e-06
, O 0 2.6073738013110415e-07
haplotypes O 0 7.97216944192769e-06
were O 0 1.4765626055179837e-08
determined O 0 7.80131514943605e-08
for O 0 3.455064856439094e-08
polymorphisms O 0 2.243977405669284e-06
both O 0 3.943257098626418e-08
within O 0 2.0831259917031275e-07
and O 0 2.394674993411172e-06
flanking O 0 0.010137012228369713
COL17A1 O 1 0.5257456302642822
. O 0 7.744882896076888e-05

Five O 0 2.508919897081796e-05
intragenic O 0 0.004275893326848745
polymorphisms O 0 4.644683576771058e-05
were O 0 2.063956401343603e-07
chosen O 0 1.8730412421064102e-07
based O 0 2.3131620707772527e-07
on O 0 3.517100424232922e-07
their O 0 1.4756693644812913e-06
informativeness O 0 0.02438339777290821
. O 0 6.157498137326911e-05

One O 0 4.0949936419565347e-07
of O 0 1.0610121137233364e-07
these O 0 1.055735268096214e-07
, O 0 1.4722535013333982e-07
not O 0 3.432908002309887e-08
previously O 0 4.1156496877192694e-07
reported O 0 1.3343851605895907e-06
, O 0 1.0499017832898971e-07
was O 0 2.271742260973042e-07
2988 O 0 4.976921991328709e-05
A O 0 6.796333309466718e-07
or O 0 2.2488244155738357e-07
C O 0 7.73463489167625e-06
that O 0 6.817285846949517e-09
introduces O 0 2.985550793255243e-07
a O 0 5.3683919531977153e-08
new O 0 1.0028595198718904e-07
restriction O 0 8.433912057626003e-07
site O 0 5.234030595602235e-07
for O 0 5.312551820679801e-07
Eco0109 O 0 0.0007139997323974967
I O 0 3.835875031654723e-05
. O 0 1.1675641871988773e-05

All O 0 1.0676060355763184e-06
the O 0 1.3278045116749126e-06
4003delTC O 0 0.000491224811412394
alleles O 0 1.3388540537562221e-05
showed O 0 2.38234929383907e-06
the O 0 1.6290239557292807e-07
same O 0 5.223738526183297e-07
haplotype O 0 0.00018632557475939393
for O 0 1.1534787347500242e-07
these O 0 1.102991831203326e-07
five O 0 1.6522046735190088e-06
polymorphic O 0 0.0022261145059019327
markers O 0 0.0023127023596316576
. O 0 8.285161311505362e-05

Fourteen O 0 0.00011321062629576772
microsatellite O 0 0.004250887781381607
polymorphisms O 0 4.3891304812859744e-05
were O 0 9.880047713295426e-08
selected O 0 5.014563342342626e-08
based O 0 3.978029639029046e-08
on O 0 2.053647740751785e-08
their O 0 3.2331037402855145e-08
high O 0 1.0040074812422972e-05
heterozygosity O 0 0.00015252744196914136
and O 0 2.8370543248001923e-08
their O 0 1.3799667186731313e-08
location O 0 1.438132244402368e-07
within O 0 3.712705165526131e-07
10q23 O 0 0.0016540312208235264
- O 0 0.002459045499563217
q25 O 0 0.0009267361601814628
near O 0 8.354246529052034e-05
COL17A1 O 0 0.021346669644117355
. O 0 4.264933886588551e-05

Three O 0 3.1176182346825954e-06
families O 0 4.377307959657628e-06
shared O 0 5.521079401660245e-06
microsatellite O 0 0.004939714912325144
polymorphisms O 0 0.00016259944823104888
covering O 0 4.0990551497088745e-05
at O 0 1.361452518722217e-06
most O 0 2.4349841964976804e-07
19 O 0 7.022832960501546e-06
cM O 0 0.0006878557032905519
, O 0 1.948520633732187e-07
whereas O 0 1.928793551542185e-07
the O 0 1.4074873710967495e-08
others O 0 3.813285687215284e-08
shared O 0 4.561990607498956e-08
smaller O 0 1.8750215247109736e-07
regions O 0 1.0424787433294114e-07
consistent O 0 2.3651912783861917e-07
with O 0 1.7858681644611352e-07
cross O 0 6.552574177476345e-06
- O 0 3.7724410503869876e-05
over O 0 5.568589500626331e-08
events O 0 2.6003108999361757e-08
during O 0 7.000527091349795e-08
passage O 0 5.960861670928352e-08
of O 0 8.095434544941327e-09
this O 0 4.5574243046075935e-08
mutation O 0 7.71881275341002e-07
through O 0 4.790609864357975e-08
several O 0 3.034550672964542e-07
generations O 0 3.552344423951581e-05
. O 0 1.57767553901067e-05

These O 0 1.691188685981615e-06
results O 0 6.678682893834775e-06
indicate O 0 4.662218998419121e-06
that O 0 2.367493010524413e-07
4003delTC O 0 0.00025129696587100625
occurs O 0 4.712018153441022e-07
on O 0 1.880099098627852e-08
a O 0 9.405533774042851e-08
single O 0 4.2173655856458936e-07
ancestral O 0 2.343794039916247e-05
allele O 0 2.3601094653713517e-05
. O 0 2.1535036012210185e-06
. O 0 8.753255315241404e-06

The O 0 3.5150533221894875e-05
haptoglobin O 0 0.04503556340932846
- O 0 0.0032664898317307234
gene O 0 6.219296483322978e-05
deletion O 0 0.00040878108120523393
responsible O 0 2.992745976371225e-05
for O 0 1.9761697330977768e-05
anhaptoglobinemia B-Disease 0 0.41282063722610474
. O 0 0.00018735277990344912

We O 0 1.1773731785069685e-06
have O 0 1.583468502985852e-07
found O 0 8.962096842424216e-08
an O 0 5.915850920246157e-08
allelic O 0 1.5197330867522396e-05
deletion O 0 6.15108001511544e-06
of O 0 5.1823356272961973e-08
the O 0 7.931650998216355e-07
haptoglobin O 0 0.005894336849451065
( O 0 5.774045348516665e-06
Hp O 0 8.807786798570305e-05
) O 0 3.4332492759858724e-07
gene O 0 2.991843928157323e-07
from O 0 2.8070571644889242e-08
an O 0 2.806998189441856e-08
individual O 0 1.1631222207597602e-07
with O 0 4.939277914672857e-06
anhaptoglobinemia B-Disease 0 0.07601816207170486
. O 0 4.5621112803928554e-05

The O 0 1.3466320524457842e-05
Hp O 0 0.00042836234206333756
gene O 0 1.1098426512035076e-05
cluster O 0 3.0553586839232594e-05
consists O 0 1.3716095281779417e-07
of O 0 3.85908904831922e-08
coding O 0 9.896068149828352e-06
regions O 0 6.0651686339952e-08
of O 0 8.450317778851968e-09
the O 0 4.799591124537983e-08
alpha O 0 2.383153741902788e-06
chain O 0 3.499719696264947e-06
and O 0 4.293145039468982e-08
beta O 0 1.3645422995978151e-06
chain O 0 5.694982405657356e-07
of O 0 1.2598191823087745e-08
the O 0 9.138614132098155e-08
haptoglobin O 0 0.0001845948863774538
gene O 0 2.533437282181694e-06
( O 0 9.006845971271105e-07
Hp O 0 4.94134155815118e-06
) O 0 2.05853787349497e-08
and O 0 2.0567945124838616e-09
of O 0 1.430521590073397e-09
the O 0 1.173850705527002e-08
alpha O 0 6.317769702945952e-07
chain O 0 2.5098531750700204e-06
and O 0 2.7521075196546008e-08
beta O 0 1.054018525792344e-06
chain O 0 4.197711689357675e-07
of O 0 1.294841478483022e-08
the O 0 2.8920786121489073e-07
haptoglobin O 0 0.0014864220283925533
- O 0 0.00017763010691851377
related O 0 9.239721293852199e-06
gene O 0 1.2138981219322886e-05
( O 0 7.84436815592926e-06
Hpr O 0 0.004369629081338644
) O 0 3.45749782582061e-07
, O 0 3.205423482199876e-08
in O 0 4.801184161351557e-08
tandem O 0 3.312387661935645e-06
from O 0 6.771477956135641e-08
the O 0 1.2886037836778996e-07
5 O 0 3.5352331906324252e-06
side O 0 1.8380804249318317e-05
. O 0 1.0479882803338114e-05

Southern O 0 0.00011232221004320309
blot O 0 0.0006704159895889461
and O 0 1.9500241705827648e-06
PCR O 0 6.986204243730754e-05
analyses O 0 5.3165172175795306e-06
have O 0 1.5170608946846187e-07
indicated O 0 6.926507012394723e-07
that O 0 5.7122777619156295e-09
the O 0 9.54630596794459e-09
individual O 0 1.9089780423087177e-08
with O 0 1.7551788289438264e-07
anhaptoglobinemia B-Disease 0 0.0008091997588053346
was O 0 9.119791144485134e-08
homozygous O 0 2.7362540322428686e-07
for O 0 7.966855619656599e-09
the O 0 2.643991514617028e-08
gene O 0 9.445783462069812e-07
deletion O 0 7.545210337411845e-06
and O 0 2.269701759871623e-08
that O 0 5.015307280586967e-09
the O 0 2.3203110544045558e-08
gene O 0 1.0993788919222425e-06
deletion O 0 8.55726557347225e-06
was O 0 5.134009128937578e-08
included O 0 3.4803900206270555e-08
at O 0 2.451110781009902e-08
least O 0 7.735420304300078e-09
from O 0 9.468023698389061e-09
the O 0 2.6504496375423514e-08
promoter O 0 5.149218395672506e-06
region O 0 1.311260007241799e-07
of O 0 2.4453903790799814e-08
Hp O 0 1.9586048438213766e-05
to O 0 1.2621285350178368e-07
Hpr O 0 0.0005135742831043899
alpha O 0 9.626850214772276e-07
but O 0 2.551436750763969e-08
not O 0 1.1322062398733124e-08
to O 0 1.629538246561424e-07
Hpr O 0 0.0022988272830843925
beta O 0 9.80375989456661e-05
( O 0 1.754659751895815e-05
Hpdel O 0 0.0018576583825051785
) O 0 5.30395891473745e-06
. O 0 7.690987331443466e-06

In O 0 4.334641289460706e-06
addition O 0 2.432946530461777e-06
, O 0 3.323819441902742e-07
we O 0 3.4096704126795885e-08
found O 0 3.429243378150204e-08
seven O 0 2.934043052960078e-08
individuals O 0 3.025078854079766e-08
with O 0 2.2972149338329473e-07
hypohaptoglobinemia B-Disease 0 0.0006077305879443884
in O 0 5.694787574839211e-08
three O 0 3.159673056529755e-08
families O 0 1.776867861735809e-07
, O 0 3.703259565668304e-08
and O 0 8.074523272227907e-09
the O 0 1.919888781287682e-08
genotypes O 0 2.516561835363973e-06
of O 0 2.3836717044645184e-09
six O 0 9.39626065843413e-09
of O 0 3.321142916234976e-09
the O 0 1.2155607187480655e-08
seven O 0 5.9127259532942844e-08
individuals O 0 3.16573540715126e-08
were O 0 8.997255385168046e-09
found O 0 3.381768109989025e-08
to O 0 4.640960682422701e-08
be O 0 4.903729973193549e-07
Hp2 O 0 0.05622867867350578
/ O 0 0.2757810056209564
Hpdel O 0 0.016215866431593895
. O 0 2.506112286937423e-05

The O 0 1.3980599760543555e-05
phenotypes O 0 0.0014999305130913854
and O 0 4.5955880523251835e-06
genotypes O 0 0.0005539933335967362
in O 0 8.605820056573066e-08
one O 0 9.975670067774445e-09
of O 0 5.709118511276756e-09
these O 0 8.952901531245061e-09
three O 0 2.810523369589646e-08
families O 0 3.259505945152341e-07
showed O 0 6.014595896886021e-07
the O 0 2.6294673105553557e-08
father O 0 2.229698736755381e-07
to O 0 1.7721218270594363e-08
be O 0 2.6439160194513533e-08
hypohaptoglobinemic B-Disease 0 0.0001622229756321758
( O 0 1.6669363276378135e-06
Hp2 O 0 7.663680298719555e-05
) O 0 3.3877535088322475e-07
and O 0 2.2805684807281068e-07
Hp2 O 0 0.0064974697306752205
/ O 0 0.00829468946903944
Hpdel O 0 0.00041335332207381725
, O 0 5.533523150802466e-08
the O 0 1.772104951669462e-08
mother O 0 2.0798604793981212e-07
to O 0 9.513768439717296e-09
be O 0 1.308691111034932e-08
Hp2 O 0 3.7531612179009244e-05
- O 0 7.57631551095983e-06
1 O 0 2.3598695975124429e-07
and O 0 2.8315409394963353e-07
Hp1 O 0 0.004634748212993145
/ O 0 0.002198651200160384
Hp2 O 0 9.031671652337536e-05
, O 0 1.2327122433930526e-08
one O 0 8.168608012226741e-10
of O 0 1.1914852438010826e-09
the O 0 4.15533030206916e-09
two O 0 6.359295312563518e-09
children O 0 4.083215543460028e-08
to O 0 6.780263461791947e-09
be O 0 1.2625927858778141e-08
hypohaptoglobinemic B-Disease 0 7.053237641230226e-05
( O 0 7.668758144063759e-07
Hp2 O 0 4.852369966101833e-05
) O 0 2.061051134205627e-07
and O 0 2.672002494819026e-07
Hp2 O 0 0.010095116682350636
/ O 0 0.007656858768314123
Hpdel O 0 0.0004348281945567578
, O 0 7.325359518972618e-08
and O 0 1.5977816403278666e-08
the O 0 7.579064487117648e-09
other O 0 1.0249135762308015e-08
child O 0 4.1308280174234824e-07
to O 0 1.2619307376837696e-08
be O 0 3.062945097553893e-08
Hp1 O 0 0.0002669190289452672
and O 0 1.4521320963467588e-06
Hp1 O 0 0.07420983165502548
/ O 0 0.02312680147588253
Hpdel O 0 0.0006200625794008374
, O 0 6.561826637607737e-08
showing O 0 1.5205198167222989e-07
an O 0 3.655705782534824e-08
anomalous O 0 7.105499662429793e-06
inheritance O 0 5.471765234688064e-06
of O 0 2.551656450577866e-07
Hp O 0 0.002543036825954914
phenotypes O 0 0.0003175590536557138
in O 0 2.9428937864395266e-07
the O 0 8.531602588845999e-07
child O 0 7.313596870517358e-05
with O 0 1.8590852050692774e-05
Hp1 O 0 0.1408722996711731
. O 0 8.198848081519827e-05

The O 0 0.00012206257088109851
Hp2 O 1 0.7942627668380737
/ O 1 0.8772972226142883
Hpdel O 0 0.05258475989103317
individuals O 0 2.300964979440323e-06
had O 0 4.0852265215107764e-07
an O 0 9.5489681939398e-08
extremely O 0 9.415492741027265e-07
low O 0 9.194656627187214e-07
level O 0 1.4161453520955547e-07
of O 0 3.063727760377333e-08
Hp O 0 2.200687595177442e-05
( O 0 7.959004619806365e-07
mean O 0 1.5495708112212014e-06
+ O 0 3.0185168725438416e-05
/ O 0 5.078031972516328e-05
- O 0 9.393677828484215e-06
SD O 0 2.0147343093412928e-05
= O 0 3.3910682759596966e-06
0 O 0 1.8901781118074723e-07
. O 0 8.230171033574152e-08
049 O 0 0.00015235460887197405
+ O 0 2.412779394944664e-05
/ O 0 1.6064705050666817e-05
- O 0 1.5149197452046792e-06
0 O 0 1.8149914637888287e-07
. O 0 5.626552379567329e-08
043 O 0 6.150861008791253e-05
mg O 0 0.00011520351108629256
/ O 0 0.00015358479868154973
ml O 0 4.935406832373701e-05
; O 0 2.7352470510777493e-07
n O 0 1.5506026329603628e-06
= O 0 3.254385774198454e-06
6 O 0 1.6510250588908093e-07
) O 0 2.7355698151154684e-08
, O 0 4.464987934937881e-09
compared O 0 1.506141877882783e-08
with O 0 2.8755036129979317e-09
the O 0 4.301355716052058e-09
level O 0 5.173960104798425e-08
( O 0 3.4517515956622447e-08
1 O 0 2.3815598382270764e-08
. O 0 7.655368783332506e-09
64 O 0 6.240087486730772e-07
+ O 0 1.8112226825905964e-05
/ O 0 1.7347583707305603e-05
- O 0 1.0570665835984983e-06
1 O 0 5.815076420390142e-08
. O 0 6.20772127035707e-08
07 O 0 1.8758562873699702e-05
mg O 0 7.401240873150527e-05
/ O 0 0.00010318266868125647
ml O 0 1.9818618966382928e-05
) O 0 3.443387086576877e-08
obtained O 0 2.9014429969720368e-08
from O 0 5.052389795423551e-08
52 O 0 2.2627395992458332e-06
healthy O 0 1.50726245919941e-05
volunteers O 0 1.6662846746839932e-06
having O 0 1.1164879651914816e-06
phenotype O 0 0.00021083018509671092
Hp2 O 0 0.0004286487237550318
, O 0 1.2853143971369718e-07
whereas O 0 4.3345812628103886e-07
the O 0 1.571667525013254e-07
serum O 0 0.00010607060539769009
Hp O 0 6.7291452978679445e-06
level O 0 3.759389599622409e-08
of O 0 3.799293768480538e-09
an O 0 1.924236592287798e-08
individual O 0 1.008845202932207e-07
with O 0 2.824027205861057e-06
Hp1 O 0 0.20931342244148254
/ O 0 0.06460091471672058
Hpdel O 0 0.0025846294593065977
was O 0 4.011871624243213e-06
0 O 0 1.9606270143412985e-05
. O 0 8.092355528788175e-06

50 O 0 9.411905193701386e-05
mg O 0 0.04810529574751854
/ O 0 0.1306789219379425
ml O 0 0.002183470642194152
, O 0 1.1291140822322632e-07
which O 0 8.372124327138408e-09
was O 0 9.762386454781335e-09
approximately O 0 7.567768633975902e-09
half O 0 4.967505518038706e-09
the O 0 3.051077612781228e-09
level O 0 1.7989441047916443e-08
of O 0 9.406464052119645e-09
Hp O 0 5.4972792895569e-06
in O 0 5.0586287159148924e-08
control O 0 7.610298098370549e-07
sera O 0 2.8344360543997027e-05
from O 0 5.23457970302843e-08
the O 0 1.7523038309263939e-07
Hp1 O 0 0.000524535367731005
phenotype O 0 3.052472311537713e-05
( O 0 1.5276098963568074e-07
1 O 0 7.337692409237206e-08
. O 0 2.127207388014085e-08
26 O 0 3.011349463122315e-07
+ O 0 1.8633629224495962e-05
/ O 0 1.482555308029987e-05
- O 0 7.986072318999504e-07
0 O 0 5.218091558845117e-08
. O 0 6.54813403500043e-09
33 O 0 2.2459140325281624e-07
mg O 0 2.891705844376702e-05
/ O 0 6.820184353273362e-05
ml O 0 2.1375059077399783e-05
; O 0 1.6354012188912748e-07
n O 0 1.5095894241312635e-06
= O 0 2.821152293108753e-06
9 O 0 1.6584641571171232e-07
) O 0 2.7586979811644596e-08
, O 0 1.3564930512188766e-08
showing O 0 1.9725837319128914e-07
a O 0 5.568466576733044e-07
gene O 0 2.128179585270118e-05
- O 0 0.0019499772461131215
dosage O 0 0.0003916620626114309
effect O 0 1.8224813175038435e-05
. O 0 9.616926035960205e-06

The O 0 2.7667028916766867e-06
other O 0 7.02712100064673e-07
allele O 0 1.8325303244637325e-05
( O 0 5.730707016482484e-06
Hp2 O 0 0.000325247849104926
) O 0 1.2404890981088101e-07
of O 0 1.8641875598746083e-08
individuals O 0 2.3628736300906894e-07
with O 0 4.390381036500912e-06
Hp2 O 1 0.9020244479179382
/ O 1 0.7791318297386169
Hpdel O 0 0.02039814181625843
was O 0 6.916526444911142e-07
found O 0 6.636833660422781e-08
to O 0 8.649836402696565e-09
have O 0 5.116283841033464e-09
, O 0 4.324685498602321e-09
in O 0 1.7325463286255172e-09
all O 0 2.3411099725478834e-09
exons O 0 6.761139843547426e-07
, O 0 3.834919226619604e-08
no O 0 5.993043572516399e-08
mutation O 0 4.623731513220264e-07
, O 0 2.2831878609963496e-08
by O 0 4.648464368983696e-08
DNA O 0 2.8021358957630582e-06
sequencing O 0 6.609990123251919e-06
. O 0 8.759944648772944e-06

On O 0 3.8440518324023287e-07
the O 0 3.9800863049777035e-08
basis O 0 1.6372514011209205e-08
of O 0 1.1544708300448292e-08
the O 0 2.4031427514614734e-08
present O 0 1.3811455801260308e-07
study O 0 1.8922089850548218e-07
, O 0 1.2140892735601483e-08
the O 0 5.477122311248195e-09
mechanism O 0 8.990105726525144e-08
of O 0 2.280485311700886e-08
anhaptoglobinemia B-Disease 0 0.0001732145028654486
and O 0 1.4339287091047481e-08
the O 0 8.75609007522371e-09
mechanism O 0 8.300323628418482e-08
of O 0 2.155712941487309e-08
anomalous O 0 3.4458822483429685e-05
inheritance O 0 1.5029979294922668e-05
of O 0 1.0100463896378642e-06
Hp O 0 0.012607757933437824
phenotypes O 0 0.0003233483002986759
were O 0 2.2956206180424488e-07
well O 0 1.1442680261097848e-06
explained O 0 3.8572310586459935e-05
. O 0 1.54758872668026e-05

However O 0 1.3972003216622397e-05
, O 0 1.8014286524703493e-06
the O 0 5.21794220276206e-07
mechanism O 0 5.863171736564254e-06
of O 0 5.5821383284637704e-06
hypohaptoglobinemia B-Disease 0 0.18340656161308289
remains O 0 0.0007677722605876625
unknown O 0 0.0004817172302864492

ATM O 0 0.0027586177457123995
mutations O 0 0.00044871619320474565
and O 0 2.4310671506100334e-05
phenotypes O 0 0.12767498195171356
in O 0 0.011523721739649773
ataxia B-Disease 1 0.9995201826095581
- I-Disease 1 0.9989458918571472
telangiectasia I-Disease 1 0.9990493655204773
families O 0 2.1343059415812604e-05
in O 0 3.3291806289525994e-07
the O 0 2.396785134806123e-07
British O 0 3.076894927289686e-06
Isles O 0 5.159457487025065e-06
: O 0 1.9726364541838848e-07
expression O 0 2.7392037083018295e-08
of O 0 2.4218753225113687e-08
mutant O 0 9.648758350522257e-06
ATM O 0 3.597714385250583e-05
and O 0 1.8354982955770538e-07
the O 0 1.7835292283052695e-06
risk O 0 0.023323792964220047
of O 0 0.0003348383179400116
leukemia B-Disease 1 0.9997848868370056
, O 1 0.923194944858551
lymphoma B-Disease 1 0.9998520612716675
, O 0 0.029789652675390244
and O 0 0.15799406170845032
breast B-Disease 1 0.9992457628250122
cancer I-Disease 1 0.9983627200126648
. O 0 0.0013227981980890036

We O 0 2.810405703712604e-06
report O 0 1.4701533928018762e-06
the O 0 8.673995210983776e-08
spectrum O 0 7.048195698189375e-07
of O 0 1.1260343057983846e-07
59 O 0 2.505443262634799e-05
ATM O 0 0.000206460477784276
mutations O 0 1.892812542791944e-05
observed O 0 6.670630682492629e-06
in O 0 5.060069088358432e-05
ataxia B-Disease 1 0.9991208910942078
- I-Disease 1 0.9964027404785156
telangiectasia I-Disease 1 0.9982113838195801
( O 0 0.0024448330514132977
A B-Disease 1 0.8082178831100464
- I-Disease 1 0.9985172152519226
T I-Disease 1 0.9993940591812134
) O 0 0.00027337035862728953
patients O 0 0.0010714784730225801
in O 0 1.9160918895977375e-07
the O 0 1.0238935601591947e-06
British O 0 4.685755993705243e-05
Isles O 0 0.0003404121089261025
. O 0 2.3586648239870556e-05

Of O 0 4.0761224227026105e-06
51 O 0 0.00015668115520384163
ATM O 0 0.002444630954414606
mutations O 0 8.220126619562507e-05
identified O 0 1.6772933122410905e-06
in O 0 1.6361188670543925e-07
families O 0 3.05230798858247e-07
native O 0 1.3255254316391074e-07
to O 0 1.3631535011882079e-08
the O 0 4.57118858321337e-08
British O 0 1.6923891053011175e-06
Isles O 0 5.165399215911748e-06
, O 0 6.175633870952879e-08
11 O 0 1.881177524865052e-07
were O 0 1.8765200948678284e-08
founder O 0 4.488695594773162e-06
mutations O 0 8.512820954820199e-07
, O 0 8.327117662076944e-09
and O 0 3.757051114661181e-09
2 O 0 1.1909836672430174e-08
of O 0 2.2472104177495567e-09
these O 0 1.1777438579940736e-08
11 O 0 1.0582912182144355e-06
conferred O 0 2.6964364224113524e-05
a O 0 9.446113836020231e-06
milder O 1 0.5255908370018005
clinical O 0 0.038634348660707474
phenotype O 0 0.0016119357896968722
with O 0 5.12725705448247e-07
respect O 0 7.324785542550671e-07
to O 0 9.402867249264091e-07
both O 0 3.0269166018115357e-05
cerebellar B-Disease 1 0.9981052875518799
degeneration I-Disease 1 0.9989166259765625
and O 0 2.4838087483658455e-05
cellular O 0 0.0014139220584183931
features O 0 0.00011803698725998402
. O 0 3.833308073808439e-05

We O 0 2.0440186290215934e-06
report O 0 1.6735576764403959e-06
, O 0 1.088296812667977e-07
in O 0 5.163411387343331e-08
two O 0 1.4643350709775405e-07
A B-Disease 0 0.0041315266862511635
- I-Disease 1 0.9233944416046143
T I-Disease 1 0.9963287711143494
families O 0 3.5486769434101006e-07
, O 0 2.4779279073072757e-08
an O 0 2.4670201881349385e-08
ATM O 0 1.181734842248261e-05
mutation O 0 1.6009655610105256e-06
( O 0 8.360381684724416e-07
7271T O 0 0.00014957773964852095
- O 0 0.0012864927994087338
- O 0 0.0027198803145438433
> O 0 0.0025914350990206003
G O 0 0.0004470888525247574
) O 0 2.896461808177264e-07
that O 0 2.5494813371551572e-08
may O 0 7.587051698010328e-08
be O 0 2.899759543595337e-09
associated O 0 2.8844040045328256e-08
with O 0 1.6105744293781754e-08
an O 0 2.1421914198072045e-07
increased O 0 0.00011889336019521579
risk O 0 0.06488721817731857
of O 0 0.0001956181658897549
breast B-Disease 1 0.99972003698349
cancer I-Disease 1 0.9986466765403748
in O 0 8.901718615561549e-07
both O 0 7.782364832564781e-07
homozygotes O 0 0.017540739849209785
and O 0 2.8549488888529595e-06
heterozygotes O 0 0.008339669555425644
( O 0 4.250217898515984e-06
relative O 0 4.556261501420522e-06
risk O 0 1.4486238796962425e-05
12 O 0 1.1944146649511822e-07
. O 0 2.1280069262274992e-08
7 O 0 2.6962996457768895e-07
; O 0 8.211290491999534e-07
P O 0 0.0005935949739068747
= O 0 7.840296166250482e-05
. O 0 2.296562229275878e-07
0025 O 0 0.0025429099332541227
) O 0 1.3049513825080794e-07
, O 0 1.1525962406722101e-08
although O 0 1.2644050251253702e-08
there O 0 8.079976687724866e-09
is O 0 2.0380429788247056e-08
a O 0 9.769931921255193e-07
less O 0 2.8543898224597797e-05
severe O 1 0.9975979924201965
A B-Disease 1 0.8215762376785278
- I-Disease 1 0.9988717436790466
T I-Disease 1 0.9994662404060364
phenotype O 0 0.00037348378100432456
in O 0 3.5873028991773026e-08
terms O 0 3.1570767333732874e-08
of O 0 2.1239721093024855e-08
the O 0 1.6254979584573448e-07
degree O 0 1.6029813195928e-05
of O 0 5.95432284171693e-05
cerebellar B-Disease 1 0.9976274371147156
degeneration I-Disease 1 0.9984436631202698
. O 0 0.002355327131226659

This O 0 5.003355909138918e-06
mutation O 0 3.7103851354913786e-05
( O 0 2.1844600269105285e-05
7271T O 0 0.002477991860359907
- O 0 0.03348954766988754
- O 0 0.009247825480997562
> O 0 0.002128120046108961
G O 0 9.403481089975685e-05
) O 0 7.328657147809281e-08
also O 0 3.344931664983619e-09
allows O 0 2.5825845906268796e-09
expression O 0 2.475871507812144e-09
of O 0 1.9746224655392552e-09
full O 0 7.796718648478418e-08
- O 0 3.592607527025393e-06
length O 0 1.7680240205208975e-07
ATM O 0 1.4353414599099779e-06
protein O 0 5.3008612610483397e-08
at O 0 2.0937648059771163e-08
a O 0 3.80281903744617e-08
level O 0 3.059687117001886e-07
comparable O 0 1.389264980389271e-06
with O 0 1.1037916181066976e-07
that O 0 1.0232049163505508e-07
in O 0 1.1170470770593965e-06
unaffected O 0 0.00033244764199480414
individuals O 0 6.368599315464962e-06
. O 0 2.5475097572780214e-05

In O 0 2.999808884851518e-06
addition O 0 2.073391669910052e-06
, O 0 2.5496862576801504e-07
we O 0 3.3696828438678494e-08
have O 0 3.157136774234459e-08
studied O 0 5.527857638298883e-07
18 O 0 1.8032171283266507e-05
A B-Disease 0 0.24660274386405945
- I-Disease 1 0.9984764456748962
T I-Disease 1 0.9996434450149536
patients O 0 0.045054350048303604
, O 0 1.3337142945601954e-07
in O 0 8.752837743486452e-08
15 O 0 6.374027634592494e-07
families O 0 1.3122649988872581e-06
, O 0 2.7763715024775593e-06
who O 0 4.7724090109113604e-05
developed O 1 0.5454586148262024
leukemia B-Disease 1 0.9996613264083862
, O 0 0.24227532744407654
lymphoma B-Disease 1 0.9997077584266663
, O 0 0.0008858782821334898
preleukemic O 1 0.98944491147995
T O 1 0.9977534413337708
- O 1 0.6543060541152954
cell O 0 0.054359473288059235
proliferation O 1 0.8515589237213135
, O 0 0.0007127607241272926
or O 0 0.49641695618629456
Hodgkin B-Disease 1 0.999849796295166
lymphoma I-Disease 1 0.9998809099197388
, O 0 4.155157876084559e-05
mostly O 0 3.8393800423364155e-06
in O 0 1.9907345631509088e-05
childhood O 0 0.18973752856254578
. O 0 0.0001008889521472156

A O 0 5.93999493503361e-06
wide O 0 2.8889246550534153e-06
variety O 0 9.050768312590662e-07
of O 0 3.2263770322060736e-07
ATM O 0 0.0017916561337187886
mutation O 0 3.4112537832697853e-05
types O 0 2.8224062589288224e-06
, O 0 1.831897691317863e-07
including O 0 3.1616025353287114e-07
missense O 0 7.94785883044824e-05
mutations O 0 3.5803968785330653e-06
and O 0 7.800512236144641e-08
in O 0 2.675776329397195e-07
- O 0 0.00022467842791229486
frame O 0 0.00012396917736623436
deletions O 0 2.4758932340773754e-05
, O 0 2.1089296353693499e-07
were O 0 3.944912307929371e-08
seen O 0 9.043640716299706e-07
in O 0 2.432932149076805e-07
these O 0 2.7401397346693557e-06
patients O 0 0.04600094258785248
. O 0 4.307155541027896e-05

We O 0 9.284231623496453e-07
also O 0 1.4176588081227237e-07
show O 0 6.145729258832944e-08
that O 0 6.930469531596373e-09
25 O 0 2.2753106065920292e-08
% O 0 1.0879414702458234e-08
of O 0 5.401141756067318e-09
all O 0 1.5199080394268094e-07
A B-Disease 0 0.15962177515029907
- I-Disease 1 0.9990197420120239
T I-Disease 1 0.9996929168701172
patients O 0 0.0037056095898151398
carried O 0 1.631348141017952e-07
in O 0 8.572253307193023e-08
- O 0 6.94104892318137e-05
frame O 0 2.2112802980700508e-05
deletions O 0 1.1679238923534285e-05
or O 0 1.12549912500981e-06
missense O 0 0.00023546023294329643
mutations O 0 7.408764304273063e-06
, O 0 2.7717568684693106e-08
many O 0 5.318399054488054e-09
of O 0 7.665538426238072e-09
which O 0 1.4363540579154233e-08
were O 0 5.022045890257232e-09
also O 0 2.174958702028107e-08
associated O 0 9.933882694213025e-08
with O 0 1.7067247171098643e-08
expression O 0 8.803115747468837e-08
of O 0 1.282148502923519e-07
mutant O 0 9.283202234655619e-05
ATM O 0 0.0005615970003418624
protein O 0 3.7729263567598537e-05
. O 0 1.140004678745754e-05

The O 0 3.464935070951469e-05
DMPK O 0 0.2516845166683197
gene O 0 0.0007284695748239756
of O 0 0.0013140911469236016
severely O 1 0.9985925555229187
affected O 1 0.9985674619674683
myotonic B-Disease 1 0.9998238682746887
dystrophy I-Disease 1 0.9999034404754639
patients O 1 0.9987220168113708
is O 0 0.0001669885532464832
hypermethylated O 0 0.3715651035308838
proximal O 0 0.005079277791082859
to O 0 1.1723803936547483e-06
the O 0 1.2825364592572441e-06
largely O 0 7.965132681420073e-06
expanded O 0 0.00023687789507675916
CTG O 0 0.31069985032081604
repeat O 0 0.005772050004452467
. O 0 6.144073267932981e-05

Using O 0 9.50150570133701e-06
methylation O 0 8.471274486510083e-05
- O 0 0.0008958664839155972
sensitive O 0 1.1202444511582144e-05
restriction O 0 1.326442725257948e-05
enzymes O 0 5.5000373322400264e-06
, O 0 1.402666782723827e-07
we O 0 1.3624414485491343e-08
characterized O 0 1.2538617966129095e-06
the O 0 9.849168591813395e-09
methylation O 0 3.6850951801170595e-07
pattern O 0 4.7141440973064164e-07
on O 0 4.063921643648882e-09
the O 0 7.981487470942739e-09
5 O 0 3.4960319084120783e-08
side O 0 2.6016056864364145e-08
of O 0 6.044932110427226e-09
the O 0 1.1324399196155355e-07
CTG O 0 0.0025807935744524
repeat O 0 1.1463124792499002e-05
in O 0 2.6529985319712068e-08
the O 0 8.098819392898804e-08
DMPK O 0 0.0004311014199629426
gene O 0 4.889766387350392e-07
of O 0 1.8634871423728327e-08
normal O 0 1.126139068219345e-06
individuals O 0 1.1852485926056033e-07
and O 0 3.4315144148422405e-07
of O 0 1.024517769110389e-05
patients O 1 0.9864106774330139
affected O 0 0.1008509024977684
with O 0 0.46004489064216614
myotonic B-Disease 1 0.9998267292976379
dystrophy I-Disease 1 0.9998528957366943
, O 0 3.128128082607873e-05
showing O 0 2.9628630727529526e-05
expansions O 0 1.7121952623710968e-05
of O 0 1.104735218859787e-07
the O 0 9.919443755279644e-07
repetitive O 0 0.00808224268257618
sequence O 0 3.5002751246793196e-05
. O 0 5.990945646772161e-05

The O 0 3.494890052024857e-06
gene O 0 7.507441750931321e-06
segment O 0 3.6851904496870702e-06
analyzed O 0 5.216340355218563e-07
corresponds O 0 3.0402600259549217e-07
to O 0 3.074674737035821e-08
the O 0 1.860454830193703e-07
genomic O 0 2.992380723298993e-05
SacI O 0 0.0035809199325740337
- O 0 0.00024287526321131736
HindIII O 0 0.00018059690773952752
fragment O 0 3.7264474030962447e-06
carrying O 0 5.706812657990668e-07
exons O 0 8.545334821974393e-06
11 O 0 6.710841716994764e-06
- O 0 0.0002154936082661152
15 O 0 7.632883352926001e-06
. O 0 8.19309389044065e-06

There O 0 1.3944494412498898e-06
is O 0 3.7284624454514415e-07
constitutive O 0 5.665336175297853e-06
methylation O 0 1.748390673128597e-06
in O 0 3.04282735896777e-07
intron O 0 0.00025601181550882757
12 O 0 1.5823576404727646e-07
at O 0 5.892056620382391e-08
restriction O 0 9.592432093086245e-08
sites O 0 1.5950625709137967e-08
of O 0 1.5781370876766232e-08
SacII O 0 8.102478750515729e-05
and O 0 1.5376805606592825e-07
HhaI O 0 0.00012328426237218082
, O 0 7.467930629445618e-08
localized O 0 4.043854460178409e-06
1 O 0 1.8225071585220576e-07
, O 0 5.279288473047927e-08
159 O 0 1.987836185435299e-06
- O 0 4.3542959247133695e-06
1 O 0 7.915044619721812e-08
, O 0 1.5299331579399222e-08
232 O 0 3.355669662141736e-07
bp O 0 4.6799661390650726e-07
upstream O 0 4.943962395032031e-08
of O 0 6.292572241051175e-09
the O 0 7.79829534280907e-08
CTG O 0 0.0025272017810493708
repeat O 0 9.665642573963851e-05
, O 0 2.727645949107682e-07
whereas O 0 6.351612569233112e-07
most O 0 2.714136471126949e-08
, O 0 4.086230731559226e-08
if O 0 8.509758231411979e-09
not O 0 7.376640409617607e-10
all O 0 6.081183334671891e-10
, O 0 1.0122791493927252e-09
of O 0 5.754254850387497e-10
the O 0 2.2607398175722437e-09
other O 0 1.9325112621260132e-09
sites O 0 1.2453674536061499e-08
of O 0 1.6383447487555713e-08
SacII O 0 0.0003946952929254621
, O 0 5.430636065284489e-07
HhaI O 0 0.00035651231883093715
, O 0 1.0257490146159398e-07
and O 0 4.243306150897297e-08
HpaII O 0 5.364887692849152e-05
in O 0 2.0019927049474973e-08
this O 0 1.548504968695852e-08
region O 0 2.0548316115309717e-07
are O 0 1.2258376536067317e-08
unmethylated O 0 0.00011422396346461028
, O 0 1.0848937392893276e-07
in O 0 6.030308696836073e-08
normal O 0 3.0123317174002295e-07
individuals O 0 3.230570300161162e-08
and O 0 2.3407006111142437e-08
most O 0 3.8615038278067004e-08
of O 0 2.96042827585552e-07
the O 0 2.544213020883035e-05
patients O 0 0.13021549582481384
. O 0 8.2735154137481e-05

In O 0 1.0397388905403204e-06
a O 0 3.750058681362134e-07
number O 0 1.669365587986249e-07
of O 0 1.220000285684364e-06
young O 0 0.001313369139097631
and O 0 0.0007047665421850979
severely O 1 0.9990733861923218
affected O 1 0.6025680303573608
patients O 0 0.2067449390888214
, O 0 3.757361639600276e-07
however O 0 3.8345095987324385e-08
, O 0 1.1049412051988838e-08
complete O 0 4.7955467152860365e-08
methylation O 0 4.17835650523557e-08
of O 0 2.2308797031911354e-09
these O 0 7.0429928555881816e-09
restriction O 0 1.7692418907699903e-07
sites O 0 3.2340164324295984e-08
was O 0 2.069170434992884e-08
found O 0 2.1105929448594907e-08
in O 0 4.550310706008531e-08
the O 0 2.601269102342485e-07
mutated O 0 0.00016743627202231437
allele O 0 3.558023308869451e-05
. O 0 7.677065696043428e-06

In O 0 3.2922384889388923e-06
most O 0 5.187467877476593e-07
of O 0 4.623184679530823e-07
these O 0 4.630095645552501e-06
patients O 0 0.0822061151266098
, O 0 3.495910277706571e-06
the O 0 7.271143658726942e-06
onset O 1 0.9942415952682495
of O 0 7.222127896966413e-05
the O 0 0.3459162414073944
disease O 1 0.9996962547302246
was O 0 0.4375936686992645
congenital O 1 0.9991125464439392
. O 0 0.004102850798517466

Preliminary O 0 1.7524838767712936e-05
in O 0 3.947723143937765e-06
vivo O 0 0.0002793589956127107
footprinting O 0 0.007173515390604734
data O 0 4.0929089095698146e-07
gave O 0 3.193721909156011e-07
evidence O 0 1.3371135310080717e-07
for O 0 7.393466461280696e-08
protein O 0 3.442328079472645e-06
- O 0 6.665071123279631e-05
DNA O 0 2.0146735550952144e-06
contact O 0 3.4052126807182503e-07
in O 0 2.199287330029165e-08
normal O 0 1.7607381153084134e-07
genes O 0 1.0182112930579024e-07
at O 0 7.832879589386721e-08
an O 0 1.221579708499121e-07
Sp1 O 0 0.0010793739929795265
consensus O 0 8.763529280031435e-08
binding O 0 6.28880698627654e-08
site O 0 4.856343238657246e-08
upstream O 0 6.900043558744073e-08
of O 0 6.728371193531757e-09
the O 0 1.211512881127419e-07
CTG O 0 0.003200106555595994
repeat O 0 1.2555139619507827e-05
and O 0 1.9077040391835e-08
for O 0 8.952064867173704e-09
a O 0 8.047926769449987e-08
significant O 0 2.3727461950784345e-07
reduction O 0 1.8631550346981385e-06
of O 0 4.190893410083163e-09
this O 0 8.305799603647301e-09
interaction O 0 5.7434604627815133e-08
in O 0 6.177860711886751e-08
cells O 0 1.1398101378290448e-06
with O 0 1.2974179242064565e-07
a O 0 6.406573902495438e-06
hypermethylated O 0 0.13377727568149567
DMPK O 0 0.2785458564758301
gene O 0 5.1698825700441375e-05
. O 0 2.618340204207925e-06
. O 0 8.665841960464604e-06

The O 0 0.00047470515710301697
hemochromatosis B-Disease 1 0.9927147030830383
gene O 0 0.0002855966449715197
product O 0 6.558229506481439e-05
complexes O 0 5.049906758358702e-05
with O 0 3.907149448423297e-07
the O 0 1.0098104894495918e-06
transferrin O 0 0.007851630449295044
receptor O 0 3.914192348020151e-05
and O 0 3.2125640814228973e-07
lowers O 0 0.00015019287820905447
its O 0 4.298733102814367e-08
affinity O 0 4.951115784024296e-07
for O 0 9.482612028932635e-08
ligand O 0 1.177953072328819e-05
binding O 0 6.495582510979148e-06
. O 0 1.4955244296288583e-05

We O 0 9.142201633949298e-06
recently O 0 1.9885295841959305e-05
reported O 0 1.8624799622557475e-06
the O 0 8.628715875147464e-08
positional O 0 2.610683168313699e-06
cloning O 0 1.5647998452550382e-06
of O 0 3.801368819722484e-08
a O 0 1.7060108348232461e-06
candidate O 0 1.338233778369613e-05
gene O 0 0.0003106729709543288
for O 0 0.00048222692566923797
hereditary B-Disease 1 0.9978316426277161
hemochromatosis I-Disease 1 0.9993748068809509
called O 0 0.4300578534603119
HFE O 1 0.9897356033325195
. O 0 0.0014178676065057516

The O 0 4.759239800478099e-06
gene O 0 1.4764050320081878e-05
product O 0 3.5269392810732825e-06
, O 0 1.0843661613080258e-07
a O 0 4.590488700273454e-08
member O 0 2.7558844095665336e-08
of O 0 1.8255594369520622e-08
the O 0 2.3126766279801814e-07
major O 0 2.8492875571828336e-05
histocompatibility O 1 0.9307078123092651
complex O 0 0.00014376660692505538
class O 0 0.0009148982353508472
I O 0 0.00020723079796880484
- O 0 0.001080959104001522
like O 0 1.6038721923905541e-06
family O 0 1.215633460560639e-06
, O 0 6.761165849411555e-08
was O 0 2.031584855899382e-08
found O 0 4.6177182078110945e-09
to O 0 1.496157198133119e-09
have O 0 1.8050060335284002e-09
a O 0 3.796514036480403e-08
mutation O 0 7.765831355754926e-07
, O 0 3.885419630478282e-07
Cys O 0 0.013416176661849022
- O 0 0.00022546469699591398
282 O 0 0.00011338834883645177
- O 0 0.0013106151018291712
- O 0 0.001152301556430757
> O 0 0.0014451037859544158
Tyr O 0 0.0045610712841153145
( O 0 1.552840103613562e-06
C282Y O 0 2.0178629711153917e-05
) O 0 6.687967868401756e-08
, O 0 1.2372608715338629e-08
in O 0 1.4655245905714764e-08
85 O 0 4.2143500422753277e-07
% O 0 8.53841015668877e-08
of O 0 1.5384051721412106e-07
patient O 0 0.0009808822069317102
chromosomes O 0 4.756783528137021e-05
. O 0 2.3883114408818074e-05

This O 0 4.174090008746134e-06
mutation O 0 3.579613985493779e-05
eliminates O 0 5.222317486186512e-05
the O 0 2.2491890661058278e-07
ability O 0 5.31457374108868e-07
of O 0 1.3665670905993466e-07
HFE O 0 0.02459593303501606
to O 0 1.6567473437589797e-07
associate O 0 2.5628460207371973e-06
with O 0 2.0966197098459816e-06
beta2 O 0 0.20128782093524933
- O 0 0.040471844375133514
microglobulin O 0 0.01783348247408867
( O 0 1.1308526154607534e-05
beta2m O 0 0.0008647536160424352
) O 0 6.582058063031582e-07
and O 0 3.684156979488762e-07
prevents O 0 0.000161825300892815
cell O 0 0.00032761460170149803
- O 0 0.0013093786546960473
surface O 0 4.490032006287947e-05
expression O 0 7.481854026991641e-06
. O 0 8.635508493171073e-06

A O 0 1.6093350495793857e-05
second O 0 5.568781944020884e-06
mutation O 0 1.8123473637388088e-05
that O 0 9.813226142796339e-08
has O 0 1.468967525397602e-07
no O 0 1.3189256264922733e-07
effect O 0 7.199557785497745e-07
on O 0 3.88495266179234e-07
beta2m O 0 0.008275897242128849
association O 0 6.230094004422426e-05
, O 0 1.4679566220365814e-06
H63D O 0 0.01754956692457199
, O 0 1.7560662968207907e-07
was O 0 4.8055543544478496e-08
found O 0 9.58048840260517e-09
in O 0 5.0720068145437835e-09
eight O 0 9.900020359054906e-09
out O 0 1.054515319509619e-08
of O 0 3.118005054147943e-08
nine O 0 3.2140608254849212e-06
patients O 0 0.0016920536290854216
heterozygous O 0 2.795329919536016e-06
for O 0 1.33529383106179e-07
the O 0 1.3227148656369536e-06
C282Y O 0 0.0022970594000071287
mutant O 0 0.0005790783325210214
. O 0 3.146798553643748e-05

In O 0 4.432865353010129e-06
this O 0 6.705479336233111e-07
report O 0 1.4905516536600771e-06
, O 0 8.997601952387413e-08
we O 0 2.0102767450680403e-08
demonstrate O 0 1.0331653044204359e-07
in O 0 7.716415240111019e-08
cultured O 0 9.302975740865804e-06
293 O 0 0.00012167153181508183
cells O 0 3.566468512872234e-05
overexpressing O 0 0.012153270654380322
wild O 0 5.5020544095896184e-05
- O 0 0.0012752782786265016
type O 0 0.00011461925896583125
or O 0 1.3812195902573876e-06
mutant O 0 5.816737757413648e-05
HFE O 0 0.007908612489700317
proteins O 0 5.6661299652205344e-08
that O 0 3.713442886521534e-09
both O 0 6.803529295495991e-09
the O 0 6.775638183853516e-08
wild O 0 6.885404218337499e-06
- O 0 0.0003603254444897175
type O 0 2.335886165383272e-05
and O 0 6.531808480758627e-07
H63D O 0 0.0466805025935173
HFE O 0 0.07104659825563431
proteins O 0 5.544615646613238e-07
form O 0 1.3858165175406612e-06
stable O 0 1.8391483536106534e-05
complexes O 0 1.280801461689407e-05
with O 0 2.7735029561881674e-07
the O 0 1.9421327124291565e-06
transferrin O 0 0.01709708757698536
receptor O 0 0.00027746614068746567
( O 0 2.7342135581420735e-05
TfR O 0 0.015730353072285652
) O 0 8.171775334631093e-06
. O 0 1.169610368378926e-05

The O 0 2.5855690182652324e-05
C282Y O 0 0.002122075529769063
mutation O 0 0.0001072962477337569
nearly O 0 1.2569587852340192e-05
completely O 0 1.2582046110765077e-05
prevents O 0 3.0069699278101325e-05
the O 0 1.2402240656683716e-07
association O 0 1.1852309853566112e-06
of O 0 2.6543805375922602e-08
the O 0 3.545666231730138e-07
mutant O 0 0.00011847823043353856
HFE O 0 0.057411037385463715
protein O 0 2.2438211999542546e-06
with O 0 1.4393922356248368e-06
the O 0 1.1168501259817276e-05
TfR O 0 0.1492380052804947
. O 0 4.503926538745873e-05

Studies O 0 1.0512986591493245e-05
on O 0 2.266852106913575e-06
cell O 0 0.0002900004619732499
- O 0 0.0008593040984123945
associated O 0 7.018426913418807e-06
transferrin O 0 0.00017805129755288363
at O 0 3.3975700830524147e-07
37 O 0 1.1590964277274907e-06
degrees O 0 1.341311985925131e-06
C O 0 2.9179978810134344e-05
suggest O 0 1.4556995608927537e-07
that O 0 7.91460319504722e-09
the O 0 8.985922761439724e-08
overexpressed O 0 0.0001541925739729777
wild O 0 1.3995153494761325e-05
- O 0 0.0014742609346285462
type O 0 0.00023137935204431415
HFE O 0 0.01219748891890049
protein O 0 1.8233865830552531e-06
decreases O 0 2.1591793029074324e-06
the O 0 2.2988052350569887e-08
affinity O 0 3.1673789635533467e-07
of O 0 3.970494688587678e-08
the O 0 8.283272450171353e-07
TfR O 0 0.005532063078135252
for O 0 4.780059498443734e-06
transferrin O 0 0.04756829887628555
. O 0 4.008226460427977e-05

The O 0 6.283062975853682e-05
overexpressed O 0 0.04176739230751991
H63D O 0 0.2452487051486969
protein O 0 4.750446169055067e-05
does O 0 2.973153414131957e-06
not O 0 3.960601446806322e-08
have O 0 1.059858867336061e-08
this O 0 1.320117970493584e-08
effect O 0 1.9235490356095397e-07
, O 0 1.0665142546883999e-08
providing O 0 9.512080900719866e-09
the O 0 2.109605823363836e-09
first O 0 3.808464654753152e-09
direct O 0 7.693661707719457e-09
evidence O 0 3.619295441126269e-08
for O 0 9.707778581002913e-09
a O 0 1.1588748805024807e-07
functional O 0 1.795117668734747e-06
consequence O 0 2.096879597957013e-06
of O 0 8.851623078953708e-08
the O 0 3.5515988656698028e-06
H63D O 0 0.2634715437889099
mutation O 0 0.0002904309658333659
. O 0 1.6968957424978726e-05

Addition O 0 7.508336693717865e-06
of O 0 3.849470431305235e-06
soluble O 0 0.002724242629483342
wild O 0 0.00025954327429644763
- O 0 0.1774744689464569
type O 0 0.05778687447309494
HFE O 1 0.9870411157608032
/ O 0 0.15134212374687195
beta2m O 0 0.013773104175925255
heterodimers O 0 0.005687899421900511
to O 0 7.160759309954301e-07
cultured O 0 7.64630749472417e-05
cells O 0 1.9255681763752364e-05
also O 0 1.9836799936001626e-07
decreased O 0 4.850783625443e-06
the O 0 4.14977989748877e-08
apparent O 0 1.2811001397494692e-06
affinity O 0 1.5111983486804093e-07
of O 0 1.2115008551916162e-08
the O 0 9.580254811680788e-08
TfR O 0 0.00017765701340977103
for O 0 9.712741722012197e-09
its O 0 2.3531852022529165e-08
ligand O 0 9.255879831471248e-07
under O 0 8.911623012863856e-07
steady O 0 7.662803545827046e-05
- O 0 0.00024983540060929954
state O 0 3.745826688827947e-07
conditions O 0 1.857311303865572e-06
, O 0 2.449517211289276e-08
both O 0 1.0690213159136874e-08
in O 0 1.1837077806831076e-07
293 O 0 8.37374827824533e-05
cells O 0 8.817642083158717e-06
and O 0 3.896514897405723e-07
in O 0 2.761188397926162e-06
HeLa O 0 0.16956625878810883
cells O 0 0.0002483271236997098
. O 0 1.3946762010164093e-05

Furthermore O 0 2.3891179807833396e-05
, O 0 7.404091775242705e-07
at O 0 4.3778112512882217e-07
4 O 0 6.744479605913511e-07
degrees O 0 1.6344515643140767e-06
C O 0 3.514031050144695e-05
, O 0 2.8587495037868393e-08
the O 0 1.995089249362536e-08
added O 0 2.5579180373824784e-07
soluble O 0 8.04259252618067e-06
complex O 0 7.047509598123725e-07
of O 0 6.983729008425144e-07
HFE O 1 0.9235778450965881
/ O 0 0.030085811391472816
beta2m O 0 0.000471285980893299
inhibited O 0 2.8001220471196575e-06
binding O 0 1.2724922271445394e-07
of O 0 1.0892500057479992e-07
transferrin O 0 0.0005632389802485704
to O 0 7.613484740431886e-07
HeLa O 0 0.013375760987401009
cell O 0 0.00013358370051719248
TfR O 0 0.0026418082416057587
in O 0 2.1730622279392264e-07
a O 0 1.787597284419462e-06
concentration O 0 0.00035525482962839305
- O 0 0.0012600768823176622
dependent O 0 1.045094813889591e-05
manner O 0 1.1817990525742061e-05
. O 0 1.443863038730342e-05

Scatchard O 0 0.0003684524563141167
plots O 0 7.835126780264545e-06
of O 0 1.6791213397482352e-07
these O 0 1.4626657218741457e-07
data O 0 4.660458046146232e-07
indicate O 0 6.894833290971292e-07
that O 0 3.3625948248072746e-08
the O 0 7.386292111277726e-08
added O 0 1.772438167790824e-06
heterodimer O 0 0.0015592463314533234
substantially O 0 5.154031896381639e-05
reduced O 0 1.561975977892871e-06
the O 0 6.318781942127316e-08
affinity O 0 1.676675992712262e-06
of O 0 7.088384563758154e-07
TfR O 0 0.0408184640109539
for O 0 1.0604608178255148e-05
transferrin O 0 0.0650746151804924
. O 0 6.100408427300863e-05

These O 0 1.2837664371545543e-06
results O 0 1.7240479337488068e-06
establish O 0 1.2754521776514594e-06
a O 0 1.384585289088136e-06
molecular O 0 3.084287891397253e-05
link O 0 3.51973321812693e-05
between O 0 3.998022293671966e-06
HFE O 0 0.09522757679224014
and O 0 7.286578096454832e-08
a O 0 1.0936029326558128e-07
key O 0 2.5200679942827264e-07
protein O 0 2.977635062961781e-07
involved O 0 1.233034794267951e-07
in O 0 2.148550350966616e-07
iron O 0 0.0018687850097194314
transport O 0 1.2495771443354897e-05
, O 0 1.8887330099914834e-07
the O 0 5.234410309640225e-07
TfR O 0 0.008479062467813492
, O 0 5.8474082464954336e-08
and O 0 2.1562268415209473e-08
raise O 0 2.1186399123962474e-07
the O 0 2.3468876619858747e-08
possibility O 0 4.677971503497247e-07
that O 0 1.9769409220771195e-08
alterations O 0 4.369154339656234e-06
in O 0 2.26808758441166e-08
this O 0 2.9025608583310714e-08
regulatory O 0 1.3358876458369195e-05
mechanism O 0 1.7339111764158588e-06
may O 0 1.0862105881415118e-07
play O 0 6.442877786838608e-09
a O 0 3.934227166269011e-08
role O 0 1.5072359360601695e-07
in O 0 1.886466662881503e-07
the O 0 2.3139705263020005e-06
pathogenesis O 1 0.7011311054229736
of O 0 0.0006799867260269821
hereditary B-Disease 1 0.9987053871154785
hemochromatosis I-Disease 1 0.9996125102043152
. O 0 0.0005748083931393921
. O 0 0.00020090701582375914

Genomic O 0 0.00011800356151070446
organization O 0 6.068372840672964e-06
of O 0 1.1102470125479158e-06
the O 0 1.7966856830753386e-05
UBE3A O 1 0.8816071152687073
/ O 1 0.5257202386856079
E6 O 0 0.37533631920814514
- O 0 0.0522649884223938
AP O 0 0.0011138119734823704
gene O 0 1.6708256225683726e-05
and O 0 1.8459676311977091e-06
related O 0 9.449666686123237e-05
pseudogenes O 0 0.0013021666090935469
. O 0 4.489346974878572e-05

The O 0 1.2377501661831047e-05
UBE3A O 0 0.0011377263581380248
gene O 0 5.997308562655235e-06
encodes O 0 2.9594586976600112e-06
the O 0 1.285862822442141e-06
E6 O 0 0.0019280224805697799
- O 0 0.0006845557945780456
AP O 0 0.00010128222493221983
ubiquitin O 0 8.023744885576889e-05
- O 0 8.248701487900689e-05
protein O 0 1.3721919458475895e-06
ligase O 0 2.5923513021552935e-05
and O 0 1.3092882511500648e-07
has O 0 1.7820420339376142e-07
recently O 0 5.147226715962461e-07
been O 0 1.793110193659686e-08
shown O 0 6.426666487868715e-08
to O 0 6.650265049756854e-08
be O 0 8.027672606658598e-07
mutated O 0 0.18977850675582886
in O 1 0.7594578266143799
Angelman B-Disease 1 0.9998916387557983
syndrome I-Disease 1 0.9999635219573975
patients O 1 0.9989042282104492
who O 0 0.0004100096703041345
lack O 0 0.004101403057575226
15q11 O 0 0.2669043242931366
- O 0 0.04012308642268181
q13 O 0 0.0018652768339961767
deletions O 0 5.880167373106815e-05
or O 0 2.808556928357575e-06
chromosome O 0 0.00013244475121609867
15 O 0 5.814896576339379e-05
paternal O 0 0.006091790273785591
uniparental B-Disease 1 0.9766849279403687
disomy I-Disease 1 0.6015805006027222
. O 0 0.0002436978102196008

Previous O 0 6.890800432302058e-05
UBE3A O 0 0.0028923796489834785
cDNA O 0 3.8410806155297905e-05
analysis O 0 4.917872956866631e-06
has O 0 6.747992529199109e-07
shown O 0 3.576041933683882e-07
a O 0 5.216002136876341e-07
coding O 0 3.8355752622010186e-05
region O 0 3.9791416384105105e-07
of O 0 4.95014305101904e-08
approximately O 0 1.0775351029224112e-06
2 O 0 2.4108749130391516e-05
. O 0 9.90258195088245e-06

6 O 0 3.877586277667433e-05
kb O 0 0.00016918781329877675
and O 0 4.916297484669485e-07
a O 0 9.446756621400709e-07
3 O 0 1.2011182661808562e-05
- O 0 0.0007320318836718798
untranslated O 0 0.0002875221543945372
region O 0 1.6583389879087918e-06
( O 0 5.042642214903026e-07
UTR O 0 2.2133644961286336e-05
) O 0 3.241594015435112e-08
of O 0 1.8237287235933763e-08
< O 0 2.6818597689270973e-05
50 O 0 1.5286371990441694e-07
bp O 0 2.265840521431528e-06
, O 0 1.555660134044956e-08
whereas O 0 5.1071019413484464e-08
Northern O 0 1.0239913805776268e-08
analysis O 0 2.1522536641782608e-08
has O 0 9.881815365986313e-09
indicated O 0 4.169909573192854e-08
mRNA O 0 2.039182334101497e-08
sizes O 0 5.495773081065636e-08
of O 0 1.7277589137165705e-08
5 O 0 1.7764012909537996e-06
- O 0 0.0001049182828865014
8 O 0 1.2114579476474319e-05
kb O 0 0.0008526081219315529
. O 0 1.6999796571326442e-05

We O 0 1.2114335277146893e-06
have O 0 1.3319221636720613e-07
analyzed O 0 3.43746876296791e-07
additional O 0 2.1805585959100426e-07
cDNA O 0 8.351301403308753e-06
clones O 0 4.678923505707644e-05
and O 0 8.300924747572935e-08
provide O 0 1.1497895968659577e-07
evidence O 0 8.005839902125444e-08
for O 0 2.1275239348028663e-08
an O 0 8.882318525138544e-08
additional O 0 1.255771621799795e-06
0 O 0 2.449743442412e-05
. O 0 7.439548880938673e-06

5 O 0 1.6085186871350743e-05
kb O 0 8.907361916499212e-05
of O 0 7.155973094086221e-07
5 O 0 1.1664389603538439e-05
- O 0 0.00030156277352944016
UTR O 0 0.0002727478859014809
and O 0 2.4002301302061824e-07
> O 0 2.7661548301693983e-05
2 O 0 1.0384368351878948e-06
kb O 0 1.9354787582415156e-05
of O 0 3.08430259110537e-07
3 O 0 4.7624340368201956e-05
- O 0 0.005494262091815472
UTR O 0 0.006964672356843948
. O 0 2.747339749475941e-05

We O 0 1.2105281257390743e-06
have O 0 1.2341806154836377e-07
established O 0 7.959143744074026e-08
the O 0 4.7870933883586986e-08
genomic O 0 2.362723307669512e-06
organization O 0 1.2766943768838246e-07
of O 0 4.317328006209209e-08
UBE3A O 0 0.000624041655100882
and O 0 7.871636675815807e-09
the O 0 7.924271017145657e-09
sequence O 0 6.168875898993065e-08
of O 0 2.4114862640089996e-07
intron O 0 0.03312976285815239
- O 0 0.0030675495509058237
exon O 0 0.0010035875020548701
borders O 0 3.967413431382738e-05
. O 0 2.4476794351357967e-05

We O 0 9.573237775839516e-07
have O 0 1.2624704481822846e-07
also O 0 3.445942908797406e-08
mapped O 0 1.7777526295503776e-07
two O 0 1.0768078873013565e-08
highly O 0 9.763433439502478e-08
homologous O 0 1.502263671682158e-06
processed O 0 8.282063959086372e-07
pseudogenes O 0 3.101880065514706e-05
, O 0 1.2848711321566952e-06
UBE3AP1 O 0 0.004031315445899963
and O 0 3.8965853832451103e-07
UBE3AP2 O 0 0.0003279580269008875
, O 0 2.248077635158552e-08
to O 0 3.93046750701842e-09
chromosomes O 0 7.353762754291893e-08
2 O 0 1.3035172230502212e-07
and O 0 1.8585213368282893e-08
21 O 0 1.5510862283463211e-07
, O 0 3.183124519523517e-08
respectively O 0 6.179263323247142e-08
, O 0 1.2150923822673576e-08
and O 0 9.832482383842489e-09
determined O 0 9.593620831083172e-08
their O 0 8.58832507333318e-08
genomic O 0 3.3786036510718986e-05
organization O 0 1.0576087333902251e-05
. O 0 1.2689572940871585e-05

These O 0 3.1468198358197697e-06
results O 0 4.428741704032291e-06
will O 0 8.864208922432226e-08
form O 0 7.157809989166708e-08
the O 0 1.0670983208171947e-08
basis O 0 7.887747344170748e-09
for O 0 1.3085114325406266e-08
studies O 0 9.593987471134824e-08
of O 0 2.849136393479057e-08
mutation O 0 2.6133859591936925e-06
and O 0 2.4186030600503727e-07
imprinting O 0 7.821784674888477e-05
of O 0 8.40922712086467e-06
UBE3A O 0 0.3095998764038086
. O 0 6.374774966388941e-05

Mutation O 0 0.00018568089581094682
spectrum O 0 5.6130393204512075e-05
and O 0 7.455322247551521e-06
genotype O 0 0.005527188070118427
- O 0 0.07801821827888489
phenotype O 0 0.018640387803316116
analyses O 0 0.0008317849133163691
in O 0 0.0037341301795095205
Cowden B-Disease 1 0.9981118440628052
disease I-Disease 1 0.9990994930267334
and O 0 0.013671372085809708
Bannayan B-Disease 1 0.9962552785873413
- I-Disease 1 0.9984365105628967
Zonana I-Disease 1 0.9987861514091492
syndrome I-Disease 1 0.9995800852775574
, O 0 0.00026299248565919697
two O 0 0.0004731741501018405
hamartoma B-Disease 1 0.9970595240592957
syndromes I-Disease 1 0.9971416592597961
with O 0 0.004492012318223715
germline O 1 0.9890918731689453
PTEN O 1 0.9896044731140137
mutation O 0 0.01321050152182579
. O 0 0.00019751809304580092

The O 0 0.000980679295025766
tumour B-Disease 1 0.9951689839363098
suppressor O 0 0.4635242521762848
gene O 0 0.0030587746296077967
PTEN O 1 0.6903934478759766
, O 0 9.048567335412372e-07
which O 0 2.1971830221900746e-07
maps O 0 3.3773642371670576e-06
to O 0 2.195646629843395e-06
10q23 O 0 0.002906329929828644
. O 0 5.3785443014930934e-05

3 O 0 1.7894104757942841e-06
and O 0 1.0656891191729301e-07
encodes O 0 1.6409880743140093e-07
a O 0 7.346178421130389e-08
403 O 0 8.239750286520575e-07
amino O 0 1.029068670277411e-07
acid O 0 1.264835191250313e-06
dual O 0 7.308255476345948e-07
specificity O 0 1.1329696008033352e-06
phosphatase O 0 0.0001516570191597566
( O 0 5.187577016840805e-07
protein O 0 5.706594947696431e-07
tyrosine O 0 9.574777322995942e-06
phosphatase O 0 0.00263443635776639
; O 0 6.068077254894888e-06
PTPase O 0 0.0009136921144090593
) O 0 2.9850411920051556e-07
, O 0 3.327599173985618e-08
was O 0 3.163701478570147e-08
shown O 0 2.9819194224955936e-08
recently O 0 6.729554513640323e-08
to O 0 3.80624998186363e-09
play O 0 1.2650540170966451e-08
a O 0 1.5401990083319106e-07
broad O 0 1.9039354810956866e-05
role O 0 4.774182343680877e-06
in O 0 8.099311344267335e-06
human O 0 0.00040276043000631034
malignancy B-Disease 1 0.9954727292060852
. O 0 0.00017449191363994032

Somatic O 0 0.008166607469320297
PTEN O 0 0.2003866732120514
deletions O 0 0.00021706311963498592
and O 0 2.4068367565632798e-06
mutations O 0 1.072479244612623e-05
were O 0 7.362660880971816e-08
observed O 0 1.176896034849051e-06
in O 0 2.8728850338666234e-06
sporadic B-Disease 0 0.05356646329164505
breast I-Disease 1 0.9993706345558167
, I-Disease 0 0.055871739983558655
brain I-Disease 1 0.9987909197807312
, I-Disease 1 0.7762634754180908
prostate I-Disease 1 0.9998410940170288
and I-Disease 1 0.9658640027046204
kidney I-Disease 1 0.9999188184738159
cancer I-Disease 1 0.9998082518577576
cell O 0 0.06441771984100342
lines O 0 2.8140637368778698e-05
and O 0 1.8742635177204647e-07
in O 0 2.2738187510640273e-07
several O 0 6.17112505096884e-07
primary O 0 0.00045926281018182635
tumours B-Disease 1 0.9963561296463013
such O 0 6.193662557052448e-05
as O 0 0.014585359953343868
endometrial B-Disease 1 0.9988089799880981
carcinomas I-Disease 1 0.9996999502182007
, O 1 0.998166561126709
malignant B-Disease 1 0.9998804330825806
melanoma I-Disease 1 0.9998944997787476
and O 1 0.996950626373291
thyroid B-Disease 1 0.9996063113212585
tumours I-Disease 1 0.9987261891365051
. O 0 0.01871557906270027

In O 0 8.481617442157585e-06
addition O 0 1.602527299837675e-05
, O 0 1.7578337065060623e-05
PTEN O 0 0.06326599419116974
was O 0 9.717180091683986e-07
identified O 0 3.1667264011048246e-07
as O 0 5.523041934907269e-08
the O 0 2.16655834606172e-07
susceptibility O 0 0.0003125654475297779
gene O 0 7.860139703552704e-06
for O 0 4.855277893511811e-06
two O 0 0.0005626884521916509
hamartoma B-Disease 1 0.9990873336791992
syndromes I-Disease 1 0.9996011853218079
Cowden B-Disease 1 0.9995585083961487
disease I-Disease 1 0.9994148015975952
( O 0 0.00028006889624521136
CD B-Disease 0 0.0006702003302052617
; O 0 4.019537664134987e-05
MIM O 0 0.08149271458387375
158350 O 0 0.000995479873381555
) O 0 1.1465292573120678e-06
and O 0 1.0562181387285818e-06
Bannayan B-Disease 0 0.017697006464004517
- I-Disease 0 0.01812494918704033
Zonana I-Disease 0 0.44927719235420227
( I-Disease 0 1.7481756003689952e-05
BZS I-Disease 0 0.0035308643709868193
) I-Disease 0 2.0259758457541466e-06
or I-Disease 0 7.62331046644249e-06
Ruvalcaba I-Disease 0 0.27928099036216736
- I-Disease 0 0.26642608642578125
Riley I-Disease 0 0.291705459356308
- I-Disease 1 0.9916722178459167
Smith I-Disease 1 0.9523084759712219
syndrome I-Disease 1 0.9991600513458252
( O 0 0.001063245814293623
MIM O 1 0.8532251715660095
153480 O 0 0.04319190979003906
) O 0 3.532554910634644e-05
. O 0 2.492564635758754e-05

Constitutive O 0 0.0002174689288949594
DNA O 0 1.948927456396632e-05
from O 0 1.7338848010695074e-06
37 O 0 4.568753411149373e-06
CD B-Disease 0 8.004769370018039e-06
families O 0 5.936626052971405e-07
and O 0 1.1680664613322733e-07
seven O 0 1.9393266939005116e-06
BZS B-Disease 0 0.04193924739956856
families O 0 1.2596890428540064e-06
was O 0 6.212897005752893e-07
screened O 0 1.0051437129732221e-05
for O 0 4.40926305600442e-06
germline O 0 0.18244385719299316
PTEN O 1 0.9334975481033325
mutations O 0 0.0016599486116319895
. O 0 7.99142217147164e-05

PTEN O 1 0.5028002262115479
mutations O 0 6.551491242134944e-05
were O 0 2.1340230205169064e-07
identified O 0 3.322855661735957e-07
in O 0 2.8434683940758987e-08
30 O 0 6.46697486672565e-08
of O 0 1.74514678263904e-08
37 O 0 6.702998689434025e-07
( O 0 3.726742079379619e-07
81 O 0 2.008797082453384e-06
% O 0 4.44908465624394e-08
) O 0 5.850018780506616e-08
CD B-Disease 0 9.640632470109267e-07
families O 0 6.382239092772579e-08
, O 0 1.8445296845470693e-08
including O 0 6.510713035368099e-08
missense O 0 8.843875548336655e-06
and O 0 6.293727494721679e-08
nonsense O 0 6.699997356918175e-06
point O 0 2.799679066356475e-07
mutations O 0 1.813792096072575e-06
, O 0 6.892887682852233e-08
deletions O 0 1.5864341094129486e-06
, O 0 7.158233472637221e-08
insertions O 0 2.5399303922313266e-06
, O 0 1.4290965566488012e-07
a O 0 1.0694454886106541e-06
deletion O 0 0.0008698757737874985
/ O 0 0.0020629370119422674
insertion O 0 1.680379682511557e-05
and O 0 7.360904987763206e-07
splice O 0 0.00021788713638670743
site O 0 3.071191531489603e-05
mutations O 0 0.0001287511404370889
. O 0 2.2664224161417224e-05

These O 0 2.3393558876705356e-06
mutations O 0 6.774281700927531e-06
were O 0 5.06582189530036e-08
scattered O 0 2.2049938763757382e-07
over O 0 6.470984459383544e-08
the O 0 2.247893249318622e-08
entire O 0 2.5311379658887745e-07
length O 0 6.336716751320637e-07
of O 0 2.1008678174894158e-07
PTEN O 0 0.056870587170124054
, O 0 5.171227002165324e-08
with O 0 1.2944339822240636e-08
the O 0 1.1372923935937251e-08
exception O 0 3.9187021627640206e-08
of O 0 1.913968095124119e-09
the O 0 6.923229101118977e-09
first O 0 1.7437294275168824e-08
, O 0 4.3415397499302344e-08
fourth O 0 3.321696055991197e-07
and O 0 1.1719126291609427e-07
last O 0 2.3018890260573244e-06
exons O 0 3.5159788239980116e-05
. O 0 1.249445995199494e-05

A O 0 2.222086550318636e-05
hot O 0 6.841334834462032e-05
spot O 0 8.92204752744874e-06
for O 0 1.8670112922336557e-06
PTEN O 0 0.0706544816493988
mutation O 0 9.856923497864045e-06
in O 0 1.412137180523132e-07
CD B-Disease 0 7.620039468747564e-06
was O 0 9.965708613890456e-08
identified O 0 6.669534968750668e-08
in O 0 2.143646149477263e-08
exon O 0 6.782659511372913e-06
5 O 0 4.894198823990337e-08
that O 0 2.3813995220223205e-09
contains O 0 1.1085171891522805e-08
the O 0 1.882442113299021e-08
PTPase O 0 7.11631219019182e-05
core O 0 1.7562582570462837e-06
motif O 0 2.6743578018795233e-06
, O 0 9.551095914162033e-09
with O 0 4.31402513711987e-09
13 O 0 1.8320474026722877e-08
of O 0 4.248267959638952e-09
30 O 0 7.817715186320129e-08
( O 0 5.9081379788494814e-08
43 O 0 1.0035923736495533e-07
% O 0 2.6292017452078653e-08
) O 0 5.649209455782511e-08
CD B-Disease 0 3.3174680993397487e-06
mutations O 0 1.0499703648747527e-06
identified O 0 9.716376325741294e-08
in O 0 3.896179734397265e-08
this O 0 2.674720178674761e-07
exon O 0 0.00061501917662099
. O 0 2.156932168873027e-05

Seven O 0 1.88516048638121e-06
of O 0 4.243258047154086e-07
30 O 0 1.6912401861191029e-06
( O 0 8.346106028511713e-07
23 O 0 4.986009116692003e-07
% O 0 9.465426842325542e-08
) O 0 1.9849814236749808e-08
were O 0 8.439650645009067e-10
within O 0 1.8529987544368964e-09
the O 0 4.9556478920465e-09
core O 0 3.7104470607118856e-07
motif O 0 1.8093555809173267e-06
, O 0 1.1852186787564278e-08
the O 0 8.445516286315069e-09
majority O 0 3.630191258707782e-08
( O 0 2.340441618287059e-08
five O 0 1.658253867553583e-09
of O 0 1.794672965793609e-09
seven O 0 1.3194282999506868e-08
) O 0 9.425392910600294e-09
of O 0 1.6464259955384364e-09
which O 0 8.481385371794659e-09
were O 0 2.467024984298405e-08
missense O 0 4.22354532929603e-05
mutations O 0 5.413693997979863e-06
, O 0 1.5450626733581885e-07
possibly O 0 4.4824574274571205e-07
pointing O 0 5.702482326341851e-07
to O 0 5.662486035618031e-09
the O 0 2.7839430316589642e-08
functional O 0 4.208293660212803e-07
significance O 0 2.2578069547307678e-07
of O 0 6.16714714851696e-08
this O 0 8.187097364498186e-07
region O 0 5.134301682119258e-05
. O 0 2.449995736242272e-05

Germline O 1 0.8103880882263184
PTEN O 1 0.7164808511734009
mutations O 0 6.0908922023372725e-05
were O 0 1.3492710593254742e-07
identified O 0 1.575389063646071e-07
in O 0 1.139161742713668e-08
four O 0 6.7502750056291916e-09
of O 0 1.2524017378723329e-08
seven O 0 4.815675538338837e-07
( O 0 2.6498107672523474e-06
57 O 0 8.217290087486617e-06
% O 0 1.966469653780223e-06
) O 0 5.625383892038371e-06
BZS B-Disease 0 0.012861289083957672
families O 0 5.604088528343709e-06
studied O 0 1.3284618944453541e-05
. O 0 1.9147240891470574e-05

Interestingly O 0 0.0008318173349834979
, O 0 3.4217864595120773e-06
none O 0 7.950674785206502e-07
of O 0 5.7665001662599025e-08
these O 0 1.1156510026921751e-07
mutations O 0 4.179211828159168e-06
was O 0 2.1352404644403578e-07
observed O 0 2.242451131451162e-07
in O 0 1.0875954359335083e-07
the O 0 7.870887088756717e-07
PTPase O 0 0.0034377200063318014
core O 0 0.00010765165643533692
motif O 0 0.0005005786661058664
. O 0 3.924590419046581e-05

It O 0 1.686508198872616e-06
is O 0 3.642058459263353e-07
also O 0 1.1433720459308461e-07
worthy O 0 5.71467694499006e-07
of O 0 2.3827910311524647e-08
note O 0 8.160407105606282e-07
that O 0 9.241450271701979e-09
a O 0 2.225105610875744e-08
single O 0 5.555953919156309e-08
nonsense O 0 3.4697202409006422e-06
point O 0 2.3149495120833308e-07
mutation O 0 3.3420367344660917e-06
, O 0 2.0902500352804054e-07
R233X O 0 1.9917049939977005e-05
, O 0 2.4676932497413873e-08
was O 0 1.3682173616302862e-08
observed O 0 1.9979985665941058e-08
in O 0 8.755939084892361e-09
the O 0 3.4661404413327546e-08
germline O 0 2.862979999918025e-05
DNA O 0 3.252457361213601e-07
from O 0 3.8163417315217885e-08
two O 0 3.1424420399162045e-08
unrelated O 0 8.234508641180582e-06
CD B-Disease 0 2.9924034606665373e-05
families O 0 1.2677805898420047e-06
and O 0 3.3576031910342863e-07
one O 0 2.048071564786369e-06
BZS B-Disease 0 0.34408774971961975
family O 0 7.062445365590975e-05
. O 0 2.2932426873012446e-05

Genotype O 0 0.37926626205444336
- O 1 0.5605494379997253
phenotype O 0 0.01181589812040329
studies O 0 2.213251264038263e-06
were O 0 3.9959914488463255e-08
not O 0 9.738786665991483e-09
performed O 0 4.706633305318064e-08
on O 0 1.0140245976231199e-08
this O 0 2.0829860503113196e-08
small O 0 1.4228925238057855e-07
group O 0 4.0512551890969917e-07
of O 0 1.2296662816879689e-06
BZS B-Disease 0 0.44832393527030945
families O 0 5.306794264470227e-05
. O 0 3.1063911592355e-05

However O 0 1.730599433358293e-05
, O 0 9.702265742816962e-06
genotype O 0 0.0022251331247389317
- O 0 0.0032305140048265457
phenotype O 0 0.0002594463003333658
analysis O 0 1.7273180219490314e-06
inthe O 0 0.00013433147978503257
group O 0 4.889151341558318e-07
of O 0 1.0999477240147826e-07
CD B-Disease 0 4.2798743379535154e-05
families O 0 7.997977604645712e-07
revealed O 0 6.294591798905458e-07
two O 0 1.2126798232259262e-08
possible O 0 8.921795568994639e-08
associations O 0 1.2702140850251453e-07
worthy O 0 3.41628805244909e-07
of O 0 1.3045242219789088e-08
follow O 0 4.131096034143411e-07
- O 0 1.3122877135174349e-05
up O 0 9.69728901623057e-08
in O 0 6.667881535804554e-08
independent O 0 2.6914545969702885e-07
analyses O 0 8.678297490405384e-06
. O 0 5.9884673646593e-06

The O 0 2.265183866256848e-06
first O 0 1.400062160428206e-06
was O 0 1.6480657905049156e-06
an O 0 7.666951660212362e-07
association O 0 1.9495833839755505e-05
noted O 0 5.292496894071519e-07
in O 0 1.7139210939376426e-08
the O 0 1.6340814923410107e-08
group O 0 1.0038833408998471e-07
of O 0 1.1110661546354095e-07
CD B-Disease 0 0.0010955339530482888
families O 0 0.00032687795464880764
with O 0 0.10140200704336166
breast B-Disease 1 0.9994891881942749
disease I-Disease 1 0.9988283514976501
. O 0 0.0016220833640545607

A O 0 1.0762230886030011e-05
correlation O 0 5.498401151271537e-06
was O 0 3.5039971635342226e-07
observed O 0 1.61339443138786e-07
between O 0 1.1895630080971387e-07
the O 0 2.52089961350066e-07
presence O 0 7.635162546648644e-06
/ O 0 0.0009527035872451961
absence O 0 1.0432927410874981e-06
of O 0 6.626638082707359e-08
a O 0 7.938318049127702e-06
PTEN O 0 0.2931879162788391
mutation O 0 8.345824426214676e-06
and O 0 1.0029608432660098e-07
the O 0 3.454169075212121e-07
type O 0 9.799459076020867e-05
of O 0 9.638549272494856e-06
breast O 1 0.9969954490661621
involvement O 0 0.004971719346940517
( O 0 0.0008800634532235563
unaffected O 0 0.10243672132492065
versus O 1 0.6019482612609863
benign O 1 0.9973607659339905
versus O 1 0.9902386665344238
malignant O 1 0.9988200068473816
) O 0 0.00039085737080313265
. O 0 0.0001005747399176471

Specifically O 0 1.3381533790379763e-05
and O 0 4.394685788611241e-07
more O 0 1.1680954514758923e-07
directly O 0 1.6012938885978656e-07
, O 0 2.082291672422798e-07
an O 0 2.3234159129970067e-07
association O 0 1.4158757039695047e-05
was O 0 1.6505904909536184e-07
also O 0 1.617713962787093e-08
observed O 0 2.054827064057463e-08
between O 0 1.257910309249155e-08
the O 0 1.3006980381646827e-08
presence O 0 8.69315783802449e-08
of O 0 9.360434205518686e-08
a O 0 7.953910244395956e-05
PTEN O 1 0.9893121123313904
mutation O 0 0.08376464247703552
and O 0 0.19740693271160126
malignant B-Disease 1 0.9994839429855347
breast I-Disease 1 0.9995046854019165
disease I-Disease 1 0.9989919066429138
. O 0 0.007761402055621147

Secondly O 0 0.0015492950333282351
, O 0 8.685716238687746e-06
there O 0 1.098504753827001e-06
appeared O 0 1.3087706065562088e-06
to O 0 5.128919511321328e-08
be O 0 2.3916882696539687e-08
an O 0 2.0560077018672018e-07
interdependent O 0 0.00045083180884830654
association O 0 9.564245374349412e-06
between O 0 3.030247626156779e-07
mutations O 0 3.2080313303595176e-06
upstream O 0 4.029938054372906e-07
and O 0 9.488324792528147e-09
within O 0 1.449312936330216e-08
the O 0 7.885314801114873e-08
PTPase O 0 9.516938735032454e-05
core O 0 2.2009464828443015e-06
motif O 0 3.0633736969321035e-06
, O 0 1.1569022184687583e-08
the O 0 6.528555029916561e-09
core O 0 1.7702780041872757e-07
motif O 0 3.0078362556196225e-07
containing O 0 3.1266580435840297e-08
the O 0 8.893435321510879e-09
majority O 0 4.305379519564667e-08
of O 0 6.871857749501942e-08
missense O 0 0.0002501879644114524
mutations O 0 6.976459189900197e-06
, O 0 3.687351579628739e-08
and O 0 8.403288731528846e-09
the O 0 1.1447201408998353e-08
involvement O 0 2.490888846296002e-07
of O 0 1.3554481981259414e-08
all O 0 6.261685570052578e-08
major O 0 3.0005872758920304e-05
organ O 0 0.01042088121175766
systems O 0 0.0003871556546073407
( O 0 1.4584785276383627e-05
central O 0 2.3097936718841083e-05
nervous O 0 0.0462496243417263
system O 0 0.0013619173550978303
, O 0 0.00245024636387825
thyroid O 1 0.9994832277297974
, O 0 0.06493078917264938
breast O 1 0.999407172203064
, O 0 0.1338188201189041
skin O 1 0.999178946018219
and O 0 0.19363707304000854
gastrointestinal O 1 0.9991121888160706
tract O 1 0.9962312579154968
) O 0 0.0005176135455258191
. O 0 0.00011760476627387106

However O 0 6.900687822053442e-06
, O 0 4.04593464509162e-07
these O 0 3.635402023860479e-08
observations O 0 2.9598155038002005e-07
would O 0 5.38917674930417e-08
need O 0 7.076875618849954e-08
to O 0 9.699949288233256e-09
be O 0 4.09052569594337e-09
confirmed O 0 3.0634414116548214e-08
by O 0 3.6206331266441794e-09
studying O 0 1.7248481753995293e-08
a O 0 2.4338181248140245e-08
larger O 0 4.7368665434532886e-08
number O 0 1.182976028246685e-08
of O 0 5.443807538085821e-08
CD B-Disease 0 5.9246613091090694e-05
families O 0 6.743373887729831e-06
. O 0 1.01073419500608e-05

Molecular O 0 0.03691688925027847
defects O 1 0.8652880787849426
leading O 0 3.406358155189082e-05
to O 0 1.3661099274031585e-06
human O 0 1.6579862858634442e-05
complement B-Disease 0 0.0011604090686887503
component I-Disease 1 0.8176673650741577
C6 I-Disease 1 0.9992530941963196
deficiency I-Disease 1 0.9995144605636597
in O 0 2.2659939986624522e-06
an O 0 2.2104752588347765e-06
African O 0 8.100370177999139e-05
- O 0 0.005078332964330912
American O 0 1.9104854800389148e-05
family O 0 6.427944754250348e-05
. O 0 3.5283530451124534e-05

Complement B-Disease 0 0.0043783001601696014
component I-Disease 1 0.7912597060203552
C6 I-Disease 1 0.9977285265922546
deficiency I-Disease 1 0.9992978572845459
( O 0 0.0020913826301693916
C6D B-Disease 1 0.9471069574356079
) O 0 8.349675772478804e-05
was O 0 7.836089207557961e-05
diagnosed O 1 0.840785801410675
in O 0 1.4147038029932446e-07
a O 0 5.635304773932148e-07
16 O 0 9.884711289487313e-06
- O 0 0.00044347578659653664
year O 0 6.7852797656087205e-06
- O 0 0.0002084278967231512
old O 0 2.4034530724748038e-05
African O 0 1.1710546459653415e-05
- O 0 0.0004834677674807608
American O 0 9.247989510186017e-06
male O 0 0.00011346697283443063
with O 0 0.0008478980744257569
meningococcal B-Disease 1 0.9982149600982666
meningitis I-Disease 1 0.9976644515991211
. O 0 0.0011062371777370572

The O 0 0.0003932500840164721
patients O 0 0.09287333488464355
father O 0 2.398980905127246e-05
and O 0 3.9433857068615907e-07
two O 0 2.1957984586151724e-07
brothers O 0 2.886719084926881e-05
also O 0 4.472469754546182e-07
had O 0 1.189941372103931e-06
C6D B-Disease 0 0.01596815511584282
, O 0 1.6078418241249892e-07
but O 0 2.7231591204213146e-08
gave O 0 1.9690202179845073e-07
no O 0 1.2213268973937375e-07
history O 0 1.3927523241363815e-06
of O 0 4.283463113097241e-06
meningitis B-Disease 1 0.9989270567893982
or O 0 3.442820889176801e-05
other O 0 2.7960659281234257e-05
neisserial B-Disease 1 0.9899249076843262
infection I-Disease 1 0.9948849081993103
. O 0 0.00022048543905839324

By O 0 1.252076572200167e-06
using O 0 8.571940384172194e-07
exon O 0 7.621962868142873e-05
- O 0 3.482957254163921e-05
specific O 0 4.14778696722351e-07
polymerase O 0 4.297460327506997e-05
chain O 0 5.369627251639031e-05
reaction O 0 8.568902558181435e-06
( O 0 7.21117032753682e-07
PCR O 0 6.359070994221838e-06
) O 0 3.5998880321130855e-07
/ O 0 1.64632383530261e-05
single O 0 9.027908731695788e-08
- O 0 4.860151875618612e-06
strand O 0 5.584255973190011e-07
conformation O 0 3.7293301602403517e-07
polymorphism O 0 3.3616080941101245e-07
as O 0 1.0750492052125082e-08
a O 0 2.2668853461027538e-08
screening O 0 1.8526591816225846e-07
step O 0 1.769848445576372e-08
and O 0 1.4506065237895882e-09
nucleotide O 0 7.470590368541252e-09
sequencing O 0 1.1018559398223715e-08
of O 0 2.64195376686871e-09
target O 0 5.0412332086580136e-08
exons O 0 4.718862669506052e-07
, O 0 1.818913908380182e-08
we O 0 2.267571685976577e-09
determined O 0 1.1068861383023432e-08
that O 0 3.2160165641670346e-09
the O 0 2.343081284550408e-08
proband O 0 3.946124706999399e-05
was O 0 8.217230629270489e-08
a O 0 1.4902346379130904e-07
compound O 0 4.769881343236193e-06
heterozygote O 0 1.879681076388806e-05
for O 0 1.450671476277421e-07
two O 0 1.1309888350297115e-06
C6 O 1 0.7849215865135193
gene O 0 0.00017438578652217984
mutations O 0 0.00016483456420246512
. O 0 1.64369739650283e-05

The O 0 1.4939970469640684e-06
first O 0 7.014962193352403e-07
, O 0 6.450393357226858e-07
1195delC O 0 3.587635001167655e-05
located O 0 4.7310155082413985e-07
in O 0 1.369710247445255e-07
exon O 0 2.856619903468527e-05
7 O 0 2.062066869257251e-06
, O 0 6.647044159535653e-08
is O 0 1.377846903238833e-08
a O 0 4.181705293149207e-08
novel O 0 4.64090760488034e-07
mutation O 0 5.977963155601174e-07
, O 0 4.454338231596466e-09
while O 0 2.920747199652851e-09
the O 0 2.8970728038757443e-09
second O 0 3.242521628976647e-08
, O 0 5.245903977879607e-08
1936delG O 0 7.613167781528318e-06
in O 0 5.15570590664538e-08
exon O 0 3.200152059434913e-05
12 O 0 1.1208118166905479e-06
, O 0 8.228381886965508e-08
has O 0 3.505152434968295e-08
been O 0 8.351868530098727e-09
described O 0 2.464363717535889e-07
before O 0 8.55312904946004e-08
to O 0 1.3035248969117674e-07
cause O 0 9.563189087202772e-05
C6D B-Disease 0 0.0030375535134226084
in O 0 9.2146464680809e-08
an O 0 2.5698798822304525e-07
unrelated O 0 5.239196980255656e-05
African O 0 4.6080567699391395e-05
- O 0 0.0016931244172155857
American O 0 7.432570782839321e-06
individual O 0 3.8925468288653065e-06
. O 0 2.2073949367040768e-05

Both O 0 2.0915827917633578e-05
mutations O 0 0.00030005883309058845
result O 0 5.6036264140857384e-05
in O 0 1.3093661436869297e-05
premature O 0 0.059117674827575684
termination O 0 0.004365189466625452
codons O 0 0.0001378903107251972
and O 0 1.2449929272406735e-05
C6 O 0 0.45141807198524475
null O 0 0.0002517156535759568
alleles O 0 0.00032140527036972344
. O 0 4.1691055230330676e-05

Allele O 0 0.00019194617925677449
- O 0 0.00017096813826356083
specific O 0 1.1950087355216965e-06
PCR O 0 2.937220415333286e-05
indicated O 0 1.8046957848127931e-06
that O 0 1.7921049533242694e-08
the O 0 6.242260042199632e-08
probands O 0 0.00021424368605948985
two O 0 1.2886381739463104e-07
brothers O 0 4.2367119021946564e-05
also O 0 6.602320468118705e-07
inherited O 0 0.0004752738168463111
the O 0 2.9486474772966176e-07
1195delC O 0 0.0006148014217615128
mutation O 0 1.4630176110586035e-06
from O 0 2.944880606037259e-08
their O 0 2.912276642064171e-08
heterozygous O 0 2.8817371457989793e-06
mother O 0 4.096948941878509e-06
and O 0 4.8011294495609036e-08
the O 0 2.2024403278919635e-07
1936delG O 0 0.00029771626577712595
mutation O 0 2.0759021026606206e-06
from O 0 7.479376762375978e-08
their O 0 1.2879698374490545e-07
homozygous O 0 2.465408579155337e-05
father O 0 3.1625080737285316e-05
. O 0 4.625121619028505e-06
. O 0 1.9023693312192336e-05

PAX6 O 1 0.8968379497528076
mutations O 0 0.008117022924125195
reviewed O 0 0.0016468162648379803
. O 0 0.00039243686478585005

Mutations O 0 0.000978663214482367
in O 0 2.7182062694919296e-05
PAX6 O 0 0.2829042673110962
are O 0 3.9053168165992247e-07
responsible O 0 4.305956281314138e-06
for O 0 1.7467889392719371e-06
human O 0 6.51966838631779e-05
aniridia B-Disease 1 0.7716597318649292
and O 0 3.3066800142478314e-07
have O 0 4.1980477760716894e-08
also O 0 3.0261578132240174e-08
been O 0 2.9105606813573104e-08
found O 0 3.0585786703341e-07
in O 0 2.645889253471978e-06
patients O 0 0.04852868616580963
with O 0 0.00028091127751395106
Peters B-Disease 1 0.9934561848640442
anomaly I-Disease 1 0.9949927926063538
, O 0 0.0023685088381171227
with O 1 0.8236672878265381
congenital B-Disease 1 0.9999293088912964
cataracts I-Disease 1 0.9999097585678101
, O 0 0.001576885231770575
with O 0 0.003114678431302309
autosomal B-Disease 1 0.9983450174331665
dominant I-Disease 1 0.9246004819869995
keratitis I-Disease 1 0.9982485771179199
, O 0 3.587501487345435e-05
and O 0 1.104030161513947e-05
with O 0 0.00029698965954594314
isolated B-Disease 1 0.7206564545631409
foveal I-Disease 1 0.9957696199417114
hypoplasia I-Disease 1 0.9975407123565674
. O 0 0.002339396858587861

No O 0 1.6838430383359082e-05
locus O 0 1.9709641492227092e-05
other O 0 2.2703517288391595e-07
than O 0 9.092866548598977e-07
chromosome O 0 0.0001571548928041011
11p13 O 0 0.0016549795400351286
has O 0 1.2594440477187163e-06
been O 0 3.9976237076189136e-07
implicated O 0 5.8980418543796986e-05
in O 0 2.408111186014139e-06
aniridia B-Disease 1 0.6201088428497314
, O 0 1.219894443238445e-06
and O 0 8.53767460284871e-07
PAX6 O 0 0.1476883888244629
is O 0 2.1594252075374243e-07
clearly O 0 3.98921457644974e-07
the O 0 1.4080168853070063e-07
major O 0 3.277527866885066e-06
, O 0 2.220302945943331e-07
if O 0 4.5214321175990335e-08
not O 0 4.9314059502592045e-09
only O 0 6.941873742505322e-09
, O 0 9.016413571316662e-08
gene O 0 3.259336608607555e-06
responsible O 0 8.85735425981693e-06
. O 0 1.1576786164368968e-05

Twenty O 0 3.136821396765299e-05
- O 0 6.39826466795057e-05
eight O 0 5.908385105612979e-07
percent O 0 1.0953361879728618e-06
of O 0 2.1394639304617158e-07
identified O 0 1.6145630070241168e-05
PAX6 O 0 0.1645176112651825
mutations O 0 2.4863158614607528e-05
are O 0 6.135270496088197e-07
C O 0 0.011898942291736603
- O 0 0.0309135802090168
T O 0 0.06349408626556396
changes O 0 4.79667221497948e-07
at O 0 3.107950306002749e-07
CpG O 0 4.0331491618417203e-05
dinucleotides O 0 6.569107790710405e-05
, O 0 2.8284796727007233e-08
20 O 0 2.0182563176263102e-08
% O 0 1.1203075800381157e-08
are O 0 1.7314297773296516e-09
splicing O 0 2.1347273104765918e-07
errors O 0 5.12599115154444e-07
, O 0 9.978923465325806e-09
and O 0 1.8135781765238335e-09
more O 0 1.896724111105641e-09
than O 0 6.228497273497169e-09
30 O 0 3.831212325167144e-08
% O 0 3.923069868960738e-08
are O 0 8.237611481831664e-09
deletion O 0 8.641043677926064e-06
or O 0 3.995134818524093e-07
insertion O 0 1.5941212041070685e-05
events O 0 2.9734737836406566e-06
. O 0 1.0208748790319078e-05

There O 0 4.753487701236736e-06
is O 0 1.0654091511241859e-06
a O 0 5.757719918619841e-06
noticeably O 0 0.0013036489253863692
elevated O 0 0.0004237461544107646
level O 0 2.683422337668162e-07
of O 0 1.645039482411903e-08
mutation O 0 1.080845095202676e-06
in O 0 1.51698511530185e-08
the O 0 2.505640672723075e-08
paired O 0 2.8023391678289045e-06
domain O 0 3.9456503486690053e-07
compared O 0 5.330862791197433e-07
with O 0 2.9330641027058846e-08
the O 0 2.1518019366340013e-08
rest O 0 8.626822989299399e-08
of O 0 3.18954249678427e-08
the O 0 6.424277216865448e-07
gene O 0 3.0410621548071504e-05
. O 0 1.3224766007624567e-05

Increased O 0 4.236065433360636e-05
mutation O 0 9.711931852507405e-06
in O 0 2.617039456254133e-07
the O 0 3.0669556849716173e-07
homeodomain O 0 0.0005431522731669247
is O 0 1.2648879987864348e-07
accounted O 0 4.1692342733767873e-07
for O 0 2.868438819803032e-08
by O 0 6.981831290886475e-08
the O 0 3.730717708094744e-07
hypermutable O 0 0.0006751755718141794
CpG O 0 0.0001655619707889855
dinucleotide O 0 0.00018414609075989574
in O 0 4.117239598144806e-07
codon O 0 1.5152207197388634e-05
240 O 0 2.8829857910750434e-05
. O 0 1.4757321878278162e-05

Very O 0 4.39232417193125e-06
nearly O 0 2.6013583465100965e-06
all O 0 5.469806296787283e-07
mutations O 0 0.00011013976472895592
appear O 0 1.9019356841454282e-05
to O 0 8.688547836754879e-07
cause O 0 0.0009608370019122958
loss O 0 3.007285158673767e-05
of O 0 1.4970913397860386e-08
function O 0 3.186769603757966e-08
of O 0 5.35134692114525e-09
the O 0 8.875933588115004e-08
mutant O 0 1.1630965673248284e-05
allele O 0 1.5944137885526288e-06
, O 0 1.5177405998656468e-08
and O 0 1.815273931171646e-09
more O 0 1.3359816586344664e-09
than O 0 3.721419838953466e-09
80 O 0 4.237224260350558e-08
% O 0 1.4778727575048833e-08
of O 0 1.6453469697808032e-08
exonic O 0 8.981857536127791e-05
substitutions O 0 6.975408837206487e-07
result O 0 8.706961693860649e-07
in O 0 3.6609884546123794e-07
nonsense O 0 7.919428026070818e-05
codons O 0 5.073094507679343e-05
. O 0 1.4733669559063856e-05

In O 0 4.933271156914998e-06
a O 0 2.376818656557589e-06
gene O 0 5.6883991419454105e-06
with O 0 3.835534130303131e-07
such O 0 4.943835278936604e-07
extraordinarily O 0 7.155474304454401e-05
high O 0 2.6000784600910265e-06
sequence O 0 2.5868214947877277e-07
conservation O 0 8.91719992068829e-07
throughout O 0 5.3249181064529694e-08
evolution O 0 3.626275031365367e-07
, O 0 5.684260884208925e-08
there O 0 2.441736413061335e-08
are O 0 1.3382445374077179e-08
presumed O 0 9.362544915347826e-06
undiscovered O 0 0.00035530832246877253
missense O 0 0.0004608790623024106
mutations O 0 1.581205833645072e-05
, O 0 1.021991735683514e-07
these O 0 8.908766169213322e-09
are O 0 5.279709114347497e-09
hypothesized O 0 5.492246373250964e-07
to O 0 1.1673979116721966e-08
exist O 0 4.746760851048748e-08
in O 0 3.6805918313120856e-08
as O 0 2.1076085943150247e-07
- O 0 0.00021944769832771271
yet O 0 2.6504249035497196e-06
unidentified O 0 5.7149976782966405e-05
phenotypes O 0 0.0006766877486370504
. O 0 2.875428663173807e-06
. O 0 8.322806934302207e-06

Genetic O 0 0.0008053319761529565
heterogeneity O 0 0.0005662314943037927
and O 0 3.8107448290247703e-06
penetrance O 0 0.0015682425582781434
analysis O 0 7.74271541104099e-07
of O 0 1.8112910993295372e-07
the O 0 5.34398259333102e-06
BRCA1 O 0 0.019709773361682892
and O 0 2.5482095225015655e-05
BRCA2 O 0 0.1881726086139679
genes O 0 0.0010931716533377767
in O 0 0.05478138104081154
breast B-Disease 1 0.9995279312133789
cancer I-Disease 1 0.9993929862976074
families O 0 0.0039031491614878178
. O 0 0.0005872193723917007

The O 1 0.667297899723053
Breast B-Disease 1 0.9982643723487854
Cancer I-Disease 1 0.9978396892547607
Linkage O 1 0.6629360914230347
Consortium O 0 0.04920500889420509
. O 0 0.0005751324933953583

The O 0 3.205386065019411e-06
contribution O 0 5.217124453338329e-06
of O 0 1.9334579519636463e-06
BRCA1 O 0 0.05406581610441208
and O 0 9.457284613745287e-05
BRCA2 O 1 0.9832135438919067
to O 0 0.19222129881381989
inherited B-Disease 1 0.9998458623886108
breast I-Disease 1 0.9999080896377563
cancer I-Disease 1 0.9998791217803955
was O 0 9.844313171925023e-05
assessed O 0 4.6162287617335096e-05
by O 0 2.6732436708698515e-07
linkage O 0 4.4778029405279085e-05
and O 0 1.2459382503493543e-07
mutation O 0 2.199758682763786e-06
analysis O 0 2.5643419121479383e-07
in O 0 1.573372685470531e-07
237 O 0 1.7368509361403994e-05
families O 0 1.6561217819344165e-07
, O 0 6.235332250525971e-09
each O 0 9.616091256603454e-10
with O 0 7.67597008177745e-09
at O 0 4.17835650523557e-08
least O 0 3.533398640342966e-08
four O 0 1.8513081556648103e-07
cases O 0 4.2848201701417565e-05
of O 0 0.00032906612614169717
breast B-Disease 1 0.9997707009315491
cancer I-Disease 1 0.9991872906684875
, O 0 1.7956621150005958e-06
collected O 0 1.421189381289878e-06
by O 0 1.5348032320616767e-05
the O 0 0.009011358954012394
Breast B-Disease 1 0.9994851350784302
Cancer I-Disease 1 0.9992539286613464
Linkage O 0 0.36572301387786865
Consortium O 0 0.005580491852015257
. O 0 0.00011080076365033165

Families O 0 1.4267885489971377e-05
were O 0 2.4990930569401826e-07
included O 0 2.5999392505582364e-07
without O 0 1.684487926922884e-07
regard O 0 3.881234817981749e-07
to O 0 6.24137896920729e-08
the O 0 2.88299105477563e-07
occurrence O 0 0.0001831998524721712
of O 0 9.563571074977517e-05
ovarian B-Disease 1 0.9993226528167725
or I-Disease 0 0.0005393526516854763
other I-Disease 0 0.00016781890008132905
cancers I-Disease 1 0.9965887069702148
. O 0 0.00020993211364839226

Overall O 0 0.35136908292770386
, O 0 0.03333822265267372
disease O 1 0.9983627200126648
was O 0 1.2598292414622847e-05
linked O 0 5.163792957318947e-05
to O 0 3.512414536999131e-07
BRCA1 O 0 0.00012535208952613175
in O 0 3.125120073832477e-08
an O 0 1.9604753376256667e-08
estimated O 0 3.47298367842086e-07
52 O 0 4.913475777357235e-07
% O 0 2.338955518155217e-08
of O 0 7.782838373771028e-09
families O 0 1.4254376878852781e-07
, O 0 5.0317321864667974e-08
to O 0 3.6177564055606126e-08
BRCA2 O 0 9.663602213549893e-06
in O 0 1.2418521322388187e-08
32 O 0 9.134501510743576e-08
% O 0 1.905260482715221e-08
of O 0 8.951432484138877e-09
families O 0 1.2243263824984751e-07
, O 0 2.2537232524655337e-08
and O 0 9.234701892069097e-09
to O 0 3.874981668872124e-09
neither O 0 6.966069321379109e-08
gene O 0 3.592123221096699e-08
in O 0 4.859611824059584e-09
16 O 0 3.3443082969597526e-08
% O 0 1.9440060228248512e-08
( O 0 2.8389054662625313e-08
95 O 0 3.6612391340895556e-08
% O 0 1.6385165224619413e-08
confidence O 0 1.5068766856529692e-07
interval O 0 4.272975218100328e-07
[ O 0 5.440197128336877e-06
CI O 0 0.0013239601394161582
] O 0 1.2611795909833745e-06
6 O 0 1.295511395937865e-07
% O 0 6.721396772491062e-08
- O 0 6.238556125026662e-06
28 O 0 2.802419771796849e-07
% O 0 1.1729211735200806e-07
) O 0 1.2884954969649698e-07
, O 0 6.315263334499832e-08
suggesting O 0 1.6664722579662339e-06
other O 0 2.710914088766003e-07
predisposition O 0 0.005884082987904549
genes O 0 1.7037855286616832e-05
. O 0 1.8111984900315292e-05

The O 0 5.033219622418983e-06
majority O 0 7.623215878993506e-06
( O 0 4.302438355807681e-06
81 O 0 1.1937481758650392e-05
% O 0 3.6785993984267407e-07
) O 0 3.1988216164791083e-07
of O 0 1.2058548009008518e-06
the O 0 0.003965534269809723
breast B-Disease 1 0.9996743202209473
- I-Disease 1 0.9997537732124329
ovarian I-Disease 1 0.9999427795410156
cancer I-Disease 1 0.9998267292976379
families O 0 2.2402660761144944e-05
were O 0 1.4096869449531368e-07
due O 0 3.60940384780406e-06
to O 0 3.6584580698217906e-07
BRCA1 O 0 0.0010400499450042844
, O 0 6.119866213794012e-08
with O 0 2.0242589826580115e-08
most O 0 2.217111472191391e-08
others O 0 8.357800851399588e-08
( O 0 3.1669318900640064e-07
14 O 0 2.453880654229579e-07
% O 0 1.8890679598371207e-07
) O 0 3.487620858777518e-07
due O 0 1.9528119992173743e-06
to O 0 1.304951751990302e-06
BRCA2 O 0 0.005371816921979189
. O 0 1.949986835825257e-05

Conversely O 0 0.0005664660129696131
, O 0 1.4261000842452631e-06
the O 0 1.5152622268033156e-07
majority O 0 3.4119676683985745e-07
of O 0 7.863821593900866e-08
families O 0 2.742241576925153e-06
with O 0 2.359386371608707e-06
male B-Disease 0 0.00021408831526059657
and I-Disease 0 0.0002509713522158563
female I-Disease 1 0.7511279582977295
breast I-Disease 1 0.9997910857200623
cancer I-Disease 1 0.9992008805274963
were O 0 3.6465206676439266e-07
due O 0 7.180945885920664e-06
to O 0 1.0735451496657333e-06
BRCA2 O 0 0.006448004860430956
( O 0 9.753447557159234e-06
76 O 0 8.70392905198969e-05
% O 0 2.1452224245877005e-06
) O 0 3.3666206036286894e-06
. O 0 6.313297490123659e-06

The O 0 3.506578423184692e-06
largest O 0 1.0635752005327959e-05
proportion O 0 6.026921710144961e-06
( O 0 2.0962897906429134e-06
67 O 0 6.671884420939023e-06
% O 0 3.1286151624954073e-07
) O 0 1.1918567821567194e-07
of O 0 1.650586689549982e-08
families O 0 3.954570786390832e-07
due O 0 5.966014100522443e-07
to O 0 9.66792068624045e-09
other O 0 7.646758781731933e-09
genes O 0 1.72618840110772e-07
was O 0 6.312241396244644e-08
found O 0 4.074735571180099e-08
in O 0 1.6065305530332807e-08
families O 0 4.1416985396836026e-08
with O 0 1.4304730733272208e-08
four O 0 3.5676244181104266e-08
or O 0 2.2497468421533995e-07
five O 0 1.6078863041002478e-07
cases O 0 5.001576482754899e-06
of O 0 1.167089976661373e-05
female O 1 0.8161829710006714
breast B-Disease 1 0.9996637105941772
cancer I-Disease 1 0.9989389777183533
only O 0 1.591371801623609e-05
. O 0 6.538732850458473e-05

These O 0 4.537208496913081e-06
estimates O 0 3.0244582376326434e-05
were O 0 4.333407446210913e-07
not O 0 5.891550358683162e-07
substantially O 0 6.249742727959529e-05
affected O 0 2.0930076516378904e-06
either O 0 6.235655547470742e-08
by O 0 3.9357807679607504e-08
changing O 0 3.529512753175368e-07
the O 0 9.151713697974628e-08
assumed O 0 6.101129656599369e-06
penetrance O 0 0.0009598630131222308
model O 0 3.109511681032018e-06
for O 0 7.254502065734414e-07
BRCA1 O 0 0.0012937553692609072
or O 0 1.889864620352455e-07
by O 0 4.5660733860586333e-08
including O 0 2.28843774152665e-07
or O 0 2.1525652300624643e-06
excluding O 0 5.815944678033702e-05
BRCA1 O 0 0.004948518704622984
mutation O 0 3.4052442060783505e-05
data O 0 6.804993063269649e-06
. O 0 1.4051910511625465e-05

Among O 0 5.316352326190099e-05
those O 0 1.855181653809268e-05
families O 0 0.0007468839758075774
with O 0 0.04418133944272995
disease O 1 0.999526858329773
due O 0 0.0003482099564280361
to O 0 1.0826714060385711e-05
BRCA1 O 0 0.017545850947499275
that O 0 7.435141213818497e-08
were O 0 1.6605049779627734e-08
tested O 0 3.5889050309378945e-07
by O 0 2.9297022585694776e-09
one O 0 1.4584354834923374e-09
of O 0 1.5379548745642069e-09
the O 0 1.4382401047896565e-08
standard O 0 8.283747092718841e-07
screening O 0 1.1818291341114673e-06
methods O 0 9.093892572309414e-08
, O 0 7.837153503942318e-08
mutations O 0 4.636519008727191e-07
were O 0 5.0928878891909335e-09
detected O 0 1.1229051466443707e-07
in O 0 1.5665840846779133e-09
the O 0 2.171815394191867e-09
coding O 0 1.9975306031483342e-07
sequence O 0 1.3417357003220332e-08
or O 0 1.445891939511057e-08
splice O 0 3.351626958192355e-07
sites O 0 8.632152770360335e-09
in O 0 2.9563658188180852e-09
an O 0 5.762681887233612e-09
estimated O 0 1.278839079077443e-07
63 O 0 2.1695109353458975e-07
% O 0 2.1445538678221965e-08
( O 0 4.176746770667705e-08
95 O 0 1.6273763492336002e-07
% O 0 1.7845437128016783e-07
CI O 0 0.0007766559137962759
51 O 0 1.1907575299119344e-06
% O 0 3.6556920690600236e-07
- O 0 2.19792163989041e-05
77 O 0 3.5686157389136497e-06
% O 0 6.437162483052816e-07
) O 0 1.7638956251175841e-06
. O 0 3.819513040070888e-06

The O 0 1.0766727427835576e-05
estimated O 0 1.8997134247911163e-05
sensitivity O 0 1.0989115253323689e-05
was O 0 2.3618441957751202e-07
identical O 0 1.6849988071498956e-07
for O 0 1.764374779611444e-08
direct O 0 6.712940603392781e-08
sequencing O 0 5.296263339005236e-07
and O 0 9.743973805598216e-08
other O 0 1.820451984713145e-07
techniques O 0 5.991580110276118e-06
. O 0 1.3842651242157444e-05

The O 0 7.474095127690816e-06
penetrance O 0 0.0019062362844124436
of O 0 2.240308049294981e-06
BRCA2 O 0 0.0016128262504935265
was O 0 3.786827278418059e-07
estimated O 0 3.1479675044465694e-07
by O 0 4.223177185735949e-08
maximizing O 0 9.92176069303241e-07
the O 0 1.4792300362387323e-07
LOD O 0 0.0005103610455989838
score O 0 2.2867142490667902e-07
in O 0 1.4204970284481533e-06
BRCA2 O 0 0.006363326217979193
- O 0 0.0036447206512093544
mutation O 0 1.0671952622942626e-05
families O 0 2.556228366756841e-07
, O 0 2.2446629444061728e-08
over O 0 2.600633308702527e-08
all O 0 2.155342748721978e-08
possible O 0 1.1875628160851193e-06
penetrance O 0 0.0015091031091287732
functions O 0 1.9628009795269463e-06
. O 0 1.3447966921376064e-05

The O 0 1.193445405078819e-05
estimated O 0 0.00017215411935467273
cumulative O 0 0.0066962530836462975
risk O 0 0.13519591093063354
of O 0 0.00042301687062717974
breast B-Disease 1 0.9995684027671814
cancer I-Disease 1 0.997946560382843
reached O 0 3.942704097426031e-06
28 O 0 1.1247319662288646e-06
% O 0 1.484996658973614e-07
( O 0 1.0217169688075955e-07
95 O 0 1.84829133331732e-07
% O 0 1.354229084427061e-07
CI O 0 0.0003538035089150071
9 O 0 3.667753958325193e-07
% O 0 8.342351520695956e-08
- O 0 2.0575212147377897e-06
44 O 0 1.1355935214396595e-07
% O 0 2.4665403941526165e-08
) O 0 1.1577830250075749e-08
by O 0 3.1779907594398082e-09
age O 0 7.236578625224865e-08
50 O 0 1.8854031225146173e-08
years O 0 1.701465635051136e-08
and O 0 6.992303624997476e-09
84 O 0 2.6353475846008223e-07
% O 0 1.635958923884573e-08
( O 0 2.979275848247198e-08
95 O 0 8.74215970725345e-08
% O 0 6.255299211943566e-08
CI O 0 0.0001341472816420719
43 O 0 1.7944725527740957e-07
% O 0 5.399331826083653e-08
- O 0 3.391630798432743e-06
95 O 0 1.5734912039988558e-07
% O 0 2.3305656071670455e-08
) O 0 2.5210914245121785e-08
by O 0 2.4716829472026802e-08
age O 0 1.9716367205546703e-06
70 O 0 2.997858473463566e-06
years O 0 7.104422365955543e-06
. O 0 1.2067096577084158e-05

The O 0 0.005824606865644455
corresponding O 1 0.9860223531723022
ovarian B-Disease 1 0.9996311664581299
cancer I-Disease 1 0.9994774460792542
risks O 1 0.8899276852607727
were O 0 1.1350264685461298e-05
0 O 0 0.00031652950565330684
. O 0 3.7456633435795084e-05

4 O 0 8.071066986303777e-06
% O 0 1.1779447959270328e-06
( O 0 7.434729241140303e-07
95 O 0 8.467099519293697e-07
% O 0 5.757916028414911e-07
CI O 0 0.0021039056591689587
0 O 0 5.789698889202555e-07
% O 0 1.1900418428467674e-07
- O 0 1.5981983096935437e-06
1 O 0 4.8984855283151774e-08
% O 0 1.728942322642979e-08
) O 0 9.835952496928257e-09
by O 0 6.330516999497604e-09
age O 0 1.0559930530007478e-07
50 O 0 1.9159012154545962e-08
years O 0 1.3403749221652106e-08
and O 0 4.2998871130350835e-09
27 O 0 2.450535951936672e-08
% O 0 8.853509925188519e-09
( O 0 1.718635012082359e-08
95 O 0 6.35444834529153e-08
% O 0 8.036928988985892e-08
CI O 0 0.00012984177737962455
0 O 0 1.2712817465398984e-07
% O 0 5.829802063317402e-08
- O 0 2.26074234888074e-06
47 O 0 3.382940008123114e-07
% O 0 3.3474098160013455e-08
) O 0 3.7288252485723206e-08
by O 0 3.291228978241634e-08
age O 0 2.605571808089735e-06
70 O 0 2.7253756798018003e-06
years O 0 4.623079348675674e-06
. O 0 5.9401536418590695e-06

The O 0 0.0001692681689746678
lifetime O 0 0.2792843282222748
risk O 1 0.9437709450721741
of O 0 0.05597038194537163
breast B-Disease 1 0.9997259974479675
cancer I-Disease 1 0.9995360374450684
appears O 0 0.00042963007581420243
similar O 0 3.864153313770657e-06
to O 0 4.52248912097275e-07
the O 0 3.9244687286554836e-06
risk O 0 0.009279539808630943
in O 0 1.3944196325610392e-05
BRCA1 O 1 0.8157404065132141
carriers O 0 0.002048016060143709
, O 0 3.07681091271661e-07
but O 0 2.3278644789570535e-08
there O 0 6.5315441943880614e-09
was O 0 6.7003504966578475e-09
some O 0 2.9710855997677754e-09
suggestion O 0 8.317518052081141e-08
of O 0 1.641932811935476e-08
a O 0 2.1869448119105073e-06
lower O 0 0.000448893551947549
risk O 0 0.0008818864007480443
in O 0 3.0978144422988407e-06
BRCA2 O 0 0.02281772531569004
carriers O 0 0.0008781356154941022
< O 0 0.0014308526879176497
50 O 0 5.215882765696733e-07
years O 0 3.802805110808549e-07
of O 0 2.40850084765043e-07
age O 0 6.636499165324494e-05
. O 0 3.0187902666511945e-05

Eye B-Disease 1 0.9588199257850647
movement I-Disease 0 0.0045053656212985516
abnormalities I-Disease 1 0.9657086730003357
correlate O 0 0.0006366188172250986
with O 0 8.372661977773532e-05
genotype O 0 0.19217510521411896
in O 0 0.0008238958544097841
autosomal O 1 0.9961516261100769
dominant O 1 0.9945441484451294
cerebellar B-Disease 1 0.9984943866729736
ataxia I-Disease 1 0.9989150762557983
type I-Disease 1 0.9938836693763733
I I-Disease 0 0.10974998027086258
. O 0 0.0007563434774056077

We O 0 1.4564909179171082e-05
compared O 0 0.00010183190170209855
horizontal O 0 0.0008249009842984378
eye O 0 0.011070938780903816
movements O 0 1.2563163181766868e-05
( O 0 1.1203587746422272e-05
visually O 0 6.008315904182382e-05
guided O 0 7.803829066688195e-05
saccades O 0 0.12225313484668732
, O 0 1.8281505163031397e-06
antisaccades O 0 0.00044798877206631005
, O 0 1.2984675379357213e-07
and O 0 3.614280430497274e-08
smooth O 0 3.075539552810369e-06
pursuit O 0 3.5007644783036085e-06
) O 0 1.2621863731965277e-07
in O 0 1.7645902516960632e-08
control O 0 1.3430293677174632e-07
subjects O 0 1.663831454834508e-07
( O 0 5.981121944387269e-07
n O 0 8.026501745916903e-06
= O 0 4.3041502067353576e-05
14 O 0 7.789856795170635e-07
) O 0 4.097165628991206e-07
and O 0 2.8965061460439756e-07
patients O 0 1.6527590560144745e-05
with O 0 1.4495009637016665e-08
three O 0 1.3635644613430031e-08
forms O 0 5.353024334908696e-07
of O 0 1.1274952385065262e-06
autosomal O 1 0.7904676795005798
dominant O 0 0.10948093235492706
cerebellar B-Disease 1 0.9973784685134888
ataxias I-Disease 1 0.9869874715805054
type I-Disease 0 0.3325023651123047
I I-Disease 0 0.0031838377472013235
spinocerebellar B-Disease 1 0.9916428327560425
ataxias I-Disease 0 0.002146118553355336
1 I-Disease 0 1.1302124676149106e-06
and I-Disease 0 7.27972917502484e-08
2 I-Disease 0 3.0696301678290183e-07
( O 0 5.37507105491386e-07
SCA1 B-Disease 0 6.518848385894671e-05
, O 0 4.933045616439813e-08
n O 0 1.686096538833226e-06
= O 0 6.400918664439814e-06
11 O 0 2.9999981165929057e-07
; O 0 1.656169104080618e-07
SCA2 B-Disease 0 2.375047370151151e-05
, O 0 4.571493761318379e-08
n O 0 8.405006042266905e-07
= O 0 1.8417913452140056e-06
10 O 0 4.481602289274633e-08
) O 0 5.358213073236584e-08
and O 0 2.1672322247923148e-07
SCA3 B-Disease 0 0.2334221750497818
/ O 0 0.01144570391625166
Machado B-Disease 0 0.0014204097678884864
- I-Disease 0 0.10449410229921341
Joseph I-Disease 0 0.004845066927373409
disease I-Disease 1 0.9939680099487305
( O 0 2.912182389991358e-05
MJD B-Disease 0 0.12866374850273132
) O 0 8.758304375078296e-07
( O 0 8.353630960300507e-07
n O 0 1.2510508895502426e-05
= O 0 4.045390960527584e-05
16 O 0 1.2207370900796377e-06
) O 0 1.4055284509595367e-06
. O 0 1.9185947621735977e-06

In O 0 3.32413510477636e-05
SCA1 B-Disease 0 0.005552612245082855
, O 0 4.4604125832847785e-06
saccade O 0 0.00022116147738415748
amplitude O 0 9.733867955219466e-06
was O 0 2.174238488805713e-06
significantly O 0 2.8964672310394235e-05
increased O 0 3.11931603391713e-06
, O 0 5.225222707849753e-07
resulting O 0 2.2506495952256955e-05
in O 0 4.4487892409961205e-06
hypermetria B-Disease 0 0.023470209911465645
. O 0 4.330747469794005e-05

The O 0 5.584795871982351e-06
smooth O 0 0.0001758528669597581
pursuit O 0 0.00035309523809701204
gain O 0 0.00025988175184465945
was O 0 8.535137749277055e-05
decreased O 0 0.0022369492799043655
. O 0 3.9898026443552226e-05

In O 0 6.354696961352602e-05
SCA2 B-Disease 0 0.032769642770290375
, O 0 1.7758608009899035e-05
saccade O 0 0.0008031252073124051
velocity O 0 8.433956099906936e-05
was O 0 9.035790571942925e-05
markedly O 0 0.01046838890761137
decreased O 0 0.0028177876956760883
. O 0 8.945471199695021e-05

The O 0 2.3206887362903217e-06
percentage O 0 3.567125077097444e-06
of O 0 2.6043667844533047e-07
errors O 0 3.409949567867443e-05
in O 0 2.9332597932807403e-06
antisaccades O 0 0.011824298650026321
was O 0 3.108859345957171e-06
greatly O 0 7.793039003445301e-06
increased O 0 1.2033010534651112e-06
and O 0 1.6780680311967444e-07
was O 0 4.511319104949507e-07
significantly O 0 1.9070756025030278e-05
correlated O 0 1.4835976799076889e-05
with O 0 9.686789780971594e-06
age O 0 0.02909703180193901
at O 0 0.09889286011457443
disease O 1 0.9989407658576965
onset O 1 0.997399091720581
. O 0 0.0010933995945379138

In O 0 2.178406020902912e-06
addition O 0 1.215254428643675e-06
, O 0 1.5912587514321785e-07
a O 0 1.7502779314781947e-07
correlation O 0 5.494236461345281e-07
between O 0 2.3598020959525456e-07
smooth O 0 1.1002075552823953e-05
pursuit O 0 7.189908501459286e-06
gain O 0 5.714001076739805e-07
and O 0 1.2783533342997089e-08
the O 0 9.312065785138657e-09
number O 0 1.6259701141052574e-08
of O 0 2.8194745027576573e-07
trinucleotide O 1 0.76258784532547
repeats O 0 0.00015923148021101952
was O 0 3.6143744637229247e-06
found O 0 3.5274570109322667e-06
. O 0 1.217352746607503e-05

In O 0 0.00010378242586739361
SCA3 B-Disease 1 0.8387093544006348
, O 0 0.00013487361138686538
gaze B-Disease 0 0.11684634536504745
- I-Disease 0 0.43427714705467224
evoked I-Disease 0 0.16172540187835693
nystagmus I-Disease 1 0.6555509567260742
was O 0 2.2077301764511503e-06
often O 0 3.2393754167969746e-07
present O 0 2.007844130957892e-07
as O 0 1.1716119985294426e-07
was O 0 5.879538775843685e-07
saccade O 0 0.00021604886569548398
hypometria O 0 0.00038564298301935196
and O 0 2.299262007454672e-07
smooth O 0 2.0287454390199855e-05
pursuit O 0 4.80859525850974e-05
gain O 0 2.7249387130723335e-05
was O 0 1.600766154297162e-05
markedly O 0 0.0033854334615170956
decreased O 0 0.001576476963236928
. O 0 4.0434315451420844e-05

Three O 0 2.371982191107236e-06
major O 0 7.227332844195189e-06
criteria O 0 1.837450895436632e-06
, O 0 2.642338756686513e-07
saccade O 0 2.7919362764805555e-05
amplitude O 0 1.5381058346974896e-06
, O 0 2.2913903308108274e-07
saccade O 0 2.1702489902963862e-05
velocity O 0 6.072519340705185e-07
, O 0 5.691725135648085e-08
and O 0 1.734273169518019e-08
presence O 0 1.1587975023985564e-07
of O 0 1.9772319603816868e-07
gaze B-Disease 0 0.003598154056817293
- I-Disease 0 0.025033315643668175
evoked I-Disease 0 0.0017044231062754989
nystagmus I-Disease 0 0.005881536286324263
, O 0 5.026897653692686e-08
permitted O 0 2.3863250930844515e-08
the O 0 1.1059364979359998e-08
correct O 0 3.7650448803105974e-07
assignment O 0 6.500265214981482e-08
of O 0 2.927713405043164e-09
90 O 0 2.856618230850927e-08
% O 0 7.514807442987603e-09
of O 0 2.8552060715725247e-09
the O 0 3.5453137314789274e-08
SCA1 B-Disease 0 0.00011878603982040659
, O 0 1.5167305633667638e-08
90 O 0 2.3397051407414438e-08
% O 0 4.6720884938622476e-09
of O 0 2.9469413576066472e-09
the O 0 4.396261488182063e-08
SCA2 B-Disease 0 0.0001748823415255174
, O 0 2.08102441945357e-08
and O 0 9.232429931671504e-09
93 O 0 2.5942725301320024e-07
% O 0 1.1771239982749648e-08
of O 0 1.1230461005595771e-08
the O 0 1.0466302455824916e-06
patients O 0 0.001977685373276472
with O 0 2.070198888759478e-06
SCA3 B-Disease 1 0.7349475026130676
to O 0 1.3434598145067866e-07
their O 0 1.866027190544628e-07
genetically O 0 7.858852768549696e-05
confirmed O 0 2.9185073799453676e-05
patient O 0 0.0005029506864957511
group O 0 8.472543413517997e-07
and O 0 1.1245234077250643e-07
, O 0 1.1763479079718309e-07
therefore O 0 1.260942354974759e-07
, O 0 1.6143701486726059e-07
may O 0 4.6830911060169456e-07
help O 0 1.6109081570903072e-06
orient O 0 8.895139035303146e-05
diagnoses O 0 0.0015469732461497188
of O 0 4.1862179500640195e-07
SCA1 B-Disease 0 0.34982648491859436
, O 0 6.242775725695537e-06
SCA2 B-Disease 0 0.013108760118484497
, O 0 2.888583310323156e-07
and O 0 6.469268782893778e-07
SCA3 B-Disease 0 0.10598450899124146
at O 0 7.708146654294978e-07
early O 0 2.130396296706749e-06
clinical O 0 0.0001298192364629358
stages O 0 2.1726447812397964e-05
of O 0 2.4271901111205807e-06
the O 0 0.00038278460851870477
diseases O 1 0.9984766840934753
. O 0 2.345046232221648e-05
. O 0 5.985875031910837e-05

Genetic O 0 7.079308852553368e-05
basis O 0 1.3350064591577393e-06
and O 0 2.7616256375040393e-06
molecular O 0 0.0004581480170600116
mechanism O 0 0.00399034796282649
for O 0 0.08240924030542374
idiopathic B-Disease 1 0.9995638728141785
ventricular I-Disease 1 0.9987398982048035
fibrillation I-Disease 1 0.9985034465789795
. O 0 0.1028979942202568

Ventricular B-Disease 1 0.9927418231964111
fibrillation I-Disease 1 0.996235191822052
causes O 0 0.009160853922367096
more O 0 5.428435088106198e-07
than O 0 6.821722990935086e-07
300 O 0 3.6350877508084523e-06
, O 0 1.8471635030437028e-06
000 O 0 6.193698209244758e-05
sudden O 0 0.003632955951616168
deaths O 0 1.367305958410725e-05
each O 0 1.836620100448272e-08
year O 0 4.5014948568677937e-07
in O 0 2.703756933897239e-07
the O 0 1.182287860501674e-06
USA O 0 0.0001788004010450095
alone O 0 2.2762953449273482e-05
. O 0 1.1159335372212809e-05

In O 0 1.5994487512216438e-06
approximately O 0 1.5726195670140442e-06
5 O 0 4.317852926760679e-06
- O 0 3.31777919200249e-05
12 O 0 2.2020624612650863e-07
% O 0 4.7083567267236504e-08
of O 0 1.8346490548992733e-08
these O 0 5.2967479291510244e-08
cases O 0 1.849673367360083e-06
, O 0 8.523001326921076e-08
there O 0 3.266183057348826e-08
are O 0 1.6096622701411434e-08
no O 0 6.47575689072255e-07
demonstrable O 0 0.06978993862867355
cardiac O 1 0.9857184290885925
or O 0 9.264791151508689e-05
non O 0 0.06791693717241287
- O 1 0.9978450536727905
cardiac O 1 0.998691976070404
causes O 0 0.00031998296617530286
to O 0 3.129325065742705e-08
account O 0 4.905507111629959e-08
for O 0 1.6529527968600632e-08
the O 0 6.430431653825508e-08
episode O 0 1.6061298993008677e-06
, O 0 7.516172217947314e-08
which O 0 3.53452414003641e-08
is O 0 1.1594375592949291e-07
therefore O 0 1.1715387699950952e-06
classified O 0 0.0016187207074835896
as O 0 0.002475918270647526
idiopathic B-Disease 1 0.9995297193527222
ventricular I-Disease 1 0.99904865026474
fibrillation I-Disease 1 0.9992006421089172
( O 0 0.2978576123714447
IVF B-Disease 1 0.993992269039154
) O 0 0.0002555713872425258
. O 0 5.4491498303832486e-05

A O 0 3.542564081726596e-05
distinct O 0 2.9046021154499613e-05
group O 0 6.297075742622837e-05
of O 0 0.0001990420714719221
IVF B-Disease 1 0.9989456534385681
patients O 1 0.9856936931610107
has O 0 4.011221335531445e-06
been O 0 7.616907282681495e-08
found O 0 4.014226462345505e-08
to O 0 1.0815338846725808e-08
present O 0 7.955121361646889e-08
with O 0 1.9909955994990014e-07
a O 0 5.967151537333848e-06
characteristic O 0 0.0008291862322948873
electrocardiographic O 0 0.2969454228878021
pattern O 0 0.005720490589737892
. O 0 0.00012246247206348926

Because O 0 1.6362794212909648e-06
of O 0 6.027974563949101e-08
the O 0 8.241197946290413e-08
small O 0 1.4589906527362473e-07
size O 0 1.6712101569282822e-07
of O 0 1.098226221074583e-08
most O 0 5.896519894577068e-08
pedigrees O 0 5.6954122555907816e-06
and O 0 5.278311832057625e-08
the O 0 2.41135751366528e-07
high O 0 0.00012227959814481437
incidence O 0 0.07174007594585419
of O 0 1.3597591532743536e-06
sudden B-Disease 0 0.30458179116249084
death I-Disease 0 8.575963875046e-05
, O 0 3.1827002544559946e-07
however O 0 1.3115251817907847e-07
, O 0 1.7403809238203394e-07
molecular O 0 7.897603609308135e-06
genetic O 0 1.0315165127394721e-05
studies O 0 5.906796332055819e-07
of O 0 5.941428753430955e-07
IVF B-Disease 1 0.8468257188796997
have O 0 1.5268145148183976e-07
not O 0 9.563184732996888e-08
yet O 0 4.732333138690592e-07
been O 0 3.220324629182869e-07
done O 0 2.844944219759782e-06
. O 0 6.205535100889392e-06

Because O 0 0.031297314912080765
IVF B-Disease 1 0.9897301197052002
causes O 1 0.9944419264793396
cardiac O 1 0.9986472725868225
rhythm O 1 0.8831073045730591
disturbance O 1 0.9204759001731873
, O 0 6.956986453587888e-06
we O 0 4.857427029492101e-07
investigated O 0 5.619394414679846e-06
whether O 0 4.2581191905810556e-07
malfunction O 0 0.0004488584236241877
of O 0 7.724749906401485e-08
ion O 0 4.079871723661199e-05
channels O 0 4.155362603341928e-06
could O 0 5.548643002839526e-06
cause O 0 0.0005282993661239743
the O 0 1.3261163985589519e-05
disorder O 1 0.9774572849273682
by O 0 1.5706110900737258e-07
studying O 0 1.1351229431966203e-06
mutations O 0 5.361604507925222e-06
in O 0 2.676332542250748e-07
the O 0 1.944582891155733e-06
cardiac O 1 0.5001809597015381
sodium O 0 6.205480895005167e-05
channel O 0 1.317020632995991e-05
gene O 0 6.66687628836371e-05
SCN5A O 0 0.035192690789699554
. O 0 3.834894596366212e-05

We O 0 2.592071496110293e-06
have O 0 3.6547859849633824e-07
now O 0 4.252510734659154e-07
identified O 0 3.7195593449723674e-07
a O 0 3.7440622691065073e-07
missense O 0 4.541232920018956e-05
mutation O 0 4.012307726952713e-06
, O 0 1.2179933150946454e-07
a O 0 8.141564080688113e-07
splice O 0 0.0005268192035146058
- O 0 0.005518614314496517
donor O 0 7.930454012239352e-05
mutation O 0 6.71217321723816e-06
, O 0 4.9069946328472724e-08
and O 0 2.993795789052456e-08
a O 0 5.55234123567061e-07
frameshift O 0 0.001343845622614026
mutation O 0 1.974606220755959e-06
in O 0 2.5916360613109646e-08
the O 0 6.602679292200264e-08
coding O 0 7.682214345550165e-06
region O 0 3.3919627639988903e-07
of O 0 1.1979625469393795e-07
SCN5A O 0 0.0031132777221500874
in O 0 6.811374078097288e-07
three O 0 1.7065998463294818e-06
IVF B-Disease 1 0.6215940117835999
families O 0 3.539626413839869e-05
. O 0 2.526880598452408e-05

We O 0 7.187976507339044e-07
show O 0 2.6594639734867087e-07
that O 0 2.4006460819236963e-08
sodium O 0 2.4538877596569364e-07
channels O 0 3.3423312117975e-08
with O 0 2.4681781951585435e-08
the O 0 1.3021183065120567e-07
missense O 0 0.00010069767449749634
mutation O 0 3.962951814173721e-05
recover O 0 0.0006090755923651159
from O 0 1.1064438467656146e-06
inactivation O 0 0.005539571400731802
more O 0 1.204076482963501e-07
rapidly O 0 1.3054524060862605e-05
than O 0 3.608170828783841e-08
normal O 0 7.136652868666715e-08
and O 0 7.54186046947325e-09
that O 0 8.719208466345663e-09
the O 0 7.337888519032276e-08
frameshift O 0 0.0006994098075665534
mutation O 0 3.944799118471565e-06
causes O 0 2.629265281939297e-06
the O 0 2.0123177790765112e-08
sodium O 0 7.820711402928282e-07
channel O 0 1.3892407935145457e-07
to O 0 1.8059953532656436e-08
be O 0 3.205790477522896e-08
non O 0 4.640142833522987e-06
- O 0 0.00017364262021146715
functional O 0 2.8227614166098647e-05
. O 0 1.0834440217877273e-05

Our O 0 5.8152477322437335e-06
results O 0 3.907226982846623e-06
indicate O 0 2.442641516609001e-06
that O 0 2.1850924269983807e-07
mutations O 0 1.0187072803091723e-05
in O 0 1.3248786672193091e-06
cardiac O 1 0.5392659902572632
ion O 0 0.00023505379795096815
- O 0 0.00018732099852059036
channel O 0 6.223411332939577e-07
genes O 0 1.987266244896091e-07
contribute O 0 2.6356769922131207e-07
to O 0 2.5256202462742294e-08
the O 0 2.1626979673783353e-07
risk O 0 2.0193894670228474e-05
of O 0 4.1706897491167183e-07
developing O 0 0.0014838397037237883
IVF B-Disease 1 0.9016929268836975
. O 0 1.4776982425246388e-05
. O 0 2.33131959248567e-05

Molecular O 0 0.000420967087848112
heterogeneity O 0 0.0008882089168764651
in O 0 2.3091570255928673e-05
mucopolysaccharidosis B-Disease 0 0.2979893684387207
IVA I-Disease 1 0.8202905058860779
in O 0 1.1442832601460395e-06
Australia O 0 7.887869060141384e-07
and O 0 6.894045156968787e-08
Northern O 0 1.62714982820944e-07
Ireland O 0 3.512374462388834e-07
: O 0 2.985943581279571e-07
nine O 0 1.1710735492442836e-07
novel O 0 2.418078111077193e-06
mutations O 0 5.074833552498603e-06
including O 0 6.34398475085618e-07
T312S O 0 0.0006450210348702967
, O 0 1.999917031980658e-07
a O 0 2.6316254775338166e-07
common O 0 2.03032777790213e-06
allele O 0 7.666164492547978e-06
that O 0 5.946655505795206e-07
confers O 0 0.0013463431969285011
a O 0 0.00043465098133310676
mild O 1 0.9945711493492126
phenotype O 1 0.5524916052818298
. O 0 0.0002076554810628295

Mucopolysaccharidosis B-Disease 1 0.6200932860374451
IVA I-Disease 1 0.9777557849884033
( O 0 0.002319540362805128
MPS B-Disease 0 0.2809838652610779
IVA I-Disease 1 0.9952834248542786
) O 0 2.93106149911182e-05
is O 0 6.463795671152184e-06
an O 0 9.571984264766797e-05
autosomal B-Disease 1 0.9967411160469055
recessive I-Disease 1 0.9991580247879028
lysosomal I-Disease 1 0.9996737241744995
storage I-Disease 1 0.9995470643043518
disorder I-Disease 1 0.9998181462287903
caused O 1 0.9081240296363831
by O 0 1.1705633369274437e-05
a O 0 0.00023734229034744203
genetic B-Disease 1 0.7276050448417664
defect I-Disease 1 0.9831970930099487
in O 0 1.1591634574870113e-05
N O 0 0.007774380501359701
- O 0 0.009924884885549545
acetylgalactosamine O 0 0.02073221653699875
- O 0 0.0009722515824250877
6 O 0 9.367896564071998e-05
- O 0 0.008157753385603428
sulfate O 0 0.11429726332426071
sulfatase O 1 0.6668742895126343
( O 0 6.493453838629648e-05
GALNS O 0 0.024887017905712128
) O 0 9.468391908740159e-06
. O 0 8.249191523646004e-06

Previous O 0 2.3343029170064256e-05
studies O 0 9.108383892453276e-06
of O 0 3.598580633479287e-06
patients O 0 0.004721420351415873
from O 0 7.279714964170125e-07
a O 0 3.582008957891958e-06
British O 0 5.103869625600055e-05
- O 0 0.002151506021618843
Irish O 0 1.0177536751143634e-05
population O 0 1.6552532144942234e-07
showed O 0 2.6245126605317637e-07
that O 0 8.41586356159496e-09
the O 0 6.33154613183251e-08
I113F O 0 0.00015245386748574674
mutation O 0 1.4489338582279743e-06
is O 0 7.212020314284473e-09
the O 0 6.804957486394869e-09
most O 0 8.397488926448204e-09
common O 0 1.5875239967044763e-07
single O 0 4.846007755077153e-07
mutation O 0 2.640468483150471e-05
among O 0 1.2300285561650526e-05
MPS B-Disease 1 0.5704996585845947
IVA I-Disease 1 0.9994901418685913
patients O 1 0.804078996181488
and O 0 1.113021335186204e-05
produces O 0 0.00392531743273139
a O 0 0.011314339935779572
severe O 1 0.9985364675521851
clinical O 1 0.9832346439361572
phenotype O 1 0.9036436676979065
. O 0 0.0003554060822352767

We O 0 1.9712381345016183e-06
studied O 0 2.5873321192193544e-06
mutations O 0 3.928014848497696e-06
in O 0 1.21288152854504e-07
the O 0 2.2534315746725042e-07
GALNS O 0 0.0023151978384703398
gene O 0 1.0512168273635325e-06
from O 0 2.2052230974622944e-07
23 O 0 3.2939972243184457e-06
additional O 0 1.2903347851533908e-05
MPS B-Disease 0 0.07381269335746765
IVA I-Disease 1 0.9990922212600708
patients O 0 0.04915924370288849
( O 0 1.6787192862466327e-06
15 O 0 1.2766018642196286e-07
from O 0 2.7367859090077218e-08
Australia O 0 3.329205355839804e-08
, O 0 6.471969182797466e-09
8 O 0 1.653204861895574e-08
from O 0 7.100791066250167e-09
Northern O 0 2.9029040504724435e-08
Ireland O 0 7.996591477876791e-08
) O 0 2.6682737797045775e-08
, O 0 5.3109485698144e-09
with O 0 1.833613438861903e-08
various O 0 2.952429269953427e-07
clinical O 0 0.1213861033320427
phenotypes O 1 0.5326586365699768
( O 0 0.005860702600330114
severe O 1 0.9919458031654358
, O 0 3.239646048314171e-06
16 O 0 4.326459475123556e-06
cases O 0 4.674836873164168e-06
; O 0 1.5009446769909118e-06
intermediate O 0 6.512658274004934e-06
, O 0 6.76379670494498e-07
4 O 0 1.1004677617165726e-05
cases O 0 3.450459553278051e-05
; O 0 7.560532685602084e-05
mild O 0 0.3959493935108185
, O 0 2.2875397007737774e-06
3 O 0 1.7935906726052053e-05
cases O 0 4.274265666026622e-05
) O 0 5.641355528496206e-06
. O 0 9.189096999762114e-06

We O 0 1.511006757937139e-06
found O 0 3.780891120186425e-07
two O 0 7.806316659753065e-08
common O 0 3.343997605043114e-06
mutations O 0 3.2836717309692176e-06
that O 0 9.463509975660145e-09
together O 0 1.9203024947955782e-08
accounted O 0 1.4279780202741676e-07
for O 0 7.0442962574190915e-09
32 O 0 4.148687793303907e-08
% O 0 7.579556537962162e-09
of O 0 2.4658053376924727e-09
the O 0 3.0120208549533345e-08
44 O 0 1.3245729633126757e-06
unrelated O 0 2.499353104212787e-05
alleles O 0 1.1445078598626424e-05
in O 0 1.9644057829282247e-06
these O 0 7.824754902685527e-06
patients O 0 0.16468288004398346
. O 0 8.312479621963575e-05

One O 0 1.9934061583626317e-06
is O 0 4.964174422639189e-07
the O 0 6.105956913415866e-07
T312S O 0 0.00048317897017113864
mutation O 0 1.1402264135540463e-05
, O 0 1.5307801959352219e-07
a O 0 4.1475021816950175e-07
novel O 0 7.343723609665176e-06
mutation O 0 1.781375249265693e-05
found O 0 9.879479421215365e-07
exclusively O 0 4.106309461349156e-06
in O 0 4.689511115429923e-05
milder O 1 0.9862939119338989
patients O 1 0.9190289974212646
. O 0 0.0002142602315871045

The O 0 2.7905941806238843e-06
other O 0 1.790902786069637e-07
is O 0 1.4931922009964183e-07
the O 0 1.642534925849759e-07
previously O 0 2.15562818084436e-06
described O 0 2.944287371065002e-05
I113F O 0 0.0010856748558580875
that O 0 1.6148550230354886e-06
produces O 0 0.0004014314617961645
a O 0 0.001134418067522347
severe O 1 0.9979671835899353
phenotype O 1 0.8014395236968994
. O 0 0.0003378760302439332

The O 0 9.540859537082724e-06
I113F O 0 0.0002901680418290198
and O 0 1.816159965528641e-06
T312S O 0 0.00012867873010691255
mutations O 0 2.1755990928795654e-06
accounted O 0 3.5549501831155794e-07
for O 0 2.7150685255605822e-08
8 O 0 3.4148385452681396e-07
( O 0 1.2199835452975094e-07
18 O 0 4.930627994781389e-08
% O 0 2.1092487756391165e-08
) O 0 1.085845635628857e-08
and O 0 5.648140177783034e-09
6 O 0 1.0470161271314282e-07
( O 0 3.7327886559523904e-08
14 O 0 1.6087261300867794e-08
% O 0 1.3013234045899935e-08
) O 0 7.988249173251916e-09
of O 0 5.985273610065178e-09
44 O 0 7.700667197241273e-07
unrelated O 0 1.2675336620304734e-05
alleles O 0 4.594720394379692e-06
, O 0 8.256591854660655e-07
respectively O 0 8.734458788239863e-06
. O 0 8.930433068599086e-06

The O 0 6.23634923613281e-06
relatively O 0 2.0563365978887305e-05
high O 0 8.540861745132133e-05
residual O 0 0.0019456206355243921
GALNS O 0 0.019652126356959343
activity O 0 2.2527835881192004e-06
seen O 0 4.1338034861837514e-07
when O 0 4.1329315081384266e-08
the O 0 4.579278112259999e-08
T312S O 0 9.743146620166954e-06
mutant O 0 3.1485787985729985e-06
cDNA O 0 2.2933149921300355e-06
is O 0 2.1355458557081874e-07
overexpressed O 0 5.134140155860223e-05
in O 0 2.1445217157634033e-07
mutant O 0 2.8873882911284454e-05
cells O 0 2.327333049834124e-06
provides O 0 1.0180675502624581e-07
an O 0 1.9884867086261693e-08
explanation O 0 4.378930498205591e-07
for O 0 2.220175900902177e-07
the O 0 1.8820363038685173e-05
mild O 1 0.9972313046455383
phenotype O 1 0.6209369897842407
in O 0 5.863469414180145e-05
patients O 0 0.054715346544981
with O 0 5.211539701122092e-06
this O 0 6.55207441013772e-06
mutation O 0 0.0003321549447719008
. O 0 4.224246004014276e-05

The O 0 1.134755962084455e-06
distribution O 0 2.595054411358433e-07
and O 0 3.6969499461747546e-08
relative O 0 5.220102750058686e-08
frequencies O 0 1.0313220499824638e-08
of O 0 6.536578833760132e-09
the O 0 6.020609788492948e-08
I113F O 0 3.3297099435003474e-05
and O 0 1.1734358906778652e-07
T312S O 0 0.00014442640531342477
mutations O 0 1.842270989982353e-06
in O 0 2.7470884234048754e-08
Australia O 0 7.464811346835631e-08
corresponded O 0 1.952363533064272e-07
to O 0 5.59771207164772e-09
those O 0 8.904348369753734e-09
observed O 0 4.943661124912069e-08
in O 0 3.584457886063319e-08
Northern O 0 1.491390548835625e-07
Ireland O 0 2.23867544946188e-07
and O 0 7.784025868318167e-09
are O 0 1.0348585322006443e-09
unique O 0 4.439647760534626e-09
to O 0 1.8248135225107376e-09
these O 0 1.759813184065706e-09
two O 0 1.4091420474926508e-08
populations O 0 1.2550592600746313e-06
, O 0 1.2508934332799981e-07
suggesting O 0 7.137523425626568e-07
that O 0 1.0456206567255322e-08
both O 0 2.7850528994122214e-08
mutations O 0 1.203208057631855e-06
were O 0 1.1270631539161968e-08
probably O 0 1.6484668208249786e-07
introduced O 0 6.044657396842013e-08
to O 0 1.0043081921651265e-08
Australia O 0 3.694377426199935e-08
by O 0 1.479807743010042e-08
Irish O 0 7.732561471129884e-07
migrants O 0 1.5562632427190692e-07
during O 0 1.5462183000636287e-07
the O 0 9.638447551196805e-08
19th O 0 5.241930921329185e-06
century O 0 1.5016426004876848e-05
. O 0 1.8724656911217608e-05

Haplotype O 0 0.0004603159904945642
analysis O 0 3.4433460314176045e-06
using O 0 1.0605139095787308e-06
6 O 0 1.5928080756566487e-05
RFLPs O 0 0.00032450203434564173
provides O 0 4.6227569328038953e-07
additional O 0 8.175209131877637e-08
data O 0 2.728842041221924e-08
that O 0 1.0526403748656321e-08
the O 0 9.122539523787054e-08
I113F O 0 8.920674008550122e-05
mutation O 0 3.653932253655512e-06
originated O 0 4.060127878346975e-07
from O 0 1.2216693789923738e-07
a O 0 7.873874778852041e-07
common O 0 7.6023648034606595e-06
ancestor O 0 5.255490759736858e-05
. O 0 3.558297612471506e-05

The O 0 1.5960752079990925e-06
other O 0 3.1621664220438106e-07
9 O 0 7.265091880981345e-06
novel O 0 1.458054430258926e-05
mutations O 0 2.2051268388167955e-05
identified O 0 1.0852771765712532e-06
in O 0 1.9491004366045672e-07
these O 0 2.8033446142217144e-07
23 O 0 6.187901453813538e-05
patients O 0 0.0002638156875036657
were O 0 4.444213885790305e-09
each O 0 2.7342539343777617e-09
limited O 0 6.768778604282488e-08
to O 0 1.4684289340038958e-08
a O 0 1.4300371731224004e-07
single O 0 1.0875700127144228e-06
family O 0 2.7709682399290614e-05
. O 0 2.0230980226187967e-05

These O 0 7.881703254497552e-07
data O 0 9.455608278585714e-07
provide O 0 4.128780233259022e-07
further O 0 1.2562803419768898e-07
evidence O 0 1.394850954739013e-07
for O 0 8.159304343280382e-08
extensive O 0 7.5512289186008275e-06
allelic O 0 0.00043190806172788143
heterogeneity O 0 0.0002312917640665546
in O 0 4.1352368498337455e-06
MPS B-Disease 0 0.004435752518475056
IVA I-Disease 1 0.9949842691421509
in O 0 1.4015520719112828e-05
British O 0 0.0012462480226531625
- O 1 0.7275995016098022
Irish O 0 0.005581761710345745
patients O 0 0.00616883160546422
and O 0 1.1540156918954381e-07
provide O 0 1.0669602801272049e-07
evidence O 0 8.35727433923239e-08
for O 0 9.864886685306828e-09
their O 0 1.0200361444390182e-08
transmission O 0 1.3707115158467786e-06
to O 0 1.3018024880295798e-08
Australia O 0 7.816298364105023e-08
by O 0 7.980714400446232e-08
British O 0 6.4182845562754665e-06
- O 0 0.00016927414981182665
Irish O 0 5.832020178786479e-06
migrants O 0 1.6287533526337938e-06
. O 0 8.521560630470049e-07
. O 0 4.6549548642360605e-06

Identification O 0 9.727623364597093e-06
of O 0 3.44926866091555e-06
constitutional O 0 0.00016174462507478893
WT1 O 1 0.9445427656173706
mutations O 0 0.0009053843677975237
, O 0 1.128534222516464e-05
in O 0 3.124702561763115e-05
patients O 1 0.5234969258308411
with O 0 0.0015780179528519511
isolated O 1 0.9953077435493469
diffuse B-Disease 1 0.9993079900741577
mesangial I-Disease 1 0.9998564720153809
sclerosis I-Disease 1 0.9998965263366699
, O 0 9.918479008774739e-06
and O 0 2.6958986154568265e-07
analysis O 0 7.149036491682637e-07
of O 0 1.1262765156061505e-06
genotype O 0 0.08734377473592758
/ O 1 0.677431583404541
phenotype O 0 0.0004564559494610876
correlations O 0 1.9853655430779327e-06
by O 0 1.7445344724364986e-08
use O 0 1.4465265429919327e-08
of O 0 3.3981010005845746e-08
a O 0 3.0234316454880172e-06
computerized O 0 0.001679905573837459
mutation O 0 0.00015933597751427442
database O 0 0.00011682215699693188
. O 0 3.062996256630868e-05

Constitutional O 0 1.660655834712088e-05
mutations O 0 7.05376305631944e-06
of O 0 2.2893676998592127e-07
the O 0 2.120753606504877e-06
WT1 O 0 0.01627839170396328
gene O 0 1.159637008640857e-06
, O 0 8.753489311175144e-08
encoding O 0 4.3430222262941243e-07
a O 0 3.201603703928413e-06
zinc O 0 0.012318991124629974
- O 0 0.0005007394938729703
finger O 0 6.021055378369056e-05
transcription O 0 8.762859579292126e-06
factor O 0 5.679520654666703e-06
involved O 0 2.2034960238670465e-06
in O 0 3.7156078178668395e-05
renal O 1 0.9994983673095703
and O 0 2.6953925043926574e-05
gonadal O 1 0.9788569211959839
development O 0 1.223649724124698e-05
, O 0 2.5445729079365265e-07
are O 0 7.587367178985005e-09
found O 0 7.480988983843417e-08
in O 0 1.825767270702272e-07
most O 0 1.4337313132273266e-06
patients O 0 0.03598914295434952
with O 0 0.0003945071657653898
Denys B-Disease 1 0.9955881834030151
- I-Disease 1 0.9979007244110107
Drash I-Disease 1 0.9986122846603394
syndrome I-Disease 1 0.9996821880340576
( O 0 0.029437104240059853
DDS B-Disease 1 0.9985822439193726
) O 0 3.417492553126067e-05
, O 0 1.3550286894314922e-05
or O 0 0.0003273598267696798
diffuse B-Disease 1 0.9953469634056091
mesangial I-Disease 1 0.9992697834968567
sclerosis I-Disease 1 0.9997692704200745
( O 0 0.31287723779678345
DMS B-Disease 1 0.9973390698432922
) O 0 1.2740219972329214e-05
associated O 0 7.578173153888201e-06
with O 0 5.535683612833964e-06
pseudohermaphroditism B-Disease 1 0.9244272708892822
and O 0 7.88211909821257e-05
/ O 1 0.7832523584365845
or O 0 0.0032492652535438538
Wilms B-Disease 1 0.998747706413269
tumor I-Disease 1 0.9977018237113953
( O 0 0.001160195330157876
WT B-Disease 1 0.987440824508667
) O 0 3.4269800380570814e-05
. O 0 1.8620025002746843e-05

Most O 0 0.0001489132846472785
mutations O 0 0.00953731220215559
in O 0 0.002704357262700796
DDS B-Disease 1 0.999168872833252
patients O 1 0.6289118528366089
lie O 0 3.128605385427363e-05
in O 0 2.406221142337017e-07
exon O 0 3.585647573345341e-05
8 O 0 6.446850875363452e-07
or O 0 1.039141679370914e-07
exon O 0 3.8997254705464e-06
9 O 0 1.9087200087142264e-07
, O 0 2.059574732982128e-08
encoding O 0 2.2485500039692852e-07
zinc O 0 5.875475108041428e-05
finger O 0 1.3482767826644704e-05
2 O 0 5.357774170988705e-07
or O 0 4.2786632548086345e-07
zinc O 0 0.00025030941469594836
finger O 0 2.2850603272672743e-05
3 O 0 4.151380323946796e-07
, O 0 3.1017052037896065e-08
respectively O 0 3.585066465916498e-08
, O 0 5.522269752589182e-09
with O 0 9.173258597172662e-09
a O 0 1.7736019231051614e-07
hot O 0 1.185757173516322e-05
spot O 0 2.0980457975383615e-06
( O 0 1.183194854093017e-06
R394W O 0 2.350455724808853e-05
) O 0 2.0008805279303488e-07
in O 0 2.7515099532138265e-07
exon O 0 0.00010560735972831026
9 O 0 2.3123349819798023e-05
. O 0 1.1337013347656466e-05

We O 0 1.0441906397318235e-06
analyzed O 0 9.659847819420975e-07
a O 0 1.6027331639634212e-07
series O 0 3.4481922739360016e-07
of O 0 3.333593667775858e-07
24 O 0 4.398012606543489e-05
patients O 0 0.0027965179178863764
, O 0 2.3026544226922852e-07
10 O 0 2.805184919907333e-07
with O 0 1.2288562629692024e-06
isolated B-Disease 0 0.0007635873625986278
DMS I-Disease 1 0.9956983327865601
( O 0 0.00010519556963117793
IDMS B-Disease 1 0.7542320489883423
) O 0 4.911302085019997e-07
, O 0 6.073943836781837e-08
10 O 0 1.9180188814971189e-07
with O 0 2.3409872937918408e-06
DDS B-Disease 1 0.9847742319107056
, O 0 1.9447742261036183e-07
and O 0 9.352011431928986e-08
4 O 0 3.418276946831611e-06
with O 0 3.1598523491993546e-05
urogenital B-Disease 1 0.9971440434455872
abnormalities I-Disease 1 0.990445613861084
and O 0 0.00010592404578346759
/ O 1 0.833690345287323
or O 0 0.00022066631936468184
WT B-Disease 1 0.9842097759246826
. O 0 9.553627751301974e-05

We O 0 1.534242619527504e-05
report O 0 4.990600791643374e-05
WT1 O 0 0.045695193111896515
heterozygous O 0 8.875100320437923e-05
mutations O 0 0.00010058395127998665
in O 0 5.134419097885257e-06
16 O 0 0.00040541027556173503
patients O 0 0.03767060115933418
, O 0 4.912492386210943e-07
4 O 0 7.935024655125744e-07
of O 0 1.7023072018673702e-07
whom O 0 7.49256469134707e-06
presented O 0 2.6788638933794573e-05
with O 0 0.00024984637275338173
IDMS B-Disease 1 0.992384672164917
. O 0 0.0002572405501268804

One O 0 8.64639241626719e-06
male O 0 1.4795821698498912e-05
and O 0 1.0097343192683184e-06
two O 0 8.52685570862377e-06
female O 0 0.06570909917354584
IDMS B-Disease 1 0.9982838034629822
patients O 1 0.9531815648078918
with O 0 0.0024920033756643534
WT1 O 1 0.995628833770752
mutations O 0 0.23406648635864258
underwent O 1 0.9862415790557861
normal O 0 0.004528061952441931
puberty O 1 0.6475897431373596
. O 0 0.00022780013387091458

Two O 0 1.953631544893142e-05
mutations O 0 0.0012854124652221799
associated O 0 0.0001445340021746233
with O 0 5.407473145169206e-05
IDMS B-Disease 1 0.97468101978302
are O 0 5.129399127667966e-08
different O 0 3.185614971812356e-08
from O 0 1.0009997595261666e-06
those O 0 2.803151573971263e-06
described O 0 0.0008838425856083632
in O 0 0.0032284525223076344
DDS B-Disease 1 0.9990673661231995
patients O 1 0.9879664778709412
. O 0 0.0004637853417079896

No O 0 0.00018231321882922202
WT1 O 0 0.347064733505249
mutations O 0 5.532106661121361e-05
were O 0 1.7663386131516745e-07
detected O 0 3.074706455663545e-06
in O 0 7.091063025654876e-08
the O 0 2.121846875979827e-07
six O 0 7.050016847642837e-06
other O 0 6.11472423770465e-05
IDMS B-Disease 1 0.998999297618866
patients O 1 0.7808747291564941
, O 0 8.913304554880597e-06
suggesting O 0 0.00019460130715742707
genetic O 0 0.0007947713602334261
heterogeneity O 0 0.0022682207636535168
of O 0 2.59855150943622e-05
this O 0 0.007136603817343712
disease O 1 0.9985750913619995
. O 0 0.0010100452927872539

We O 0 1.3861686966265552e-05
analyzed O 0 0.0001495882897870615
genotype O 0 0.045802876353263855
/ O 1 0.6060866713523865
phenotype O 0 0.002742784097790718
correlations O 0 1.9386761778150685e-05
, O 0 6.585386103097335e-08
on O 0 7.066648599618475e-09
the O 0 3.0577951282140248e-09
basis O 0 1.8152531700010854e-09
of O 0 1.4691903249541838e-09
the O 0 5.440285999469552e-09
constitution O 0 1.4884101950940476e-08
of O 0 1.2469766552669626e-08
a O 0 1.0610783647280186e-06
WT1 O 0 0.01808418147265911
mutation O 0 1.7425080613975297e-06
database O 0 4.384421288250451e-07
of O 0 1.520038495073095e-07
84 O 0 0.0006356932572089136
germ O 1 0.8462764024734497
- O 0 0.0008305291412398219
line O 0 4.608851668308489e-06
mutations O 0 1.1625182878560736e-06
, O 0 1.1314247316818182e-08
to O 0 4.982773749162561e-09
compare O 0 2.214479195572494e-07
the O 0 6.570854527154779e-09
distribution O 0 2.9624690256468966e-08
and O 0 3.634133349805779e-08
type O 0 3.950028258259408e-06
of O 0 2.996686632172896e-08
mutations O 0 7.758475476293825e-06
, O 0 5.002621961125442e-08
according O 0 3.601405040853933e-08
to O 0 3.1899439534299745e-08
the O 0 3.824693237675092e-07
different O 0 3.87707177651464e-06
symptoms O 1 0.9812856912612915
. O 0 9.178078471450135e-05

This O 0 4.408968834468396e-06
demonstrated O 0 1.262742625840474e-05
( O 0 3.995681709056953e-06
1 O 0 1.1970698778895894e-06
) O 0 1.91861161624729e-07
the O 0 5.177059492211811e-08
association O 0 1.1862350675073685e-06
between O 0 5.83804755649453e-08
mutations O 0 3.3095668072746776e-07
in O 0 1.543341987542135e-08
exons O 0 5.178170567887719e-07
8 O 0 2.2798812437940796e-07
and O 0 4.099650396938159e-08
9 O 0 8.569782039558049e-07
and O 0 4.583249335610162e-07
DMS B-Disease 0 0.4403950273990631
; O 0 8.475500976601325e-07
( O 0 5.146558805790846e-07
2 O 0 1.0285716598446015e-06
) O 0 7.574298024337622e-07
among O 0 1.0718551948230015e-06
patients O 0 0.00111213733907789
with O 0 3.975924300902989e-06
DMS B-Disease 1 0.8765811324119568
, O 0 2.837638923836039e-08
a O 0 1.0837558406251446e-08
higher O 0 1.5754755722241498e-08
frequency O 0 8.361241476961823e-09
of O 0 4.788707208547294e-09
exon O 0 7.170208391471533e-06
8 O 0 5.22393747814931e-07
mutations O 0 7.844643619137059e-07
among O 0 1.4325473784992937e-07
46 O 0 1.7901214960147627e-05
, O 0 1.7082418708014302e-05
XY O 1 0.9143281579017639
patients O 0 0.0017578051192685962
with O 0 4.788234946317971e-07
female O 0 7.89075238571968e-06
phenotype O 0 0.00012907898053526878
than O 0 1.4960274086206482e-07
among O 0 7.322983606172784e-07
46 O 0 0.00012382691784296185
, O 0 6.085277709644288e-05
XY O 1 0.9885683059692383
patients O 0 0.005700834561139345
with O 0 7.975370976964768e-07
sexual O 0 1.2540706848085392e-05
ambiguity O 0 2.4323449906660244e-05
or O 0 4.519864432950271e-06
male O 0 4.905395326204598e-05
phenotype O 0 0.002986965235322714
; O 0 1.2135357110309997e-06
and O 0 6.168699684394596e-08
( O 0 3.453800445640809e-07
3 O 0 1.8897706866027875e-07
) O 0 2.6875962788608376e-08
statistically O 0 2.832123513485385e-08
significant O 0 2.152816058753615e-08
evidence O 0 3.639856416270959e-08
that O 0 5.907605071797661e-09
mutations O 0 9.813899737309839e-08
in O 0 6.4062142257625965e-09
exons O 0 5.438192260953656e-07
8 O 0 1.4996240338405187e-07
and O 0 1.608342614645153e-08
9 O 0 1.8069640361773054e-07
preferentially O 0 3.4077919508490595e-07
affect O 0 1.1137905886471344e-07
amino O 0 2.9124153755333282e-08
acids O 0 2.462854631346545e-08
with O 0 7.674389124190384e-09
different O 0 8.064210632596769e-09
functions O 0 1.0580050968655996e-07
. O 0 9.505226330475125e-07
. O 0 8.088389222393744e-06

The O 0 4.021573477075435e-05
185delAG O 0 0.021632784977555275
BRCA1 O 0 0.012122887186706066
mutation O 0 4.942631858284585e-05
originated O 0 1.8463443893779186e-06
before O 0 9.923013521984103e-08
the O 0 3.648259649935426e-08
dispersion O 0 1.966587660717778e-06
of O 0 3.4017062944258214e-08
Jews O 0 2.622446118039079e-07
in O 0 2.7458678886205234e-08
the O 0 6.004199093467832e-08
diaspora O 0 8.7137402715598e-07
and O 0 4.0768732390006335e-08
is O 0 2.9079027186185158e-08
not O 0 2.0259895094909552e-08
limited O 0 5.374804459279403e-07
to O 0 4.165005691447732e-07
Ashkenazim O 0 0.0006250943406485021
. O 0 1.651996535656508e-05

The O 0 1.3501270586857572e-05
185delAG O 0 0.002224512631073594
mutation O 0 0.00015559198800474405
in O 0 5.005293587601045e-06
BRCA1 O 0 0.004113441798835993
is O 0 1.3954193036624929e-06
detected O 0 1.4239897609513719e-05
in O 0 5.303243142407155e-07
Ashkenazi O 0 7.409735553665087e-05
Jews O 0 9.11293739136454e-07
both O 0 1.235487275152991e-06
in O 0 0.00016878065071068704
familial B-Disease 1 0.9991532564163208
breast I-Disease 1 0.9998059868812561
and I-Disease 1 0.9983997941017151
ovarian I-Disease 1 0.9999690055847168
cancer I-Disease 1 0.9998576641082764
and O 0 3.531677975843195e-06
in O 0 7.210578587546479e-07
the O 0 4.7562403437950707e-07
general O 0 6.2759595493844245e-06
population O 0 4.610214546119096e-06
. O 0 9.022242920764256e-06

All O 0 1.0840207323781215e-05
tested O 0 0.0006738433730788529
Ashkenazi O 0 0.0009984676726162434
mutation O 0 6.375893281074241e-05
carriers O 0 2.415958806523122e-05
share O 0 2.2603663296649756e-07
the O 0 7.200862484069148e-08
same O 0 2.4269442633340077e-07
allelic O 0 0.0002439656382193789
pattern O 0 3.9223305066116154e-05
at O 0 2.3045929538056953e-06
the O 0 4.349374194134725e-06
BRCA1 O 0 0.018047140911221504
locus O 0 0.0006072349497117102
. O 0 5.743204746977426e-05

Our O 0 7.114830168575281e-06
previous O 0 7.253675903484691e-06
study O 0 6.425162155210273e-06
showed O 0 5.8664277275966015e-06
that O 0 1.3524478958970576e-07
this O 0 3.0953523832977226e-07
Ashkenazi O 0 0.00014712604752276093
mutation O 0 9.318923730461393e-06
also O 0 2.0953073942564515e-07
occurs O 0 1.4278638218456763e-06
in O 0 7.210098118548558e-08
Iraqi O 0 5.042194857196591e-07
Jews O 0 1.0903954006380445e-07
with O 0 8.054300337789755e-08
a O 0 1.0838156185855041e-06
similar O 0 1.6671217963448726e-05
allelic O 0 0.017510153353214264
pattern O 0 0.003029894083738327
. O 0 0.00011331883433740586

We O 0 1.6108742784126662e-06
extended O 0 9.118823527387576e-07
our O 0 1.1480528883112129e-07
analysis O 0 1.1200773286645926e-07
to O 0 2.0877392259421867e-08
other O 0 3.557967787060079e-08
non O 0 1.4227475730876904e-06
- O 0 3.1724943255539984e-05
Ashkenazi O 0 4.746226750285132e-06
subsets O 0 3.998882220912492e-07
354 O 0 3.169493822952063e-07
of O 0 9.98593119305724e-09
Moroccan O 0 3.9071346691343933e-07
origin O 0 4.62694238478889e-08
, O 0 4.242068385451603e-08
200 O 0 2.1656536830505502e-07
Yemenites O 0 3.2885312975849956e-05
and O 0 1.0832705754637573e-07
150 O 0 7.639093269062869e-07
Iranian O 0 1.7050934957296704e-06
Jews O 0 3.09925053443294e-06
. O 0 1.0494645721337292e-05

Heteroduplex O 0 0.0011642471654340625
analysis O 0 4.396955318952678e-06
complemented O 0 3.5766940982284723e-06
by O 0 1.0879605838454154e-07
direct O 0 2.0254067578662216e-07
DNA O 0 1.3325081908988068e-06
sequencing O 0 8.568490557081532e-07
of O 0 5.715102133763139e-07
abnormally O 0 0.007189229596406221
migrating O 0 6.032350029272493e-06
bands O 0 2.404735141681158e-06
were O 0 5.066469270786911e-07
employed O 0 1.3532568118534982e-05
. O 0 1.9118560885544866e-05

Four O 0 5.151439950168424e-07
of O 0 1.978829828885864e-07
Moroccan O 0 2.377861619606847e-06
origin O 0 2.448929308229708e-07
( O 0 4.1025728592103405e-07
1 O 0 1.2457468301363406e-07
. O 0 2.129521448068772e-08
1 O 0 1.0902747504815125e-07
% O 0 4.962877397929333e-08
) O 0 2.7772870225817314e-08
and O 0 4.377266105137778e-09
none O 0 7.46085060399082e-09
of O 0 3.8912464361828825e-09
the O 0 8.257813988166163e-08
Yemenites O 0 0.00013072839647065848
or O 0 9.385050958599095e-08
Iranians O 0 6.083578796278744e-08
was O 0 3.8342609087749224e-08
a O 0 7.863581430456179e-08
carrier O 0 3.6254077713238075e-06
of O 0 5.501856037426478e-08
the O 0 1.3951957953395322e-06
185delAG O 0 0.0023495524656027555
mutation O 0 0.00013374419359024614
. O 0 1.6779104043962434e-05

BRCA1 O 0 0.2403714507818222
allelic O 0 0.006913174409419298
patterns O 0 4.35740475950297e-05
were O 0 1.845167076908183e-07
determined O 0 2.8495773563008697e-07
for O 0 1.502406199449524e-08
four O 0 1.1233374230812387e-08
of O 0 1.0756850521431716e-08
these O 0 1.1346902084596877e-08
individuals O 0 1.630031754018546e-08
and O 0 7.443907712456621e-09
for O 0 1.1244908115770613e-08
12 O 0 1.550039172570905e-07
additional O 0 4.944901093040244e-07
non O 0 1.6021178453229368e-05
- O 0 0.0030895245727151632
Ashkenazi O 0 0.000642050348687917
185delAG O 0 0.007385075092315674
mutation O 0 0.0006607584073208272
carriers O 0 0.0035250275395810604
who O 0 0.0003635865869000554
had O 0 0.035096339881420135
breast B-Disease 1 0.9990799427032471
/ I-Disease 1 0.9988396763801575
ovarian I-Disease 1 0.9996442794799805
cancer I-Disease 1 0.9991075396537781
. O 0 0.003101776586845517

Six O 0 6.20437494944781e-05
non O 0 0.0006571380072273314
- O 0 0.12183523178100586
Ashkenazi O 0 0.0004514943575486541
individuals O 0 4.5484364363801433e-07
shared O 0 3.2336993172066286e-07
the O 0 3.801456216478982e-07
common O 0 2.6861802325583994e-05
Ashkenazi O 0 0.0038145952858030796
haplotype O 0 0.010815408080816269
, O 0 1.632742794299702e-07
four O 0 6.246809647336704e-08
had O 0 1.7426097542738717e-07
a O 0 3.9392023154505296e-07
closely O 0 1.8680425455386285e-06
related O 0 7.89489240560215e-06
pattern O 0 1.583804805704858e-05
, O 0 8.949421470560992e-08
and O 0 1.6616453990536684e-08
the O 0 1.7700815035937012e-08
rest O 0 2.1152442286620499e-07
( O 0 6.383657478181703e-07
n O 0 6.8036238189961296e-06
= O 0 1.9217633962398395e-05
6 O 0 3.646486277375516e-07
) O 0 5.317296114526471e-08
displayed O 0 1.7324390455542016e-07
a O 0 2.1549199402670638e-07
distinct O 0 4.487783826334635e-06
BRCA1 O 0 0.0061796861700713634
allelic O 0 0.0029407956171780825
pattern O 0 0.0021545556373894215
. O 0 9.49262102949433e-05

We O 0 3.989323886344209e-06
conclude O 0 9.715405212773476e-06
that O 0 3.846992910894187e-07
the O 0 1.347395254924777e-06
185delAG O 0 0.007694161031395197
BRCA1 O 0 0.010452338494360447
mutation O 0 3.558898242772557e-05
occurs O 0 1.8872866576202796e-06
in O 0 9.79503127496173e-08
some O 0 1.8322121775327105e-07
non O 0 3.966611620853655e-05
- O 0 0.01304886769503355
Ashkenazi O 0 0.00029707825160585344
populations O 0 2.575146936578676e-06
at O 0 7.711779517194373e-07
rates O 0 4.711816018243553e-06
comparable O 0 2.021182126554777e-06
with O 0 9.87418999898182e-08
that O 0 9.616356777542023e-08
of O 0 1.2404931339915493e-06
Ashkenazim O 0 0.007420002948492765
. O 0 4.74722619401291e-05

The O 0 1.97279337044165e-06
majority O 0 1.5977731209204649e-06
of O 0 3.741627949693793e-07
Jewish O 0 2.7903366571990773e-05
185delAG O 0 0.09577362984418869
mutation O 0 0.00044968671863898635
carriers O 0 0.00015083410835359246
have O 0 7.419232872507564e-08
a O 0 4.3442403807603114e-07
common O 0 3.8299194784485735e-06
allelic O 0 0.0007641550619155169
pattern O 0 4.111445741727948e-05
, O 0 1.9809878892829147e-07
supporting O 0 1.259596501768101e-06
the O 0 3.631899119227455e-07
founder O 0 5.7681070757098496e-05
effect O 0 2.5947699668904534e-06
notion O 0 1.789651037142903e-06
, O 0 1.0801529981563363e-07
but O 0 3.041608209741753e-08
dating O 0 5.384090400184505e-07
the O 0 5.7441503997779364e-08
mutations O 0 6.359067583616707e-07
origin O 0 8.767068848669624e-09
to O 0 3.3853293501806547e-09
an O 0 1.074036770631892e-08
earlier O 0 1.8322087669275788e-07
date O 0 1.660708477402295e-07
than O 0 1.1680598532848308e-07
currently O 0 6.754501669092861e-07
estimated O 0 1.1557668585737702e-05
. O 0 8.757270734349731e-06

However O 0 3.985996954725124e-06
, O 0 2.9957783453937736e-07
the O 0 5.351860110636153e-08
different O 0 5.0714771049342744e-08
allelic O 0 7.17682924005203e-05
pattern O 0 1.4660911801911425e-05
at O 0 8.262192068286822e-07
the O 0 7.836268878236297e-07
BRCA1 O 0 0.0008162463782355189
locus O 0 6.126078005763702e-06
even O 0 6.95803521466587e-08
in O 0 1.7202189894760522e-08
some O 0 2.8234614646294176e-08
Jewish O 0 2.9300558708200697e-06
mutation O 0 0.0002043390995822847
carriers O 0 0.0004756778653245419
, O 0 8.448007520200917e-07
might O 0 8.358962304555462e-07
suggest O 0 2.825512126491958e-07
that O 0 9.007437462571488e-09
the O 0 1.000627847247415e-07
mutation O 0 5.450910521176411e-06
arose O 0 3.4085339848388685e-06
independently O 0 6.237654019969341e-07
. O 0 9.119701189774787e-07
. O 0 8.72686541697476e-06

Crystal O 0 0.0020470833405852318
structure O 0 2.946618951682467e-05
of O 0 1.182463847726467e-06
the O 0 7.569419540232047e-05
hemochromatosis B-Disease 1 0.9985021352767944
protein O 0 0.00035260021104477346
HFE O 0 0.3746154010295868
and O 0 3.1790477805770934e-07
characterization O 0 2.048516762442887e-06
of O 0 1.889085510242694e-08
its O 0 8.32931448258023e-08
interaction O 0 6.309003310889238e-07
with O 0 4.721523055195576e-06
transferrin O 0 0.11074432730674744
receptor O 0 0.0013997741043567657
. O 0 1.691341276455205e-05

HFE O 0 0.27832645177841187
is O 0 1.5203533621388488e-05
an O 0 1.4728064343216829e-05
MHC O 1 0.7194246649742126
- O 0 0.002018274972215295
related O 0 7.30422561900923e-06
protein O 0 9.47395847106236e-07
that O 0 4.7328292396287e-08
is O 0 1.257114519148672e-07
mutated O 0 1.7324273358099163e-05
in O 0 1.410401182511123e-06
the O 0 4.677750985138118e-05
iron B-Disease 1 0.9981098175048828
- I-Disease 1 0.9985706806182861
overload I-Disease 1 0.9988988637924194
disease I-Disease 1 0.9993610978126526
hereditary B-Disease 1 0.998298704624176
hemochromatosis I-Disease 1 0.9991660118103027
. O 0 0.01244746707379818

HFE O 0 0.05877208337187767
binds O 0 6.044394467608072e-05
to O 0 5.627921837003669e-06
transferrin O 0 0.004167243372648954
receptor O 0 0.00020984145521651953
( O 0 1.3572531315730885e-05
TfR O 0 0.001729545067064464
) O 0 2.7221213372286e-07
and O 0 5.6329305664348794e-08
reduces O 0 2.453193246765295e-06
its O 0 3.45541408819372e-08
affinity O 0 5.730766474698612e-07
for O 0 1.7573596267084213e-07
iron O 0 0.0022316956892609596
- O 0 0.00021655127056874335
loaded O 0 1.567363869980909e-05
transferrin O 0 0.008101976476609707
, O 0 5.880026037630159e-06
implicating O 0 0.0332772321999073
HFE O 1 0.8478760719299316
in O 0 2.8411315724952146e-05
iron O 1 0.5235859751701355
metabolism O 0 0.011925720609724522
. O 0 5.679178866557777e-05

The O 0 6.095668868510984e-05
2 O 0 0.0002397033094894141
. O 0 0.00014530314365401864

6 O 0 5.533330840989947e-05
A O 0 2.2600681404583156e-05
crystal O 0 0.000997188501060009
structure O 0 2.017989754676819e-05
of O 0 2.4133876195264747e-06
HFE O 1 0.8133354187011719
reveals O 0 2.116586074407678e-05
the O 0 1.5131105612908868e-07
locations O 0 5.41552935828804e-07
of O 0 7.509017450502142e-06
hemochromatosis B-Disease 1 0.9993988275527954
mutations O 0 0.00015662232181057334
and O 0 1.220965259562945e-06
a O 0 1.6086474715848453e-05
patch O 1 0.6806427240371704
of O 0 1.4474325098490226e-06
histidines O 0 0.05957123264670372
that O 0 1.1276139844085264e-07
could O 0 5.434584693375655e-08
be O 0 7.271039770273546e-09
involved O 0 1.8523216738230985e-07
in O 0 1.4562772321369266e-06
pH O 0 0.00693906843662262
- O 0 0.0011071438202634454
dependent O 0 1.2968706869287416e-05
interactions O 0 1.1207007446500938e-05
. O 0 1.6857375157997012e-05

We O 0 2.4901862616388826e-06
also O 0 8.054443583205284e-07
demonstrate O 0 2.671446964086499e-06
that O 0 8.234385404648492e-07
soluble O 0 0.0009771628538146615
TfR O 0 0.031204024329781532
and O 0 3.1118077004066436e-06
HFE O 0 0.4585812985897064
bind O 0 1.075624913937645e-05
tightly O 0 1.1005726037183194e-06
at O 0 1.4104440992923628e-07
the O 0 2.7159179794011834e-08
basic O 0 3.7535937735810876e-07
pH O 0 1.515241001470713e-05
of O 0 1.3679173349601115e-08
the O 0 2.3555747930004145e-07
cell O 0 6.698886136291549e-05
surface O 0 8.79547769727651e-06
, O 0 5.447619599863174e-08
but O 0 1.0032666253323441e-08
not O 0 1.9941637230402876e-09
at O 0 1.8072599416996127e-08
the O 0 5.803796199188582e-08
acidic O 0 7.66596058383584e-05
pH O 0 4.2512085201451555e-05
of O 0 6.115345172474917e-07
intracellular O 0 0.00039444625144824386
vesicles O 0 0.0010912467259913683
. O 0 2.897895683418028e-05

TfR O 0 0.3115897476673126
HFE O 0 0.21017153561115265
stoichiometry O 0 0.0005559124401770532
( O 0 7.417459528369363e-06
2 O 0 3.171164507875801e-06
1 O 0 1.9260653516539605e-06
) O 0 4.2569010361148685e-07
differs O 0 1.6195698435694794e-06
from O 0 5.228806685408927e-07
TfR O 0 0.004061935003846884
transferrin O 0 0.0009247541893273592
stoichiometry O 0 3.768996612052433e-05
( O 0 6.254600748434314e-07
2 O 0 3.990409425114194e-07
2 O 0 4.3804715232909075e-07
) O 0 7.416572600504878e-08
, O 0 1.202485577778134e-08
implying O 0 5.914530731843115e-08
a O 0 2.77160761008588e-09
different O 0 8.320890643176426e-10
mode O 0 1.8954375846647054e-08
of O 0 3.8209502228880865e-09
binding O 0 1.531183215774945e-07
for O 0 2.049938245818339e-07
HFE O 0 0.06066809594631195
and O 0 8.527063641849963e-07
transferrin O 0 0.0025941552594304085
to O 0 3.5537433973331645e-07
TfR O 0 0.006613193079829216
, O 0 4.746878445871516e-08
consistent O 0 6.557035447940507e-08
with O 0 1.3250623709382126e-08
our O 0 3.538470139119454e-08
demonstration O 0 5.731159831157129e-07
that O 0 1.512715357421257e-07
HFE O 0 0.020074596628546715
, O 0 1.1753985518225818e-06
transferrin O 0 0.0013118652859702706
, O 0 1.8630896647664485e-07
and O 0 2.1943560568615794e-07
TfR O 0 0.0007837184821255505
form O 0 6.668523724329134e-07
a O 0 2.2563053789781407e-06
ternary O 0 0.0012296658242121339
complex O 0 0.0007834747084416449
. O 0 8.332845027325675e-05

Identification O 0 3.244741719754529e-06
of O 0 2.8508168270491296e-07
three O 0 4.989995545656711e-07
novel O 0 1.45573267218424e-05
mutations O 0 3.773996013478609e-06
and O 0 3.131361125952026e-08
a O 0 5.689380699891444e-08
high O 0 2.608358613542805e-07
frequency O 0 3.1804422206960226e-08
of O 0 1.5316498291895186e-08
the O 0 3.0644619641861937e-07
Arg778Leu O 0 0.004252912476658821
mutation O 0 7.470482523785904e-05
in O 0 1.889397026388906e-05
Korean O 0 0.4965701103210449
patients O 1 0.9714248180389404
with O 0 0.020735980942845345
Wilson B-Disease 1 0.9928882718086243
disease I-Disease 1 0.9979380965232849
. O 0 0.0003659835201688111

Four O 0 2.8827576898038387e-05
mutations O 0 0.00041880624485202134
- O 0 0.005871336441487074
- O 0 0.0011240221792832017
R778L O 0 0.0002229188830824569
, O 0 7.08561344708869e-07
A874V O 0 5.0827897212002426e-05
, O 0 2.7069509656030277e-07
L1083F O 0 1.779775629984215e-05
, O 0 1.3920696062541538e-07
and O 0 1.1657429155320642e-07
2304delC O 0 0.00019509177946019918
- O 0 6.162433419376612e-05
- O 0 4.446736511454219e-06
in O 0 1.2401171645137765e-08
the O 0 3.0866733169432337e-08
copper O 0 1.0568515790509991e-05
- O 0 3.253665681768325e-06
transporting O 0 3.042879370696028e-07
enzyme O 0 8.676342986291274e-07
, O 0 3.585278705031669e-07
P O 0 0.0003347502206452191
- O 0 8.809744758764282e-05
type O 0 4.0496597648598254e-05
ATPase O 0 0.00041924044489860535
( O 0 2.786854793157545e-06
ATP7B O 0 0.0005370432045310736
) O 0 1.0165889108293413e-07
, O 0 1.137965099928806e-08
were O 0 8.90214124638078e-09
identified O 0 3.23121781775626e-07
in O 0 1.2376347058307147e-06
Korean O 0 0.13186411559581757
Patients O 1 0.9578118324279785
with O 0 0.004236915614455938
Wilson B-Disease 1 0.9892416596412659
disease I-Disease 1 0.9979702830314636
. O 0 0.00036226180964149535

Arg778Leu O 0 0.011013420298695564
, O 0 2.760345978458645e-06
the O 0 2.526018363369076e-07
most O 0 1.9146233398714685e-07
frequently O 0 8.471024557366036e-07
reported O 0 2.209063268310274e-06
mutation O 0 5.285505721985828e-07
of O 0 1.266514626507842e-08
this O 0 3.8294153625884064e-08
enzyme O 0 2.576955239419476e-06
, O 0 3.709756057901359e-08
was O 0 2.1191000953990624e-08
found O 0 8.851027466505457e-09
in O 0 2.7633781929381485e-09
six O 0 1.7588812184499147e-08
of O 0 3.6061550190424896e-08
eight O 0 7.566467957076384e-06
unrelated O 0 0.028005288913846016
patients O 0 0.06680025160312653
studied O 0 9.111651593229908e-07
, O 0 3.549156701865286e-08
an O 0 1.4687091542953112e-08
allele O 0 2.796524825043889e-07
frequency O 0 8.241276816534082e-08
of O 0 1.0804765082639278e-07
37 O 0 1.3385529200604651e-05
. O 0 8.489128049404826e-06

5 O 0 2.3835515094106086e-05
% O 0 3.5006075904675527e-06
, O 0 5.945124144091096e-07
which O 0 8.608135004806172e-08
is O 0 1.603497565838552e-07
considerably O 0 6.587335519725457e-06
higher O 0 3.596473447942117e-07
than O 0 3.9467334289611244e-08
those O 0 3.361607525675936e-08
in O 0 7.671889790117348e-08
other O 0 2.886413597025239e-07
Asian O 0 0.00020008727733511478
populations O 0 6.491602107416838e-05
. O 0 2.064798172796145e-05

The O 0 1.0522509228394483e-06
novel O 0 1.5549295540040475e-06
single O 0 3.403556831926835e-07
nucleotide O 0 2.354097887291573e-06
deletion O 0 0.0002448632731102407
, O 0 3.846072104352061e-06
2304delC O 0 0.001289169886149466
, O 0 6.213276719790883e-07
was O 0 2.562875067724235e-07
found O 0 1.742001529692061e-07
in O 0 2.4010725496736995e-07
one O 0 2.990069106090232e-06
patient O 0 0.004688203800469637
. O 0 3.3600830647628754e-05

Since O 0 4.2565620788082015e-06
a O 0 4.5751662014481553e-07
mutation O 0 1.1480149169074139e-06
at O 0 2.306670126017707e-07
cDNA O 0 3.2068046493805014e-06
nucleotide O 0 5.397351742431056e-06
2302 O 0 0.028822461143136024
( O 0 5.723628419218585e-06
2302insC O 0 0.00019580031221266836
) O 0 5.075556259726e-07
had O 0 1.0187979171405459e-07
been O 0 2.5024407435125795e-08
previously O 0 1.5014329335372167e-07
described O 0 1.1611731451921514e-06
, O 0 2.614434535530563e-08
this O 0 7.493910381128899e-09
region O 0 3.403685866487649e-08
of O 0 1.0593090848942666e-08
the O 0 6.526938705064822e-07
ATP7B O 0 0.30866432189941406
gene O 0 3.824639497906901e-05
may O 0 4.0470717976859305e-06
be O 0 1.5164519595600723e-07
susceptible O 0 0.00026251899544149637
to O 0 7.659328957743128e-07
gene O 0 0.0003319747920613736
rearrangements O 0 0.49163171648979187
causing O 1 0.9947463274002075
Wilson B-Disease 1 0.9917293190956116
disease I-Disease 1 0.9977717995643616
. O 0 0.0006718322983942926

Disruption O 0 0.00010183433187194169
of O 0 6.724909553668112e-07
splicing O 0 9.621081517252605e-06
regulated O 0 1.9490330487315077e-06
by O 0 5.267571054901055e-07
a O 0 4.965342668583617e-06
CUG O 0 0.061692286282777786
- O 0 0.00118873396422714
binding O 0 1.914621861942578e-05
protein O 0 0.00017290787945967168
in O 0 0.0007037439499981701
myotonic B-Disease 1 0.9975848197937012
dystrophy I-Disease 1 0.9976680874824524
. O 0 0.0019696953240782022

Myotonic B-Disease 1 0.9958516359329224
dystrophy I-Disease 1 0.9983521699905396
( O 1 0.9503426551818848
DM B-Disease 1 0.9984675049781799
) O 0 0.0001992621400859207
is O 0 4.188013463135576e-06
caused O 0 9.684538235887885e-05
by O 0 1.6722432860660774e-07
a O 0 1.6539577245566761e-06
CTG O 0 0.0024540373124182224
expansion O 0 2.6525792691245442e-06
in O 0 3.5688898947228154e-08
the O 0 5.97382481259956e-08
3 O 0 1.6822514226078056e-06
untranslated O 0 7.882818317739293e-05
region O 0 5.597329391093808e-07
of O 0 1.9659316308207053e-07
the O 0 2.3158350813901052e-05
DM B-Disease 1 0.9972856044769287
gene O 0 0.00046845327597111464
. O 0 4.134588016313501e-05

One O 0 6.811810180806788e-06
model O 0 7.282113074325025e-05
of O 0 0.00012618894106708467
DM B-Disease 1 0.9990770816802979
pathogenesis O 1 0.9704836010932922
suggests O 0 7.30699539417401e-05
that O 0 1.912174525386945e-07
RNAs O 0 7.202976121334359e-06
from O 0 2.778929619751125e-08
the O 0 1.7651455408440597e-08
expanded O 0 2.547846236211626e-07
allele O 0 1.8152061898035754e-07
create O 0 5.167874661538008e-08
a O 0 9.734723249721355e-08
gain O 0 1.2290331596886972e-06
- O 0 1.9671257177833468e-05
of O 0 9.822194613207103e-08
- O 0 6.302109977696091e-05
function O 0 1.446044279873604e-07
mutation O 0 1.8553342329141742e-07
by O 0 5.142768433330502e-09
the O 0 7.929834566766658e-09
inappropriate O 0 1.597968264377414e-07
binding O 0 1.7410043184895585e-08
of O 0 8.009227059346813e-09
proteins O 0 7.637390098125252e-08
to O 0 5.382807799492184e-08
the O 0 1.1830785524580278e-06
CUG O 0 0.016759933903813362
repeats O 0 0.00048354730824939907
. O 0 2.1152849512873217e-05

Data O 0 1.745743429637514e-05
presented O 0 1.0611355719447602e-05
here O 0 1.1522135991981486e-06
indicate O 0 6.148660531835048e-07
that O 0 1.6331281216253046e-08
the O 0 5.296485028338793e-08
conserved O 0 1.046837951435009e-06
heterogeneous O 0 0.00011096105299657211
nuclear O 0 0.0002972783404402435
ribonucleoprotein O 0 0.06646609306335449
, O 0 1.0452357628309983e-06
CUG O 0 0.000925728352740407
- O 0 6.435108844016213e-06
binding O 0 2.433382348954183e-07
protein O 0 5.731033638767258e-07
( O 0 1.9780250113399234e-06
CUG O 0 0.012572096660733223
- O 0 0.0007386906654573977
BP O 0 0.00015337274817284197
) O 0 1.8549734193129552e-07
, O 0 3.371959067521857e-08
may O 0 5.2364271141414065e-08
mediate O 0 1.2238400586284115e-06
the O 0 2.4909127205319237e-07
trans O 0 0.00011220467422390357
- O 0 0.00010539589857216924
dominant O 0 1.0061335160571616e-06
effect O 0 1.2747258892886748e-07
of O 0 1.7874009827778536e-08
the O 0 3.09633549022692e-07
RNA O 0 1.4177308912621811e-05
. O 0 6.26410201221006e-06

CUG O 1 0.709517240524292
- O 0 0.04146602377295494
BP O 0 0.0006247989367693663
was O 0 6.627648758694704e-07
found O 0 1.1680977252126468e-07
to O 0 3.783076252261708e-08
bind O 0 7.730054676358122e-07
to O 0 4.5007048754541756e-08
the O 0 7.909035844022583e-07
human O 0 9.869954374153167e-05
cardiac O 1 0.9978311657905579
troponin O 1 0.9980695843696594
T O 1 0.9793874025344849
( O 0 1.044413511408493e-05
cTNT O 0 0.00024092775129247457
) O 0 5.605176625067543e-07
pre O 0 1.7338290490442887e-05
- O 0 1.9244669601903297e-05
messenger O 0 1.2589948710228782e-06
RNA O 0 2.2571782665181672e-07
and O 0 1.7851897737841682e-08
regulate O 0 3.939672126307414e-07
its O 0 8.671083406852631e-08
alternative O 0 1.6977528503048234e-06
splicing O 0 2.1761263269581832e-05
. O 0 1.2291829989408143e-05

Splicing O 0 4.390331741888076e-05
of O 0 4.777370122610591e-06
cTNT O 0 0.003663900075480342
was O 0 2.962928010674659e-05
disrupted O 0 0.0024279518984258175
in O 0 0.0007412899867631495
DM B-Disease 1 0.9992998838424683
striated O 1 0.9970596432685852
muscle O 1 0.7308325171470642
and O 0 1.3568575241151848e-06
in O 0 1.0690579301808611e-06
normal O 0 1.1078069292125292e-05
cells O 0 2.514663719921373e-05
expressing O 0 5.430643795989454e-06
transcripts O 0 4.375851403892739e-06
that O 0 3.890625634994649e-07
contain O 0 1.9996410628664307e-05
CUG O 0 0.06923355907201767
repeats O 0 0.000991260283626616
. O 0 3.376142922206782e-05

Altered O 0 3.255800766055472e-05
expression O 0 1.944267523867893e-06
of O 0 3.233168683891563e-07
genes O 0 3.582767249099561e-06
regulated O 0 1.1255646313657053e-05
posttranscriptionally O 0 0.0009517717408016324
by O 0 4.097034889127826e-06
CUG O 1 0.5986730456352234
- O 0 0.08025410026311874
BP O 0 0.0016938451444730163
therefore O 0 1.3917923524786602e-06
may O 0 3.9930123421072494e-06
contribute O 0 2.096559364872519e-05
to O 0 2.795676664391067e-05
DM B-Disease 1 0.9987897276878357
pathogenesis O 1 0.9348213076591492
. O 0 1.2833323125960305e-05
. O 0 3.0152799809002317e-05

Identification O 0 3.656707121990621e-06
of O 0 4.6232730710471515e-07
a O 0 2.191977046095417e-06
novel O 0 1.775793316483032e-05
nonsense O 0 7.709183410042897e-05
mutation O 0 2.609667490105494e-06
and O 0 1.888318301723757e-08
a O 0 6.138441932534988e-08
missense O 0 4.011152668681461e-06
substitution O 0 2.0217767371377704e-07
in O 0 5.940873748500053e-08
the O 0 3.3512017694192764e-07
vasopressin O 0 0.0007113516912795603
- O 0 0.010424599051475525
neurophysin O 0 0.01706583797931671
II O 0 0.0014124055160209537
gene O 0 4.80794767554471e-07
in O 0 2.5570786377215882e-08
two O 0 4.564131828033169e-08
Spanish O 0 6.365739409375237e-06
kindreds O 0 0.002327878726646304
with O 0 0.00034871845855377614
familial B-Disease 1 0.9965208768844604
neurohypophyseal I-Disease 1 0.9974258542060852
diabetes I-Disease 1 0.9993306398391724
insipidus I-Disease 1 0.9936690926551819
. O 0 0.00403296435251832

Familial B-Disease 1 0.9821177124977112
neurohypophyseal I-Disease 1 0.9909674525260925
diabetes I-Disease 1 0.9988013505935669
insipidus I-Disease 1 0.9967494010925293
( O 0 0.05794496834278107
FNDI B-Disease 1 0.9946346282958984
) O 0 4.664040170609951e-05
is O 0 8.717499440535903e-06
an O 0 0.0003455877595115453
autosomal B-Disease 1 0.9986317753791809
dominant I-Disease 1 0.9991278052330017
disease I-Disease 1 0.9998645782470703
caused O 1 0.9986164569854736
by O 0 0.059649016708135605
deficiency O 1 0.9996050000190735
in O 0 3.820664460363332e-06
the O 0 1.0345302143832669e-05
antidiuretic O 0 0.1163695827126503
hormone O 0 0.0009102754411287606
arginine O 0 6.142479833215475e-05
vasopressin O 0 0.00018513057148084044
( O 0 4.925063421978848e-06
AVP O 0 0.00021149760868865997
) O 0 6.742852320940074e-08
encoded O 0 1.8830130343872042e-08
by O 0 4.03483682021033e-08
the O 0 3.9469600210395583e-07
AVP O 0 0.030283890664577484
- O 0 0.0025277547538280487
neurophysin O 0 0.010912544094026089
II O 0 0.04153923690319061
( O 0 6.001393194310367e-05
AVP O 0 0.15957951545715332
- O 0 0.0021587074734270573
NPII O 0 0.0021068949718028307
) O 0 8.870431429386372e-07
gene O 0 2.2048666323826183e-06
on O 0 6.427059702218685e-07
chromosome O 0 0.0001557784271426499
20p13 O 0 0.002401778707280755
. O 0 3.667072087409906e-05

In O 0 4.054380951856729e-06
this O 0 5.086667442810722e-07
study O 0 1.5124541050681728e-06
, O 0 9.583233406829095e-08
we O 0 1.7314141231850044e-08
analyzed O 0 9.103645481900458e-08
two O 0 9.026527969524523e-09
families O 0 1.0093513935771625e-07
with O 0 9.715729021309016e-08
FNDI B-Disease 0 0.0004933389718644321
using O 0 1.5213402093650075e-08
direct O 0 2.9821126901197204e-08
automated O 0 1.316185489486088e-06
fluorescent O 0 5.892736226087436e-06
, O 0 5.6302237538830013e-08
solid O 0 5.245653937890893e-07
phase O 0 1.1852603165607434e-06
, O 0 2.3553091921257874e-08
single O 0 5.312248063660263e-08
- O 0 3.480315399428946e-06
stranded O 0 2.134548111598633e-07
DNA O 0 7.19637256452188e-08
sequencing O 0 5.435766325945224e-08
of O 0 5.423608229193633e-08
PCR O 0 2.5232515326933935e-05
- O 0 0.00018446784815751016
amplified O 0 0.000125797902001068
AVP O 0 0.03543646261096001
- O 0 0.001739532221108675
NPII O 0 0.007040912285447121
DNA O 0 8.148505003191531e-05
. O 0 1.9218989109504037e-05

In O 0 1.5821386796233128e-06
one O 0 1.6641058664390584e-07
of O 0 1.012575481240674e-07
the O 0 1.0923245099547785e-06
families O 0 6.628574283240596e-06
, O 0 2.1601144908345304e-06
affected O 0 4.587207968143048e-06
individuals O 0 8.256790806626668e-08
presented O 0 3.9576494259563333e-07
a O 0 3.4453225339348137e-07
novel O 0 2.7786493319581496e-06
nonsense O 0 3.100507819908671e-05
mutation O 0 2.5407055090909125e-06
in O 0 5.475223829876086e-08
exon O 0 6.289488737820648e-06
3 O 0 4.9390145306915656e-08
of O 0 4.6183790125553514e-09
the O 0 2.03208880833472e-08
gene O 0 1.725184546330638e-07
, O 0 8.07658739887529e-09
consisting O 0 1.6691675597257927e-08
in O 0 1.9326854783230374e-08
a O 0 2.3257837256096536e-07
G O 0 9.621318167774007e-05
to O 0 1.5508376804973523e-07
T O 0 0.0007549248402938247
transition O 0 2.9740562013103045e-07
at O 0 8.014028196612344e-08
nucleotide O 0 4.2977330849680584e-07
2101 O 0 0.0003432093362789601
, O 0 1.9311121590703806e-08
which O 0 4.904905814839822e-09
produces O 0 4.513952944762423e-08
a O 0 1.263585325261829e-08
stop O 0 7.175607663612027e-08
signal O 0 6.279937281306047e-08
in O 0 1.9925147753951933e-08
codon O 0 6.992545991124643e-07
82 O 0 7.571722107968526e-06
( O 0 4.547214757621987e-06
Glu O 0 0.006147722713649273
) O 0 3.393651866190339e-07
of O 0 4.666533186536981e-07
NPII O 0 0.021030310541391373
. O 0 2.4002692953217775e-05

The O 0 4.0474857087247074e-05
premature O 0 0.025361066684126854
termination O 0 0.0005818533827550709
eliminates O 0 5.9853100538020954e-05
part O 0 2.1974156538817624e-07
of O 0 6.692702214650126e-08
the O 0 8.143528589243942e-07
C O 0 0.0020520067773759365
- O 0 0.0002680170873645693
terminal O 0 1.181178231490776e-05
domain O 0 8.450692945416449e-08
of O 0 2.242044239153529e-08
NPII O 0 0.0002053572825388983
, O 0 1.3383159469526618e-08
including O 0 5.633400412818901e-09
a O 0 2.0943918599414246e-08
cysteine O 0 4.3020716589126096e-07
residue O 0 9.004355092656624e-07
in O 0 2.4243481888674978e-08
position O 0 1.0644174608387402e-07
85 O 0 1.7039815247699153e-06
, O 0 4.8452406531396264e-08
which O 0 9.356629249168691e-09
could O 0 7.684803904339788e-09
be O 0 1.0976748399116332e-09
involved O 0 7.10024927741415e-09
in O 0 7.46449480004685e-09
the O 0 3.188721464653099e-08
correct O 0 3.585474360079388e-06
folding O 0 5.910429172217846e-05
of O 0 2.523690056932537e-07
the O 0 8.25399092718726e-06
prohormone O 0 0.2403586357831955
. O 0 4.3705433199647814e-05

In O 0 1.3007620509597473e-06
the O 0 3.6712535234073584e-07
second O 0 5.840257699674112e-07
family O 0 7.811333944118815e-07
, O 0 5.5032202794791374e-08
a O 0 1.297499636621069e-07
G279A O 0 8.80607058206806e-06
substitution O 0 2.0080318563486799e-07
at O 0 1.2112701597288833e-07
position O 0 8.435973342102443e-08
- O 0 2.1962162009003805e-06
1 O 0 2.5586299301494364e-08
of O 0 2.4737756287862567e-09
the O 0 1.2852404474017476e-08
signal O 0 3.59448137032814e-07
peptide O 0 1.8781655626298743e-06
was O 0 6.889339232429847e-08
observed O 0 9.779891030348153e-08
in O 0 3.8567858240412534e-08
all O 0 7.701887483335668e-08
affected O 0 1.0617510270094499e-05
individuals O 0 3.270380830144859e-06
. O 0 1.651960519666318e-05

This O 0 5.990706085867714e-06
missense O 0 0.000225878888159059
mutation O 0 3.811698479694314e-05
, O 0 1.1790530152211431e-06
which O 0 1.1595574278544518e-06
replaces O 0 0.014408864080905914
Ala O 0 0.43239590525627136
with O 0 1.711068944132421e-05
Thr O 1 0.8673769235610962
, O 0 2.7459261673357105e-06
is O 0 1.2651740917135612e-06
frequent O 0 0.00021614014985971153
among O 0 0.0012785656144842505
FNDI B-Disease 1 0.999447762966156
patients O 0 0.27281737327575684
and O 0 4.453839892448741e-07
is O 0 1.325333442991905e-07
thought O 0 1.236219731026722e-07
to O 0 1.2845346120116119e-08
reduce O 0 6.813239110670111e-07
the O 0 7.148079905761051e-09
efficiency O 0 2.679479109701788e-07
of O 0 2.9730543360528827e-08
cleavage O 0 4.700166391558014e-05
by O 0 2.8663174589382834e-07
signal O 0 5.497897745954106e-06
peptidases O 0 0.00027789821615442634
. O 0 2.770042556221597e-06
. O 0 1.1692289263010025e-05

Genetic O 0 0.0006456089322455227
heterogeneity O 0 0.0023949916940182447
of O 0 0.0009393692016601562
Saethre B-Disease 1 0.9952740669250488
- I-Disease 1 0.998450517654419
Chotzen I-Disease 1 0.9988217949867249
syndrome I-Disease 1 0.9996839761734009
, O 0 2.423664409434423e-05
due O 0 4.02997357014101e-05
to O 0 1.8908933725469979e-06
TWIST O 0 0.0017165450844913721
and O 0 2.020304418692831e-05
FGFR O 1 0.6660719513893127
mutations O 0 0.0009839681442826986
. O 0 4.828113742405549e-05

Thirty O 0 0.00027658953331410885
- O 0 0.0032508173026144505
two O 0 5.284555300022475e-06
unrelated O 0 0.010845011100172997
patients O 0 0.003422885900363326
with O 0 9.600620387573144e-07
features O 0 1.8760405509965494e-05
of O 0 3.88885528082028e-05
Saethre B-Disease 1 0.9975850582122803
- I-Disease 1 0.9989259839057922
Chotzen I-Disease 1 0.9993840456008911
syndrome I-Disease 1 0.999815046787262
, O 0 2.516107815608848e-05
a O 0 6.162456702440977e-05
common O 0 0.008225701749324799
autosomal B-Disease 1 0.9920201897621155
dominant I-Disease 0 0.3296809494495392
condition I-Disease 1 0.8712454438209534
of O 0 0.001512448419816792
craniosynostosis B-Disease 1 0.9994593262672424
and O 0 0.027559321373701096
limb B-Disease 1 0.998561680316925
anomalies I-Disease 0 0.3911628723144531
, O 0 1.450224885957141e-06
were O 0 6.377834438353602e-08
screened O 0 1.9603596683737123e-06
for O 0 1.4836520279004617e-07
mutations O 0 8.043666639423463e-06
in O 0 7.046239716146374e-07
TWIST O 0 0.002284250222146511
, O 0 1.4308873687696178e-05
FGFR2 O 0 0.07888789474964142
, O 0 1.8998988480234402e-06
and O 0 2.8888609904242912e-06
FGFR3 O 0 0.060175783932209015
. O 0 3.114676655968651e-05

Nine O 0 1.6859208699315786e-05
novel O 0 1.5977358998497948e-05
and O 0 1.491891225668951e-06
three O 0 3.5486973501974717e-06
recurrent O 1 0.6756553053855896
TWIST O 0 0.02006969042122364
mutations O 0 5.29144708707463e-05
were O 0 5.717927109571974e-08
found O 0 3.2941434824351745e-07
in O 0 5.590682121692225e-07
12 O 0 7.570812158519402e-06
families O 0 1.8361552065471187e-05
. O 0 1.9440749383647926e-05

Seven O 0 9.613028851163108e-06
families O 0 4.313881163398037e-06
were O 0 6.918387640553192e-08
found O 0 6.179604383760307e-08
to O 0 1.3462654102625038e-08
have O 0 1.8853672401064614e-08
the O 0 1.5039063328003976e-07
FGFR3 O 0 0.07297784835100174
P250R O 0 0.0037888179067522287
mutation O 0 1.47358468893799e-05
, O 0 7.376042532314386e-08
and O 0 1.507225277919133e-08
one O 0 9.210338269838303e-09
individual O 0 1.706698604664325e-08
was O 0 3.230496403716643e-08
found O 0 1.5103966077845143e-08
to O 0 5.1878115137071745e-09
have O 0 1.1133844068922372e-08
an O 0 2.3366999357676832e-07
FGFR2 O 0 0.008812562562525272
VV269 O 0 0.0009327986626885831
- O 0 0.0005794300232082605
270 O 0 4.221197377773933e-05
deletion O 0 0.00037790442002005875
. O 0 1.8090477169607766e-05

To O 0 1.5717964743089397e-06
date O 0 9.289298077419517e-07
, O 0 1.7022991016801825e-07
our O 0 5.8667911417842333e-08
detection O 0 2.069815764116356e-06
rate O 0 1.4817176463566284e-07
for O 0 3.429269312960059e-08
TWIST O 0 4.943876774632372e-05
or O 0 1.0157415317735285e-06
FGFR O 0 0.004265055991709232
mutations O 0 2.085206006086082e-06
is O 0 4.567214162420896e-08
68 O 0 1.0972202062475844e-06
% O 0 9.700008263280324e-08
in O 0 3.677981794680818e-07
our O 0 1.1520661246322561e-05
Saethre B-Disease 1 0.9882849454879761
- I-Disease 1 0.9987037181854248
Chotzen I-Disease 1 0.9992796778678894
syndrome I-Disease 1 0.9999145269393921
patients O 1 0.9046947956085205
, O 0 2.281450178998057e-06
including O 0 8.053652322814742e-07
our O 0 2.0748236693179933e-06
five O 0 2.4947237761807628e-05
patients O 0 0.44273072481155396
elsewhere O 0 2.3154596419772133e-05
reported O 0 1.3602711987914518e-05
with O 0 3.5456325804261724e-06
TWIST O 0 0.013663137331604958
mutations O 0 0.001464600907638669
. O 0 4.747022467199713e-05

More O 0 4.777378990183934e-07
than O 0 1.9041347343318193e-07
35 O 0 4.268796089945681e-07
different O 0 1.0649352333302886e-07
TWIST O 0 0.00034339865669608116
mutations O 0 1.5476536646019667e-05
are O 0 5.2931930838440167e-08
now O 0 3.5110014096062514e-07
known O 0 2.4842725565576984e-07
in O 0 8.075728175072072e-08
the O 0 3.77995377220941e-07
literature O 0 4.781536517839413e-06
. O 0 1.1923066267627291e-05

The O 0 2.4477994884364307e-06
most O 0 5.66589164918696e-07
common O 0 2.821808493536082e-06
phenotypic O 0 2.1559408196480945e-05
features O 0 6.902083441673312e-06
, O 0 2.8650686090259114e-07
present O 0 1.0146634821239786e-07
in O 0 1.0782382986462835e-08
more O 0 3.4057754394467565e-09
than O 0 4.310184209543877e-09
a O 0 2.8129475637683754e-08
third O 0 7.233239074366793e-08
of O 0 4.673186637660365e-08
our O 0 1.90004755040718e-06
patients O 0 0.0007265585009008646
with O 0 7.98060568740766e-07
TWIST O 0 0.0006660112994723022
mutations O 0 7.91393449617317e-06
, O 0 1.0026203511870335e-07
are O 0 4.486682669835318e-08
coronal B-Disease 0 0.00019450818945188075
synostosis I-Disease 0 0.003337925300002098
, O 0 2.323228727618698e-06
brachycephaly B-Disease 0 0.0021495013497769833
, O 0 8.798700037004892e-06
low B-Disease 0 0.010429661720991135
frontal I-Disease 1 0.9972510933876038
hairline I-Disease 1 0.9991143345832825
, O 0 0.0007333121611736715
facial B-Disease 1 0.9925069212913513
asymmetry I-Disease 0 0.3048763573169708
, O 0 0.0009924302576109767
ptosis B-Disease 1 0.9986171722412109
, O 0 8.432315371464938e-05
hypertelorism B-Disease 1 0.9679142832756042
, O 0 7.454731985490071e-06
broad B-Disease 0 0.0007607742445543408
great I-Disease 0 0.00023602643341291696
toes I-Disease 0 0.0034399160649627447
, O 0 2.931095423264196e-06
and O 0 5.4583179007750005e-06
clinodactyly B-Disease 0 0.013688531704246998
. O 0 5.937177411396988e-05

Significant O 0 6.739067612215877e-05
intra O 0 0.0014753233408555388
- O 0 0.0012342117261141539
and O 0 2.338735839657602e-06
interfamilial O 0 0.002993927337229252
phenotypic O 0 0.00010922190267592669
variability O 0 0.000280245702015236
is O 0 2.2414333500364592e-07
present O 0 2.9310572813301405e-07
for O 0 1.2716891717445833e-07
either O 0 1.7050821270458982e-06
TWIST O 0 0.0023652303498238325
mutations O 0 0.0002507558383513242
or O 0 4.925072789774276e-05
FGFR O 1 0.9256097078323364
mutations O 0 0.001436500926502049
. O 0 5.489027171279304e-05

The O 0 9.379525181429926e-06
overlap O 0 5.6646938901394606e-05
in O 0 4.529375019046711e-06
clinical O 0 0.00048059262917377055
features O 0 2.945110736618517e-06
and O 0 1.235704729651843e-07
the O 0 1.3014901867336448e-07
presence O 0 6.526776701321069e-07
, O 0 2.981020585934857e-08
in O 0 9.130700640014311e-09
the O 0 6.357573134607719e-09
same O 0 9.503811959632458e-09
genes O 0 3.254889691106655e-08
, O 0 5.24854337768943e-09
of O 0 3.918505964151109e-09
mutations O 0 2.866055126560241e-07
for O 0 3.3742089122767993e-09
more O 0 5.764638988381421e-09
than O 0 4.0314830584975425e-08
one O 0 4.625813403436041e-07
craniosynostotic B-Disease 0 0.1111142635345459
condition I-Disease 0 0.007062310352921486
- O 0 6.763325654901564e-05
such O 0 8.890793168347955e-08
as O 0 4.920922833662189e-07
Saethre B-Disease 0 0.0036880960687994957
- I-Disease 0 0.0007622804841957986
Chotzen I-Disease 0 0.0007616785005666316
, I-Disease 0 1.3133981155988295e-06
Crouzon I-Disease 0 0.0009988110978156328
, I-Disease 0 3.809923327935394e-06
and I-Disease 0 3.095177817158401e-05
Pfeiffer I-Disease 1 0.9980416297912598
syndromes I-Disease 1 0.9990077614784241
- O 0 0.0008918571984395385
support O 0 2.7145048875354405e-07
the O 0 8.485483249387471e-08
hypothesis O 0 1.1242161690461216e-06
that O 0 4.2783163678450364e-08
TWIST O 0 4.145532147958875e-05
and O 0 2.4145973043232516e-07
FGFRs O 0 6.084425695007667e-05
are O 0 3.19380211166731e-09
components O 0 2.3389867820355903e-08
of O 0 2.0925738919430614e-09
the O 0 5.7043725298910886e-09
same O 0 1.9651814398002898e-08
molecular O 0 7.243468758133531e-07
pathway O 0 4.914056717097992e-07
involved O 0 2.805825971563536e-08
in O 0 1.4672868253740035e-08
the O 0 4.924988417087661e-08
modulation O 0 5.978429726383183e-06
of O 0 3.3498577067803126e-06
craniofacial O 1 0.9991052746772766
and O 0 8.080765837803483e-05
limb O 1 0.9883944988250732
development O 0 7.904745871201158e-05
in O 0 8.247633559221867e-06
humans O 0 5.7175810070475563e-05
. O 0 4.016224011138547e-06
. O 0 1.9884404537151568e-05

Mutation O 0 0.0003045476623810828
analysis O 0 6.156683230074123e-05
of O 0 0.0003279233060311526
UBE3A O 1 0.991361677646637
in O 1 0.9908018708229065
Angelman B-Disease 1 0.9995562434196472
syndrome I-Disease 1 0.9998010993003845
patients O 1 0.9964454770088196
. O 0 0.03433351218700409

Angelman B-Disease 1 0.9986566305160522
syndrome I-Disease 1 0.9995419979095459
( O 0 0.009971766732633114
AS B-Disease 0 0.000483989977510646
) O 0 1.908556805574335e-05
is O 0 2.821916268658242e-06
caused O 0 0.00018878754053730518
by O 0 6.916724260008777e-07
chromosome O 0 0.00015637431351933628
15q11 O 0 0.003988222219049931
- O 0 0.000493392173666507
q13 O 0 9.854813106358051e-05
deletions O 0 3.8163016142789274e-06
of O 0 8.413316265887261e-08
maternal O 0 2.6304705897928216e-05
origin O 0 1.5354237348219613e-07
, O 0 1.4203490650288586e-07
by O 0 5.25469658896327e-07
paternal O 0 0.0008390056318603456
uniparental B-Disease 1 0.905200719833374
disomy I-Disease 0 0.24975892901420593
( O 0 0.00012060914741596207
UPD B-Disease 1 0.8781707882881165
) O 0 6.738230808878143e-07
15 O 0 5.285555744194426e-07
, O 0 2.890225800911139e-07
by O 0 9.075886282516876e-07
imprinting O 0 0.054964829236269
defects O 1 0.9305000901222229
, O 0 5.642456812893215e-07
and O 0 7.354366715617289e-08
by O 0 1.3770618068065232e-07
mutations O 0 3.757827244044165e-06
in O 0 2.88848980289913e-07
the O 0 2.785356400636374e-06
UBE3A O 0 0.20237796008586884
gene O 0 0.00010658070823410526
. O 0 2.2595595510210842e-05

UBE3A O 0 0.003684365889057517
encodes O 0 1.5176097804214805e-05
a O 0 9.150479854724836e-06
ubiquitin O 0 0.0006381976418197155
- O 0 0.0006888975040055811
protein O 0 8.400979822908994e-06
ligase O 0 0.00021002402354497463
and O 0 2.037069407379022e-06
shows O 0 4.7361252654809505e-05
brain O 0 0.14256715774536133
- O 0 0.0004635665682144463
specific O 0 4.56772067991551e-06
imprinting O 0 0.0008605816401541233
. O 0 3.809740155702457e-05

Here O 0 1.1429742698965129e-05
we O 0 1.696927256489289e-06
describe O 0 3.402965376153588e-05
UBE3A O 0 0.027774710208177567
coding O 0 0.0012751397443935275
- O 0 0.001956154592335224
region O 0 2.1558216758421622e-05
mutations O 0 1.9503178918967023e-05
detected O 0 4.989956323697697e-06
by O 0 1.6594292162608326e-07
SSCP O 0 0.0010933250887319446
analysis O 0 8.252915222328738e-07
in O 0 2.9694422210013727e-07
13 O 0 5.104889623908093e-06
AS B-Disease 0 8.778417395660654e-06
individuals O 0 5.8750322295964e-07
or O 0 3.059966275031911e-06
families O 0 1.3753777238889597e-05
. O 0 2.1803309209644794e-05

Two O 0 9.82820893113967e-07
identical O 0 7.557914159406209e-06
de O 0 1.5873461961746216e-05
novo O 0 2.084658990497701e-05
5 O 0 6.228337042557541e-06
- O 0 0.0002305161760887131
bp O 0 2.812502316373866e-05
duplications O 0 6.811732419009786e-06
in O 0 1.6830074400786543e-07
exon O 0 2.3150580091169104e-05
16 O 0 1.0155778227272094e-06
were O 0 1.2063684096119687e-07
found O 0 2.0799188860110007e-06
. O 0 7.999068657227326e-06

Among O 0 2.536860847612843e-06
the O 0 1.9926940808545623e-07
other O 0 7.330950069217579e-08
11 O 0 7.162138331295864e-07
unique O 0 4.632417756056384e-07
mutations O 0 4.538385383057175e-06
, O 0 6.325232959625282e-08
8 O 0 1.5573485256936692e-07
were O 0 6.869457447322702e-09
small O 0 5.2778894144012156e-08
deletions O 0 8.073754997894866e-07
or O 0 1.3567419898663502e-07
insertions O 0 1.985395465453621e-05
predicted O 0 6.770229811081663e-05
to O 0 3.7011625408922555e-07
cause O 0 0.0002979229320771992
frameshifts O 0 0.00339246797375381
, O 0 1.8108316623965948e-07
1 O 0 1.7614671321553033e-07
was O 0 2.30232011233511e-08
a O 0 3.009643734230849e-08
mutation O 0 9.006684820178634e-08
to O 0 2.062290116455756e-09
a O 0 1.5295887223487625e-08
stop O 0 9.392554289888722e-08
codon O 0 1.7748085667790292e-07
, O 0 1.4450483476480258e-08
1 O 0 3.857021368958158e-08
was O 0 1.7959957077096078e-08
a O 0 1.040470465341059e-07
missense O 0 1.1960317351622507e-05
mutation O 0 9.041226576300687e-07
, O 0 1.5125934282878006e-08
and O 0 2.0426817570751155e-08
1 O 0 2.256037703318725e-07
was O 0 1.492718126883119e-07
predicted O 0 2.0949128156644292e-06
to O 0 1.2728691878294285e-08
cause O 0 1.4184420251694974e-06
insertion O 0 4.2862231453000277e-07
of O 0 5.778101996867235e-09
an O 0 6.182469292070891e-08
isoleucine O 0 2.863621739379596e-05
in O 0 2.5498072986351872e-08
the O 0 3.455552644027193e-08
hect O 0 1.3403820958046708e-05
domain O 0 4.1754486090894716e-08
of O 0 7.64261809393929e-09
the O 0 1.1541389710600924e-07
UBE3A O 0 0.0007382474141195416
protein O 0 1.5103339023880835e-07
, O 0 1.3991710900995713e-08
which O 0 2.981849656080726e-09
functions O 0 5.040162953662275e-09
in O 0 3.017276384298384e-08
E2 O 0 2.9121019906597212e-05
binding O 0 2.249262109899064e-07
and O 0 1.5350958904036816e-07
ubiquitin O 0 2.6795689336722717e-05
transfer O 0 4.065058419655543e-06
. O 0 1.4216477211448364e-05

Eight O 0 2.886242100430536e-06
of O 0 5.635498041556275e-07
the O 0 3.437331997702131e-06
cases O 0 3.159415427944623e-05
were O 0 9.507148774900998e-07
familial O 0 0.2866283059120178
, O 0 9.96239919004438e-07
and O 0 9.243074572395926e-08
five O 0 1.8054430483971373e-07
were O 0 2.0879190287814708e-07
sporadic O 0 9.828385373111814e-05
. O 0 2.001031862164382e-05

In O 0 6.419288638426224e-06
two O 0 8.500453077431303e-06
familial O 1 0.630926787853241
cases O 0 5.7593184465076774e-05
and O 0 5.870842869626358e-07
one O 0 3.3196502613463963e-07
sporadic O 0 4.657226600102149e-05
case O 0 1.1945863661821932e-05
, O 0 1.6439059891126817e-06
mosaicism O 0 0.02046210877597332
for O 0 2.2834615265310276e-06
UBE3A O 1 0.639587938785553
mutations O 0 2.5376122721354477e-05
was O 0 4.026822466585145e-07
detected O 0 1.9824253740807762e-06
in O 0 1.3272503096573018e-08
the O 0 3.1390392507546494e-08
mother O 0 3.6447409001993947e-07
of O 0 9.037036896586415e-09
three O 0 7.257907697066912e-08
AS B-Disease 0 5.618901468551485e-06
sons O 0 1.8069473298965022e-05
, O 0 7.038228488909226e-08
in O 0 1.9268110662551408e-08
the O 0 6.168134802919667e-08
maternal O 0 1.2463826351449825e-05
grandfather O 0 1.3476060303219128e-06
of O 0 5.486365139972804e-09
two O 0 8.80561312754935e-09
AS B-Disease 0 2.2358014462042775e-07
first O 0 5.450498363757106e-08
cousins O 0 2.0888262497464893e-06
, O 0 2.9152277036814667e-08
and O 0 1.047499154083198e-08
in O 0 2.3277223704099015e-08
the O 0 5.898285593275432e-08
mother O 0 1.6554331523366272e-06
of O 0 5.992552587485989e-08
an O 0 7.885341801738832e-07
AS B-Disease 0 5.946850069449283e-05
daughter O 0 0.002915547462180257
. O 0 3.110108445980586e-05

The O 0 1.0571835673545138e-06
frequencies O 0 5.430429155239835e-07
with O 0 2.0613126139323867e-07
which O 0 7.406832480683079e-08
we O 0 2.867115078686311e-08
detected O 0 7.237446766339417e-07
mutations O 0 1.2169668650585663e-07
were O 0 5.221364673957396e-09
5 O 0 4.207515047482957e-08
( O 0 4.590707902707436e-08
14 O 0 2.1162323449175346e-08
% O 0 6.863668300383097e-09
) O 0 2.4873165749284e-09
of O 0 1.2337795229910853e-09
35 O 0 4.0485197416728624e-08
in O 0 1.5640292616581064e-08
sporadic O 0 1.2800022659575916e-06
cases O 0 2.421691078779986e-07
and O 0 1.7496494919555516e-08
8 O 0 1.8066987195197726e-07
( O 0 8.757898228850536e-08
80 O 0 3.453562769095697e-08
% O 0 8.088520075943961e-09
) O 0 4.616018678404998e-09
of O 0 2.6923152596225464e-09
10 O 0 3.1837629421715974e-07
in O 0 1.159477733381209e-06
familial O 0 0.20192654430866241
cases O 0 0.00014307544915936887
. O 0 8.703876119398046e-06
. O 0 2.4879193006199785e-05

The O 0 0.000471169245429337
hemochromatosis B-Disease 1 0.9876404404640198
845 O 0 0.15279316902160645
G O 0 0.19027280807495117
- O 0 0.012479123659431934
- O 0 0.0006594681181013584
> O 0 6.448364001698792e-05
A O 0 2.487724373168021e-07
and O 0 1.0456809462766614e-07
187 O 0 1.0996212040481623e-05
C O 0 0.0007400964386761189
- O 0 0.0025210068561136723
- O 0 0.002827935153618455
> O 0 0.0027403109706938267
G O 0 0.002621595747768879
mutations O 0 5.0464510422898456e-05
: O 0 2.864307134586852e-05
prevalence O 0 0.003923468291759491
in O 0 1.969552840819233e-06
non O 0 0.00011916553194168955
- O 0 0.0850604772567749
Caucasian O 0 0.005855153780430555
populations O 0 8.990333299152553e-05
. O 0 2.1546788047999144e-05

Hemochromatosis B-Disease 1 0.9903501272201538
, O 0 0.0015987264923751354
the O 0 0.03882452845573425
inherited B-Disease 1 0.9994235038757324
disorder I-Disease 1 0.9995524287223816
of I-Disease 0 5.284609505906701e-05
iron I-Disease 1 0.9925746917724609
metabolism I-Disease 0 0.15540699660778046
, O 0 1.5429381164722145e-05
leads O 0 0.00020794114971067756
, O 0 7.017750704108039e-06
if O 0 1.767295179888606e-05
untreated O 0 0.358887255191803
, O 0 1.0852285186047084e-06
to O 0 1.8821353933162754e-06
progressive O 0 0.07736580818891525
iron B-Disease 1 0.9937908053398132
overload I-Disease 1 0.9960200190544128
and O 0 0.0001584782003192231
premature B-Disease 1 0.7636597156524658
death I-Disease 0 0.005539628677070141
. O 0 0.00013027520617470145

The O 0 0.0009333929629065096
hemochromatosis B-Disease 1 0.9914382696151733
gene O 0 0.0014325216179713607
, O 0 0.00019073259318247437
HFE O 1 0.9844526648521423
, O 0 2.889352253987454e-05
recently O 0 5.3110517910681665e-05
has O 0 6.784469519516279e-07
been O 0 9.660735855732128e-08
identified O 0 2.5118333724094555e-07
, O 0 3.272917936669728e-08
and O 0 1.9966462261322704e-08
characterization O 0 4.7265595526369e-07
of O 0 1.160548901424363e-08
this O 0 9.358166863648876e-08
gene O 0 3.4831844004656887e-06
has O 0 8.673234219713777e-08
shown O 0 3.4633117707016936e-08
that O 0 2.771116003330576e-09
it O 0 2.0902604092043475e-09
contains O 0 1.1783685138766486e-08
two O 0 7.353437858625966e-09
mutations O 0 4.4620534822570335e-07
that O 0 4.5557539962715055e-09
result O 0 2.3382417779771458e-08
in O 0 3.9479890467930545e-09
amino O 0 2.017551992139488e-08
acid O 0 2.5706344786158297e-07
substitutions O 0 1.0201085132166554e-07
- O 0 1.4108384220890002e-06
cDNA O 0 5.996371328365058e-07
nucleotides O 0 1.7994231029661023e-06
845 O 0 7.982297393027693e-05
G O 0 0.00036365020787343383
- O 0 0.0002696112496778369
- O 0 9.227890404872596e-05
> O 0 3.032420681847725e-05
A O 0 4.134524829169095e-07
( O 0 3.204910683507478e-07
C282Y O 0 2.436943304928718e-06
) O 0 2.647574603997782e-08
and O 0 2.131923260151325e-08
187 O 0 2.0221771137585165e-06
C O 0 8.860640809871256e-05
- O 0 0.0003359565162099898
- O 0 0.0005343530210666358
> O 0 0.0005984751041978598
G O 0 0.0003851457149721682
( O 0 6.599917924177134e-06
H63D O 0 0.001768594840541482
) O 0 4.189751507510664e-06
. O 0 6.175791440909961e-06

Although O 0 0.015182308852672577
hemochromatosis B-Disease 1 0.9977291226387024
is O 0 6.0042507357138675e-06
common O 0 8.576571417506784e-06
in O 0 1.2337575299170567e-06
Caucasians O 0 0.0003754570207092911
, O 0 2.3556699488835875e-06
affecting O 0 0.00013438913447316736
> O 0 0.008917147293686867
= O 0 0.00035378834581933916
1 O 0 5.063019216322573e-06
/ O 0 0.00011295096919639036
300 O 0 7.000179635952009e-08
individuals O 0 6.464074164824751e-09
of O 0 4.928481622812342e-09
northern O 0 1.337831605496831e-07
European O 0 2.6145897891183267e-07
origin O 0 4.588527957594124e-08
, O 0 6.714464717560986e-08
it O 0 1.859499931811115e-08
has O 0 4.268519049333008e-08
not O 0 7.589176398425934e-09
been O 0 1.3022023459541288e-08
recognized O 0 5.250548440471903e-08
in O 0 8.198131240533257e-08
other O 0 3.5602019465841295e-07
populations O 0 2.6910003725788556e-05
. O 0 1.4748612557013985e-05

The O 0 1.5704224551882362e-06
present O 0 8.705451364221517e-07
study O 0 7.673147024434002e-07
used O 0 1.6361251198304672e-07
PCR O 0 7.152444595703855e-06
and O 0 1.6125500224006828e-07
restriction O 0 4.9455611588200554e-06
- O 0 4.58144313597586e-05
enzyme O 0 1.5662749319744762e-06
digestion O 0 1.5491865497097024e-06
to O 0 3.5558833655358058e-09
analyze O 0 2.8078121161456693e-08
the O 0 2.0258261734795724e-09
frequency O 0 4.043864798575214e-09
of O 0 2.975582891195927e-09
the O 0 8.895424485899639e-08
845 O 0 0.00018415275553707033
G O 0 0.000673849368467927
- O 0 0.0002258192398585379
- O 0 4.080945655005053e-05
> O 0 3.0082030662015313e-06
A O 0 4.64429916746667e-08
and O 0 2.7723279671931778e-08
187 O 0 1.4534344927596976e-06
C O 0 2.9326105504878797e-05
- O 0 9.293635957874358e-05
- O 0 8.747829997446388e-05
> O 0 0.0001267550396732986
G O 0 4.805839489563368e-05
mutations O 0 1.1556603567441925e-06
in O 0 1.8970078485835984e-07
HLA O 0 0.006450460758060217
- O 0 5.676390628650552e-06
typed O 0 2.3720944852811954e-07
samples O 0 7.876565888409459e-08
from O 0 1.7350116365832946e-07
non O 0 8.872360922396183e-06
- O 0 0.0015244617825374007
Caucasian O 0 0.00021552361431531608
populations O 0 7.438615625687817e-07
, O 0 3.1280361412200364e-08
comprising O 0 2.2082915052124008e-07
Australian O 0 1.5137586615310283e-06
Aboriginal O 0 1.4878305591992103e-06
, O 0 1.4552608718076954e-07
Chinese O 0 4.241494195866835e-07
, O 0 2.678549151369225e-07
and O 0 7.059119866426045e-07
Pacific O 0 0.00010945190297206864
Islanders O 0 0.00014001713134348392
. O 0 1.5470071957679465e-05

Results O 0 1.4970582924433984e-05
showed O 0 4.7625539991713595e-06
that O 0 1.686304216264034e-07
the O 0 6.926923106220784e-07
845 O 0 0.003576976479962468
G O 0 0.1072603240609169
- O 0 0.10499674826860428
- O 0 0.010102828964591026
> O 0 0.0006211398867890239
A O 0 2.373262759647332e-06
mutation O 0 3.8671687434543855e-06
was O 0 6.292814447306228e-08
present O 0 1.9593500155679067e-08
in O 0 8.355725000797065e-09
these O 0 5.951191539566025e-09
populations O 0 5.4968314344705504e-08
( O 0 1.4029498451861855e-08
allele O 0 1.950182060284078e-08
frequency O 0 7.331744100724791e-09
0 O 0 2.7976710725852172e-08
. O 0 3.3678437816320184e-09
32 O 0 2.9802876611029205e-08
% O 0 2.3317349828744227e-08
) O 0 2.222395245610187e-08
, O 0 1.023419216039656e-08
and O 0 9.81743397687751e-09
, O 0 2.936338638903635e-08
furthermore O 0 1.684112049815667e-07
, O 0 1.0685850426739307e-08
it O 0 3.015830918329243e-09
was O 0 1.2854830977460097e-08
always O 0 1.6971743121985128e-08
seen O 0 3.010108784451404e-08
in O 0 1.2780778213539179e-08
conjunction O 0 7.099682761690929e-07
with O 0 2.8717672648781445e-06
HLA O 1 0.9664276838302612
haplotypes O 0 0.0013920365599915385
common O 0 4.50827519671293e-06
in O 0 7.670747095289698e-07
Caucasians O 0 0.00014785313396714628
, O 0 2.2682439748678007e-07
suggesting O 0 2.3174818579718703e-06
that O 0 2.3534686022230744e-07
845 O 0 0.002219937741756439
G O 0 0.08676232397556305
- O 0 0.09771300107240677
- O 0 0.029397854581475258
> O 0 0.00446906266734004
A O 0 3.861448931274936e-06
may O 0 4.055994793361606e-07
have O 0 3.4008227345339037e-09
been O 0 2.3199291376840847e-09
introduced O 0 1.53446588768702e-08
into O 0 8.79465300585025e-09
these O 0 1.80344112976627e-08
populations O 0 8.679089660290629e-07
by O 0 9.147086643679359e-07
Caucasian O 0 0.0021254727616906166
admixture O 0 0.014666851609945297
. O 0 8.505019650328904e-05

187 O 0 0.0006912340177223086
C O 0 0.0072823697701096535
- O 0 0.05888171121478081
- O 0 0.030055541545152664
> O 0 0.00795355997979641
G O 0 0.00025430499226786196
was O 0 1.4971291761867178e-07
present O 0 5.3947101008589016e-08
at O 0 3.8536903446129145e-08
an O 0 1.512844427509208e-08
allele O 0 2.0075148654541408e-07
frequency O 0 6.433707255837362e-08
of O 0 1.0521088711357152e-07
2 O 0 8.056701517489273e-06
. O 0 6.8725917117262725e-06

68 O 0 7.928125705802813e-05
% O 0 1.5837509863558807e-06
in O 0 9.205616890994861e-08
the O 0 6.287704223950641e-08
two O 0 8.960028452520419e-08
populations O 0 3.0495193641399965e-06
analyzed O 0 2.5042895686056e-06
( O 0 1.507488946117519e-06
Australian O 0 2.3625700578122633e-06
Aboriginal O 0 2.6728434932010714e-06
and O 0 2.747021312643483e-07
Chinese O 0 4.081681254319847e-06
) O 0 7.93820436228998e-06
. O 0 1.2621153473446611e-05

In O 0 1.5330491578424699e-06
the O 0 2.832259440310736e-07
Australian O 0 1.1319890518279863e-06
Aboriginal O 0 8.735506753509981e-07
samples O 0 2.55315370623066e-07
, O 0 1.979033470433933e-07
187 O 0 8.273584171547554e-06
C O 0 0.00033913488732650876
- O 0 0.0010181424440816045
- O 0 0.0009923373581841588
> O 0 0.0004705718019977212
G O 0 9.855339885689318e-05
was O 0 6.200857427529627e-08
found O 0 1.26416876966573e-08
to O 0 2.7273940883532077e-09
be O 0 5.557011295564962e-09
associated O 0 4.240992268478294e-07
with O 0 3.2709890547266696e-06
HLA O 1 0.9867542386054993
haplotypes O 0 0.004877335391938686
common O 0 8.88638442120282e-06
in O 0 3.964262759836856e-06
Caucasians O 0 0.008574440144002438
, O 0 2.2165377231431194e-06
suggesting O 0 4.284271653887117e-06
that O 0 2.5302973938323703e-08
it O 0 1.769527990802544e-08
was O 0 9.010929602482065e-08
introduced O 0 6.762222710676724e-07
by O 0 4.4809357291342167e-07
recent O 0 3.768867100006901e-05
admixture O 0 0.006068398244678974
. O 0 6.986184598645195e-05

In O 0 1.0737018101281137e-06
the O 0 2.2899355656136322e-07
Chinese O 0 4.470853411930875e-07
samples O 0 3.1320871585194254e-07
analyzed O 0 4.712840677711938e-07
, O 0 1.5235099226629245e-07
187 O 0 7.428106073348317e-06
C O 0 0.000372731446987018
- O 0 0.0014128972543403506
- O 0 0.0007604096899740398
> O 0 0.0006359390681609511
G O 0 6.757934897905216e-05
was O 0 1.165671719149941e-07
present O 0 7.88623211178674e-08
in O 0 3.8830037851766974e-08
association O 0 4.685896897171915e-07
with O 0 1.2346676570018644e-08
a O 0 3.9220822145580314e-08
wide O 0 3.4509949387029337e-07
variety O 0 2.470514743890817e-07
of O 0 7.539590001215402e-07
HLA O 1 0.9899084568023682
haplotypes O 0 0.0012087897630408406
, O 0 3.5540415410650894e-07
showing O 0 7.717671905993484e-07
this O 0 2.7745498343278996e-08
mutation O 0 1.063883019014611e-06
to O 0 1.421427153758259e-08
be O 0 2.003325860755467e-08
widespread O 0 2.9411446575977607e-06
and O 0 6.758381232430111e-08
likely O 0 2.2921028630662477e-07
to O 0 1.1877805405902109e-08
predate O 0 9.329079148301389e-06
the O 0 1.341019384426545e-08
more O 0 3.414395166601025e-08
genetically O 0 3.0974038054409903e-06
restricted O 0 2.1974690298520727e-06
845 O 0 0.005306297447532415
G O 0 0.1419813334941864
- O 0 0.11988145858049393
- O 0 0.00629440089687705
> O 0 0.0006500168819911778
A O 0 1.3553983080782928e-05
mutation O 0 5.7847377320285887e-05
. O 0 1.3680650226888247e-05

Genotype O 0 0.15944696962833405
- O 0 0.45614439249038696
phenotype O 0 0.06095873564481735
correlations O 0 0.006781887728720903
in O 0 0.006464346777647734
attenuated B-Disease 1 0.9921040534973145
adenomatous I-Disease 1 0.9984641075134277
polyposis I-Disease 1 0.9980443716049194
coli I-Disease 1 0.9955451488494873
. O 0 0.009374337270855904

Germ O 1 0.7237171530723572
- O 0 0.0012028968194499612
line O 0 1.0142470273422077e-05
mutations O 0 3.857374849758344e-06
of O 0 3.841815896521439e-07
the O 0 2.7130963644594885e-05
tumor B-Disease 1 0.9927194118499756
suppressor O 0 0.20611920952796936
APC O 0 0.0081599410623312
are O 0 7.861179938117857e-07
implicated O 0 0.0014095514779910445
in O 0 0.00044219085248187184
attenuated B-Disease 1 0.9953977465629578
adenomatous I-Disease 1 0.9992671608924866
polyposis I-Disease 1 0.99936443567276
coli I-Disease 1 0.9990060925483704
( O 0 0.18303972482681274
AAPC B-Disease 1 0.9972781538963318
) O 0 1.0557877430983353e-05
, O 0 1.3685380508832168e-06
a O 0 6.4624150581948925e-06
variant O 0 0.006717297714203596
of O 0 0.0002848550502676517
familial B-Disease 1 0.9991337656974792
adenomatous I-Disease 1 0.999339759349823
polyposis I-Disease 1 0.9994226694107056
( O 1 0.7302435040473938
FAP B-Disease 1 0.9908219575881958
) O 0 0.0004567781288642436
. O 0 0.0001496065524406731

AAPC B-Disease 1 0.979528546333313
is O 0 4.318738319852855e-06
recognized O 0 7.737252758488466e-07
by O 0 8.504035520218167e-08
the O 0 1.2612814259682636e-07
occurrence O 0 3.6597004964278312e-06
of O 0 4.730789555651427e-07
< O 0 0.010474570095539093
100 O 0 1.6865753423189744e-05
colonic B-Disease 1 0.8824297785758972
adenomas I-Disease 0 0.10055965185165405
and O 0 3.347499557548872e-07
a O 0 2.999042408191599e-06
later O 0 5.6422501074848697e-05
onset O 1 0.998548686504364
of O 0 0.4472272992134094
colorectal B-Disease 1 0.9999315738677979
cancer I-Disease 1 0.999823272228241
( O 0 0.0008832182502374053
age O 0 0.0005167604540474713
> O 0 0.005971395876258612
40 O 0 3.400712103029946e-06
years O 0 4.267951680958504e-06
) O 0 3.348436393935117e-06
. O 0 7.257336619659327e-06

The O 0 1.2654251122512505e-06
aim O 0 1.5982274135240004e-06
of O 0 9.244467946700752e-08
this O 0 9.305109927026933e-08
study O 0 4.387194394439575e-07
was O 0 2.512954608846485e-07
to O 0 3.121093641311745e-07
assess O 0 8.818199421511963e-05
genotype O 0 0.001149376155808568
- O 0 0.010469717904925346
phenotype O 0 0.003927911631762981
correlations O 0 0.00034629899892024696
in O 0 7.394242857117206e-05
AAPC B-Disease 1 0.9884910583496094
families O 0 0.00011878705117851496
. O 0 6.14064047113061e-05

By O 0 1.720811837913061e-06
protein O 0 6.625565674767131e-06
- O 0 5.060725015937351e-05
truncation O 0 1.9774857719312422e-05
test O 0 1.203353804157814e-06
( O 0 4.772379611495126e-07
PTT O 0 1.5221811509036343e-06
) O 0 5.382899814776465e-08
assay O 0 1.5491615101836942e-07
, O 0 6.784584449803788e-09
the O 0 3.942074666696271e-09
entire O 0 8.892455127806898e-08
coding O 0 1.1079231398980482e-06
region O 0 2.9471564744198986e-08
of O 0 3.6237006728612187e-09
the O 0 9.172421755465621e-08
APC B-Disease 0 0.00016435979341622442
gene O 0 1.970268385775853e-06
was O 0 2.090903876705852e-07
screened O 0 1.5500437484661234e-06
in O 0 7.935980761430983e-08
affected O 0 1.3608398603537353e-06
individuals O 0 1.5269661446382088e-07
from O 0 1.7442287116864463e-06
11 O 0 0.00033049442572519183
AAPC B-Disease 1 0.9978300929069519
kindreds O 0 0.003414392936974764
, O 0 1.5286460097740928e-07
and O 0 2.419931455222013e-08
their O 0 4.75174282144053e-08
phenotypic O 0 1.0798222319863271e-05
differences O 0 1.1595802789088339e-05
were O 0 1.0531645102673792e-06
examined O 0 0.00028604461112990975
. O 0 5.308317849994637e-05

Five O 0 5.19611821800936e-05
novel O 0 0.0006627425318583846
germ O 1 0.926635205745697
- O 0 0.023715248331427574
line O 0 0.00029287789948284626
APC B-Disease 0 0.011757579632103443
mutations O 0 2.7116406272398308e-05
were O 0 1.2305092411679652e-07
identified O 0 6.271116035350133e-07
in O 0 3.9585478361914284e-07
seven O 0 1.1868147339555435e-05
kindreds O 0 0.014172251336276531
. O 0 6.524719356093556e-05

Mutations O 0 7.324122270802036e-05
were O 0 1.8977118543261895e-07
located O 0 1.5322510193982453e-07
in O 0 1.5066792258267014e-08
three O 0 3.701675632683532e-09
different O 0 2.148724975725713e-09
regions O 0 1.3992272229756963e-08
of O 0 5.526442414804933e-09
the O 0 1.671044458362303e-07
APC B-Disease 0 0.00016886273806449026
gene O 0 1.7479187590652145e-06
( O 0 1.6915808487283357e-07
1 O 0 6.03977099444819e-08
) O 0 1.0864692256973285e-08
at O 0 6.614816250305466e-09
the O 0 2.472879678805384e-09
5 O 0 1.6766946941970673e-08
end O 0 2.7926118306709213e-08
spanning O 0 1.6023464866066206e-07
exons O 0 1.535417908371528e-07
4 O 0 4.9907757926348495e-08
and O 0 1.0287484641935407e-08
5 O 0 4.826949506764322e-08
, O 0 9.416300628117824e-09
( O 0 1.571618923890128e-08
2 O 0 2.2137859545523497e-08
) O 0 5.790182555642787e-09
within O 0 5.0878585788893815e-09
exon O 0 8.464466532132064e-07
9 O 0 1.1721004256060041e-07
, O 0 7.902882792620858e-09
and O 0 6.8260685992527215e-09
( O 0 3.36898224873039e-08
3 O 0 3.265628478743565e-08
) O 0 8.576893861800272e-09
at O 0 6.384793582725479e-09
the O 0 5.7995217517259334e-09
3 O 0 2.2444922365139064e-07
distal O 0 2.875391328416299e-05
end O 0 1.98379737526011e-07
of O 0 3.397673253857647e-08
the O 0 6.324098649201915e-07
gene O 0 3.255297997384332e-05
. O 0 1.176333080366021e-05

Variability O 0 0.00018851665663532913
in O 0 6.801650442866958e-07
the O 0 5.661516411237244e-07
number O 0 2.398027390881907e-06
of O 0 0.0008685422944836318
colorectal B-Disease 1 0.9998639822006226
adenomas I-Disease 1 0.9993625283241272
was O 0 2.9753187845926732e-05
most O 0 1.414114535691624e-06
apparent O 0 0.00010876221494982019
in O 0 3.4521306702117727e-07
individuals O 0 1.9865272804509004e-07
with O 0 4.2779902287293226e-07
mutations O 0 8.965154847828671e-06
in O 0 2.4252548769254645e-07
region O 0 1.9280757896922296e-06
1 O 0 1.6931576283241156e-06
, O 0 5.487387397806742e-07
and O 0 2.9268774142110487e-06
upper O 0 0.4499135911464691
- O 1 0.9976054430007935
gastrointestinal O 1 0.9990202188491821
manifestations O 0 0.005531656555831432
were O 0 7.185838057921501e-07
more O 0 6.472863788076211e-06
severe O 1 0.975459098815918
in O 0 2.0331335690570995e-06
them O 0 1.7223667327925796e-06
. O 0 2.6632038498064503e-05

In O 0 5.1035949582001194e-06
individuals O 0 2.1350765564420726e-06
with O 0 1.1081577895311057e-06
mutations O 0 8.720468940737192e-06
in O 0 1.539232812319824e-07
either O 0 3.2695683671590814e-07
region O 0 1.302954728998884e-06
2 O 0 8.117824563669274e-07
or O 0 1.137685572416558e-07
region O 0 1.524972361721666e-07
3 O 0 6.906416416541106e-08
, O 0 5.73759928457207e-09
the O 0 2.3834854090409863e-09
average O 0 4.058276559248952e-08
number O 0 6.226798632269492e-09
of O 0 8.89476226006991e-08
adenomas B-Disease 0 0.1484915167093277
tended O 0 3.07333152704814e-06
to O 0 1.6849048378730913e-08
be O 0 6.294012866447929e-09
lower O 0 7.493727025575936e-07
than O 0 1.0445941001080428e-08
those O 0 1.2725998033147334e-08
in O 0 1.9137939233360157e-08
individuals O 0 2.7828283677422405e-08
with O 0 1.0723197618744962e-07
mutations O 0 4.440795237314887e-06
in O 0 1.3811416010867106e-07
region O 0 2.0432801193237538e-06
1 O 0 1.6652616068313364e-06
, O 0 3.7389881413218973e-07
although O 0 6.868345394650532e-07
age O 0 4.403485218062997e-05
at O 0 6.096343349781819e-05
diagnosis O 1 0.5865197777748108
was O 0 4.629283012036467e-06
similar O 0 1.8697748600970954e-05
. O 0 2.421243152639363e-05

In O 0 3.0279328711912967e-05
all O 0 1.7722857592161745e-05
AAPC B-Disease 1 0.9869211912155151
kindreds O 0 0.0020549457985907793
, O 0 1.2475735502448515e-06
a O 0 1.6063995644799434e-06
predominance O 0 0.000310542673105374
of O 0 7.923433258838486e-06
right O 0 0.018307313323020935
- O 1 0.9965257048606873
sided O 1 0.9979774355888367
colorectal B-Disease 1 0.999752938747406
adenomas I-Disease 1 0.9987539052963257
and O 0 0.05412288382649422
rectal B-Disease 1 0.9988874793052673
polyp I-Disease 1 0.9980079531669617
sparing O 0 0.03957004100084305
was O 0 5.972293365630321e-05
observed O 0 7.78952453401871e-05
. O 0 4.586268187267706e-05

No O 0 0.008184758014976978
desmoid B-Disease 1 0.9901948571205139
tumors I-Disease 1 0.9971290230751038
were O 0 1.061203988683701e-06
found O 0 1.327080326518626e-06
in O 0 1.0530932286201278e-06
these O 0 2.237088438050705e-06
kindreds O 0 0.005059544928371906
. O 0 7.745991024421528e-05

Our O 0 2.4240325728897005e-06
data O 0 2.894290901167551e-06
suggest O 0 3.5286748243379407e-06
that O 0 1.9568764741961786e-07
, O 0 9.252111681234965e-07
in O 0 6.683283118036343e-06
AAPC B-Disease 1 0.9963493347167969
families O 0 1.5519104863415123e-06
, O 0 3.707323159574116e-08
the O 0 1.2820061456864096e-08
location O 0 3.127278702663716e-08
of O 0 1.7144376585065402e-08
the O 0 1.1785234619310359e-06
APC B-Disease 0 0.013565185479819775
mutation O 0 0.0004069259448442608
may O 0 1.6883404896361753e-05
partially O 0 6.315501377684996e-05
predict O 0 1.8424694644636475e-05
specific O 0 1.098980533242866e-06
phenotypic O 0 6.922143802512437e-05
expression O 0 3.130079494439997e-05
. O 0 3.705971539602615e-05

This O 0 2.9005414035054855e-06
should O 0 5.614876386061951e-07
help O 0 3.958491276989662e-07
in O 0 3.6448930984533945e-08
the O 0 4.261165287289259e-08
design O 0 2.2488511604024097e-06
of O 0 5.146715693626902e-07
tailored O 0 0.014198938384652138
clinical O 0 0.22078020870685577
- O 0 0.08777973055839539
management O 0 9.803217108128592e-05
protocols O 0 2.9088128030707594e-06
in O 0 5.518798218417942e-08
this O 0 7.181755989904559e-08
subset O 0 1.9694083675858565e-05
of O 0 3.4010838135145605e-05
FAP B-Disease 1 0.9979764819145203
patients O 1 0.8780069351196289
. O 0 2.335743556614034e-05
. O 0 3.397809632588178e-05

Wilms B-Disease 1 0.9889016151428223
' I-Disease 0 0.01749359257519245
tumor I-Disease 0 0.4552222490310669
1 O 0 4.5490064621844795e-06
and O 0 1.026537347570411e-06
Dax O 0 0.0008900826214812696
- O 0 2.7925754693569615e-05
1 O 0 3.906754670879309e-07
modulate O 0 2.5923632165358867e-06
the O 0 3.1170779379863234e-07
orphan O 0 0.0007681322167627513
nuclear O 0 6.710184243274853e-05
receptor O 0 0.000199787798919715
SF O 0 0.28086140751838684
- O 0 2.6932930268230848e-05
1 O 0 2.4085397853923496e-07
in O 0 4.168104084101287e-08
sex O 0 1.3378408993958146e-06
- O 0 3.896829002769664e-05
specific O 0 3.167058650888066e-07
gene O 0 5.427837550087133e-06
expression O 0 4.256979991623666e-06
. O 0 1.1574965355976019e-05

Products O 0 3.784462023759261e-05
of O 0 6.790782663301798e-06
steroidogenic O 0 0.1245180144906044
factor O 0 3.385040690773167e-05
1 O 0 7.648345672350843e-06
( O 0 1.906815668917261e-05
SF O 0 0.1941688060760498
- O 0 9.482957830186933e-05
1 O 0 1.6153202295754454e-06
) O 0 1.5970160802680766e-06
and O 0 6.5194749367947225e-06
Wilms B-Disease 1 0.9965086579322815
tumor I-Disease 1 0.64426189661026
1 O 0 7.702276889176574e-06
( O 0 9.164680704998318e-06
WT1 O 0 0.011647360399365425
) O 0 1.0902935088097365e-07
genes O 0 2.5422266958230466e-08
are O 0 1.7204903057788101e-09
essential O 0 1.5451121271325974e-08
for O 0 3.2380469860981975e-08
mammalian O 0 1.0068120900541544e-05
gonadogenesis O 0 0.0004744585894513875
prior O 0 9.563456160321948e-07
to O 0 2.3678769878188177e-07
sexual O 0 1.8781329345074482e-05
differentiation O 0 0.0007068439153954387
. O 0 4.389900641399436e-05

In O 0 6.372742518578889e-06
males O 0 1.9417033399804495e-05
, O 0 1.1892235306731891e-05
SF O 1 0.8419885635375977
- O 0 0.0002973701630253345
1 O 0 1.907165710690606e-06
participates O 0 4.598095983965322e-06
in O 0 5.6391652236698064e-08
sexual O 0 7.813211482243787e-07
development O 0 2.2083820283569366e-07
by O 0 3.780075630288593e-08
regulating O 0 1.0071319138660328e-06
expression O 0 6.536506447218926e-08
of O 0 3.292107919605769e-08
the O 0 7.652101317034976e-07
polypeptide O 0 0.001360748428851366
hormone O 0 0.009686166420578957
Mullerian O 0 0.4169456958770752
inhibiting O 0 0.006455517373979092
substance O 0 0.006314963102340698
( O 0 0.000356106786057353
MIS O 0 0.19901104271411896
) O 0 1.8378632375970483e-05
. O 0 1.3203418347984552e-05

Here O 0 1.4164321328280494e-05
, O 0 1.088750991584675e-06
we O 0 2.2737386018434336e-07
show O 0 9.164593848254299e-07
that O 0 8.283146257781482e-07
WT1 O 0 0.1346886307001114
- O 0 0.0020245902705937624
KTS O 0 0.07502680271863937
isoforms O 0 3.9208362068166025e-06
associate O 0 1.687711687736737e-06
and O 0 3.181067711466312e-07
synergize O 0 0.002103380858898163
with O 0 1.5344943676609546e-05
SF O 1 0.9615362882614136
- O 0 0.00012299716763664037
1 O 0 5.270877636576188e-07
to O 0 1.3910251084325864e-07
promote O 0 4.609950792655582e-06
MIS O 0 0.006095950026065111
expression O 0 7.059362360450905e-06
. O 0 1.111934852815466e-05

In O 0 2.0122610294492915e-05
contrast O 0 0.00022615860507357866
, O 0 5.6759734434308484e-05
WT1 O 0 0.49484771490097046
missense O 0 0.0024231222923845053
mutations O 0 0.00014460692182183266
, O 0 1.4606754348278628e-06
associated O 0 4.41560860053869e-06
with O 0 3.4658939966902835e-06
male B-Disease 0 0.0005848935106769204
pseudohermaphroditism I-Disease 1 0.9862090349197388
in O 0 0.001192925265058875
Denys B-Disease 1 0.9950876832008362
- I-Disease 1 0.9982597231864929
Drash I-Disease 1 0.9987642765045166
syndrome I-Disease 1 0.9996863603591919
, O 0 2.2911310225026682e-05
fail O 0 0.0001754124095896259
to O 0 1.2517756431407179e-06
synergize O 0 0.04729343578219414
with O 0 8.977063407655805e-05
SF O 1 0.9941881895065308
- O 0 0.006032329984009266
1 O 0 2.35032584896544e-05
. O 0 1.3906970707466826e-05

Additionally O 0 3.38808968081139e-05
, O 0 2.986734671139857e-06
the O 0 3.834740255115321e-06
X O 0 0.010074486024677753
- O 0 0.0019329728092998266
linked O 0 1.834159775171429e-05
, O 0 2.179876474883713e-07
candidate O 0 6.676496582258551e-07
dosage O 0 9.238650090992451e-05
- O 0 6.629206473007798e-05
sensitive O 0 1.462184741285455e-06
sex O 0 2.28977251026663e-06
- O 0 0.00010031870624516159
reversal O 0 3.27667330566328e-05
gene O 0 2.312324568265467e-06
, O 0 4.309594601181743e-07
Dax O 0 0.0002582315937615931
- O 0 2.0712965124403127e-05
1 O 0 3.394739565010241e-07
, O 0 1.7143992181445356e-07
antagonizes O 0 5.046373917139135e-05
synergy O 0 1.3068401131022256e-05
between O 0 2.1065727651148336e-06
SF O 1 0.5869081020355225
- O 0 0.0001517322234576568
1 O 0 1.708788659016136e-06
and O 0 6.541052925967961e-07
WT1 O 0 0.009899802505970001
, O 0 3.720264274420515e-08
most O 0 4.934538999634697e-09
likely O 0 1.077724309794803e-08
through O 0 1.7310830546790612e-09
a O 0 6.413085174017397e-09
direct O 0 2.281785960178695e-08
interaction O 0 2.5579228690730815e-07
with O 0 5.426098141469993e-06
SF O 1 0.979802668094635
- O 0 0.0018931969534605742
1 O 0 1.7113168723881245e-05
. O 0 1.449733736080816e-05

We O 0 5.770153165940428e-06
propose O 0 3.5173776268493384e-05
that O 0 1.4618614159189747e-06
WT1 O 0 0.007939264178276062
and O 0 2.8195709091960452e-06
Dax O 0 0.00852903537452221
- O 0 0.0002658797020558268
1 O 0 1.7172477555504884e-06
functionally O 0 5.364755452319514e-06
oppose O 0 2.732916186687362e-07
each O 0 6.345628023041172e-09
other O 0 1.4685802796066127e-08
in O 0 9.201527007007826e-08
testis O 0 0.00026470812736079097
development O 0 8.128871513690683e-07
by O 0 9.680339871920296e-07
modulating O 0 0.002860037609934807
SF O 1 0.8845421075820923
- O 0 0.0006473714020103216
1 O 0 1.1214234291401226e-05
- O 0 0.000474959088023752
mediated O 0 0.0001824123610276729
transactivation O 0 0.0019628400914371014
. O 0 2.9962407097627874e-06
. O 0 1.3133018910593819e-05

A O 0 0.0001830866967793554
mouse O 0 0.0016320919385179877
model O 0 0.0009378554532304406
for O 0 0.008625861257314682
Prader B-Disease 1 0.9986372590065002
- I-Disease 1 0.9989570379257202
Willi I-Disease 1 0.9993929862976074
syndrome I-Disease 1 0.9994514584541321
imprinting O 1 0.9638780951499939
- O 1 0.9133256077766418
centre O 0 0.004467042163014412
mutations O 0 0.0017120951088145375
. O 0 7.750521035632119e-05

Imprinting O 0 0.00022486572561319917
in O 0 2.2098893168731593e-06
the O 0 5.060026524006389e-06
15q11 O 0 0.007230360992252827
- O 0 0.002379117300733924
q13 O 0 0.0001853607245720923
region O 0 9.099242674892594e-07
involves O 0 4.1478341472611646e-07
an O 0 8.660736483534492e-08
imprinting O 0 5.9904661611653864e-05
centre O 0 9.248245078197215e-06
( O 0 2.6867230644711526e-06
IC O 0 0.00043553466093726456
) O 0 1.1627605545072583e-07
, O 0 1.868687427020177e-08
mapping O 0 1.1024492607702996e-07
in O 0 5.9818043851578295e-09
part O 0 1.0420826868084987e-08
to O 0 5.710000472447518e-09
the O 0 1.4535403103366207e-08
promoter O 0 3.2405421279690927e-06
and O 0 3.467998510586767e-08
first O 0 9.502056741439446e-08
exon O 0 3.330148319946602e-05
of O 0 1.4366712548508076e-06
SNRPN O 0 0.265769362449646
. O 0 4.2309788113925606e-05

Deletion O 0 0.00014268551603890955
of O 0 1.0095128573084367e-06
this O 0 2.3339478048001183e-06
IC O 0 0.009066511876881123
abolishes O 0 0.0004882287757936865
local O 0 6.370910341502167e-07
paternally O 0 7.0397843956016e-05
derived O 0 5.742473945247184e-07
gene O 0 1.179335299639206e-06
expression O 0 4.3666616988957685e-07
and O 0 6.666431886515056e-07
results O 0 7.946025289129466e-05
in O 0 0.005975524429231882
Prader B-Disease 1 0.9993280172348022
- I-Disease 1 0.9992642998695374
Willi I-Disease 1 0.999503493309021
syndrome I-Disease 1 0.9997709393501282
( O 1 0.7750577926635742
PWS B-Disease 1 0.998298704624176
) O 0 0.00043491728138178587
. O 0 0.00011263464693911374

We O 0 1.527879362583917e-06
have O 0 8.892624947520744e-08
created O 0 3.178477925303014e-07
two O 0 1.3294322798174107e-07
deletion O 0 0.000414205773267895
mutations O 0 5.99514642090071e-05
in O 0 2.8906331408506958e-06
mice O 0 0.0032086193095892668
to O 0 4.454916052054614e-06
understand O 0 0.0005560586578212678
PWS B-Disease 1 0.9982703924179077
and O 0 1.2074042388121597e-07
the O 0 4.212171944573129e-08
mechanism O 0 4.819939363187586e-07
of O 0 1.221040406562679e-07
this O 0 1.924275238707196e-06
IC O 0 0.023481320589780807
. O 0 2.964454142784234e-05

Mice O 0 0.033160191029310226
harbouring O 0 0.009008582681417465
an O 0 1.3419807146419771e-05
intragenic O 0 0.0651136040687561
deletion O 0 0.001840905286371708
in O 0 8.744210390432272e-06
Snrpn O 0 0.025476675480604172
are O 0 4.681787402205373e-07
phenotypically O 0 0.0008246946381404996
normal O 0 6.4026157815533224e-06
, O 0 6.93789786510024e-07
suggesting O 0 4.424599865160417e-06
that O 0 4.32186766374798e-08
mutations O 0 2.0591132852132432e-06
of O 0 1.4676203363706009e-07
SNRPN O 0 0.041960109025239944
are O 0 4.2906318498125984e-08
not O 0 4.9516348354927686e-08
sufficient O 0 1.343881535831315e-06
to O 0 1.93831533579214e-06
induce O 0 0.006246304139494896
PWS B-Disease 1 0.9949146509170532
. O 0 0.00013493126607500017

Mice O 0 0.0010618059895932674
with O 0 1.7360556512358016e-06
a O 0 1.28720512293512e-06
larger O 0 5.535366653930396e-06
deletion O 0 0.00014242697216104716
involving O 0 6.926203695911681e-06
both O 0 7.808741884218762e-07
Snrpn O 0 0.0015709006693214178
and O 0 4.467145799935679e-07
the O 0 3.6980543427489465e-06
putative O 0 0.08827541023492813
PWS O 1 0.998924195766449
- O 0 0.3821824789047241
IC O 0 0.04181230813264847
lack O 0 3.0986418551037787e-06
expression O 0 8.836120457544894e-08
of O 0 1.6911510414274744e-08
the O 0 1.2768404644702969e-07
imprinted O 0 5.850522211403586e-05
genes O 0 1.5440022025359212e-06
Zfp127 O 0 0.0005489964969456196
( O 0 1.3295809822011506e-06
mouse O 0 1.4767317225050647e-05
homologue O 0 9.313637747254688e-06
of O 0 1.4447127227867895e-07
ZNF127 O 0 0.012159832753241062
) O 0 1.217955514221103e-06
, O 0 1.3572769148595398e-06
Ndn O 0 0.009642981924116611
and O 0 7.668567718610575e-07
Ipw O 0 0.0010358878644183278
, O 0 4.0710384041631187e-07
and O 0 1.9212811253055406e-07
manifest O 0 8.218332368414849e-06
several O 0 7.29920088815561e-07
phenotypes O 0 0.004454232752323151
common O 0 0.0005444104317575693
to O 0 0.0008791093132458627
PWS B-Disease 1 0.9985800981521606
infants O 1 0.9754834175109863
. O 0 0.00028330530039966106

These O 0 1.0541934898355976e-06
data O 0 8.518960044057167e-07
demonstrate O 0 7.724210604465043e-07
that O 0 1.5517423790356588e-08
both O 0 5.568650429665922e-09
the O 0 5.316390883081112e-09
position O 0 8.779033500161404e-09
of O 0 8.149750208019668e-09
the O 0 1.2998552278986608e-07
IC O 0 0.000827618467155844
and O 0 2.6800917041214234e-08
its O 0 1.5706449474350848e-08
role O 0 3.6635583455790766e-08
in O 0 6.779409922330615e-09
the O 0 3.969856887664491e-09
coordinate O 0 9.110542009693745e-08
expression O 0 1.3127610110075238e-08
of O 0 3.4765403889025492e-09
genes O 0 4.0969926118350486e-08
is O 0 1.128226667646004e-08
conserved O 0 9.890607088891556e-08
between O 0 2.906559188886604e-07
mouse O 0 5.660460374201648e-05
and O 0 1.4211268251074216e-07
human O 0 2.879638714148314e-07
, O 0 5.333141217533921e-08
and O 0 2.068471971483632e-08
indicate O 0 2.2956315604005795e-07
that O 0 7.274479685293045e-09
the O 0 4.4921545594434065e-08
mouse O 0 6.348454917315394e-06
is O 0 1.3054526348810214e-08
a O 0 4.4120543662984346e-08
suitable O 0 4.855032784689683e-07
model O 0 9.056578846866614e-07
system O 0 2.288496716573718e-07
in O 0 5.91344484490719e-09
which O 0 2.4449042790308795e-09
to O 0 2.541905352870799e-09
investigate O 0 7.37439620479563e-08
the O 0 7.282170422229228e-09
molecular O 0 2.0993698512938863e-07
mechanisms O 0 1.1525770560183446e-07
of O 0 1.7433769983199454e-08
imprinting O 0 1.855687878560275e-05
in O 0 3.201855136580889e-08
this O 0 1.3853598268553924e-08
region O 0 7.752439756814056e-08
of O 0 1.586566611422313e-08
the O 0 3.254896512316918e-07
genome O 0 2.487757956259884e-05
. O 0 1.2204320682940306e-06
. O 0 6.696100172121078e-06

Mutations O 0 2.585741640359629e-05
of O 0 4.4636624352278886e-07
the O 0 1.0260871476930333e-06
ATM O 0 0.00017777241009753197
gene O 0 4.019633342977613e-05
detected O 0 9.557654266245663e-05
in O 0 2.539454544603359e-05
Japanese O 1 0.7571849226951599
ataxia B-Disease 1 0.999677300453186
- I-Disease 1 0.9995629191398621
telangiectasia I-Disease 1 0.9996939897537231
patients O 1 0.9849742650985718
: O 0 2.00677641259972e-05
possible O 0 2.490138740540715e-06
preponderance O 0 0.00016783250612206757
of O 0 3.851235774732231e-08
the O 0 1.1857233772616382e-07
two O 0 3.933375865017297e-07
founder O 0 0.00021726643899455667
mutations O 0 0.0001415558363078162
4612del165 O 0 0.0010459371842443943
and O 0 6.004977421980584e-06
7883del5 O 0 0.0034889501985162497
. O 0 3.47884779330343e-05

The O 0 1.752116259012837e-05
ATM O 0 0.0012237586779519916
( O 0 0.00019889199757017195
A O 0 0.023203935474157333
- O 1 0.9870036244392395
T O 1 0.9975336790084839
, O 0 3.472775915724924e-06
mutated O 0 5.372167288442142e-05
) O 0 3.961176275879552e-07
gene O 0 8.170094361048541e-07
on O 0 1.877899222790802e-07
human O 0 7.756189006613567e-06
chromosome O 0 0.0006096058059483767
11q22 O 0 0.011676279827952385
. O 0 5.5840071581769735e-05

3 O 0 4.6802313590887934e-05
has O 0 4.793604148289887e-06
recently O 0 4.781066763825947e-06
been O 0 6.762468274246203e-08
identified O 0 1.1004114242041396e-07
as O 0 1.3314618740878359e-08
the O 0 1.888372125335991e-08
gene O 0 4.1978796616604086e-07
responsible O 0 3.704729465425771e-07
for O 0 4.5160325612414454e-07
the O 0 2.826635136443656e-05
human O 0 0.33342480659484863
recessive B-Disease 1 0.9994595646858215
disease I-Disease 1 0.9998830556869507
ataxia B-Disease 1 0.9998331069946289
- I-Disease 1 0.9993537068367004
telangiectasia I-Disease 1 0.999279797077179
( O 0 0.0530213825404644
A B-Disease 1 0.7927440404891968
- I-Disease 1 0.9944449067115784
T I-Disease 1 0.9966828227043152
) O 0 4.52294698334299e-05
. O 0 1.7753391148289666e-05

In O 0 1.1330853340041358e-06
order O 0 3.1489705065723683e-07
to O 0 4.6000774744925366e-08
define O 0 8.279150165435567e-07
the O 0 3.201257356977294e-07
types O 0 2.000737913476769e-05
of O 0 5.742695429944433e-05
disease O 1 0.9995392560958862
- O 0 0.46762484312057495
causing O 0 0.0014133809600025415
ATM O 0 0.0001683927548583597
mutations O 0 6.165798822621582e-06
in O 0 8.0078530118044e-07
Japanese O 0 0.0016441841144114733
A B-Disease 1 0.9624453186988831
- I-Disease 1 0.9995526671409607
T I-Disease 1 0.9998193383216858
patients O 0 0.08429877460002899
as O 0 5.518587542496789e-08
well O 0 1.5307854539514665e-08
as O 0 7.539673774203948e-09
to O 0 6.559859766497311e-09
look O 0 1.6144780090598942e-07
for O 0 1.513765113259069e-08
possible O 0 4.225094869525492e-07
mutational O 0 0.000770424259826541
hotspots O 0 2.3690570742473938e-05
, O 0 1.663260320583504e-07
reverse O 0 7.96887070464436e-06
- O 0 4.208990503684618e-06
transcribed O 0 1.7411876740425214e-07
RNA O 0 1.5573114353628625e-07
derived O 0 5.180655193726125e-08
from O 0 9.062689798611245e-08
ten O 0 7.839543627596868e-07
patients O 0 9.283697727369145e-05
belonging O 0 1.9947664497976803e-07
to O 0 3.4407545257408856e-08
eight O 0 3.8990424400253687e-07
unrelated O 0 9.19452213565819e-05
Japanese O 0 0.001317514106631279
A B-Disease 1 0.6402776837348938
- I-Disease 1 0.997687816619873
T I-Disease 1 0.9988617897033691
families O 0 1.6061253518273588e-06
was O 0 1.3947885690868134e-07
analyzed O 0 1.5964693034220545e-07
for O 0 1.993081077955594e-08
mutations O 0 4.4674780497189204e-07
by O 0 1.5888470983327352e-08
the O 0 1.246777401320287e-07
restriction O 0 7.727999218332116e-06
endonuclease O 0 0.0005451944889500737
fingerprinting O 0 7.221679697977379e-05
method O 0 3.115525487373816e-06
. O 0 1.097761469281977e-05

As O 0 6.956488959986018e-06
has O 0 1.7853143390311743e-06
been O 0 3.013877574176149e-07
reported O 0 3.7221354887151392e-06
by O 0 1.2707496921393613e-07
others O 0 4.950190373165242e-07
, O 0 2.390808617747098e-07
mutations O 0 6.031701786923804e-07
that O 0 8.65242810732525e-09
lead O 0 1.6378329803501401e-07
to O 0 2.8740906543589517e-08
exon O 0 3.3467345929238945e-05
skipping O 0 2.7995427444693632e-05
or O 0 1.5436709190908005e-06
premature O 0 0.00055802206043154
protein O 0 7.051261832202727e-07
truncation O 0 7.281767466338351e-06
were O 0 1.6072721820137303e-08
also O 0 6.091207183089864e-08
predominant O 0 6.194999855324568e-07
in O 0 1.273989482797333e-07
our O 0 1.2467837677831994e-06
mutants O 0 0.00019692648493219167
. O 0 1.3510441021935549e-05

Six O 0 3.418661663090461e-06
different O 0 7.099249614839209e-07
mutations O 0 1.2709238944808021e-05
were O 0 6.424620835332462e-08
identified O 0 1.3181836777675926e-07
on O 0 1.68487908069892e-08
12 O 0 4.9226031251237146e-08
of O 0 1.6920608914006152e-08
the O 0 1.9103043769064243e-07
16 O 0 4.462310243980028e-06
alleles O 0 3.846123945550062e-05
examined O 0 0.00015637773321941495
. O 0 2.4352275431738235e-05

Four O 0 1.437604623788502e-06
were O 0 2.5057059360733547e-07
deletions O 0 1.3172541002859361e-05
involving O 0 3.1248362120095408e-06
a O 0 1.1515182904986432e-06
loss O 0 2.621155363158323e-05
of O 0 1.4897707067973442e-08
a O 0 1.0591539734150501e-07
single O 0 1.2720082054329396e-07
exon O 0 1.1188916687387973e-05
exon O 0 1.1430396625655703e-05
7 O 0 3.594714428345469e-07
, O 0 4.594325275775191e-08
exon O 0 2.58533941632777e-06
16 O 0 1.0193129895696984e-07
, O 0 5.479737197333634e-08
exon O 0 4.616849309968529e-06
33 O 0 8.113970011436322e-07
or O 0 3.365161944657302e-07
exon O 0 7.786984497215599e-05
35 O 0 1.3812781617161818e-05
. O 0 1.048981175699737e-05

The O 0 1.760828354235855e-06
others O 0 4.622391145403526e-07
were O 0 4.822808108428944e-08
minute O 0 2.5872557785078243e-07
deletions O 0 3.7770205381093547e-06
, O 0 2.506626231024711e-07
4649delA O 0 2.9572402127087116e-05
in O 0 1.3441311352835328e-07
exon O 0 1.603926284587942e-05
33 O 0 1.32644890982192e-06
and O 0 1.912688816219088e-07
7883del5 O 0 4.5227614464238286e-05
in O 0 6.937547141205869e-07
exon O 0 0.0002420638338662684
55 O 0 5.91584830544889e-05
. O 0 1.7575988749740645e-05

The O 0 1.390430497849593e-05
mutations O 0 0.00016236813098657876
4612del165 O 0 0.0010596899082884192
and O 0 1.873893211268296e-06
7883del5 O 0 0.00010598972585285082
were O 0 4.4352400863090224e-08
found O 0 4.081206839146034e-08
in O 0 8.643504578742522e-09
more O 0 5.01346120174162e-09
than O 0 1.0725567101133038e-08
two O 0 1.8637928533848935e-08
unrelated O 0 8.752954272495117e-06
families O 0 3.4337796250838437e-07
; O 0 2.0070285700057866e-07
44 O 0 5.611771598523774e-07
% O 0 7.182467953725791e-08
( O 0 5.532404401265012e-08
7 O 0 2.341173654940576e-08
of O 0 2.573448565357239e-09
16 O 0 3.551966898385217e-08
) O 0 6.441354560848822e-09
of O 0 1.2421548234442525e-09
the O 0 1.3626518580167613e-08
mutant O 0 1.8951901665786863e-06
alleles O 0 3.774025003622228e-07
had O 0 1.3397716713825503e-08
one O 0 2.062254589318968e-09
of O 0 4.946449916332085e-09
the O 0 5.732253782753105e-08
two O 0 2.7265795665698533e-07
mutations O 0 4.77743087685667e-05
. O 0 1.2672424418269657e-05

The O 0 1.678128137427848e-05
4612del165 O 0 0.0031591481529176235
mutations O 0 3.7507994420593604e-05
in O 0 1.2390395909278595e-07
three O 0 2.4275129462125733e-08
different O 0 1.331642174307035e-08
families O 0 7.236786103703707e-08
were O 0 3.6328977603972135e-09
all O 0 5.520901069644424e-09
ascribed O 0 2.820819418047904e-07
to O 0 1.0027137342660808e-08
the O 0 8.832616060772125e-08
same O 0 2.3175393835117575e-06
T O 1 0.8269873857498169
- O 0 0.0010926681570708752
- O 0 8.133731171255931e-05
> O 0 8.461839570372831e-06
A O 0 2.706950397168839e-08
substitution O 0 6.385891992977122e-08
at O 0 3.619247124220237e-08
the O 0 3.782996671475303e-08
splice O 0 1.116954445024021e-05
donor O 0 1.0465410923643503e-05
site O 0 1.1133863608847605e-06
in O 0 5.499064741343318e-07
intron O 0 0.005405300296843052
33 O 0 4.229614569339901e-05
. O 0 1.2760149729729164e-05

Microsatellite O 0 0.0030681006610393524
genotyping O 0 0.00034411801607348025
around O 0 1.7354713008899125e-06
the O 0 7.128339802875416e-07
ATM O 0 0.00017799020861275494
locus O 0 3.436103725107387e-05
also O 0 5.142829877513577e-07
indicated O 0 3.889233539666748e-06
that O 0 4.4423689615769035e-08
a O 0 5.484452572090959e-07
common O 0 4.113038357900223e-06
haplotype O 0 0.0012397917453199625
was O 0 6.326319379468259e-08
shared O 0 2.7901892352133473e-08
by O 0 1.3174692448103542e-08
the O 0 6.600475899176672e-08
mutant O 0 1.6942163711064495e-05
alleles O 0 7.518117399740731e-06
in O 0 5.263553930490161e-07
both O 0 1.9044014152314048e-06
mutations O 0 0.00017666425264906138
. O 0 2.6162957510678098e-05

This O 0 5.906570549996104e-06
suggests O 0 1.6795145711512305e-05
that O 0 1.1442970304642586e-07
these O 0 4.2040333880777325e-08
two O 0 2.6588401169647113e-07
founder O 0 0.0005611325614154339
mutations O 0 0.00011576800170587376
may O 0 1.3385046031544334e-06
be O 0 2.3875269761219897e-08
predominant O 0 1.5065648995005176e-06
among O 0 3.3982541935984045e-07
Japanese O 0 1.8154456483898684e-05
ATM O 0 0.0006303716800175607
mutant O 0 0.0002890382311306894
alleles O 0 0.00010143281542696059
. O 0 2.2075928427511826e-05

W474C O 0 0.0002614417171571404
amino O 0 6.622387900279136e-06
acid O 0 4.6343793655978516e-05
substitution O 0 8.475293725496158e-06
affects O 0 1.959808105311822e-05
early O 0 1.6739346619942808e-07
processing O 0 8.187380728941207e-08
of O 0 7.13564274334999e-09
the O 0 2.5658088986801886e-08
alpha O 0 5.655148811456456e-07
- O 0 6.295119874266675e-07
subunit O 0 1.0065867428465936e-07
of O 0 3.801528336566662e-08
beta O 0 3.091370308538899e-05
- O 0 0.000480505550513044
hexosaminidase O 0 0.00010598092922009528
A O 0 3.2263864113701857e-07
and O 0 5.2760270818907884e-08
is O 0 1.4820793126091303e-07
associated O 0 2.3962602426763624e-06
with O 0 6.8490967350953724e-06
subacute O 1 0.9966803789138794
G B-Disease 0 0.3317592740058899
( I-Disease 0 0.00021873036166653037
M2 I-Disease 0 0.2658962607383728
) I-Disease 0 1.9677992895594798e-05
gangliosidosis I-Disease 0 0.0030914649832993746
. O 0 1.7694521375233307e-05

Mutations O 0 5.6655531807336956e-05
in O 0 9.061356536221865e-07
the O 0 1.4705668718306697e-06
HEXA O 0 0.033979784697294235
gene O 0 9.47985142829566e-07
, O 0 2.588385328294862e-08
encoding O 0 3.817688565277422e-08
the O 0 1.3598114634305603e-08
alpha O 0 2.798034586248832e-07
- O 0 5.563397849073226e-07
subunit O 0 7.957427783367166e-08
of O 0 2.254862607742325e-08
beta O 0 1.0756238225440029e-05
- O 0 5.108675031806342e-05
hexosaminidase O 0 5.179495565243997e-05
A O 0 3.2305612762684177e-07
( O 0 3.622811561854178e-07
Hex O 0 1.941849177455879e-06
A O 0 1.4804689385528036e-07
) O 0 4.415421628323202e-08
, O 0 7.539141755330547e-09
that O 0 6.599693236353232e-09
abolish O 0 6.418472366931383e-07
Hex O 0 2.049622935373918e-06
A O 0 1.0272621011608862e-06
enzyme O 0 2.893041164497845e-05
activity O 0 0.00010717628902057186
cause O 1 0.7608912587165833
Tay B-Disease 1 0.9986956715583801
- I-Disease 1 0.9988887906074524
Sachs I-Disease 1 0.9993676543235779
disease I-Disease 1 0.9992350339889526
( O 0 0.0005925848381593823
TSD B-Disease 1 0.9921230673789978
) O 0 4.54039854957955e-06
, O 0 5.006526180295623e-07
the O 0 2.4469381969538517e-06
fatal O 0 0.49865975975990295
infantile B-Disease 0 0.2549727261066437
form I-Disease 0 1.960600684469682e-06
of I-Disease 0 9.946649015546427e-07
G I-Disease 0 0.03083883225917816
( I-Disease 0 3.107007432845421e-05
M2 I-Disease 0 0.03238892927765846
) I-Disease 0 4.685553449235158e-06
gangliosidosis I-Disease 0 0.0007484115776605904
, I-Disease 0 9.215716545440955e-07
Type I-Disease 0 6.632950680796057e-05
1 I-Disease 0 8.301166417368222e-06
. O 0 7.366365480265813e-06

Less O 0 0.008155850693583488
severe O 1 0.9952598214149475
, O 0 0.004112080670893192
subacute O 1 0.9970648884773254
( O 0 0.1546367108821869
juvenile O 1 0.9971792697906494
- O 1 0.9961323738098145
onset O 1 0.9988518953323364
) O 0 0.0026852870360016823
and O 0 0.0030855468939989805
chronic O 1 0.9996447563171387
( O 0 0.0022689371835440397
adult O 0 0.011074582114815712
- O 1 0.9679180383682251
onset O 1 0.996640682220459
) O 0 5.159363809070783e-06
variants O 0 5.997079824737739e-06
are O 0 3.707803841734858e-08
characterized O 0 7.481240118067944e-06
by O 0 3.3581788017045255e-08
a O 0 4.1881230572471395e-07
broad O 0 4.889483898296021e-05
spectrum O 0 2.903912536567077e-05
of O 0 2.1497771740541793e-06
clinical O 0 0.12765651941299438
manifestations O 0 0.002496525878086686
and O 0 4.785021587849769e-07
are O 0 3.893445921221428e-08
associated O 0 6.157227971925749e-07
with O 0 1.8047423111511307e-07
residual O 0 6.824237061664462e-05
levels O 0 6.20505716142361e-07
of O 0 3.6663333702335876e-08
Hex O 0 7.742900379525963e-06
A O 0 1.5241828350553988e-06
enzyme O 0 1.780595448508393e-05
activity O 0 6.529630354634719e-06
. O 0 1.136099763243692e-05

We O 0 3.4602694540808443e-06
identified O 0 4.103533683519345e-06
a O 0 7.806829671608284e-06
1422 O 0 0.24994613230228424
G O 0 0.047588348388671875
- O 0 0.009264379739761353
- O 0 0.0013418588787317276
> O 0 0.00023686641361564398
C O 0 1.4113596989773214e-05
( O 0 1.2034658425363887e-07
amino O 0 5.8755372123187044e-08
acid O 0 1.881961225080886e-06
W474C O 0 3.5712030239665182e-06
) O 0 1.5604296521587457e-08
substitution O 0 2.6784768181187246e-08
in O 0 1.5911448825178809e-09
the O 0 7.977830618344228e-10
first O 0 1.059068166497923e-09
position O 0 1.932924043046569e-09
of O 0 3.029627437811655e-09
exon O 0 2.5883837224682793e-06
13 O 0 7.672489488186329e-08
of O 0 4.169742240378582e-08
HEXA O 0 0.0019770869985222816
of O 0 3.741613241459163e-08
a O 0 8.399412649851001e-07
non O 0 1.3047580068814568e-05
- O 0 0.00042170551023446023
Jewish O 0 5.509182301466353e-06
proband O 0 0.0014503869460895658
who O 0 2.0179156763333594e-06
manifested O 0 0.0001176451551145874
a O 0 2.4828284949762747e-05
subacute O 1 0.9921965599060059
variant O 0 0.0024132803082466125
of O 0 4.40998655903968e-06
G B-Disease 0 0.13500194251537323
( I-Disease 0 0.00012806753511540592
M2 I-Disease 0 0.2309354543685913
) I-Disease 0 2.2585900296689942e-05
gangliosidosis I-Disease 0 0.0035571844782680273
. O 0 2.354035859752912e-05

On O 0 1.2006770475636586e-06
the O 0 1.0176282785323565e-06
second O 0 7.921635187813081e-06
maternally O 0 0.010614564642310143
inherited O 0 0.09880467504262924
allele O 0 4.6041041059652343e-05
, O 0 6.638516651946702e-07
we O 0 1.4851383411951247e-07
identified O 0 1.3713232647205587e-06
the O 0 4.558904038276523e-06
common O 0 0.08969324827194214
infantile O 1 0.9995661377906799
disease O 1 0.9996558427810669
- O 1 0.5263587832450867
causing O 0 0.002538528060540557
4 O 0 2.6711548343882896e-05
- O 0 0.000412729597883299
bp O 0 2.9538467060774565e-05
insertion O 0 1.3450725418806542e-05
, O 0 1.9121796412946424e-06
+ O 0 0.0008802466909401119
TATC O 0 0.013609077781438828
1278 O 0 0.0018818257376551628
, O 0 2.995286934037722e-07
in O 0 3.9437128407371347e-07
exon O 0 0.00020321177726145834
11 O 0 2.598933133413084e-05
. O 0 2.02121191250626e-05

Pulse O 0 0.0019474643049761653
- O 0 0.00048529228661209345
chase O 0 3.897746864822693e-05
analysis O 0 1.651908519306744e-06
using O 0 1.2393365977914073e-06
proband O 0 0.003741663182154298
fibroblasts O 0 0.0002265341317979619
revealed O 0 1.943476036103675e-06
that O 0 2.1585186971151415e-08
the O 0 6.218671444457868e-08
W474C O 0 3.097726221312769e-05
- O 0 5.087345471110893e-06
containing O 0 2.357363655391964e-07
alpha O 0 1.374801286146976e-06
- O 0 4.722802259493619e-06
subunit O 0 8.267165867437143e-07
precursor O 0 1.9494402749842266e-06
was O 0 6.651064410334584e-08
normally O 0 6.920037520785627e-08
synthesized O 0 2.0561684266340308e-07
, O 0 1.3068253146286679e-08
but O 0 3.953912308674035e-09
not O 0 2.1752355472415275e-09
phosphorylated O 0 1.8503689602766826e-07
or O 0 3.217840571778652e-08
secreted O 0 1.2809654492684786e-07
, O 0 5.539951608568572e-09
and O 0 4.903951467127854e-09
the O 0 3.2183866238710834e-08
mature O 0 1.5659596101613715e-05
lysosomal O 0 0.004407492931932211
alpha O 0 9.001358193927445e-06
- O 0 2.959443736472167e-05
subunit O 0 3.0536607482645195e-06
was O 0 7.258197456394555e-07
not O 0 2.1357983825964766e-07
detected O 0 2.0832438167417422e-05
. O 0 5.04657145938836e-06

When O 0 3.9403062146448065e-06
the O 0 1.483919618294749e-06
W474C O 0 8.251352846855298e-05
- O 0 1.184539905807469e-05
containing O 0 4.6542487552869716e-07
alpha O 0 2.2714809801982483e-06
- O 0 6.7269825194671284e-06
subunit O 0 1.0288640623912215e-06
was O 0 8.041250225687691e-07
transiently O 0 0.0002869809977710247
co O 0 3.8134694477776065e-05
- O 0 9.62371541390894e-06
expressed O 0 3.470010412343072e-08
with O 0 6.859742107678812e-09
the O 0 1.756896139681885e-08
beta O 0 1.1106166084573488e-06
- O 0 5.449302307170001e-07
subunit O 0 2.8870898560739988e-08
to O 0 2.6762796423440705e-09
produce O 0 2.8378714489463164e-08
Hex O 0 8.323142992594512e-07
A O 0 2.2090392803875147e-07
( O 0 7.112938646969269e-07
alphabeta O 0 3.943088813684881e-05
) O 0 1.962041551450966e-07
in O 0 3.270984336722904e-07
COS O 0 0.02183048240840435
- O 0 5.383188181440346e-05
7 O 0 6.721639920215239e-07
cells O 0 4.629705756542535e-07
, O 0 6.202995894710739e-09
the O 0 4.938079278815621e-09
mature O 0 3.8998976492621296e-07
alpha O 0 6.708178830194811e-07
- O 0 3.712145826284541e-06
subunit O 0 2.5073723008972593e-07
was O 0 2.9948125757073285e-08
present O 0 1.2801979032417421e-08
, O 0 6.576396316404498e-09
but O 0 2.7091389132039012e-09
its O 0 9.141714052418592e-09
level O 0 7.172953075951227e-08
was O 0 1.5882894999208474e-08
much O 0 1.6768577637549242e-08
lower O 0 8.038262677700914e-08
than O 0 1.5790938556747847e-09
that O 0 7.766596255009972e-10
from O 0 4.136099462925813e-09
normal O 0 2.907431273513339e-08
alpha O 0 3.5213227533859026e-07
- O 0 4.18777426602901e-06
subunit O 0 1.3532545608541113e-06
transfections O 0 7.074336463119835e-05
, O 0 4.103851836134709e-08
although O 0 1.8155622782956016e-08
higher O 0 5.34996189571757e-08
than O 0 6.689343745591714e-09
in O 0 1.4681573290431515e-08
those O 0 3.341375176546535e-08
cells O 0 1.5185938764261664e-06
transfected O 0 5.805040927953087e-06
with O 0 2.003960197782817e-08
an O 0 3.1203967409965117e-08
alpha O 0 2.7779315132647753e-06
- O 0 5.216757199377753e-05
subunit O 0 1.146234899351839e-05
associated O 0 1.1494848877191544e-05
with O 0 5.037459050072357e-05
infantile O 1 0.9916365742683411
TSD B-Disease 1 0.9886099100112915
. O 0 0.00031034171115607023

Furthermore O 0 7.00593227520585e-05
, O 0 1.0623906518958393e-06
the O 0 2.117266433288023e-07
precursor O 0 3.0531948596035363e-06
level O 0 8.830998865505535e-08
of O 0 9.107028908772463e-09
the O 0 3.5339308368520506e-08
W474C O 0 1.0177574949921109e-05
alpha O 0 1.5500127119594254e-06
- O 0 4.320159405324375e-06
subunit O 0 2.7816668080049567e-07
was O 0 2.359279349661847e-08
found O 0 1.1195002258546083e-08
to O 0 1.1276651612490696e-08
accumulate O 0 4.367975179775385e-06
in O 0 8.988816802002475e-09
comparison O 0 5.040560324687249e-08
to O 0 3.50433526641325e-09
the O 0 8.215096158892266e-09
normal O 0 1.8573913962427469e-07
alpha O 0 2.465457328071352e-06
- O 0 1.8455331883160397e-05
subunit O 0 5.5141235861810856e-06
precursor O 0 4.307184281060472e-05
levels O 0 2.000260974455159e-05
. O 0 6.313026915449882e-06

We O 0 2.57236843026476e-06
conclude O 0 8.701485057827085e-06
that O 0 3.8607424812653335e-07
the O 0 2.3830195914342767e-06
1422 O 0 0.185153529047966
G O 0 0.059045907109975815
- O 0 0.05548081547021866
- O 0 0.016086162999272346
> O 0 0.003045246936380863
C O 0 0.00010469322296557948
mutation O 0 1.4868320477035013e-06
is O 0 7.652113609424305e-09
the O 0 1.4879901755193714e-08
cause O 0 1.008073581942881e-06
of O 0 9.103836617896377e-08
Hex B-Disease 0 0.0008651158423162997
A I-Disease 0 0.0009290719754062593
enzyme I-Disease 1 0.9751446843147278
deficiency I-Disease 1 0.9994476437568665
in O 0 2.731969971137005e-06
the O 0 8.740925295569468e-06
proband O 0 0.030127963051199913
. O 0 4.2235249566147104e-05

The O 0 6.543381914525526e-06
resulting O 0 2.3285154384211637e-05
W474C O 0 9.155247244052589e-05
substitution O 0 3.80848496206454e-06
clearly O 0 1.296242203352449e-06
interferes O 0 3.928479145542951e-06
with O 0 9.816332635637082e-08
alpha O 0 1.8577967466626433e-06
- O 0 7.975743756105658e-06
subunit O 0 5.123063715473108e-07
processing O 0 3.6161702610115753e-07
, O 0 2.692876321930271e-08
but O 0 5.089217047782313e-09
because O 0 4.854516344465765e-09
the O 0 3.6110949785950197e-09
base O 0 2.9792133204864513e-08
substitution O 0 3.348205268594029e-07
falls O 0 6.192977707542013e-06
at O 0 8.720588695609877e-09
the O 0 2.045526859006941e-09
first O 0 2.2059534199314612e-09
position O 0 5.322438045851641e-09
of O 0 5.989910345505223e-09
exon O 0 6.151755314931506e-06
13 O 0 1.8987634575751144e-07
, O 0 5.544172054783303e-08
aberrant O 0 4.363233074400341e-06
splicing O 0 1.4323209143185522e-06
may O 0 2.1151474527414393e-07
also O 0 1.79087145113499e-08
contribute O 0 2.5150453097921854e-07
to O 0 9.698342751107702e-08
Hex B-Disease 0 0.00024390376347582787
A I-Disease 0 0.0007851034752093256
deficiency I-Disease 1 0.9989609718322754
in O 0 6.049485250514408e-07
this O 0 1.1198395668543526e-06
proband O 0 0.01903054490685463
. O 0 4.025753696623724e-06
. O 0 1.4929053577361628e-05

Two O 0 2.0988100004615262e-05
frequent O 0 0.00247805449180305
missense O 0 0.2515486776828766
mutations O 0 0.20753206312656403
in O 0 0.14297865331172943
Pendred B-Disease 1 0.9975359439849854
syndrome I-Disease 1 0.9991787075996399
. O 0 0.010786296799778938

Pendred B-Disease 1 0.9941934943199158
syndrome I-Disease 1 0.9992579817771912
is O 0 0.1647118330001831
an O 1 0.972881555557251
autosomal B-Disease 1 0.9995976090431213
recessive I-Disease 1 0.9998137354850769
disorder I-Disease 1 0.9999125003814697
characterized O 1 0.9980672001838684
by O 0 0.2181265950202942
early O 1 0.9939140677452087
childhood O 1 0.999397873878479
deafness B-Disease 1 0.9997549653053284
and O 1 0.9835113286972046
goiter B-Disease 1 0.9989632368087769
. O 0 0.01294267550110817

A O 0 1.0134667718375567e-05
century O 0 3.5787616070592776e-06
after O 0 1.953534592757933e-06
its O 0 4.38115250744886e-07
recognition O 0 3.4898710055131232e-06
as O 0 3.3246037673961837e-06
a O 0 0.002337563317269087
syndrome O 1 0.9994571805000305
by O 0 9.039985343406443e-06
Vaughan O 0 0.010388319380581379
Pendred O 0 0.18292400240898132
, O 0 1.4652092431788333e-05
the O 0 0.0001439979241695255
disease O 1 0.998324453830719
gene O 0 0.00013542184024117887
( O 0 8.826428529573604e-05
PDS O 0 0.07485765218734741
) O 0 3.446121183969808e-07
was O 0 1.056909866292699e-07
mapped O 0 5.926082167206914e-07
to O 0 1.2165445184564305e-07
chromosome O 0 7.810455281287432e-05
7q22 O 0 0.004642580170184374
- O 0 0.01035899668931961
q31 O 0 0.003397524356842041
. O 0 2.59316002484411e-05

1 O 0 2.8253010896150954e-05
and O 0 1.6203315453822142e-06
, O 0 1.3594479923995095e-06
recently O 0 4.010445081803482e-06
, O 0 5.150791082542128e-08
found O 0 2.5847445073168274e-08
to O 0 1.494030499316068e-08
encode O 0 2.6462626578904747e-07
a O 0 2.2266226551437285e-06
putative O 0 0.0006027526687830687
sulfate O 0 0.2210288643836975
transporter O 0 0.03726809471845627
. O 0 4.471547435969114e-05

We O 0 9.888358363241423e-07
performed O 0 6.081688184167433e-07
mutation O 0 1.1712081686710007e-06
analysis O 0 1.0138876405108022e-07
of O 0 6.290559184662925e-08
the O 0 1.5885445918684127e-06
PDS B-Disease 1 0.6051023602485657
gene O 0 0.00013626196596305817
in O 0 8.742009413253982e-06
patients O 0 0.009564443491399288
from O 0 1.3616953538075904e-06
14 O 0 2.5242430638172664e-05
Pendred B-Disease 0 0.012360281310975552
families O 0 7.738094041087606e-07
originating O 0 2.3603242027547822e-07
from O 0 3.5511810381194664e-08
seven O 0 4.124812491568264e-08
countries O 0 3.0735140654769566e-08
and O 0 9.286085145276957e-08
identified O 0 7.663347787456587e-07
all O 0 2.221713657490909e-07
mutations O 0 4.859440741711296e-05
. O 0 1.57308422785718e-05

The O 0 3.4904733183793724e-06
mutations O 0 9.108149242820218e-06
include O 0 2.9091464170960535e-07
three O 0 3.298393025374935e-08
single O 0 1.2530054505077715e-07
base O 0 4.536203448424203e-07
deletions O 0 1.6924825558817247e-06
, O 0 3.399189907327127e-08
one O 0 1.817249462021664e-08
splice O 0 5.714323833672097e-06
site O 0 4.2768198227349785e-07
mutation O 0 1.4413619737752015e-06
and O 0 1.659571609025079e-07
10 O 0 3.7028717088105623e-06
missense O 0 0.000491649319883436
mutations O 0 0.00014437381469178945
. O 0 3.375215601408854e-05

One O 0 7.278504654095741e-06
missense O 0 0.00042209686944261193
mutation O 0 8.747262472752482e-05
( O 0 2.4294724425999448e-05
L236P O 0 0.0007642165292054415
) O 0 8.653865393171145e-07
was O 0 6.888419079587038e-08
found O 0 2.9814700042152253e-08
in O 0 1.1583551895455457e-08
a O 0 7.893906683875684e-08
homozygous O 0 5.720626177208032e-07
state O 0 2.5972971329224492e-08
in O 0 2.1049444853815658e-08
two O 0 3.486229971372268e-08
consanguineous O 0 0.0006022659945301712
families O 0 2.6441992417858273e-07
and O 0 1.550029793406793e-08
in O 0 1.2179650177301937e-08
a O 0 4.2123087240497625e-08
heterozygous O 0 1.62998901487299e-07
state O 0 1.2006727168056841e-08
in O 0 1.4759319100221546e-08
five O 0 6.126359863856123e-08
additional O 0 7.968209274622495e-07
non O 0 4.401218393468298e-05
- O 0 0.009356618858873844
consanguineous O 0 0.014325039461255074
families O 0 2.466941805323586e-05
. O 0 2.5842082322924398e-05

Another O 0 3.6142861063126475e-05
missense O 0 0.0007358122384175658
mutation O 0 0.0001974202023120597
( O 0 2.8956854293937795e-05
T416P O 0 0.0008186770719476044
) O 0 1.0074008969240822e-06
was O 0 1.0761656454860713e-07
found O 0 3.373335388801024e-08
in O 0 8.527501371702328e-09
a O 0 7.259236411982783e-08
homozygous O 0 5.106167577650922e-07
state O 0 2.4784622354445673e-08
in O 0 1.722914788615526e-08
one O 0 1.4044597484996757e-08
family O 0 1.3526620534776157e-07
and O 0 1.100408919540996e-08
in O 0 1.8762158049412392e-08
a O 0 1.8219596142898808e-07
heterozygous O 0 1.4284712506196229e-06
state O 0 5.0596320022577856e-08
in O 0 4.9472546947981755e-08
four O 0 4.985338932783634e-07
families O 0 1.1914484275621362e-05
. O 0 2.4050328647717834e-05

Pendred B-Disease 1 0.9622188806533813
patients O 0 0.05432746559381485
in O 0 2.334762712052907e-06
three O 0 3.95845245293458e-06
non O 0 0.00030762283131480217
- O 0 0.061494164168834686
consanguineous O 0 0.011209127493202686
families O 0 1.4935196759324754e-06
were O 0 3.0482116386565394e-08
shown O 0 5.8733746755024185e-08
to O 0 1.3249132457815449e-08
be O 0 1.9455898225828605e-08
compound O 0 6.535910415550461e-06
heterozygotes O 0 0.0002905204310081899
for O 0 8.872140142557328e-07
L236P O 0 0.0006793302018195391
and O 0 3.2559876217419514e-06
T416P O 0 0.0026758243329823017
. O 0 3.0390096071641892e-05

In O 0 2.315032133992645e-06
total O 0 6.256456686060119e-07
, O 0 1.9692568287155154e-07
one O 0 2.4140950571904796e-08
or O 0 2.7325189222437984e-08
both O 0 2.8922970685130167e-09
of O 0 5.415563109067989e-09
these O 0 2.5684579796347862e-08
mutations O 0 7.219179565254308e-07
were O 0 3.037177620512921e-09
found O 0 9.130787681499442e-09
in O 0 3.7345389003462515e-09
nine O 0 7.370709376175455e-09
of O 0 5.857697438216292e-09
the O 0 8.680201091237905e-08
14 O 0 1.4154555856293882e-06
families O 0 1.747803821672278e-06
analyzed O 0 1.78084010258317e-05
. O 0 1.2624812370631844e-05

The O 0 1.226167228196573e-06
identification O 0 5.492428840625507e-07
of O 0 1.4638993661719724e-07
two O 0 5.982057587061718e-07
frequent O 0 0.000596271944232285
PDS B-Disease 1 0.7068663239479065
mutations O 0 2.0308998500695452e-05
will O 0 1.4771266876323352e-07
facilitate O 0 2.2084398096922087e-06
the O 0 4.7693947635707445e-06
molecular O 0 0.01184795517474413
diagnosis O 1 0.9947482943534851
of O 0 0.017779789865016937
Pendred B-Disease 1 0.9982258677482605
syndrome I-Disease 1 0.9993987083435059
. O 0 0.003941885195672512

Insertional O 0 0.0050142984837293625
mutation O 0 5.822004459332675e-05
by O 0 1.8980842924065655e-06
transposable O 0 0.0004185617435723543
element O 0 1.0964253306156024e-05
, O 0 2.5617905521357898e-06
L1 O 0 0.0018843405414372683
, O 0 4.1155789176627877e-07
in O 0 2.884495415855781e-07
the O 0 4.731141871161526e-06
DMD B-Disease 1 0.9964827299118042
gene O 0 6.226388359209523e-05
results O 0 3.2181684218812734e-05
in O 0 9.412901272298768e-05
X B-Disease 1 0.9767395257949829
- I-Disease 1 0.986951470375061
linked I-Disease 1 0.8933282494544983
dilated I-Disease 1 0.9917282462120056
cardiomyopathy I-Disease 1 0.9976593255996704
. O 0 0.0035012071020901203

X B-Disease 1 0.9700744152069092
- I-Disease 1 0.9891626834869385
linked I-Disease 1 0.9874852299690247
dilated I-Disease 1 0.9966889023780823
cardiomyopathy I-Disease 1 0.9994144439697266
( O 0 0.012870367616415024
XLDCM B-Disease 1 0.7630292773246765
) O 0 5.189573585084872e-06
is O 0 5.665870048687793e-07
a O 0 4.6985210246930365e-06
clinical O 0 0.001981117995455861
phenotype O 0 0.00037179156788624823
of O 0 7.367830221483018e-07
dystrophinopathy B-Disease 0 0.03421211242675781
which O 0 4.0989786498357716e-07
is O 0 9.48848878579156e-07
characterized O 0 0.0006043953471817076
by O 0 1.0693917829485144e-05
preferential O 0 0.15397463738918304
myocardial B-Disease 1 0.9993233680725098
involvement I-Disease 0 0.0009959936141967773
without O 0 5.087063527753344e-06
any O 0 2.9998259378771763e-06
overt O 0 0.001535248477011919
clinical O 0 0.29142826795578003
signs O 0 0.17916852235794067
of O 0 0.002992794616147876
skeletal B-Disease 1 0.9989474415779114
myopathy I-Disease 1 0.9990839958190918
. O 0 0.027839841321110725

To O 0 1.4571609199265367e-06
date O 0 1.5040741345728748e-06
, O 0 2.590485337350401e-07
several O 0 1.9711357879259594e-07
mutations O 0 1.9148299543303438e-05
in O 0 7.290662324521691e-06
the O 0 0.007923419587314129
Duchenne B-Disease 1 0.9994860887527466
muscular I-Disease 1 0.9995653033256531
dystrophy I-Disease 1 0.9996715784072876
gene O 1 0.5219038128852844
, O 0 0.0236026830971241
DMD O 1 0.9995224475860596
, O 0 4.769703991769347e-06
have O 0 1.2122386294777243e-07
been O 0 2.115195769647471e-07
identified O 0 4.1531484384904616e-06
in O 0 3.3662706755421823e-06
patients O 0 0.03132788836956024
with O 0 1.128851727116853e-05
XLDCM B-Disease 1 0.766740083694458
, O 0 3.1041321335578687e-07
but O 0 3.3429369494797356e-08
a O 0 7.907348020808058e-08
pathogenic O 0 9.191718959300488e-07
correlation O 0 5.004158509791523e-08
of O 0 1.1447987446899788e-08
these O 0 1.3162214429485175e-07
cardiospecific O 0 0.00400170125067234
mutations O 0 4.686980173573829e-05
in O 0 4.551427537080599e-06
DMD O 1 0.998246431350708
with O 0 2.6871020963881165e-06
the O 0 1.8528127839090303e-05
XLDCM B-Disease 1 0.9695871472358704
phenotype O 0 0.02158699743449688
has O 0 1.3602806347989826e-06
remained O 0 1.099374571822409e-06
to O 0 1.0480870571427658e-07
be O 0 3.345971038015705e-07
elucidated O 0 0.0004707804473582655
. O 0 1.3947679690318182e-05

We O 0 7.354727131314576e-06
report O 0 3.1678939649282256e-06
here O 0 7.999246065537591e-08
the O 0 2.472814664145062e-08
identification O 0 3.114385549451981e-08
of O 0 5.04367347886614e-09
a O 0 7.214045893988441e-08
unique O 0 1.0148840345891585e-07
de O 0 7.850346719351364e-07
novo O 0 2.16262287722202e-06
L1 O 0 3.907993595930748e-05
insertion O 0 1.4063839444133919e-06
in O 0 4.425032784638461e-08
the O 0 2.482687762039859e-07
muscle O 0 0.0005811745068058372
exon O 0 0.00010487937834113836
1 O 0 5.814155429106904e-06
in O 0 3.516802280500997e-06
DMD O 1 0.9961515069007874
in O 0 7.357256208706531e-07
three O 0 7.508938779210439e-06
XLDCM B-Disease 1 0.9904738068580627
patients O 0 0.009394267573952675
from O 0 5.093419872537197e-07
two O 0 4.78622609989543e-07
unrelated O 0 0.00023375039745587856
Japanese O 0 0.00031227865838445723
families O 0 4.8870690079638734e-05
. O 0 3.835966708720662e-05

The O 0 3.4310537557757925e-06
insertion O 0 1.7018710423144512e-05
was O 0 8.155731165970792e-07
a O 0 6.387488156178733e-07
5 O 0 6.136374850029824e-06
- O 0 6.504081829916686e-05
truncated O 0 3.839021246676566e-06
form O 0 4.1760060298656754e-08
of O 0 1.636539437299689e-08
human O 0 3.2430847340947366e-07
L1 O 0 8.854465704644099e-05
inversely O 0 7.767905572109157e-07
integrated O 0 4.970986537955469e-07
in O 0 2.0847430448611703e-08
the O 0 4.4332612247899306e-08
5 O 0 1.8036876099358778e-06
- O 0 7.983348041307181e-05
untranslated O 0 3.6171139072394e-05
region O 0 1.8344816510307282e-07
in O 0 2.1770711455815217e-08
the O 0 1.1892204554442287e-07
muscle O 0 0.000995144248008728
exon O 0 0.00011107179307145998
1 O 0 1.440108803762996e-06
, O 0 1.099509248092545e-07
which O 0 2.4938593412571208e-08
affected O 0 1.437867496179024e-07
the O 0 7.89280463209252e-09
transcription O 0 3.881975203512411e-07
or O 0 3.587494745715958e-08
the O 0 1.0515808668287718e-08
stability O 0 1.998654965973401e-07
of O 0 1.4784873769713158e-08
the O 0 2.296255559031124e-07
muscle O 0 0.0003920974850188941
form O 0 2.2633389562543016e-07
of O 0 1.3423762368347525e-07
dystrophin O 0 0.041019659489393234
transcripts O 0 3.7018792227172526e-06
but O 0 2.3110796831815605e-08
not O 0 2.1804902328170783e-09
that O 0 2.1562627239291032e-09
of O 0 1.6052135620725494e-08
the O 0 1.5057432847243035e-06
brain O 0 0.05876501649618149
or O 0 1.2114416676922701e-05
Purkinje O 1 0.5195488333702087
cell O 0 0.0003388425975572318
form O 0 6.763656074326718e-06
, O 0 5.667988602908736e-07
probably O 0 8.945511353886104e-07
due O 0 1.4645277701674786e-07
to O 0 5.0745128099549675e-09
its O 0 1.0681001860746164e-08
unique O 0 6.027986643175609e-08
site O 0 2.589200960301241e-07
of O 0 1.3503728268915438e-07
integration O 0 3.114138962700963e-05
. O 0 1.661479655012954e-05

We O 0 3.907409336534329e-06
speculate O 0 6.579060482181376e-06
that O 0 3.079287935747743e-08
this O 0 9.699727243628331e-09
insertion O 0 2.292763241484863e-07
of O 0 1.0965266028506448e-08
an O 0 6.44149196205035e-08
L1 O 0 0.0005308734253048897
sequence O 0 2.598197170300409e-06
in O 0 1.3723982192459516e-05
DMD O 1 0.9989755153656006
is O 0 2.4838911372171424e-07
responsible O 0 1.5272208031547052e-07
for O 0 9.783599708157453e-09
some O 0 2.2508694907941162e-09
of O 0 4.0186289851362744e-09
the O 0 3.4554272332343317e-08
population O 0 8.041345012088641e-08
of O 0 3.09609049509163e-07
Japanese O 0 0.0027062147855758667
patients O 0 0.09980853646993637
with O 0 3.79583980247844e-05
XLDCM B-Disease 1 0.934050440788269
. O 0 1.4787385225645266e-05
. O 0 2.6118881578440778e-05

Severe O 1 0.9887987971305847
early O 1 0.7032886743545532
- O 1 0.9970224499702454
onset O 1 0.999380350112915
obesity B-Disease 1 0.999430239200592
, O 1 0.7340292930603027
adrenal B-Disease 1 0.9989932179450989
insufficiency I-Disease 1 0.999241828918457
and O 0 0.011993951164186
red O 1 0.9955272078514099
hair O 1 0.997557520866394
pigmentation O 1 0.9963706731796265
caused O 1 0.511888861656189
by O 0 0.00043727518641389906
POMC O 1 0.9941593408584595
mutations O 0 0.002026753732934594
in O 0 1.7596179532120004e-05
humans O 0 0.0002145519683836028
. O 0 5.641437746817246e-05

Sequential O 0 2.3813885491108522e-05
cleavage O 0 5.299263648339547e-05
of O 0 1.7741247404501337e-07
the O 0 1.8355737552155915e-07
precursor O 0 4.021183485747315e-06
protein O 0 1.136680680247082e-06
pre O 0 0.00013731875515077263
- O 0 0.0006336149526759982
pro O 0 0.0001931288279592991
- O 0 0.000548067968338728
opiomelanocortin O 0 0.00069612474180758
( O 0 4.842321231990354e-06
POMC O 0 0.0016664505237713456
) O 0 1.0703418240609608e-07
generates O 0 2.677205941381544e-07
the O 0 2.403904488801345e-07
melanocortin O 0 0.0007101655937731266
peptides O 0 1.4922306945663877e-05
adrenocorticotrophin O 0 0.001342311268672347
( O 0 4.5561396291304845e-06
ACTH O 0 0.0005881842225790024
) O 0 5.902477369090775e-07
, O 0 6.12220105722372e-07
melanocyte O 0 0.016939615830779076
- O 0 0.0004753295797854662
stimulating O 0 0.00016973621677607298
hormones O 0 6.216326437424868e-05
( O 0 7.865695806685835e-06
MSH O 0 0.10143496841192245
) O 0 1.5814282505743904e-07
alpha O 0 2.2373029651134857e-07
, O 0 1.882083289217462e-08
beta O 0 3.4672387982936925e-07
and O 0 9.889358665304826e-09
gamma O 0 2.9153150649108284e-07
as O 0 2.3855410979933822e-09
well O 0 2.4367383666401565e-09
as O 0 5.01870411895311e-09
the O 0 4.787824181562428e-08
opioid O 0 0.00036696402821689844
- O 0 0.00010544786346144974
receptor O 0 1.871258791652508e-05
ligand O 0 3.286057471996173e-05
beta O 0 0.0007673018844798207
- O 0 0.009607955813407898
endorphin O 0 0.1056203618645668
. O 0 2.07117209356511e-05

While O 0 6.757582468708279e-06
a O 0 2.652999228303088e-06
few O 0 2.2425033421313856e-06
cases O 0 8.662627806188539e-06
of O 0 1.403090118401451e-05
isolated O 1 0.9229757189750671
ACTH B-Disease 1 0.9985989928245544
deficiency I-Disease 1 0.9993159770965576
have O 0 1.2888375522379647e-06
been O 0 1.2272786307221395e-06
reported O 0 5.512721691047773e-05
( O 0 8.609288488514721e-05
OMIM O 1 0.9329617619514465
201400 O 0 0.003097357926890254
) O 0 2.0060153929080116e-06
, O 0 9.431714715901762e-07
an O 0 4.0211289160652086e-05
inherited O 1 0.9971153736114502
POMC O 1 0.9992325305938721
defect O 1 0.9971502423286438
has O 0 7.949864084366709e-06
not O 0 1.9456014399565902e-07
been O 0 2.646237646786176e-07
described O 0 8.714175237400923e-06
so O 0 6.462128681050672e-07
far O 0 3.8570874494325835e-06
. O 0 1.3093974303046707e-05

Recent O 0 3.585886588552967e-05
studies O 0 4.8247361519315746e-06
in O 0 5.898453991903807e-07
animal O 0 8.212439752242062e-06
models O 0 2.7921328182856087e-06
elucidated O 0 9.46462660067482e-06
a O 0 1.0678723327828266e-07
central O 0 8.099700465891146e-08
role O 0 7.009278135683417e-08
of O 0 5.712934125767788e-08
alpha O 0 5.1475777581799775e-05
- O 0 0.006796753033995628
MSH O 0 0.34751567244529724
in O 0 1.5009856468850558e-08
the O 0 6.857583390029731e-09
regulation O 0 1.4674847648166178e-07
of O 0 1.6925774559695128e-08
food O 0 8.917428999666299e-07
intake O 0 8.281455734504561e-07
by O 0 1.1010745204487193e-08
activation O 0 3.2733589705458144e-07
of O 0 2.5948855508772795e-08
the O 0 6.555196705448907e-07
brain O 0 0.002818700158968568
melanocortin O 0 0.013404939323663712
- O 0 0.00011713002459146082
4 O 0 4.8826650527189486e-06
- O 0 7.845838263165206e-05
receptor O 0 1.4419791114050895e-05
( O 0 3.5963885238743387e-06
MC4 O 0 0.04273653402924538
- O 0 0.00014917990483809263
R O 0 0.00031380666769109666
; O 0 4.208927748550195e-07
refs O 0 9.445573596167378e-06
3 O 0 4.905235755359172e-07
- O 0 5.689207227987936e-06
5 O 0 8.958507891065892e-08
) O 0 9.78535474871478e-09
and O 0 2.757633676964133e-09
the O 0 6.690428211442168e-09
linkage O 0 1.2569578302645823e-06
of O 0 1.7049489997589262e-07
human O 0 7.407723023789003e-05
obesity B-Disease 1 0.9891506433486938
to O 0 8.62695515024825e-08
chromosome O 0 2.9872958293708507e-06
2 O 0 1.4828005134859268e-07
in O 0 8.508606264001628e-09
close O 0 3.062068643089333e-08
proximity O 0 6.673275976254445e-08
to O 0 1.3239104035278615e-08
the O 0 1.6603853225660714e-07
POMC O 0 0.03806210681796074
locus O 0 3.0151879855111474e-06
, O 0 4.2280451140186415e-08
led O 0 5.637208033704155e-08
to O 0 4.235081174641664e-09
the O 0 6.460573409583503e-09
proposal O 0 1.355169558792113e-07
of O 0 1.0346202117261782e-08
an O 0 1.8007193602898042e-07
association O 0 1.5426643585669808e-05
of O 0 2.167683987863711e-06
POMC O 1 0.9800851941108704
with O 0 0.0002058866375591606
human O 0 0.012998692691326141
obesity B-Disease 1 0.9966912269592285
. O 0 0.00041412049904465675

The O 0 2.3072143449098803e-06
dual O 0 5.329396117303986e-06
role O 0 1.2582783028847189e-06
of O 0 6.127481810835889e-07
alpha O 0 0.0003256096097175032
- O 0 0.09524630010128021
MSH O 1 0.8744505643844604
in O 0 5.380358629736293e-07
regulating O 0 2.7593101549427956e-05
food O 0 1.3727594705414958e-05
intake O 0 3.615210152929649e-05
and O 0 1.2386442449496826e-06
influencing O 0 0.0003248192952014506
hair O 1 0.938096284866333
pigmentation O 1 0.6355964541435242
predicts O 0 0.001160031883046031
that O 0 1.5291460897515208e-07
the O 0 6.885318271088181e-07
phenotype O 0 0.0006135221337899566
associated O 0 2.7689306989486795e-06
with O 0 6.898727065163257e-07
a O 0 3.9688402466708794e-05
defect O 1 0.5983021855354309
in O 0 2.182898242608644e-05
POMC O 1 0.9793756604194641
function O 0 9.168289579974953e-06
would O 0 3.408712700547767e-06
include O 0 0.00032752371043898165
obesity B-Disease 1 0.9988130331039429
, O 0 1.7220205336343497e-05
alteration O 0 0.005375131964683533
in O 0 0.0001229475747095421
pigmentation O 1 0.9921191930770874
and O 0 0.011423340998589993
ACTH B-Disease 1 0.9958095550537109
deficiency I-Disease 1 0.9980100989341736
. O 0 0.00042237393790856004

The O 0 3.73516081708658e-06
observation O 0 1.3290676179167349e-05
of O 0 8.018116091079719e-07
these O 0 7.404793905152474e-06
symptoms O 1 0.7957143187522888
in O 0 8.013644219317939e-07
two O 0 1.1052743502659723e-06
probands O 0 0.1468711793422699
prompted O 0 6.64065228193067e-05
us O 0 7.415002301058848e-07
to O 0 1.174751051991052e-08
search O 0 8.002878360002796e-08
for O 0 5.636788813490057e-08
mutations O 0 1.110430275730323e-06
within O 0 1.003293803591987e-07
their O 0 6.916777124388318e-07
POMC O 1 0.6372575759887695
genes O 0 4.139918746659532e-05
. O 0 2.573583878984209e-05

Patient O 0 0.022704578936100006
1 O 0 2.8011425456497818e-05
was O 0 9.622555126043153e-07
found O 0 1.0759665514115113e-07
to O 0 1.5022715516010976e-08
be O 0 5.4231499291290675e-09
a O 0 5.502401378976174e-08
compound O 0 2.0959159883204848e-06
heterozygote O 0 6.607532213820377e-06
for O 0 8.696603437385875e-09
two O 0 9.963633473830669e-09
mutations O 0 3.5258526054349204e-07
in O 0 4.502928874217105e-08
exon O 0 2.3308259187615477e-05
3 O 0 1.2156601769675035e-06
( O 0 2.2178212475409964e-06
G7013T O 0 0.00010287928307661787
, O 0 3.6759479371539783e-07
C7133delta O 0 7.132108294172212e-05
) O 0 4.550371457412439e-08
which O 0 3.963486427949192e-09
interfere O 0 2.7632268029265106e-08
with O 0 3.154426719831349e-09
appropriate O 0 1.2908910385078798e-08
synthesis O 0 1.2626703949081275e-07
of O 0 1.1026322255247578e-07
ACTH O 0 0.001088130404241383
and O 0 2.3358429643849377e-06
alpha O 0 0.0002783179224934429
- O 0 0.09180722385644913
MSH O 1 0.9518516659736633
. O 0 3.720039967447519e-05

Patient O 0 0.006191962398588657
2 O 0 1.62236210599076e-05
was O 0 1.2026883950966294e-06
homozygous O 0 1.1457279924798058e-06
for O 0 3.502131917798579e-08
a O 0 1.3887891725516965e-07
mutation O 0 1.3871864439352066e-06
in O 0 1.200570238779619e-07
exon O 0 5.688165401807055e-05
2 O 0 6.200554253155133e-06
( O 0 6.095546723372536e-06
C3804A O 0 8.992433868115768e-05
) O 0 5.566066647588741e-07
which O 0 5.364798312257335e-07
abolishes O 0 0.0017660425510257483
POMC O 0 0.29087716341018677
translation O 0 3.056110654142685e-05
. O 0 2.0219329599058256e-05

These O 0 2.0743034383485792e-06
findings O 0 3.029342678928515e-06
represent O 0 1.0057424049136898e-07
the O 0 2.7192353257987634e-08
first O 0 2.6320062573859104e-08
examples O 0 1.588593221413248e-07
of O 0 8.286276909075241e-08
a O 0 5.90361887589097e-05
genetic B-Disease 0 0.4507181644439697
defect I-Disease 1 0.705133318901062
within O 0 7.569560693809763e-07
the O 0 4.250647634762572e-06
POMC O 1 0.8181687593460083
gene O 0 3.8143878100527218e-06
and O 0 1.5256415508702048e-07
define O 0 8.542303476133384e-06
a O 0 2.8601882149814628e-05
new O 0 0.006619012448936701
monogenic B-Disease 1 0.9985563158988953
endocrine I-Disease 1 0.9993346333503723
disorder I-Disease 1 0.9994503855705261
resulting O 0 0.011508344672620296
in O 0 0.00030743161914870143
early O 0 0.2180669903755188
- O 1 0.9990031123161316
onset O 1 0.9995668530464172
obesity B-Disease 1 0.9995918869972229
, O 0 0.25827497243881226
adrenal B-Disease 1 0.9987491369247437
insufficiency I-Disease 1 0.9986975193023682
and O 0 0.004443463869392872
red O 1 0.9914987683296204
hair O 1 0.9966488480567932
pigmentation O 1 0.9884036183357239
. O 0 5.4284038924379274e-05
. O 0 6.364205910358578e-05

A O 0 5.830816735397093e-05
European O 0 9.594071161700413e-05
multicenter O 0 0.08936088532209396
study O 0 3.7212957977317274e-05
of O 0 6.290227611316368e-05
phenylalanine B-Disease 1 0.9961245656013489
hydroxylase I-Disease 1 0.998487114906311
deficiency I-Disease 1 0.9998006224632263
: O 0 0.00015175073349382728
classification O 0 0.00017406600818503648
of O 0 1.6388109713716403e-07
105 O 0 9.372183740197215e-06
mutations O 0 2.12789086617704e-06
and O 0 1.770301061299051e-08
a O 0 8.513870142223823e-08
general O 0 3.594995519051736e-07
system O 0 9.62841227192257e-07
for O 0 2.939303556104278e-07
genotype O 0 0.000161352741997689
- O 0 0.00013302950537763536
based O 0 1.0664958836059668e-06
prediction O 0 5.719647742807865e-05
of O 0 3.399013166927034e-06
metabolic O 1 0.8971008658409119
phenotype O 0 0.13788750767707825
. O 0 8.646574860904366e-05

Phenylketonuria B-Disease 1 0.9874542951583862
( O 0 0.01751728542149067
PKU B-Disease 1 0.994330883026123
) O 0 0.00022163160610944033
and O 0 0.00025113363517448306
mild B-Disease 1 0.9970723390579224
hyperphenylalaninemia I-Disease 1 0.9971342086791992
( O 0 0.033062174916267395
MHP B-Disease 1 0.9982976317405701
) O 0 8.709557732800022e-05
are O 0 2.657168442965485e-05
allelic B-Disease 1 0.997718095779419
disorders I-Disease 1 0.9997819066047668
caused O 0 0.17283599078655243
by O 0 1.5634736882930156e-06
mutations O 0 6.205226782185491e-06
in O 0 6.205660696423365e-08
the O 0 6.214473557974998e-08
gene O 0 1.7566117094247602e-06
encoding O 0 7.0998771661834326e-06
phenylalanine O 0 0.0023792656138539314
hydroxylase O 0 0.07415758818387985
( O 0 0.0029105613939464092
PAH O 1 0.9967042803764343
) O 0 3.573645153664984e-05
. O 0 1.7162201402243227e-05

Previous O 0 4.716968396678567e-05
studies O 0 5.9873882491956465e-06
have O 0 3.1245721743289323e-07
suggested O 0 8.831720492707973e-07
that O 0 3.109215640506591e-08
the O 0 1.296052687393967e-07
highly O 0 7.024480510153808e-06
variable O 0 0.00012229185085743666
metabolic O 1 0.8565104007720947
phenotypes O 1 0.6509829759597778
of O 0 0.20988574624061584
PAH B-Disease 1 0.9997808337211609
deficiency I-Disease 1 0.9996218681335449
correlate O 0 0.2644493281841278
with O 0 0.06237475946545601
PAH O 1 0.9986695051193237
genotypes O 1 0.6788205504417419
. O 0 0.00020679419685620815

We O 0 5.643227723339805e-06
identified O 0 3.930660113837803e-06
both O 0 1.4804380725763622e-06
causative O 0 0.0011051185429096222
mutations O 0 0.00036117591662332416
in O 0 6.775680958526209e-05
686 O 1 0.9867308139801025
patients O 0 0.14916421473026276
from O 0 1.9993956357211573e-06
seven O 0 7.631326297996566e-06
European O 0 3.699270382639952e-05
centers O 0 6.578649481525645e-05
. O 0 3.2802217901917174e-05

On O 0 3.870028137953341e-07
the O 0 4.4866482085126336e-08
basis O 0 1.3593109748910592e-08
of O 0 1.0836855857121463e-08
the O 0 5.290447191441672e-08
phenotypic O 0 2.0337502064649016e-06
characteristics O 0 1.1951660781051032e-06
of O 0 5.685041060132789e-07
297 O 0 0.019155221059918404
functionally O 0 0.37405240535736084
hemizygous O 1 0.9949122667312622
patients O 0 0.019887465983629227
, O 0 1.3025181999637425e-07
105 O 0 3.3615566508160555e-07
of O 0 1.4514680124477763e-08
the O 0 5.3458609983181304e-08
mutations O 0 2.9938533430140524e-07
were O 0 1.7644714578324283e-09
assigned O 0 1.1721055237501332e-08
to O 0 1.070479704878835e-09
one O 0 1.0911537229318924e-09
of O 0 3.6230993760710817e-09
four O 0 5.584938378433435e-08
arbitrary O 0 1.9335889192007016e-06
phenotype O 0 0.0013387614162638783
categories O 0 5.451519973576069e-05
. O 0 2.6960737159242854e-05

We O 0 3.3094700029323576e-06
proposed O 0 6.743425728927832e-06
and O 0 4.382891347631812e-07
tested O 0 2.829337518051034e-06
a O 0 1.4616561827551777e-07
simple O 0 2.8141769803369243e-07
model O 0 5.694623723684344e-07
for O 0 8.894813419146885e-08
correlation O 0 1.173382656816102e-06
between O 0 9.32123612074065e-07
genotype O 0 0.0001039471389958635
and O 0 8.571416856284486e-07
phenotypic O 0 6.369282345985994e-05
outcome O 0 6.34885800536722e-05
. O 0 5.3926731197861955e-05

The O 0 7.21114838597714e-06
observed O 0 1.9358367353561334e-05
phenotype O 0 0.00032953641493804753
matched O 0 1.4978323633840773e-05
the O 0 1.3418633670880808e-06
predicted O 0 0.00031005541677586734
phenotype O 0 0.00018547670333646238
in O 0 3.0509781367982214e-07
79 O 0 1.2937625797349028e-05
% O 0 3.780955637466832e-08
of O 0 1.0944267714307898e-08
the O 0 1.1591887982831395e-07
cases O 0 9.924968935592915e-07
, O 0 1.9254811078894818e-08
and O 0 5.6121653990715e-09
in O 0 3.583492391712184e-09
only O 0 1.4693640748575376e-09
5 O 0 3.507413026682116e-08
of O 0 4.251521090736787e-08
184 O 0 0.0005547606269828975
patients O 0 0.0006227092817425728
was O 0 6.265807428462722e-08
the O 0 3.7579198419734894e-08
observed O 0 4.011494638689328e-07
phenotype O 0 3.4557779144961387e-06
more O 0 3.3083025208213712e-09
than O 0 4.68102578921048e-09
one O 0 1.1566595681244962e-08
category O 0 5.08110190367006e-07
away O 0 7.277578362163695e-08
from O 0 6.889352022199091e-08
that O 0 1.4349224386478454e-07
expected O 0 5.083494670543587e-06
. O 0 9.11382358026458e-06

Among O 0 2.0920438146276865e-06
the O 0 3.187675758908881e-07
seven O 0 1.4786672863920103e-06
contributing O 0 2.916498669947032e-05
centers O 0 2.9723369152634405e-06
, O 0 7.54613722619979e-08
the O 0 5.907134692506588e-08
proportion O 0 3.655532282209606e-06
of O 0 8.060506502260978e-07
patients O 0 0.009926211088895798
for O 0 2.1807831274145428e-07
whom O 0 1.675526846156572e-06
the O 0 2.284279787545529e-07
observed O 0 3.864197424263693e-06
phenotype O 0 0.000141547730891034
did O 0 4.8569546606813674e-08
not O 0 3.828317662879499e-09
match O 0 6.596877000220047e-08
the O 0 6.200833979619347e-08
predicted O 0 8.916264050640166e-06
phenotype O 0 4.388899014884373e-06
was O 0 2.687924194333391e-08
4 O 0 9.30322840986264e-08
% O 0 8.352923686061331e-08
- O 0 4.537589575193124e-06
23 O 0 2.6821328447113046e-07
% O 0 1.2896830980935192e-07
( O 0 1.3476150115820928e-06
P O 0 0.0010826142970472574
< O 0 0.0009272625320591033
. O 0 5.951216621724598e-07
0001 O 0 0.0005832259776070714
) O 0 2.1704484254314593e-07
, O 0 6.072854574767916e-08
suggesting O 0 4.876541197518236e-07
that O 0 8.839336373966944e-09
differences O 0 7.561870773997725e-08
in O 0 5.598523422634116e-09
methods O 0 2.0905126518755424e-08
used O 0 2.0470032779940084e-08
for O 0 1.0014526452550854e-07
mutation O 0 2.3596636310685426e-05
detection O 0 0.0002190101658925414
or O 0 2.1146173821762204e-05
phenotype O 0 0.04662620648741722
classification O 0 0.0018668115371838212
may O 0 5.645266583087505e-07
account O 0 3.5275803611511947e-08
for O 0 7.54088169685474e-09
a O 0 1.357606578267223e-07
considerable O 0 1.6109112266349257e-06
proportion O 0 3.168377361362218e-06
of O 0 1.50898483752826e-06
genotype O 0 0.018590088933706284
- O 0 0.2134159952402115
phenotype O 0 0.014516329392790794
inconsistencies O 0 0.0012101606698706746
. O 0 5.4909636673983186e-05

Our O 0 3.658423565866542e-06
data O 0 2.2919637103768764e-06
indicate O 0 4.424190592544619e-06
that O 0 9.952029813575791e-07
the O 0 7.974202890181914e-05
PAH O 1 0.9991409778594971
- O 0 0.00867275521159172
mutation O 0 1.0871078302443493e-05
genotype O 0 4.592262939695502e-06
is O 0 8.758127556518502e-09
the O 0 8.573753262908212e-09
main O 0 2.1834301833223435e-07
determinant O 0 7.223818556667538e-06
of O 0 1.3066827477814513e-06
metabolic O 1 0.920922040939331
phenotype O 0 0.0637945830821991
in O 0 3.0275545213953592e-05
most O 0 0.0003016884147655219
patients O 1 0.9951889514923096
with O 1 0.9512471556663513
PAH B-Disease 1 0.9995417594909668
deficiency I-Disease 1 0.9989558458328247
. O 0 0.0011611328227445483

In O 0 1.770086782926228e-06
the O 0 5.149568664819526e-07
present O 0 8.180869031093607e-07
study O 0 6.863323847028369e-07
, O 0 1.0811402972876749e-07
the O 0 1.0060685440294037e-07
classification O 0 5.898700328543782e-05
of O 0 2.9075201837258646e-06
105 O 0 0.057087719440460205
PAH O 1 0.9995558857917786
mutations O 0 5.7700159231899306e-05
may O 0 1.7131603158304642e-07
allow O 0 8.188735911573986e-09
the O 0 1.0908713043988882e-08
prediction O 0 4.4900986040374846e-07
of O 0 4.097154615578802e-09
the O 0 4.024437672001113e-08
biochemical O 0 2.5470095351920463e-05
phenotype O 0 4.918135527987033e-05
in O 0 2.0646925236178504e-07
> O 0 0.00012390133633743972
10 O 0 2.5601244146855606e-07
, O 0 1.8115052569100953e-07
000 O 0 5.34101718585589e-06
genotypes O 0 0.00013643293641507626
, O 0 9.692074343092827e-08
which O 0 3.399047088237239e-08
may O 0 8.32116811011474e-08
be O 0 1.2395111603780151e-09
useful O 0 1.081562750471221e-08
for O 0 1.4155128624793178e-08
the O 0 1.0957283080870184e-07
management O 0 1.3242736713436898e-05
of O 0 1.2729879017570056e-06
hyperphenylalaninemia B-Disease 1 0.9053301215171814
in O 0 5.5900913139339536e-05
newborns O 0 0.2614470422267914
. O 0 6.782799027860165e-05

Somatic O 0 0.0005837209173478186
instability O 0 0.00020752660930156708
of O 0 7.421355121550732e-07
the O 0 5.684060397470603e-06
CTG O 0 0.1692223846912384
repeat O 0 0.0011125910095870495
in O 0 3.8272396523097996e-06
mice O 0 0.0006843663286417723
transgenic O 0 0.0003150020493194461
for O 0 2.4346771169803105e-05
the O 0 0.007480707950890064
myotonic B-Disease 1 0.9997462630271912
dystrophy I-Disease 1 0.999825656414032
region O 0 0.0029155751690268517
is O 0 8.690322829352226e-06
age O 0 7.45894358260557e-05
dependent O 0 3.2963855574053014e-06
but O 0 5.6646275226057696e-08
not O 0 1.0023121888025344e-08
correlated O 0 2.9950498969810724e-07
to O 0 1.3506428864218378e-08
the O 0 2.960729084122704e-08
relative O 0 2.1886346530664014e-06
intertissue O 0 0.0003913603432010859
transcription O 0 5.7615048717707396e-05
levels O 0 6.491391832241789e-05
and O 0 1.1597461707424372e-05
proliferative O 1 0.9880250096321106
capacities O 0 0.0007879854529164732
. O 0 4.0238061046693474e-05

A O 0 5.393856190494262e-05
( O 0 4.426346640684642e-05
CTG O 0 0.0029158771503716707
) O 0 2.7028852400690084e-06
nexpansion O 0 7.327880302909762e-05
in O 0 7.630691811755241e-08
the O 0 2.254514868127444e-07
3 O 0 6.970601134526078e-06
- O 0 0.00027590314857661724
untranslated O 0 0.0001387286902172491
region O 0 1.0280558626618586e-06
( O 0 2.6820740117727837e-07
UTR O 0 1.5758829249534756e-05
) O 0 2.56352450378472e-08
of O 0 1.0278854212231181e-08
the O 0 3.732525613031612e-07
DM O 1 0.9527333974838257
protein O 0 2.1006385395594407e-06
kinase O 0 2.9679733415832743e-05
gene O 0 4.5451251935446635e-06
( O 0 2.360856115046772e-06
DMPK O 0 0.0012874457752332091
) O 0 3.137555495413835e-07
is O 0 1.71482113842103e-07
responsible O 0 5.420730303740129e-06
for O 0 6.379446131177247e-05
causing O 1 0.9904316067695618
myotonic B-Disease 1 0.9994171857833862
dystrophy I-Disease 1 0.9995597004890442
( O 1 0.9298545122146606
DM B-Disease 1 0.998794436454773
) O 0 0.00046955954167060554
. O 0 8.792590233497322e-05

Major O 0 0.0018778961384668946
instability O 0 0.023790616542100906
, O 0 1.93689425032062e-06
with O 0 5.43862768154213e-07
very O 0 2.7965356252934725e-07
large O 0 1.1425941011111718e-06
expansions O 0 9.700979717308655e-06
between O 0 2.787551522942522e-07
generations O 0 2.532309054004145e-06
and O 0 1.5850973511533084e-07
high O 0 1.7874917830340564e-06
levels O 0 8.207877044696943e-07
of O 0 1.557436206667262e-07
somatic O 0 0.0006145799998193979
mosaicism O 0 0.048627860844135284
, O 0 8.519098741999187e-07
is O 0 4.656965870708518e-07
observed O 0 4.189443643554114e-06
in O 0 1.405758121109102e-05
patients O 0 0.08321451395750046
. O 0 8.710854308446869e-05

There O 0 2.468699449309497e-06
is O 0 3.5985766544399667e-07
a O 0 2.5011721049850166e-07
good O 0 3.14617864205502e-07
correlation O 0 4.812874863091565e-07
between O 0 6.063098680897383e-07
repeat O 0 0.0001481407234678045
size O 0 4.115086539968615e-06
( O 0 1.8459256523328804e-07
at O 0 5.2424429242137194e-08
least O 0 4.9025608461761294e-08
in O 0 1.68595363447821e-07
leucocytes O 0 0.004522824659943581
) O 0 4.108420853299322e-06
, O 0 7.105289569153683e-06
clinical O 0 0.013730097562074661
severity O 0 0.06793637573719025
and O 0 1.313700067839818e-06
age O 0 7.342065509874374e-05
of O 0 1.763108593877405e-05
onset O 1 0.9953548908233643
. O 0 0.00037274087662808597

The O 0 0.00028383111930452287
trinucleotide O 1 0.9768046736717224
repeat O 0 0.13392938673496246
instability O 0 0.017545126378536224
mechanisms O 0 7.131815073080361e-05
involved O 0 4.382960105431266e-05
in O 0 0.00031955132726579905
DM B-Disease 1 0.999312162399292
and O 0 3.315463618491776e-05
other O 0 4.2878975364146754e-05
human O 0 0.40936124324798584
genetic B-Disease 1 0.9991117119789124
diseases I-Disease 1 0.9996771812438965
are O 0 7.55947894504061e-06
unknown O 0 0.00011547958274604753
. O 0 8.858166256686673e-05

We O 0 4.608979452314088e-06
studied O 0 1.0981907507812139e-05
somatic O 0 0.00018790666945278645
instability O 0 0.0002504879666958004
by O 0 3.915830006917531e-07
measuring O 0 3.202252264600247e-05
the O 0 1.9047138266614638e-06
CTG O 0 0.059161558747291565
repeat O 0 9.968286758521572e-05
length O 0 1.561578187647683e-06
at O 0 1.3599493797755713e-07
several O 0 2.400247645084619e-08
ages O 0 9.79285118773987e-07
in O 0 1.426032802953614e-08
various O 0 2.6331010261060328e-08
tissues O 0 2.0996330931666307e-06
of O 0 4.816740784008289e-08
transgenic O 0 5.607090497505851e-05
mice O 0 1.2236590919201262e-05
carrying O 0 1.2741377020120126e-07
a O 0 3.285553020759835e-07
( O 0 2.002002020162763e-06
CTG O 0 0.0016057159518823028
) O 0 6.367794185280218e-07
55expansion O 0 3.3427604648750275e-05
surrounded O 0 7.006437385825848e-07
by O 0 2.3361957701695246e-08
45 O 0 1.8614450425502582e-07
kb O 0 6.466699687734945e-06
of O 0 3.6526113689205886e-08
the O 0 6.976612780817959e-07
human O 0 7.221101259347051e-05
DM B-Disease 1 0.998934805393219
region O 0 2.1428015770652564e-06
, O 0 5.986760243104072e-08
using O 0 9.808416479017978e-08
small O 0 1.7172003481391585e-06
- O 0 0.0005612976965494454
pool O 0 0.0002219035231973976
PCR O 0 0.00020914374908898026
. O 0 1.4943297173886094e-05

These O 0 3.750534597202204e-05
mice O 0 0.001320436829701066
have O 0 2.648666566074098e-07
been O 0 7.271944468811853e-08
shown O 0 1.2618036748790473e-07
to O 0 4.607190007277495e-08
reproduce O 0 1.8658686258277157e-06
the O 0 1.1693526857925463e-07
intergenerational O 0 6.360080442391336e-05
and O 0 1.6174739414509531e-07
somatic O 0 9.471507837588433e-06
instability O 0 8.373575838049874e-06
of O 0 1.9110764526431012e-08
the O 0 2.0093689556688332e-07
55 O 0 3.301521064713597e-05
CTG O 0 0.18519428372383118
repeat O 0 0.00032116423244588077
suggesting O 0 3.1466818199987756e-06
that O 0 1.38176554642655e-08
surrounding O 0 1.3711073165723064e-07
sequences O 0 7.570486104668817e-08
and O 0 2.826424960744589e-08
the O 0 1.1055931281589437e-07
chromatin O 0 7.468687545042485e-05
environment O 0 2.8255221877770964e-06
are O 0 2.8549841601943626e-08
involved O 0 6.555584945999726e-07
in O 0 1.6466896113342955e-06
instability O 0 0.003583083162084222
mechanisms O 0 0.00017036129429470748
. O 0 6.269178993534297e-05

As O 0 2.120393446602975e-06
observed O 0 5.216857630330196e-07
in O 0 3.2819951201190634e-08
some O 0 8.51008330471359e-09
of O 0 2.2278106470707826e-08
the O 0 1.9543078906281153e-06
tissues O 0 0.005478487350046635
of O 0 0.0015803280984982848
DM B-Disease 1 0.9999010562896729
patients O 1 0.8755507469177246
, O 0 1.0063206445920514e-06
there O 0 9.303334991273005e-08
is O 0 4.922621954506212e-08
a O 0 2.733922315201198e-07
tendency O 0 4.981435722584138e-06
for O 0 7.551896885615861e-08
repeat O 0 3.3436437661293894e-05
length O 0 9.258828299607558e-07
and O 0 1.4598256825593126e-07
somatic O 0 4.2898649553535506e-05
mosaicism O 0 0.00243458547629416
to O 0 2.816227429036644e-08
increase O 0 1.8800494672177592e-07
with O 0 2.438534352222632e-08
the O 0 2.630179629647955e-08
age O 0 5.464352170747588e-07
of O 0 5.534937486117997e-08
the O 0 1.938241439347621e-06
mouse O 0 0.0004599396779667586
. O 0 8.768025509198196e-06

Furthermore O 0 0.00010162042599404231
, O 0 1.2153309398854617e-06
we O 0 1.8445565785896179e-07
observed O 0 1.463977525872906e-07
no O 0 3.978666995863023e-08
correlation O 0 1.4995697483755066e-07
between O 0 5.601527419685226e-08
the O 0 1.5564711475235526e-07
somatic O 0 4.891447315458208e-05
mutation O 0 8.237310976255685e-05
rate O 0 4.71582607133314e-05
and O 0 1.6270290871034376e-05
tissue O 0 0.30443939566612244
proliferation O 0 0.3077976405620575
capacity O 0 9.370836050948128e-05
. O 0 1.963426075235475e-05

The O 0 1.206956039823126e-05
somatic O 0 0.0005639660521410406
mutation O 0 0.00014987270697019994
rates O 0 1.1378138879081234e-05
in O 0 1.128825530827271e-07
different O 0 8.08256928053197e-08
tissues O 0 2.15578456845833e-05
were O 0 1.3498857143190435e-08
also O 0 1.1531900767636216e-08
not O 0 4.006063036854357e-09
correlated O 0 1.2205491373151744e-07
to O 0 2.6659985330468317e-09
the O 0 1.6976988703731877e-08
relative O 0 1.742355152600794e-06
inter O 0 0.0003090163809247315
- O 0 0.006731247995048761
tissue O 0 0.00014695162826683372
difference O 0 3.279730265148828e-07
in O 0 1.6631261701149924e-08
transcriptional O 0 5.149937010173744e-07
levels O 0 4.318719604157195e-08
of O 0 1.5605955416830852e-09
the O 0 3.990992869518095e-09
three O 0 1.3351824534879597e-08
genes O 0 2.411251784906199e-07
( O 0 2.0202437553962227e-06
DMAHP O 0 0.0024988758377730846
, O 0 3.838703150904621e-07
DMPK O 0 0.00042586427298374474
and O 0 1.2330465892773645e-07
59 O 0 3.877648850902915e-06
) O 0 1.7689684739252698e-07
surrounding O 0 6.528445055664633e-07
the O 0 2.838202703969728e-07
repeat O 0 0.000226674135774374
. O 0 2.7003834475181065e-06
. O 0 1.1119402188342065e-05

A O 0 7.864535291446373e-05
novel O 0 0.00017659756122156978
missense O 0 0.005896578077226877
mutation O 0 0.0006673697498627007
in O 0 1.5344752682722174e-05
patients O 0 0.012838352471590042
from O 0 6.468716492236126e-06
a O 0 0.0002301863132743165
retinoblastoma B-Disease 1 0.9939024448394775
pedigree O 0 0.13206087052822113
showing O 0 7.820576138328761e-05
only O 0 1.4648534261141322e-06
mild O 0 0.05858407914638519
expression O 0 1.3136899497112609e-06
of O 0 1.3377591585594928e-06
the O 0 0.00012201369099784642
tumor B-Disease 1 0.9970916509628296
phenotype O 0 0.33658677339553833
. O 0 0.00017030654998961836

We O 0 7.38620656193234e-07
have O 0 5.397210856017409e-08
used O 0 2.3250468217383968e-08
single O 0 4.681340826095948e-08
strand O 0 8.025636475395004e-07
conformation O 0 9.9906753803225e-07
polymorphism O 0 6.860319672341575e-07
analysis O 0 4.914694429203337e-08
to O 0 6.585785250479148e-09
study O 0 2.087400829964281e-08
the O 0 1.0589616294964799e-08
27 O 0 7.750784192239735e-08
exons O 0 1.0701743491381421e-07
of O 0 1.507029878666799e-08
the O 0 6.83449968619243e-07
RB1 O 0 0.29221418499946594
gene O 0 2.758261871349532e-06
in O 0 7.681715175067438e-08
individuals O 0 8.290529507348765e-08
from O 0 1.1465692040246722e-07
a O 0 1.408476464348496e-06
family O 0 2.270030563522596e-05
showing O 0 0.00023236424021888524
mild O 0 0.10507916659116745
expression O 0 1.122836124523019e-06
of O 0 5.74663715724455e-07
the O 0 3.815939635387622e-05
retinoblastoma B-Disease 1 0.989188015460968
phenotype O 0 0.3054806888103485
. O 0 0.00012918241554871202

In O 0 9.84653252089629e-06
this O 0 3.455296791798901e-06
family O 0 0.0001385263167321682
affected O 0 0.0006734125199727714
individuals O 0 6.54886825941503e-05
developed O 0 0.23784862458705902
unilateral B-Disease 1 0.9818218350410461
tumors I-Disease 1 0.999775230884552
and O 0 2.279651653225301e-06
, O 0 3.565210136002861e-07
as O 0 3.107869872565061e-08
a O 0 5.5280899857734767e-08
result O 0 8.909449178418072e-08
of O 0 2.8062862256206245e-08
linkage O 0 4.3146454117959365e-05
analysis O 0 1.9846554550895235e-06
, O 0 2.8315780582488514e-06
unaffected O 0 0.0013608845183625817
mutation O 0 7.469108095392585e-05
carriers O 0 3.124598151771352e-05
were O 0 1.8598369067035492e-08
also O 0 3.579702578804245e-08
identified O 0 7.472418417364679e-08
within O 0 7.780970889825767e-08
the O 0 9.756449799169786e-07
pedigree O 0 0.00328832701779902
. O 0 2.1017183826188557e-05

A O 0 6.153908543637954e-06
single O 0 1.0214591839030618e-06
band O 0 1.613078779882926e-06
shift O 0 1.6697921410013805e-06
using O 0 3.379235238298861e-07
SSCP O 0 0.0011125209275633097
was O 0 2.2291224865966797e-07
identified O 0 2.5089769906117e-07
in O 0 7.34128988710836e-08
exon O 0 2.422892430331558e-05
21 O 0 3.4404007465127506e-07
which O 0 1.744630928612878e-08
resulted O 0 1.4851214302780136e-07
in O 0 1.0856840759743136e-08
a O 0 5.752373510858888e-08
missense O 0 4.354013526608469e-06
mutation O 0 4.1614961787672655e-07
converting O 0 2.4579514956712956e-07
a O 0 2.533601445975364e-06
cys O 0 0.39749887585639954
- O 0 0.0025781942531466484
- O 0 0.0003954999556299299
> O 0 0.00010548377031227574
arg O 0 1.0781297532957979e-05
at O 0 2.1428448349070095e-08
nucleotide O 0 7.335201956948367e-08
position O 0 4.047948465313311e-08
28 O 0 1.2224805345795176e-07
in O 0 4.8494012361288696e-08
the O 0 3.608694498780096e-07
exon O 0 0.00021755232592113316
. O 0 1.0385971108917147e-05

The O 0 9.345622856926639e-06
mutation O 0 9.736057108966634e-05
destroyed O 0 4.294498648960143e-05
an O 0 2.3043160126690054e-06
NdeI O 0 0.0041006519459187984
restriction O 0 3.262875179643743e-05
enzyme O 0 8.997022086987272e-05
site O 0 2.893297642003745e-05
. O 0 1.6391863027820364e-05

Analysis O 0 4.302746219764231e-06
of O 0 3.1277414791475167e-07
all O 0 2.1938622296602261e-07
family O 0 1.5438872651429847e-06
members O 0 3.770131939972998e-08
demonstrated O 0 1.5490610394408577e-07
that O 0 1.1966215573977479e-08
the O 0 9.267860434647446e-08
missense O 0 0.00018785921565722674
mutation O 0 7.242956053232774e-05
co O 0 0.0021914460230618715
- O 0 0.044899363070726395
segregated O 0 0.0034363199956715107
with O 0 0.0012657700572162867
patients O 1 0.9957269430160522
with O 0 0.05225173383951187
tumors B-Disease 1 0.9998005032539368
or O 0 2.0873923858744092e-05
who O 0 1.1348674888722599e-06
, O 0 1.3364414996885898e-07
as O 0 1.4376723811437842e-08
a O 0 5.005055925266788e-08
result O 0 1.1294071100564906e-07
of O 0 2.6164000743733595e-08
linkage O 0 2.2094483938417397e-05
analysis O 0 5.679816581505293e-07
had O 0 1.8181306415954168e-07
been O 0 5.213963305550351e-08
predicted O 0 1.5593816442560637e-06
to O 0 1.7826208065230276e-08
carry O 0 2.1995982990574703e-07
the O 0 7.563802455479163e-07
predisposing O 0 0.0009208552073687315
mutation O 0 0.00014587021723855287
. O 0 2.8829335860791616e-05

These O 0 6.904926976858405e-07
observations O 0 1.025328060677566e-06
point O 0 3.072852337027143e-07
to O 0 6.710521205377518e-08
another O 0 1.2615485900369094e-07
region O 0 1.4719826424425264e-07
of O 0 2.2071750649388377e-08
the O 0 1.0910241599049186e-06
RB1 O 1 0.6514890789985657
gene O 0 3.4978575058630668e-06
where O 0 1.1022642354419077e-07
mutations O 0 3.777795143378171e-07
only O 0 4.303842171538008e-09
modify O 0 3.250460451909021e-07
the O 0 5.976284800368603e-09
function O 0 7.954480629734917e-09
of O 0 3.6437999284544276e-09
the O 0 7.991971529008879e-08
gene O 0 1.004239265967044e-06
and O 0 3.2669866811829706e-08
raise O 0 2.731847814629873e-07
important O 0 2.352902583879768e-08
questions O 0 2.7286765202916285e-07
for O 0 2.749597740603349e-07
genetic O 0 0.00015023756714072078
counseling O 0 0.0004443098441697657
in O 0 5.304087835611426e-07
families O 0 8.468568921671249e-07
with O 0 5.513947485269455e-07
these O 0 4.770745363202877e-07
distinctive O 0 0.0006468588835559785
phenotypes O 0 0.007959027774631977
. O 0 1.1260348401265219e-05
. O 0 2.9798480682075024e-05

Maternal B-Disease 0 0.20461899042129517
disomy I-Disease 1 0.9324418902397156
and O 0 0.2643042504787445
Prader B-Disease 1 0.9988059997558594
- I-Disease 1 0.999298095703125
Willi I-Disease 1 0.9995442032814026
syndrome I-Disease 1 0.9995442032814026
consistent O 0 0.00017327228852082044
with O 0 4.16670081904158e-05
gamete O 0 0.3405965566635132
complementation O 1 0.6678377985954285
in O 0 7.528475407525548e-07
a O 0 9.289395279665769e-07
case O 0 1.4775381487197592e-06
of O 0 1.941359073498461e-07
familial O 0 0.020215336233377457
translocation O 0 0.000628327252343297
( O 0 3.247750782975345e-06
3 O 0 1.3208090194893884e-06
; O 0 4.041785075514781e-07
15 O 0 2.9750574981335376e-07
) O 0 2.7749368314289313e-07
( O 0 8.77908519214543e-07
p25 O 0 0.00016802048776298761
; O 0 1.3104278195896768e-06
q11 O 0 4.080183134647086e-05
. O 0 2.530940150791139e-07
2 O 0 2.559958829806419e-06
) O 0 3.0936309940443607e-06
. O 0 4.822343726118561e-06

Maternal B-Disease 0 0.1923077553510666
uniparental I-Disease 1 0.9620286822319031
disomy I-Disease 1 0.8231750130653381
( I-Disease 0 0.002943847794085741
UPD I-Disease 1 0.9808025360107422
) I-Disease 0 4.1203252294508275e-06
for I-Disease 0 4.3763003532149014e-07
chromosome I-Disease 0 1.9296803657198325e-05
15 I-Disease 0 3.48295429830614e-07
is O 0 2.696623191411618e-08
responsible O 0 3.917364566063952e-08
for O 0 7.010559244235992e-09
an O 0 1.277707362135061e-08
estimated O 0 2.464716146732826e-07
30 O 0 8.248731120374941e-08
% O 0 4.275852916180156e-08
of O 0 9.541139434077195e-08
cases O 0 5.5623600928811356e-05
of O 0 0.0006976662552915514
Prader B-Disease 1 0.9992802739143372
- I-Disease 1 0.999154806137085
Willi I-Disease 1 0.9991839528083801
syndrome I-Disease 1 0.9996370077133179
( O 1 0.745537281036377
PWS B-Disease 1 0.9972053170204163
) O 0 0.0002851107274182141
. O 0 8.037100633373484e-05

We O 0 4.102586899534799e-06
report O 0 1.6076409110610257e-06
on O 0 6.166617794178819e-08
an O 0 7.25552666835938e-08
unusual O 0 7.012426408437022e-07
case O 0 9.649527328292606e-07
of O 0 3.4421401551298914e-07
maternal B-Disease 0 0.0015601745108142495
disomy I-Disease 0 0.06707869470119476
15 I-Disease 0 3.017806011484936e-05
in O 0 2.5514389562886208e-05
PWS B-Disease 1 0.9989023208618164
that O 0 1.074012558888171e-07
is O 0 2.1381946879728275e-08
most O 0 5.853431517266472e-09
consistent O 0 7.379448163646884e-08
with O 0 6.49557989618188e-08
adjacent O 0 1.770083486007934e-06
- O 0 3.187998663634062e-05
1 O 0 2.0147761858879676e-07
segregation O 0 1.0843791642400902e-06
of O 0 8.24064461113494e-09
a O 0 6.076713248148735e-07
paternal O 0 8.587174670537934e-05
t O 0 0.003940331283956766
( O 0 3.528179775003082e-07
3 O 0 1.5240549089412525e-07
; O 0 6.080028924770886e-08
15 O 0 4.591889890548373e-08
) O 0 4.703501232938834e-08
( O 0 3.378455346592091e-07
p25 O 0 5.9730849898187444e-05
; O 0 1.4346460375236347e-07
q11 O 0 2.683962293303921e-06
. O 0 6.836361698958626e-09
2 O 0 2.3170073859546392e-08
) O 0 7.435592142002179e-09
with O 0 9.430284109157583e-09
simultaneous O 0 2.1218551182755618e-07
maternal O 0 8.086809975793585e-05
meiotic O 0 0.007631585001945496
nondisjunction O 0 0.0021082607563585043
for O 0 1.057737222254218e-06
chromosome O 0 5.941855852142908e-05
15 O 0 7.874469702073839e-06
. O 0 9.76924548012903e-06

The O 0 4.700247154687531e-05
patient O 0 0.008831570856273174
( O 0 0.00017102013225667179
J O 0 0.20622874796390533
. O 0 1.1222761031604023e-06
B O 0 3.043092874577269e-05
. O 0 4.6892854044244814e-08
) O 0 2.2347775185949104e-08
, O 0 5.266633795741882e-09
a O 0 3.1091627050727766e-08
17 O 0 1.0289818419551011e-06
- O 0 4.843489296035841e-05
year O 0 1.902402686937421e-06
- O 0 0.00027270891587249935
old O 0 6.516143912449479e-05
white O 0 0.0003563310601748526
male O 0 2.0779145415872335e-05
with O 0 3.7520763726206496e-05
PWS B-Disease 1 0.9992533326148987
, O 0 7.322543638110801e-07
was O 0 6.712479461157272e-08
found O 0 1.5083699622664426e-08
to O 0 2.8117121964044145e-09
have O 0 2.8269624419152706e-09
47 O 0 6.994200418830587e-08
chromosomes O 0 3.317801500202222e-08
with O 0 1.5364456373845314e-08
a O 0 4.949151843902655e-07
supernumerary O 0 0.0002398009382886812
, O 0 1.330274699284928e-06
paternal O 0 7.387244113488123e-05
der O 0 0.00021138570446055382
( O 0 2.161873169370665e-07
15 O 0 3.7176114631165547e-08
) O 0 5.73152902916263e-09
consisting O 0 3.4246332436538296e-09
of O 0 4.35720792779648e-09
the O 0 4.602113534701857e-08
short O 0 2.643115067257895e-06
arm O 0 2.300584856129717e-05
and O 0 4.015267762724761e-08
the O 0 2.739421347541793e-07
proximal O 0 0.0026681977324187756
long O 0 8.728790271561593e-05
arm O 0 6.341197149595246e-05
of O 0 1.0335831746033364e-07
chromosome O 0 2.239779132651165e-05
15 O 0 1.2647857374759042e-06
, O 0 4.861487354901328e-07
and O 0 1.171605845229351e-06
distal O 0 0.034892044961452484
chromosome O 0 0.07368174195289612
arm O 1 0.6246302127838135
3p O 1 0.9405790567398071
. O 0 0.00017391850997228175

The O 0 9.550585673423484e-05
t O 0 0.021850885823369026
( O 0 5.346087618818274e-06
3 O 0 1.7216424339494552e-06
; O 0 5.822856223858253e-07
15 O 0 2.5364300881847157e-07
) O 0 7.65032126537335e-08
was O 0 1.6093368415681653e-08
present O 0 9.54687084941952e-09
in O 0 4.638099682097163e-09
the O 0 7.721446593222936e-09
balanced O 0 2.6554749865681515e-07
state O 0 8.459885236788978e-08
in O 0 1.7975709454276512e-07
the O 0 2.6409534257254563e-06
patients O 0 0.017635870724916458
father O 0 9.274716830987018e-06
and O 0 5.386021371123206e-07
a O 0 1.1268329217273276e-05
sister O 0 0.00040793695370666683
. O 0 3.171432763338089e-05

Fluorescent O 0 0.00010625293361954391
in O 0 1.6161446865226026e-06
situ O 0 4.711187648354098e-05
hybridization O 0 3.2602320061414503e-06
analysis O 0 1.3755316103924997e-06
demonstrated O 0 3.0497985790134408e-06
that O 0 3.265641623784177e-07
the O 0 1.2120564861106686e-05
PWS B-Disease 1 0.99857497215271
critical O 0 3.4946184314321727e-05
region O 0 3.867515715683112e-06
resided O 0 1.2098079196221079e-06
on O 0 1.9856667421436214e-08
the O 0 3.394583458771194e-08
derivative O 0 5.071287432656391e-06
chromosome O 0 7.1943190960155334e-06
3 O 0 3.83139564519297e-07
and O 0 1.4738978926231994e-08
that O 0 2.8448285949167484e-09
there O 0 4.807220399527523e-09
was O 0 1.601290122721366e-08
no O 0 1.7376603267393875e-08
deletion O 0 1.967478283404489e-06
of O 0 6.047206113635184e-08
the O 0 7.360017207247438e-06
PWS B-Disease 1 0.9981516003608704
region O 0 7.796947443239333e-07
on O 0 1.2998398801755684e-08
the O 0 1.7994965517686978e-08
normal O 0 1.0153777907362382e-07
pair O 0 1.4747620014077256e-07
of O 0 1.1319647796881327e-07
15s O 0 0.0013600923120975494
present O 0 2.7264520667813485e-06
in O 0 1.1793390513048507e-05
J O 1 0.7866987586021423
. O 0 5.6021624914137647e-05

B O 0 0.048634544014930725
. O 0 0.0007338346913456917

Methylation O 0 1.2826641977881081e-05
analysis O 0 2.621091198307113e-06
at O 0 1.1423370551710832e-06
exon O 0 1.4643612303189002e-05
alpha O 0 5.084766598884016e-07
of O 0 3.648621316187928e-08
the O 0 1.1999463822576217e-07
small O 0 1.2304709571253625e-06
nuclear O 0 0.00019071840506512672
ribonucleoprotein O 0 0.3413260877132416
- O 0 0.000269502546871081
associated O 0 4.24591144110309e-06
polypeptide O 0 9.683161624707282e-05
N O 0 0.0001033902881317772
( O 0 6.249072612263262e-06
SNRPN O 0 0.0009313257178291678
) O 0 4.5762394051962474e-07
gene O 0 1.3536301821659436e-06
showed O 0 5.937724267823796e-07
a O 0 2.1305213238065335e-07
pattern O 0 3.7408894968393724e-06
characteristic O 0 4.6780382945144083e-07
of O 0 1.5432153332994858e-08
only O 0 2.1964241980754196e-08
the O 0 1.916387901701455e-07
maternal O 0 0.00014766854292247444
chromosome O 0 4.3499945604708046e-05
15 O 0 6.1717050812148955e-06
in O 0 1.0933981684502214e-05
J O 0 0.4938649535179138
. O 0 2.8926824597874656e-05

B O 0 0.037977274507284164
. O 0 0.0004732065717689693

Maternal B-Disease 0 0.02468828856945038
disomy I-Disease 0 0.02100331522524357
was O 0 8.07983087725006e-06
confirmed O 0 4.184592398814857e-06
by O 0 3.151833709580387e-07
polymerase O 0 6.633077282458544e-05
chain O 0 1.352338404103648e-05
reaction O 0 1.3474235629473696e-06
analysis O 0 1.3802015530473e-07
of O 0 8.647712945730746e-08
microsatellite O 0 0.00017603016749490052
repeats O 0 7.983369869180024e-06
at O 0 1.0827334762097962e-07
the O 0 1.1302227420628697e-07
gamma O 0 2.393049180682283e-05
- O 0 6.585427763639018e-05
aminobutyric O 0 0.00023507620790041983
acid O 0 2.264786780870054e-05
receptor O 0 2.1534424377023242e-05
beta3 O 0 0.00015796226216480136
subunit O 0 1.3485570889315568e-05
( O 0 9.078102266357746e-06
GABRB3 O 0 0.003315214766189456
) O 0 5.165665697859367e-06
locus O 0 7.390668906737119e-05
. O 0 1.1057993106078357e-05

A O 0 9.935328125720844e-05
niece O 0 0.003887441009283066
( O 0 4.233828076394275e-05
B O 0 0.0003645782417152077
. O 0 3.833522725926741e-07
B O 0 2.6021423764177598e-05
. O 0 1.7199369040099555e-08
) O 0 8.075724977629761e-09
with O 0 3.1200380057327948e-09
45 O 0 1.2763019974215695e-08
chromosomes O 0 1.8722907668689004e-08
and O 0 2.5007886872430163e-09
the O 0 7.100330545739553e-09
derivative O 0 3.5363186157155724e-07
3 O 0 6.556697229598285e-08
but O 0 8.88789042363669e-09
without O 0 1.3854918989864018e-08
the O 0 5.537028258117971e-08
der O 0 6.812994251959026e-05
( O 0 2.0141729351053073e-07
15 O 0 5.8016599524535195e-08
) O 0 6.809815999986313e-08
demonstrated O 0 2.2812122324467055e-07
a O 0 4.2204314354421513e-07
phenotype O 0 3.517424192978069e-05
consistent O 0 2.0133701639224455e-07
with O 0 4.9527400847182435e-08
that O 0 4.407705489484215e-08
reported O 0 6.321463956737716e-07
for O 0 5.430844041143246e-08
haploinsufficiency O 0 8.701787737663835e-05
of O 0 3.600272577841679e-07
distal O 0 0.002769381972029805
3 O 0 0.00017237108841072768
p O 0 0.01254898589104414
. O 0 3.033548637176864e-05

Uniparental B-Disease 1 0.9761034846305847
disomy I-Disease 1 0.9553472399711609
associated O 0 0.0001996179489651695
with O 0 1.461140072933631e-05
unbalanced O 0 0.004533350467681885
segregation O 0 0.0003749564057216048
of O 0 1.4016305840414134e-06
non O 0 0.0003886597405653447
- O 0 0.13294321298599243
Robertsonian O 0 0.11813943833112717
translocations O 0 0.0015913373790681362
has O 0 2.8420317903510295e-06
been O 0 4.3432544316601707e-07
reported O 0 4.738768438983243e-06
previously O 0 5.941298582001764e-07
but O 0 7.296397086520301e-08
has O 0 5.67948212903957e-08
not O 0 5.389770407759897e-09
, O 0 8.245644167459432e-09
to O 0 3.1412659140528376e-09
our O 0 5.6332174480644426e-09
knowledge O 0 1.824355067014949e-08
, O 0 1.592627363322663e-08
been O 0 5.5914588514838215e-09
observed O 0 4.467204917091294e-08
in O 0 2.911299112895449e-08
a O 0 6.1286738173294e-07
case O 0 9.568980203766841e-06
of O 0 1.553162837808486e-05
PWS B-Disease 1 0.9957348704338074
. O 0 0.0001803298364393413

Furthermore O 0 0.00024717795895412564
, O 0 4.562148660625098e-06
our O 0 7.658124445697467e-07
findings O 0 1.3245073660073103e-06
are O 0 1.4828253291909732e-08
best O 0 4.832642375163232e-08
interpreted O 0 9.96981555090315e-08
as O 0 6.706004995749026e-08
true O 0 1.7446096762796515e-06
gamete O 0 0.001011597691103816
complementation O 0 0.3381335735321045
resulting O 0 0.0003058739530388266
in O 0 3.540588295436464e-05
maternal B-Disease 0 0.27946922183036804
UPD I-Disease 1 0.9921665191650391
15 I-Disease 0 0.0003630902210716158
and O 0 0.00042402336839586496
PWS B-Disease 1 0.981964111328125

Schwartz B-Disease 1 0.9538975954055786
- I-Disease 1 0.9908203482627869
Jampel I-Disease 1 0.9949367046356201
syndrome I-Disease 1 0.9990971088409424
type I-Disease 0 0.022164976224303246
2 I-Disease 0 0.0007236938108690083
and O 0 0.0006614250014536083
Stuve B-Disease 1 0.9969946146011353
- I-Disease 1 0.9987188577651978
Wiedemann I-Disease 1 0.999358594417572
syndrome I-Disease 1 0.9997758269309998
: O 0 6.462517194449902e-05
a O 0 4.0426898522127885e-06
case O 0 4.9066011342802085e-06
for O 0 7.945353672766942e-07
" O 0 5.557168606173946e-06
lumping O 0 0.0020526014268398285
" O 0 7.405409178318223e-06
. O 0 1.556602910568472e-05

Recent O 0 7.008598186075687e-05
studies O 0 7.157528216339415e-06
demonstrated O 0 1.698867095001333e-06
the O 0 9.870649364529527e-08
existence O 0 2.94081786478273e-07
of O 0 5.2226223345996914e-08
a O 0 1.2967761904292274e-06
genetically O 0 1.5512887330260128e-05
distinct O 0 1.0522679758651066e-06
, O 0 1.7542919295010506e-07
usually O 0 1.518679368928133e-07
lethal O 0 1.622420541025349e-06
form O 0 1.5750465820474346e-07
of O 0 1.697042364412482e-07
the O 0 2.6077390430145897e-05
Schwartz B-Disease 1 0.7812654376029968
- I-Disease 1 0.9957850575447083
Jampel I-Disease 1 0.9979484677314758
syndrome I-Disease 1 0.9995577931404114
( O 0 0.013259263709187508
SJS B-Disease 1 0.9976352453231812
) O 0 1.0015823136200197e-05
of O 0 1.9591989257605746e-05
myotonia B-Disease 1 0.9986509680747986
and O 0 0.002984068589285016
skeletal B-Disease 1 0.9993901252746582
dysplasia I-Disease 1 0.9995554089546204
, O 0 8.544226147932932e-06
which O 0 8.114101319733891e-07
we O 0 1.7040741795426584e-06
called O 0 0.0001835873699747026
SJS B-Disease 1 0.9974210262298584
type I-Disease 0 0.0006173847941681743
2 I-Disease 0 2.8747168471454643e-05
. O 0 1.5837140381336212e-05

This O 0 0.001198233338072896
disorder O 1 0.9981581568717957
is O 0 7.621187705808552e-06
reminiscent O 0 0.000381550780730322
of O 0 2.1766616100649117e-06
another O 0 8.819191862130538e-05
rare O 0 0.018935488536953926
condition O 0 0.031880903989076614
, O 0 6.980252692301292e-06
the O 0 6.837923137936741e-05
Stuve B-Disease 1 0.9973556995391846
- I-Disease 1 0.9985270500183105
Wiedemann I-Disease 1 0.9987818598747253
syndrome I-Disease 1 0.9997381567955017
( O 0 0.0022602593526244164
SWS B-Disease 1 0.8788133859634399
) O 0 6.207300202731858e-07
, O 0 2.0481945028905102e-08
which O 0 9.115075805254946e-09
comprises O 0 3.333361462409812e-07
campomelia B-Disease 0 0.00024092683452181518
at O 0 2.076724058497348e-06
birth O 0 0.0002080952690448612
with O 0 0.0008938773535192013
skeletal B-Disease 1 0.9992994070053101
dysplasia I-Disease 1 0.9997754693031311
, O 0 0.00628428952768445
contractures B-Disease 1 0.9966821074485779
, O 0 5.012324891140452e-06
and O 0 1.3969253132017911e-06
early B-Disease 0 1.7301061234320514e-05
death I-Disease 0 0.00031415210105478764
. O 0 3.164040754199959e-05

To O 0 3.392022108528181e-06
test O 0 4.961508693668293e-06
for O 0 6.160869929772161e-07
possible O 0 5.645628789352486e-06
nosologic O 0 0.015100260265171528
identity O 0 9.0775656644837e-06
between O 0 2.7852267521666363e-05
these O 0 0.0002408218861091882
disorders O 1 0.9996024966239929
, O 0 1.476833745073236e-06
we O 0 3.822468030989512e-08
reviewed O 0 1.3507747098628897e-07
the O 0 8.479897672941661e-09
literature O 0 1.76266272688963e-08
and O 0 4.067015613173908e-09
obtained O 0 1.0183176968325824e-08
a O 0 1.9406456885917578e-08
follow O 0 6.357830528713748e-08
- O 0 1.2325814395808266e-06
up O 0 4.360765970545799e-09
of O 0 1.1617663497887065e-09
the O 0 3.0840943132659504e-09
only O 0 3.2044071840431343e-09
two O 0 4.739450787383248e-08
surviving O 0 0.0013908485416322947
patients O 0 0.0019300549756735563
, O 0 1.3879390792226332e-07
one O 0 7.988816719262104e-08
with O 0 8.0517393143964e-06
SJS B-Disease 1 0.9971851706504822
type I-Disease 0 1.5235304999805521e-05
2 I-Disease 0 5.669464258062362e-07
at O 0 1.0085893364930598e-07
age O 0 5.365995434658544e-07
10 O 0 4.396865449507459e-08
years O 0 3.707273421582613e-08
and O 0 9.11571884643081e-09
another O 0 1.1371042063501591e-07
with O 0 1.408062757946027e-06
SWS B-Disease 0 0.24503666162490845
at O 0 1.7500619833299424e-06
age O 0 1.0357582141296007e-05
7 O 0 1.3978520655655302e-05
years O 0 1.549059379613027e-05
. O 0 1.0632274097588379e-05

Patients O 1 0.7013473510742188
reported O 0 0.00014051601465325803
as O 0 3.5013219985557953e-06
having O 0 5.346404213923961e-05
either O 0 0.0017407864797860384
neonatal O 1 0.9990831613540649
SJS B-Disease 1 0.9987791180610657
or O 0 9.526644862489775e-05
SWS B-Disease 0 0.454784631729126
presented O 0 1.3793753623758676e-06
a O 0 3.3805341104198305e-07
combination O 0 8.033347512537148e-06
of O 0 5.801930456073023e-07
a O 0 0.00037636925117112696
severe O 1 0.9988395571708679
, O 0 0.021060870960354805
prenatal O 1 0.9980034232139587
- O 1 0.9993358254432678
onset O 1 0.999703586101532
neuromuscular B-Disease 1 0.9998123049736023
disorder I-Disease 1 0.999767005443573
( O 0 0.4008006751537323
with O 1 0.6720730662345886
congenital B-Disease 1 0.9998241066932678
joint I-Disease 1 0.998863697052002
contractures I-Disease 1 0.9996638298034668
, O 1 0.9112087488174438
respiratory O 1 0.9997265934944153
and O 0 0.00023649046488571912
feeding O 0 0.017687376588582993
difficulties O 0 0.041478026658296585
, O 0 1.1655582966341171e-05
tendency O 0 0.0004698947013821453
to O 0 9.872323971649166e-06
hyperthermia B-Disease 1 0.9968372583389282
, O 0 2.369034064031439e-06
and O 0 8.842145575727045e-07
frequent O 0 4.994876144337468e-05
death O 0 5.748224430135451e-05
in O 0 1.8520686353440396e-06
infancy O 0 0.001442733220756054
) O 0 4.4055457237845985e-07
with O 0 1.5879101056270883e-07
a O 0 4.281755991542013e-06
distinct O 0 9.246440458809957e-05
campomelic B-Disease 1 0.934814989566803
- I-Disease 1 0.9863342642784119
metaphyseal I-Disease 1 0.9923403263092041
skeletal I-Disease 1 0.9965125918388367
dysplasia I-Disease 1 0.9976369142532349
. O 0 0.0021444365847855806

The O 0 2.174773499064031e-06
similarity O 0 2.9356385766732274e-06
of O 0 6.019794795975031e-07
the O 0 6.445206054195296e-06
clinical O 0 0.006191464606672525
and O 0 8.38681899040239e-06
radiographic O 1 0.5286864042282104
findings O 0 5.211472307564691e-05
is O 0 2.913185994657397e-07
so O 0 3.3251507147724624e-07
extensive O 0 3.968560486100614e-05
that O 0 5.052846518083243e-06
these O 0 5.317316026776098e-05
disorders O 1 0.9996143579483032
appear O 0 2.873909807021846e-06
to O 0 3.571498297105791e-08
be O 0 1.2391311976500674e-08
a O 0 2.0484726803715603e-07
single O 0 7.703766300437564e-07
entity O 0 1.8261873265146278e-05
. O 0 1.527853419247549e-05

The O 0 6.7322134782443754e-06
follow O 0 5.517010777111864e-06
- O 0 4.9879890866577625e-05
up O 0 2.3493247169881215e-07
observation O 0 2.175349322897091e-07
of O 0 1.1052700976676988e-08
an O 0 3.530414360852774e-08
identical O 0 3.774564731884311e-07
and O 0 3.024876704671442e-08
unique O 0 1.6391142310112627e-07
pattern O 0 2.5247223675251007e-05
of O 0 1.1489785720186774e-05
progressive O 1 0.9965673685073853
bone B-Disease 1 0.9997895359992981
dysplasia I-Disease 1 0.9997074007987976
in O 0 3.17593730869703e-06
the O 0 1.9070511143581825e-06
two O 0 4.3059276322310325e-06
patients O 0 0.05901394039392471
( O 0 4.274819730198942e-06
one O 0 2.0226617891694332e-07
with O 0 2.5605088012525812e-05
SJS B-Disease 1 0.9986045956611633
type I-Disease 0 4.692485526902601e-05
2 I-Disease 0 5.092055062050349e-07
, O 0 3.084189970081752e-08
one O 0 1.3285014865971334e-08
with O 0 7.736367706456804e-07
SWS B-Disease 0 0.1861140877008438
) O 0 6.048452405593707e-07
surviving O 0 1.1029894267267082e-05
beyond O 0 4.00675571654574e-06
infancy O 0 0.0006788458558730781
adds O 0 1.0111362826137338e-05
to O 0 1.0325581278891605e-08
the O 0 1.4119804880863285e-08
evidence O 0 7.782648481224896e-08
in O 0 3.3776235142113364e-08
favor O 0 2.487674635176518e-07
of O 0 1.8966714776524896e-07
identity O 0 1.1512281162140425e-05
. O 0 2.2217729565454647e-05

The O 0 5.377632987801917e-06
hypothesis O 0 5.254879215499386e-05
that O 0 1.0856399057956878e-05
SWS B-Disease 1 0.9521873593330383
and O 0 0.0003137280000373721
SJS B-Disease 1 0.9983605742454529
type I-Disease 0 0.0003223258536309004
2 I-Disease 0 2.4242060590040637e-06
are O 0 3.904511558516788e-08
the O 0 1.2608788892976008e-06
same O 0 5.3050887800054625e-05
disorder O 1 0.9970383644104004
should O 0 2.8697527909571363e-07
be O 0 2.8052532741185132e-08
testable O 0 1.1166978310939157e-06
by O 0 8.92121718720773e-08
molecular O 0 3.6941946746082976e-06
methods O 0 1.1866164868479245e-06
. O 0 2.279751697642496e-06
. O 0 8.490260370308533e-06

A O 0 0.00023329263785853982
mouse O 0 0.003106524934992194
model O 0 0.0019446930382400751
of O 0 0.03815018758177757
severe O 1 0.9994261264801025
von B-Disease 1 0.999506950378418
Willebrand I-Disease 1 0.9997933506965637
disease I-Disease 1 0.9998725652694702
: O 1 0.9968119263648987
defects O 1 0.9988013505935669
in O 0 0.07347963750362396
hemostasis O 1 0.9972513318061829
and O 0 0.08643665164709091
thrombosis B-Disease 1 0.9976563453674316
. O 0 0.0025456352159380913

von B-Disease 1 0.969556450843811
Willebrand I-Disease 1 0.985042154788971
factor I-Disease 0 0.11041617393493652
( I-Disease 0 0.32312580943107605
vWf I-Disease 1 0.9916325211524963
) I-Disease 1 0.9853197336196899
deficiency I-Disease 1 0.9994884729385376
causes O 1 0.9987578392028809
severe O 1 0.9997623562812805
von B-Disease 1 0.9997110962867737
Willebrand I-Disease 1 0.9996780157089233
disease I-Disease 1 0.999782383441925
in O 0 0.00557190366089344
humans O 0 0.030773982405662537
. O 0 0.0007821755716577172

We O 0 7.880170187490876e-07
generated O 0 6.437045954044152e-07
a O 0 1.272424583476095e-06
mouse O 0 0.00015203779912553728
model O 0 1.0253387699776795e-05
for O 0 1.7604135109650088e-06
this O 0 2.2837184587842785e-05
disease O 1 0.9577447772026062
by O 0 4.996185793970653e-07
using O 0 1.4999145605543163e-06
gene O 0 2.6007059204857796e-05
targeting O 0 2.7812111511593685e-05
. O 0 2.7667038011713885e-05

vWf B-Disease 1 0.9777833819389343
- I-Disease 1 0.9904870390892029
deficient I-Disease 1 0.9927144646644592
mice O 0 0.02395366132259369
appeared O 0 3.420276698307134e-05
normal O 0 1.0652949640643783e-05
at O 0 6.119205409049755e-06
birth O 0 2.9863369491067715e-05
; O 0 5.941734571024426e-07
they O 0 1.5598049074583287e-08
were O 0 2.6494387128650487e-08
viable O 0 1.5734267435618676e-06
and O 0 6.280056936702749e-07
fertile O 0 0.00015712851018179208
. O 0 2.77155741059687e-05

Neither O 0 0.0021308630239218473
vWf O 0 0.3840121924877167
nor O 0 0.0027557264547795057
vWf O 1 0.7608364820480347
propolypeptide O 1 0.7913523316383362
( O 0 0.021680906414985657
von B-Disease 1 0.9906546473503113
Willebrand I-Disease 1 0.9968876242637634
antigen O 1 0.9198062419891357
II O 0 0.08888284116983414
) O 0 1.274519604521629e-06
were O 0 6.630886417724469e-08
detectable O 0 5.092165338282939e-06
in O 0 1.717387192456954e-07
plasma O 0 6.816419045208022e-05
, O 0 1.3610462019642e-06
platelets O 0 0.005899535957723856
, O 0 7.525977139266615e-07
or O 0 2.0550367025862215e-06
endothelial O 0 0.005033882334828377
cells O 0 9.121406492340611e-07
of O 0 2.5592644448124702e-08
the O 0 5.593274181592278e-07
homozygous O 0 0.00012474563845898956
mutant O 0 0.0015845191664993763
mice O 0 0.004335970617830753
. O 0 2.8125559765612707e-05

The O 0 0.0001141056272899732
mutant O 0 0.04541461542248726
mice O 1 0.653352677822113
exhibited O 0 0.12328709661960602
defects O 1 0.9962235689163208
in O 0 0.00014422602544073015
hemostasis O 1 0.9907209873199463
with O 0 2.81521806755336e-05
a O 0 0.0008547026664018631
highly O 0 0.07689064741134644
prolonged O 1 0.9987964630126953
bleeding O 1 0.9982155561447144
time O 0 3.110009856754914e-06
and O 0 4.007638381153811e-06
spontaneous O 0 0.0005192289245314896
bleeding O 1 0.8370202779769897
events O 0 3.0147947427394683e-07
in O 0 7.27180591297838e-08
approximately O 0 1.9995452760213084e-07
10 O 0 2.783768593417335e-07
% O 0 3.9268957152671646e-07
of O 0 1.4642863561675767e-06
neonates O 0 0.12048520892858505
. O 0 4.0668743167771026e-05

As O 0 3.53487916981976e-06
in O 0 4.805151547770947e-06
the O 0 3.710933742695488e-05
human O 0 0.01316528208553791
disease O 1 0.998673677444458
, O 0 8.49015975745715e-07
the O 0 5.153474376129452e-07
factor O 0 3.088090306846425e-05
VIII O 0 0.019922437146306038
level O 0 1.2816426533390768e-06
in O 0 7.320833361745827e-08
these O 0 7.75187771751007e-08
mice O 0 7.228997856145725e-05
was O 0 2.942967114449857e-07
reduced O 0 1.853294861575705e-06
strongly O 0 1.6007030012588075e-07
as O 0 8.420889763272044e-09
a O 0 5.514105794190982e-08
result O 0 8.841582399554682e-08
of O 0 9.25130905216065e-09
the O 0 5.3209788575259154e-08
lack O 0 1.153878429249744e-06
of O 0 1.0557372576158741e-07
protection O 0 4.567291398416273e-05
provided O 0 5.746112492488464e-06
by O 0 1.1571157301659696e-05
vWf O 0 0.06751058995723724
. O 0 3.31579904013779e-05

Defective O 1 0.9854135513305664
thrombosis B-Disease 1 0.9955621957778931
in O 0 0.0002899722312577069
mutant O 0 0.14979881048202515
mice O 0 0.02804039977490902
was O 0 3.0132391657389235e-06
also O 0 4.039950738388143e-07
evident O 0 3.218686288164463e-06
in O 0 6.87430983248305e-08
an O 0 4.4329738102533156e-08
in O 0 4.136284132982837e-07
vivo O 0 9.630074782762676e-05
model O 0 5.5803495342843235e-05
of O 0 0.0001024038065224886
vascular B-Disease 1 0.999090313911438
injury I-Disease 1 0.9930058717727661
. O 0 0.000488206249428913

In O 0 1.5950921579133137e-06
this O 0 2.1352302326249628e-07
model O 0 1.6819080883578863e-06
, O 0 2.6726343094196636e-07
the O 0 4.633071455373283e-07
exteriorized O 0 0.0014140933053568006
mesentery O 0 0.001398897380568087
was O 0 1.770324843164417e-06
superfused O 0 0.0007849883404560387
with O 0 4.352402811491629e-06
ferric O 1 0.7765987515449524
chloride O 0 0.0003218409838154912
and O 0 1.6327614105193788e-07
the O 0 1.8471671126008005e-07
accumulation O 0 0.0001215570664498955
of O 0 1.8663205310076592e-06
fluorescently O 1 0.6341066360473633
labeled O 0 0.014998282305896282
platelets O 0 0.0125094223767519
was O 0 1.1519641702761874e-06
observed O 0 1.3308166444403469e-06
by O 0 2.516979520805762e-06
intravital O 0 0.006366468966007233
microscopy O 0 0.0004557281790766865
. O 0 4.0451825043419376e-05

We O 0 4.759743660542881e-06
conclude O 0 1.8764483684208244e-05
that O 0 5.110600227453688e-07
these O 0 5.579283879342256e-07
mice O 0 0.0009732781327329576
very O 0 1.461969532101648e-05
closely O 0 0.0017345044761896133
mimic O 1 0.9965763688087463
severe O 1 0.9994291663169861
human O 1 0.9979752898216248
von B-Disease 1 0.9997841715812683
Willebrand I-Disease 1 0.9998928308486938
disease I-Disease 1 0.9999086856842041
and O 0 2.4013777874642983e-05
will O 0 4.499211456732155e-07
be O 0 2.2039063907186573e-08
very O 0 2.6041227840778447e-08
useful O 0 2.067414861528505e-08
for O 0 1.0475490697103851e-08
investigating O 0 2.7917604938920704e-07
the O 0 1.295152696201285e-08
role O 0 7.03079550135044e-08
of O 0 1.0410997930421217e-07
vWf O 0 0.02149135433137417
in O 0 8.210068926928216e-07
normal O 0 2.5175480914185755e-05
physiology O 0 0.002447831677272916
and O 0 9.383488759340253e-06
in O 0 0.00018990311946254224
disease O 1 0.9985153079032898
models O 0 0.0001402532507199794
. O 0 9.233503078576177e-06
. O 0 1.979155422304757e-05

Oral O 0 0.005496841389685869
contraceptives O 0 0.006503927521407604
and O 0 7.3076053013210185e-06
the O 0 5.740521373809315e-05
risk O 1 0.7630401253700256
of O 0 0.0243533942848444
hereditary B-Disease 1 0.9988964796066284
ovarian I-Disease 1 0.9998345375061035
cancer I-Disease 1 0.9994774460792542
. O 0 0.040715113282203674

Hereditary B-Disease 1 0.986320436000824
Ovarian I-Disease 1 0.9983945488929749
Cancer I-Disease 1 0.9981557726860046
Clinical O 1 0.9552400708198547
Study O 0 0.0027314575854688883
Group O 0 0.0011690403334796429
. O 0 0.000403480400564149

BACKGROUND O 0 0.0004938584170304239
Women O 0 1.8194423319073394e-05
with O 0 1.8334775404582615e-06
mutations O 0 8.975327546068002e-06
in O 0 7.112857502988845e-08
either O 0 1.5571227152122447e-07
the O 0 3.671302408747579e-07
BRCA1 O 0 0.0005753079312853515
or O 0 3.5339519399713026e-07
the O 0 5.466775974127813e-07
BRCA2 O 0 0.0002667175722308457
gene O 0 1.105976480175741e-06
have O 0 3.452633734468691e-08
a O 0 2.395483306827373e-06
high O 0 0.0010281879222020507
lifetime O 0 0.453217476606369
risk O 1 0.9227097630500793
of O 0 0.11293501406908035
ovarian B-Disease 1 0.9997755885124207
cancer I-Disease 1 0.99925297498703
. O 0 0.002875040750950575

Oral O 0 0.07685035467147827
contraceptives O 1 0.9713810682296753
protect O 1 0.9770264029502869
against O 1 0.9973130822181702
ovarian B-Disease 1 0.9998928308486938
cancer I-Disease 1 0.9997454285621643
in O 0 4.131624154979363e-05
general O 0 5.9223057178314775e-05
, O 0 2.8778317755495664e-06
but O 0 1.0915690040746995e-07
it O 0 1.9411086071841055e-08
is O 0 1.864457921385565e-08
not O 0 7.67472574381145e-09
known O 0 8.035549114993046e-08
whether O 0 3.717732255381634e-08
they O 0 1.1885736839190031e-08
also O 0 1.429343257086657e-07
protect O 0 1.7953565475181676e-05
against O 0 4.1914456232916564e-05
hereditary B-Disease 0 0.09948471188545227
forms I-Disease 0 0.008430012501776218
of I-Disease 0 0.33388999104499817
ovarian I-Disease 1 0.9998276233673096
cancer I-Disease 1 0.9995830655097961
. O 0 0.009781778790056705

METHODS O 0 2.4280734578496777e-05
We O 0 6.761578788427869e-06
enrolled O 0 0.00012812274508178234
207 O 0 0.0032527928706258535
women O 0 0.0007994582992978394
with O 0 0.11734340339899063
hereditary B-Disease 1 0.9993860721588135
ovarian I-Disease 1 0.9999312162399292
cancer I-Disease 1 0.9996981620788574
and O 0 2.260393102915259e-06
161 O 0 9.220919309882447e-06
of O 0 4.7244956391523374e-08
their O 0 6.02616978540027e-08
sisters O 0 4.0335739868169185e-06
as O 0 7.630605125541479e-08
controls O 0 6.963916234781209e-07
in O 0 7.36447347549074e-08
a O 0 1.2038967724947724e-06
case O 0 2.1007143004680984e-05
- O 0 0.0005928667378611863
control O 0 1.2601331945916172e-05
study O 0 2.5907993403961882e-05
. O 0 1.840748700487893e-05

All O 0 2.082284936477663e-06
the O 0 8.548986443202011e-06
patients O 0 0.0009231282165274024
carried O 0 5.117984755997895e-07
a O 0 1.2400577134030755e-06
pathogenic O 0 3.931760511477478e-05
mutation O 0 3.6268775147618726e-06
in O 0 1.371554674278741e-07
either O 0 1.0506264516152442e-06
BRCA1 O 0 0.00189280416816473
( O 0 4.695766165241366e-06
179 O 0 2.7437419703346677e-05
women O 0 1.5569031575068948e-06
) O 0 5.025450491302763e-07
or O 0 1.4896309039613698e-06
BRCA2 O 0 0.000981122488155961
( O 0 5.466288712341338e-06
28 O 0 6.853925697214436e-06
women O 0 5.523681011254666e-06
) O 0 2.850359351214138e-06
. O 0 7.706221367698163e-06

The O 0 7.426604952343041e-06
control O 0 1.4423985703615472e-05
women O 0 3.745916046682396e-06
were O 0 1.2754493639022257e-07
enrolled O 0 4.121728125028312e-06
regardless O 0 2.432732912893698e-07
of O 0 4.2231288688299173e-08
whether O 0 4.500610657487414e-07
or O 0 5.419615831669944e-07
not O 0 3.308871754370557e-08
they O 0 2.3425808848287488e-08
had O 0 2.3841555218950816e-07
either O 0 9.256816042579885e-07
mutation O 0 3.82771177100949e-05
. O 0 1.2716926903522108e-05

Lifetime O 0 0.0007980672526173294
histories O 0 6.525254138978198e-05
of O 0 4.56786438007839e-06
oral O 0 0.010677637532353401
- O 0 0.15389429032802582
contraceptive O 0 0.0043625496327877045
use O 0 1.225159138584786e-07
were O 0 8.87423734496906e-09
obtained O 0 4.581182366791836e-08
by O 0 5.411590464632354e-08
interview O 0 1.3247384913483984e-06
or O 0 3.306941209757497e-08
by O 0 8.273260299063168e-09
written O 0 2.106924767986129e-08
questionnaire O 0 2.2022818484401796e-06
and O 0 6.016912834638788e-08
were O 0 6.036465549641434e-08
compared O 0 2.684930404939223e-05
between O 0 1.8221946447738446e-05
patients O 0 0.026251917704939842
and O 0 5.141878318681847e-07
control O 0 6.051491709513357e-06
women O 0 1.0939612593574566e-06
, O 0 9.318003435510036e-08
after O 0 2.8134041940575116e-07
adjustment O 0 3.052912461498636e-06
for O 0 3.069811072009543e-08
year O 0 1.9300814813050238e-07
of O 0 1.0631269731220527e-07
birth O 0 2.1803058189107105e-05
and O 0 1.6587850950600114e-06
parity O 0 0.000453155895229429
. O 0 1.5552615877822973e-05

RESULTS O 0 2.526155367377214e-05
The O 0 4.401646037877072e-06
adjusted O 0 0.00033013697247952223
odds O 0 0.19642502069473267
ratio O 0 0.23155900835990906
for O 1 0.945932924747467
ovarian B-Disease 1 0.9999463558197021
cancer I-Disease 1 0.999883770942688
associated O 0 0.00011759984045056626
with O 0 1.630663746254868e-07
any O 0 3.7840216293716367e-08
past O 0 7.204200613841749e-08
use O 0 3.6371776701571434e-08
of O 0 9.848665172285109e-08
oral O 0 0.0005360405775718391
contraceptives O 0 0.007176011335104704
was O 0 5.275995135889389e-06
0 O 0 3.264655242674053e-05
. O 0 1.144946782005718e-05

5 O 0 1.5041207007016055e-05
( O 0 3.759457968044444e-06
95 O 0 3.401266667424352e-06
percent O 0 1.6872257901923149e-06
confidence O 0 8.399820785598422e-07
interval O 0 3.385990225979185e-07
, O 0 3.414336546825325e-08
0 O 0 8.06261510888362e-08
. O 0 7.824066727835088e-09
3 O 0 2.0812862544516975e-08
to O 0 6.339736735583301e-09
0 O 0 2.0395719957377878e-07
. O 0 3.1577751968825396e-08
8 O 0 7.602043297083583e-07
) O 0 1.2077997553205932e-06
. O 0 2.6931825232168194e-06

The O 0 0.00014914166240487248
risk O 0 0.00798929762095213
decreased O 0 4.354028351372108e-05
with O 0 1.4061973274692718e-07
increasing O 0 1.0296336085957591e-06
duration O 0 9.53670621584024e-07
of O 0 1.6134059421801794e-08
use O 0 1.212178517562279e-07
( O 0 8.958530770541984e-07
P O 0 4.688679109676741e-05
for O 0 3.6413215553920963e-08
trend O 0 1.5794070122865378e-06
, O 0 6.635212912442512e-08
< O 0 2.523343027860392e-05
0 O 0 2.6355186832915933e-07
. O 0 3.4159846507009206e-08
001 O 0 1.509077446826268e-05
) O 0 2.3577317875833614e-08
; O 0 7.034508087144786e-09
use O 0 1.5698085054083322e-09
for O 0 1.8673966817317478e-09
six O 0 1.3354193306724937e-08
or O 0 2.8508976512853224e-08
more O 0 1.0909483094678762e-08
years O 0 1.5049823787194327e-07
was O 0 5.274004877264815e-08
associated O 0 6.754888204341114e-08
with O 0 1.8765200948678284e-08
a O 0 3.15894453706278e-07
60 O 0 4.463493496587034e-06
percent O 0 2.467911508574616e-05
reduction O 0 0.0003315263020340353
in O 0 6.963942723814398e-06
risk O 0 0.00261137168854475
. O 0 2.287855932081584e-05

Oral O 0 0.006224524229764938
- O 0 0.22172054648399353
contraceptive O 0 0.12768128514289856
use O 0 0.0001585790450917557
protected O 0 0.49848368763923645
against O 1 0.9961270689964294
ovarian B-Disease 1 0.9999178647994995
cancer I-Disease 1 0.999678373336792
both O 0 1.1224977924939594e-06
for O 0 3.3632690588092373e-07
carriers O 0 1.1411923878767993e-05
of O 0 5.207443365407016e-08
the O 0 7.405207611554943e-07
BRCA1 O 0 0.0017009183065965772
mutation O 0 1.1429939149820711e-05
( O 0 1.3472050568452687e-06
odds O 0 1.3426797522697598e-05
ratio O 0 5.262439231046301e-07
, O 0 3.628433020708144e-08
0 O 0 4.6507874884582634e-08
. O 0 6.46141140592249e-09
5 O 0 2.507773189108775e-08
; O 0 2.3723472963865788e-08
95 O 0 5.454949913996643e-08
percent O 0 3.995587860572414e-08
confidence O 0 9.0807027675055e-08
interval O 0 5.095620281281299e-08
, O 0 5.8149289827724715e-09
0 O 0 1.823078576990156e-08
. O 0 1.580606645568139e-09
3 O 0 4.039655276955045e-09
to O 0 1.1308027847434232e-09
0 O 0 1.7371831972923246e-08
. O 0 3.466852804834275e-09
9 O 0 5.450477758017769e-08
) O 0 7.932179357794666e-09
and O 0 1.6849973638599636e-09
for O 0 2.271905330530899e-09
carriers O 0 1.705049754718857e-07
of O 0 4.598180503023741e-09
the O 0 1.2547668859497207e-07
BRCA2 O 0 0.00017961050616577268
mutation O 0 3.2708642265788512e-06
( O 0 4.2569496372379945e-07
odds O 0 8.638827239337843e-06
ratio O 0 2.7933637625210395e-07
, O 0 1.679130257059569e-08
0 O 0 5.749883413841417e-08
. O 0 4.62039695392491e-09
4 O 0 2.362143014522644e-08
; O 0 1.8071323992785437e-08
95 O 0 4.570473421949828e-08
percent O 0 4.110361473408375e-08
confidence O 0 5.908790967623645e-08
interval O 0 7.147946234908886e-08
, O 0 7.564593396125474e-09
0 O 0 2.22116636194869e-08
. O 0 2.800675469316616e-09
2 O 0 1.4434286654818607e-08
to O 0 3.862157704759284e-09
1 O 0 6.055574175434231e-08
. O 0 2.4236591400494945e-08
1 O 0 2.8312277322584123e-07
) O 0 6.007664978824323e-07
. O 0 1.8414839360048063e-06

CONCLUSIONS O 0 0.0003327222366351634
Oral O 0 0.005252162925899029
- O 0 0.1702711433172226
contraceptive O 0 0.05025479942560196
use O 0 5.711131052521523e-06
may O 0 2.590068288554903e-05
reduce O 0 0.0003088461235165596
the O 0 2.865960414055735e-05
risk O 1 0.5720398426055908
of O 0 0.17588649690151215
ovarian B-Disease 1 0.9999498128890991
cancer I-Disease 1 0.999858021736145
in O 0 1.9675891962833703e-05
women O 0 1.9043967768084258e-05
with O 0 5.896800303162308e-06
pathogenic O 0 0.0009212198783643544
mutations O 0 2.778825000859797e-05
in O 0 3.784397506478854e-07
the O 0 6.62253341943142e-06
BRCA1 O 0 0.09934049844741821
or O 0 0.00012728336150757968
BRCA2 O 0 0.12733562290668488
gene O 0 0.002599429339170456

A O 0 0.00011530386109370738
Japanese O 0 0.0004545086994767189
family O 0 7.506752444896847e-05
with O 0 3.547317101038061e-05
adrenoleukodystrophy B-Disease 1 0.9972472786903381
with O 0 6.468035280704498e-07
a O 0 1.0080793799716048e-06
codon O 0 1.3010155271331314e-05
291 O 0 0.00020615789981093258
deletion O 0 0.00047801670734770596
: O 0 7.532715244451538e-06
a O 0 6.6842458181781694e-06
clinical O 0 0.002160418312996626
, O 0 2.881096861528931e-06
biochemical O 0 0.001017112866975367
, O 0 1.1889411325682886e-05
pathological O 0 0.02526736445724964
, O 0 2.680460738702095e-06
and O 0 2.0782613319170196e-06
genetic O 0 0.0003838833072222769
report O 0 5.0551974709378555e-05
. O 0 2.58477266470436e-05

We O 0 3.021180418727454e-06
report O 0 5.520257673197193e-06
a O 0 2.0338316062407102e-06
Japanese O 0 9.862147271633148e-05
family O 0 0.00017460343951825052
with O 0 0.002846365561708808
adrenoleukodystrophy B-Disease 1 0.9994206428527832
( O 0 0.25802096724510193
ALD B-Disease 1 0.9993923902511597
) O 0 5.546868351302692e-07
with O 0 2.620885375392845e-08
a O 0 3.9030524590089044e-08
three O 0 1.3434463319583756e-08
base O 0 1.9591824695908144e-07
pair O 0 1.243425799657416e-06
deletion O 0 5.8120527683058754e-05
( O 0 4.029997853649547e-06
delGAG O 0 0.0003285228740423918
291 O 0 2.3308350137085654e-05
) O 0 2.1610033229535475e-07
in O 0 3.742320302535518e-07
the O 0 1.1383946002752054e-05
ALD B-Disease 1 0.9959661960601807
gene O 0 0.0003512314578983933
. O 0 4.461635398911312e-05

A O 0 1.3365362065087538e-05
variety O 0 3.7599600091198226e-06
of O 0 7.047886469990772e-07
phenotypes O 0 0.0008304714574478567
were O 0 2.1657155002685613e-07
observed O 0 1.2666615702983108e-06
within O 0 3.425354293540295e-07
this O 0 1.319568923463521e-06
family O 0 9.044419130077586e-05
. O 0 4.653861469705589e-05

While O 0 7.464058398909401e-06
the O 0 8.259496098617092e-06
proband O 0 0.030643075704574585
( O 0 8.017878280952573e-05
patient O 0 0.001111145713366568
1 O 0 8.184433681890368e-06
) O 0 1.2339588693066617e-06
was O 0 2.536147007958789e-07
classified O 0 1.648549982746772e-06
as O 0 1.9787893990041994e-08
having O 0 1.3902786122343969e-07
a O 0 4.1218953583666007e-07
rare O 0 9.833207514020614e-06
intermediate O 0 2.062452222162392e-05
type O 0 4.790588718606159e-05
of O 0 6.363204647641396e-07
adult O 0 0.0010309239150956273
cerebral O 1 0.989173173904419
and O 0 0.00019103652448393404
cerebello O 1 0.9955755472183228
- O 1 0.9915617108345032
brain O 1 0.9305775165557861
stem O 0 0.0020323668140918016
forms O 0 2.3820243768568616e-06
, O 0 2.7539618940863875e-07
his O 0 9.628392945160158e-07
younger O 0 3.5712124372366816e-05
brother O 0 2.676667645573616e-05
( O 0 8.261047696578316e-06
patient O 0 8.224265911849216e-05
2 O 0 1.2429491107468493e-06
) O 0 3.352880071361142e-07
and O 0 2.0238850595433178e-07
nephew O 0 0.0003036083362530917
( O 0 8.853326107782777e-06
patient O 0 0.0001055027823895216
3 O 0 2.804015366564272e-06
) O 0 1.2656388435061672e-06
had O 0 1.8560045873527997e-06
a O 0 7.589339656988159e-05
childhood O 1 0.9801202416419983
ALD B-Disease 1 0.998307466506958
type O 0 0.30340680480003357
. O 0 0.0002629175141919404

Another O 0 7.444397488143295e-05
nephew O 0 0.0036274059675633907
( O 0 0.00013943757221568376
patient O 0 0.000900402432307601
4 O 0 6.414582003344549e-06
) O 0 7.222774343063065e-07
of O 0 2.4276664589706343e-07
patient O 0 0.002793805208057165
1 O 0 9.62010926741641e-06
was O 0 1.249272600034601e-06
classified O 0 6.231735824258067e-06
as O 0 6.660432916305581e-08
having O 0 4.14621268873816e-07
an O 0 1.062165779330826e-06
adolescent O 0 0.01672002114355564
form O 0 6.936099816812202e-05
. O 0 4.735172478831373e-05

The O 0 5.592225534201134e-06
tau O 0 8.827066631056368e-05
level O 0 2.0785309970960952e-06
in O 0 3.675169750749774e-07
the O 0 1.8630591966939392e-06
cerebrospinal O 0 0.0830884724855423
fluid O 0 0.0017812821315601468
( O 0 0.00010049594129668549
CSF O 0 0.42245280742645264
) O 0 1.5648580529159517e-06
in O 0 5.178052333576488e-07
patient O 0 9.398962720297277e-05
1 O 0 6.796735192438064e-07
was O 0 6.848162570349814e-08
as O 0 1.8793246070458736e-08
high O 0 2.184975755881169e-07
as O 0 1.2787580772055662e-08
that O 0 4.7864542551678824e-08
of O 0 3.1620566005585715e-06
patients O 1 0.9399282932281494
with O 1 0.6853094100952148
Alzheimers B-Disease 1 0.9998384714126587
disease I-Disease 1 0.9995954632759094
( O 0 0.0012459179852157831
AD B-Disease 0 0.003866072976961732
) O 0 2.2137359337648377e-05
. O 0 1.7910591850522906e-05

His O 0 6.378679245244712e-05
brain O 0 0.004767955746501684
magnetic O 0 4.612818520399742e-05
resonance O 0 0.00016645250434521586
image O 0 0.0018821322591975331
( O 0 0.000158421098603867
MRI O 0 0.021650223061442375
) O 0 9.883033271762542e-06
showed O 0 5.4224332416197285e-05
abnormalities B-Disease 0 0.008030391298234463
in I-Disease 0 2.3038363394789485e-07
the I-Disease 0 7.364556608990824e-07
bilateral I-Disease 0 0.00054842175450176
cerebellar I-Disease 1 0.9947435855865479
hemispheres I-Disease 0 0.0030288686975836754
and O 0 0.00037498032907024026
brain O 1 0.9883254766464233
stem O 0 0.043827276676893234
, O 0 8.29204566343833e-07
but O 0 1.1012491540896008e-07
not O 0 2.2137690791623754e-08
in O 0 1.6967867111361556e-07
the O 0 1.1378822819096968e-05
cerebral O 1 0.9912428855895996
white O 0 0.0004243203438818455
matter O 0 3.859494768221339e-07
, O 0 5.91304178954033e-08
where O 0 3.77703450737954e-08
marked O 0 6.783479875593912e-07
reductions O 0 2.7273179057374364e-06
of O 0 7.853074635022494e-08
the O 0 1.2923495887662284e-05
cerebral O 1 0.9967413544654846
blood O 0 0.001369103672914207
flow O 0 1.0002773706219159e-05
and O 0 3.715067293796892e-07
oxygen O 0 1.4794889466429595e-05
metabolism O 0 3.025006435564137e-06
were O 0 9.335505701812963e-09
clearly O 0 7.513320809948709e-08
demonstrated O 0 1.3017756828048732e-07
by O 0 6.463188384486784e-08
positron O 0 0.00011635301052592695
emission O 0 2.6658182832761668e-05
tomography O 0 0.00017670080706011504
( O 0 2.6960635295836255e-05
PET O 0 0.0005066834855824709
) O 0 8.32527621241752e-06
. O 0 9.869547284324653e-06

In O 0 9.09746959223412e-05
patients O 0 0.006839995738118887
2 O 0 4.160593562119175e-06
and O 0 2.661620612798288e-07
3 O 0 8.958197668107459e-07
, O 0 1.1825298429357645e-07
the O 0 1.431813956287442e-07
autopsy O 0 3.292701512691565e-05
findings O 0 2.0561641576932743e-05
showed O 0 0.0001024208904709667
massive O 0 0.15223395824432373
demyelination B-Disease 1 0.9971139430999756
of I-Disease 0 5.5003733905323315e-06
the I-Disease 0 0.0003082672192249447
cerebral I-Disease 1 0.9981667995452881
white I-Disease 0 0.0011299456236883998
matter I-Disease 0 4.571502358885482e-07
with O 0 1.598200043417819e-07
sparing O 0 8.784547389950603e-06
of O 0 1.3321380265551852e-07
the O 0 3.1159802347247023e-06
U O 0 0.4241192042827606
- O 0 0.11974599957466125
fibers O 0 0.0011406688718125224
, O 0 6.836638277718521e-08
compatible O 0 2.611250806694443e-07
with O 0 7.097015952695074e-08
the O 0 2.0235455622241716e-07
findings O 0 7.95401956565911e-06
of O 0 1.4488629858533386e-05
childhood O 1 0.9769933819770813
ALD B-Disease 1 0.9972924590110779
. O 0 0.000846848008222878

Oleic O 0 0.003047637641429901
and O 0 1.23483905554167e-05
erucic O 0 0.016960756853222847
acids O 0 1.4205473235051613e-05
( O 0 1.3263364053273108e-05
Lorenzos O 0 0.0007739950087852776
Oil O 0 4.112372153031174e-06
) O 0 2.2021860957011086e-07
were O 0 2.8417661113167014e-08
administered O 0 9.358289503325068e-07
to O 0 3.294385351182427e-07
patients O 0 0.0003318020317237824
1 O 0 4.911133260065981e-07
and O 0 4.6644682782925884e-08
4 O 0 5.79012976231752e-07
, O 0 4.8529170015854106e-08
but O 0 3.587823016459879e-08
sufficient O 0 6.605500857403968e-07
effectiveness O 0 6.89660873831599e-06
was O 0 1.3582126712208265e-07
not O 0 4.81626294401849e-08
obtained O 0 9.206422646457213e-07
. O 0 4.762204753205879e-06

The O 0 8.307493772008456e-06
findings O 0 1.3471817510435358e-05
in O 0 4.379724032332888e-07
this O 0 2.33633883794937e-07
family O 0 3.5532455058273626e-06
suggest O 0 1.8683434745980776e-06
that O 0 1.354686247623249e-07
delGAG291 O 0 9.55441064434126e-05
is O 0 3.780948532039474e-08
part O 0 2.8598183376971065e-08
of O 0 2.56084646821364e-08
the O 0 5.718002284993418e-07
cause O 0 9.148151730187237e-05
of O 0 2.8388785722199827e-06
Japanese O 0 0.04354800656437874
ALD B-Disease 1 0.9984330534934998
with O 0 4.0004055335884914e-05
phenotypic O 0 0.0014742581406608224
variations O 0 0.0004357231664471328
. O 0 0.0001830081600928679

Moreover O 0 0.0001911870640469715
, O 0 1.7067058024622384e-06
although O 0 2.061241843875905e-07
the O 0 5.685442872049862e-08
scale O 0 2.3462082481273683e-06
of O 0 3.0595817435141726e-08
the O 0 1.2748888877922582e-07
study O 0 8.625159466646437e-07
is O 0 5.5475673832461325e-08
limited O 0 1.5782613616011076e-07
, O 0 3.357602551545824e-08
there O 0 1.0170501774098284e-08
is O 0 1.3377621677079787e-08
a O 0 7.576061733516326e-08
possibility O 0 1.728108827592223e-06
that O 0 2.8711656341329217e-07
PET O 0 0.0003585126542020589
can O 0 7.287883931894612e-07
detect O 0 0.0001289470965275541
an O 0 4.565639301290503e-06
insidious B-Disease 1 0.8440199494361877
lesion I-Disease 1 0.8826707601547241
which O 0 1.6678475844855711e-07
is O 0 1.5937463615500747e-07
undetectable O 0 6.021020817570388e-05
by O 0 5.486262821818855e-08
computed O 0 1.6886825733308797e-06
tomogram O 0 0.0015086348867043853
( O 0 2.097297146974597e-05
CT O 0 0.08128751069307327
) O 0 2.3063114440446952e-07
or O 0 3.0611349188802706e-07
MRI O 0 7.387343066511676e-05
analysis O 0 1.3644729790485144e-07
, O 0 1.6483497233821254e-08
and O 0 3.2919491577132476e-09
that O 0 1.152175910235087e-09
the O 0 2.508733665251839e-09
higher O 0 3.155890837547304e-08
level O 0 2.940233478909704e-08
of O 0 8.50599413126929e-09
tau O 0 6.59782244838425e-06
reflects O 0 9.994871419394258e-08
the O 0 1.1240939734591393e-08
process O 0 9.358792141256345e-08
of O 0 1.7664038978182361e-06
neuronal B-Disease 0 0.2482260912656784
degeneration I-Disease 1 0.9987257122993469
in O 0 0.003437438514083624
ALD B-Disease 1 0.9973337650299072
. O 0 0.0008838497451506555

Lorenzos O 0 0.015169311314821243
Oil O 0 3.469193688943051e-05
should O 0 5.087657086733088e-07
be O 0 3.1449005177819345e-08
given O 0 2.742172888758887e-08
in O 0 3.299708239978827e-08
the O 0 8.538002305158443e-08
early O 0 1.6591869780313573e-06
stage O 0 4.202960917609744e-05
. O 0 2.6071850243170047e-06
. O 0 7.929094863357022e-06

Nonsense O 0 0.0005912621272727847
mutation O 0 2.7255415261606686e-05
in O 0 8.094447139228578e-07
exon O 0 3.130079494439997e-05
4 O 0 1.3888555940866354e-06
of O 0 1.4158320027490845e-07
human O 0 4.217448349663755e-06
complement O 0 0.00011492132034618407
C9 O 1 0.8635852336883545
gene O 0 1.1879833436978515e-05
is O 0 1.7241680438928597e-07
the O 0 2.0833284963828191e-07
major O 0 9.591957677912433e-06
cause O 0 6.74894472467713e-05
of O 0 1.7597388932699687e-06
Japanese O 0 0.011702150106430054
complement B-Disease 0 0.27590277791023254
C9 I-Disease 1 0.9969093203544617
deficiency I-Disease 1 0.998023271560669
. O 0 0.00047282714513130486

Deficiency B-Disease 1 0.9934744238853455
of I-Disease 0 4.625808855962532e-07
the I-Disease 0 5.325212555362668e-07
ninth I-Disease 0 7.057982202240964e-06
component I-Disease 0 1.3428939382720273e-06
of I-Disease 0 5.9198576707331085e-08
human I-Disease 0 1.4320900163511396e-06
complement I-Disease 0 1.1081673619628418e-05
( O 0 2.2874130081618205e-05
C9 O 0 0.12337790429592133
) O 0 2.1746606648775924e-07
is O 0 1.8644293220404506e-08
the O 0 3.246172397552982e-08
most O 0 2.829770266998821e-07
common O 0 8.799703209660947e-05
complement B-Disease 1 0.8836806416511536
deficiency I-Disease 1 0.9998860359191895
in O 0 6.521017439808929e-06
Japan O 0 0.00025655378703959286
but O 0 6.89966100253514e-07
is O 0 2.383905410852094e-07
rare O 0 5.75794501855853e-06
in O 0 7.678199409610897e-08
other O 0 1.069782555873644e-07
countries O 0 1.048576450557448e-06
. O 0 9.562475497659761e-06

We O 0 1.264416596313822e-06
studied O 0 7.796850809427269e-07
the O 0 1.1164236468630406e-07
molecular O 0 1.6838212104630657e-06
basis O 0 5.095416781841777e-07
of O 0 2.567585397628136e-05
C9 B-Disease 1 0.9972805976867676
deficiency I-Disease 1 0.9985418319702148
in O 0 5.199937731958926e-06
four O 0 2.923148167610634e-05
Japanese O 0 0.15512709319591522
C9 B-Disease 1 0.9977770447731018
- I-Disease 1 0.9981924891471863
deficient I-Disease 1 0.9976442456245422
patients O 1 0.9605855345726013
who O 0 0.0008362129447050393
had O 0 0.003763307351619005
suffered O 1 0.9974274039268494
from O 0 0.06325370073318481
meningococcal B-Disease 1 0.9985318183898926
meningitis I-Disease 1 0.9979619979858398
. O 0 0.002708008047193289

Direct O 0 1.8022122958427644e-06
sequencing O 0 3.2378084142692387e-06
of O 0 7.046730843285332e-07
amplified O 0 4.6943925553932786e-05
C9 O 0 0.004068043082952499
cDNA O 0 5.318241619534092e-06
and O 0 2.1239767988845415e-07
DNA O 0 1.0480845276106265e-06
revealed O 0 9.927847486324026e-07
a O 0 1.2729401532851625e-07
nonsense O 0 2.6565767257125117e-06
substitution O 0 1.2668016324823839e-06
( O 0 2.081836100842338e-06
CGA O 0 0.0003702418180182576
- O 0 0.000980464043095708
- O 0 0.00037057531881146133
> O 0 0.0005101825809106231
TGA O 0 0.00042401207610964775
) O 0 2.5032809602976158e-08
at O 0 1.1166616964430887e-08
codon O 0 5.7993588598037604e-08
95 O 0 3.588829144973715e-08
in O 0 7.61267671123278e-09
exon O 0 8.410410146098002e-07
4 O 0 8.130501782943611e-08
in O 0 2.4033170120674185e-08
the O 0 1.1448187819951272e-07
four O 0 8.118722689687274e-06
C9 B-Disease 1 0.9911397099494934
- I-Disease 1 0.8283572196960449
deficient I-Disease 0 0.38975122570991516
individuals O 0 9.911878805723973e-06
. O 0 1.8097396605298854e-05

An O 0 7.312582511076471e-06
allele O 0 5.2875984692946076e-05
- O 0 9.642893564887345e-05
specific O 0 1.774007614585571e-06
polymerase O 0 0.0006215956527739763
chain O 0 0.001121941371820867
reaction O 0 9.464655886404216e-05
system O 0 1.5438045011251234e-05
designed O 0 7.178795840445673e-06
to O 0 1.0523617532953722e-07
detect O 0 3.769316208490636e-06
exclusively O 0 7.245580579962052e-09
only O 0 1.297302931746458e-09
one O 0 8.884037949741241e-10
of O 0 1.0351526302798675e-09
the O 0 8.607901946788843e-09
normal O 0 1.4816539817275043e-07
and O 0 3.880419896518106e-08
mutant O 0 7.856242518755607e-06
alleles O 0 1.7756221950548934e-06
indicated O 0 8.963050959209795e-07
that O 0 3.8968765991853616e-09
all O 0 2.3658028869277814e-09
the O 0 2.204663118732242e-08
four O 0 5.128039788360184e-07
patients O 0 0.000275167083600536
were O 0 9.818782231718615e-09
homozygous O 0 1.7500508420198457e-07
for O 0 7.696333348405915e-09
the O 0 1.6950878034549532e-08
mutation O 0 4.4585993919099565e-07
in O 0 3.2365960578317754e-08
exon O 0 1.3348330867302138e-05
4 O 0 2.0433762415450474e-07
and O 0 1.1063035820768619e-08
that O 0 3.6624245858263293e-09
the O 0 1.861806886438444e-08
parents O 0 1.7700992316349584e-07
of O 0 1.0027734020923162e-07
patient O 0 0.00013342624879442155
2 O 0 1.1653354476948152e-06
were O 0 1.0992261678666182e-07
heterozygous O 0 1.8776046999846585e-05
. O 0 1.1972426364081912e-05

The O 0 1.8543486248745467e-06
common O 0 2.7060420961788623e-06
mutation O 0 3.3472583709226456e-06
at O 0 5.123894197822665e-07
codon O 0 2.1467615169967758e-06
95 O 0 1.0509971843930543e-06
in O 0 1.4820737703757914e-07
exon O 0 4.245941818226129e-05
4 O 0 2.0193710952298716e-06
might O 0 1.634489166235653e-07
be O 0 5.514523060412557e-09
responsible O 0 1.8451565608756937e-07
for O 0 2.0555411595069017e-07
most O 0 5.485260317072971e-06
Japanese O 0 0.14250406622886658
C9 B-Disease 1 0.998333752155304
deficiency I-Disease 1 0.9990944862365723
. O 0 3.344890137668699e-05
. O 0 3.547087180777453e-05

BRCA1 O 0 0.0008142328006215394
required O 0 2.1864734662813134e-06
for O 0 1.5282145113815204e-06
transcription O 0 0.0007053400622680783
- O 0 0.11097442358732224
coupled O 0 0.012485641986131668
repair O 0 0.31060293316841125
of O 0 1.668060212978162e-05
oxidative O 1 0.8243948221206665
DNA O 0 0.029250871390104294
damage O 1 0.6869673132896423
. O 0 0.00015165904187597334

The O 0 0.012818179093301296
breast B-Disease 1 0.9978020787239075
and I-Disease 1 0.9717736840248108
ovarian I-Disease 1 0.9996856451034546
cancer I-Disease 1 0.9993481040000916
susceptibility O 1 0.7926866412162781
gene O 0 0.00046143162762746215
BRCA1 O 0 0.0026204523164778948
encodes O 0 8.380774488614406e-06
a O 0 7.313014975807164e-06
zinc O 0 0.0394539013504982
finger O 0 0.0001427459210390225
protein O 0 1.6205633528443286e-06
of O 0 2.687069127205177e-07
unknown O 0 6.30898875897401e-06
function O 0 1.1196047125849873e-05
. O 0 1.9392624380998313e-05

Association O 0 3.7812726077390835e-05
of O 0 3.2127138638315955e-07
the O 0 1.0092491038449225e-06
BRCA1 O 0 0.00019772554514929652
protein O 0 5.749005254074291e-07
with O 0 1.0127898519840528e-07
the O 0 2.513395713776845e-07
DNA O 0 2.4074928660411388e-05
repair O 0 0.02619660273194313
protein O 0 1.927306038851384e-05
Rad51 O 0 0.0060625565238296986
and O 0 5.765367916410469e-08
changes O 0 6.52372733611628e-08
in O 0 4.930484021059556e-09
the O 0 3.447545360302229e-09
phosphorylation O 0 2.135036325512374e-08
and O 0 6.60260157658854e-09
cellular O 0 1.8674833768272947e-07
localization O 0 8.973026410785678e-08
of O 0 2.4126853848116525e-09
the O 0 1.5905571970620258e-08
protein O 0 3.3296632295787276e-07
after O 0 1.0371066991865519e-06
exposure O 0 5.886989310965873e-05
to O 0 1.1644272746025308e-07
DNA O 0 9.864327876130119e-05
- O 0 0.025583703070878983
damaging O 0 0.0010035712039098144
agents O 0 3.319435109006008e-07
are O 0 3.15047010701619e-09
consistent O 0 4.382188834028966e-08
with O 0 1.596121634861447e-08
a O 0 1.2004844052171393e-07
role O 0 3.662762537715025e-07
for O 0 6.87601982463093e-07
BRCA1 O 0 0.004749958403408527
in O 0 4.299776719562942e-06
DNA O 0 0.0006170750712044537
repair O 1 0.6976190805435181
. O 0 0.00013208933523856103

Here O 0 8.666140274726786e-06
, O 0 3.806948996043502e-07
it O 0 4.5141248961044766e-08
is O 0 5.7794164121105496e-08
shown O 0 7.613290620156477e-08
that O 0 1.8236285370676342e-07
mouse O 0 0.0006535251741297543
embryonic O 0 0.024758627638220787
stem O 1 0.5619362592697144
cells O 0 0.016068551689386368
deficient B-Disease 1 0.8470578789710999
in I-Disease 0 3.5590719562605955e-06
BRCA1 I-Disease 0 0.006948400288820267
are O 0 7.930745482553903e-08
defective O 0 0.00035850913263857365
in O 0 5.88263517897758e-08
the O 0 3.2299912078315174e-08
ability O 0 5.292436000559064e-08
to O 0 4.744015402735613e-09
carry O 0 2.757603745351389e-08
out O 0 4.961125910085684e-08
transcription O 0 1.478396006859839e-05
- O 0 0.000884048524312675
coupled O 0 0.0003169196716044098
repair O 0 0.005970846861600876
of O 0 7.675020583519654e-07
oxidative O 0 0.2982715666294098
DNA O 0 0.0058980537578463554
damage O 0 0.09918469190597534
, O 0 4.1075330159401346e-07
and O 0 6.24237941337924e-08
are O 0 5.106936384891014e-08
hypersensitive O 0 0.0006182588986121118
to O 0 6.783246817576583e-07
ionizing O 0 0.0027039048727601767
radiation O 0 0.0005071797058917582
and O 0 9.182134590446367e-07
hydrogen O 0 5.087585304863751e-05
peroxide O 0 0.0024073412641882896
. O 0 2.6518800950725563e-05

These O 0 2.3019481432129396e-06
results O 0 8.093605174508411e-06
suggest O 0 8.399385478696786e-06
that O 0 1.3931309013059945e-06
BRCA1 O 0 0.003304056590422988
participates O 0 3.492346513667144e-05
, O 0 2.7326083795742306e-07
directly O 0 1.526238122551149e-07
or O 0 2.7910576250178565e-07
indirectly O 0 1.0867800028790953e-06
, O 0 6.085598158733774e-08
in O 0 9.016206803380555e-08
transcription O 0 3.652804298326373e-05
- O 0 0.00942152552306652
coupled O 0 0.0016578953946009278
repair O 0 0.030897699296474457
of O 0 2.6908412564807804e-06
oxidative O 1 0.6101580858230591
DNA O 0 0.014059898443520069
damage O 0 0.4093751907348633
. O 0 1.5198766050161794e-05
. O 0 3.579422991606407e-05

Truncation O 0 0.0011055365903303027
mutations O 0 6.885472976136953e-05
in O 0 7.154424679356453e-07
the O 0 1.139306959885289e-06
transactivation O 0 0.0015199880581349134
region O 0 5.969695848762058e-06
of O 0 1.1359231848473428e-06
PAX6 O 1 0.5505813360214233
result O 0 1.2676980986725539e-05
in O 0 1.8555480210125097e-06
dominant O 0 0.00046908133663237095
- O 0 0.012302489951252937
negative O 0 8.485682337777689e-05
mutants O 0 0.0009159972541965544
. O 0 2.325304740224965e-05

PAX6 O 0 0.04639791324734688
is O 0 1.7826466773840366e-06
a O 0 1.0859034773602616e-06
transcription O 0 6.134631348686526e-06
factor O 0 1.1379756870155688e-06
with O 0 4.835897371435749e-08
two O 0 2.6851829204588284e-08
DNA O 0 2.526262051105732e-06
- O 0 1.030379189614905e-05
binding O 0 1.935947580022912e-07
domains O 0 1.2324251201789593e-06
( O 0 7.039919296403241e-07
paired O 0 3.2071961868496146e-06
box O 0 7.518719939980656e-06
and O 0 2.416454378817434e-07
homeobox O 0 0.00042750281863845885
) O 0 3.880745680362452e-08
and O 0 7.954921166231088e-09
a O 0 5.3219736173559795e-08
proline O 0 6.134841896709986e-06
- O 0 1.9906661691493355e-05
serine O 0 4.738718871521996e-06
- O 0 4.3876654672203586e-05
threonine O 0 9.417204637429677e-06
( O 0 5.517426416190574e-06
PST O 0 0.0008983278530649841
) O 0 2.092109752993565e-06
- O 0 5.759362466051243e-05
rich O 0 7.219149665615987e-06
transactivation O 0 0.000578937353566289
domain O 0 2.3760350813972764e-05
. O 0 1.7651576854404993e-05

PAX6 O 1 0.9496771097183228
regulates O 0 0.08023045212030411
eye O 0 0.4032033383846283
development O 0 5.821577360620722e-05
in O 0 4.003848971478874e-06
animals O 0 9.884946848615073e-06
ranging O 0 3.9326565456576645e-05
from O 0 2.0631566712836502e-06
jellyfish O 0 6.82469762978144e-05
to O 0 1.507427214164636e-07
Drosophila O 0 2.5357094273203984e-06
to O 0 4.935275796924543e-07
humans O 0 1.7803018636186607e-05
. O 0 9.402102477906737e-06

Heterozygous O 0 0.00018220512720290571
mutations O 0 3.6088273191126063e-05
in O 0 9.153352493740385e-07
the O 0 1.2649304608203238e-06
human O 0 4.640938277589157e-05
PAX6 O 1 0.661054253578186
gene O 0 2.1038680642959662e-05
result O 0 1.5641373920516344e-06
in O 0 9.166930681203667e-08
various O 0 2.7982696337858215e-07
phenotypes O 0 0.0007489770068787038
, O 0 3.3154658467537956e-06
including O 0 3.0779796361457556e-05
aniridia B-Disease 1 0.9963675737380981
, O 0 0.00044211605563759804
Peters B-Disease 1 0.984026312828064
anomaly I-Disease 1 0.9652611613273621
, O 0 0.00021963314793538302
autosomal B-Disease 1 0.980972170829773
dominant I-Disease 1 0.6239902377128601
keratitis I-Disease 1 0.9977360963821411
, O 0 0.0003960868634749204
and O 0 0.0005625970079563558
familial B-Disease 1 0.997288703918457
foveal I-Disease 1 0.9973810315132141
dysplasia I-Disease 1 0.9982929825782776
. O 0 0.010166567750275135

It O 0 3.486381501716096e-06
is O 0 5.663390538757085e-07
believed O 0 3.209835313100484e-07
that O 0 1.259823978472241e-08
the O 0 2.4518262975448124e-08
mutated O 0 3.6306669244368095e-06
allele O 0 5.383269012781966e-07
of O 0 9.37590840521807e-08
PAX6 O 0 0.017610294744372368
produces O 0 4.124515726289246e-06
an O 0 2.2533026822202373e-07
inactive O 0 3.183092485414818e-05
protein O 0 8.258842171926517e-06
and O 0 5.906322712689871e-06
aniridia B-Disease 1 0.9186473488807678
is O 0 1.1832752534246538e-05
caused O 0 0.0005073369247838855
due O 0 8.733783943171147e-06
to O 0 2.2712665668223053e-06
genetic O 0 0.0008664267370477319
haploinsufficiency O 0 0.23683536052703857
. O 0 9.989496174966916e-05

However O 0 3.7739455365226604e-06
, O 0 7.920056077637128e-07
several O 0 4.4046092284588667e-07
truncation O 0 0.00031581908115185797
mutations O 0 2.236419459222816e-05
have O 0 3.167577844465086e-08
been O 0 1.6566580995913682e-08
found O 0 2.1451349141443643e-08
to O 0 8.444372312510495e-09
occur O 0 5.343679987390715e-08
in O 0 1.4584252028271294e-08
the O 0 1.0290118268585502e-07
C O 0 0.0002333845040993765
- O 0 4.660487684304826e-05
terminal O 0 8.144964340317529e-06
half O 0 4.747937509819167e-08
of O 0 2.6873303227148426e-07
PAX6 O 1 0.6512005925178528
in O 0 5.110969141242094e-06
patients O 0 0.0047438060864806175
with O 0 3.3877452096930938e-06
Aniridia B-Disease 1 0.7346283793449402
resulting O 0 1.142590645031305e-05
in O 0 9.421118818409013e-08
mutant O 0 3.165160933349398e-06
proteins O 0 6.27393887953076e-08
that O 0 7.022550096991154e-09
retain O 0 8.695214859244516e-08
the O 0 4.318406965353461e-08
DNA O 0 2.7810060601041187e-06
- O 0 3.2887852285057306e-05
binding O 0 2.9015100722062925e-07
domains O 0 8.848286370266578e-07
but O 0 2.6500046601540816e-08
have O 0 6.52894094343992e-09
lost O 0 6.269476671150187e-08
most O 0 4.617542348483994e-09
of O 0 1.0850671472439899e-08
the O 0 4.699434441590711e-07
transactivation O 0 0.0005205875495448709
domain O 0 2.394025977991987e-05
. O 0 1.4138463484414387e-05

It O 0 3.670700380098424e-06
is O 0 5.115427939017536e-07
not O 0 7.344399932662782e-08
clear O 0 2.0060181782355357e-07
whether O 0 1.78448075871529e-07
such O 0 3.493326516945672e-07
mutants O 0 0.00010959101200569421
really O 0 4.833946604776429e-06
behave O 0 4.3431568883534055e-06
as O 0 2.2323199289076e-07
loss O 0 0.00016914443403948098
- O 0 3.346108860569075e-05
of O 0 1.3944719512437587e-07
- O 0 0.00016749279166106135
function O 0 7.172336609073682e-07
mutants O 0 1.8848419131245464e-05
as O 0 2.1609497480312712e-07
predicted O 0 2.9128850655979477e-05
by O 0 2.1442856450448744e-06
haploinsufficiency O 0 0.004398840945214033
. O 0 2.4122178729157895e-05

Contrary O 0 9.536447578284424e-06
to O 0 1.8855689631891437e-07
this O 0 6.210693470620754e-08
theory O 0 2.0904732878079813e-07
, O 0 6.104279748342378e-08
our O 0 2.5583565488318527e-08
data O 0 8.57361115436106e-08
showed O 0 1.9861654720898514e-07
that O 0 5.08987696434815e-09
these O 0 6.044033273866489e-09
mutants O 0 1.6944788967521163e-06
are O 0 1.3063742088093022e-08
dominant O 0 1.9269455151516013e-06
- O 0 2.689538086997345e-05
negative O 0 4.5578070739793475e-07
in O 0 1.8539724067068164e-07
transient O 0 8.24259186629206e-05
transfection O 0 0.0003782212152145803
assays O 0 1.622289005354105e-06
when O 0 5.498278810023294e-08
they O 0 7.548911717947249e-09
are O 0 1.2186621489718164e-08
coexpressed O 0 6.613080040551722e-05
with O 0 8.341634156749933e-07
wild O 0 8.366221300093457e-05
- O 0 0.025917794555425644
type O 0 0.005137090105563402
PAX6 O 1 0.5868270993232727
. O 0 4.013826037407853e-05

We O 0 2.213247171312105e-06
found O 0 6.670845209555409e-07
that O 0 1.1198637395182232e-07
the O 0 4.6893035232642433e-07
dominant O 0 0.0001865184458438307
- O 0 0.01026819460093975
negative O 0 2.4143302653101273e-05
effects O 0 9.037462587002665e-05
result O 0 3.8711945649083646e-07
from O 0 2.044685487589959e-08
the O 0 2.8506963900554183e-08
enhanced O 0 1.249964839189488e-06
DNA O 0 4.78217486943322e-07
binding O 0 1.7435407073662645e-07
ability O 0 1.392039052916516e-07
of O 0 3.36737002726295e-08
these O 0 3.769596901292971e-07
mutants O 0 0.00015342085680458695
. O 0 1.7968450265470892e-05

Kinetic O 0 2.0043358745169826e-05
studies O 0 1.7973275134863798e-06
of O 0 1.1951691192280123e-07
binding O 0 1.1288530004094355e-06
and O 0 4.087237073235883e-07
dissociation O 0 0.0001747284986777231
revealed O 0 2.557040488682105e-06
that O 0 1.3959883027325759e-08
various O 0 2.8961460785126292e-08
truncation O 0 1.1272585652477574e-05
mutants O 0 4.847227955906419e-06
have O 0 3.165234474522549e-08
3 O 0 4.901355055153545e-07
- O 0 2.0666817363235168e-05
5 O 0 9.574187060934491e-07
- O 0 1.7336007658741437e-05
fold O 0 1.2975247045687865e-06
higher O 0 2.837730761484636e-08
affinity O 0 3.345896715245544e-08
to O 0 1.8111480093452315e-09
various O 0 3.0215943080946772e-09
DNA O 0 3.7126804386389267e-07
- O 0 2.4127109554683557e-06
binding O 0 5.581275175359224e-08
sites O 0 1.0451401522004744e-08
when O 0 1.4893786648428886e-08
compared O 0 1.257161272860685e-07
with O 0 3.658056257904718e-08
the O 0 2.545084782923368e-07
wild O 0 4.372065086499788e-05
- O 0 0.010297122411429882
type O 0 0.004343322478234768
PAX6 O 0 0.47592514753341675
. O 0 5.669519669027068e-05

These O 0 1.1255227718720562e-06
results O 0 1.230670477525564e-06
provide O 0 1.6369304489671777e-07
a O 0 1.3626186046167277e-07
new O 0 1.5929487062749104e-07
insight O 0 7.168671345425537e-07
into O 0 2.7953722891993493e-08
the O 0 3.346822197158872e-08
role O 0 1.481548110859876e-07
of O 0 2.0053830951383134e-07
mutant O 0 0.0010309849167242646
PAX6 O 1 0.9080799221992493
in O 0 5.736461389460601e-05
causing O 0 0.470547080039978
aniridia B-Disease 1 0.9789689779281616
. O 0 1.7580883650225587e-05
. O 0 3.5461271181702614e-05

Reversal O 1 0.7300651669502258
of O 0 0.36259743571281433
severe O 1 0.9991961121559143
hypertrophic B-Disease 1 0.9994805455207825
cardiomyopathy I-Disease 1 0.9994118213653564
and O 0 0.00012212753063067794
excellent O 0 0.0012541702017188072
neuropsychologic O 0 0.08576158434152603
outcome O 0 2.71846820396604e-05
in O 0 1.5776728332639323e-06
very B-Disease 0 4.627336238627322e-06
- I-Disease 0 0.005726743023842573
long I-Disease 0 0.0003859977296087891
- I-Disease 0 0.0038215345703065395
chain I-Disease 0 0.0004367036744952202
acyl I-Disease 0 0.011403271928429604
- I-Disease 0 0.04565737769007683
coenzyme I-Disease 0 0.021955104544758797
A I-Disease 0 0.025334330275654793
dehydrogenase I-Disease 1 0.9912912845611572
deficiency I-Disease 1 0.9969751834869385
. O 0 0.00039010465843603015

Very B-Disease 0 7.842585182515904e-05
- I-Disease 0 0.003541571320965886
long I-Disease 0 0.0003267277788836509
- I-Disease 0 0.0015888020861893892
chain I-Disease 0 0.00014662592730019242
acyl I-Disease 0 0.0006098650046624243
- I-Disease 0 0.00042791443411260843
coenzyme I-Disease 0 0.0003299019590485841
A I-Disease 0 8.017755317268893e-05
dehydrogenase I-Disease 0 0.21185363829135895
( I-Disease 0 0.0008409502916038036
VLCAD I-Disease 1 0.9945658445358276
) I-Disease 0 0.0354069322347641
deficiency I-Disease 1 0.999496340751648
is O 0 4.789961622009287e-06
a O 0 0.00014413747703656554
disorder O 1 0.983040988445282
of O 0 9.202086062032322e-07
fatty O 0 0.004463887307792902
acid O 0 0.0006350250914692879
beta O 0 0.00010241669224342331
oxidation O 0 5.577960837399587e-05
that O 0 2.3042230168357491e-07
reportedly O 0 6.4048144849948585e-06
has O 0 1.5926737262361712e-07
high O 0 3.3216817882930627e-06
rates O 0 5.457037786982255e-06
of O 0 1.1884466175615671e-06
morbidity O 1 0.846711277961731
and O 0 1.2947697541676462e-05
mortality O 0 0.02499285899102688
. O 0 2.9451915906975046e-05

We O 0 1.9484923541313037e-06
describe O 0 1.1244134157095687e-06
the O 0 6.545975850258401e-08
outcome O 0 1.7234940230537177e-07
of O 0 3.314537977416876e-08
a O 0 3.6784413737223076e-07
5 O 0 5.579876415140461e-06
- O 0 0.00038420912460424006
year O 0 6.922479315107921e-06
- O 0 0.0004923698143102229
old O 0 0.00011958614777540788
girl O 0 0.002219947287812829
with O 0 0.0025914302095770836
VLCAD B-Disease 1 0.9995799660682678
deficiency I-Disease 1 0.9998282194137573
who O 0 1.6933901179072564e-06
was O 0 1.6671476998908474e-07
first O 0 6.038699496002664e-08
seen O 0 1.7843905197878485e-07
at O 0 9.545981072278664e-08
5 O 0 2.780356567200215e-07
months O 0 6.208371701177384e-07
of O 0 4.15286109500812e-07
age O 0 0.00729526299983263
with O 0 0.2497905045747757
severe O 1 0.9996967315673828
hypertrophic B-Disease 1 0.999771773815155
cardiomyopathy I-Disease 1 0.9998438358306885
, O 1 0.9893877506256104
hepatomegaly B-Disease 1 0.9996224641799927
, O 1 0.9742811918258667
encephalopathy B-Disease 1 0.9995228052139282
, O 0 0.00036562103196047246
and O 0 0.00035478302743285894
hypotonia B-Disease 1 0.9946866035461426
. O 0 0.0006336279329843819

Biochemical O 0 0.04365963116288185
studies O 0 0.048496928066015244
indicated O 1 0.988167941570282
VLCAD B-Disease 1 0.9991204142570496
deficiency I-Disease 1 0.9996787309646606
caused O 1 0.519777774810791
by O 0 6.656535333604552e-06
a O 0 3.944070340367034e-05
stable O 0 0.0011806271504610777
yet O 0 4.867385723628104e-05
inactive O 0 0.0007431127014569938
enzyme O 0 0.000263083289610222
. O 0 2.5882729460136034e-05

Molecular O 0 0.0001860150950960815
genetic O 0 5.03496230521705e-05
analysis O 0 1.3273132708491175e-06
of O 0 4.4093036422054865e-07
her O 0 3.489443406579085e-05
VLCAD O 0 0.15209776163101196
gene O 0 2.7691614377545193e-05
revealed O 0 1.5608125977450982e-05
a O 0 3.732155619218247e-06
T1372C O 0 0.002500831848010421
( O 0 1.2079877706128173e-05
F458L O 0 0.00018879528215620667
) O 0 8.393823236474418e-07
missense O 0 2.4414408471784554e-05
mutation O 0 4.148572315898491e-06
and O 0 2.8991701128688874e-07
a O 0 1.0653437129803933e-05
1668 O 0 0.3278650641441345
ACAG O 1 0.6292824149131775
1669 O 0 0.057928718626499176
splice O 0 0.0006227727863006294
site O 0 4.695650568464771e-05
mutation O 0 0.00019332263036631048
. O 0 2.685079198272433e-05

After O 0 0.00014767207903787494
initial O 0 0.0003563597856555134
treatment O 0 0.002906758338212967
with O 0 1.4688354895042721e-05
intravenous O 0 0.029445648193359375
glucose O 0 0.00169039994943887
and O 0 2.147966188204009e-05
carnitine O 1 0.8799092769622803
, O 0 1.2785613989763078e-06
the O 0 7.534702604061749e-07
patient O 0 9.491715900367126e-05
has O 0 1.5064915714901872e-07
thrived O 0 3.2872687825147295e-06
on O 0 1.9517448990313824e-08
a O 0 2.5958516403079557e-07
low O 0 2.112025504175108e-05
- O 0 0.000165647390531376
fat O 0 1.0197286428592633e-05
diet O 0 3.056244850085932e-06
supplemented O 0 5.59664670163329e-07
with O 0 1.6805199720693054e-07
medium O 0 2.4206197849707678e-05
- O 0 0.00023619187413714826
chain O 0 4.187833837931976e-05
triglyceride O 0 6.862779264338315e-05
oil O 0 3.0205815164663363e-06
and O 0 8.952219445745868e-07
carnitine O 0 0.060314033180475235
and O 0 5.349722300707072e-07
avoidance O 0 0.00033495709067210555
of O 0 1.2907182735943934e-06
fasting O 0 0.0002625693450681865
. O 0 5.2065690397284925e-05

Her O 0 0.010792494751513004
ventricular O 1 0.9889664053916931
hypertrophy O 1 0.9880358576774597
resolved O 0 0.00039638776797801256
significantly O 0 7.55911969463341e-05
over O 0 1.436646584807022e-06
1 O 0 4.3052664295828436e-06
year O 0 2.770259015960619e-06
, O 0 4.372124351448292e-07
and O 0 3.187529955539503e-07
cognitively O 0 0.00038550939643755555
, O 0 1.6697477178695408e-07
she O 0 9.28571424196889e-08
is O 0 6.063177071524706e-09
in O 0 1.0520723847662339e-08
the O 0 4.337880810112438e-08
superior O 0 5.451565357361687e-06
range O 0 1.0739004210336134e-06
for O 0 3.7148939213693666e-07
age O 0 8.47445844556205e-05
. O 0 1.2177755706943572e-05

Clinical O 0 0.007415498606860638
recognition O 0 0.0004935174947604537
of O 0 0.023405900225043297
VLCAD B-Disease 1 0.999634861946106
deficiency I-Disease 1 0.9998706579208374
is O 0 1.3225471775513142e-05
important O 0 9.361681918562681e-07
because O 0 3.9248587313522876e-07
it O 0 1.1938493749141799e-08
is O 0 4.563859512529689e-09
one O 0 2.4685957722425655e-09
of O 0 7.24425364140302e-09
the O 0 3.040152876110369e-07
few O 0 9.673966815171298e-06
directly O 0 0.00023388685076497495
treatable O 1 0.9994300007820129
causes O 1 0.622664213180542
of O 0 0.0011907381704077125
cardiomyopathy B-Disease 1 0.9996912479400635
in O 0 0.00011551515490282327
children O 0 0.00022515880118589848
. O 0 2.291004238941241e-05
. O 0 3.9268485124921426e-05

Cloning O 0 4.501843795878813e-05
of O 0 3.229160085993499e-07
a O 0 8.173585683834972e-07
novel O 0 1.0102834266945138e-06
member O 0 1.1910206154652769e-07
of O 0 3.2062551724720834e-08
the O 0 2.761989321697911e-07
low O 0 7.616992661496624e-05
- O 0 0.002102678408846259
density O 0 0.00010973834287142381
lipoprotein O 1 0.5827302932739258
receptor O 0 0.00032274529803544283
family O 0 3.8271056837402284e-05
. O 0 1.8545253624324687e-05

A O 0 5.4967445066722576e-06
gene O 0 2.2545093543158146e-06
encoding O 0 9.098574196286791e-07
a O 0 8.262381356871629e-07
novel O 0 8.695860742591321e-06
transmembrane O 0 0.00019134717877022922
protein O 0 1.3759895409748424e-06
was O 0 8.136242257705817e-08
identified O 0 2.582600799883039e-08
by O 0 3.3668161592004253e-09
DNA O 0 4.7131191394100824e-08
sequence O 0 2.662437559308728e-08
analysis O 0 5.616216114390227e-08
within O 0 1.3783363783659297e-07
the O 0 4.520907623373205e-06
insulin B-Disease 1 0.5156866312026978
- I-Disease 1 0.99284827709198
dependent I-Disease 1 0.9702073931694031
diabetes I-Disease 1 0.9998053908348083
mellitus I-Disease 1 0.999373733997345
( O 0 0.0016147630522027612
IDDM B-Disease 0 0.23011831939220428
) O 0 9.598445103620179e-06
locus O 0 8.411113230977207e-05
IDDM4 O 0 0.006712073460221291
on O 0 5.575482646236196e-06
chromosome O 0 0.00065616361098364
11q13 O 0 0.005155777093023062
. O 0 5.8110443205805495e-05

Based O 0 2.14153897104552e-06
on O 0 3.5280925203551305e-07
its O 0 7.69749533446884e-07
chromosomal O 0 0.0003016286063939333
position O 0 8.437741030320467e-07
, O 0 1.8043947136447969e-07
this O 0 2.023629797065496e-08
gene O 0 4.028312901027675e-07
is O 0 1.3844986490596511e-08
a O 0 9.121478683482565e-08
candidate O 0 3.0218845381568826e-07
for O 0 6.055447556718718e-07
conferring O 0 0.0010293282102793455
susceptibility O 1 0.8430899977684021
to O 0 0.0007625928265042603
diabetes B-Disease 1 0.9985186457633972
. O 0 0.0006897370330989361

The O 0 4.149525466345949e-06
gene O 0 1.2372272976790555e-05
, O 0 1.966559466382023e-06
termed O 0 6.52742528473027e-05
low O 0 4.9808113544713706e-05
- O 0 0.00018107487994711846
density O 0 1.0850053513422608e-05
lipoprotein O 0 0.006972832605242729
receptor O 0 1.0863865099963732e-05
related O 0 1.3751474625678384e-06
protein O 0 4.4439539692575636e-07
5 O 0 7.92404478033859e-07
( O 0 1.3887827208236558e-06
LRP5 O 0 0.00020589877385646105
) O 0 2.5670376047060017e-08
, O 0 3.913314561287962e-09
encodes O 0 1.0884126488974744e-08
a O 0 3.7062890534400594e-09
protein O 0 1.434711194292504e-08
of O 0 6.382505191027121e-09
1615 O 0 4.288163381716004e-06
amino O 0 1.8860756512140142e-08
acids O 0 1.4632678180248604e-08
that O 0 1.804118077153305e-09
contains O 0 1.1328714855096678e-08
conserved O 0 2.757319528257085e-08
modules O 0 5.9305939714704436e-08
which O 0 2.8775117844048737e-09
are O 0 1.0926428650748221e-09
characteristic O 0 1.3427649214747817e-08
of O 0 4.072759907103318e-09
the O 0 8.102789905706231e-08
low O 0 1.7372516595060006e-05
- O 0 0.00039736684993840754
density O 0 5.826586493640207e-05
lipoprotein O 0 0.3963731825351715
( O 0 6.149341788841411e-05
LDL O 0 0.3260018229484558
) O 0 4.643901320378063e-06
receptor O 0 4.6160086640156806e-05
family O 0 1.0504548299650196e-05
. O 0 9.062116987479385e-06

These O 0 8.896117833501194e-07
modules O 0 3.2623656807118095e-06
include O 0 5.201730459702958e-07
a O 0 2.813066259932384e-07
putative O 0 7.4307845352450386e-06
signal O 0 6.533627470162173e-07
peptide O 0 5.42560428584693e-07
for O 0 1.4470010967215785e-08
protein O 0 1.504956514963851e-07
export O 0 1.6267183866602863e-07
, O 0 3.863095088263435e-08
four O 0 3.0116163429738663e-07
epidermal O 0 0.03506748378276825
growth O 0 8.232034451793879e-05
factor O 0 2.0862578821834177e-05
( O 0 9.861859325610567e-06
EGF O 0 0.03265823423862457
) O 0 1.7658939555076358e-07
repeats O 0 1.6987795561362873e-06
with O 0 7.060817353021775e-08
associated O 0 4.0359381614507583e-07
spacer O 0 1.7619453501538374e-05
domains O 0 1.16598687327496e-06
, O 0 1.5684871357279917e-07
three O 0 5.363397690416605e-07
LDL O 0 0.3463987410068512
- O 0 0.0006271623424254358
receptor O 0 2.4795628633000888e-05
( O 0 2.500237542335526e-06
LDLR O 0 0.0004611974291037768
) O 0 1.1792605647542587e-07
repeats O 0 8.891129823496158e-07
, O 0 5.453667295540754e-09
a O 0 1.448942565929201e-08
single O 0 4.46884129701175e-08
transmembrane O 0 8.406421329709701e-06
spanning O 0 2.1744294826930854e-06
domain O 0 4.1670796235848684e-07
, O 0 4.401849906798816e-08
and O 0 1.8485728503492282e-08
a O 0 2.3748718547267345e-07
cytoplasmic O 0 2.9483337129931897e-05
domain O 0 1.163433898909716e-05
. O 0 1.60460240294924e-05

The O 0 1.0929414884230937e-06
encoded O 0 1.0517893542782986e-06
protein O 0 2.2730303044227185e-06
has O 0 1.640111975120817e-07
a O 0 9.135442269325722e-08
unique O 0 1.7212913405728614e-07
organization O 0 2.9176538873798563e-07
of O 0 2.63238376874142e-07
EGF O 1 0.5037826895713806
and O 0 1.54448377998051e-06
LDLR O 0 0.03145794942975044
repeats O 0 0.00011842852836707607
; O 0 1.9276878902019234e-06
therefore O 0 4.834163291889126e-07
, O 0 1.2694889619524474e-06
LRP5 O 0 0.01186168659478426
likely O 0 9.464376944379183e-07
represents O 0 2.3039680741021584e-07
a O 0 5.6132819281629054e-08
new O 0 1.3163270295990515e-07
category O 0 7.348742769863748e-07
of O 0 4.4019841993758746e-08
the O 0 2.0934048734488897e-06
LDLR O 0 0.08700624853372574
family O 0 9.334563947049901e-05
. O 0 3.8523423427250236e-05

Both O 0 4.739867108582985e-06
human O 0 1.0303025192115456e-05
and O 0 8.189094842236955e-06
mouse O 0 0.03349386900663376
LRP5 O 1 0.9252830743789673
cDNAs O 0 0.028568265959620476
have O 0 2.355682653387703e-07
been O 0 8.099097215108486e-08
isolated O 0 5.876410682503774e-07
and O 0 9.040536319560033e-09
the O 0 5.913737943785691e-09
encoded O 0 2.6448894629993447e-08
mature O 0 2.255887068258744e-07
proteins O 0 9.655205523984023e-09
are O 0 1.6134452662797116e-09
95 O 0 7.606366381196494e-08
% O 0 2.5853756469018663e-08
identical O 0 3.1026110036691534e-07
, O 0 4.5338332199662545e-08
indicating O 0 3.3342294614158163e-07
a O 0 7.830802672970094e-08
high O 0 9.992905916078598e-07
degree O 0 3.00443332434952e-07
of O 0 8.098680126522595e-08
evolutionary O 0 1.0623627531458624e-05
conservation O 0 2.239151217509061e-05
. O 0 1.7586147578185773e-06
. O 0 6.49107460048981e-06

The O 0 1.5241685105138458e-05
APC B-Disease 0 0.0009322526166215539
variants O 0 5.102935028844513e-05
I1307K O 0 0.0005743398214690387
and O 0 1.6646692984068068e-06
E1317Q O 0 0.0009427601471543312
are O 0 1.864642968030239e-06
associated O 0 0.012468626722693443
with O 1 0.9728409647941589
colorectal B-Disease 1 0.9999549388885498
tumors I-Disease 1 0.9999216794967651
, O 0 8.425571286352351e-05
but O 0 6.577928957085533e-07
not O 0 3.3564816703801625e-08
always O 0 9.502165454478018e-08
with O 0 9.26577499171799e-08
a O 0 1.017249928736419e-06
family O 0 1.3601712453237269e-05
history O 0 2.6895279006566852e-05
. O 0 3.069072408834472e-05

Classical O 0 0.11876829713582993
familial B-Disease 1 0.9931566119194031
adenomatous I-Disease 1 0.9956679344177246
polyposis I-Disease 1 0.9979230761528015
( O 0 0.0514543391764164
FAP B-Disease 1 0.982633650302887
) O 0 1.3952362678537611e-05
is O 0 1.0547142892392003e-06
a O 0 1.2033861821691971e-05
high O 0 0.01803615875542164
- O 1 0.9940947890281677
penetrance O 1 0.9976651668548584
autosomal B-Disease 1 0.9987812638282776
dominant I-Disease 1 0.9976377487182617
disease I-Disease 1 0.9995546936988831
that O 0 2.012777258642018e-05
predisposes O 0 0.11396829038858414
to O 0 8.367496775463223e-07
hundreds O 0 5.634903573081829e-06
or O 0 7.415372692776145e-06
thousands O 0 0.00013739288260694593
of O 0 0.013111358508467674
colorectal B-Disease 1 0.9998993873596191
adenomas I-Disease 1 0.9996918439865112
and I-Disease 0 0.19858747720718384
carcinoma I-Disease 1 0.9998354911804199
and O 0 1.3276398931338917e-06
that O 0 1.4091372690927528e-07
results O 0 6.900023095113283e-07
from O 0 5.094075277156662e-07
truncating O 0 0.000420917960582301
mutations O 0 9.181992936646566e-06
in O 0 3.0524535077347537e-07
the O 0 1.7784898318495834e-06
APC B-Disease 0 0.00796192605048418
gene O 0 9.173440776066855e-05
. O 0 2.266599767608568e-05

A O 0 0.0001563422556500882
variant O 0 0.003078681183978915
of O 0 6.340109393931925e-05
FAP B-Disease 1 0.9890193343162537
is O 0 0.015375719405710697
attenuated B-Disease 1 0.9960629343986511
adenomatous I-Disease 1 0.999171257019043
polyposis I-Disease 1 0.9991986155509949
coli I-Disease 1 0.9969862103462219
, O 0 3.581510327421711e-06
which O 0 3.2783106007627794e-07
results O 0 3.180447492923122e-06
from O 0 8.01325495558558e-06
germ O 1 0.8655816316604614
- O 0 0.0006596215534955263
line O 0 1.7613305089980713e-06
mutations O 0 3.283739431481081e-07
in O 0 7.487880537837555e-09
the O 0 6.258864981845136e-09
5 O 0 8.969501408273572e-08
and O 0 1.1949042644232577e-08
3 O 0 6.287092446655151e-08
regions O 0 2.3393303294483303e-08
of O 0 1.115061287748631e-08
the O 0 4.194734231077746e-07
APC B-Disease 0 0.00110640749335289
gene O 0 4.499522765399888e-05
. O 0 1.191246246889932e-05

Attenuated B-Disease 1 0.987016499042511
adenomatous I-Disease 1 0.9977542757987976
polyposis I-Disease 1 0.9991889595985413
coli I-Disease 1 0.9991518259048462
patients O 1 0.9944849610328674
have O 0 3.5729088267544284e-05
" O 0 7.508341514039785e-05
multiple O 0 0.01202234998345375
" O 1 0.5536298155784607
colorectal B-Disease 1 0.999830961227417
adenomas I-Disease 1 0.9992918968200684
( O 0 5.239587335381657e-05
typically O 0 1.510643642177456e-06
fewer O 0 4.7070912501112616e-07
than O 0 2.061005233144897e-08
100 O 0 5.216977427835445e-08
) O 0 3.2289868556745205e-08
without O 0 2.0138459788654473e-08
the O 0 1.0629688773633461e-07
florid O 0 0.001584596000611782
phenotype O 0 8.264787902589887e-05
of O 0 6.505778173959698e-07
classical O 0 0.0002593359677121043
FAP B-Disease 1 0.9550208449363708
. O 0 8.901265391614288e-05

Another O 0 2.5386772904312238e-05
group O 0 1.50542082337779e-05
of O 0 1.0548880709393416e-05
patients O 0 0.3699767291545868
with O 0 5.7579512940719724e-05
multiple O 0 0.019147314131259918
adenomas B-Disease 1 0.9966332316398621
has O 0 3.6005169476993615e-06
no O 0 6.996408501436235e-07
mutations O 0 2.4707792363187764e-06
in O 0 4.274401277370998e-08
the O 0 3.6822916626988444e-07
APC B-Disease 0 0.002344762673601508
gene O 0 2.5836632175924024e-06
, O 0 4.3874660349274563e-08
and O 0 1.6989233131425863e-08
their O 0 3.6582097351356424e-08
phenotype O 0 0.00010133855539606884
probably O 0 2.670659569048439e-07
results O 0 3.62214755966761e-08
from O 0 8.64460858451821e-09
variation O 0 8.37973246348156e-08
at O 0 4.6022190502981175e-08
a O 0 1.6189771656627272e-07
locus O 0 8.191836059268098e-06
, O 0 7.517764544218153e-08
or O 0 1.308953727630069e-07
loci O 0 1.3122649988872581e-06
, O 0 9.001602307989742e-08
elsewhere O 0 1.7997855650264682e-07
in O 0 7.934860946079425e-08
the O 0 4.174939078893658e-07
genome O 0 4.783284748555161e-05
. O 0 1.275924932997441e-05

Recently O 0 0.00011645580525510013
, O 0 1.6744340882723918e-06
however O 0 1.9369798565094243e-07
, O 0 8.17324448121326e-08
a O 0 4.355299552116776e-07
missense O 0 7.432048732880503e-05
variant O 0 7.257503602886572e-05
of O 0 7.498530862903863e-07
APC B-Disease 0 0.018133515492081642
( O 0 2.1694315364584327e-05
I1307K O 0 0.0005712448619306087
) O 0 5.352779339773406e-07
was O 0 1.6456614559956506e-07
described O 0 9.611530913389288e-07
that O 0 8.318803423890131e-08
confers O 0 3.220265352865681e-05
an O 0 2.2354697648552246e-06
increased O 0 0.0014596565160900354
risk O 1 0.728062629699707
of O 0 0.14794005453586578
colorectal B-Disease 1 0.9999510049819946
tumors I-Disease 1 0.9998451471328735
, O 0 4.0785878809401765e-05
including O 0 2.5781235308386385e-05
multiple O 0 0.006810562685132027
adenomas B-Disease 1 0.9966586828231812
, O 0 2.1685998945031315e-05
in O 0 2.7486654289532453e-05
Ashkenazim O 0 0.08429562300443649
. O 0 8.948362665250897e-05

We O 0 1.3259835895951255e-06
have O 0 1.167825871561945e-07
studied O 0 1.0456809462766614e-07
a O 0 3.745640597685451e-08
set O 0 9.026273062318069e-08
of O 0 5.412766768131405e-07
164 O 0 0.006738645024597645
patients O 0 0.4715741276741028
with O 0 0.0008762475335970521
multiple O 1 0.9936766028404236
colorectal B-Disease 1 0.9998249411582947
adenomas I-Disease 1 0.9993257522583008
and I-Disease 0 0.009499914012849331
/ I-Disease 1 0.9967195391654968
or I-Disease 0 0.00422704080119729
carcinoma I-Disease 1 0.9990323781967163
and O 0 1.0757886457213317e-06
analyzed O 0 6.1307423493417446e-06
codons O 0 4.369693488115445e-05
1263 O 0 0.005391919054090977
- O 0 0.0011283298954367638
1377 O 0 0.0035039393696933985
( O 0 1.4732339650436188e-06
exon O 0 2.5034034479176626e-05
15G O 0 2.471409061399754e-05
) O 0 3.509942558821422e-08
of O 0 8.675579366013153e-09
the O 0 9.37151085622645e-08
APC B-Disease 0 9.240561485057697e-05
gene O 0 5.2907630561094265e-06
for O 0 2.6533052732702345e-06
germ O 1 0.8495194911956787
- O 0 0.00443450640887022
line O 0 3.676316191558726e-05
variants O 0 6.888409552630037e-05
. O 0 1.549083026475273e-05

Three O 0 4.5046697778161615e-05
patients O 0 0.004669590387493372
with O 0 1.0567622439339175e-06
the O 0 1.249352294507844e-06
I1307K O 0 0.0011847814312204719
allele O 0 1.1804574569396209e-05
were O 0 5.330558039418065e-08
detected O 0 1.736135118335369e-06
, O 0 1.5031544009502795e-08
each O 0 6.093993309974621e-09
of O 0 1.6016726078760257e-07
Ashkenazi O 0 0.00018373654165770859
descent O 0 2.8294967705733143e-05
. O 0 2.9212642402853817e-05

Four O 0 9.672447049524635e-05
patients O 0 0.018485406413674355
had O 0 5.8326104408479296e-06
a O 0 2.070332811854314e-05
germ O 1 0.7128994464874268
- O 0 0.0009537616278976202
line O 0 1.5270565199898556e-05
E1317Q O 0 0.00031424526241607964
missense O 0 0.00011135983368149027
variant O 0 3.378571636858396e-05
of O 0 3.1026138458400965e-07
APC O 0 0.001887214370071888
that O 0 1.6302004723911523e-07
was O 0 1.406073977250344e-07
not O 0 5.8891997944954255e-09
present O 0 4.0555683256116026e-08
in O 0 4.541466935847893e-08
controls O 0 1.2523224768301588e-06
; O 0 1.1778185182720335e-07
one O 0 3.105912638190489e-09
of O 0 3.6695146921061905e-09
these O 0 9.58875112644364e-09
individuals O 0 3.620531430215124e-08
had O 0 5.9217210690576394e-08
an O 0 5.3037638281239197e-08
unusually O 0 5.525619599211495e-06
large O 0 7.595348705535798e-08
number O 0 3.1583173409899246e-08
of O 0 4.4643775254371576e-07
metaplastic B-Disease 0 0.11991611123085022
polyps I-Disease 0 0.022853096947073936
of I-Disease 0 4.82803613977012e-07
the I-Disease 0 1.0917601684923284e-05
colorectum I-Disease 0 0.0389409065246582
. O 0 4.5836142817279324e-05

There O 0 6.463117642852012e-06
is O 0 1.1747911230486352e-06
increasing O 0 5.021377091907198e-06
evidence O 0 1.0360894293626188e-06
that O 0 1.0177782172604566e-07
there O 0 2.477663940680941e-07
exist O 0 2.2478327537100995e-06
germ O 0 0.09363643825054169
- O 0 4.6742279664613307e-05
line O 0 2.3883930566626077e-07
variants O 0 1.1184910420070082e-07
of O 0 9.928688093907567e-09
the O 0 2.102248686242092e-07
APC B-Disease 0 0.0007012939895503223
gene O 0 3.282889110778342e-06
that O 0 6.573539224064007e-08
predispose O 0 6.105897227826063e-06
to O 0 1.1370993924231243e-08
the O 0 3.0694540242848234e-08
development O 0 1.0323434480596916e-06
of O 0 6.504732027678983e-06
multiple O 1 0.9360201358795166
colorectal B-Disease 1 0.9999133348464966
adenomas I-Disease 1 0.9997748732566833
and I-Disease 1 0.9254976511001587
carcinoma I-Disease 1 0.9999245405197144
, O 0 7.4066447268705815e-06
but O 0 1.7207480595970992e-07
without O 0 1.1155913171023712e-07
the O 0 1.766480153264638e-07
florid O 0 0.0041055502369999886
phenotype O 0 4.991733658243902e-05
of O 0 1.422070425860511e-07
classical O 0 5.613275061477907e-05
FAP B-Disease 1 0.6634148955345154
, O 0 3.5186437230549927e-07
and O 0 1.3358618389247567e-07
possibly O 0 1.1409314311094931e-06
with O 0 2.2691253889206564e-06
importance O 0 0.001617959002032876
for O 1 0.909140944480896
colorectal B-Disease 1 0.9999650716781616
cancer I-Disease 1 0.9999402761459351
risk O 1 0.6504336595535278
in O 0 1.3358418300413177e-06
the O 0 5.215236456024286e-07
general O 0 3.5725827274291078e-06
population O 0 1.6319874021064606e-06
. O 0 1.3381038570514647e-06
. O 0 6.883401511004195e-06

Genomic O 0 0.00015779274690430611
structure O 0 3.3352964237565175e-05
of O 0 4.58993827123777e-06
the O 0 0.00045227250666357577
human O 1 0.8945050239562988
congenital B-Disease 1 0.9995346069335938
chloride I-Disease 1 0.9989216327667236
diarrhea I-Disease 1 0.9996761083602905
( O 1 0.8596315383911133
CLD B-Disease 1 0.9978061318397522
) O 0 0.00040663700201548636
gene O 0 0.00030921882716938853
. O 0 5.8579371398082e-05

Congenital B-Disease 1 0.9969518184661865
chloride I-Disease 1 0.9962384700775146
diarrhea I-Disease 1 0.9994117021560669
( O 1 0.9509322643280029
CLD B-Disease 1 0.9982855916023254
) O 0 0.00017103005666285753
is O 0 9.607108040654566e-06
caused O 0 0.0004171155160292983
by O 0 3.3770248819564586e-07
mutations O 0 4.6277909859782085e-06
in O 0 5.2259803595688936e-08
a O 0 2.6062204483423557e-07
gene O 0 1.4354495760926511e-06
which O 0 1.381982315251662e-07
encodes O 0 7.901670869614463e-06
an O 0 2.8659274903475307e-05
intestinal O 1 0.9966745376586914
anion O 1 0.6416992545127869
transporter O 0 0.24116264283657074
. O 0 9.660702926339582e-05

We O 0 3.3020555747498292e-06
report O 0 2.2390884168999037e-06
here O 0 6.612585679022231e-08
the O 0 4.158170696655361e-08
complete O 0 7.253734111145604e-07
genomic O 0 3.7149295621929923e-06
organization O 0 1.5550556042853714e-07
of O 0 2.536811471998135e-08
the O 0 3.249896280976827e-07
human O 0 1.08664135041181e-05
CLD B-Disease 1 0.9397804141044617
gene O 0 2.707539351831656e-06
which O 0 1.1982915282260365e-07
spans O 0 1.4854267647024244e-05
approximately O 0 8.797087502898648e-07
39kb O 0 0.00034099273034371436
, O 0 8.085453373496421e-08
and O 0 7.678301727764847e-08
comprises O 0 7.143577249735245e-07
21 O 0 3.4120628242817475e-06
exons O 0 5.1779257773887366e-05
. O 0 1.2176720701972954e-05

All O 0 4.5166716517996974e-06
exon O 0 0.0011102337157353759
/ O 0 0.003033172572031617
intron O 0 0.0006068250513635576
boundaries O 0 9.836365961746196e-07
conform O 0 8.597799023846164e-06
to O 0 5.038527319811692e-07
the O 0 7.757343155390117e-06
GT O 1 0.8308969736099243
/ O 1 0.8920335173606873
AG O 1 0.8317927122116089
rule O 0 8.776406320976093e-05
. O 0 4.017797618871555e-05

An O 0 7.626296678608924e-07
analysis O 0 5.18660726811504e-07
of O 0 9.058887684432193e-08
the O 0 3.1412201906277915e-07
putative O 0 5.916005829931237e-05
promoter O 0 5.47929885215126e-05
region O 0 4.6772439077358285e-07
sequence O 0 1.3488823924490134e-07
shows O 0 1.911326705794636e-07
a O 0 7.463763722626027e-07
putative O 0 0.00019904169312212616
TATA O 0 0.06697596609592438
box O 0 6.313255289569497e-05
and O 0 5.626840788863774e-07
predicts O 0 0.00011175587133038789
multiple O 0 1.4713581322212121e-06
transcription O 0 1.0797439244925044e-05
factor O 0 6.799913080612896e-06
binding O 0 3.608299266488757e-06
sites O 0 6.745914561179234e-06
. O 0 1.3875932381779421e-05

The O 0 7.2941952566907275e-06
genomic O 0 6.707810098305345e-05
structure O 0 1.2746053471346386e-05
was O 0 3.602367542043794e-07
determined O 0 1.4057427222269325e-07
using O 0 3.158600492270125e-08
DNA O 0 2.0836822045566805e-07
from O 0 1.1570876701227917e-08
several O 0 8.785080218842722e-09
sources O 0 1.640173685757418e-08
including O 0 3.4368980550425476e-08
multiple O 0 1.0227829534414923e-06
large O 0 3.9648148231208324e-06
- O 0 0.0006886434857733548
insert O 0 0.00010005847434513271
libaries O 0 6.420568388421088e-05
and O 0 5.4536386073777976e-08
genomic O 0 3.7591785257973243e-06
DNA O 0 7.09125743014738e-06
from O 0 1.1923441888939124e-05
Finnish O 0 0.43914595246315
CLD B-Disease 1 0.998807430267334
patients O 0 0.43976521492004395
and O 0 8.575181709602475e-06
controls O 0 0.00026177565450780094
. O 0 5.131668513058685e-05

Exon O 0 0.003615791443735361
- O 0 0.0008831252926029265
specific O 0 3.740133024621173e-06
primers O 0 7.884044316597283e-05
developed O 0 5.7926258705265354e-06
in O 0 7.821697067811328e-08
this O 0 3.0096664715983934e-08
study O 0 2.005943571248281e-07
will O 0 3.652506563867064e-08
facilitate O 0 4.742426256143517e-07
mutation O 0 5.935368335485691e-06
screening O 0 1.192803665617248e-05
studies O 0 2.7208752726437524e-06
of O 0 4.243761395628098e-06
patients O 1 0.6173259615898132
with O 0 0.0001233119983226061
the O 0 0.002984720980748534
disease O 1 0.9985925555229187
. O 0 0.00036059279227629304

Genomic O 0 2.6007877750089392e-05
sequencing O 0 3.970831585320411e-06
of O 0 4.844880550081143e-07
a O 0 2.8122984076617286e-05
BAC O 0 0.2725057303905487
clone O 1 0.6606026291847229
H O 1 0.9101682305335999
_ O 0 9.00251543498598e-05
RG364P16 O 0 0.000790563237387687
revealed O 0 3.2808734431455377e-06
the O 0 4.282791010723486e-08
presence O 0 4.166419032003432e-08
of O 0 6.496221782725797e-09
another O 0 6.806764218936223e-08
, O 0 3.1441928172171174e-08
highly O 0 7.093673559666058e-08
homologous O 0 3.6163220329399337e-07
gene O 0 2.3027182294299564e-07
3 O 0 7.645887478702207e-08
of O 0 2.8827484399585046e-08
the O 0 1.9071584347329917e-06
CLD B-Disease 1 0.9093056321144104
gene O 0 2.0733284600282786e-06
, O 0 1.7989474798696392e-08
with O 0 1.0601297617540695e-08
a O 0 7.614698915858753e-08
similar O 0 4.010855434444238e-07
genomic O 0 1.7585374735062942e-05
structure O 0 2.107960608555004e-05
, O 0 5.950433319412696e-07
recently O 0 4.2400720303703565e-06
identified O 0 9.787613635126036e-07
as O 0 1.7363502138323383e-06
the O 0 0.00047980438102968037
Pendred B-Disease 1 0.9988002777099609
syndrome I-Disease 1 0.9998065829277039
gene O 0 0.007834099233150482
( O 0 0.001271803048439324
PDS B-Disease 1 0.7685146331787109
) O 0 9.83077916316688e-06
. O 0 1.921326656884048e-06
. O 0 1.4199026736605447e-05

The O 0 9.842473082244396e-05
APCI1307K O 1 0.9066547155380249
allele O 0 0.047679800540208817
and O 0 0.044731490314006805
cancer B-Disease 1 0.9995172023773193
risk O 0 0.04637864604592323
in O 0 7.247855933201208e-07
a O 0 1.8133164303435478e-06
community O 0 2.130361963281757e-06
- O 0 0.00013105403922963887
based O 0 2.8618381975320517e-07
study O 0 8.156189892360999e-07
of O 0 4.5618688204740465e-07
Ashkenazi O 0 0.0004909781273454428
Jews O 0 1.711731601972133e-05
. O 0 2.6590314519125968e-05

Mutations O 0 0.0006942541804164648
in O 0 1.7936932636075653e-05
APC O 0 0.022033631801605225
are O 0 3.585241984183085e-06
classically O 0 0.10549325495958328
associated O 0 0.0013397900620475411
with O 0 0.016970595344901085
familial B-Disease 1 0.9995074272155762
adenomatous I-Disease 1 0.9996176958084106
polyposis I-Disease 1 0.9995790123939514
( O 1 0.502985417842865
FAP B-Disease 1 0.9947669506072998
) O 0 2.316148857062217e-05
, O 0 5.172172677703202e-06
a O 0 0.00011176727275596932
highly O 0 0.09652139991521835
penetrant O 1 0.9981067180633545
autosomal B-Disease 1 0.9992029070854187
dominant I-Disease 1 0.9982271790504456
disorder I-Disease 1 0.9997966885566711
characterized O 1 0.991592526435852
by O 0 0.010445530526340008
multiple O 1 0.99793940782547
intestinal O 1 0.9997705817222595
polyps B-Disease 1 0.9988067150115967
and O 0 3.879491123370826e-05
, O 0 2.2184216504683718e-05
without O 0 2.8864797059213743e-05
surgical O 0 0.46208828687667847
intervention O 0 0.00010173881310038269
, O 0 8.11712766335404e-07
the O 0 8.858468731887115e-07
development O 0 0.00023117932141758502
of O 0 0.020637795329093933
colorectal B-Disease 1 0.999889612197876
cancer I-Disease 1 0.9997537732124329
( O 0 0.07071089744567871
CRC B-Disease 1 0.9025301337242126
) O 0 5.2065934141865e-05
. O 0 2.2637739675701596e-05

APC B-Disease 0 0.0055359178222715855
is O 0 2.4029419364524074e-05
a O 0 0.00042266235686838627
tumour O 1 0.9971984624862671
- O 0 0.19739869236946106
suppressor O 0 0.011686248704791069
gene O 0 1.4573231055692304e-05
, O 0 4.056052773648844e-07
and O 0 1.1484793276395067e-06
somatic O 0 0.001187626039609313
loss O 0 0.1370825618505478
occurs O 0 0.0006875492981635034
in O 0 0.00027588685043156147
tumours B-Disease 1 0.9955732822418213
. O 0 0.0002504716976545751

The O 0 0.00014328159159049392
germline O 0 0.3227261006832123
T O 1 0.9078782200813293
- O 0 0.00036119951982982457
to O 0 1.1082232731496333e-06
- O 0 0.00016688319738022983
A O 0 2.9485618142643943e-06
transversion O 0 0.0002249744429718703
responsible O 0 1.9885875701675104e-07
for O 0 1.6361523691443836e-08
the O 0 8.269808660088529e-08
APC O 0 7.574128539999947e-05
I1307K O 0 1.4001949239172973e-05
allele O 0 2.566920613844559e-07
converts O 0 4.798794961402564e-08
the O 0 2.5401716285955445e-08
wild O 0 4.839744747187069e-07
- O 0 3.921928055206081e-06
type O 0 3.613522494561039e-07
sequence O 0 3.771743095626334e-08
to O 0 4.194910019350573e-08
a O 0 4.174631158093689e-06
homopolymer O 0 0.39076340198516846
tract O 1 0.9316686987876892
( O 0 8.479850657749921e-05
A8 O 1 0.5703648328781128
) O 0 1.040749793901341e-06
that O 0 9.642235454521142e-08
is O 0 4.495248617786274e-07
genetically O 0 8.686152432346717e-05
unstable O 0 0.012768019922077656
and O 0 2.81806524071726e-06
prone O 0 0.0015329798916354775
to O 0 1.2003724805254024e-06
somatic O 0 0.0005013326881453395
mutation O 0 0.00035191315691918135
. O 0 3.168841794831678e-05

The O 0 2.3433874957845546e-05
I1307K O 0 0.0012639777269214392
allele O 0 6.503511394839734e-05
was O 0 3.0435317057708744e-06
found O 0 1.7518186723464169e-06
in O 0 1.5641941217836575e-06
6 O 0 4.3886113417102024e-05
. O 0 2.5763218218344264e-05

1 O 0 7.565775376860984e-06
% O 0 1.3671788110514171e-06
of O 0 1.184676079901692e-06
unselected O 0 0.11124380677938461
Ashkenazi O 0 0.0008221747120842338
Jews O 0 1.7964053995456197e-06
and O 0 2.865328099233011e-07
higher O 0 3.3101234748755815e-06
proportions O 0 0.00015587113739456981
of O 0 4.157140551797056e-07
Ashkenazim O 0 0.0024371265899389982
with O 0 1.4765028026886284e-06
family O 0 5.508141839527525e-06
or O 0 3.218424069473258e-07
personal O 0 1.1593562021516846e-06
histories O 0 1.8173632270190865e-05
of O 0 2.3391553440887947e-06
CRC B-Disease 1 0.5747101306915283
( O 0 8.346921822521836e-05
ref O 0 0.05036921054124832
. O 0 3.346267476445064e-07
2 O 0 2.5558947527315468e-06
) O 0 2.4834223495417973e-06
. O 0 3.2238719995802967e-06

To O 0 1.8541469444244285e-06
evaluate O 0 4.479009930946631e-06
the O 0 2.0519216548109398e-07
role O 0 6.124537321738899e-07
of O 0 7.977508289513935e-07
I1307K O 0 0.23963439464569092
in O 0 0.00024253164883702993
cancer B-Disease 1 0.9973435997962952
, O 0 6.536619139296818e-07
we O 0 1.9997052902454016e-07
genotyped O 0 0.0002263167261844501
5 O 0 1.7788375998861738e-06
, O 0 1.3185134548621136e-06
081 O 0 0.01574292965233326
Ashkenazi O 0 5.382089511840604e-05
volunteers O 0 1.1476034842416993e-06
in O 0 1.1824035084373463e-07
a O 0 1.2154085879956256e-06
community O 0 4.056856141687604e-06
survey O 0 4.125262057641521e-05
. O 0 1.559089832881e-05

Risk O 0 0.047565214335918427
of O 0 0.0002534749510232359
developing O 1 0.990047812461853
colorectal B-Disease 1 0.9996088147163391
, I-Disease 0 0.20281971991062164
breast I-Disease 1 0.9990952014923096
and I-Disease 0 1.5496607375098392e-05
other I-Disease 0 1.2143531421315856e-05
cancers I-Disease 1 0.598824143409729
were O 0 8.211355151388489e-08
compared O 0 6.5485696723044384e-06
between O 0 3.3865856039483333e-06
genotyped O 0 0.09076424688100815
I1307K O 0 0.008212306536734104
carriers O 0 4.2086765461135656e-05
and O 0 2.1153006457552692e-07
non O 0 6.960344762774184e-06
- O 0 0.0001335602719336748
carriers O 0 3.7125105336599518e-06
and O 0 1.1732709026546218e-08
their O 0 1.2576583330314861e-08
first O 0 2.5564889938323176e-07
- O 0 0.00015592272393405437
degree O 0 8.664585948281456e-06
relatives O 0 2.9189972337917425e-05
. O 0 1.5688681742176414e-05

Sperm O 0 3.823283259407617e-05
DNA O 0 1.3253691577119753e-05
analysis O 0 6.877548003103584e-06
in O 0 6.905645477672806e-06
a O 0 0.000525543699041009
Friedreich B-Disease 1 0.9953706860542297
ataxia I-Disease 1 0.9972859621047974
premutation O 1 0.9443836808204651
carrier O 0 0.01820429414510727
suggests O 0 3.5217006370658055e-05
both O 0 4.884905706603604e-07
meiotic O 0 0.0021264348179101944
and O 0 9.900494433168205e-07
mitotic O 0 0.0006512824911624193
expansion O 0 3.341956835356541e-05
in O 0 1.1515875257828156e-06
the O 0 3.4953366139234276e-06
FRDA B-Disease 0 0.052820492535829544
gene O 0 0.00013055113959126174
. O 0 2.577951454441063e-05

Friedreich B-Disease 1 0.992683470249176
ataxia I-Disease 1 0.9961115717887878
is O 0 7.074813765939325e-05
usually O 0 3.397317050257698e-05
caused O 0 0.00040128990076482296
by O 0 1.209296414117489e-07
an O 0 9.950191071084191e-08
expansion O 0 1.4154636573948665e-06
of O 0 8.173509513653698e-08
a O 0 6.968327852518996e-06
GAA O 0 0.007379944436252117
trinucleotide O 1 0.6598600745201111
repeat O 0 9.643151861382648e-05
in O 0 4.262897448370495e-07
intron O 0 0.0004927596892230213
1 O 0 4.86847397951351e-07
of O 0 1.075504911796088e-07
the O 0 2.8857743927801494e-06
FRDA B-Disease 0 0.029809147119522095
gene O 0 7.676508539589122e-05
. O 0 1.577338480274193e-05

Occasionally O 0 6.349003524519503e-05
, O 0 2.4575672341597965e-06
a O 0 1.0772063205877203e-06
fully O 0 3.448097686487017e-06
expanded O 0 6.144841790955979e-06
allele O 0 5.802024588774657e-06
has O 0 1.4910051504557487e-07
been O 0 2.528719811323299e-08
found O 0 5.512675116392529e-08
to O 0 3.895139499832112e-08
arise O 0 1.5791902114870027e-06
from O 0 4.285928767444602e-08
a O 0 2.2942899136069173e-07
premutation O 0 5.20864014106337e-05
of O 0 3.1332131555927845e-08
100 O 0 2.7723868356588355e-07
or O 0 6.130848646535014e-07
less O 0 2.708334932322032e-06
triplet O 0 0.0013869056710973382
repeats O 0 0.0005670891841873527
. O 0 2.9545819415943697e-05

We O 0 2.7730002329917625e-06
have O 0 2.3023602579996805e-07
examined O 0 1.363659066555556e-06
the O 0 7.075417585156174e-08
sperm O 0 1.0193631396759884e-06
DNA O 0 8.703077014615701e-07
of O 0 3.0028806463633373e-07
a O 0 3.0755705665796995e-05
premutation O 0 0.1860007345676422
carrier O 0 0.0037247352302074432
. O 0 4.743981116916984e-05

This O 0 4.2522042349446565e-06
mans O 0 0.000218348199268803
leucocyte O 0 0.0019445884972810745
DNA O 0 1.0870249752770178e-05
showed O 0 1.9836925275740214e-06
one O 0 8.431500475580833e-08
normal O 0 5.523974095922313e-07
allele O 0 4.867443408329564e-07
and O 0 1.2358079004570754e-08
one O 0 8.06841171652195e-09
allele O 0 1.2642078672797652e-07
of O 0 1.2514989933265497e-08
approximately O 0 2.2754241513212037e-07
100 O 0 9.224061159329722e-07
repeats O 0 5.787584086647257e-05
. O 0 7.94087736721849e-06

His O 0 1.6216537915170193e-05
sperm O 0 3.3618329325690866e-05
showed O 0 4.626414010999724e-06
an O 0 1.3947777688372298e-07
expanded O 0 9.40474194521812e-07
allele O 0 1.0700126722440473e-06
in O 0 2.6361966831700556e-08
a O 0 1.0535627126273539e-07
tight O 0 1.346234171251126e-06
range O 0 1.0963722729684378e-07
centering O 0 1.637995552528082e-07
on O 0 1.059165644079485e-08
a O 0 2.6154221899332697e-08
size O 0 1.357138046387263e-07
of O 0 4.3714447173215376e-08
approximately O 0 3.1803017463971628e-06
320 O 0 0.000265736278379336
trinucleotide O 1 0.5688539147377014
repeats O 0 0.0006932736141607165
. O 0 2.3739694370306097e-05

His O 0 0.00016223828424699605
affected O 0 0.0006774985231459141
son O 0 0.0008251273538917303
has O 0 8.35954870126443e-06
repeat O 0 0.00025732838548719883
sizes O 0 7.412382728944067e-06
of O 0 5.966788307887327e-07
1040 O 0 0.00205960008315742
and O 0 4.744443685922306e-06
540 O 0 0.000306704401737079
. O 0 2.5006071155075915e-05

These O 0 1.915753500725259e-06
data O 0 2.886735046558897e-06
suggest O 0 3.313724391773576e-06
that O 0 1.6292025861730508e-07
expansion O 0 6.078642400098033e-06
occurs O 0 3.7414991993500735e-07
in O 0 1.3449743541116277e-08
two O 0 7.965214265936993e-09
stages O 0 1.5315906694013393e-06
, O 0 1.443599284556285e-08
the O 0 3.982035590155419e-09
first O 0 7.287047409931802e-09
during O 0 9.252494237443898e-08
meiosis O 0 2.1639598344336264e-06
followed O 0 6.636985716568233e-08
by O 0 1.2739452159848952e-08
a O 0 1.3822696587340033e-07
second O 0 1.2934044661960797e-06
mitotic O 0 0.0021650127600878477
expansion O 0 0.0002618952712509781
. O 0 3.0002041967236437e-05

We O 0 1.895276909635868e-06
also O 0 2.5217124743903696e-07
show O 0 6.126663265604293e-08
that O 0 5.32851229806397e-09
in O 0 5.653312928899368e-09
all O 0 8.098537840339759e-09
informative O 0 1.745541794662131e-06
carrier O 0 8.048781455727294e-05
father O 0 2.9767763862764696e-06
to O 0 1.5258888197422493e-07
affected O 0 9.061684977496043e-06
child O 0 8.538051588402595e-06
transmissions O 0 3.303182893432677e-06
, O 0 2.2673134481010493e-08
with O 0 1.0142160888904073e-08
the O 0 1.2572722418724425e-08
notable O 0 6.555309539635346e-08
exception O 0 6.166359156623002e-08
of O 0 6.515666672868292e-09
the O 0 2.112397794462595e-07
premutation O 0 0.004231245722621679
carrier O 0 3.3940785215236247e-05
, O 0 3.305824947119618e-08
the O 0 4.3387164083696916e-08
expansion O 0 6.589974418602651e-06
size O 0 8.786323633103166e-06
decreases O 0 3.869393185595982e-05
. O 0 8.137605504998646e-07
. O 0 5.910633717576275e-06

The O 0 1.2319033885432873e-05
R496H O 0 0.000672368798404932
mutation O 0 3.0013143259566277e-05
of O 0 1.3899301620767801e-06
arylsulfatase O 0 0.11449269950389862
A O 0 0.00015699584037065506
does O 0 6.258927896851674e-05
not O 0 2.829515688063111e-05
cause O 0 0.40066787600517273
metachromatic B-Disease 1 0.9949264526367188
leukodystrophy I-Disease 1 0.9963313937187195
. O 0 0.0008880071109160781

Deficiency B-Disease 1 0.9913150668144226
of I-Disease 0 1.2863527445006184e-05
arylsulfatase I-Disease 0 0.07564245909452438
A I-Disease 0 0.0002500198024790734
( O 0 0.00027878215769305825
ARSA O 1 0.8305137753486633
) O 0 1.5038323908811435e-05
enzyme O 0 0.00017441707313992083
activity O 0 0.00019018523744307458
causes O 1 0.7398240566253662
metachromatic B-Disease 1 0.9956774115562439
leukodystrophy I-Disease 1 0.9973717927932739
( O 0 0.04795790836215019
MLD B-Disease 1 0.9900636076927185
) O 0 0.00013701061834581196
. O 0 5.1588020141934976e-05

A O 0 6.717853466398083e-06
number O 0 9.748850970936473e-07
of O 0 2.6638019789970713e-06
ARSA O 1 0.9473834037780762
gene O 0 0.00015931788948364556
mutations O 0 0.00013600703096017241
responsible O 0 3.8867008697707206e-05
for O 0 3.9581886085215956e-05
MLD B-Disease 1 0.9973140358924866
have O 0 2.9539714887505397e-06
been O 0 1.565682055115758e-06
identified O 0 1.6820216842461377e-05
. O 0 2.201302777393721e-05

Recently O 0 4.793051994056441e-05
, O 0 9.675208048065542e-07
the O 0 4.4987396563556104e-07
R496H O 0 0.0001489875721745193
mutation O 0 9.99219082586933e-06
of O 0 1.3630739204018028e-06
ARSA O 1 0.8284566402435303
was O 0 8.904511901164369e-07
proposed O 0 8.750631650400464e-07
to O 0 3.055919250982697e-08
be O 0 1.0986682674740678e-08
a O 0 3.500977356907242e-07
cause O 0 2.5938570615835488e-05
of O 0 2.0491459054028383e-06
MLD B-Disease 1 0.9965213537216187
( O 0 8.02972208475694e-05
Draghia O 0 0.04527014121413231
et O 0 0.00047936715418472886
al O 0 2.1948653738945723e-05
. O 0 2.1535392136229348e-07
, O 0 6.385502615557925e-07
1997 O 0 1.6961612345767207e-05
) O 0 2.774163931462681e-06
. O 0 3.876413757097907e-06

We O 0 3.0583735224354314e-06
have O 0 5.914970415688003e-07
investigated O 0 5.581121968134539e-06
the O 0 3.693444341479335e-07
R496H O 0 0.0005264808423817158
mutation O 0 8.58468956721481e-06
and O 0 5.248706003158077e-08
found O 0 4.8433744126441525e-08
this O 0 1.9704772924455938e-08
mutation O 0 5.436698984340183e-07
at O 0 3.6286891713643854e-08
a O 0 4.111827678343616e-08
relatively O 0 1.233545248169321e-07
high O 0 6.596575019557349e-08
frequency O 0 1.503925872725631e-08
in O 0 3.788171998309053e-09
an O 0 7.036225824208486e-09
African O 0 9.342384288402172e-08
American O 0 4.116528273812037e-08
population O 0 2.850190661263241e-08
( O 0 9.883855511816364e-08
f O 0 2.6930051717499737e-06
= O 0 2.153973809981835e-06
0 O 0 1.0061261690452739e-07
. O 0 1.5565387201377234e-08
09 O 0 1.9942920062021585e-06
, O 0 3.00085041260445e-08
n O 0 2.3833467821532395e-06
= O 0 9.977060472010635e-06
61 O 0 1.3255802286948892e-06
subjects O 0 9.813597898755688e-07
) O 0 1.1640591992545524e-06
. O 0 3.45294165526866e-06

The O 0 4.650343907997012e-05
ARSA O 0 0.44934001564979553
enzyme O 0 5.544354280573316e-05
activity O 0 2.0813556602661265e-06
in O 0 2.2493392748401675e-07
subjects O 0 5.271510872262297e-07
with O 0 9.738771922229716e-08
and O 0 7.68747483448351e-08
without O 0 1.1397141719271531e-07
the O 0 2.846160782610241e-07
R496H O 0 0.0012141064507886767
mutation O 0 8.586540388932917e-06
was O 0 2.477663940680941e-07
determined O 0 1.3318764047198783e-07
and O 0 2.8712960897792073e-08
found O 0 6.31371008807946e-08
to O 0 2.8452967981706934e-08
be O 0 6.884544490048938e-08
normal O 0 3.8108209992060438e-06
. O 0 7.0219016379269306e-06

It O 0 2.1915504930802854e-06
is O 0 5.49523747395142e-07
therefore O 0 1.6560112214847322e-07
concluded O 0 9.174344199891493e-07
that O 0 2.591359127279702e-08
the O 0 9.885798135655932e-08
R496H O 0 0.00010496391041669995
mutation O 0 5.829996098327683e-06
of O 0 8.117414154185099e-07
ARSA O 1 0.9646088480949402
does O 0 6.21565902747534e-07
not O 0 1.4995519492799758e-08
negatively O 0 1.2679072369792266e-07
influence O 0 2.4300005563304694e-08
the O 0 1.4357103950146666e-08
activity O 0 1.1271517763589145e-07
of O 0 2.460639336732129e-07
ARSA O 1 0.8198593258857727
and O 0 1.7802364027375006e-07
is O 0 1.4226455391508352e-07
not O 0 7.861406459142017e-08
a O 0 2.493584588592057e-06
cause O 0 0.0002710060216486454
of O 0 7.584304694319144e-05
MLD B-Disease 1 0.9845898151397705

Down O 0 0.00014040245150681585
- O 0 0.0001302954478887841
regulation O 0 1.2559090464492328e-05
of O 0 2.529178800614318e-06
transmembrane O 0 0.009565974585711956
carbonic O 1 0.7245413064956665
anhydrases O 1 0.8991169333457947
in O 0 0.020399680361151695
renal B-Disease 1 0.9994382262229919
cell I-Disease 1 0.9978152513504028
carcinoma I-Disease 1 0.9997064471244812
cell O 0 0.0017066223081201315
lines O 0 2.1558955268119462e-05
by O 0 2.507666522433283e-06
wild O 0 0.00021937738347332925
- O 0 0.26421821117401123
type O 0 0.09827946871519089
von B-Disease 1 0.7612447142601013
Hippel I-Disease 1 0.9869215488433838
- I-Disease 1 0.8466998934745789
Lindau I-Disease 1 0.9323515295982361
transgenes O 0 0.04718882963061333
. O 0 0.00021617561287712306

To O 0 3.8110572404548293e-06
discover O 0 2.4036387912929058e-05
genes O 0 1.9551430341380183e-06
involved O 0 2.696983528949204e-06
in O 0 9.689477337815333e-06
von B-Disease 1 0.5764091610908508
Hippel I-Disease 1 0.9860842823982239
- I-Disease 1 0.7451258301734924
Lindau I-Disease 1 0.9706599116325378
( O 0 0.00043676907080225646
VHL B-Disease 1 0.8828907608985901
) O 0 1.2387775313982274e-05
- O 0 0.002053077332675457
mediated O 0 0.0012191020650789142
carcinogenesis O 1 0.6629346609115601
, O 0 3.8831180972920265e-06
we O 0 2.985868832183769e-06
used O 0 0.0002745245292317122
renal B-Disease 1 0.9995332956314087
cell I-Disease 1 0.995425283908844
carcinoma I-Disease 1 0.9994657635688782
cell O 0 0.005358307622373104
lines O 0 0.0001478043559473008
stably O 0 0.001929834601469338
transfected O 0 0.008400020189583302
with O 0 2.1904532331973314e-05
wild O 0 0.0015208270633593202
- O 0 0.4887769818305969
type O 0 0.27335676550865173
VHL O 1 0.989204466342926
- O 0 0.03039630502462387
expressing O 0 0.0006113935960456729
transgenes O 0 0.012172814458608627
. O 0 0.00010452303831698373

Large O 0 5.3984873375156894e-05
- O 0 0.00013518186460714787
scale O 0 1.9402001271373592e-05
RNA O 0 4.353407348389737e-06
differential O 0 1.1212920071557164e-05
display O 0 5.419851277110865e-06
technology O 0 5.046994829172036e-06
applied O 0 2.0887833329652494e-07
to O 0 3.1861496552210156e-08
these O 0 2.5809265835619044e-08
cell O 0 5.18932620252599e-06
lines O 0 1.0154005849472014e-06
identified O 0 1.5347650617059116e-07
several O 0 2.9089790132275084e-08
differentially O 0 3.6927401652064873e-06
expressed O 0 2.1385702098086767e-07
genes O 0 1.6919004508508806e-07
, O 0 2.4618637795015275e-08
including O 0 4.595473512836179e-08
an O 0 1.854025413194904e-07
alpha O 0 4.818785600946285e-05
carbonic O 0 0.03930783271789551
anhydrase O 0 0.044695060700178146
gene O 0 4.6699013182660565e-05
, O 0 7.053022727632197e-06
termed O 0 0.0026994720101356506
CA12 O 0 0.49587979912757874
. O 0 6.873166421428323e-05

The O 0 1.0517612736293813e-06
deduced O 0 2.256892912555486e-06
protein O 0 8.464127745355654e-07
sequence O 0 6.977876978453423e-07
was O 0 5.408019774222339e-07
classified O 0 1.0577100511000026e-06
as O 0 1.4160097094872981e-08
a O 0 5.263001412458834e-08
one O 0 6.779748673579888e-08
- O 0 6.407820910681039e-05
pass O 0 2.339871571166441e-06
transmembrane O 0 0.0005105687887407839
CA O 0 2.9493770853150636e-05
possessing O 0 7.972261073518894e-07
an O 0 5.6277972504403806e-08
apparently O 0 3.5580433177528903e-07
intact O 0 7.330306175390433e-07
catalytic O 0 5.517492809303803e-07
domain O 0 1.3428268630377715e-07
in O 0 3.390707092876255e-08
the O 0 1.880031419432271e-07
extracellular O 0 7.35547801014036e-05
CA O 0 0.00026933453045785427
module O 0 9.661715739639476e-05
. O 0 8.471690307487734e-06

Reintroduced O 0 0.001033634296618402
wild O 0 0.0009324853308498859
- O 0 0.33984360098838806
type O 0 0.16279864311218262
VHL B-Disease 1 0.9827255010604858
strongly O 0 1.8296841517440043e-05
inhibited O 0 2.1539679437410086e-05
the O 0 1.5149487353482982e-07
overexpression O 0 4.908637492917478e-06
of O 0 4.1341376544323793e-08
the O 0 7.574565756840457e-07
CA12 O 0 0.021123554557561874
gene O 0 1.0973438293149229e-05
in O 0 9.975975672205095e-07
the O 0 3.860101423924789e-05
parental O 1 0.7701424360275269
renal B-Disease 1 0.9995115995407104
cell I-Disease 1 0.9980977177619934
carcinoma I-Disease 1 0.9995155334472656
cell O 1 0.500117301940918
lines O 0 0.003102471586316824
. O 0 0.00024096682318486273

Similar O 0 6.220941031642724e-06
results O 0 1.5040784546727082e-06
were O 0 5.949537396077176e-08
obtained O 0 2.531862151045061e-07
with O 0 2.698053776839515e-06
CA9 O 1 0.7698754668235779
, O 0 1.7571768751167838e-07
encoding O 0 7.601738616358489e-07
another O 0 3.916344212484546e-06
transmembrane O 0 0.00504049239680171
CA O 0 6.416785618057474e-05
with O 0 1.0048393050965387e-07
an O 0 1.8448784544489172e-07
intact O 0 1.5088413420016877e-05
catalytic O 0 2.3791637431713752e-05
domain O 0 1.5810112017788924e-05
. O 0 1.1496899787744042e-05

Although O 0 1.9264089132775553e-06
both O 0 1.8174198146425624e-07
domains O 0 6.717602332173556e-07
of O 0 9.190775074330304e-08
the O 0 2.104502527799923e-06
VHL B-Disease 1 0.60374516248703
protein O 0 2.122872274412657e-06
contribute O 0 5.635003503812186e-07
to O 0 1.2353224221328674e-08
regulation O 0 4.6929898189773667e-07
of O 0 6.874466862427653e-08
CA12 O 0 0.0028110938146710396
expression O 0 4.644059856673266e-07
, O 0 9.776645981673937e-08
the O 0 8.66402487531559e-08
elongin O 0 7.192148768808693e-05
binding O 0 7.108314434844942e-07
domain O 0 1.2869030570072937e-06
alone O 0 3.090637846980826e-06
could O 0 4.6366250217033667e-07
effectively O 0 1.1302510756650008e-05
regulate O 0 0.0004323983157519251
CA9 O 1 0.6784575581550598
expression O 0 4.5779925130773336e-05
. O 0 3.9031892811181024e-05

We O 0 1.3038437828072347e-05
mapped O 0 0.0002004736161325127
CA12 O 0 0.023686157539486885
and O 0 1.393871662003221e-05
CA9 O 1 0.7189703583717346
loci O 0 1.645516931603197e-05
to O 0 8.821551773507963e-07
chromosome O 0 7.533701864304021e-05
bands O 0 1.980662091227714e-05
15q22 O 0 0.0009431617800146341
and O 0 8.605361472291406e-06
17q21 O 0 0.003461284562945366
. O 0 4.114500916330144e-05

2 O 0 3.302680124761537e-05
respectively O 0 2.6350176995038055e-05
, O 0 3.7284237350831972e-06
regions O 0 1.4825425751041621e-05
prone O 0 0.0013315476244315505
to O 0 3.535178905167413e-07
amplification O 0 6.0361177020240575e-05
in O 0 8.703160006007238e-07
some O 0 3.2526388622500235e-06
human O 0 0.0014216277049854398
cancers B-Disease 1 0.9885954260826111
. O 0 0.00013729858619626611

Additional O 0 3.804658490480506e-06
experiments O 0 2.1447478957270505e-06
are O 0 4.8031079558086276e-08
needed O 0 1.592379135217925e-07
to O 0 1.4175391527260217e-08
define O 0 1.4119379443400248e-07
the O 0 1.56031667586376e-08
role O 0 2.3231412171753618e-07
of O 0 1.0706128250603797e-06
CA O 0 0.08006294816732407
IX O 1 0.8110462427139282
and O 0 6.299603228399064e-06
CA O 0 0.0010754393879324198
XII O 0 0.020527010783553123
enzymes O 0 4.503341131112393e-07
in O 0 7.808472091141994e-09
the O 0 6.359234472341768e-09
regulation O 0 1.591043314874696e-07
of O 0 2.2535342480978215e-08
pH O 0 1.9220897229388356e-05
in O 0 2.2417406597696754e-08
the O 0 3.222342570552428e-08
extracellular O 0 5.114523901283974e-06
microenvironment O 0 7.92574355727993e-05
and O 0 4.780605777909841e-08
its O 0 1.6549991244119155e-07
potential O 0 5.706710453523556e-06
impact O 0 7.025460945442319e-05
on O 0 5.892207263968885e-05
cancer B-Disease 1 0.9987332224845886
cell O 0 0.023695409297943115
growth O 0 0.0017891200259327888
. O 0 4.945507680531591e-05

A O 0 3.5361772461328655e-06
gene O 0 2.7518929073266918e-06
encoding O 0 1.30925855046371e-06
a O 0 1.9193707885278855e-06
transmembrane O 0 0.0001531684392830357
protein O 0 1.252751189895207e-05
is O 0 4.68233292849618e-06
mutated O 0 0.004940565675497055
in O 0 0.0003836392716038972
patients O 1 0.9976651668548584
with O 1 0.9910271763801575
diabetes B-Disease 1 0.9999101161956787
mellitus I-Disease 1 0.9997479319572449
and O 1 0.9788461923599243
optic B-Disease 1 0.9992769360542297
atrophy I-Disease 1 0.9992778897285461
( O 1 0.9940859079360962
Wolfram B-Disease 1 0.9991503953933716
syndrome I-Disease 1 0.999758780002594
) O 0 0.003079972229897976
. O 0 0.00029374283622018993

Wolfram B-Disease 1 0.992087185382843
syndrome I-Disease 1 0.9990423321723938
( O 1 0.7907442450523376
WFS B-Disease 1 0.9940869808197021
; O 0 0.17118459939956665
OMIM O 1 0.9955878257751465
222300 O 1 0.6915183067321777
) O 0 0.00010961963562294841
is O 0 4.2810948798432946e-05
an O 0 0.003759840503334999
autosomal B-Disease 1 0.9989472031593323
recessive I-Disease 1 0.9995988011360168
neurodegenerative I-Disease 1 0.9998774528503418
disorder I-Disease 1 0.9997816681861877
defined O 0 0.02328755147755146
by O 0 0.0020441864617168903
young O 1 0.7484674453735352
- O 1 0.9969931840896606
onset O 1 0.9982171654701233
non O 1 0.6682886481285095
- O 1 0.9964725375175476
immune O 1 0.997246265411377
insulin B-Disease 1 0.9939287900924683
- I-Disease 1 0.9970812201499939
dependent I-Disease 1 0.9914757013320923
diabetes I-Disease 1 0.9997641444206238
mellitus I-Disease 1 0.9992868304252625
and O 0 0.08661870658397675
progressive O 1 0.9957874417304993
optic B-Disease 1 0.9985768795013428
atrophy I-Disease 1 0.9967812299728394
. O 0 0.0019427521619945765

Linkage O 0 0.00029493827605620027
to O 0 3.6328870010038372e-06
markers O 0 6.16129909758456e-05
on O 0 3.282838861196069e-06
chromosome O 0 0.003166736103594303
4p O 1 0.9768581390380859
was O 0 5.937820333201671e-06
confirmed O 0 2.3148488708102377e-06
in O 0 1.493324646162364e-07
five O 0 8.922830829760642e-07
families O 0 1.252686524821911e-05
. O 0 1.4358180123963393e-05

On O 0 4.3864204712917854e-07
the O 0 1.5087562132976018e-07
basis O 0 1.0059879684831685e-07
of O 0 7.12280893822026e-07
meiotic O 1 0.8104973435401917
recombinants O 1 0.9943736791610718
and O 0 0.03194350004196167
disease O 1 0.9994339346885681
- O 0 0.33557289838790894
associated O 0 0.0001158256345661357
haplotypes O 0 0.0006740250973962247
, O 0 9.363984645460732e-07
the O 0 1.2346556559350574e-06
WFS B-Disease 1 0.7804835438728333
gene O 0 4.468442512006732e-06
was O 0 2.2084557826929085e-07
localized O 0 5.1131432883266825e-06
to O 0 6.982045164249939e-08
a O 0 2.6878171865973854e-06
BAC O 0 0.021776020526885986
/ O 0 0.016415346413850784
P1 O 0 0.0032513493206351995
contig O 0 2.2217604055185802e-05
of O 0 1.4217227395363352e-08
less O 0 7.18877259942019e-08
than O 0 1.1720925385816372e-07
250 O 0 3.446927394179511e-06
kb O 0 0.0012376527301967144
. O 0 1.6126579794217832e-05

Mutations O 0 7.169756281655282e-05
in O 0 7.265704766723502e-07
a O 0 1.3356940371522796e-06
novel O 0 1.3086346370982938e-05
gene O 0 1.6920834241318516e-05
( O 0 5.148152467882028e-06
WFS1 O 0 0.0004839823523070663
) O 0 6.055527990156406e-08
encoding O 0 7.401438040233188e-08
a O 0 1.3606849336156301e-07
putative O 0 1.486298151576193e-05
transmembrane O 0 3.361621202202514e-05
protein O 0 3.3136660704258247e-07
were O 0 7.032241011728502e-09
found O 0 2.9579521054756697e-08
in O 0 1.3137278820352094e-08
all O 0 1.0319694432325832e-08
affected O 0 9.373965212944313e-07
individuals O 0 6.415485387378794e-08
in O 0 2.2271188981903833e-07
six O 0 1.7253836631425656e-05
WFS B-Disease 1 0.9970369338989258
families O 0 2.1453943190863356e-06
, O 0 1.5126431662793038e-07
and O 0 2.5434538031277043e-08
these O 0 4.07769000787539e-08
mutations O 0 2.711707338676206e-06
were O 0 4.5517257518667975e-08
associated O 0 5.299165422911756e-06
with O 0 1.4667848518001847e-05
the O 0 0.0008970520575530827
disease O 1 0.9988747239112854
phenotype O 1 0.6749136447906494
. O 0 0.00032349320827051997

WFS1 O 0 0.21805529296398163
appears O 0 3.466395355644636e-05
to O 0 3.43028744964613e-07
function O 0 7.838108331270632e-07
in O 0 3.652639577467198e-07
survival O 0 0.00014381870278157294
of O 0 4.864928655479162e-07
islet O 0 0.0038431461434811354
beta O 0 0.010078899562358856
- O 0 0.02877412922680378
cells O 0 4.347256981418468e-05
and O 0 9.844831083682948e-07
neurons O 0 6.474181282101199e-05
. O 0 1.2760507388520637e-06
. O 0 5.147804131411249e-06

Stable O 0 7.042632205411792e-05
interaction O 0 2.7850908281834563e-06
between O 0 5.418168598225748e-07
the O 0 1.439925938484521e-07
products O 0 5.294829179547378e-07
of O 0 5.283338211370392e-08
the O 0 2.0307809336372884e-06
BRCA1 O 0 0.010885295458137989
and O 0 3.8744070479879156e-05
BRCA2 O 0 0.4793727397918701
tumor B-Disease 1 0.8198348879814148
suppressor O 0 0.0004081464430782944
genes O 0 1.454685161661473e-06
in O 0 9.007653147818928e-07
mitotic O 0 0.001406240975484252
and O 0 1.3433738786261529e-05
meiotic O 1 0.5411575436592102
cells O 0 0.0029258315917104483
. O 0 8.850212179822847e-05

BRCA1 O 0 0.062445513904094696
and O 0 2.1575060600298457e-05
BRCA2 O 0 0.0030574763659387827
account O 0 1.1040986009902554e-06
for O 0 2.2530619503413618e-07
most O 0 1.6042913841829431e-07
cases O 0 2.227852519354201e-06
of O 0 6.397937681867916e-07
familial O 1 0.7690906524658203
, O 0 0.0001846012455644086
early O 0 0.05037420615553856
onset O 1 0.9996684789657593
breast B-Disease 1 0.999613344669342
and I-Disease 0 0.22329865396022797
/ I-Disease 1 0.9993231296539307
or I-Disease 1 0.9951430559158325
ovarian I-Disease 1 0.9999274015426636
cancer I-Disease 1 0.9997492432594299
and O 0 7.611256478412542e-07
encode O 0 8.074155175563646e-07
products O 0 9.605629429643159e-07
that O 0 2.5741321962868824e-08
each O 0 2.6426656418720995e-08
interact O 0 1.0405751709186006e-06
with O 0 3.0414978482440347e-06
hRAD51 O 0 0.010387755930423737
. O 0 3.404867311473936e-05

Results O 0 1.3634075003210455e-05
presented O 0 3.732746563400724e-06
here O 0 5.041454755883024e-07
show O 0 7.388792369056318e-07
that O 0 4.944990905642044e-07
BRCA1 O 0 0.0020385077223181725
and O 0 2.4046205453487346e-06
BRCA2 O 0 0.002737894654273987
coexist O 0 7.288951564987656e-06
in O 0 6.778908101523484e-08
a O 0 5.358816679290612e-07
biochemical O 0 5.8592653658706695e-05
complex O 0 9.972255611501168e-06
and O 0 9.924410733219702e-07
colocalize O 0 0.0008983530569821596
in O 0 8.287317996291677e-07
subnuclear O 0 0.003708513919264078
foci O 0 0.0001311239175265655
in O 0 4.921570280203014e-07
somatic O 0 3.9624341297894716e-05
cells O 0 2.2271960915531963e-06
and O 0 1.4250429281048582e-08
on O 0 5.660024005038622e-09
the O 0 1.8089808762056236e-08
axial O 0 1.8755899873212911e-06
elements O 0 2.2257810883274942e-07
of O 0 6.73051772537292e-07
developing O 0 0.0007598831434734166
synaptonemal O 0 0.2871924042701721
complexes O 0 0.01404127012938261
. O 0 6.519047019537538e-05

Like O 0 0.0004533330211415887
BRCA1 O 0 0.006710565648972988
and O 0 2.0492439944064245e-05
RAD51 O 1 0.6147717833518982
, O 0 1.804454041121062e-05
BRCA2 O 0 0.0014218294527381659
relocates O 0 0.00016094755847007036
to O 0 1.9242220332671423e-06
PCNA O 0 0.058359649032354355
+ O 0 0.00014600645226892084
replication O 0 7.513659511459991e-06
sites O 0 4.834818128074403e-07
following O 0 1.1681595424306579e-06
exposure O 0 7.198433740995824e-05
of O 0 2.4093117190204794e-07
S O 0 0.0031770714558660984
phase O 0 5.572288137045689e-05
cells O 0 1.8931863451143727e-05
to O 0 7.17509408332262e-07
hydroxyurea O 0 0.018276339396834373
or O 0 2.2986330804997124e-05
UV O 0 0.328306645154953
irradiation O 0 0.000826063216663897
. O 0 1.7986812963499688e-05

Thus O 0 2.655012758623343e-05
, O 0 1.3986868907522876e-05
BRCA1 O 0 0.004777747206389904
and O 0 3.2144348551810253e-06
BRCA2 O 0 0.00037204381078481674
participate O 0 1.5393781893635605e-07
, O 0 5.2754838719693e-08
together O 0 2.873805371450544e-08
, O 0 3.0875860090873175e-08
in O 0 1.1548056733090561e-08
a O 0 1.3517244212835067e-07
pathway O 0 5.413817689259304e-06
( O 0 4.893974164588144e-06
s O 0 0.00017856339400168508
) O 0 8.446148314078528e-08
associated O 0 3.3849627101290025e-08
with O 0 4.934924913158056e-09
the O 0 7.811734370477552e-09
activation O 0 2.417092730411241e-07
of O 0 2.18965201526089e-08
double O 0 8.584558599977754e-06
- O 0 0.00043799920240417123
strand O 0 3.596253372961655e-05
break O 0 3.6956982512492687e-05
repair O 0 0.05833874270319939
and O 0 2.5376568828505697e-06
/ O 0 0.0008911484037525952
or O 0 9.398268616678251e-07
homologous O 0 2.943406070698984e-05
recombination O 0 0.0001960734516615048
. O 0 3.981315603596158e-05

Dysfunction O 1 0.8524900078773499
of O 0 2.3101579245121684e-06
this O 0 4.021824224764714e-06
pathway O 0 9.446027979720384e-05
may O 0 2.3474283352697967e-06
be O 0 1.4455528329904155e-08
a O 0 2.0006439171993406e-07
general O 0 1.3053751217739773e-06
phenomenon O 0 5.380900802265387e-06
in O 0 2.217606365206848e-08
the O 0 2.110770047636379e-08
majority O 0 7.652467104435345e-08
of O 0 5.954316861789266e-08
cases O 0 1.7490461686975323e-05
of O 0 2.7568563382374123e-05
hereditary B-Disease 1 0.9985905289649963
breast I-Disease 1 0.9995827078819275
and I-Disease 0 0.1636938601732254
/ I-Disease 1 0.9990838766098022
or I-Disease 1 0.9930526614189148
ovarian I-Disease 1 0.9998778104782104
cancer I-Disease 1 0.9996252059936523
. O 0 0.00017430682783015072
. O 0 0.000166723330039531

A O 0 3.232831659261137e-05
novel O 0 4.540739246294834e-05
Arg362Ser O 0 0.0012327288277447224
mutation O 0 4.718822310678661e-06
in O 0 1.1239465180779007e-07
the O 0 3.259524703480565e-07
sterol O 0 0.00048053078353405
27 O 0 3.41798149747774e-05
- O 0 0.0009022269514389336
hydroxylase O 0 0.00034187352866865695
gene O 0 6.479509011114715e-06
( O 0 4.024770532851107e-06
CYP27 O 0 0.002338266232982278
) O 0 3.861865423004929e-07
: O 0 9.307541404268704e-08
its O 0 2.5477751464109133e-08
effects O 0 6.368061349348864e-07
on O 0 1.7594112833307918e-08
pre O 0 2.34142044064356e-06
- O 0 1.9424328456807416e-06
mRNA O 0 1.2225051193581749e-07
splicing O 0 2.7445651085145073e-07
and O 0 8.961891495573582e-08
enzyme O 0 4.3323184399923775e-06
activity O 0 4.16189914176357e-06
. O 0 5.5694613365631085e-06

A O 0 2.2258871467784047e-05
novel O 0 1.7479424059274606e-05
C O 0 4.949272988596931e-05
to O 0 5.9171593846940596e-08
A O 0 3.8574043514927325e-07
mutation O 0 8.159333333424001e-07
in O 0 2.8518927663867544e-08
the O 0 1.1681824219067494e-07
sterol O 0 0.0001716500846669078
27 O 0 8.449017514067236e-06
- O 0 0.00013604866398964077
hydroxylase O 0 0.0001065005490090698
gene O 0 5.647847501677461e-06
( O 0 2.793422027025372e-06
CYP27 O 0 0.0006742164841853082
) O 0 1.0501881320124085e-07
was O 0 2.6992475810061478e-08
identified O 0 1.5708007339299e-08
by O 0 7.775893706707393e-09
sequencing O 0 3.077350640978693e-07
amplified O 0 1.1545209417818114e-05
CYP27 O 0 0.00117749092169106
gene O 0 2.6312420686736004e-06
products O 0 9.527306588097417e-07
from O 0 1.5989560608886677e-07
a O 0 5.996673735353397e-06
patient O 0 0.004461741540580988
with O 0 9.753210906637833e-05
cerebrotendinous B-Disease 1 0.9920477271080017
xanthomatosis I-Disease 1 0.9925320744514465
( O 0 0.0037808639463037252
CTX B-Disease 1 0.9915940761566162
) O 0 4.0232454921351746e-05
. O 0 3.3520209399284795e-05

The O 0 3.483529781078687e-06
mutation O 0 1.679896013229154e-05
changed O 0 1.0895237210206687e-06
the O 0 2.5446868789913424e-07
adrenodoxin O 0 0.000108416672446765
cofactor O 0 6.557430879183812e-06
binding O 0 8.838368330543744e-07
residue O 0 9.827132089412771e-06
362Arg O 0 4.5745702664135024e-05
to O 0 2.476114389082795e-07
362Ser O 0 0.00021272461162880063
( O 0 8.06254320195876e-06
CGT O 0 0.0024118125438690186
362Arg O 0 0.00030377513030543923
to O 0 3.466991529421648e-06
AGT O 1 0.967437744140625
362Ser O 0 0.0018779445672407746
) O 0 5.349298817236559e-07
, O 0 3.6731581332105634e-08
and O 0 1.8701671322673974e-08
was O 0 1.1400750565826456e-07
responsible O 0 1.6124189414767898e-06
for O 0 3.8085029245849e-06
deficiency O 1 0.9977401494979858
in O 0 7.083951913955389e-08
the O 0 1.4241794588087942e-07
sterol O 0 0.00024122472677845508
27 O 0 1.3989988474349957e-05
- O 0 0.00031478769960813224
hydroxylase O 0 7.694993109907955e-05
activity O 0 1.2661841708450083e-07
, O 0 1.982881236983758e-08
as O 0 3.896207800835327e-09
confirmed O 0 1.3864039694055919e-08
by O 0 2.2301183122408474e-09
expression O 0 7.278324165582717e-09
of O 0 8.505425697080682e-09
mutant O 0 1.2085371281500557e-06
cDNA O 0 2.6555358090263326e-06
into O 0 1.9219223759137094e-06
COS O 0 0.14951109886169434
- O 0 0.0005085031734779477
1 O 0 1.8377388187218457e-05
cells O 0 9.961368778022006e-05
. O 0 1.4756167729501612e-05

Quantitative O 0 3.92861184081994e-05
analysis O 0 7.303118309209822e-06
showed O 0 2.5185402137140045e-06
that O 0 2.4000918585898035e-08
the O 0 2.3275893212826304e-08
expression O 0 5.6848900698014404e-08
of O 0 3.260083758505061e-08
CYP27 O 0 0.0006741435499861836
gene O 0 4.3322836518200347e-07
mRNA O 0 1.899969959140435e-07
in O 0 5.301852112893357e-08
the O 0 3.8004048974471516e-07
patient O 0 9.125559154199436e-05
represented O 0 2.5465565158810932e-06
52 O 0 3.376948006916791e-05
. O 0 1.45162357512163e-05

5 O 0 7.371762876573484e-06
% O 0 1.0785488484543748e-06
of O 0 2.434368866488512e-07
the O 0 7.969334205881751e-07
normal O 0 1.5339413948822767e-05
level O 0 2.745812525972724e-05
. O 0 2.3839902496547438e-05

As O 0 1.211614971907693e-06
the O 0 4.788280421053059e-07
mutation O 0 4.794957476406125e-06
occurred O 0 4.6044931423239177e-07
at O 0 4.2071697237133776e-08
the O 0 1.3166503443073907e-08
penultimate O 0 5.715494353353279e-07
nucleotide O 0 3.981915952522286e-08
of O 0 1.781254432842161e-08
exon O 0 7.36104948373395e-06
6 O 0 8.887654416867008e-07
( O 0 2.519236659281887e-07
- O 0 5.602776695923239e-07
2 O 0 1.1433344937472611e-08
position O 0 4.098061445745316e-09
of O 0 5.047089413068306e-09
exon O 0 2.3386264729197137e-06
6 O 0 8.776657978160074e-07
- O 0 1.3714613487536553e-05
intron O 0 2.92643944703741e-05
6 O 0 3.7192219792814285e-07
splice O 0 2.2298399926512502e-06
site O 0 7.444691618729848e-08
) O 0 8.96821550355753e-09
of O 0 2.549431332710128e-09
the O 0 1.811826066955291e-08
gene O 0 3.701275943512883e-07
, O 0 2.584226876933826e-08
we O 0 1.1593144222388219e-08
hypothesized O 0 3.032690472082322e-07
that O 0 7.3751951212841504e-09
the O 0 9.371081688414051e-08
mutation O 0 9.927857718139421e-06
may O 0 8.879097777025891e-07
partially O 0 8.177827339750365e-07
affect O 0 4.2915729636661126e-08
the O 0 4.264204100934421e-09
normal O 0 3.3816458966384744e-08
splicing O 0 2.1741007572018134e-07
efficiency O 0 5.947857744104112e-07
in O 0 4.6750145088481077e-08
exon O 0 2.181241688958835e-05
6 O 0 1.2794579333785805e-06
and O 0 7.286175218723656e-08
cause O 0 1.7210843452630797e-06
alternative O 0 1.825995354920451e-07
splicing O 0 1.947581949934829e-06
elsewhere O 0 3.9023123576953367e-07
, O 0 2.99852764840125e-08
which O 0 1.4602817621778286e-08
resulted O 0 8.459068112642854e-07
in O 0 2.2539646238328714e-07
decreased O 0 3.109467797912657e-05
transcript O 0 8.013621481950395e-06
in O 0 3.7945596886856947e-07
the O 0 3.7529889596044086e-06
patient O 0 0.007840647362172604
. O 0 3.655884211184457e-05

Transfection O 0 0.0014528627507388592
of O 0 6.4676860347390175e-06
constructed O 0 0.0003274365735705942
minigenes O 0 0.01761704497039318
, O 0 5.548424155676912e-07
with O 0 9.704578474156733e-08
or O 0 6.732481949711655e-08
without O 0 2.363319318021695e-08
the O 0 2.7174051453471293e-08
mutation O 0 6.432854320337356e-07
, O 0 3.2086592938185277e-08
into O 0 2.0916856158237351e-07
COS O 0 0.1473112255334854
- O 0 0.0003453654353506863
1 O 0 2.171919732063543e-06
cells O 0 2.4916948859754484e-06
confirmed O 0 7.643510002708354e-08
that O 0 4.205964021508635e-09
the O 0 4.344977355685842e-08
mutant O 0 1.7622311133891344e-05
minigene O 0 0.00019816133135464042
was O 0 6.410189712369174e-08
responsible O 0 2.5425855199046055e-08
for O 0 4.793669461378158e-09
a O 0 2.1219394241711598e-08
mRNA O 0 7.506473309604189e-08
species O 0 2.0571407688407817e-08
alternatively O 0 1.2907216273561062e-07
spliced O 0 3.938067720810068e-07
at O 0 4.9399659474147484e-08
an O 0 6.509508665430985e-08
activated O 0 4.886936494585825e-06
cryptic O 0 5.066892754257424e-06
5 O 0 1.800774356297552e-07
splice O 0 2.4801940980978543e-06
site O 0 2.0961269342478772e-07
88 O 0 1.0460016710567288e-06
bp O 0 1.93767414202739e-06
upstream O 0 9.505410503152234e-08
from O 0 6.678138042559567e-09
the O 0 5.757188947796976e-09
3 O 0 4.9864844697822264e-08
end O 0 6.704699728743435e-08
of O 0 6.440238564664469e-08
exon O 0 0.00010458655742695555
6 O 0 1.720699219731614e-05
. O 0 1.0316798579879105e-05

Our O 0 3.433331585256383e-06
data O 0 1.8758421447273577e-06
suggest O 0 1.844749931478873e-06
that O 0 5.116744716815447e-08
the O 0 6.335580593486156e-08
C O 0 8.652992619317956e-06
to O 0 9.594441685578659e-09
A O 0 7.304027604959629e-08
mutation O 0 1.296390195193453e-07
at O 0 1.0114400872396345e-08
the O 0 3.979454099578561e-09
penultimate O 0 3.7819370390934637e-07
nucleotide O 0 2.1017189766325828e-08
of O 0 6.090449033990808e-09
exon O 0 1.5268044535332592e-06
6 O 0 9.138335599345737e-08
of O 0 1.0214203705061209e-08
the O 0 1.414361037177514e-07
CYP27 O 0 0.004424565937370062
gene O 0 1.1821390444310964e-06
not O 0 2.194619241890905e-08
only O 0 7.421723324796403e-08
causes O 0 0.000563250738196075
the O 0 1.2902437447337434e-05
deficiency B-Disease 1 0.9984172582626343
in I-Disease 0 8.637361048613457e-08
the I-Disease 0 1.9168923870438448e-07
sterol I-Disease 0 0.00020919321104884148
27 I-Disease 0 1.2033012353640515e-05
- I-Disease 0 0.00014277655282057822
hydroxylase I-Disease 0 4.104922845726833e-05
activity I-Disease 0 1.7387219486408867e-07
, O 0 2.5452443708218198e-08
but O 0 1.4709351070507637e-08
also O 0 1.383645997776739e-08
partially O 0 2.7965887738901074e-07
leads O 0 6.22809608330499e-08
to O 0 4.59267557317844e-09
alternative O 0 5.084261900378806e-08
pre O 0 1.0338537776988233e-06
- O 0 5.927540200900694e-07
mRNA O 0 2.9310507798641083e-08
splicing O 0 6.074140657119642e-08
of O 0 1.3030122758550533e-08
the O 0 1.88584607485609e-07
gene O 0 1.838425851019565e-05
. O 0 8.743618309381418e-06

To O 0 1.909954107759404e-06
our O 0 5.438555490400176e-07
knowledge O 0 5.324908443071763e-07
, O 0 1.106339837519954e-07
this O 0 1.1787282261366272e-08
is O 0 1.6929519119912584e-08
the O 0 1.420375639327176e-08
first O 0 4.0372231779883805e-08
report O 0 2.1588076037915016e-07
regarding O 0 7.967573623091084e-08
effects O 0 2.6371831154392567e-06
on O 0 2.9755675257092662e-08
pre O 0 3.2978980470943497e-06
- O 0 9.195384791382821e-07
mRNA O 0 2.0102614683992215e-08
splicing O 0 3.9365389170598064e-08
of O 0 3.685486582583053e-09
a O 0 4.4534996135325855e-08
mutation O 0 2.2306898017632193e-07
at O 0 3.882152199707889e-08
the O 0 4.878168979871589e-08
- O 0 5.84737472308916e-06
2 O 0 5.823311610697601e-08
position O 0 7.351628639185037e-09
of O 0 4.185269908418832e-09
a O 0 2.1797954730118363e-07
5 O 0 2.509690375518403e-06
splice O 0 9.345626313006505e-05
site O 0 1.0751193258329295e-05
. O 0 7.728234777459875e-06

ATM O 0 0.009133570827543736
germline O 0 0.02565710060298443
mutations O 0 0.0003538856690283865
in O 0 7.803791959304363e-05
classical O 0 0.32978555560112
ataxia B-Disease 1 0.9993639588356018
- I-Disease 1 0.999037504196167
telangiectasia I-Disease 1 0.999384880065918
patients O 1 0.8195402026176453
in O 0 2.8664726414717734e-06
the O 0 2.630406243042671e-06
Dutch O 0 0.00016792888345662504
population O 0 1.1859504411404487e-05
. O 0 1.875595080491621e-05

Germline O 0 0.013941596262156963
mutations O 0 3.623286829679273e-05
in O 0 5.745869771089929e-07
the O 0 8.362845278497844e-07
ATM O 0 0.00015641922072973102
gene O 0 3.710089913511183e-06
are O 0 7.21462427577535e-08
responsible O 0 2.636949375300901e-06
for O 0 1.5368465028586797e-05
the O 0 0.021282542496919632
autosomal B-Disease 1 0.9996340274810791
recessive I-Disease 1 0.9998148083686829
disorder I-Disease 1 0.9999464750289917
ataxia B-Disease 1 0.9998076558113098
- I-Disease 1 0.9994328618049622
telangiectasia I-Disease 1 0.9992293119430542
( O 0 0.22010481357574463
A B-Disease 1 0.9831757545471191
- I-Disease 1 0.9975300431251526
T I-Disease 1 0.9980645775794983
) O 0 7.478516636183485e-05
. O 0 2.367950219195336e-05

In O 0 6.353845492412802e-06
our O 0 2.3311295080929995e-06
study O 0 4.0632294258102775e-06
, O 0 2.198235193873188e-07
we O 0 1.4747331356090854e-08
have O 0 3.539231130389453e-09
determined O 0 2.4185887070871104e-08
the O 0 1.4569349282567146e-08
ATM O 0 4.46528156317072e-06
mutation O 0 2.2936728782951832e-07
spectrum O 0 1.7963010634503007e-07
in O 0 2.3767947610053852e-08
19 O 0 8.113536864584603e-07
classical O 0 1.774146039679181e-05
A B-Disease 1 0.5056788921356201
- I-Disease 1 0.9991268515586853
T I-Disease 1 0.9997332692146301
patients O 0 0.08336682617664337
, O 0 1.619571605715464e-07
including O 0 8.947407792447848e-08
some O 0 1.1221793982940653e-07
immigrant O 0 7.236029432533542e-06
populations O 0 2.079545993183274e-06
, O 0 4.878029002952644e-08
as O 0 1.0621071133698479e-08
well O 0 4.973838674260378e-09
as O 0 4.9733364093640375e-09
12 O 0 2.3457239706203836e-08
of O 0 1.2693901041416211e-08
Dutch O 0 2.0792745090147946e-06
ethnic O 0 7.487740276701516e-07
origin O 0 2.987085053973715e-06
. O 0 2.315969868504908e-05

Both O 0 5.982697075523902e-07
the O 0 4.334465586453007e-07
protein O 0 1.2858579339081189e-06
truncation O 0 1.2997716112295166e-05
test O 0 1.3503153013516567e-06
( O 0 5.19272475685284e-07
PTT O 0 1.503798785051913e-06
) O 0 2.142472865784839e-08
and O 0 5.142258174828385e-09
the O 0 1.0733138822160981e-08
restriction O 0 5.035649905948958e-07
endonuclease O 0 0.0001160697647719644
fingerprinting O 0 6.872208905406296e-05
( O 0 2.8510526135505643e-06
REF O 0 0.0010853600688278675
) O 0 1.5107048056961503e-08
method O 0 4.235799710983201e-09
were O 0 1.6500097954619264e-09
used O 0 4.719665547270324e-09
and O 0 5.948014081269548e-09
compared O 0 5.328474017574081e-08
for O 0 3.180816721126689e-09
their O 0 5.018368831599673e-09
detection O 0 1.4152639096209896e-06
efficiency O 0 3.599276965360332e-07
, O 0 1.5821878918131915e-08
identifying O 0 1.5138438413941913e-07
76 O 0 9.591981324774679e-07
% O 0 2.0921241628002463e-08
and O 0 5.307981165714182e-09
60 O 0 2.993042258481182e-08
% O 0 1.1080691031395418e-08
of O 0 9.277088430792446e-09
the O 0 2.07494508686068e-07
mutations O 0 7.733233360340819e-06
, O 0 6.46489013433893e-07
respectively O 0 7.057760285533732e-06
. O 0 1.1351098692102823e-05

Most O 0 0.0003987732343375683
patients O 0 0.008904512971639633
were O 0 1.9936709350076853e-07
found O 0 3.1474272077502974e-07
to O 0 1.5969003186455666e-07
be O 0 2.7106088396067207e-07
compound O 0 0.00011485426512081176
heterozygote O 0 0.00512697733938694
. O 0 4.4709719077218324e-05

Seventeen O 0 0.00014066026778891683
mutations O 0 5.943288851995021e-05
were O 0 2.395628939666494e-07
distinct O 0 1.0215254633294535e-06
, O 0 1.3122408404342423e-07
of O 0 2.3832502193954497e-08
which O 0 5.438535310986481e-08
10 O 0 1.3461735193232016e-07
were O 0 3.2761096946387624e-08
not O 0 1.20404209269509e-07
reported O 0 6.585174560314044e-06
previously O 0 5.64239371669828e-06
. O 0 1.4542257304128725e-05

Mutations O 0 0.00010012394341174513
are O 0 5.099023496768496e-07
small O 0 1.7083814327634173e-06
deletions O 0 3.644293610705063e-05
or O 0 2.975255029014079e-06
point O 0 4.6045638555369806e-06
mutations O 0 8.401334343943745e-05
frequently O 0 7.664855729672126e-06
affecting O 0 5.9740192227764055e-05
splice O 0 0.00039662152994424105
sites O 0 1.7288492017542012e-05
. O 0 2.8616124836844392e-05

Moreover O 0 0.0004504960961639881
, O 0 9.388179023517296e-06
a O 0 1.8141718101105653e-05
16 O 0 7.076338806655258e-05
. O 0 7.892438588896766e-05

7 O 0 7.044109952403232e-05
- O 0 0.00037771332426927984
kb O 0 0.00033118671854026616
genomic O 0 1.0715744792832993e-05
deletion O 0 7.86727832746692e-06
of O 0 3.741335063978113e-08
the O 0 5.094648614090147e-08
3 O 0 2.870190769499459e-07
end O 0 1.3108750351875642e-07
of O 0 1.6932716562223504e-08
the O 0 2.061127730712542e-07
gene O 0 3.3402493500034325e-06
, O 0 7.307413341095526e-08
most O 0 1.6084069187627392e-08
likely O 0 9.653295052203248e-08
a O 0 2.8801432350178402e-08
result O 0 4.430911104691404e-08
of O 0 3.8293914705889165e-09
recombination O 0 5.14172199927998e-07
between O 0 2.6439714417847426e-08
two O 0 2.1405694994314217e-08
LINE O 0 2.7936032438447e-06
elements O 0 5.105149512019125e-07
, O 0 5.0326639211562e-07
was O 0 1.3130850220477441e-06
identified O 0 8.821570190775674e-06
. O 0 8.99700080481125e-06

The O 0 2.913054458986153e-06
most O 0 9.466318147133279e-07
frequently O 0 3.060912149521755e-06
found O 0 1.1716416565832333e-06
mutation O 0 7.4978256634494755e-06
, O 0 1.0805033667793396e-07
identified O 0 6.933129270692007e-08
in O 0 1.4781912582861878e-08
three O 0 3.605693876806981e-08
unrelated O 0 5.440987297333777e-05
Turkish O 0 0.0003261116216890514
A B-Disease 0 0.49321168661117554
- I-Disease 1 0.9973681569099426
T I-Disease 1 0.9991053938865662
individuals O 0 1.0066019058285747e-06
, O 0 2.5432603933950304e-07
was O 0 1.1497512275582267e-07
previously O 0 1.371565048202683e-07
described O 0 1.8820550451437157e-07
to O 0 6.459365931021921e-09
be O 0 5.8347939813074845e-09
a O 0 2.6922555207420373e-07
Turkish O 0 1.4647300304204691e-05
A B-Disease 0 0.013141068629920483
- I-Disease 1 0.9604188203811646
T I-Disease 1 0.9972598552703857
founder O 0 0.0013236487284302711
mutation O 0 0.00023856080952100456
. O 0 1.4321010894491337e-05

The O 0 2.0135018985456554e-06
presence O 0 1.4366986533786985e-06
of O 0 2.0088323537947872e-07
a O 0 6.28445241090958e-06
founder O 0 0.000250085664447397
mutation O 0 3.972270860685967e-05
among O 0 2.2894658968652948e-07
relatively O 0 4.5733423803540063e-07
small O 0 1.2432012397312064e-07
ethnic O 0 1.4193064146184042e-07
population O 0 9.27415584328628e-08
groups O 0 2.7794598622676858e-08
in O 0 1.5677110809519945e-07
Western O 0 1.7315119293925818e-06
Europe O 0 1.584793494657788e-06
could O 0 8.830913600377244e-08
indicate O 0 2.1990089749124309e-07
a O 0 1.3394580378189858e-07
high O 0 2.790306780298124e-06
carrier O 0 6.078283149690833e-06
frequency O 0 1.408308349937215e-07
in O 0 7.351281539058618e-08
such O 0 2.0702015035567456e-07
communities O 0 2.0576212591549847e-06
. O 0 1.0714284144341946e-05

In O 0 8.903455454856157e-05
patients O 0 0.0016869972459971905
of O 0 2.792338023027696e-07
Dutch O 0 1.7028742149705067e-05
ethnic O 0 7.570153002234292e-07
origin O 0 6.896424338265206e-07
, O 0 7.816319111952907e-07
however O 0 4.890680997959862e-07
, O 0 1.8565592085906246e-07
no O 0 4.203255912216264e-07
significant O 0 2.626295554364333e-06
founder O 0 8.477222581859678e-05
effect O 0 9.579242941981647e-06
could O 0 6.809295882703736e-07
be O 0 2.749353598119342e-07
identified O 0 3.985765033576172e-06
. O 0 6.559451321663801e-06

The O 0 6.421486432373058e-06
observed O 0 1.4907030163158197e-05
genetic O 0 2.87792081508087e-05
heterogeneity O 0 3.9283386286115274e-05
including O 0 1.974239864921401e-07
the O 0 1.0585420540110135e-07
relative O 0 9.992734248953639e-07
high O 0 1.069150698640442e-06
percentage O 0 3.7832390376024705e-07
of O 0 1.046433126816737e-07
splice O 0 0.000558751227799803
- O 0 0.003636192297562957
site O 0 3.6495130188995972e-06
mutations O 0 2.030407358688535e-06
had O 0 9.824368873978528e-08
no O 0 9.399096256856865e-08
reflection O 0 6.420382305805106e-07
on O 0 1.353138117110575e-07
the O 0 3.1383144687424647e-06
phenotype O 0 0.0035746488720178604
. O 0 1.863874786067754e-05

All O 0 3.401881622266956e-05
patients O 0 0.0921747162938118
manifested O 0 0.0007781038293614984
classical O 0 0.0002557956613600254
A B-Disease 1 0.6089617609977722
- I-Disease 1 0.9950160384178162
T I-Disease 1 0.9974253177642822
and O 0 1.031207943924528e-06
increased O 0 4.605213689501397e-06
cellular O 0 4.4204829464433715e-05
radioresistant O 0 0.0005546791362576187
DNA O 0 1.193053958559176e-05
synthesis O 0 1.9535031242412515e-05
. O 0 1.5898065612418577e-05

Determination O 0 7.046488008199958e-06
of O 0 2.391520013134141e-07
the O 0 2.3065511811637407e-07
genomic O 0 1.006629736366449e-05
structure O 0 2.243138624180574e-06
of O 0 5.855991247472048e-08
the O 0 1.1768219110308564e-06
COL4A4 O 0 0.017954956740140915
gene O 0 4.742181772598997e-06
and O 0 2.156716902845801e-07
of O 0 1.097381300496636e-06
novel O 0 0.0030279657803475857
mutations O 0 0.2598281502723694
causing O 1 0.9942212104797363
autosomal B-Disease 1 0.9978348612785339
recessive I-Disease 1 0.9986728429794312
Alport I-Disease 1 0.9992653727531433
syndrome I-Disease 1 0.9995563626289368
. O 0 0.2740817964076996

Autosomal B-Disease 1 0.9922061562538147
recessive I-Disease 1 0.9978293776512146
Alport I-Disease 1 0.999213457107544
syndrome I-Disease 1 0.9994320273399353
is O 0 0.0005111373029649258
a O 0 0.0024118113797158003
progressive O 1 0.9890393018722534
hematuric B-Disease 1 0.9970601201057434
glomerulonephritis I-Disease 1 0.9989608526229858
characterized O 1 0.9886334538459778
by O 0 0.006883714813739061
glomerular B-Disease 1 0.9987280964851379
basement I-Disease 1 0.9959347248077393
membrane I-Disease 1 0.8418618440628052
abnormalities I-Disease 1 0.9937942028045654
and O 0 6.175909220473841e-06
associated O 0 8.239143426180817e-06
with O 0 7.962769927871705e-07
mutations O 0 5.431363661045907e-06
in O 0 6.193197776838133e-08
either O 0 1.5354443405612983e-07
the O 0 3.3645329722276074e-07
COL4A3 O 0 0.0033605077769607306
or O 0 4.315805313126475e-07
the O 0 3.748521066881949e-07
COL4A4 O 0 0.0021601624321192503
gene O 0 6.025354082339618e-07
, O 0 1.166979313182992e-08
which O 0 4.261764718904715e-09
encode O 0 3.219786393060531e-08
the O 0 6.283471520873718e-08
alpha3 O 0 0.000182365023647435
and O 0 2.209586000390118e-06
alpha4 O 0 0.25599560141563416
type O 0 0.29640594124794006
IV O 1 0.996316134929657
collagen O 1 0.9671468138694763
chains O 0 0.000771961291320622
, O 0 4.736748905997956e-06
respectively O 0 1.3916986972617451e-05
. O 0 1.3846479305357207e-05

To O 0 2.9993254884175258e-06
date O 0 2.6899097065324895e-06
, O 0 8.800191722002637e-07
mutation O 0 6.709798981319182e-06
screening O 0 2.3778752620273735e-06
in O 0 2.909744800660974e-08
the O 0 1.9395836048374804e-08
two O 0 3.4056988340580574e-08
genes O 0 1.0052310699393274e-06
has O 0 3.428923491810565e-07
been O 0 1.673206782015768e-07
hampered O 0 0.0001648293691687286
by O 0 4.822725330200228e-08
the O 0 6.550759934498274e-08
lack O 0 8.259451078629354e-07
of O 0 1.2322460918312572e-07
genomic O 0 5.693537605111487e-05
structure O 0 6.266942364163697e-05
information O 0 6.617179678869434e-06
. O 0 1.7377024050801992e-05

We O 0 4.72813781016157e-06
report O 0 2.0131678866164293e-06
here O 0 1.4639482515121927e-07
the O 0 3.780825608146188e-08
complete O 0 2.5944063963834196e-07
characterization O 0 7.212903483377886e-07
of O 0 6.825352283357233e-09
the O 0 1.6472213815177383e-08
48 O 0 9.490735664030581e-08
exons O 0 1.7207678126851533e-07
of O 0 8.918779492717022e-09
the O 0 1.755220608856689e-07
COL4A4 O 0 0.003225235966965556
gene O 0 1.1246042959101032e-06
, O 0 2.3816369321139064e-08
a O 0 9.522195654199095e-08
comprehensive O 0 4.033235200040508e-06
gene O 0 2.6108075417141663e-06
screen O 0 2.3623470042366534e-06
, O 0 2.4773184392756775e-08
and O 0 4.5553538718934306e-09
the O 0 6.022869758481875e-09
subsequent O 0 2.034943946682688e-07
detection O 0 8.498536203660478e-07
of O 0 1.221995304945267e-08
10 O 0 4.0026517922342464e-07
novel O 0 6.218675025593257e-06
mutations O 0 4.025237649329938e-05
in O 0 9.240020517609082e-06
eight O 0 0.06515462696552277
patients O 1 0.9992793202400208
diagnosed O 1 0.9996095299720764
with O 1 0.9750152230262756
autosomal B-Disease 1 0.9993404746055603
recessive I-Disease 1 0.9992995262145996
Alport I-Disease 1 0.9994275569915771
syndrome I-Disease 1 0.9995788931846619
. O 0 0.25650060176849365

Furthermore O 0 0.0001129880256485194
, O 0 1.556021402393526e-06
we O 0 1.9326361666571756e-07
identified O 0 1.516271197488095e-07
a O 0 4.107046791546054e-08
glycine O 0 6.721959948663425e-07
to O 0 1.894472667629543e-08
alanine O 0 1.1666787713693338e-06
substitution O 0 1.3486328498402145e-07
in O 0 4.089692495767849e-08
the O 0 1.2688411743511097e-07
collagenous O 0 0.012932641431689262
domain O 0 8.029732612158114e-07
that O 0 4.1450338272852605e-08
is O 0 7.257769141233439e-08
apparently O 0 8.408052281083656e-07
silent O 0 2.4169621610781178e-06
in O 0 2.442980218120283e-08
the O 0 9.780319487617817e-08
heterozygous O 0 1.3502995898306835e-05
carriers O 0 6.0059672250645235e-05
, O 0 3.2889954582060454e-07
in O 0 4.7666117097833194e-07
11 O 0 1.3764536561211571e-05
. O 0 1.3448455320030916e-05

5 O 0 5.355926532502053e-06
% O 0 5.196459369471995e-07
of O 0 1.0630093782992844e-07
all O 0 7.43377981393678e-08
control O 0 3.124696377199143e-06
individuals O 0 2.909423812980094e-07
, O 0 4.4194909065709e-08
and O 0 1.3862954340027045e-08
in O 0 9.733475359041677e-09
one O 0 7.872416496468304e-09
control O 0 1.0694642327280235e-07
individual O 0 2.388615705228858e-08
homozygous O 0 2.879358760310424e-07
for O 0 2.356216732835037e-08
this O 0 8.247535276950657e-08
glycine O 0 1.5793764760019258e-05
substitution O 0 1.1111251296824776e-05
. O 0 8.082204658421688e-06

There O 0 1.2106286703783553e-05
has O 0 1.3753572147834348e-06
been O 0 7.106741861662158e-08
no O 0 4.0998301642503066e-08
previous O 0 5.317499329748898e-08
finding O 0 2.7817510073191443e-08
of O 0 2.959203548869027e-09
a O 0 6.128778551328651e-08
glycine O 0 2.016517100855708e-06
substitution O 0 4.054911642015213e-07
that O 0 3.1971438829714316e-08
is O 0 2.8984780797713938e-08
not O 0 1.1982728587156544e-08
associated O 0 1.5960218036070728e-07
with O 0 6.056729517922577e-08
any O 0 2.953065632027574e-07
obvious O 0 5.529638292500749e-05
phenotype O 0 0.0017019972437992692
in O 0 2.5902727429638617e-06
homozygous O 0 0.00014702156477142125
individuals O 0 1.1484691640362144e-05
. O 0 3.840124554699287e-05

Founder O 0 0.005353712011128664
BRCA1 O 0 0.021010594442486763
and O 0 3.2782580092316493e-05
BRCA2 O 0 0.017777757719159126
mutations O 0 0.00018258634372614324
in O 0 1.7902752006193623e-05
French O 0 0.009609525091946125
Canadian O 1 0.5697600245475769
breast B-Disease 1 0.9987136125564575
and I-Disease 1 0.9873358607292175
ovarian I-Disease 1 0.9998319149017334
cancer I-Disease 1 0.9994978904724121
families O 0 0.020845891907811165
. O 0 0.0009886205662041903

We O 0 2.3072097974363714e-06
have O 0 1.6792189683201286e-07
identified O 0 1.7484761372088542e-07
four O 0 4.385023189001913e-08
mutations O 0 7.404339044114749e-07
in O 0 1.0130946748176939e-08
each O 0 8.834043718763951e-09
of O 0 3.578467442366673e-07
the O 0 0.001815082156099379
breast B-Disease 1 0.9997435212135315
cancer I-Disease 1 0.9996938705444336
- O 1 0.7454788684844971
susceptibility O 0 0.023913037031888962
genes O 0 7.019498298177496e-06
, O 0 2.5433505470573436e-06
BRCA1 O 0 0.0007123247487470508
and O 0 1.253885670848831e-06
BRCA2 O 0 0.0006219311035238206
, O 0 4.152773840360169e-07
in O 0 1.722875822451897e-06
French O 0 0.0015165298245847225
Canadian O 0 0.18047884106636047
breast B-Disease 1 0.9995531439781189
cancer I-Disease 1 0.9996040463447571
and O 1 0.980658769607544
breast B-Disease 1 0.9997606873512268
/ I-Disease 1 0.9997021555900574
ovarian I-Disease 1 0.9999337196350098
cancer I-Disease 1 0.9997724890708923
families O 0 0.001030752551741898
from O 0 9.098198643187061e-05
Quebec O 0 0.0019476122688502073
. O 0 0.00012625660747289658

To O 0 6.705833129672101e-06
identify O 0 7.120772352209315e-05
founder O 0 0.0009765299619175494
effects O 0 0.00083086674567312
, O 0 1.3207825304561993e-06
we O 0 1.8440552196352655e-07
examined O 0 3.2333371109416476e-06
independently O 0 4.2186809423583327e-07
ascertained O 0 4.2372248572064564e-05
French O 0 0.000358602061169222
Canadian O 0 0.006759220734238625
cancer B-Disease 1 0.9950376152992249
families O 0 5.033921297581401e-07
for O 0 1.938980886961872e-08
the O 0 1.590766451897707e-08
distribution O 0 3.920167301885158e-08
of O 0 1.3470488724465213e-08
these O 0 9.058887684432193e-08
eight O 0 2.7997186862194212e-06
mutations O 0 0.00012752415204886347
. O 0 1.7478705558460206e-05

Mutations O 0 6.605283851968125e-05
were O 0 2.5623128863117017e-07
found O 0 3.2428127383354877e-07
in O 0 2.1748928702436388e-07
41 O 0 1.5709467788838083e-06
of O 0 3.749236157091218e-07
97 O 0 0.00023633672390133142
families O 0 1.911739309434779e-05
. O 0 2.0610130377463065e-05

Six O 0 1.7535336382934474e-06
of O 0 2.5465902808718965e-07
eight O 0 1.69844111042039e-06
mutations O 0 6.047568604117259e-06
were O 0 5.94225681993521e-08
observed O 0 6.6337065618427e-07
at O 0 5.890033776267956e-07
least O 0 8.42540657686186e-07
twice O 0 1.0248919352306984e-05
. O 0 1.0144975931325462e-05

The O 0 4.1705930925672874e-05
BRCA1 O 0 0.029703956097364426
C4446T O 0 0.006742967292666435
mutation O 0 6.432659574784338e-05
was O 0 3.689891912017629e-07
the O 0 1.1134443411719985e-07
most O 0 1.0479791257012039e-07
common O 0 2.5000849745993037e-06
mutation O 0 6.361533905874239e-06
found O 0 1.1507724906323347e-07
, O 0 5.401299318918973e-08
followed O 0 1.6570665195558831e-07
by O 0 1.3390109643296455e-07
the O 0 2.6144052753807046e-06
BRCA2 O 0 0.014216864481568336
8765delAG O 0 0.011374720372259617
mutation O 0 0.00035877470509149134
. O 0 2.9814767913194373e-05

Together O 0 5.404871899372665e-06
, O 0 1.0276598914060742e-06
these O 0 1.6475064512633253e-07
mutations O 0 1.3454820191327599e-06
were O 0 1.0974409825337261e-08
found O 0 2.6359099791761764e-08
in O 0 1.2173472008214503e-08
28 O 0 1.0996015475939203e-07
of O 0 3.76222999420861e-08
41 O 0 4.169880412518978e-06
families O 0 4.4033404833498935e-07
identified O 0 2.0963386759831337e-07
to O 0 3.389892455629706e-08
have O 0 5.5566960810438104e-08
a O 0 1.839812966863974e-06
mutation O 0 5.08280390931759e-05
. O 0 9.351721018902026e-06

The O 0 6.359780400089221e-06
odds O 0 8.924714347813278e-05
of O 0 2.3257638304130523e-07
detection O 0 8.628305295133032e-06
of O 0 1.6569140726119258e-08
any O 0 1.2083162026499394e-08
of O 0 8.370208526287115e-09
the O 0 9.105764320338494e-08
four O 0 9.543512078380445e-07
BRCA1 O 0 0.005073153413832188
mutations O 0 1.954235449375119e-05
was O 0 1.15675425149675e-06
18 O 0 1.784426967788022e-05
. O 0 1.7214031686307862e-05

7x O 0 0.18598121404647827
greater O 0 7.700682544964366e-06
if O 0 7.749304131721146e-07
one O 0 9.830198166582704e-08
or O 0 5.732405838898558e-07
more O 0 1.7999244619204546e-06
cases O 0 0.008194801397621632
of O 1 0.5325993895530701
ovarian B-Disease 1 0.9999589920043945
cancer I-Disease 1 0.9998530149459839
were O 0 8.947507694756496e-07
also O 0 3.619240658281342e-07
present O 0 4.765048231547553e-07
in O 0 2.1245440962047724e-07
the O 0 8.316334856317553e-07
family O 0 3.596918759285472e-05
. O 0 3.063597978325561e-05

The O 0 6.127042070147581e-06
odds O 0 7.110214937711135e-05
of O 0 1.7035186772318411e-07
detection O 0 5.715168754250044e-06
of O 0 1.36245432713622e-08
any O 0 1.033255525584309e-08
of O 0 1.026825291461364e-08
the O 0 1.1958850620885642e-07
four O 0 1.7285947251366451e-06
BRCA2 O 0 0.013699350878596306
mutations O 0 4.391658876556903e-05
was O 0 2.402974587312201e-06
5 O 0 1.9491077182465233e-05
. O 0 1.2458456694730558e-05

3x O 0 0.0036873503122478724
greater O 0 1.795520802261308e-05
if O 0 8.91804120328743e-07
there O 0 6.503998406515166e-08
were O 0 1.0909379177803658e-08
at O 0 8.615888447138786e-08
least O 0 7.636588605919314e-08
five O 0 3.1673243938712403e-07
cases O 0 6.927439972059801e-05
of O 0 0.0013036570744588971
breast B-Disease 1 0.9997369647026062
cancer I-Disease 1 0.9993695616722107
in O 0 6.954373020562343e-06
the O 0 7.92690298112575e-06
family O 0 0.0001775911368895322
. O 0 5.575668910751119e-05

Interestingly O 0 9.797907841857523e-05
, O 0 8.642499551569927e-07
the O 0 3.378455346592091e-07
presence O 0 1.823282104851387e-06
of O 0 3.05567959912878e-06
a O 0 0.136402890086174
breast B-Disease 1 0.9996284246444702
cancer I-Disease 1 0.999397873878479
case O 0 0.0010651452466845512
< O 0 0.11484497040510178
36 O 0 2.1239980014797766e-06
years O 0 2.187878322956749e-07
of O 0 2.3972418716766697e-08
age O 0 2.438542651361786e-06
was O 0 4.555217003598955e-08
strongly O 0 6.879897540557067e-08
predictive O 0 1.4460249531111913e-07
of O 0 4.009984788666543e-09
the O 0 1.4067842890597149e-08
presence O 0 2.2257635734490577e-08
of O 0 1.9861583488989254e-09
any O 0 3.6547764814542916e-09
of O 0 8.119912742188262e-09
the O 0 1.450666076152629e-07
eight O 0 3.4708853036136134e-06
mutations O 0 9.611662244424224e-05
screened O 0 0.00011431407619966194
. O 0 1.774080010363832e-05

Carriers O 0 7.467128307325765e-05
of O 0 2.8626268999687454e-07
the O 0 1.9479631419017096e-07
same O 0 4.3743477817770327e-07
mutation O 0 9.180591405311134e-06
, O 0 6.070932556667685e-08
from O 0 2.220683548159741e-08
different O 0 8.319879007956388e-09
families O 0 2.0598308481112326e-07
, O 0 5.274387149256654e-08
shared O 0 1.5374517658983677e-07
similar O 0 1.4924603419785853e-06
haplotypes O 0 0.0005251970142126083
, O 0 4.231675916344102e-07
indicating O 0 1.7095139810408e-06
that O 0 8.259386063969032e-09
the O 0 5.1706059878142696e-08
mutant O 0 5.794565367978066e-06
alleles O 0 7.384122113762714e-07
were O 0 1.8096296017233726e-08
likely O 0 6.783719896930052e-08
to O 0 3.5795575392683077e-09
be O 0 1.148847017518051e-09
identical O 0 2.6632298144591005e-08
by O 0 7.068091001372068e-09
descent O 0 1.0385888060682191e-07
for O 0 1.6247053480356044e-08
a O 0 1.8562582226877566e-07
mutation O 0 3.446292794251349e-06
in O 0 1.2212127842303744e-07
the O 0 5.209112146076222e-07
founder O 0 9.271825547330081e-05
population O 0 4.6839495553285815e-06
. O 0 9.140937436313834e-06

The O 0 1.0906882152994513e-06
identification O 0 1.012434267977369e-06
of O 0 4.047246875416022e-07
common O 0 3.803006620728411e-05
BRCA1 O 0 0.013616127893328667
and O 0 4.9457730710855685e-06
BRCA2 O 0 0.004665412474423647
mutations O 0 4.652048119169194e-06
will O 0 9.758407060189711e-08
facilitate O 0 1.5200427014860907e-06
carrier O 0 0.00014801252109464258
detection O 0 2.5751010980457067e-05
in O 0 2.17589376916294e-06
French O 0 0.0005404505645856261
Canadian O 0 0.12199904769659042
breast B-Disease 1 0.9993289709091187
cancer I-Disease 1 0.9995570778846741
and O 1 0.9715868234634399
breast B-Disease 1 0.9996994733810425
/ I-Disease 1 0.9996284246444702
ovarian I-Disease 1 0.9998730421066284
cancer I-Disease 1 0.9995953440666199
families O 0 0.008495744317770004
. O 0 0.0010673882206901908

Are O 0 1.4158810699882451e-05
Dp71 O 0 0.007381656672805548
and O 0 4.3932421249337494e-05
Dp140 O 0 0.2943819761276245
brain O 1 0.6245644688606262
dystrophin O 0 0.08094432950019836
isoforms O 0 8.778088522376493e-05
related O 0 0.0007487700786441565
to O 0 7.105348049663007e-05
cognitive B-Disease 1 0.7806060910224915
impairment I-Disease 1 0.9963057041168213
in O 1 0.7523632049560547
Duchenne B-Disease 1 0.9983830451965332
muscular I-Disease 1 0.9987558126449585
dystrophy I-Disease 1 0.9984419941902161
? O 1 0.9487864375114441

Molecular O 0 0.00016540511569473892
study O 0 1.5325522326747887e-05
and O 0 1.5210825949907303e-06
neuropsychological O 0 0.0008465060382150114
analysis O 0 7.955255796332494e-07
were O 0 3.1609086903472416e-08
performed O 0 1.6107101430407056e-07
concurrently O 0 5.848423256793467e-07
on O 0 1.5708328646724112e-06
49 O 0 0.0013258038088679314
patients O 1 0.7702350616455078
with O 0 0.1884814202785492
Duchenne B-Disease 1 0.9996510744094849
muscular I-Disease 1 0.9997968077659607
dystrophy I-Disease 1 0.9998071789741516
( O 1 0.9697272181510925
DMD B-Disease 1 0.99959796667099
) O 0 8.37444622447947e-06
in O 0 5.3214762374409474e-08
order O 0 3.215404831280466e-08
to O 0 1.0298871089275963e-08
find O 0 2.6829457766552878e-08
a O 0 6.616711090146055e-08
molecular O 0 1.129059796767251e-06
explanation O 0 3.1481778250963544e-07
for O 0 7.891949849181401e-08
the O 0 2.525527406760375e-06
cognitive B-Disease 0 0.02035750076174736
impairment I-Disease 1 0.9366247653961182
observed O 0 3.209283750038594e-05
in O 0 4.75319211545866e-05
most O 0 0.002414361108094454
DMD B-Disease 1 0.9986602067947388
patients O 1 0.9756507277488708
. O 0 0.0004367349320091307

Complete O 0 6.353699973260518e-06
analysis O 0 8.074062520790903e-07
of O 0 1.8753971176010964e-07
the O 0 1.9246201645728434e-06
dystrophin O 0 0.07800836116075516
gene O 0 5.762316959589953e-06
was O 0 1.1500220153948248e-07
performed O 0 4.627851879490663e-08
to O 0 8.094399817082376e-09
define O 0 8.949883323339236e-08
the O 0 9.422570279582487e-09
localization O 0 5.095367896501557e-07
of O 0 1.3829361655837147e-08
deletions O 0 2.3803916064935038e-06
and O 0 7.659315315322601e-08
duplications O 0 1.1987905963906087e-05
in O 0 4.8137739128151225e-08
relation O 0 3.757834576845198e-07
to O 0 6.865058566063453e-08
the O 0 5.951148409621965e-07
different O 0 6.105524334998336e-06
DMD B-Disease 1 0.9958674907684326
promoters O 0 0.010787788778543472
. O 0 9.59764001891017e-05

Qualitative O 0 6.366582965711132e-06
analysis O 0 9.058661021299486e-07
of O 0 1.5566595834570762e-07
the O 0 1.1140247124785674e-06
Dp71 O 0 0.002462536096572876
transcript O 0 1.7070888134185225e-05
and O 0 9.659003552542345e-08
testing O 0 3.406229325264576e-07
for O 0 6.024076348865037e-09
the O 0 5.527307056496511e-09
specific O 0 6.3517311410521415e-09
first O 0 1.2232264978706553e-08
exon O 0 2.815572543113376e-06
of O 0 3.6010753490245406e-08
Dp140 O 0 3.2200532587012276e-05
were O 0 1.8753320674136376e-08
also O 0 4.549451659840997e-08
carried O 0 1.5616808468621457e-07
out O 0 8.171263061740319e-07
. O 0 5.972907274554018e-06

Neuropsychological O 0 0.005293511785566807
analysis O 0 2.7764701371779665e-05
assessed O 0 4.783143231179565e-05
verbal O 0 5.469964162330143e-05
and O 0 9.60410397965461e-06
visuospatial O 0 0.11344173550605774
intelligence O 0 5.3554926125798374e-05
, O 0 1.0958470966215828e-06
verbal O 0 3.966543226852082e-05
memory O 0 0.0002846381685230881
, O 0 8.505217010679189e-07
and O 0 5.870775794392102e-07
reading O 0 5.441816756501794e-05
skills O 0 3.8525628042407334e-05
. O 0 2.171134838135913e-05

Comparison O 0 1.5690566215198487e-05
of O 0 1.01301952781796e-06
molecular O 0 5.870888344361447e-05
and O 0 4.215490207570838e-06
psychometric O 0 0.004185840021818876
findings O 0 2.7851710910908878e-05
demonstrated O 0 2.0652846615121234e-06
that O 0 8.792392947043481e-08
deletions O 0 3.6406208892003633e-06
and O 0 1.1068991767615444e-07
duplications O 0 1.5555166100966744e-05
that O 0 2.1768553182255346e-08
were O 0 1.973166163793394e-08
localized O 0 6.9984830588509794e-06
in O 0 5.1639926113011825e-08
the O 0 9.013387369805059e-08
distal O 0 9.758736268850043e-05
part O 0 8.170797372031302e-08
of O 0 3.382232804938212e-08
the O 0 2.2079629502513853e-07
gene O 0 2.8178478714835364e-06
seemed O 0 4.0844861359801143e-07
to O 0 2.1221540080773593e-08
be O 0 2.3150372285840604e-08
preferentially O 0 2.736353053478524e-06
associated O 0 1.1858928701258264e-05
with O 0 2.9511744287447073e-05
cognitive B-Disease 0 0.36974045634269714
impairment I-Disease 1 0.9939051270484924
. O 0 0.0002366368134971708

Two O 0 7.590389486722415e-06
altered O 0 0.00010149599256692454
Dp71 O 0 0.00033335090847685933
transcripts O 0 2.282301238665241e-06
and O 0 6.197180368872068e-08
two O 0 2.244679997431831e-08
deleted O 0 1.3329847661225358e-06
Dp140 O 0 9.289996341976803e-06
DNA O 0 2.775985308289819e-07
sequences O 0 9.769021858119231e-08
were O 0 1.4382868229745327e-08
found O 0 1.118597836580193e-07
in O 0 5.682666710526973e-07
four O 0 7.309427746804431e-05
patients O 1 0.9912125468254089
with O 1 0.6404451131820679
severe O 1 0.9994644522666931
cerebral B-Disease 1 0.9993569254875183
dysfunction I-Disease 1 0.9984604120254517
. O 0 0.012208265252411366

These O 0 3.6290052776166704e-06
findings O 0 9.475897968513891e-06
suggest O 0 1.2899602097604657e-06
that O 0 2.2869535598601942e-08
some O 0 9.66386437539768e-09
sequences O 0 6.341928582287437e-08
located O 0 6.757182546834883e-08
in O 0 1.3746601190689489e-08
the O 0 3.15700425801424e-08
distal O 0 1.9288689145469107e-05
part O 0 4.283231902491025e-08
of O 0 1.4938596137881177e-08
the O 0 1.1224447860058717e-07
gene O 0 1.3212991234468063e-06
and O 0 5.37404716283163e-08
, O 0 6.390266804601197e-08
in O 0 2.724748782156894e-08
particular O 0 7.854453087929869e-08
, O 0 1.2789122649792262e-07
some O 0 2.7564632887333573e-07
DMD B-Disease 1 0.9789677262306213
isoforms O 0 2.067529294436099e-06
expressed O 0 1.148016053775791e-06
in O 0 6.493010005215183e-07
the O 0 1.381006859446643e-05
brain O 1 0.6956595778465271
may O 0 3.4043628147628624e-06
be O 0 2.4144082289012658e-08
related O 0 7.514494768656732e-07
to O 0 1.065209502826292e-07
the O 0 3.851357632811414e-06
cognitive B-Disease 0 0.37149879336357117
impairment I-Disease 1 0.9979639053344727
associated O 0 0.001953745260834694
with O 0 0.002849469194188714
DMD B-Disease 1 0.9989262223243713
. O 0 5.502170097315684e-05
. O 0 4.819553214474581e-05

I1307K O 0 0.005260442849248648
APC O 0 0.001963276183232665
and O 0 5.079588390799472e-06
hMLH1 O 0 0.001688195625320077
mutations O 0 1.3379071788222063e-05
in O 0 1.874849857586014e-07
a O 0 1.4934713590264437e-06
non O 0 4.319627259974368e-05
- O 0 0.0012894209939986467
Jewish O 0 3.6483404528553365e-06
family O 0 2.2723024812876247e-05
with O 0 0.00011692760017467663
hereditary B-Disease 1 0.9948369264602661
non I-Disease 1 0.996870219707489
- I-Disease 1 0.999427318572998
polyposis I-Disease 1 0.999653697013855
colorectal I-Disease 1 0.9998263716697693
cancer I-Disease 1 0.9994400143623352
. O 0 0.022420518100261688

We O 0 8.328197509399615e-06
describe O 0 1.7642656530370004e-05
a O 0 1.0405253306089435e-05
French O 0 0.0002562897279858589
Canadian O 0 0.0010058532934635878
hereditary B-Disease 1 0.9759377837181091
non I-Disease 1 0.9923344254493713
- I-Disease 1 0.999093770980835
polyposis I-Disease 1 0.9995386600494385
colorectal I-Disease 1 0.9998962879180908
cancer I-Disease 1 0.999782383441925
( O 1 0.9018996953964233
HNPCC B-Disease 1 0.998869001865387
) O 0 7.719047425780445e-05
kindred O 0 0.0003751820477191359
which O 0 2.2526323562033213e-07
carries O 0 1.710791025288927e-06
a O 0 1.0999367532349424e-06
novel O 0 1.998196057684254e-05
truncating O 0 0.007040518801659346
mutation O 0 0.00027548731304705143
in O 0 8.583167073084041e-06
hMLH1 O 0 0.013906119391322136
. O 0 7.025869126664475e-05

Interestingly O 0 0.00013299816055223346
, O 0 1.520405248811585e-06
the O 0 9.164497782876424e-07
I1307K O 0 0.0017400059150531888
APC O 0 0.0036010511685162783
polymorphism O 0 4.404283026815392e-05
, O 0 4.046251262934675e-07
associated O 0 4.178261292508978e-07
with O 0 1.2228046841755713e-07
an O 0 1.8981166931553162e-06
increased O 0 0.002374540315940976
risk O 1 0.9082208275794983
of O 0 0.3269398510456085
colorectal B-Disease 1 0.9999648332595825
cancer I-Disease 1 0.999872088432312
, O 0 9.610406777937897e-06
is O 0 4.899036980532401e-07
also O 0 9.568932313186451e-08
present O 0 2.4701236611690547e-07
in O 0 2.2640232089088386e-07
this O 0 5.033834895584732e-07
family O 0 2.480438161001075e-05
. O 0 1.898811387945898e-05

The O 0 2.1876245227758773e-05
I1307K O 0 0.00133410410489887
polymorphism O 0 0.00010717711120378226
has O 0 1.5309482250813744e-06
previously O 0 7.383487741208228e-07
only O 0 2.618756589356508e-08
been O 0 4.121029917314445e-08
identified O 0 8.254601624457791e-08
in O 0 3.589095953770993e-08
individuals O 0 5.6792327285393185e-08
of O 0 2.3157267037277052e-07
self O 0 0.00036826933501288295
- O 0 0.09882311522960663
reported O 0 9.719906665850431e-05
Ashkenazi O 0 0.00016337430861312896
Jewish O 0 4.810759492102079e-06
origins O 0 4.067347617819905e-05
. O 0 2.9980874387547374e-05

In O 0 6.9597472247551195e-06
addition O 0 4.259761681169039e-06
, O 0 5.983199002912443e-07
in O 0 2.0223397712015867e-07
this O 0 1.805937159815585e-07
family O 0 4.1826651795418e-06
, O 0 2.8706617172247206e-07
there O 0 2.4766055162217526e-07
appears O 0 2.982840669574216e-06
to O 0 1.6169396488407983e-08
be O 0 3.882928201193181e-09
no O 0 1.827698525858068e-08
relationship O 0 1.2202697519114736e-07
between O 0 4.047840462817476e-08
the O 0 6.414005326860206e-08
I1307K O 0 1.9080162019236013e-05
polymorphism O 0 9.939452638718649e-07
and O 0 2.2092136120477335e-08
the O 0 3.161656536576629e-08
presence O 0 7.477821100110305e-07
or O 0 9.82490973910899e-07
absence O 0 6.210318679222837e-05
of O 0 4.643873398890719e-05
cancer B-Disease 1 0.9988711476325989
. O 0 2.0203640815452673e-05
. O 0 3.7727040762547404e-05

Identification O 0 1.8022896028924151e-06
of O 0 1.7635345272992708e-07
a O 0 8.923103678171174e-07
novel O 0 3.3171295399370138e-06
mutation O 0 1.3442148656395148e-06
of O 0 4.788152807577717e-08
the O 0 3.730696107595577e-07
CPO O 0 9.276229684473947e-05
gene O 0 3.068086698476691e-06
in O 0 1.9395879746753053e-07
a O 0 5.794101525680162e-06
Japanese O 0 0.0008972281939350069
hereditary B-Disease 1 0.7195748686790466
coproporphyria I-Disease 1 0.9006528854370117
family O 0 0.0015472185332328081
. O 0 0.00012867283658124506

Hereditary B-Disease 1 0.7348617315292358
coproporphyria I-Disease 1 0.8711385130882263
( O 0 0.0070871212519705296
HCP B-Disease 1 0.992109477519989
) O 0 6.789781036786735e-05
is O 0 1.1300009646220133e-05
an O 0 0.00039704598020762205
autosomal B-Disease 1 0.9988732933998108
dominant I-Disease 1 0.9986543655395508
disease I-Disease 1 0.9997747540473938
characterized O 1 0.7633974552154541
by O 0 0.00010935216414509341
a O 0 0.01744152046740055
deficiency B-Disease 1 0.999214768409729
of I-Disease 0 6.586280051124049e-06
coproporphyrinogen I-Disease 1 0.6042066216468811
oxidase I-Disease 0 0.007801491767168045
( O 0 5.4958774853730574e-05
CPO O 0 0.0011801088694483042
) O 0 2.117857320627081e-06
caused O 0 1.0614108759909868e-05
by O 0 2.7136291436136162e-08
a O 0 2.006883050853503e-07
mutation O 0 1.4181553069647634e-06
in O 0 9.318234361899158e-08
the O 0 6.196164008542837e-07
CPO O 0 0.0007196489023044705
gene O 0 3.746349102584645e-05
. O 0 6.839925390522694e-06

Only O 0 1.7862066670204513e-06
11 O 0 4.095382337254705e-06
mutations O 0 1.590950660101953e-06
of O 0 6.821411346891182e-08
the O 0 4.250864549248945e-07
gene O 0 1.2798833267879672e-05
have O 0 4.0427642034046585e-07
been O 0 1.3314995612745406e-06
reported O 0 0.0001949606667039916
in O 0 0.0003801722195930779
HCP B-Disease 1 0.9983028173446655
patients O 1 0.963360607624054
. O 0 0.00022522492508869618

We O 0 2.933917357950122e-06
report O 0 3.2899158668442396e-06
another O 0 1.4986804899308481e-06
mutation O 0 8.585205250710715e-06
in O 0 4.913682118967699e-07
a O 0 6.397372999344952e-06
Japanese O 0 0.00020215778204146773
family O 0 0.00010734719398897141
. O 0 4.973155591869727e-05

Polymerase O 0 0.0009110954706557095
chain O 0 0.00047606005682609975
reaction O 0 0.00013024128566030413
- O 0 8.467010775348172e-05
single O 0 6.231720135474461e-07
strand O 0 7.618600648129359e-06
conformational O 0 5.351760592020582e-06
polymorphism O 0 8.369874535674171e-07
and O 0 1.1394115873031296e-08
direct O 0 1.4907172385392187e-08
sequence O 0 5.2617565415857825e-08
analyses O 0 2.3810154914372106e-07
demonstrated O 0 1.9750459046008473e-07
a O 0 1.1832382540433173e-07
C O 0 9.646007129049394e-06
to O 0 4.903421313429135e-08
T O 0 0.00013546213449444622
substitution O 0 5.979491390917246e-08
in O 0 6.891268000686068e-09
exon O 0 4.773189630213892e-07
1 O 0 9.32194677005782e-09
of O 0 1.4929529834617483e-09
the O 0 9.346908136365073e-09
CPO O 0 1.1308205785098835e-06
gene O 0 3.384723612498419e-08
at O 0 8.696404485419862e-09
nucleotide O 0 2.763474427069923e-08
position O 0 2.384241426511835e-08
85 O 0 2.9942930268589407e-07
, O 0 1.2287005191069511e-08
which O 0 3.990543895326937e-09
lies O 0 4.228738603728743e-08
in O 0 5.724831719788881e-09
the O 0 2.6402775077372098e-08
putative O 0 7.412453669530805e-06
presequence O 0 3.41237973771058e-05
for O 0 4.369852391050699e-08
targeting O 0 6.079020522520295e-07
to O 0 2.6817056664185657e-07
mitochondria O 0 2.6722274924395606e-05
. O 0 1.0738763194240164e-05

This O 0 1.430341626473819e-06
mutation O 0 3.841372745228e-06
changes O 0 1.3417670174931118e-07
the O 0 2.0905803310711235e-08
codon O 0 1.8260998047026078e-07
for O 0 1.0520081694664896e-08
glutamine O 0 3.902371474850952e-07
to O 0 9.479388829447544e-09
a O 0 4.871799674788235e-08
termination O 0 5.266232619760558e-06
codon O 0 4.999641305403202e-07
at O 0 1.2395464921155508e-07
amino O 0 2.5785163870750694e-07
acid O 0 8.798062481218949e-06
position O 0 9.547489980832324e-07
29 O 0 1.5179774891294073e-05
. O 0 1.318621616519522e-05

MaeI O 0 0.0028030374087393284
restriction O 0 2.9657690902240574e-05
analysis O 0 4.4629318836086895e-06
showed O 0 2.5377803467563353e-06
two O 0 5.0305615673096327e-08
other O 0 1.8173747662331152e-07
carriers O 0 5.7285888033220544e-05
in O 0 2.912638592533767e-07
the O 0 9.568856285113725e-07
family O 0 3.281967656221241e-05
. O 0 2.6402474759379402e-05

The O 0 9.922916069626808e-05
C O 1 0.5130202174186707
- O 1 0.8344364762306213
T O 1 0.9425598978996277
mutation O 0 1.7228941942448728e-05
is O 0 9.794918298666744e-08
located O 0 5.938449731957007e-08
within O 0 1.9916370774808456e-08
a O 0 1.176871933239454e-07
recently O 0 3.6407109860192577e-07
proposed O 0 2.2729298621015914e-07
putative O 0 9.661137028160738e-07
alternative O 0 5.786177581512675e-08
translation O 0 9.417489366114751e-08
initiation O 0 1.0258542033625417e-06
codon O 0 5.150337983650388e-06
( O 0 1.0227927305095363e-05
TIC O 0 0.050604335963726044
- O 0 3.070843013119884e-05
1 O 0 2.716866731589107e-07
) O 0 4.235107553540729e-08
, O 0 1.0665956118316444e-08
supporting O 0 1.7529072238176013e-07
that O 0 2.5516371238154534e-07
TIC O 0 0.09074115753173828
- O 0 2.3371207134914584e-05
1 O 0 1.0891128709999975e-07
is O 0 1.210438416165971e-08
the O 0 3.562653461131049e-08
real O 0 3.2641955840517767e-06
TIC O 0 0.01302605401724577
rather O 0 2.612192133710778e-07
than O 0 2.0287213828851236e-06
TIC O 1 0.721904993057251
- O 0 0.000545910035725683
2 O 0 6.8889576141373254e-06
. O 0 1.0672976031855796e-06
. O 0 4.332256139605306e-06

Human B-Disease 0 0.00056156498612836
complement I-Disease 0 0.011016115546226501
factor I-Disease 1 0.9495146870613098
H I-Disease 1 0.9976156949996948
deficiency I-Disease 1 0.9992884397506714
associated O 1 0.9907913208007812
with O 1 0.9958539009094238
hemolytic B-Disease 1 0.9997372031211853
uremic I-Disease 1 0.999703586101532
syndrome I-Disease 1 0.9996321201324463
. O 0 0.3392317295074463

This O 0 1.5198224900814239e-06
study O 0 1.928114443217055e-06
reports O 0 9.488869068263739e-07
on O 0 1.601863601763398e-07
six O 0 3.3656992854957934e-06
cases O 0 0.00010114092583535239
of O 0 4.516830449574627e-05
deficiency B-Disease 1 0.9994788765907288
in I-Disease 0 1.9080285085237847e-07
the I-Disease 0 6.857010959038234e-08
human I-Disease 0 1.3581220059677435e-07
complement I-Disease 0 1.0413434665679233e-06
regulatory I-Disease 0 1.7886779460241087e-05
protein I-Disease 0 5.561293164646486e-06
Factor I-Disease 0 4.290568904252723e-05
H I-Disease 0 0.1946047842502594
( O 0 2.4239623598987237e-05
FH O 0 0.08276970684528351
) O 0 8.152941433081651e-08
in O 0 1.0101522285310693e-08
the O 0 2.368721041534627e-08
context O 0 5.004826562071685e-07
of O 0 5.013271675124997e-06
an O 0 0.21431864798069
acute B-Disease 1 0.9996102452278137
renal I-Disease 1 0.9998972415924072
disease I-Disease 1 0.9996492862701416
. O 0 0.13811936974525452

Five O 0 1.2030645848426502e-06
of O 0 3.2474733302478853e-07
the O 0 7.845302434361656e-07
cases O 0 3.4104555197700392e-06
were O 0 6.893703385912886e-08
observed O 0 1.8117937088391045e-06
in O 0 3.6735686990141403e-06
children O 0 0.00020576397946570069
presenting O 0 0.049615971744060516
with O 1 0.9872243404388428
idiopathic O 1 0.9996956586837769
hemolytic B-Disease 1 0.9999061822891235
uremic I-Disease 1 0.9999179840087891
syndrome I-Disease 1 0.9998792409896851
( O 1 0.995422899723053
HUS B-Disease 1 0.9982094764709473
) O 0 0.004689256194978952
. O 0 0.00042380025843158364

Two O 0 4.42610513573527e-07
of O 0 2.3633694468117028e-07
the O 0 1.6293996623062412e-06
children O 0 2.6612309738993645e-05
exhibited O 0 0.0005529167247004807
a O 0 0.007247275207191706
homozygous O 1 0.9794836044311523
deficiency O 1 0.9997504353523254
characterized O 0 0.00316381873562932
by O 0 3.488911772819847e-07
the O 0 9.008437729107754e-08
absence O 0 6.13765791968035e-07
of O 0 1.555912376716151e-08
the O 0 9.674214851429497e-08
150 O 0 1.868953063421941e-06
- O 0 0.0002199322043452412
kD O 0 0.00033049032208509743
form O 0 7.039503913119916e-08
of O 0 6.280512110379277e-08
Factor O 0 2.443618723191321e-05
H O 0 0.002815015846863389
and O 0 2.4162140732642e-08
the O 0 1.863981324845554e-08
presence O 0 6.756885539971336e-08
, O 0 1.3589144032266631e-08
upon O 0 2.7802602886595196e-08
immunoblotting O 0 9.072624379768968e-06
, O 0 6.5807372884307824e-09
of O 0 3.0718947385821593e-09
the O 0 1.856990650139778e-08
42 O 0 1.9085266558249714e-06
- O 0 0.00013646377192344517
kD O 0 0.0021699117496609688
Factor O 0 4.121759502595523e-06
H O 0 0.0009680354851298034
- O 0 5.04852596350247e-06
like O 0 7.192379314346908e-08
protein O 0 1.2941704596869386e-07
1 O 0 4.1358384805789683e-07
( O 0 1.4849459830656997e-06
FHL O 0 0.00846449937671423
- O 0 1.1465956049505621e-05
1 O 0 1.4272387716118828e-07
) O 0 4.3751150258231064e-08
and O 0 3.2621176870861746e-08
other O 0 2.596628974060877e-07
FH O 0 0.3146871030330658
- O 0 0.00017701077740639448
related O 0 5.836783657287015e-06
protein O 0 4.031962362205377e-06
( O 0 8.375085599254817e-06
FHR O 0 0.0015869545750319958
) O 0 2.3953646177687915e-06
bands O 0 7.683928743063007e-06
. O 0 7.577934866276337e-06

Southern O 0 3.5470937291393057e-05
blot O 0 0.00024985591880977154
and O 0 4.39389395978651e-07
PCR O 0 4.1452103687333874e-06
analysis O 0 9.816744750423823e-08
of O 0 2.0299426140013566e-08
DNA O 0 2.936546650289529e-07
of O 0 4.211826620803549e-08
one O 0 9.652922017266974e-07
patient O 0 0.010681849904358387
with O 0 0.00023601877910550684
homozygous O 1 0.9175731539726257
deficiency O 1 0.9997050166130066
ruled O 0 1.4867205209156964e-05
out O 0 5.139691694466819e-08
the O 0 2.0151253110611833e-08
presence O 0 3.4677338334176966e-08
of O 0 4.7950226012005714e-09
a O 0 4.0765623765537384e-08
large O 0 1.3366761208999378e-07
deletion O 0 2.4004366423469037e-06
of O 0 4.154539823275627e-08
the O 0 2.0547406620607944e-06
FH O 1 0.6192795038223267
gene O 0 2.146925226043095e-06
as O 0 8.60984314954294e-08
the O 0 1.2664489759117714e-06
underlying O 0 0.010061198845505714
defect O 1 0.7628070116043091
for O 0 5.973831139272079e-05
the O 0 0.004175782669335604
deficiency O 1 0.9991567134857178
. O 0 0.00022794721007812768

The O 0 1.6590888662904035e-06
other O 0 1.839320020735613e-07
four O 0 4.6946013299020706e-07
children O 0 6.335771558951819e-06
presented O 0 1.789220368664246e-05
with O 0 0.00019307136244606227
heterozygous O 1 0.8332087397575378
deficiency O 1 0.9996927976608276
and O 0 5.051294920122018e-06
exhibited O 0 2.609602415759582e-05
a O 0 1.2912920510643744e-06
normal O 0 7.827329682186246e-06
immunoblotting O 0 0.0015001376159489155
pattern O 0 1.944868245118414e-06
of O 0 1.8064190143718406e-08
proteins O 0 1.4088227828779054e-07
of O 0 1.3118129515987675e-07
the O 0 9.578913704899605e-06
FH O 1 0.9515212774276733
family O 0 0.00012073641119059175
. O 0 2.6734995117294602e-05

Factor B-Disease 1 0.9474260807037354
H I-Disease 1 0.9970210194587708
deficiency I-Disease 1 0.998849630355835
is O 0 5.748694093199447e-06
the O 0 5.484334906213917e-06
only O 0 5.4146712500369176e-05
complement B-Disease 1 0.9863474369049072
deficiency I-Disease 1 0.9997368454933167
associated O 0 0.009229576215147972
with O 0 0.003691439051181078
HUS B-Disease 1 0.9965270161628723
. O 0 0.0006690430454909801

These O 0 8.101721959974384e-07
observations O 0 1.8127095700037898e-06
suggest O 0 2.04355274036061e-06
a O 0 5.148748982719553e-07
role O 0 1.5600480764987879e-06
for O 0 3.6694300433737226e-06
FH O 1 0.9541638493537903
and O 0 9.451512596569955e-06
/ O 0 0.03724544495344162
or O 0 1.2202610378153622e-05
FH O 1 0.5586434602737427
receptors O 0 1.5719324437668547e-05
in O 0 3.5660940511661465e-07
the O 0 3.158699428240652e-06
pathogenesis O 1 0.8098156452178955
of O 0 0.0007367939106188715
idiopathic O 1 0.9993129968643188
HUS B-Disease 1 0.998598039150238
. O 0 0.0002885937865357846
. O 0 0.00016616801440250129

Further O 0 7.429601282638032e-06
evidence O 0 1.6674292737661744e-06
for O 0 2.581493561137904e-07
a O 0 1.2700919569397229e-06
major O 0 4.097565761185251e-05
ancient O 0 0.00027816565125249326
mutation O 0 0.28924012184143066
underlying O 1 0.9943580031394958
myotonic B-Disease 1 0.9995676875114441
dystrophy I-Disease 1 0.9996358156204224
from O 0 0.00035155739169567823
linkage O 0 0.09885535389184952
disequilibrium O 0 0.4269370138645172
studies O 0 9.875553587335162e-06
in O 0 5.989718943055777e-07
the O 0 2.017913857343956e-06
Japanese O 0 9.489055082667619e-05
population O 0 8.574118510296103e-06
. O 0 1.7350164853269234e-05

The O 0 0.03716138377785683
myotonic B-Disease 1 0.9958806037902832
dystrophy I-Disease 1 0.9984387755393982
( O 1 0.6239189505577087
DM B-Disease 1 0.9983355402946472
) O 0 5.338558548828587e-05
mutation O 0 5.292295099934563e-05
is O 0 4.0134460732588195e-07
an O 0 6.386367203958798e-07
unstable O 0 0.0027862885035574436
( O 0 1.5961930330377072e-05
CTG O 0 0.013097446411848068
) O 0 1.6915661262828507e-06
n O 0 2.5635017664171755e-05
repeat O 0 1.5844574591028504e-05
, O 0 2.8460078738135053e-08
present O 0 1.2604176369279685e-08
at O 0 8.635165471559958e-09
a O 0 8.109002358480666e-09
copy O 0 2.6497318117435498e-08
number O 0 1.7035886035188241e-09
of O 0 5.457621465865259e-09
5 O 0 2.686633422399609e-07
- O 0 7.500349965994246e-06
37 O 0 1.7542282648719265e-07
repeats O 0 3.5316071489432943e-07
on O 0 6.195783441853564e-09
normal O 0 2.7979218941709405e-08
chromosomes O 0 3.9066122781150625e-08
but O 0 7.913426358641118e-09
amplified O 0 1.582034627745088e-07
to O 0 1.1923406262326353e-08
50 O 0 1.3549421851166699e-07
- O 0 1.2141389561293181e-05
3000 O 0 3.5283858323964523e-06
copies O 0 2.5743833020897e-07
on O 0 9.142988233179494e-07
DM B-Disease 1 0.9876020550727844
chromosomes O 0 6.589334952877834e-05
. O 0 2.2522384824696928e-05

Previous O 0 4.554651604848914e-05
findings O 0 4.1771090764086694e-05
in O 0 2.9194845865276875e-06
Caucasian O 0 0.0007508657872676849
populations O 0 4.104887921130285e-06
of O 0 8.62724903072376e-07
a O 0 0.0007764682522974908
DM B-Disease 1 0.9995922446250916
founder O 0 0.008934685960412025
chromosome O 0 0.0002341206418350339
raise O 0 3.2586901852482697e-06
a O 0 2.144889776900527e-07
question O 0 1.1028362223441945e-07
about O 0 2.201331028572895e-08
the O 0 2.1079980427884948e-08
molecular O 0 9.220797778652923e-07
events O 0 4.253938001852475e-08
involved O 0 5.453587093029455e-08
in O 0 3.70340771382871e-08
the O 0 2.554831723955431e-07
expansion O 0 8.088821778073907e-05
mutation O 0 7.267753244377673e-05
. O 0 1.0466189451108221e-05

To O 0 3.0499559215968475e-06
investigate O 0 8.586097465013154e-06
whether O 0 4.85780731196428e-07
a O 0 7.723467092546343e-07
founder O 0 2.6833946321858093e-05
chromosome O 0 1.777392390067689e-05
for O 0 5.241058147475997e-07
the O 0 2.2694957806379534e-05
DM B-Disease 1 0.9993976354598999
mutation O 0 9.39722522161901e-05
exists O 0 1.347151055597351e-06
in O 0 4.102215811485621e-08
the O 0 9.303511916414209e-08
Japanese O 0 6.711546120641287e-06
population O 0 1.394932098719437e-07
, O 0 5.184213591746811e-08
we O 0 4.0671107370826576e-08
genotyped O 0 2.3714350390946493e-05
families O 0 7.087155040608195e-08
using O 0 5.502915811916864e-08
polymorphic O 0 2.4157861844287254e-05
markers O 0 4.155449914833298e-06
near O 0 9.501139288659033e-07
the O 0 2.1414213335901877e-07
( O 0 3.922074483853066e-06
CTG O 0 0.0019597040954977274
) O 0 1.6200596064663841e-06
n O 0 2.1262729205773212e-05
repeat O 0 4.890430500381626e-05
region O 0 1.9952394723077305e-06
and O 0 4.239900306401978e-07
constructed O 0 4.237523899064399e-05
haplotypes O 0 0.00104469433426857
. O 0 3.836958057945594e-05

Six O 0 3.3693988825689303e-06
different O 0 5.192031267142738e-07
haplotypes O 0 8.325823000632226e-05
were O 0 2.2224976703455468e-07
found O 0 1.624698029445426e-06
and O 0 2.0809127818210982e-05
DM B-Disease 1 0.998638927936554
alleles O 0 3.0114579203655012e-05
were O 0 3.036892906038702e-07
always O 0 3.09642632601026e-06
haplotype O 0 0.002600116655230522
A O 0 4.432911009644158e-05
. O 0 3.5634493542602286e-05

To O 0 1.081185246221139e-06
find O 0 4.2354307083769527e-07
an O 0 2.740144289248292e-08
origin O 0 1.967645424372222e-08
of O 0 1.0648840920168823e-08
the O 0 1.713882653575638e-07
( O 0 3.66956987818412e-06
CTG O 0 0.002032620133832097
) O 0 6.191869488247903e-07
n O 0 1.7171663785120472e-05
repeat O 0 3.176297104801051e-05
mutation O 0 1.3460929721986759e-06
and O 0 9.087057328827086e-09
to O 0 4.618837312619917e-09
investigate O 0 3.95989125934193e-08
the O 0 2.9619873220809723e-09
mechanism O 0 3.2606372712962184e-08
of O 0 3.08123682124517e-09
the O 0 3.230946177268379e-08
expansion O 0 2.8613926588150207e-06
mutation O 0 8.307797543238848e-07
in O 0 1.819760697685524e-08
the O 0 4.44210641603604e-08
Japanese O 0 1.5778593933646334e-06
population O 0 2.9601023854297637e-08
we O 0 4.432092026718237e-09
have O 0 5.501307409616629e-09
studied O 0 9.363577646581689e-08
90 O 0 1.1046147392335115e-06
Japanese O 0 9.107711957767606e-05
DM B-Disease 1 0.995439350605011
families O 0 1.043871066030988e-06
comprising O 0 1.2912747706650407e-06
190 O 0 1.0272874533256982e-05
affected O 0 4.897690814686939e-06
and O 0 2.7206678510083293e-07
130 O 0 1.0476554962224327e-05
unaffected O 0 0.00012252740270923823
members O 0 1.1862612154800445e-06
. O 0 1.0459753866598476e-05

The O 0 8.919104402593803e-06
results O 0 1.5790856195962988e-05
suggest O 0 8.899723979993723e-06
that O 0 9.564571001874356e-08
a O 0 3.2511115932720713e-07
few O 0 2.4296164724546543e-07
common O 0 3.521413646012661e-06
ancestral O 0 4.351401003077626e-05
mutations O 0 8.053766578086652e-06
in O 0 7.246606514854648e-08
both O 0 2.3450870401120483e-07
Caucasian O 0 0.000618638820014894
and O 0 6.574881012966216e-07
Japanese O 0 3.2416701287729666e-05
populations O 0 1.1770655419240938e-06
have O 0 5.780968148627608e-09
originated O 0 3.114694280270669e-08
by O 0 4.458894586889528e-09
expansion O 0 6.754385850626932e-08
of O 0 2.9624167563468973e-09
an O 0 1.4819714344582735e-08
ancestral O 0 1.970458242794848e-06
n O 0 4.23443088948261e-06
= O 0 5.8294626796850935e-06
5 O 0 9.270883793988105e-08
repeat O 0 4.2284241885681695e-07
to O 0 1.1101697339199745e-08
n O 0 1.83338829629065e-06
= O 0 8.682453881192487e-06
19 O 0 6.746261647094798e-07
- O 0 2.0335839508334175e-05
37 O 0 1.1494117870824994e-06
copies O 0 1.120779870689148e-06
. O 0 3.929670583602274e-06

These O 0 7.034818736428861e-07
data O 0 5.251049515209161e-07
support O 0 6.109813170951384e-07
multistep O 0 2.3905169655336067e-05
models O 0 2.0142895209573908e-06
of O 0 5.014563839722541e-07
triplet O 0 0.01688362844288349
repeat O 0 0.0021768067963421345
expansion O 0 3.310117972432636e-05
that O 0 4.593405478203749e-08
have O 0 1.1403660238329394e-08
been O 0 1.8584788818998277e-08
proposed O 0 1.705999608248021e-07
for O 0 1.248112226903686e-07
both O 0 5.725910341425333e-06
DM B-Disease 1 0.9990386962890625
and O 0 0.00016530201537534595
Friedreichs B-Disease 1 0.9762793183326721
ataxia I-Disease 1 0.995898425579071
. O 0 2.6241068553645164e-05
. O 0 4.264400922693312e-05

The O 0 2.2138337953947484e-06
molecular O 0 2.0831404981436208e-05
basis O 0 4.8073334255605005e-06
of O 0 0.0005204852786846459
C6 B-Disease 1 0.9992669224739075
deficiency I-Disease 1 0.9996004700660706
in O 0 1.3102392131258966e-06
the O 0 6.833261068095453e-07
western O 0 6.610053333133692e-06
Cape O 0 7.577046199003235e-05
, O 0 1.1419351721997373e-06
South O 0 9.559566933603492e-06
Africa O 0 2.5449895474594086e-05
. O 0 8.626989256299566e-06

Deficiency B-Disease 1 0.9937447905540466
of I-Disease 0 3.678746338664496e-07
the I-Disease 0 3.0868093858771317e-07
sixth I-Disease 0 2.323536591575248e-06
component I-Disease 0 9.436942605134391e-07
of I-Disease 0 4.775848694293927e-08
human I-Disease 0 1.2090963537048083e-06
complement I-Disease 0 1.2361787412373815e-05
( O 0 2.9852721127099358e-05
C6 O 0 0.2375994771718979
) O 0 5.383515144785633e-07
has O 0 7.702005433429804e-08
been O 0 2.3243195812483464e-08
reported O 0 1.0256277249709456e-07
in O 0 3.800612713433793e-09
a O 0 4.312256329797037e-09
number O 0 1.4837071571349725e-09
of O 0 3.5370109063848076e-09
families O 0 7.598058715529987e-08
from O 0 3.1847278592067596e-08
the O 0 7.166526216906277e-08
western O 0 1.7689427522782353e-06
Cape O 0 3.113438287982717e-05
, O 0 4.836699645238696e-07
South O 0 7.72690873418469e-06
Africa O 0 1.658519249758683e-05
. O 0 1.5948282452882268e-05

Meningococcal B-Disease 1 0.9973217844963074
disease I-Disease 1 0.999086856842041
is O 0 0.0006849949713796377
endemic O 0 0.0698716789484024
in O 0 1.01184741652105e-06
the O 0 4.3131470306434494e-07
Cape O 0 1.1795752470789012e-05
and O 0 2.790806519215039e-08
almost O 0 2.088890305174118e-08
all O 0 1.2276510474862334e-08
pedigrees O 0 4.79907930639456e-06
of O 0 8.523925316694658e-07
total O 0 0.0011951761553063989
C6 B-Disease 1 0.9994490742683411
deficiency I-Disease 1 0.9998130202293396
( O 0 0.00067613780265674
C6Q0 O 0 0.41321831941604614
) O 0 1.7893183894557296e-06
have O 0 5.115515477882582e-08
been O 0 1.3066687643004116e-07
ascertained O 0 1.5051766240503639e-05
because O 0 5.810147740703542e-06
of O 0 0.00010055153688881546
recurrent O 1 0.9986005425453186
disease O 1 0.9990212917327881
. O 0 0.0018489477224647999

We O 0 1.199601229018299e-06
have O 0 1.3412974908533215e-07
sequenced O 0 4.757338274430367e-07
the O 0 2.468357074292271e-08
expressed O 0 6.713734279628625e-08
exons O 0 2.05522738383479e-07
of O 0 3.208139176535951e-08
the O 0 5.559743385674665e-07
C6 O 0 0.06846027076244354
gene O 0 8.379858513762883e-07
from O 0 6.144450992451311e-08
selected O 0 1.064084500512763e-07
cases O 0 3.814224385223497e-07
and O 0 2.0280463530752968e-08
have O 0 8.72656169548236e-09
found O 0 2.395952591882633e-08
three O 0 1.1058167359578874e-07
molecular O 0 0.0005023747798986733
defects O 1 0.5267007350921631
leading O 0 6.294036666076863e-06
to O 0 1.2561047242343193e-06
total O 0 0.0004948953865095973
deficiency O 1 0.999718964099884
879delG O 0 0.02494727075099945
, O 0 3.1838416703067196e-07
which O 0 2.4788970875988525e-08
is O 0 3.510659141170436e-08
the O 0 1.3103050378049375e-07
common O 0 1.0677694262994919e-05
defect O 0 0.007334833033382893
in O 0 1.1182756765037993e-07
the O 0 2.68839926320652e-07
Cape O 0 1.5397863535326906e-05
and O 0 1.8298477755251952e-07
hitherto O 0 1.0810350431711413e-05
unreported O 0 1.1601576261455193e-05
, O 0 1.6668680302700523e-07
and O 0 1.5151465504459338e-07
1195delC O 0 0.00011632726818788797
and O 0 3.607052860843396e-07
1936delG O 0 0.00018880392599385232
, O 0 6.390084195118106e-08
which O 0 7.061204954084133e-09
have O 0 5.351479703818995e-09
been O 0 1.2624218115320218e-08
previously O 0 1.931346531591771e-07
reported O 0 1.5690735608586692e-06
in O 0 5.270606493468222e-07
African O 0 5.955714004812762e-05
- O 0 0.007560670841485262
Americans O 0 2.1696074327337556e-05
. O 0 1.487374356656801e-05

We O 0 1.4905089074090938e-06
also O 0 2.322543224408946e-07
show O 0 1.7275900177082804e-07
that O 0 4.025151767450552e-08
the O 0 3.317808250358212e-07
879delG O 0 0.002116661984473467
and O 0 1.1437517059675884e-05
1195delC O 1 0.8290314674377441
defects O 1 0.7229500412940979
are O 0 5.984933437730433e-08
associated O 0 1.1856889159389539e-06
with O 0 1.2608247743628453e-06
characteristic O 0 0.0022365173790603876
C6 O 1 0.9972935318946838
/ O 1 0.620836079120636
C7 O 0 0.33729761838912964
region O 0 6.0527672758325934e-06
DNA O 0 9.456110092287418e-06
marker O 0 0.00010476092575117946
haplotypes O 0 0.00022912908752914518
, O 0 3.069106355724216e-07
although O 0 1.3240662610769505e-07
small O 0 1.4059988018289005e-07
variations O 0 1.1264484101047856e-06
were O 0 1.1790389464749751e-07
observed O 0 3.6216961234458722e-06
. O 0 1.1861100574606098e-05

The O 0 0.00010432737326482311
1936delG O 1 0.5170959830284119
defect O 0 0.29663798213005066
was O 0 2.0722886802104767e-06
observed O 0 4.1306074649583024e-07
only O 0 3.11531245245078e-08
once O 0 1.8842855808998138e-07
in O 0 4.1060438604745286e-08
the O 0 1.1941618538457988e-07
Cape O 0 1.8230584828415886e-05
, O 0 1.3348773109100875e-07
but O 0 3.596613495915335e-08
its O 0 2.7783846689999336e-07
associated O 0 1.030263229040429e-05
haplotype O 0 0.0014351848512887955
could O 0 4.1936701222766715e-07
be O 0 1.250698886678947e-07
deduced O 0 6.9233510657795705e-06
. O 0 5.636075002257712e-06

The O 0 1.1331802625136334e-06
data O 0 7.183550110312353e-07
from O 0 2.1922895143688947e-07
the O 0 3.3468037941020157e-07
haplotypes O 0 8.755749877309427e-05
indicate O 0 9.278593324779649e-07
that O 0 1.026842966211916e-08
these O 0 9.46219191888531e-09
three O 0 1.9674939721880946e-07
molecular O 0 0.001283751567825675
defects O 1 0.6138885617256165
account O 0 5.916155032537063e-07
for O 0 2.1699662511309725e-07
the O 0 2.359442760280217e-06
defects O 0 0.06701423227787018
in O 0 2.989590086599492e-08
all O 0 1.142763306205552e-08
the O 0 3.360947573582962e-07
38 O 0 3.833469236269593e-05
unrelated O 0 0.0007043723599053919
C6Q0 O 0 0.1235288754105568
individuals O 0 3.1113310683394957e-07
we O 0 3.3335961546754334e-08
have O 0 1.549878980711128e-08
studied O 0 1.255889827689316e-07
from O 0 1.5456463131613418e-07
the O 0 8.56886686051439e-07
Cape O 0 0.00016409874660894275
. O 0 2.7677804609993473e-05

We O 0 2.3686727672611596e-06
have O 0 1.653079522156986e-07
also O 0 1.0912337700119679e-07
observed O 0 2.9248528221614833e-07
the O 0 5.979559887236974e-07
879delG O 0 0.00322638638317585
defect O 0 0.0016658548265695572
in O 0 4.219079414724547e-07
two O 0 2.3542190774605842e-06
Dutch O 0 0.017089011147618294
C6 B-Disease 1 0.9987773299217224
- I-Disease 1 0.9914916157722473
deficient I-Disease 1 0.9939858913421631
kindreds O 0 0.00043913512490689754
, O 0 1.3237468010629527e-07
but O 0 3.7598915980652237e-08
the O 0 2.283099291844337e-07
879delG O 0 0.005718229338526726
defect O 0 0.011574126780033112
in O 0 1.826592637144131e-07
the O 0 5.052789902038057e-07
Cape O 0 8.041569526540115e-05
probably O 0 1.011240556181292e-06
did O 0 5.700449179357747e-08
not O 0 4.92253482420324e-09
come O 0 1.6919834422424174e-08
from O 0 2.0130931588369094e-08
The O 0 7.448995376080347e-08
Netherlands O 0 7.0867276917851996e-06
. O 0 8.621458960078598e-07
. O 0 7.190402357082348e-06

Complement B-Disease 1 0.8685948252677917
C7 I-Disease 1 0.996678352355957
deficiency I-Disease 1 0.9987672567367554
: O 0 0.00010806871432578191
seven O 0 1.0494354683032725e-05
further O 0 5.3614556236425415e-05
molecular O 0 0.018989242613315582
defects O 1 0.9661747217178345
and O 0 9.326464009973279e-07
their O 0 7.290288976946613e-07
associated O 0 9.392270294483751e-05
marker O 0 0.0012177980970591307
haplotypes O 0 0.009192908182740211
. O 0 0.00012100150343030691

Seven O 0 8.550136044505052e-06
further O 0 9.490385309618432e-06
molecular O 0 4.04245984100271e-05
bases O 0 2.25944968406111e-05
of O 0 0.0007585768471471965
C7 B-Disease 1 0.999150276184082
deficiency I-Disease 1 0.9995742440223694
are O 0 1.9778628484345973e-05
described O 0 0.0010112477466464043
. O 0 0.00013728417980019003

All O 0 5.073935653854278e-07
these O 0 2.5372477807650284e-07
new O 0 3.050866325793322e-06
molecular O 0 0.00040435660048387945
defects O 0 0.32928571105003357
involve O 0 2.5227857349818805e-06
single O 0 4.382598604024679e-07
- O 0 1.2614739716809709e-05
nucleotide O 0 1.5840727485283423e-07
events O 0 4.829970379205406e-08
, O 0 3.395606640310689e-08
deletions O 0 3.15713123200112e-07
and O 0 1.01078434511237e-08
substitutions O 0 6.506120087124145e-08
, O 0 6.355657777845636e-09
some O 0 1.5900982752725668e-09
of O 0 5.0751229885293014e-09
which O 0 4.2775905484404575e-08
alter O 0 6.328223207674455e-06
splice O 0 8.314341357618105e-06
sites O 0 1.8220534059310012e-07
, O 0 7.727535233925664e-08
and O 0 1.0330609256925527e-07
others O 0 1.3295366443344392e-06
codons O 0 4.134651317144744e-05
. O 0 1.0824277524079662e-05

They O 0 6.959082838875474e-07
are O 0 5.4953325445694645e-08
distributed O 0 1.8297815529422223e-07
along O 0 1.6376922928884596e-07
the O 0 1.1183113883816986e-06
C7 O 0 0.2169322520494461
gene O 0 4.287365754862549e-06
, O 0 3.9556336872692555e-08
but O 0 1.2507593183386234e-08
predominantly O 0 1.523666171010518e-08
towards O 0 3.524863245729648e-08
the O 0 1.3391604625212494e-07
3 O 0 3.0158723802742315e-06
end O 0 1.618452552065719e-05
. O 0 1.0315391591575462e-05

All O 0 9.778666480997344e-07
were O 0 2.8315952249613474e-07
found O 0 3.802145158715575e-07
in O 0 5.499033477462945e-07
compound O 0 5.5209442507475615e-05
heterozygous O 0 6.737859075656161e-05
individuals O 0 1.5977282600943e-05
. O 0 5.2882489399053156e-05

The O 0 0.00023741560289636254
C6 O 1 0.978019118309021
/ O 1 0.8971375226974487
C7 O 1 0.8870818614959717
marker O 0 0.002047147834673524
haplotypes O 0 0.0036453078500926495
associated O 0 4.211864870740101e-05
with O 0 1.2770949069818016e-05
most O 0 0.0002356619224883616
C7 B-Disease 1 0.9979124665260315
defects I-Disease 1 0.9938809871673584
are O 0 7.497658316424349e-07
tabulated O 0 6.169640982989222e-05
. O 0 5.385500116972253e-06
. O 0 1.820469697122462e-05

A O 0 3.7001416785642505e-05
genome O 0 5.803600652143359e-05
- O 0 6.008315904182382e-05
wide O 0 1.1058447171308217e-06
search O 0 8.379027462979138e-07
for O 0 1.2068671821907628e-06
chromosomal O 0 0.014908449724316597
loci O 0 0.002589067444205284
linked O 0 0.035019781440496445
to O 0 0.00029836694011464715
mental O 1 0.9990123510360718
health O 1 0.9808986783027649
wellness O 0 0.4721391499042511
in O 0 6.234642569324933e-06
relatives O 0 9.011077781906351e-05
at O 0 9.635797323426232e-05
high O 0 0.19378890097141266
risk O 1 0.9851925373077393
for O 1 0.6130239963531494
bipolar B-Disease 1 0.9998959302902222
affective I-Disease 1 0.9997156262397766
disorder I-Disease 1 0.9997182488441467
among O 0 3.9291891880566254e-05
the O 0 7.759547770547215e-06
Old O 0 0.00018859108968172222
Order O 0 1.3860642866347916e-05
Amish O 0 0.0011698233429342508
. O 0 5.755881647928618e-05

Bipolar B-Disease 1 0.9959681034088135
affective I-Disease 1 0.9957365989685059
disorder I-Disease 1 0.9985092282295227
( O 1 0.9412157535552979
BPAD B-Disease 1 0.9975462555885315
; O 1 0.9948977828025818
manic B-Disease 1 0.9994738698005676
- I-Disease 1 0.9994823932647705
depressive I-Disease 1 0.999767005443573
illness I-Disease 1 0.9995786547660828
) O 0 0.00011631739471340552
is O 0 2.6565564894553972e-06
characterized O 0 0.0001703117450233549
by O 0 3.420999519221368e-07
episodes O 0 9.242735359293874e-06
of O 0 1.394172250002157e-05
mania B-Disease 1 0.9986577033996582
and O 0 9.956915164366364e-05
/ O 1 0.8150935769081116
or O 0 3.764340726775117e-05
hypomania B-Disease 1 0.9842970967292786
interspersed O 0 6.372100324369967e-05
with O 0 3.0762641927140066e-06
periods O 0 0.00035840997588820755
of O 0 0.00010112830204889178
depression B-Disease 1 0.9963052272796631
. O 0 0.0004153469926677644

Compelling O 0 4.0981518395710737e-05
evidence O 0 5.514785698323976e-06
supports O 0 1.2149845133535564e-05
a O 0 2.5499978164589265e-06
significant O 0 4.265965799277183e-06
genetic O 0 5.0726299377856776e-05
component O 0 8.364022505702451e-06
in O 0 4.4761520712199854e-07
the O 0 1.5577259091514861e-06
susceptibility O 0 0.0033876029774546623
to O 0 7.500285846617771e-06
develop O 0 0.008866727352142334
BPAD B-Disease 1 0.9876276254653931
. O 0 0.00018486932094674557

To O 0 2.5942381398635916e-06
date O 0 3.391433665456134e-06
, O 0 4.7453667662011867e-07
however O 0 2.1046800213753158e-07
, O 0 2.1333596578188008e-07
linkage O 0 2.4714232495171018e-05
studies O 0 2.356167954076227e-07
have O 0 9.931075517499721e-09
attempted O 0 1.4777324963688443e-07
only O 0 8.79264039355121e-09
to O 0 4.15133172282367e-08
identify O 0 1.8287606735611917e-06
chromosomal O 0 0.0004952441668137908
loci O 0 2.654653144418262e-05
that O 0 1.1144529707962647e-06
cause O 0 0.0006170759443193674
or O 0 1.381456741000875e-06
increase O 0 7.3770092967606615e-06
the O 0 1.5196803815342719e-06
risk O 0 0.0005491425399668515
of O 0 1.9431479358900106e-06
developing O 0 0.00885817501693964
BPAD B-Disease 1 0.9902015328407288
. O 0 0.00019217620138078928

To O 0 2.7048474748880835e-06
determine O 0 1.6951722727753804e-06
whether O 0 7.90314004461834e-07
there O 0 3.707705502620229e-07
could O 0 5.05564344166487e-07
be O 0 1.00009543757551e-07
protective O 0 0.000853029836434871
alleles O 0 5.561324996961048e-06
that O 0 2.6322229018660437e-07
prevent O 0 8.409189467784017e-05
or O 0 2.3543582301499555e-06
reduce O 0 3.2158302929019555e-05
the O 0 4.941756515108864e-07
risk O 0 5.654234701069072e-05
of O 0 3.437183693222323e-07
developing O 0 0.0008369260467588902
BPAD B-Disease 1 0.9383207559585571
, O 0 2.7237857125328446e-07
similar O 0 1.0701131003543196e-07
to O 0 1.6926613000123325e-08
what O 0 2.9280892377414602e-08
is O 0 3.076963039916336e-08
observed O 0 2.7385254952605464e-07
in O 0 5.205636171012884e-07
other O 0 3.280624878243543e-05
genetic B-Disease 1 0.9987309575080872
disorders I-Disease 1 0.9998427629470825
, O 0 5.840014637215063e-05
we O 0 1.2401486856106203e-05
used O 0 0.000353637762600556
mental O 1 0.9987521171569824
health O 1 0.9842584133148193
wellness O 1 0.7545003890991211
( O 0 3.5650980862556025e-05
absence O 0 5.154676182428375e-05
of O 0 6.389879217749694e-06
any O 0 0.006287133786827326
psychiatric B-Disease 1 0.9997416138648987
disorder I-Disease 1 0.999722421169281
) O 0 1.0670231858966872e-05
as O 0 2.900663673699455e-07
the O 0 3.514592492592783e-07
phenotype O 0 6.764668069081381e-05
in O 0 6.252018636132561e-08
our O 0 1.9497214509556215e-07
genome O 0 9.008606866700575e-06
- O 0 2.6387948310002685e-05
wide O 0 1.3462778269968112e-06
linkage O 0 7.18326737114694e-06
scan O 0 2.5413576167920837e-06
of O 0 7.587829919941669e-09
several O 0 3.0017435648233004e-08
large O 0 1.0952619504678296e-06
multigeneration O 0 0.00042718692566268146
Old O 0 6.0904453675902914e-06
Order O 0 5.407720209404943e-07
Amish O 0 8.701945625944063e-05
pedigrees O 0 0.00020225165644660592
exhibiting O 0 4.904474189970642e-05
an O 0 1.1093716238974594e-06
extremely O 0 0.00014027798897586763
high O 0 0.0006718432996422052
incidence O 0 0.3518424928188324
of O 0 1.8171484043705277e-05
BPAD B-Disease 1 0.9852604269981384
. O 0 0.00014581516734324396

We O 0 3.67635152542789e-06
have O 0 3.3614475114518427e-07
found O 0 1.746672779745495e-07
strong O 0 1.5010634513146215e-07
evidence O 0 5.6074821230822636e-08
for O 0 1.748771971676888e-08
a O 0 1.6073282438355818e-07
locus O 0 4.362159870652249e-06
on O 0 5.204951207815611e-07
chromosome O 0 0.00017196492990478873
4p O 0 0.273242712020874
at O 0 1.9649621663120342e-06
D4S2949 O 0 6.906873022671789e-05
( O 0 6.122405693531618e-07
maximum O 0 5.5659239706074e-07
GENEHUNTER O 0 0.00023626936308573931
- O 0 6.627278253290569e-06
PLUS O 0 6.567711920979491e-07
nonparametric O 0 1.1074224630647223e-06
linkage O 0 6.476034286606591e-07
score O 0 5.901593880253131e-08
= O 0 1.5908262867014855e-06
4 O 0 8.07357167786904e-08
. O 0 1.912483860166958e-08
05 O 0 2.9179425382608315e-06
, O 0 3.477291343756406e-08
P O 0 2.1198304239078425e-05
= O 0 2.179087687181891e-06
5 O 0 3.780825608146188e-08
. O 0 6.861914148004189e-09
22 O 0 5.038099359921944e-08
x O 0 5.518671173376788e-07
10 O 0 5.748096043589612e-08
( O 0 1.0871931266365209e-07
- O 0 1.5188603583737859e-06
4 O 0 1.0712813036661828e-07
) O 0 4.4196344362035234e-08
; O 0 7.070008223308832e-08
SIBPAL O 0 3.579027179512195e-05
Pempirical O 0 5.932872682024026e-06
value O 0 3.892064981414478e-08
< O 0 7.780623491271399e-06
3 O 0 1.442130326267943e-07
x O 0 1.2800742297258694e-06
10 O 0 6.885213821306024e-08
( O 0 2.2149987444208818e-07
- O 0 3.3152098239952466e-06
5 O 0 6.808335228924989e-08
) O 0 3.26641362846658e-08
) O 0 1.1781888353823433e-08
and O 0 5.001283831518322e-09
suggestive O 0 8.524486929673003e-07
evidence O 0 1.9879973223169145e-08
for O 0 3.4673552917752204e-09
a O 0 3.7626822546599215e-08
locus O 0 2.0070085611223476e-06
on O 0 2.161230128194802e-07
chromosome O 0 0.00016180785314645618
4q O 0 0.23499655723571777
at O 0 9.397568874192075e-07
D4S397 O 0 3.589452171581797e-05
( O 0 2.8814079655603564e-07
maximum O 0 4.371832460492442e-07
GENEHUNTER O 0 0.00027998321456834674
- O 0 7.577182714157971e-06
PLUS O 0 4.368660881937103e-07
nonparametric O 0 1.2962248092662776e-06
linkage O 0 1.0889099257838097e-06
score O 0 5.956417936658909e-08
= O 0 1.4930868701412692e-06
3 O 0 4.067483061476196e-08
. O 0 7.22562454313902e-09
29 O 0 6.952516429237221e-08
, O 0 2.78123639674277e-08
P O 0 1.3919190678279847e-05
= O 0 1.2631295476239757e-06
2 O 0 4.056690272591368e-08
. O 0 6.4018541579002886e-09
57 O 0 9.767084208078813e-08
x O 0 5.614930387309869e-07
10 O 0 3.2237380764854606e-08
( O 0 9.029975700514115e-08
- O 0 9.536533411846904e-07
3 O 0 4.249850604765015e-08
) O 0 2.521904107766204e-08
; O 0 4.992803681602709e-08
SIBPAL O 0 1.5179833098954987e-05
Pempirical O 0 6.377752015396254e-06
value O 0 4.548835619289093e-08
< O 0 8.630428965261672e-06
1 O 0 1.041741271023966e-07
x O 0 2.366974513279274e-06
10 O 0 1.312506157091775e-07
( O 0 3.677336621876748e-07
- O 0 7.6169881140231155e-06
3 O 0 3.9599146361979365e-07
) O 0 1.2695807072304888e-07
) O 0 4.972579858986137e-08
that O 0 1.3798245213081373e-08
are O 0 6.03006782284865e-08
linked O 0 0.00011108873877674341
to O 0 3.663101961137727e-05
mental O 1 0.9952884912490845
health O 1 0.9615447521209717
wellness O 1 0.8688133358955383
. O 0 0.00020550243789330125

These O 0 3.0851956580590922e-06
findings O 0 8.257203262473922e-06
are O 0 5.8147545445308424e-08
consistent O 0 2.634699285408715e-07
with O 0 4.580867951631262e-08
the O 0 5.745235398535442e-08
hypothesis O 0 1.146548811448156e-06
that O 0 2.050250635932116e-08
certain O 0 9.995005001428581e-08
alleles O 0 3.3040018934116233e-06
could O 0 4.6462926661661186e-07
prevent O 0 8.854542102199048e-06
or O 0 6.579290356967249e-07
modify O 0 2.5905399525072426e-05
the O 0 2.051406454484095e-06
clinical O 0 0.00201834156177938
manifestations O 0 0.0006618094048462808
of O 0 8.095975317701232e-06
BPAD B-Disease 1 0.9975749850273132
and O 0 8.109251211863011e-06
perhaps O 0 5.2305163990240544e-05
other O 0 2.1529413061216474e-05
related O 0 0.47307291626930237
affective B-Disease 1 0.9972844123840332
disorders I-Disease 1 0.9988014698028564
. O 0 0.008104183711111546

Segregation O 0 0.4217212498188019
distortion O 1 0.7533963918685913
in O 0 0.20391452312469482
myotonic B-Disease 1 0.9939370155334473
dystrophy I-Disease 1 0.9964097142219543
. O 0 0.030925193801522255

Myotonic B-Disease 1 0.9947630763053894
dystrophy I-Disease 1 0.997945249080658
( O 1 0.9113937020301819
DM B-Disease 1 0.9983219504356384
) O 0 0.00035059830406680703
is O 0 3.283182377344929e-05
an O 0 0.000489461759570986
autosomal B-Disease 1 0.9988865256309509
dominant I-Disease 1 0.9974350333213806
disease I-Disease 1 0.9995787739753723
which O 0 2.2961139620747417e-06
, O 0 6.40307746380131e-07
in O 0 1.5400138408949715e-07
the O 0 5.168826646695379e-07
typical O 0 0.00010309631034033373
pedigree O 0 0.00032916147029027343
, O 0 1.2807822713511996e-07
shows O 0 7.672797153190913e-08
a O 0 7.317106565096765e-08
three O 0 1.7920952188887895e-07
generation O 0 5.2946274081477895e-05
anticipation O 0 0.00020672597747761756
cascade O 0 0.004979883320629597
. O 0 3.02980188280344e-05

This O 0 2.2938003894523717e-05
results O 0 0.0006237555644474924
in O 0 0.004941282793879509
infertility B-Disease 1 0.9985105395317078
and O 1 0.9664021134376526
congenital B-Disease 1 0.9997825026512146
myotonic I-Disease 1 0.9996789693832397
dystrophy I-Disease 1 0.9997333884239197
( O 0 0.3995573818683624
CDM B-Disease 1 0.8838971257209778
) O 0 1.8518550177759607e-06
with O 0 1.9790525129792513e-07
the O 0 3.5729161140807264e-07
disappearance O 0 3.984688737546094e-05
of O 0 9.552759365760721e-06
DM B-Disease 1 0.9988731741905212
in O 0 9.822738320508506e-06
that O 0 5.057406724517932e-06
pedigree O 0 0.0040744892321527
. O 0 5.5106404033722356e-05

The O 0 1.4122007314654184e-06
concept O 0 1.5664093098166632e-06
of O 0 5.843829171681136e-07
segregation O 0 0.006667298264801502
distortion O 0 0.0018736663041636348
, O 0 1.1534384611877613e-06
where O 0 9.002133793956091e-08
there O 0 2.870956627987198e-08
is O 0 1.5275976039674788e-08
preferential O 0 4.974776288690919e-07
transmission O 0 4.6060392833169317e-07
of O 0 2.4741013682216817e-09
the O 0 1.0076044887341595e-08
larger O 0 1.1822050538512485e-07
allele O 0 5.270173915050691e-07
at O 0 3.5986727198178414e-07
the O 0 5.088470970804337e-06
DM B-Disease 1 0.99918133020401
locus O 0 6.412332731997594e-05
, O 0 1.414230155205587e-07
has O 0 2.392208386936545e-08
been O 0 5.008166326092578e-09
put O 0 2.2956372802696023e-08
forward O 0 1.9666511974492096e-08
to O 0 1.7859491663330118e-08
explain O 0 6.940432513147243e-07
partially O 0 1.3625358405988663e-06
the O 0 1.156719520167826e-07
maintenance O 0 8.082330168690532e-05
of O 0 2.519294639569125e-06
DM B-Disease 1 0.9990437626838684
in O 0 6.638098852818075e-07
the O 0 6.650911359429301e-07
population O 0 2.230910013167886e-06
. O 0 7.5278176154824905e-06

In O 0 3.6725459722219966e-06
a O 0 2.318222414032789e-06
survey O 0 9.241254701919388e-06
of O 0 3.2645534702169243e-06
DM B-Disease 1 0.9972456693649292
in O 0 1.1675045925585437e-06
Northern O 0 1.0183330232393928e-06
Ireland O 0 2.266112915094709e-06
, O 0 5.605652404483408e-07
59 O 0 1.2760685422108509e-05
pedigrees O 0 4.076900222571567e-05
were O 0 6.062878696866392e-07
ascertained O 0 7.264462328748778e-05
. O 0 2.0100207620998845e-05

Sibships O 0 0.007046341896057129
where O 0 1.6230889059443143e-06
the O 0 2.559167455729039e-07
status O 0 1.837209282484764e-07
of O 0 1.71450302843823e-08
all O 0 1.1637586005974754e-08
the O 0 5.49064935739807e-08
members O 0 4.062574987528933e-08
had O 0 7.030835291743642e-08
been O 0 2.7401862112697017e-08
identified O 0 5.765114963196538e-08
were O 0 5.867649921498241e-09
examined O 0 1.2719584674414364e-07
to O 0 1.8062665807505596e-09
determine O 0 8.283302932454717e-09
the O 0 1.1295876234385105e-08
transmission O 0 6.924631179572316e-07
of O 0 3.3757750372842565e-08
the O 0 3.5853479403158417e-06
DM B-Disease 1 0.9984924793243408
expansion O 0 0.00010359180305385962
from O 0 2.206894350820221e-06
affected O 0 5.930507995799417e-06
parents O 0 2.5442307105549844e-07
to O 0 5.28175654324059e-08
their O 0 2.4168323875528586e-07
offspring O 0 4.7796642320463434e-05
. O 0 1.4981608728703577e-05

Where O 0 5.813517873320961e-06
the O 0 2.761780933724367e-06
transmitting O 0 0.00042970135109499097
parent O 0 0.00016957605839706957
was O 0 4.486161742534023e-06
male O 0 1.8097032807418145e-05
, O 0 6.0718402892234735e-06
58 O 0 0.0001559121737955138
. O 0 2.4358430891879834e-05

3 O 0 6.142720849311445e-06
% O 0 4.896972427559376e-07
of O 0 4.9518899203349065e-08
the O 0 3.7270049801918503e-07
offspring O 0 1.612239793757908e-05
were O 0 1.974484717948144e-07
affected O 0 7.0997011789586395e-06
, O 0 1.1306301672675545e-07
and O 0 1.5773277795005924e-08
in O 0 8.950203245206012e-09
the O 0 1.35275701751425e-08
case O 0 4.9993410300430696e-08
of O 0 1.1479014183635172e-08
a O 0 7.908296879577392e-07
female O 0 1.077650722436374e-05
transmitting O 0 0.00020920298993587494
parent O 0 7.076925976434723e-05
, O 0 2.1118871700309683e-06
68 O 0 5.946787860011682e-05
. O 0 1.1062761586799752e-05

7 O 0 8.320488996105269e-05
% O 0 2.0540201148833148e-05
were O 0 5.572803274844773e-06
affected O 0 0.0003280587261542678
. O 0 6.308753654593602e-05

Studies O 0 1.4144409760774579e-05
on O 0 2.1234695850580465e-06
meiotic O 0 0.002846081042662263
drive O 0 0.00017415850015822798
in O 0 7.56681474740617e-05
DM B-Disease 1 0.9986773133277893
have O 0 3.109915951426956e-07
shown O 0 3.266925148182054e-07
increased O 0 3.511075021833676e-07
transmission O 0 3.894040503382712e-07
of O 0 3.84955223253769e-09
the O 0 1.1135734112599494e-08
larger O 0 2.2969125268446078e-07
allele O 0 6.00673104145244e-07
at O 0 2.640555294419755e-07
the O 0 8.635340691398596e-07
DM B-Disease 1 0.9945555925369263
locus O 0 5.335820242180489e-05
in O 0 3.839614691969473e-06
non O 0 0.0008604241302236915
- O 1 0.9439330101013184
DM O 1 0.9979627132415771
heterozygotes O 0 0.024682532995939255
for O 0 2.0290472093620338e-05
CTGn O 0 0.06951914727687836
. O 0 7.067275873851031e-05

This O 0 3.0522778615704738e-06
study O 0 2.972662969114026e-06
provides O 0 1.4326336668091244e-06
further O 0 6.396217031578999e-07
evidence O 0 6.840159585408401e-07
that O 0 2.1581159614925127e-07
the O 0 4.396749773150077e-06
DM B-Disease 1 0.998646080493927
expansion O 0 0.00022123786038719118
tends O 0 1.8421129425405525e-05
to O 0 9.961033242689155e-08
be O 0 1.8395270728888136e-07
transmitted O 0 1.889690429379698e-05
preferentially O 0 2.0948664314346388e-05
. O 0 1.0174305316468235e-05

Diagnosis O 1 0.9752941131591797
of O 0 0.004241073504090309
hemochromatosis B-Disease 1 0.9924538731575012
. O 0 0.006663469132035971

If O 0 0.028088096529245377
untreated O 1 0.9933183193206787
, O 0 0.31580889225006104
hemochromatosis B-Disease 1 0.9992188215255737
can O 0 0.24827472865581512
cause O 1 0.9979766011238098
serious O 1 0.9988565444946289
illness O 1 0.9994994401931763
and O 0 2.2031363187124953e-05
early B-Disease 0 0.00020964487339369953
death I-Disease 0 0.0016931333811953664
, O 0 1.108013020711951e-05
but O 0 1.1511567208799534e-05
the O 0 0.00020852865418419242
disease O 1 0.9992425441741943
is O 0 5.0417083912179805e-06
still O 0 5.775724639534019e-05
substantially O 0 0.013259394094347954
under O 0 0.004418900702148676
- O 1 0.9952574372291565
diagnosed O 1 0.9974268078804016
. O 0 0.0001421398774255067

The O 0 5.1874062592105474e-06
cornerstone O 0 0.00010949906572932377
of O 0 1.0675154271666543e-06
screening O 0 9.82361743808724e-05
and O 0 8.072029800132441e-07
case O 0 3.958150500693591e-06
detection O 0 7.543404535681475e-06
is O 0 1.6515722123244814e-08
the O 0 1.3260459397201885e-08
measurement O 0 2.1341817557640752e-07
of O 0 1.1645739306231917e-07
serum O 0 0.0007043401710689068
transferrin O 0 0.0006289296434260905
saturation O 0 8.522767529939301e-06
and O 0 1.1001070987504136e-07
the O 0 7.505570920329774e-07
serum O 0 0.0008759350166656077
ferritin O 0 0.0019316604593768716
level O 0 2.476920599292498e-05
. O 0 1.4094160178501625e-05

Once O 0 0.00023532645718660206
the O 0 8.074087963905185e-05
diagnosis O 1 0.9481505155563354
is O 0 1.5877838450251147e-05
suspected O 0 0.00014711005496792495
, O 0 4.044494289701106e-06
physicians O 0 4.740087751997635e-05
must O 0 3.9187216316349804e-07
use O 0 1.725804736452119e-06
serum O 0 0.005080689676105976
ferritin O 0 0.011860691010951996
levels O 0 4.0399776480626315e-05
and O 0 6.620821750402683e-06
hepatic O 1 0.9903503060340881
iron O 0 0.08077369630336761
stores O 0 3.649611244327389e-05
on O 0 3.2489089790033177e-05
liver O 1 0.9979320764541626
biopsy O 0 0.18462252616882324
specimens O 0 0.00022070271370466799
to O 0 6.550018952111714e-06
assess O 0 0.012564154341816902
patients O 0 0.002176765352487564
for O 0 8.751351998625978e-08
the O 0 3.39255507242342e-07
presence O 0 3.28834107676812e-06
of O 0 5.249655259831343e-06
iron B-Disease 1 0.9524398446083069
overload I-Disease 1 0.9892570376396179
. O 0 0.0001448415277991444

Liver O 1 0.9959964752197266
biopsy O 0 0.3882850408554077
is O 0 1.8733785509539302e-06
also O 0 1.2340217381279217e-07
used O 0 3.151421523739373e-08
to O 0 7.245027244806579e-09
establish O 0 3.7352172910232184e-08
the O 0 3.768255751879224e-08
presence O 0 1.8335406082314876e-07
or O 0 3.468736906597769e-07
absence O 0 3.28507085214369e-05
of O 0 1.673803126323037e-05
cirrhosis B-Disease 1 0.9995285272598267
, O 0 7.078190719767008e-06
which O 0 2.1404832750704372e-06
can O 0 1.772454743331764e-05
affect O 0 0.0029898223001509905
prognosis O 1 0.9942743182182312
and O 0 2.2114485545898788e-05
management O 0 0.002349130343645811
. O 0 5.150455399416387e-05

A O 0 2.4382690753554925e-05
DNA O 0 2.9724318665103056e-05
- O 0 0.0001031750871334225
based O 0 3.382807847174263e-07
test O 0 3.6942719816579483e-07
for O 0 4.148474275211811e-08
the O 0 3.2191482546295447e-07
HFE O 0 0.06471635401248932
gene O 0 1.1654999525489984e-06
is O 0 2.0506806919229348e-08
commercially O 0 4.547456455838983e-08
available O 0 1.9864129896518534e-08
, O 0 5.687056159331405e-09
but O 0 1.390147330582181e-09
its O 0 2.1371699965300195e-09
place O 0 1.3552337030375838e-08
in O 0 7.626515952097179e-08
the O 0 2.3427965061273426e-06
diagnosis O 1 0.7058647871017456
of O 0 6.880958244437352e-05
hemochromatosis B-Disease 1 0.999700665473938
is O 0 7.861233825678937e-06
still O 0 4.774801709572785e-06
being O 0 2.546551741033909e-06
evaluated O 0 5.9664525906555355e-05
. O 0 1.658092332945671e-05

Currently O 0 5.647733814839739e-06
, O 0 3.216892707769148e-07
the O 0 5.6616034527223746e-08
most O 0 2.953019517804023e-08
useful O 0 2.981174418437149e-08
role O 0 4.031605982390829e-08
for O 0 9.409657941716887e-09
this O 0 1.2647138447619e-08
test O 0 1.6089262544483063e-07
is O 0 5.037011252539969e-09
in O 0 3.864522923890945e-09
the O 0 1.4935547909544766e-08
detection O 0 7.02844727129559e-06
of O 0 8.79078129401023e-07
hemochromatosis B-Disease 1 0.9991747736930847
in O 0 3.3419811984458647e-07
the O 0 1.524477966086124e-07
family O 0 1.3228952866484178e-06
members O 0 6.073236846759755e-08
of O 0 5.226010557635163e-07
patients O 0 0.006728808861225843
with O 0 1.7743798252922716e-06
a O 0 9.312722795584705e-06
proven O 0 7.270581409102306e-05
case O 0 5.679661171598127e-06
of O 0 4.145981620240491e-06
the O 0 0.0008555394015274942
disease O 1 0.99801105260849
. O 0 0.0002665434149093926

It O 0 3.6501569411484525e-06
is O 0 3.5671796467795502e-06
crucial O 0 6.537562148878351e-05
to O 0 0.0008777801413089037
diagnose O 1 0.997700035572052
hemochromatosis B-Disease 1 0.9992840886116028
before O 1 0.9685889482498169
hepatic B-Disease 1 0.9992313385009766
cirrhosis I-Disease 1 0.9995723366737366
develops O 1 0.9970235228538513
because O 0 0.3896309733390808
phlebotomy O 1 0.997730553150177
therapy O 1 0.9968491196632385
can O 1 0.7345506548881531
avert O 1 0.9994683861732483
serious O 1 0.9998257756233215
chronic O 1 0.9999752044677734
disease O 1 0.999881386756897
and O 0 4.758680006489158e-05
can O 0 2.4233738713519415e-06
even O 0 1.6162448446266353e-06
lead O 0 2.977517397084739e-06
to O 0 2.2715472880463494e-07
normal O 0 8.971826900960878e-06
life O 0 2.8973068765481003e-05
expectancy O 0 0.0030693495646119118
. O 0 4.912177701044129e-06
. O 0 1.5235102182487026e-05

Prevalence O 0 0.0027076411060988903
of O 0 1.5608457033522427e-06
the O 0 4.3767695387941785e-06
I1307K O 0 0.008914816193282604
APC B-Disease 0 0.02565028890967369
gene O 0 0.00014579526032321155
variant O 0 0.0003521334729157388
in O 0 1.7628585169404687e-07
Israeli O 0 7.726694093435071e-07
Jews O 0 7.836705151476053e-08
of O 0 9.415671797796676e-09
differing O 0 5.196549182073795e-07
ethnic O 0 1.1856832315970678e-06
origin O 0 5.500656243384583e-06
and O 0 0.0002186052588513121
risk O 1 0.9892949461936951
for O 1 0.8382312059402466
colorectal B-Disease 1 0.9998332262039185
cancer I-Disease 1 0.9994863271713257
. O 0 0.0075885881669819355

BACKGROUND O 0 0.0008095630328170955
& O 0 0.000851237797178328
AIMS O 0 5.249174500931986e-05
Israeli O 0 4.233078470861074e-06
Jews O 0 5.259128670331847e-07
of O 0 9.430772962559786e-08
European O 0 4.352108135208255e-06
birth O 0 2.5713463401189074e-05
, O 0 4.3083946366095915e-07
i O 0 6.026911592016404e-07
. O 0 6.987626477439335e-08
e O 0 1.5543631661785184e-06
. O 0 2.526477871356292e-08
, O 0 6.954877562748152e-08
Ashkenazim O 0 1.4557103895640466e-05
, O 0 9.234317133177683e-08
have O 0 1.2883113242878608e-07
the O 0 1.8710090444074012e-05
highest O 1 0.9646356105804443
colorectal B-Disease 1 0.9999443292617798
cancer I-Disease 1 0.9998571872711182
incidence O 1 0.6240147948265076
of O 0 2.50960169978498e-07
any O 0 4.956170300829399e-07
Israeli O 0 5.7681891121319495e-06
ethnic O 0 5.648095338983694e-06
group O 0 4.630593684851192e-05
. O 0 4.339453516877256e-05

The O 0 3.7391673686215654e-05
I1307K O 0 0.007454381790012121
APC B-Disease 0 0.026749437674880028
gene O 0 0.0001797803124645725
variant O 0 0.0017677976284176111
was O 0 2.3957027224241756e-06
found O 0 1.2448673487597262e-06
in O 0 1.3787533816866926e-06
6 O 0 0.00011289454414509237
. O 0 2.0722587578347884e-05

1 O 0 5.064685410616221e-06
% O 0 5.963056537439115e-07
of O 0 1.12762478465811e-07
American O 0 5.967784204585769e-07
Jews O 0 2.6357096771789656e-07
, O 0 4.572016720771899e-08
28 O 0 3.507192900542577e-07
% O 0 9.654436183836879e-08
of O 0 3.5365749795346346e-07
their O 0 0.000541161687579006
familial O 1 0.999665379524231
colorectal B-Disease 1 0.9999748468399048
cancer I-Disease 1 0.9999281167984009
cases O 0 0.020259616896510124
, O 0 1.1103232282039244e-05
but O 0 6.877207283650932e-07
not O 0 9.711874326967518e-08
in O 0 6.011430286889663e-07
non O 0 3.526176806190051e-05
- O 0 0.001420950167812407
Jews O 0 8.482814337185118e-06
. O 0 1.2477419659262523e-05

We O 0 7.409379122691462e-06
assessed O 0 3.6905596061842516e-05
the O 0 7.936614565551281e-06
I1307K O 0 0.17425690591335297
prevalence O 0 0.13722069561481476
in O 0 2.8064209800504614e-07
Israeli O 0 1.2194943792565027e-06
Jews O 0 1.0772972558470428e-07
of O 0 1.7252233419640106e-08
differing O 0 4.4215403249836527e-07
ethnic O 0 1.1537948694240185e-06
origin O 0 4.7165726755338255e-06
and O 0 0.00042835823842324317
risk O 1 0.9940382242202759
for O 1 0.8681635856628418
colorectal B-Disease 1 0.9998786449432373
cancer I-Disease 1 0.9995131492614746
. O 0 0.007487880531698465

METHODS O 0 9.816631973080803e-06
DNA O 0 7.180781267379643e-06
samples O 0 1.028607016451133e-06
from O 0 4.5707699314334604e-07
500 O 0 1.7752362282408285e-06
unrelated O 0 5.224173946771771e-06
Jews O 0 9.215525409445036e-08
of O 0 4.8453795642444675e-08
European O 0 1.7072640048354515e-06
or O 0 1.131062163040042e-06
non O 0 5.53362451682915e-06
- O 0 7.750151416985318e-05
European O 0 2.7607410402197274e-07
origin O 0 3.571634366039689e-08
, O 0 2.195448267627853e-08
with O 0 2.1656985538243134e-08
or O 0 3.2406418881691934e-08
without O 0 2.264776277627334e-08
a O 0 2.0682124102222588e-07
personal O 0 4.2772294364112895e-06
and O 0 2.8317833766777767e-06
/ O 0 0.004632988944649696
or O 0 1.860227740735354e-07
family O 0 3.8772577681811526e-07
history O 0 5.56794134354277e-07
of O 0 8.342898922819586e-07
neoplasia B-Disease 1 0.9979884624481201
, O 0 3.292532255727565e-07
were O 0 1.706933083767126e-08
examined O 0 5.804050715596532e-07
for O 0 1.390789883259913e-08
the O 0 8.374747295647467e-08
I1307K O 0 0.00011233538680244237
variant O 0 8.322155736095738e-06
by O 0 1.6705689276363955e-08
the O 0 3.5457127012250567e-08
allele O 0 1.7959309843718074e-06
- O 0 8.036244253162295e-06
specific O 0 2.1829055185662583e-07
oligonucleotide O 0 0.0001915592874865979
( O 0 1.8203794752480462e-05
ASO O 0 0.02602936141192913
) O 0 1.5378168427560013e-06
method O 0 2.182756588808843e-06
. O 0 1.061176044458989e-05

RESULTS O 0 4.6233039029175416e-05
In O 0 1.992744500967092e-06
persons O 0 4.755855115945451e-06
at O 0 3.753475903067738e-05
average O 0 0.008382299914956093
risk O 1 0.9448823928833008
for O 1 0.6954928636550903
colorectal B-Disease 1 0.9999479055404663
cancer I-Disease 1 0.9998138546943665
, O 0 9.754067286849022e-05
I1307K O 0 0.018862053751945496
was O 0 2.6328759759053355e-06
found O 0 5.662153625962674e-07
in O 0 5.320364948602219e-07
5 O 0 1.569891901453957e-05
. O 0 1.2627208889171015e-05

0 O 0 7.509504030167591e-06
% O 0 6.372873144755431e-07
of O 0 1.7026773946327012e-07
120 O 0 1.7648833363637095e-06
European O 0 2.491193527021096e-06
and O 0 8.690155368640262e-07
1 O 0 9.91382694337517e-06
. O 0 9.639349627832416e-06

6 O 0 2.1303363610059023e-05
% O 0 1.7135571397375315e-06
of O 0 5.684466373168107e-07
188 O 0 3.1969855626812205e-05
non O 0 1.3291500181367155e-05
- O 0 6.835256499471143e-05
European O 0 1.0532970691201626e-06
Jews O 0 9.74157501332229e-07
( O 0 2.6825191525858827e-06
P O 0 0.0005405321717262268
= O 0 4.3925389036303386e-05
0 O 0 1.554540972392715e-06
. O 0 2.771852791738638e-07
08 O 0 2.369181311223656e-05
) O 0 1.3810154086968396e-06
. O 0 3.214419393771095e-06

It O 0 7.130296580726281e-06
occurred O 0 1.5854097000556067e-05
in O 0 3.0804710604570573e-06
15 O 0 2.9747541702818125e-05
. O 0 2.730950654949993e-05

4 O 0 9.036114533955697e-06
% O 0 9.438813890483289e-07
of O 0 3.6435068295759265e-07
52 O 0 3.715235652634874e-05
Ashkenazi O 0 0.00044620962580665946
Israelis O 0 1.7118001778726466e-05
with O 0 6.926918285898864e-05
familial O 1 0.9976471066474915
cancer B-Disease 1 0.9985561966896057
( O 0 9.767413575900719e-05
P O 0 0.03289112448692322
= O 0 0.00039199693128466606
0 O 0 1.9177293779648608e-06
. O 0 1.6738037800223537e-07
02 O 0 0.00013895217853132635
) O 0 4.03404420978859e-08
and O 0 1.0099268088481494e-08
was O 0 1.835576668440808e-08
not O 0 5.097912314511177e-09
detected O 0 1.8089157549638912e-07
in O 0 2.7145143022266893e-08
51 O 0 1.5038247056509135e-06
non O 0 2.2067556528782006e-06
- O 0 5.8768706367118284e-05
European O 0 2.4182879769796273e-06
Jews O 0 2.34171534430061e-06
at O 0 4.378106677904725e-05
increased O 0 0.06243892014026642
cancer B-Disease 1 0.9986849427223206
risk O 0 0.33233800530433655
. O 0 8.98854123079218e-05

Colorectal B-Disease 1 0.9955449104309082
neoplasia I-Disease 1 0.9956984519958496
occurred O 0 0.0020076814107596874
personally O 0 0.000393776164855808
or O 0 1.5488084272874403e-06
in O 0 6.351648806912635e-08
the O 0 4.203175407724302e-08
families O 0 4.520906315974571e-08
of O 0 8.359104519684024e-09
13 O 0 7.645945743206539e-08
of O 0 2.7389321033410852e-08
20 O 0 2.2374360924004577e-06
Ashkenazi O 0 0.00021391120390035212
I1307K O 0 0.0006511819083243608
carriers O 0 1.2738421901303809e-05
, O 0 3.7960649734714025e-08
8 O 0 9.990431237838493e-08
of O 0 1.3467841952774506e-08
whom O 0 3.144697018342413e-07
also O 0 3.9710172927698295e-08
had O 0 2.7552694348287332e-08
a O 0 1.259554238686178e-07
personal O 0 1.0661317446647445e-06
or O 0 4.6123557240207447e-07
family O 0 2.6123368570551975e-06
history O 0 3.1830784337216755e-06
of O 0 5.890454758628039e-06
noncolonic O 1 0.9646674394607544
neoplasia B-Disease 1 0.9947988986968994
. O 0 0.00019838649313896894

CONCLUSIONS O 0 6.550129182869568e-05
The O 0 1.9612964024418034e-05
I1307K O 0 0.07151354104280472
APC O 0 0.37397149205207825
variant O 0 0.004042020533233881
may O 0 4.086288754479028e-06
represent O 0 3.263683652221516e-07
a O 0 4.203490789222997e-06
susceptibility O 0 0.008405041880905628
gene O 0 0.0003343304852023721
for O 0 0.00011638841533567756
colorectal B-Disease 1 0.999686598777771
, I-Disease 0 3.3736685054464033e-06
or I-Disease 0 1.4447253988691955e-06
other I-Disease 0 6.229153086678707e-07
, I-Disease 0 4.037524195155129e-05
cancers I-Disease 1 0.956321656703949
in O 0 2.405113718850771e-06
Ashkenazi O 0 0.0004925052635371685
Jews O 0 4.7611507625333616e-07
, O 0 9.84577255280783e-08
and O 0 9.845434334465608e-08
partially O 0 8.024098860914819e-06
explains O 0 5.543765837501269e-06
the O 0 1.032562977343332e-06
higher O 0 0.00029407654074020684
incidence O 1 0.9946272969245911
of O 0 0.13370589911937714
colorectal B-Disease 1 0.9998931884765625
cancer I-Disease 1 0.9996671676635742
in O 0 5.403808245318942e-05
European O 0 0.0003153632569592446
Israelis O 0 0.0002546618925407529
. O 0 8.636570419184864e-05

Systematic O 0 3.8266240153461695e-05
analysis O 0 6.7899859459430445e-06
of O 0 5.146606781636365e-06
coproporphyrinogen O 1 0.5728567838668823
oxidase O 0 0.3409406542778015
gene O 0 0.02320457063615322
defects O 1 0.9917773008346558
in O 0 5.748520197812468e-05
hereditary B-Disease 1 0.8318652510643005
coproporphyria I-Disease 1 0.7420462965965271
and O 0 4.514099782682024e-05
mutation O 0 0.003264638362452388
update O 0 0.014189857058227062
. O 0 5.9601177781587467e-05

Hereditary B-Disease 1 0.8693827390670776
coproporphyria I-Disease 1 0.8869403004646301
( O 0 0.0062916697934269905
HC B-Disease 1 0.994088888168335
) O 0 0.00021303842368070036
is O 0 8.376925688935444e-05
an O 0 0.006882489658892155
acute O 1 0.9995622038841248
hepatic B-Disease 1 0.999612033367157
porphyria I-Disease 1 0.9993489384651184
with O 0 0.044791556894779205
autosomal O 1 0.9982743263244629
dominant O 1 0.7296317219734192
inheritance O 1 0.9373208284378052
caused O 1 0.9429003000259399
by O 0 0.0001431369746569544
deficient B-Disease 1 0.6905092597007751
activity I-Disease 0 3.738029363375972e-06
of I-Disease 0 2.417271161903045e-06
coproporphyrinogen I-Disease 0 0.3337167501449585
III I-Disease 1 0.8033115863800049
oxidase I-Disease 0 0.0049480656161904335
( O 0 4.012119461549446e-05
CPO O 0 0.0004595268110278994
) O 0 9.451151527173351e-06
. O 0 9.958437658497132e-06

Clinical O 0 0.18351072072982788
manifestations O 0 0.00982016883790493
of O 0 7.214157085400075e-05
the O 0 0.06798341870307922
disease O 1 0.9994845390319824
are O 0 2.871447941288352e-05
characterized O 1 0.6931621432304382
by O 0 0.006848662625998259
acute O 1 0.9995177984237671
attacks O 0 0.39501872658729553
of O 0 0.24901863932609558
neurological B-Disease 1 0.9998481273651123
dysfunction I-Disease 1 0.9996646642684937
often O 0 0.0031384574249386787
precipitated O 1 0.7673943042755127
by O 0 2.0548781321849674e-05
drugs O 0 0.00509195402264595
, O 0 5.369950486056041e-06
fasting O 0 0.0001453722798032686
, O 0 3.559794640750624e-05
cyclical O 1 0.7944705486297607
hormonal O 1 0.6237569451332092
changes O 0 0.0007872210117056966
, O 0 0.0005781024810858071
or O 0 0.10769016295671463
infectious B-Disease 1 0.9986289739608765
diseases I-Disease 1 0.9982534050941467
. O 0 0.0011388788698241115

Skin O 1 0.9968133568763733
photosensitivity O 1 0.9952718615531921
may O 0 0.0009707030840218067
also O 0 3.7519762372539844e-06
be O 0 6.124280389485648e-07
present O 0 7.666522833460476e-06
. O 0 2.2046011508791707e-05

The O 0 9.2446850885608e-07
seven O 0 6.030321060279675e-07
exons O 0 2.888805965994834e-06
, O 0 2.0853561011335842e-07
the O 0 2.516355266379833e-07
exon O 0 0.0003006134938914329
/ O 0 0.0007352332468144596
intron O 0 7.974331674631685e-05
boundaries O 0 2.4678438848013684e-08
and O 0 5.270512914989922e-09
part O 0 6.87053125503212e-09
of O 0 3.6421532456643035e-09
3 O 0 1.0219976331882208e-07
noncoding O 0 2.3353504730039276e-06
sequence O 0 1.737706689652896e-08
of O 0 5.691418003550552e-09
the O 0 4.3351182199558025e-08
CPO O 0 3.5466910048853606e-06
gene O 0 8.376328963777269e-08
were O 0 3.1527904731376566e-09
systematically O 0 5.385118129197508e-08
analyzed O 0 3.0897421510189815e-08
by O 0 5.2140296524783025e-09
an O 0 2.6076714121359146e-08
exon O 0 1.7995716916630045e-05
- O 0 1.7897460566018708e-05
by O 0 1.1074187256099322e-07
- O 0 3.392246799194254e-05
exon O 0 6.893995305290446e-05
denaturing O 0 0.0005859376979060471
gradient O 0 9.365180449094623e-05
gel O 0 0.0012581737246364355
electrophoresis O 0 0.00042078414116986096
( O 0 1.3820991625834722e-05
DGGE O 0 0.0017780045745894313
) O 0 1.979307313604295e-07
strategy O 0 1.9209623758342786e-07
followed O 0 1.8861690875837667e-08
by O 0 4.367392225645972e-09
direct O 0 7.658084832939949e-09
sequencing O 0 1.293365983201511e-07
in O 0 5.034170413864558e-08
seven O 0 7.904089329713315e-07
unrelated O 0 0.0005308436811901629
heterozygous O 0 0.008257726207375526
HC B-Disease 1 0.9990469813346863
patients O 0 0.477936327457428
from O 0 8.318418622366153e-06
France O 0 6.990963447606191e-05
, O 0 1.578450905981299e-06
Holland O 0 5.844155020895414e-05
, O 0 2.5083670607273234e-07
and O 0 3.9956876207725145e-07
Czech O 0 3.970494435634464e-05
Republic O 0 7.397827630484244e-06
. O 0 1.6632708138786256e-05

Seven O 0 1.7416576156392694e-05
novel O 0 4.218626054353081e-05
mutations O 0 1.9292720025987364e-05
and O 0 1.7688300602003437e-07
two O 0 9.971260794827685e-08
new O 0 2.6454451926838374e-06
polymorphisms O 0 5.531199349206872e-05
were O 0 9.709001460578293e-07
detected O 0 0.00011367403931217268
. O 0 1.2158364370407071e-05

Among O 0 4.601745786203537e-06
these O 0 4.319156516885414e-07
mutations O 0 1.8054789734378573e-06
two O 0 4.9927368905855474e-08
are O 0 8.054591660311416e-08
missense O 0 0.00010649750038282946
( O 0 4.1819871512416285e-06
G197W O 0 0.00022272618662100285
, O 0 5.211855409470445e-07
W427R O 0 6.986730295466259e-05
) O 0 7.317706263165746e-08
, O 0 5.163526939355734e-09
two O 0 2.3784534342041752e-09
are O 0 7.01228408672705e-09
nonsense O 0 4.662103492591996e-06
( O 0 5.777432079412392e-07
Q306X O 0 2.3238480935106054e-05
, O 0 1.427423939048822e-07
Q385X O 0 1.8517952412366867e-05
) O 0 4.8066087998677176e-08
, O 0 2.6469775260551387e-09
two O 0 1.1797353094422647e-09
are O 0 1.908835089992067e-09
small O 0 4.447947787866724e-08
deletions O 0 2.2530027763423277e-06
( O 0 1.5775674455653643e-06
662de14bp O 0 6.117652810644358e-05
; O 0 5.416576982497645e-07
1168del3bp O 0 2.7100013539893553e-05
removing O 0 9.910791050060652e-07
a O 0 6.088140480642323e-08
glycine O 0 1.2321819440330728e-06
at O 0 8.079024382823263e-08
position O 0 1.284419965941197e-07
390 O 0 3.1576059882354457e-06
) O 0 5.784533385622126e-08
, O 0 6.465294521973419e-09
and O 0 1.5510670525742398e-09
one O 0 1.172183239361857e-09
is O 0 2.083390349127967e-09
a O 0 1.1252460296873323e-08
splicing O 0 5.023485982746934e-07
mutation O 0 1.5885976836216287e-06
( O 0 1.6590983022979344e-06
IVS1 O 0 0.0021414346992969513
- O 0 0.0004988455330021679
15c O 0 0.0017763975774869323
- O 0 0.0035494330804795027
- O 0 0.0013514877064153552
> O 0 0.0004735801776405424
g O 0 1.0704836313379928e-05
) O 0 4.3162245333405735e-08
which O 0 8.518560079551207e-09
creates O 0 1.6894624366159405e-07
a O 0 8.992506650429277e-08
new O 0 6.38451638224069e-07
acceptor O 0 9.13415351533331e-05
splice O 0 8.795742178335786e-05
site O 0 1.420159878762206e-05
. O 0 1.0227586244582199e-05

The O 0 1.228880682901945e-05
pathological O 0 0.00046577281318604946
significance O 0 1.0441100357638788e-06
of O 0 6.395851670504271e-08
the O 0 1.6318242046509113e-07
point O 0 1.0825409617609694e-06
mutations O 0 1.4230706256057601e-05
G197W O 0 0.00024271600705105811
, O 0 5.159591864867252e-07
W427R O 0 3.475398989394307e-05
, O 0 3.70143027339509e-08
and O 0 1.1883765083098297e-08
the O 0 1.5858496738019312e-08
in O 0 1.6053918727720884e-07
- O 0 0.00019578461069613695
frame O 0 0.0001632183266337961
deletion O 0 0.0004328061477281153
390delGly O 0 0.0002625886118039489
were O 0 2.7488967546673848e-08
assessed O 0 1.4297836514742812e-07
by O 0 6.035220323497015e-09
their O 0 2.5544202308935837e-09
respective O 0 2.181951685997774e-08
expression O 0 2.6530797114787674e-08
in O 0 1.1113667319762044e-08
a O 0 1.266116669285111e-07
prokaryotic O 0 7.413895673380466e-06
system O 0 1.1873046332766535e-06
using O 0 2.390872282376222e-07
site O 0 4.105585048819194e-06
- O 0 7.815074059180915e-05
directed O 0 3.2688744795450475e-06
mutagenesis O 0 0.00031115347519516945
. O 0 1.5960073142196052e-05

These O 0 3.0191529276635265e-06
mutations O 0 5.8247143897460774e-05
resulted O 0 8.094191798591055e-06
in O 0 1.7260502715998882e-07
the O 0 3.291945063210733e-07
absence O 0 7.633830136910547e-06
or O 0 3.0608779866270197e-07
a O 0 6.871333084745856e-07
dramatic O 0 3.283777186879888e-05
decrease O 0 3.535894938977435e-05
of O 0 5.246594696473039e-07
CPO O 0 0.000733386492356658
activity O 0 1.6376114217564464e-05
. O 0 1.3927091458754148e-05

The O 0 9.660400337452302e-07
two O 0 4.4272744048612367e-07
polymorphisms O 0 1.3568273061537184e-05
were O 0 1.1210604355937903e-07
localized O 0 1.9863084162352607e-05
in O 0 1.6590779239322728e-07
noncoding O 0 3.5749813832808286e-05
part O 0 2.9954467350989944e-08
of O 0 4.802363395839393e-09
the O 0 1.3087610106765624e-08
gene O 0 1.322614906484887e-07
1 O 0 5.760762178397272e-08
) O 0 2.909445129262167e-08
a O 0 1.7135819518898643e-07
C O 0 0.00016320835857186466
/ O 0 0.00014640868175774813
G O 0 7.784698027535342e-06
polymorphism O 0 2.4428132405773795e-07
in O 0 1.1063162830282636e-08
the O 0 4.299717204503395e-08
promotor O 0 0.000165264806128107
region O 0 3.1437733127859246e-07
, O 0 4.793114172230162e-08
142 O 0 9.148778872258845e-07
bp O 0 8.422426276410988e-07
upstream O 0 7.015082559291841e-08
from O 0 4.274864018327662e-09
the O 0 6.54558673929273e-09
transcriptional O 0 3.1556805879517924e-07
initiation O 0 5.00141027259815e-07
site O 0 6.751526484549686e-07
( O 0 1.4154069276628434e-06
- O 0 6.914319237694144e-05
142C O 0 0.00026121671544387937
/ O 0 0.0003121306945104152
G O 0 2.32089569180971e-05
) O 0 3.415254923311295e-08
, O 0 4.28882129810404e-09
and O 0 2.3019017802994313e-09
2 O 0 1.9723799482562754e-08
) O 0 8.917912630579394e-09
a O 0 1.3824114297733558e-08
6 O 0 2.689217240003927e-07
bp O 0 1.6122974102472654e-06
deletion O 0 8.688041930327017e-07
polymorphism O 0 1.4072516307805927e-07
in O 0 5.399823255203273e-09
the O 0 1.0029834740521437e-08
3 O 0 1.2336229815446131e-07
noncoding O 0 2.7910359676752705e-06
part O 0 7.919525479849199e-09
of O 0 4.379420381894761e-09
the O 0 4.427751676416847e-08
CPO O 0 9.66180505201919e-06
gene O 0 6.143713449091592e-07
, O 0 9.124436672891534e-08
574 O 0 1.2628798685909715e-05
bp O 0 2.4896116883610375e-06
downstream O 0 1.0424767538097512e-07
of O 0 3.7146827835954355e-09
the O 0 6.463975132930955e-09
last O 0 1.568647967076231e-08
base O 0 7.843879323843339e-09
of O 0 1.2473185817540866e-09
the O 0 7.059118178887047e-09
normal O 0 2.1155064189315453e-07
termination O 0 3.13898162858095e-05
codon O 0 4.172147782810498e-06
( O 0 4.626131612894824e-06
+ O 0 0.00030605425126850605
574 O 0 0.0005064780707471073
delATTCTT O 0 0.0014470593305304646
) O 0 8.283294846478384e-06
. O 0 9.649309504311532e-06

Five O 0 8.156956027960405e-05
intragenic O 0 0.18843382596969604
dimorphisms O 0 0.05472326651215553
are O 0 7.092171472322661e-07
now O 0 1.5893978115855134e-06
well O 0 2.0806281497698365e-07
characterized O 0 1.4808412743150257e-05
and O 0 2.6392603658109692e-08
the O 0 2.5476145637526315e-08
high O 0 5.135919423082669e-07
degree O 0 1.564659442010452e-07
of O 0 7.476081975710258e-08
allelic O 0 0.00047819060273468494
heterogeneity O 0 0.0007583658443763852
in O 0 1.4106088201515377e-05
HC B-Disease 1 0.9974997639656067
is O 0 8.830457431940886e-07
demonstrated O 0 5.05227433222899e-07
with O 0 1.9654811111990966e-08
seven O 0 2.3545187133322543e-08
new O 0 2.412962807341046e-08
different O 0 4.3226071611002226e-09
mutations O 0 1.3527355235964933e-07
making O 0 8.488052927191347e-09
a O 0 8.872527601511138e-09
total O 0 8.346422220029126e-09
of O 0 2.7930912693818755e-08
nineteen O 0 3.045996345463209e-05
CPO O 0 0.023978937417268753
gene B-Disease 0 0.008109835907816887
defects I-Disease 1 0.9891818165779114
reported O 0 0.00010031459532910958
so O 0 7.710455065534916e-07
far O 0 1.1919573807972483e-06
. O 0 1.1458339486125624e-06
. O 0 6.841002232249593e-06

Coincidence O 0 1.0449154615344014e-05
of O 0 2.85766532215348e-07
two O 0 2.574570032720658e-07
novel O 0 6.8249000833020546e-06
arylsulfatase O 0 0.0003469832008704543
A O 0 1.2591173117471044e-06
alleles O 0 2.207580791946384e-06
and O 0 2.52176533876991e-07
mutation O 0 2.0035695342812687e-05
459 O 0 0.0010738555574789643
+ O 0 0.0013557521160691977
1G O 0 0.003369208425283432
> O 0 6.0806898545706645e-05
A O 0 2.436399029193126e-07
within O 0 4.0058665717879194e-08
a O 0 5.234869036030432e-07
family O 0 8.530612831236795e-06
with O 0 5.517602039617486e-05
metachromatic B-Disease 1 0.9977344274520874
leukodystrophy I-Disease 1 0.9985315799713135
: O 0 6.941200354049215e-06
molecular O 0 2.04558659788745e-06
basis O 0 7.31080120885963e-08
of O 0 3.1562220215164416e-07
phenotypic O 0 0.0001848686224548146
heterogeneity O 0 0.005011625587940216
. O 0 0.00010861327609745786

In O 0 2.6896839244727744e-06
a O 0 2.5052354430954438e-06
family O 0 4.305738912080415e-06
with O 0 4.767693724261335e-07
three O 0 4.0434932202515483e-07
siblings O 0 4.239702320774086e-05
, O 0 1.6646153255805984e-07
one O 0 7.733698481615647e-08
developed O 0 5.045647412771359e-06
classical O 0 2.4978184228530154e-05
late O 0 0.0021720498334616423
infantile O 1 0.997138500213623
metachromatic B-Disease 1 0.9983324408531189
leukodystrophy I-Disease 1 0.998884379863739
( O 0 0.013012023642659187
MLD B-Disease 1 0.9972757697105408
) O 0 3.179697159794159e-05
, O 0 7.6140681812830735e-06
fatal O 0 0.04962471127510071
at O 0 1.470594952479587e-06
age O 0 6.290958026511362e-06
5 O 0 9.305692287853162e-07
years O 0 1.0308725677532493e-06
, O 0 3.9346329572254035e-07
with O 0 2.4776195459708106e-06
deficient O 0 0.11379452049732208
arylsulfatase O 0 0.0020506400614976883
A O 0 1.5592342606396414e-05
( O 0 2.5970477508963086e-05
ARSA O 0 0.09526928514242172
) O 0 1.5620383919667802e-07
activity O 0 9.903084219331504e-08
and O 0 6.187294587789438e-08
increased O 0 4.8067927309602965e-06
galactosylsulfatide O 0 0.003260891418904066
( O 0 4.4346230424707755e-05
GS O 1 0.7535746693611145
) O 0 7.512605861847987e-06
excretion O 0 0.00012639971100725234
. O 0 1.783425068424549e-05

The O 0 1.0847060138985398e-06
two O 0 3.5276315202281694e-07
other O 0 3.549143627878948e-07
siblings O 0 9.640162897994742e-05
, O 0 1.8576231468614424e-06
apparently O 0 3.651528913906077e-06
healthy O 0 3.6130027183389757e-06
at O 0 2.1225754665010754e-07
12 O 0 2.2938282029372203e-07
( O 0 2.070616034188788e-07
1 O 0 2.416942948002543e-07
/ O 0 7.565241503471043e-06
2 O 0 5.361382449109442e-08
) O 0 1.340702304730712e-08
and O 0 5.906151567813822e-09
15 O 0 3.7745355285778714e-08
years O 0 3.914220059186846e-08
, O 0 1.5627081850766444e-08
respectively O 0 7.495128073742308e-08
, O 0 9.596088368368783e-09
and O 0 4.906590245212783e-09
their O 0 1.0279030959736701e-08
father O 0 1.5166515368036926e-06
, O 0 2.247225125984187e-07
apparently O 0 1.4787377722313977e-06
healthy O 0 4.24115614805487e-06
as O 0 2.2777420838338003e-08
well O 0 2.3350862576876352e-08
, O 0 8.348002467073457e-08
presented O 0 3.3742478535714326e-06
ARSA O 0 0.3090675473213196
and O 0 7.69557175317459e-07
GS O 0 0.008108914829790592
values O 0 1.836581553504857e-08
within O 0 2.5333591224807606e-08
the O 0 1.509164917479211e-07
range O 0 5.35101025889162e-06
of O 0 2.1356332581490278e-05
MLD B-Disease 1 0.9963622689247131
patients O 1 0.6475447416305542
. O 0 0.00014078344975132495

Mutation O 0 0.00015010782226454467
screening O 0 1.5075154806254432e-05
and O 0 2.879496037166973e-07
sequence O 0 4.804963964488707e-07
analysis O 0 1.2007869827357354e-06
disclosed O 0 8.684937711223029e-06
the O 0 3.568025874756131e-08
involvement O 0 4.214969067106722e-07
of O 0 1.0049290288804968e-08
three O 0 6.366276039670993e-08
different O 0 3.363448399795743e-07
ARSA O 1 0.9435464143753052
mutations O 0 2.98888312499912e-06
being O 0 1.3179191959977743e-08
the O 0 9.142812729123762e-09
molecular O 0 2.384919639553118e-07
basis O 0 2.882270244697338e-08
of O 0 2.575621067535394e-07
intrafamilial O 0 0.0056218598037958145
phenotypic O 0 0.00044882806832902133
heterogeneity O 0 0.008088813163340092
. O 0 8.12830330687575e-05

The O 0 0.00014501703844871372
late O 0 0.10257221758365631
infantile O 1 0.9982307553291321
patient O 1 0.9932669401168823
inherited O 1 0.813326358795166
from O 0 4.094433734280756e-06
his O 0 3.7283916753949597e-06
mother O 0 1.4681478205602616e-05
the O 0 1.856920306408938e-07
frequent O 0 5.517957561096409e-06
0 O 0 5.641570169245824e-06
- O 0 8.420921221841127e-05
type O 0 1.812174559745472e-05
mutation O 0 6.395957370841643e-06
459 O 0 0.0002541217836551368
+ O 0 0.0003686714917421341
1G O 0 0.00229943310841918
> O 0 8.565607276977971e-05
A O 0 3.177729581693711e-07
, O 0 3.66407562069071e-08
and O 0 1.002250993309417e-08
from O 0 1.7071219104991542e-08
his O 0 6.99561439887475e-08
father O 0 5.124744575368823e-07
a O 0 9.944233880787579e-08
novel O 0 2.9817093150086293e-07
, O 0 2.674515364731178e-08
single O 0 7.52572688611508e-08
basepair O 0 3.1819996365811676e-05
microdeletion O 0 4.536685082712211e-06
of O 0 6.962877829863601e-09
guanine O 0 1.723865494795973e-07
at O 0 2.733228221529771e-08
nucleotide O 0 7.636035803670893e-08
7 O 0 1.2979130303847342e-07
in O 0 4.6802426822978305e-08
exon O 0 1.7860800653579645e-05
1 O 0 3.169087449350627e-06
( O 0 8.413093382841907e-06
7delG O 0 0.000259038177318871
) O 0 4.542819624475669e-06
. O 0 7.97477059677476e-06

The O 0 3.7659171994164353e-06
two O 0 3.0215121569199255e-06
clinically O 0 0.005249729845672846
unaffected O 0 0.0005237864097580314
siblings O 0 1.0143253348360304e-05
carried O 0 1.8642626287146413e-07
the O 0 1.4010596771640849e-07
maternal O 0 5.2943749324185774e-05
mutation O 0 3.851387373288162e-05
459 O 0 0.0014805975370109081
+ O 0 0.002971724374219775
1G O 0 0.01225117314606905
> O 0 0.00016995113401208073
A O 0 2.0425657965006394e-07
and O 0 1.2875713828464086e-08
, O 0 5.504939171174783e-09
on O 0 3.109931867584237e-09
their O 0 4.4654564490542725e-09
paternal O 0 1.724169578665169e-06
allele O 0 3.7955334164507804e-07
, O 0 1.2809941551950033e-08
a O 0 1.602365529151939e-08
novel O 0 6.93605315404966e-08
cytosine O 0 2.0779413034688332e-07
to O 0 8.243741689284434e-09
thymidine O 0 1.0087564987770747e-06
transition O 0 2.2010209477230092e-07
at O 0 8.478542667944566e-08
nucleotide O 0 5.355107646209945e-07
2435 O 0 0.00022275315131992102
in O 0 1.0479910628191647e-07
exon O 0 7.792719770804979e-06
8 O 0 3.1079326845429023e-07
, O 0 2.4968244360934477e-08
resulting O 0 8.257215711182653e-08
in O 0 5.458288043769244e-09
substitution O 0 4.454051705238271e-08
of O 0 3.408682047734146e-08
alanine O 0 2.949509143945761e-05
464 O 0 8.587502816226333e-05
by O 0 1.1378302815501229e-06
valine O 0 0.0004092086455784738
( O 0 1.4467203072854318e-05
A464V O 0 0.0006328578456304967
) O 0 6.625900368817383e-06
. O 0 8.467546649626456e-06

The O 0 2.8403754186001606e-05
fathers O 0 9.759228851180524e-05
genotype O 0 0.0005876460345461965
thus O 0 1.524358958704397e-05
was O 0 6.555466097779572e-05
7delG O 0 0.23487381637096405
/ O 0 0.3999059200286865
A464V O 0 0.00930170901119709
. O 0 6.659175414824858e-05

Mutation O 0 0.0006396106327883899
A464V O 0 0.0007013495196588337
was O 0 1.5372143025160767e-06
not O 0 1.1182308412571729e-07
found O 0 2.4641968821015325e-07
in O 0 6.092932949286478e-07
18 O 0 0.00017894827760756016
unrelated O 1 0.6565316915512085
MLD B-Disease 1 0.9991891980171204
patients O 0 0.32231780886650085
and O 0 1.950604428202496e-06
50 O 0 8.47439696372021e-06
controls O 0 7.840438047423959e-05
. O 0 3.142144123557955e-05

A464V O 0 0.001927490346133709
, O 0 5.284706730890321e-06
although O 0 3.278427584518795e-06
clearly O 0 1.8963482943945564e-05
modifying O 0 0.0015154355205595493
ARSA O 1 0.9767606258392334
and O 0 8.502976561430842e-05
GS O 1 0.9961722493171692
levels O 0 0.0001504537503933534
, O 0 1.020304580379161e-06
apparently O 0 3.3364860883011715e-06
bears O 0 8.720277037355117e-06
little O 0 9.597498547009309e-07
significance O 0 1.0515145731915254e-06
for O 0 9.80903109848441e-07
clinical O 0 0.0016045168740674853
manifestation O 0 0.001954970881342888
of O 0 1.606219302630052e-05
MLD B-Disease 1 0.998021125793457
, O 0 7.200249456218444e-06
mimicking O 0 0.0008031180477701128
the O 0 4.0025088310358115e-06
frequent O 0 0.0011137786787003279
ARSA O 1 0.9755801558494568
pseudodeficiency O 0 0.15014886856079102
allele O 0 0.0007452632999047637
. O 0 6.980150646995753e-05

Our O 0 9.78648768068524e-06
results O 0 4.250692200002959e-06
demonstrate O 0 2.613976676002494e-06
that O 0 1.0851896803387717e-07
in O 0 1.4741375764515396e-07
certain O 0 1.0840452659977018e-06
genetic O 0 0.0038818095345050097
conditions O 0 0.35374459624290466
MLD B-Disease 1 0.9986140727996826
- O 0 0.24504993855953217
like O 0 9.517374564893544e-05
ARSA O 1 0.9049691557884216
and O 0 4.774368790094741e-06
GS O 1 0.6018767356872559
values O 0 2.2732247373369319e-07
need O 0 1.6018881865420553e-07
not O 0 1.1018728152123458e-08
be O 0 3.65199106511227e-08
paralleled O 0 0.00013909334666095674
by O 0 0.0001579493109602481
clinical O 1 0.9973874688148499
disease O 1 0.9994342923164368
, O 0 1.2215242577440222e-06
a O 0 1.9422122932155617e-06
finding O 0 7.675470442336518e-06
with O 0 2.437051443848759e-05
serious O 1 0.5127589106559753
diagnostic O 0 0.4899562895298004
and O 0 0.00014178630954120308
prognostic O 1 0.9474558234214783
implications O 0 0.16495539247989655
. O 0 0.00020796633907593787

Moreover O 0 0.00019703673024196178
, O 0 6.853232662251685e-06
further O 0 3.098568777204491e-05
ARSA O 1 0.9521913528442383
alleles O 0 6.746614963049069e-05
functionally O 0 0.0001282886223634705
similar O 0 5.0547259888844565e-06
to O 0 1.4815058193562436e-06
A464V O 0 0.0162214208394289
might O 0 2.6966235964209773e-06
exist O 0 6.7633067146744e-08
which O 0 5.852627715796643e-09
, O 0 8.806705587005581e-09
together O 0 1.5388094354307214e-08
with O 0 1.1124444654342369e-07
0 O 0 2.530620804463979e-05
- O 0 0.004595370497554541
type O 0 0.0003867729101330042
mutations O 0 3.749969619093463e-05
, O 0 1.0031862984760664e-06
may O 0 1.615240762475878e-05
cause O 0 0.001395162777043879
pathological O 0 0.32801783084869385
ARSA O 1 0.9927063584327698
and O 0 3.386403477634303e-05
GS O 1 0.9975403547286987
levels O 0 4.9194022722076625e-05
, O 0 3.2393631954619195e-07
but O 0 3.251148825711425e-07
not O 0 9.342568318970734e-07
clinical O 0 0.016277285292744637
outbreak O 0 0.27402666211128235
of O 0 5.5566283663210925e-06
the O 0 0.0034734471701085567
disease O 1 0.9991255402565002
. O 0 1.754704862833023e-05
. O 0 4.578638618113473e-05

Human O 1 0.7126720547676086
MLH1 O 1 0.9891092777252197
deficiency O 1 0.9980946183204651
predisposes O 1 0.9879693984985352
to O 0 0.04045474901795387
hematological B-Disease 1 0.9980046153068542
malignancy I-Disease 1 0.9988405108451843
and O 0 0.34155699610710144
neurofibromatosis B-Disease 1 0.9990099668502808
type I-Disease 1 0.5410817861557007
1 I-Disease 0 0.001350288512185216
. O 0 0.00017048415611498058

Heterozygous O 0 0.003920100629329681
germ O 1 0.8891415596008301
- O 0 0.0036052074283361435
line O 0 1.4198430108081084e-05
mutations O 0 5.069241979072103e-06
in O 0 1.2200231935821648e-07
the O 0 4.5334095943871944e-07
DNA O 0 0.00010958170605590567
mismatch O 1 0.6508874893188477
repair O 0 0.41226354241371155
genes O 0 2.7368036171537824e-05
lead O 0 0.00018463256128598005
to O 0 0.00016518746269866824
hereditary B-Disease 1 0.9960197806358337
nonpolyposis I-Disease 1 0.9981257319450378
colorectal I-Disease 1 0.9996969699859619
cancer I-Disease 1 0.9990324974060059
. O 0 0.013273162767291069

The O 0 0.13150747120380402
disease O 1 0.9984631538391113
susceptibility O 0 0.07771128416061401
of O 0 3.766139570871019e-06
individuals O 0 8.999017154565081e-06
who O 0 4.464787707547657e-06
constitutionally O 0 1.4430604096560273e-05
lack O 0 2.4938746719271876e-05
both O 0 9.425204439139634e-07
wild O 0 0.00025863791233859956
- O 0 0.08082979172468185
type O 0 0.000818817235995084
alleles O 0 1.3888640751247294e-05
is O 0 8.432962772531027e-07
unknown O 0 6.541454240505118e-06
. O 0 1.2659933418035507e-05

We O 0 1.843256882239075e-06
have O 0 1.5311862000544352e-07
identified O 0 2.296605998708401e-07
three O 0 8.715172583606545e-08
offspring O 0 1.2470021829358302e-05
in O 0 4.762027401739033e-06
a O 0 0.002023776527494192
hereditary B-Disease 1 0.9985906481742859
nonpolyposis I-Disease 1 0.9994754195213318
colorectal I-Disease 1 0.9999465942382812
cancer I-Disease 1 0.9998441934585571
family O 0 0.21342577040195465
who O 0 0.010614239610731602
developed O 1 0.9388890862464905
hematological B-Disease 1 0.9994999170303345
malignancy I-Disease 1 0.9992890357971191
at O 0 6.719590146531118e-06
a O 0 1.408472371622338e-06
very O 0 3.4756678246594674e-07
early O 0 9.403342460245767e-07
age O 0 3.593347628338961e-06
, O 0 3.809403636978459e-08
and O 0 7.558334402801847e-09
at O 0 1.2816809835669574e-08
least O 0 2.485841532617883e-09
two O 0 1.051632447790496e-09
of O 0 3.461005704252784e-09
them O 0 2.2810116462324004e-08
displayed O 0 2.478349642842659e-06
signs O 0 8.116452227113768e-05
of O 0 1.0140913218492642e-05
neurofibromatosis B-Disease 1 0.9993213415145874
type I-Disease 0 0.012869603000581264
1 I-Disease 0 8.898074156604707e-05
( O 0 0.00011417768109822646
NF1 B-Disease 0 0.35391131043434143
) O 0 1.894161687232554e-05
. O 0 1.4235443813959137e-05

DNA O 0 4.474697561818175e-06
sequence O 0 9.792505579753197e-07
analysis O 0 1.03289789876726e-06
and O 0 3.2438333619211335e-07
allele O 0 5.42080260856892e-06
- O 0 1.8624037693371065e-05
specific O 0 8.613012880687165e-08
amplification O 0 3.166477199556539e-06
in O 0 2.553077393940839e-08
two O 0 2.6525231788809833e-08
siblings O 0 1.1041616744478233e-05
revealed O 0 5.1432793952699285e-06
a O 0 1.5804829445187352e-06
homozygous O 0 7.608252053614706e-05
MLH1 O 0 0.1564236730337143
mutation O 0 6.41677324892953e-05
( O 0 1.8229558918392286e-05
C676T O 0 0.005863375496119261
- O 0 0.11899644136428833
- O 0 0.04782957211136818
> O 0 0.009484413079917431
Arg226Stop O 0 0.0022618186194449663
) O 0 6.980292255320819e-06
. O 0 1.138698553404538e-05

Thus O 0 1.793645424186252e-05
, O 0 3.2147320325748296e-06
a O 0 8.145189895003568e-06
homozygous O 0 0.0005312621942721307
germ O 1 0.9134193658828735
- O 0 0.02195027656853199
line O 0 0.00016062175564002246
MLH1 O 0 0.2532164752483368
mutation O 0 0.00011162178998347372
and O 0 3.718950756592676e-05
consequent O 1 0.9855666160583496
mismatch O 1 0.9983288645744324
repair O 1 0.9990814924240112
deficiency O 1 0.9994930028915405
results O 0 5.467998198582791e-05
in O 0 5.700357178284321e-06
a O 0 0.00024408266472164541
mutator O 1 0.9939185380935669
phenotype O 1 0.8847362399101257
characterized O 1 0.7996032238006592
by O 0 0.009856107644736767
leukemia B-Disease 1 0.9997194409370422
and O 0 0.23229685425758362
/ O 1 0.9990341663360596
or O 1 0.9601323008537292
lymphoma B-Disease 1 0.9998798370361328
associated O 0 0.2256857454776764
with O 0 0.06399739533662796
neurofibromatosis B-Disease 1 0.999446451663971
type I-Disease 0 0.11186528205871582
1 I-Disease 0 7.14984635123983e-05
. O 0 4.637758593162289e-06
. O 0 1.4608949641115032e-05

Missense O 0 0.005510397255420685
mutations O 0 7.119353540474549e-05
in O 0 3.4647860047698487e-07
the O 0 8.515234384276482e-08
most O 0 3.318225694215471e-08
ancient O 0 1.3368010343128844e-07
residues O 0 2.1895793622661586e-07
of O 0 4.9071726238025803e-08
the O 0 1.5740764638394467e-06
PAX6 O 0 0.11425450444221497
paired O 0 2.6867543056141585e-05
domain O 0 5.768255050497828e-06
underlie O 0 0.000216382832149975
a O 0 3.5820294215227477e-06
spectrum O 0 0.00025377649581059813
of O 0 0.0001273807283723727
human O 1 0.9529762864112854
congenital B-Disease 1 0.9996316432952881
eye I-Disease 1 0.9986823201179504
malformations I-Disease 1 0.9983280301094055
. O 0 0.018154190853238106

Mutations O 0 5.096530003356747e-05
of O 0 1.1100490837634425e-06
the O 0 5.496408903127303e-06
human O 0 0.0002257529558846727
PAX6 O 1 0.9725881814956665
gene O 0 0.027759885415434837
underlie O 1 0.9925329685211182
aniridia B-Disease 1 0.9981911778450012
( O 1 0.7441427111625671
congenital B-Disease 1 0.9995668530464172
absence I-Disease 0 0.0001841794583015144
of I-Disease 0 1.3564902019425062e-06
the I-Disease 0 1.4955700862628873e-05
iris I-Disease 0 0.21112631261348724
) O 0 3.7539948607445695e-06
, O 0 4.4611513771997124e-07
a O 0 3.4754859825625317e-06
rare O 0 0.0016880816547200084
dominant O 0 0.010499653406441212
malformation B-Disease 1 0.9965789914131165
of I-Disease 0 1.0104932698595803e-05
the I-Disease 0 0.0003161489439662546
eye I-Disease 1 0.9243199825286865
. O 0 0.00014895774074830115

The O 0 3.3957605864998186e-06
spectrum O 0 1.8788799934554845e-05
of O 0 5.822722869197605e-06
PAX6 O 1 0.9156376719474792
mutations O 0 0.003294150112196803
in O 0 0.0005937737296335399
aniridia B-Disease 1 0.9990234375
patients O 1 0.788180410861969
is O 0 1.296116010962578e-06
highly O 0 2.0604334167728666e-06
biased O 0 1.3155931810615584e-06
, O 0 5.139280290222814e-08
with O 0 5.8723326645804264e-08
92 O 0 1.3393548670137534e-06
% O 0 1.3962199396644337e-08
of O 0 6.349769154923024e-09
all O 0 1.8741415530598715e-08
reported O 0 2.712607738430961e-06
mutations O 0 1.4469108009507181e-06
leading O 0 4.004728566542326e-07
to O 0 5.264969260565522e-08
premature O 0 0.00013747702178079635
truncation O 0 3.3556482321728254e-06
of O 0 1.1336063643341276e-08
the O 0 3.785501334618857e-08
protein O 0 7.691991754654737e-07
( O 0 4.94795301619888e-07
nonsense O 0 1.2765473229592317e-06
, O 0 1.3410628163512683e-08
splicing O 0 9.404924838918305e-08
, O 0 1.5466127933905227e-08
insertions O 0 3.3573530799912987e-07
and O 0 1.386827097604737e-08
deletions O 0 6.243176926545857e-07
) O 0 1.6257004631370364e-08
and O 0 2.8174884647569343e-09
just O 0 5.100411648584213e-09
2 O 0 2.3537419124863845e-08
% O 0 5.02190244944245e-09
leading O 0 4.819320942317518e-09
to O 0 6.706561417324508e-10
substitution O 0 5.835550265231859e-09
of O 0 8.604203460826909e-10
one O 0 3.5275045107141523e-09
amino O 0 2.3664451731519875e-08
acid O 0 1.524810841146973e-06
by O 0 5.533364699772392e-08
another O 0 1.036517346619803e-06
( O 0 7.99815279606264e-06
missense O 0 0.00015922677994240075
) O 0 3.611487045418471e-06
. O 0 5.345726094674319e-06

The O 0 3.0562507618014934e-06
extraordinary O 0 5.981811682431726e-06
conservation O 0 1.3492340258380864e-06
of O 0 4.9280799885309534e-08
the O 0 1.9554754260298068e-07
PAX6 O 0 0.001334401429630816
protein O 0 2.2072430283515132e-07
at O 0 2.9406990620373108e-08
the O 0 8.861805511628518e-09
amino O 0 8.714140875554222e-08
acid O 0 4.4327639443508815e-06
level O 0 1.2960789490534808e-06
amongst O 0 1.3570219152825302e-06
vertebrates O 0 2.9810787964379415e-05
predicts O 0 0.0010096003534272313
that O 0 8.025958209145756e-07
pathological O 0 0.017176691442728043
missense O 0 0.0018622588831931353
mutations O 0 4.506169352680445e-05
should O 0 4.094931114195788e-07
in O 0 2.139590264960134e-07
fact O 0 8.537804774277902e-07
be O 0 5.565266292251181e-08
common O 0 2.0238285287632607e-06
even O 0 7.764284077893535e-07
though O 0 1.829170770406563e-07
they O 0 1.2277962646578544e-08
are O 0 2.0193343885921422e-08
hardly O 0 5.9542644521570764e-06
ever O 0 1.9954964045609813e-06
seen O 0 1.5321749742724933e-05
in O 0 3.097499211435206e-05
aniridia B-Disease 1 0.9932695031166077
patients O 1 0.7633774280548096
. O 0 0.00016075091843958944

This O 0 5.179468189453473e-06
indicates O 0 2.957491233246401e-05
that O 0 1.065073433892394e-07
there O 0 6.37689794302787e-08
is O 0 6.413699082941093e-08
a O 0 4.082554596607224e-07
heavy O 0 0.0015184791991487145
ascertainment O 0 0.027686305344104767
bias O 0 8.898366104403976e-06
in O 0 3.552387184413419e-08
the O 0 3.2745727907013134e-08
selection O 0 2.35652308333556e-07
of O 0 6.154592142593174e-07
patients O 0 0.008358200080692768
for O 0 2.7815922294394113e-06
PAX6 O 0 0.49994194507598877
mutation O 0 1.2133506061218213e-05
analysis O 0 1.4867340780710947e-07
and O 0 3.6036588824117644e-08
that O 0 1.9687078633978672e-08
the O 0 1.7516320838240063e-07
missing O 0 3.91196517739445e-05
PAX6 O 1 0.8133114576339722
missense O 0 0.012800782918930054
mutations O 0 0.00034988325205631554
frequently O 0 2.87902385025518e-05
may O 0 4.040470957988873e-05
underlie O 0 0.0061005279421806335
phenotypes O 0 0.0017203260213136673
distinct O 0 1.6563206372666173e-05
from O 0 5.2789124310947955e-05
textbook O 0 0.23136486113071442
aniridia B-Disease 1 0.9793845415115356
. O 0 0.0003700685338117182

Here O 0 4.490862011152785e-06
we O 0 2.1849298548204388e-07
present O 0 2.608007889648434e-07
four O 0 2.3814966709778673e-07
novel O 0 3.598232797230594e-05
PAX6 O 1 0.5549116134643555
missense O 0 0.0007492275908589363
mutations O 0 1.044023156282492e-05
, O 0 7.473217067399673e-08
two O 0 3.105973789274685e-08
in O 0 4.955905978931696e-07
association O 0 3.882503369823098e-05
with O 0 1.2489933396864217e-05
atypical O 1 0.8653532266616821
phenotypes O 0 0.3431120812892914
ectopia B-Disease 1 0.8989657163619995
pupillae I-Disease 1 0.8239720463752747
( O 0 7.757300772937015e-05
displaced B-Disease 0 0.00023972001508809626
pupils I-Disease 0 4.044449815410189e-05
) O 0 3.932098115910776e-05
and O 0 0.0001351152459392324
congenital B-Disease 1 0.999392032623291
nystagmus I-Disease 1 0.8440269231796265
( O 0 1.5988423911039717e-05
searching B-Disease 0 6.48585228191223e-06
gaze I-Disease 0 0.00016119559586513788
) O 0 3.8195534557416977e-07
, O 0 2.4159374945043055e-08
and O 0 8.185190303322543e-09
two O 0 9.343682272344722e-09
in O 0 9.380774201872555e-08
association O 0 3.920148628822062e-06
with O 0 2.0832530367442814e-07
more O 0 1.1331609357512207e-06
recognizable O 0 0.0021492899395525455
aniridia B-Disease 1 0.9508094787597656
phenotypes O 0 0.04020019993185997
. O 0 8.884974522516131e-05

Strikingly O 0 0.0003200555802322924
, O 0 6.445854978665011e-07
all O 0 6.221649329063439e-08
four O 0 2.0468947070639842e-07
mutations O 0 1.8082585029333131e-06
are O 0 6.594710111329505e-09
located O 0 1.9298711961823756e-08
within O 0 1.43162495191973e-08
the O 0 1.0018614204909682e-07
PAX6 O 0 0.003644038923084736
paired O 0 5.372496616473654e-06
domain O 0 2.2343989769524342e-07
and O 0 2.267382548382102e-08
affect O 0 8.664421358162144e-08
amino O 0 4.010782106433908e-08
acids O 0 3.695251038493552e-08
which O 0 4.294723243702947e-09
are O 0 1.487640344244312e-09
highly O 0 2.227249851216584e-08
conserved O 0 3.7096501870337306e-08
in O 0 6.30325125428044e-09
all O 0 7.027266324399761e-09
known O 0 2.0228914365816308e-07
paired O 0 3.4935405892611016e-06
domain O 0 1.0530760619076318e-06
proteins O 0 1.5511158153458382e-06
. O 0 8.922660526877735e-06

Our O 0 3.5028883758059237e-06
results O 0 2.4728065000090282e-06
support O 0 4.818169827558449e-07
the O 0 1.1158466861616034e-07
hypothesis O 0 8.18150908798998e-07
that O 0 5.125220692292487e-09
the O 0 8.45715497632682e-09
under O 0 1.1197654714578675e-07
- O 0 1.5689913652749965e-06
representation O 0 1.9530929762368032e-08
of O 0 5.92320077430486e-08
missense O 0 0.00018540560267865658
mutations O 0 2.2228814486879855e-05
is O 0 7.255567311403865e-07
caused O 0 8.310704288305715e-05
by O 0 9.489447734267742e-07
ascertainment O 0 0.04996119439601898
bias O 0 8.72291493578814e-05
and O 0 2.1358167145990592e-07
suggest O 0 5.472383577398432e-07
that O 0 2.6480241999138343e-08
a O 0 4.0339986639992276e-07
substantial O 0 5.09752644575201e-05
burden O 0 0.0099390409886837
of O 0 9.563006460666656e-05
PAX6 B-Disease 1 0.9988871216773987
- I-Disease 1 0.9991791844367981
related I-Disease 1 0.9966655373573303
disease I-Disease 1 0.9996155500411987
remains O 0 6.567247328348458e-05
to O 0 4.490115657063143e-07
be O 0 2.607507951779553e-07
uncovered O 0 5.593488094746135e-05
. O 0 1.3763374226982705e-06
. O 0 9.300146302848589e-06

The O 0 4.435525625012815e-06
chromosomal O 0 8.046125731198117e-05
order O 0 2.0247482268587191e-07
of O 0 4.28530739782218e-08
genes O 0 7.49099740460224e-07
controlling O 0 1.2250298823346384e-05
the O 0 1.1006251270373468e-06
major O 0 0.00018731759337242693
histocompatibility O 1 0.9946046471595764
complex O 0 0.00010345045302528888
, O 0 6.264735020522494e-06
properdin O 0 0.05907602980732918
factor O 0 0.00022866531799081713
B O 0 0.003008258994668722
, O 0 2.2932078991289018e-06
and O 0 8.191484994313214e-06
deficiency B-Disease 1 0.9488320350646973
of I-Disease 0 1.6403959079980268e-08
the I-Disease 0 5.5208513316529206e-08
second I-Disease 0 1.6859037543781596e-07
component I-Disease 0 1.1671861557260854e-06
of I-Disease 0 2.0092423369533208e-07
complement I-Disease 0 2.380584555794485e-05
. O 0 1.2717387107841205e-05

The O 0 1.6591457097092643e-06
relationship O 0 1.409794663231878e-06
of O 0 5.308327999387075e-08
the O 0 7.551104630465488e-08
genes O 0 6.762068096577423e-07
coding O 0 2.1009207557654008e-05
for O 0 4.0580377458354633e-07
HLA O 0 0.01064553763717413
to O 0 1.5458548219271506e-08
those O 0 2.6104583383812496e-08
coding O 0 8.17312320577912e-06
for O 0 2.171523050265023e-07
properdin O 0 0.0022618467919528484
Factor O 0 3.679040673887357e-05
B O 0 0.0008148561464622617
allotypes O 0 0.0012662189546972513
and O 0 7.212044010884711e-07
for O 0 4.641444320441224e-06
deficiency B-Disease 1 0.9798098802566528
of I-Disease 0 4.9879087526960575e-09
the I-Disease 0 1.0516711057562134e-08
second I-Disease 0 2.5666068381724472e-08
component I-Disease 0 1.4530752423524973e-07
of I-Disease 0 1.1237360375560002e-08
complement I-Disease 0 4.005578830401646e-06
( O 0 1.1213037396373693e-05
C2 O 0 0.042826052755117416
) O 0 2.1046560050308472e-07
was O 0 7.957853398465886e-08
studied O 0 1.3639160556522256e-07
in O 0 9.353706076353774e-08
families O 0 2.177240958189941e-06
of O 0 1.1669551895465702e-05
patients O 1 0.9882475733757019
with O 0 0.2755952775478363
connective O 1 0.9993736147880554
tissue O 1 0.9993335604667664
disorders O 1 0.9991674423217773
. O 0 0.00882663857191801

Patients O 0 0.046404723078012466
were O 0 6.410054993466474e-07
selected O 0 5.36429809017136e-07
because O 0 2.2454685222328408e-07
they O 0 2.913526842007741e-08
were O 0 5.308823958216635e-08
heterozygous O 0 4.135197286814218e-06
or O 0 6.730345376126934e-06
homozygous O 0 0.0006879747379571199
for O 0 0.010072003118693829
C2 B-Disease 1 0.9991207718849182
deficiency I-Disease 1 0.999386191368103
. O 0 0.0010978971840813756

12 O 0 9.485897862759884e-06
families O 0 1.840915160755685e-06
with O 0 7.147714313759934e-07
15 O 0 1.0446076885273214e-05
matings O 0 0.0016330082435160875
informative O 0 0.0010373844997957349
for O 0 0.03178013861179352
C2 B-Disease 1 0.9994034767150879
deficiency I-Disease 1 0.9995747208595276
were O 0 4.332012395025231e-06
found O 0 3.041143463633489e-05
. O 0 4.00089738832321e-05

Of O 0 2.8758236112480517e-06
57 O 0 3.5101635148748755e-05
informative O 0 2.31642243306851e-05
meioses O 0 0.0005409275181591511
, O 0 2.2326392468130507e-07
two O 0 3.700520068150581e-08
crossovers O 0 8.903281241146033e-07
were O 0 2.6421767884698966e-08
noted O 0 3.8851305816933746e-07
between O 0 1.2900696901851916e-06
the O 0 0.00013839178427588195
C2 B-Disease 1 0.9996190071105957
deficiency I-Disease 1 0.9995361566543579
gene O 0 5.468718427437125e-06
and O 0 2.883321030822117e-07
the O 0 2.7943437999056187e-06
HLA O 1 0.9874639511108398
- O 0 0.021371610462665558
B O 0 0.00022194437042344362
gene O 0 4.445649324225087e-07
, O 0 7.212419994573338e-09
with O 0 7.080369623935212e-09
a O 0 3.7328952373627544e-08
recombinant O 0 1.6490358802911942e-06
fraction O 0 2.989163192523847e-07
of O 0 2.315633906846415e-07
0 O 0 2.8482227207859978e-05
. O 0 7.877023563196417e-06

035 O 1 0.7175953984260559
. O 0 0.002279649255797267

A O 0 2.5204259145539254e-05
lod O 0 0.00021022195869591087
score O 0 1.775042051122e-07
of O 0 3.436884910001936e-08
13 O 0 2.281142741367148e-07
was O 0 6.902518379092726e-08
calculated O 0 8.56222044376409e-08
for O 0 1.021255187083625e-07
linkage O 0 0.00038265998591668904
between O 0 0.000864519621245563
C2 B-Disease 1 0.9994819760322571
deficiency I-Disease 1 0.9996637105941772
and O 0 6.207972910488024e-05
HLA O 1 0.9960460066795349
- O 0 0.00906333327293396
B O 0 5.476927253766917e-05
at O 0 4.920303098288059e-08
a O 0 2.2607883565228803e-08
maximum O 0 3.759303268680014e-08
likelihood O 0 1.0436167485750047e-07
value O 0 1.9703709774887557e-09
of O 0 1.7224802695281483e-09
the O 0 6.899659066306185e-09
recombinant O 0 5.667232017003698e-07
fraction O 0 1.580553714575217e-07
of O 0 1.1237515451512081e-07
0 O 0 1.4944266695238184e-05
. O 0 7.5951470535073895e-06

04 O 0 0.2214953452348709
. O 0 0.0013934796443209052

18 O 0 1.8239139535580762e-05
families O 0 1.4538060213453718e-06
with O 0 1.740043984455042e-07
21 O 0 7.758991955597594e-07
informative O 0 1.921018792927498e-06
matings O 0 1.316540965490276e-05
for O 0 9.705060222131578e-08
both O 0 1.6993843132695474e-07
properdin O 0 0.0015508417272940278
Factor O 0 3.209038914064877e-05
B O 0 0.0004928417038172483
allotype O 0 0.0026873042806982994
and O 0 9.859104466158897e-06
HLA O 1 0.9794410467147827
- O 0 0.00751046696677804
B O 0 0.00012311602768022567
were O 0 1.7448680011966644e-07
found O 0 1.3516694252757588e-06
. O 0 6.8674489739350975e-06

Of O 0 2.432895826132153e-06
72 O 0 4.821328184334561e-05
informative O 0 2.0988059986848384e-05
meioses O 0 0.0009701909148134291
, O 0 4.5694622485825676e-07
three O 0 2.072271456654562e-07
recombinants O 0 0.00048492022324353456
were O 0 4.5840931051088774e-08
found O 0 4.895953864547664e-08
, O 0 1.3581085589464692e-08
giving O 0 3.466411158115079e-08
a O 0 6.60793375573121e-08
recombinant O 0 1.8486489352653734e-06
fraction O 0 3.2451083598061814e-07
of O 0 1.9019894637040125e-07
0 O 0 2.159293035219889e-05
. O 0 7.153127171477536e-06

042 O 0 0.1554306149482727
. O 0 0.0019579522777348757

A O 0 1.2039623470627703e-05
lod O 0 9.545322245685384e-05
score O 0 1.3579666813257063e-07
of O 0 8.417537600280411e-08
16 O 0 1.593769297869585e-06
between O 0 7.032161647657631e-06
HLA O 1 0.9767144918441772
- O 0 0.0059398082084953785
B O 0 9.050950757227838e-05
and O 0 1.1324528514933263e-07
Factor O 0 2.6396894554636674e-06
B O 0 2.6084531782544218e-05
allotypes O 0 1.5779174646013416e-05
was O 0 1.2236232471707353e-08
calculated O 0 1.1088999052333293e-08
at O 0 9.767322062259609e-09
a O 0 8.741355195240885e-09
maximum O 0 3.452601049502846e-08
likelihood O 0 5.999654462129911e-08
value O 0 1.508087210666531e-09
of O 0 1.4240152390598837e-09
the O 0 6.78431222311815e-09
recombinant O 0 9.132922400567622e-07
fraction O 0 1.819268504732463e-07
of O 0 1.1528056376164386e-07
0 O 0 1.490496924816398e-05
. O 0 1.0920913155132439e-05

04 O 0 0.1484539806842804
. O 0 0.0007986914715729654

A O 0 8.885688657755964e-06
crossover O 0 1.421167871740181e-05
was O 0 7.684938054808299e-07
shown O 0 1.2250973213667748e-07
to O 0 1.118772274821822e-08
have O 0 5.7788955842852374e-09
occurred O 0 3.766006528849175e-08
between O 0 1.3794614339701639e-08
genes O 0 6.36545038901204e-08
for O 0 3.880664323219207e-08
Factor O 0 3.416328127059387e-06
B O 0 6.0164573369547725e-05
and O 0 1.104144871533208e-06
HLA O 1 0.6336403489112854
- O 0 0.003141466062515974
D O 0 0.002048931084573269
, O 0 3.46150912378107e-08
in O 0 4.536177300451527e-08
which O 0 5.904431077397021e-07
HLA O 0 0.46871429681777954
- O 0 0.015570230782032013
D O 0 0.218440443277359
segregared O 0 0.0007999700028449297
with O 0 7.92304035712732e-06
HLA O 1 0.8688282370567322
- O 0 0.00040639194776304066
A O 0 4.2815313463506754e-06
and O 0 2.381401827733498e-06
B O 0 0.0009139751782640815
. O 0 8.094470103969797e-06

These O 0 2.5384508717252174e-06
studies O 0 4.1778253034863155e-06
suggest O 0 1.8332239051233046e-06
that O 0 2.639557550310201e-08
the O 0 3.885982380325004e-08
genes O 0 2.568189358953532e-07
for O 0 3.9039613852764887e-07
Factor O 0 0.00029354437720030546
B O 0 0.29072776436805725
and O 0 0.004967321641743183
C2 B-Disease 1 0.9996809959411621
deficiency I-Disease 1 0.9996583461761475
are O 0 2.3577587882073203e-08
located O 0 5.686907300628263e-08
outside O 0 2.1049846310461362e-08
those O 0 2.2933265952929105e-08
for O 0 5.775437443844567e-07
HLA O 0 0.4522903263568878
, O 0 3.59888510104156e-08
that O 0 1.0075329459624527e-09
the O 0 1.1564141866315936e-09
order O 0 3.583471519519321e-09
of O 0 1.496957224844664e-08
genese O 0 0.0002673168492037803
is O 0 9.886416592053138e-07
HLA O 0 0.07420830428600311
- O 0 3.3079129934776574e-05
A O 0 5.284245503389684e-07
, O 0 3.085749824549566e-07
- O 0 5.727338793803938e-05
B O 0 3.230360016459599e-05
, O 0 4.2957250911968003e-07
- O 0 0.00012394918303471059
D O 0 0.0007601977558806539
, O 0 2.2424339363169565e-07
Factor O 0 7.646084668522235e-06
B O 0 0.0012050482910126448
allotype O 0 0.4479983150959015
, O 0 0.008229661732912064
C2 B-Disease 1 0.9995629191398621
deficiency I-Disease 1 0.9996514320373535
, O 0 1.402086269308711e-07
that O 0 1.172396224546901e-08
the O 0 2.8524313577804605e-08
genes O 0 5.873195050298818e-07
coding O 0 0.00021283538080751896
for O 0 0.0002569851349107921
C2 B-Disease 1 0.9996210336685181
deficiency I-Disease 1 0.9996970891952515
and O 0 1.0195108188781887e-06
Factor O 0 9.609169865143485e-06
B O 0 4.6302226110128686e-05
allotypes O 0 1.7184016542159952e-05
are O 0 5.667251112839722e-09
approximately O 0 2.3071466515034444e-08
3 O 0 2.983990725624608e-07
- O 0 9.050353583006654e-06
- O 0 2.339675120310858e-06
5 O 0 9.179965587691186e-08
centimorgans O 0 4.326534053689102e-06
from O 0 1.6964074589509437e-08
the O 0 1.1102442698529558e-07
HLA O 0 0.0068949437700212
- O 0 1.2202714970044326e-05
A O 0 5.922878472119919e-07
and O 0 1.1888409972016234e-06
HLA O 1 0.7874124050140381
- O 0 0.009428853169083595
B O 0 0.00018172261479776353
loci O 0 1.1986886647719075e-06
, O 0 4.122531294115106e-08
and O 0 9.723844840436868e-09
that O 0 6.213380476793873e-09
the O 0 2.251871222824775e-08
apparent O 0 2.4561381906096358e-06
lack O 0 3.009965325873054e-07
of O 0 3.561029870979837e-08
recombinants O 0 0.00014507982996292412
between O 0 1.4886408905567805e-07
the O 0 2.523690056932537e-07
Factor O 0 2.349572787352372e-05
B O 0 0.002495104679837823
gene O 0 0.0003365216252859682
and O 0 0.0023728737141937017
C2 B-Disease 1 0.9996964931488037
deficiency I-Disease 1 0.9998613595962524
gene O 0 0.0001299740542890504
suggests O 0 7.010688023001421e-06
that O 0 9.197891337464625e-09
these O 0 3.929125913515463e-09
two O 0 1.389851167488132e-08
genes O 0 3.6145632975603803e-07
lie O 0 6.184782250784338e-07
in O 0 2.2069560401405397e-08
close O 0 9.786664634248154e-08
proximity O 0 2.796962235152023e-07
to O 0 2.8915593475176138e-08
one O 0 1.2460012044357427e-07
another O 0 3.0224603051465238e-06
. O 0 1.3377974028117023e-05

Distribution O 0 9.130962098424789e-06
of O 0 3.0067744773987215e-06
emerin O 0 0.031672924757003784
and O 0 1.3763513379672077e-05
lamins O 0 0.0913333147764206
in O 0 1.958836492121918e-06
the O 0 6.059108272893354e-06
heart O 0 0.034303080290555954
and O 0 4.145167167735053e-06
implications O 0 0.0012711877934634686
for O 0 8.90204610186629e-05
Emery B-Disease 1 0.8787292838096619
- I-Disease 1 0.9955547451972961
Dreifuss I-Disease 1 0.9958611130714417
muscular I-Disease 1 0.9980916380882263
dystrophy I-Disease 1 0.9973264932632446
. O 0 0.005822409875690937

Emerin O 0 0.00213280925527215
is O 0 8.090356686807354e-07
a O 0 8.792122230261157e-07
nuclear O 0 1.1576951692404691e-05
membrane O 0 3.006814722539275e-06
protein O 0 4.877471155850799e-07
which O 0 6.49458939960823e-08
is O 0 1.064892600766143e-07
missing O 0 2.179902367061004e-06
or O 0 2.646878328960156e-06
defective O 0 0.011649232357740402
in O 0 9.43377599469386e-05
Emery B-Disease 1 0.7785992622375488
- I-Disease 1 0.9953304529190063
Dreifuss I-Disease 1 0.9969573020935059
muscular I-Disease 1 0.9989442229270935
dystrophy I-Disease 1 0.9991074204444885
( O 0 0.15655629336833954
EDMD B-Disease 1 0.9953737854957581
) O 0 0.00021659897174686193
. O 0 5.745297312387265e-05

It O 0 7.602826030961296e-07
is O 0 1.1720210579824197e-07
one O 0 2.0053979810086275e-08
member O 0 3.681357085838499e-08
of O 0 6.906993199606859e-09
a O 0 2.6922967322207114e-07
family O 0 1.352070398752403e-06
of O 0 7.913517379165569e-07
lamina O 1 0.9801598787307739
- O 0 0.002089804271236062
associated O 0 1.0409820561108063e-06
proteins O 0 6.949414199652892e-08
which O 0 3.247318147714395e-08
includes O 0 6.056221195649414e-07
LAP1 O 0 0.0013475950108841062
, O 0 8.311521924042609e-07
LAP2 O 0 0.0010146429995074868
and O 0 2.756307821982773e-06
lamin O 0 0.10174304246902466
B O 0 0.026992883533239365
receptor O 0 0.0047383117489516735
( O 0 0.0003961422189604491
LBR O 1 0.9910261034965515
) O 0 1.379152399749728e-05
. O 0 1.3237850907898974e-05

A O 0 1.7589300114195794e-05
panel O 0 2.0445708287297748e-05
of O 0 1.3035736401434406e-06
16 O 0 4.401469777803868e-05
monoclonal O 0 0.002313407603651285
antibodies O 0 0.0011752324644476175
( O 0 3.739495514309965e-05
mAbs O 0 0.013657779432833195
) O 0 6.050898946341476e-07
has O 0 2.7096984211993913e-08
been O 0 5.736713326598419e-09
mapped O 0 3.225958522534711e-08
to O 0 2.2380439723690415e-09
six O 0 5.558876914335542e-09
specific O 0 5.78344927504304e-09
sites O 0 7.665581946980637e-09
throughout O 0 5.359948040961626e-09
the O 0 1.1044797965098496e-08
emerin O 0 1.1769098819058854e-05
molecule O 0 6.231898055375495e-07
using O 0 1.861242822087661e-07
phage O 0 0.0003278855001553893
- O 0 2.0195357137708925e-05
displayed O 0 5.893157890568546e-07
peptide O 0 2.1869009287911467e-06
libraries O 0 1.2680790462127334e-07
and O 0 1.31975035344567e-08
has O 0 1.0359451962926869e-08
been O 0 3.3564224732884895e-09
used O 0 5.833992844372915e-09
to O 0 2.1957582418963284e-08
localize O 0 7.520580402342603e-05
emerin O 0 0.0011323160724714398
in O 0 8.049428856793384e-07
human O 0 1.2718587640847545e-05
and O 0 2.566574221418705e-05
rabbit O 1 0.7010350823402405
heart O 1 0.8667246699333191
. O 0 0.0001586336293257773

Several O 0 1.4563784134224989e-05
mAbs O 0 0.0020416141487658024
against O 0 7.198265393526526e-06
different O 0 1.8453446273269947e-06
emerin O 0 0.14859876036643982
epitopes O 0 0.0038215345703065395
did O 0 1.4010585118739982e-06
not O 0 9.477350459974332e-08
recognize O 0 2.6680197606765432e-06
intercalated O 0 0.0003853855305351317
discs O 0 7.040483615128323e-05
in O 0 8.267284101748373e-07
the O 0 7.44548242437304e-06
heart O 0 0.18053099513053894
, O 0 2.554914431129873e-07
though O 0 8.948739349534662e-08
they O 0 1.0507287484529115e-08
recognized O 0 2.0041727566422196e-07
cardiomyocyte O 0 0.0002129951462848112
nuclei O 0 4.682359758589882e-06
strongly O 0 5.131777243150282e-07
, O 0 2.9656348488060758e-08
both O 0 6.603243729585984e-09
at O 0 5.002583947089079e-08
the O 0 1.0103395453597841e-07
rim O 0 3.4338921977905557e-05
and O 0 8.387200267634398e-08
in O 0 2.8471814061958867e-07
intranuclear O 0 0.0006048514624126256
spots O 0 5.035649337514769e-06
or O 0 8.605489938418032e-07
channels O 0 4.070536306244321e-06
. O 0 7.050440217426512e-06

A O 0 0.0004646163433790207
polyclonal O 0 0.27729490399360657
rabbit O 0 0.33307722210884094
antiserum O 0 0.14341290295124054
against O 0 0.00043316424125805497
emerin O 0 0.09860808402299881
did O 0 5.672537554346491e-06
recognize O 0 1.4556344467564486e-06
both O 0 1.0055774168904463e-07
nuclear O 0 9.272266652260441e-06
membrane O 0 3.2836092032084707e-06
and O 0 1.55722673866876e-07
intercalated O 0 0.00016088188567664474
discs O 0 1.0304735042154789e-05
but O 0 3.930679426389361e-08
, O 0 1.829581997014884e-08
after O 0 3.6012952620012584e-08
affinity O 0 1.7260698825793952e-07
purification O 0 5.753864797952701e-07
against O 0 7.966737314291095e-08
a O 0 1.1765924767814795e-07
pure O 0 1.0022511105489684e-06
- O 0 0.00012183128274045885
emerin O 0 4.006006201962009e-05
band O 0 7.495057019468732e-08
on O 0 1.3483134608804903e-08
a O 0 1.6202002939280646e-07
western O 0 1.2648580423046951e-06
blot O 0 0.0001445335801690817
, O 0 1.3905463447372313e-07
it O 0 5.080035592186505e-08
stained O 0 0.0001415609585819766
only O 0 2.2767517648958346e-08
the O 0 1.9013837970760505e-07
nuclear O 0 2.983866215799935e-05
membrane O 0 4.0353304939344525e-05
. O 0 1.55544257722795e-05

These O 0 3.2335221931134583e-06
results O 0 5.925103323534131e-06
would O 0 2.526681157632993e-07
not O 0 3.9404152829547456e-08
be O 0 1.218464618091275e-08
expected O 0 2.3631847057004052e-07
if O 0 2.980046929224045e-07
immunostaining O 0 0.00024498027050867677
at O 0 8.206616826100799e-07
intercalated O 0 0.00025258836103603244
discs O 0 7.328752417379292e-06
were O 0 7.379332256363114e-09
due O 0 4.9134101232084504e-08
to O 0 1.7624198767052235e-09
a O 0 9.728687189181073e-09
product O 0 3.5588637814498725e-08
of O 0 5.338827602230367e-09
the O 0 1.3381301755543973e-07
emerin O 0 0.0017630248330533504
gene O 0 2.3475088255509036e-06
and O 0 4.16393248769964e-08
, O 0 4.996328684114815e-08
therefore O 0 2.3290992245961206e-08
, O 0 1.325952325714752e-08
cast O 0 3.483451749275446e-08
some O 0 7.720710293313005e-09
doubt O 0 1.8506831622744357e-07
upon O 0 4.602877368142799e-08
the O 0 3.868969429277058e-07
hypothesis O 0 9.548271918902174e-05
that O 0 5.2177172619849443e-05
cardiac B-Disease 1 0.9990956783294678
defects I-Disease 1 0.9990180730819702
in O 0 0.00013613144983537495
EDMD B-Disease 1 0.998514711856842
are O 0 1.067511448127334e-06
caused O 0 0.00013601260434370488
by O 0 1.9893899150247307e-07
absence O 0 5.174279067432508e-06
of O 0 3.77815894125888e-07
emerin O 0 0.02520163357257843
from O 0 1.7147312973975204e-05
intercalated O 0 0.02665557526051998
discs O 0 0.0023533112835139036
. O 0 4.632903073797934e-05

Although O 0 7.836559234419838e-05
emerin O 0 0.0020472919568419456
was O 0 1.274785859095573e-06
abundant O 0 5.021033757657278e-07
in O 0 3.6659631774682566e-08
the O 0 4.296216715715673e-08
membranes O 0 2.994549731738516e-06
of O 0 7.488055331350552e-08
cardiomyocyte O 0 0.0013577109202742577
nuclei O 0 7.253060175571591e-06
, O 0 6.855834300267816e-08
it O 0 1.1124228649350698e-08
was O 0 3.709239848603829e-08
absent O 0 3.329688809117215e-07
from O 0 3.131713199877595e-08
many O 0 1.2029195772811363e-07
non O 0 2.7702153602149338e-05
- O 0 0.026653483510017395
myocyte O 0 0.39063623547554016
cells O 0 3.266031853854656e-05
in O 0 1.1662449423965882e-06
the O 0 7.825352440704592e-06
heart O 0 0.14522145688533783
. O 0 5.3060757636558264e-05

This O 0 7.802161121617246e-07
distribution O 0 8.250641485574306e-07
of O 0 6.873326015011116e-07
emerin O 0 0.003075900487601757
was O 0 6.07970491728338e-07
similar O 0 1.7038762223364756e-07
to O 0 9.308247506112366e-09
that O 0 6.928724705090872e-09
of O 0 5.9153766329700375e-08
lamin O 0 0.007796602323651314
A O 0 9.987827525037574e-07
, O 0 8.327121747697674e-08
a O 0 1.661766617644389e-07
candidate O 0 6.644723953286302e-07
gene O 0 1.21533901165094e-06
for O 0 9.858024441200541e-08
an O 0 1.0972892141580814e-06
autosomal O 0 0.01828411966562271
form O 0 3.8079931982792914e-05
of O 0 7.221266423584893e-05
EDMD B-Disease 1 0.9955441355705261
. O 0 0.00038777582813054323

In O 0 2.027752998401411e-05
contrast O 0 0.00017061425023712218
, O 0 7.517576159443706e-05
lamin O 1 0.9748964905738831
B1 O 1 0.9944961667060852
was O 0 3.858408490486909e-06
absent O 0 6.419668352464214e-06
from O 0 3.818176708136889e-07
cardiomyocyte O 0 0.0004675133968703449
nuclei O 0 1.5307063222280703e-05
, O 0 1.3538226539822062e-06
showing O 0 1.6443875210825354e-05
that O 0 4.556982730719028e-06
lamin O 1 0.9359891414642334
B1 O 1 0.993732750415802
is O 0 7.820533198810153e-08
not O 0 3.975653140031454e-09
essential O 0 1.0569094932577627e-08
for O 0 9.759799191044749e-09
localization O 0 8.19133049390075e-07
of O 0 4.337169556833942e-08
emerin O 0 0.00023035974300000817
to O 0 1.1022053314491131e-07
the O 0 9.515084684608155e-07
nuclear O 0 0.0003633984306361526
lamina O 0 0.19453567266464233
. O 0 3.4224205592181534e-05

Lamin O 1 0.9740844964981079
B1 O 1 0.9891497492790222
is O 0 4.316341801313683e-06
also O 0 7.659942866666825e-07
almost O 0 1.092293246074405e-06
completely O 0 9.965714525606018e-06
absent O 0 0.0001451736461604014
from O 0 5.6861692428356037e-05
skeletal O 1 0.9919959306716919
muscle O 1 0.9561946988105774
nuclei O 0 0.0031507022213190794
. O 0 0.00035941836540587246

In O 0 4.5317716285353526e-05
EDMD B-Disease 0 0.22362680733203888
, O 0 8.053698365984019e-07
the O 0 1.702062064623533e-07
additional O 0 4.5824234007341147e-07
absence O 0 7.265895874297712e-06
of O 0 8.940872248786036e-06
lamin O 1 0.9916877150535583
B1 O 1 0.9979385733604431
from O 0 0.0001760833984008059
heart O 1 0.8613080978393555
and O 0 6.815099186496809e-05
skeletal O 1 0.9934230446815491
muscle O 1 0.603847861289978
nuclei O 0 0.00015325797721743584
which O 0 2.4772039068921003e-06
already O 0 4.7318360884673893e-05
lack O 0 0.00018728760187514126
emerin O 0 0.05363558232784271
may O 0 1.448066200282483e-06
offer O 0 1.1915852127231119e-07
an O 0 3.0999842692835955e-08
alternative O 0 2.2935373067412002e-07
explanation O 0 3.956679677230568e-07
of O 0 7.140437929820109e-08
why O 0 6.902109817019664e-06
these O 0 3.4999092690668476e-07
tissues O 0 0.00014066294534131885
are O 0 2.2032008928363211e-07
particularly O 0 1.906070247059688e-05
affected O 0 6.597572792088613e-05
. O 0 2.830692437783e-06
. O 0 1.1762108442781027e-05

Genetic O 0 3.7603225791826844e-05
mapping O 0 5.889331077923998e-06
of O 0 7.275953066709917e-07
the O 0 5.1502888709364925e-06
copper B-Disease 0 0.014874188229441643
toxicosis I-Disease 1 0.83222895860672
locus O 0 6.336736987577751e-05
in O 0 2.190014811276342e-06
Bedlington O 0 0.018038354814052582
terriers O 0 0.00023674877593293786
to O 0 3.2307863762071065e-07
dog O 0 9.266513370675966e-05
chromosome O 0 7.0726573540014215e-06
10 O 0 2.469362812007603e-07
, O 0 4.6267221165408046e-08
in O 0 3.359889433340868e-08
a O 0 2.9532401413234766e-07
region O 0 3.1649678930989467e-06
syntenic O 0 0.00022929717670194805
to O 0 1.3465586334859836e-07
human O 0 2.1119899429322686e-06
chromosome O 0 0.00016390671953558922
region O 0 0.00010479250340722501
2p13 O 0 0.015521074645221233
- O 0 0.018271975219249725
p16 O 0 0.002873706631362438
. O 0 4.369568341644481e-05

Abnormal O 1 0.9638528227806091
hepatic B-Disease 1 0.9910611510276794
copper I-Disease 0 0.2823483347892761
accumulation I-Disease 0 0.06275341659784317
is O 0 5.31437262907275e-06
recognized O 0 8.86322777660098e-06
as O 0 2.6298786906409077e-05
an O 0 0.008633417077362537
inherited B-Disease 1 0.9997443556785583
disorder I-Disease 1 0.9998010993003845
in O 0 8.969507325673476e-05
man O 0 0.002554617589339614
, O 0 3.9644932257942855e-05
mouse O 0 0.010074932128190994
, O 0 3.171684147673659e-05
rat O 0 0.03125590831041336
and O 0 5.118783519719727e-06
dog O 0 0.0017277849838137627
. O 0 3.810869748122059e-05

The O 0 1.1346606697770767e-05
major O 0 0.00010955589095829055
cause O 0 0.0007821512990631163
of O 0 1.6983414752758108e-05
hepatic B-Disease 1 0.997520387172699
copper I-Disease 0 0.28644245862960815
accumulation I-Disease 0 0.03860420361161232
in O 0 3.955637112085242e-06
man O 0 3.188910341123119e-05
is O 0 6.805413477195543e-07
a O 0 1.6049667465267703e-05
dysfunctional O 0 0.47564661502838135
ATP7B O 1 0.8985891938209534
gene O 0 0.00351850432343781
, O 0 0.0007588880253024399
causing O 1 0.9744027853012085
Wilson B-Disease 1 0.9884251356124878
disease I-Disease 1 0.9989111423492432
( O 0 0.019993333145976067
WD B-Disease 1 0.9944011569023132
) O 0 9.972544648917392e-05
. O 0 6.069034134270623e-05

Mutations O 0 9.567319648340344e-05
in O 0 9.97610868580523e-07
the O 0 2.442473714836524e-06
ATP7B O 0 0.05572458729147911
genes O 0 1.909364073071629e-06
have O 0 9.110384979749142e-08
also O 0 1.337048445293476e-07
been O 0 8.493400827092046e-08
demonstrated O 0 1.8327327779843472e-06
in O 0 6.934279781489749e-07
mouse O 0 0.00042854290222749114
and O 0 7.936667316243984e-06
rat O 0 0.018068525940179825
. O 0 2.265177681692876e-05

The O 0 5.641857933369465e-05
ATP7B O 0 0.2013874351978302
gene O 0 6.986190419411287e-05
has O 0 1.3680499932888779e-06
been O 0 1.6531267021946405e-07
excluded O 0 6.344710641315032e-07
in O 0 6.323858059431586e-08
the O 0 2.5347856080770725e-07
much O 0 7.873252798162866e-06
rarer O 0 0.029173023998737335
human O 0 0.002465698402374983
copper B-Disease 1 0.9967466592788696
overload I-Disease 1 0.9991464614868164
disease O 1 0.9992895126342773
non B-Disease 0 0.013467495329678059
- I-Disease 1 0.7733876705169678
Indian I-Disease 0 0.010615687817335129
childhood I-Disease 1 0.9954955577850342
cirrhosis I-Disease 1 0.998896598815918
, O 0 3.604727316997014e-05
indicating O 0 0.0005143496091477573
genetic O 0 0.002758210990577936
heterogeneity O 0 0.025608576834201813
. O 0 0.00025066526723094285

By O 0 1.2141829756728839e-05
investigating O 0 0.00016017621965147555
the O 0 1.836787305364851e-05
common O 0 0.002116790972650051
autosomal O 1 0.990815281867981
recessive O 1 0.9957411289215088
copper B-Disease 1 0.993899941444397
toxicosis I-Disease 1 0.9975523352622986
( O 0 0.007261780556291342
CT B-Disease 1 0.8839577436447144
) O 0 4.078011897945544e-06
in O 0 2.4191992906708037e-06
Bedlington O 0 0.08847840130329132
terriers O 0 0.0004661921120714396
, O 0 1.8805012302891555e-07
we O 0 1.4518417579267862e-08
have O 0 5.316837192737012e-09
identified O 0 2.7829820226088486e-08
a O 0 7.253658651507067e-08
new O 0 1.1084072184530669e-06
locus O 0 8.754882583161816e-05
involved O 0 2.7169700842932798e-05
in O 0 0.0008190485532395542
progressive O 1 0.9970677495002747
liver B-Disease 1 0.9996777772903442
disease I-Disease 1 0.9994736313819885
. O 0 0.011982699856162071

We O 0 5.259035333438078e-06
examined O 0 2.026347465289291e-05
whether O 0 1.7873074966701097e-06
the O 0 6.192948603711557e-06
WD B-Disease 1 0.988918125629425
gene O 0 0.00016837861039675772
ATP7B O 0 0.04508819431066513
was O 0 1.4969377843954135e-06
also O 0 3.0627819569417625e-07
causative O 0 4.121683741686866e-05
for O 0 7.25164511550247e-07
CT B-Disease 0 0.02451135218143463
by O 0 1.2311912200857478e-07
investigating O 0 2.1457872207975015e-06
the O 0 4.223410599024646e-07
chromosomal O 0 0.0011982618598267436
co O 0 0.0004359371087048203
- O 0 8.592727681389078e-05
localization O 0 6.918037797731813e-06
of O 0 1.4395772041098098e-07
ATP7B O 0 0.0009356264490634203
and O 0 1.7353426073896117e-07
C04107 O 0 1.0905802810157184e-05
, O 0 2.7856904338818822e-08
using O 0 3.0411502649485556e-08
fluorescence O 0 6.656026130258397e-07
in O 0 7.811201641061416e-08
situ O 0 3.047768768738024e-05
hybridization O 0 6.8128042585158255e-06
( O 0 4.58054546470521e-06
FISH O 0 8.945205081545282e-06
) O 0 3.479897259239806e-06
. O 0 5.366218829294667e-06

C04107 O 0 0.000885562680196017
is O 0 3.1433494314114796e-06
an O 0 1.8699442989600357e-06
anonymous O 0 3.655758700915612e-05
microsatellite O 0 0.05346289649605751
marker O 0 0.0011630312073975801
closely O 0 6.670468428637832e-05
linked O 0 0.0007303108577616513
to O 0 3.163229121128097e-05
CT B-Disease 1 0.9676728844642639
. O 0 9.780955588212237e-05

However O 0 2.8671656764345244e-05
, O 0 1.3303546438692138e-05
BAC O 0 0.00166354572866112
clones O 0 0.00046650756848976016
containing O 0 2.150087311747484e-05
ATP7B O 0 0.013018148951232433
and O 0 5.648314527206821e-07
C04107 O 0 4.238845212967135e-05
mapped O 0 1.0006809816331952e-06
to O 0 6.789765194525899e-08
the O 0 3.0792944016866386e-07
canine O 0 0.0027377749793231487
chromosome O 0 4.820082176593132e-05
regions O 0 3.8482880881929304e-06
CFA22q11 O 0 0.0008582763839513063
and O 0 6.977676889619033e-07
CFA10q26 O 0 0.0021249731071293354
, O 0 4.111248017579783e-07
respectively O 0 5.074331852483738e-07
, O 0 1.562431748425297e-07
demonstrating O 0 2.5578599434084026e-06
that O 0 1.5116063423192827e-06
WD B-Disease 1 0.9652519822120667
cannot O 0 6.570443247255753e-07
be O 0 5.154417692665447e-08
homologous O 0 7.84020267019514e-06
to O 0 4.429856744536664e-06
CT B-Disease 1 0.6061182618141174
. O 0 2.6213203454972245e-05

The O 0 1.5047489796415903e-05
copper O 0 0.0008297334425151348
transport O 0 7.57402740418911e-05
genes O 0 2.191575367760379e-05
CTR1 O 0 0.02067624032497406
and O 0 2.23364122575731e-06
CTR2 O 0 0.0013384866761043668
were O 0 3.117327196378028e-08
also O 0 3.543238236147772e-08
excluded O 0 1.2557605089114077e-07
as O 0 9.817284762903e-09
candidate O 0 1.1060191695833055e-07
genes O 0 1.988286157939001e-07
for O 0 6.628293931498774e-07
CT B-Disease 0 0.47128310799598694
since O 0 2.2440984537297481e-07
they O 0 4.060992431220711e-09
both O 0 9.011079882270678e-09
mapped O 0 7.774730761411774e-07
to O 0 3.8569555727008265e-07
canine O 0 0.027017492800951004
chromosome O 0 0.0009260975639335811
region O 0 0.00018074385297950357
CFA11q22 O 0 0.041305188089609146
. O 0 4.5173215767135844e-05

2 O 0 0.0007737796986475587
- O 0 0.00681797880679369
22 O 0 0.0001676815008977428
. O 0 9.696096822153777e-05

5 O 0 0.0012565689394250512
. O 0 0.0007002695347182453

A O 0 3.3318849546049023e-06
transcribed O 0 3.4195190892205574e-06
sequence O 0 5.79346590257046e-07
identified O 0 2.8007579544464534e-07
from O 0 7.094553211572929e-08
the O 0 2.0480662499267055e-07
C04107 O 0 0.0005399171495810151
- O 0 0.00040501431794837117
containing O 0 4.500555860431632e-06
BAC O 0 0.0005625634803436697
was O 0 1.148933534977914e-07
found O 0 1.709927666126987e-08
to O 0 2.5592630237269987e-09
be O 0 1.7985041234069854e-09
homologous O 0 9.515731846931885e-08
to O 0 1.0713708142873202e-08
a O 0 7.90148391160983e-08
gene O 0 5.888887812943722e-07
expressed O 0 1.0150583307222405e-07
from O 0 8.215726410298885e-08
human O 0 1.0160273404835607e-06
chromosome O 0 7.131924212444574e-05
2p13 O 0 0.005600888282060623
- O 0 0.002691104542464018
p16 O 0 0.00019163108663633466
, O 0 8.07981095363175e-08
a O 0 1.1108204489573836e-07
region O 0 3.0397586670005694e-07
devoid O 0 5.762233854511578e-07
of O 0 1.5057054270073422e-08
any O 0 9.494103636598084e-08
positional O 0 1.5977404473233037e-05
candidate O 0 7.103392817953136e-06
genes O 0 1.899371090985369e-05
. O 0 2.1546007701545022e-05

Molecular O 0 1.6336773114744574e-05
analysis O 0 9.962589047063375e-07
of O 0 1.3782626240299578e-07
the O 0 4.988139608030906e-07
APC B-Disease 0 0.00024153287813533098
gene O 0 2.826683839884936e-06
in O 0 1.9367490722288494e-07
205 O 0 1.4501858458970673e-05
families O 0 3.952655447392317e-07
: O 0 1.0570878430371522e-06
extended O 0 2.14625583794259e-06
genotype O 0 0.00030793267069384456
- O 0 0.0017444477416574955
phenotype O 0 0.0001630655606277287
correlations O 0 2.3253291146829724e-05
in O 0 3.0600483569287462e-06
FAP B-Disease 0 0.10384704917669296
and O 0 3.549677884961966e-08
evidence O 0 5.934316504863091e-08
for O 0 1.0465605271292588e-08
the O 0 1.1999538251927788e-08
role O 0 6.40697450648986e-08
of O 0 8.125478956344523e-08
APC B-Disease 0 0.00037087665987201035
amino O 0 5.0457820179872215e-06
acid O 0 0.0017637802520766854
changes O 0 0.0015512568643316627
in O 0 0.1667347103357315
colorectal B-Disease 1 0.9996902942657471
cancer I-Disease 1 0.9995552897453308
predisposition O 1 0.994433581829071
. O 0 0.0014129570918157697

BACKGROUND O 0 0.0009286254062317312
/ O 0 0.0026676480192691088
AIMS O 0 3.146726521663368e-05
The O 0 2.6735699520941125e-06
development O 0 0.00031419791048392653
of O 0 0.04407745972275734
colorectal B-Disease 1 0.9999284744262695
cancer I-Disease 1 0.9996623992919922
and O 0 5.796339337393874e-07
a O 0 4.640464794647414e-07
variable O 0 1.6944594563028659e-06
range O 0 8.419414712079742e-07
of O 0 6.767500053683762e-07
extracolonic O 0 0.10952373594045639
manifestations O 0 0.02139464020729065
in O 0 0.002057088539004326
familial B-Disease 1 0.9993632435798645
adenomatous I-Disease 1 0.999576985836029
polyposis I-Disease 1 0.9996932744979858
( O 1 0.5907514095306396
FAP B-Disease 1 0.9975404739379883
) O 0 6.633904831687687e-06
is O 0 9.817437529591189e-08
the O 0 2.538742727153931e-08
result O 0 1.1478952188781477e-07
of O 0 1.584292697032197e-08
the O 0 3.1298446856453666e-07
dominant O 0 7.882856152718887e-05
inheritance O 0 0.004963462706655264
of O 0 0.008723716251552105
adenomatous B-Disease 1 0.9995484948158264
polyposis I-Disease 1 0.9994613528251648
coli I-Disease 1 0.9988149404525757
( O 0 0.004958921577781439
APC B-Disease 0 0.18837995827198029
) O 0 4.042247746838257e-05
gene O 0 0.0002018547966144979
mutations O 0 0.00045369056169874966
. O 0 3.681413363665342e-05

In O 0 1.783593916115933e-06
this O 0 2.5141341097878467e-07
study O 0 4.563922857414582e-07
, O 0 5.851369166975928e-08
direct O 0 6.234121485704236e-08
mutation O 0 4.4631173068410135e-07
analysis O 0 4.651666074551031e-08
of O 0 1.2352352918298948e-08
the O 0 3.2518960324523505e-07
APC B-Disease 0 0.0004955316544510424
gene O 0 1.0216384680461488e-06
was O 0 3.512929680482557e-08
performed O 0 2.8066450497021833e-08
to O 0 1.3723441938395808e-08
determine O 0 3.6557273119797173e-07
genotype O 0 0.00012575832079164684
- O 0 0.00025980419013649225
phenotype O 0 2.931888957391493e-05
correlations O 0 1.3896915334044024e-06
for O 0 7.32598763875103e-08
nine O 0 2.449947942295694e-06
extracolonic O 0 0.023561472073197365
manifestations O 0 8.468545274809003e-05
and O 0 6.364430049643488e-08
to O 0 2.520793351834527e-08
investigate O 0 1.1725828699127305e-06
the O 0 3.007773159424687e-07
incidence O 0 0.0011151997605338693
of O 0 9.334962669527158e-07
APC B-Disease 0 0.014215026050806046
mutations O 0 0.00016969608259387314
in O 0 2.9316932341316715e-05
non O 0 0.16470330953598022
- O 1 0.9971528053283691
FAP O 1 0.998815655708313
colorectal B-Disease 1 0.9997414946556091
cancer I-Disease 1 0.9990880489349365
. O 0 0.0037661255337297916

METHODS O 0 1.7717009541229345e-05
The O 0 6.013407528371317e-06
APC B-Disease 0 0.000616835430264473
gene O 0 7.134881343517918e-06
was O 0 5.610123707810999e-07
analysed O 0 1.8269984138896689e-06
in O 0 3.508959309783677e-07
190 O 0 1.0304606803401839e-05
unrelated O 0 0.00013638650125358254
FAP B-Disease 0 0.14744117856025696
and O 0 4.205367076792754e-06
15 O 0 0.00019273954967502505
non O 0 0.14956888556480408
- O 1 0.9984629154205322
FAP O 1 0.9994076490402222
colorectal B-Disease 1 0.9999274015426636
cancer I-Disease 1 0.999834418296814
patients O 0 0.36120352149009705
using O 0 9.965544450096786e-06
denaturing O 0 0.16740640997886658
gradient O 0 0.0008898412925191224
gel O 0 0.005860296543687582
electrophoresis O 0 4.698355769505724e-05
, O 0 5.4761432721761594e-08
the O 0 2.528005893509544e-08
protein O 0 5.607876687463431e-07
truncation O 0 8.02047270553885e-06
test O 0 4.5869794007558085e-07
, O 0 3.506135470843219e-08
and O 0 3.0056678923529034e-08
direct O 0 4.029599836030684e-07
sequencing O 0 7.484794423362473e-06
. O 0 9.192191100737546e-06

RESULTS O 0 0.00044928432907909155
Chain O 0 0.0004668017500080168
terminating O 0 7.569290755782276e-05
signals O 0 2.2303418063529534e-06
were O 0 1.1347144379669771e-07
only O 0 8.277304885950798e-08
identified O 0 1.5775555084474036e-06
in O 0 2.2222632196644554e-06
patients O 0 0.0022048086393624544
belonging O 0 1.0549196076681255e-06
to O 0 1.1162831015099073e-07
the O 0 1.9231249552831287e-06
FAP B-Disease 0 0.3209955394268036
group O 0 2.301726271980442e-05
( O 0 3.3822976547526196e-05
105 O 0 0.0009049104410223663
patients O 0 0.043817728757858276
) O 0 1.321237414231291e-05
. O 0 1.1818452549050562e-05

Amino O 0 9.339547432318795e-06
acid O 0 5.768904520664364e-05
changes O 0 2.001642997129238e-06
were O 0 8.703775478124953e-08
identified O 0 3.7518867657126975e-07
in O 0 1.7054465217825054e-07
four O 0 2.4875801045709522e-06
patients O 0 0.0025716933887451887
, O 0 7.105698784926062e-08
three O 0 1.2874510346705392e-08
of O 0 3.803631543064512e-08
whom O 0 1.0343636631660047e-06
belonged O 0 5.737985020459746e-07
to O 0 3.079857435750455e-08
the O 0 2.2690358036925318e-07
non O 0 0.00010814717825269327
- O 1 0.6966310739517212
FAP O 1 0.9937735795974731
group O 0 0.00462656794115901
of O 0 0.43037185072898865
colorectal B-Disease 1 0.9998916387557983
cancer I-Disease 1 0.9998512268066406
patients O 1 0.9971520900726318
. O 0 0.0025243472773581743

Genotype O 0 0.10135246068239212
- O 0 0.18155886232852936
phenotype O 0 0.014365414157509804
correlations O 0 0.00028538834885694087
identified O 0 1.6381831301259808e-05
significant O 0 5.622793196380371e-06
differences O 0 7.739091415714938e-06
in O 0 1.2317948971940496e-07
the O 0 8.117362426673935e-08
nature O 0 3.5460988101476687e-07
of O 0 1.0095131131038215e-07
certain O 0 5.386789325712016e-06
extracolonic O 1 0.6437051892280579
manifestations O 0 0.20186935365200043
in O 0 0.001962876645848155
FAP B-Disease 1 0.998813271522522
patients O 0 0.23502767086029053
belonging O 0 3.48600906363572e-06
to O 0 1.2678044924996357e-07
three O 0 5.262981517262233e-07
mutation O 0 0.00011538821854628623
subgroups O 0 0.00012813019566237926
. O 0 4.017767059849575e-05

CONCLUSIONS O 0 0.0001630226179258898
Extended O 0 0.00018718300270847976
genotype O 0 0.007483148481696844
- O 0 0.015344937331974506
phenotype O 0 0.0009842137806117535
correlations O 0 2.0342025891295634e-05
made O 0 4.7030079031173955e-07
in O 0 1.8522722200486896e-07
this O 0 2.101498921547318e-07
study O 0 1.9806752789008897e-06
may O 0 4.156220825279888e-07
have O 0 5.486270548971106e-09
the O 0 1.4532631098518323e-08
potential O 0 1.2317114794768713e-07
to O 0 5.12224929138938e-09
determine O 0 1.0723848475890918e-08
the O 0 8.574784438053484e-09
most O 0 1.3975255619413929e-08
appropriate O 0 1.276071230904563e-07
surveillance O 0 1.1294450814602897e-05
and O 0 4.317280399845913e-06
prophylactic O 1 0.5566527843475342
treatment O 1 0.5344623327255249
regimens O 0 0.1776273250579834
for O 0 7.723474482190795e-06
those O 0 3.828339686151594e-05
patients O 0 0.4491177797317505
with O 0 4.310935764806345e-05
mutations O 0 0.0031227280851453543
associated O 0 0.00017137221584562212
with O 0 0.000101287238067016
life O 0 0.010180731303989887
threatening O 1 0.9181988835334778
conditions O 0 0.12413902580738068
. O 0 0.0003445163310971111

This O 0 1.671249833634647e-06
study O 0 2.058987547570723e-06
also O 0 1.5135897513118834e-07
provided O 0 2.276795925126862e-07
evidence O 0 2.8758131520589814e-07
for O 0 6.384528461467198e-08
the O 0 2.0187846416774846e-07
pathological O 0 0.00022334542882163078
nature O 0 1.7729897194840305e-07
of O 0 1.2861771203631633e-08
amino O 0 3.2253683457383886e-07
acid O 0 1.5664942111470737e-05
changes O 0 8.417776484748174e-07
in O 0 4.5620950572811125e-07
APC O 0 0.000572834222111851
associated O 0 1.1107204045401886e-06
with O 0 3.5061060543739586e-07
both O 0 2.2450026335718576e-06
FAP B-Disease 1 0.8285804390907288
and O 0 0.00012351795157883316
non O 1 0.6338144540786743
- O 1 0.9983737468719482
FAP O 1 0.9990467429161072
colorectal B-Disease 1 0.9998607635498047
cancer I-Disease 1 0.9997534155845642
patients O 1 0.9975311160087585
. O 0 0.0004780059971380979
. O 0 0.0003004547324962914

Inherited B-Disease 1 0.9945178627967834
colorectal I-Disease 1 0.9991956353187561
polyposis I-Disease 1 0.9988226294517517
and O 1 0.9879806637763977
cancer B-Disease 1 0.999453604221344
risk O 0 0.05541699752211571
of O 0 2.361930228289566e-06
the O 0 2.5911946067935787e-05
APC O 0 0.08591829240322113
I1307K O 0 0.021118398755788803
polymorphism O 0 0.000735058740247041
. O 0 4.926486872136593e-05

Germ O 1 0.883104145526886
- O 0 0.0018694103928282857
line O 0 1.393667025695322e-05
and O 0 1.0922120736722718e-06
somatic O 0 5.363199670682661e-05
truncating O 0 0.00024214669247157872
mutations O 0 1.7412621673429385e-06
of O 0 3.9315416699992056e-08
the O 0 5.137280822964385e-07
APC B-Disease 0 0.0007067351834848523
gene O 0 2.3273842089110985e-06
are O 0 3.046950425300565e-08
thought O 0 9.123546647060721e-07
to O 0 2.334056944164331e-06
initiate O 0 0.17621035873889923
colorectal B-Disease 1 0.9993340373039246
tumor I-Disease 1 0.998404324054718
formation O 1 0.825287938117981
in O 0 0.31671854853630066
familial B-Disease 1 0.9994314312934875
adenomatous I-Disease 1 0.9995063543319702
polyposis I-Disease 1 0.9998408555984497
syndrome I-Disease 1 0.9997909665107727
and O 0 0.15733182430267334
sporadic O 1 0.9965536594390869
colorectal O 1 0.9995576739311218
carcinogenesis O 1 0.9972931742668152
, O 0 0.0005176877602934837
respectively O 0 0.00059281982248649
. O 0 0.00014750291302334517

Recently O 0 3.534660572768189e-05
, O 0 1.7228218212039792e-06
an O 0 1.16482874545909e-06
isoleucine O 0 0.0036445907317101955
- O 0 0.004335829056799412
- O 0 0.0006258761277422309
> O 0 0.00016521282668691128
lysine O 0 9.812149983190466e-06
polymorphism O 0 8.978981895779725e-07
at O 0 2.4230541839642683e-07
codon O 0 1.3103604032949079e-06
1307 O 0 6.448536441894248e-05
( O 0 5.732570116379065e-07
I1307K O 0 5.262015292828437e-06
) O 0 1.9070673928922588e-08
of O 0 6.831981647081875e-09
the O 0 9.837081194064012e-08
APC B-Disease 0 0.00013698240218218416
gene O 0 5.998727488076838e-07
has O 0 3.9018317465888686e-08
been O 0 5.308770756329295e-09
identified O 0 1.585420328353848e-08
in O 0 7.805121882142885e-09
6 O 0 2.411907189525664e-07
% O 0 7.008315350276462e-08
- O 0 2.758590653684223e-06
7 O 0 6.718742895372998e-08
% O 0 7.507988009081146e-09
of O 0 5.819589254940638e-09
the O 0 1.6338829311735026e-07
Ashkenazi O 0 5.526844324776903e-05
Jewish O 0 2.8432245926524047e-06
population O 0 2.928471985796932e-06
. O 0 8.034849088289775e-06

To O 0 1.4172428564052097e-05
assess O 0 0.000173255437402986
the O 0 2.8817812562920153e-06
risk O 0 8.672991680214182e-05
of O 0 9.064695660754296e-08
this O 0 3.4430431128384953e-07
common O 0 2.977461917907931e-05
APC B-Disease 0 0.05923387035727501
allelic O 0 0.13626384735107422
variant O 1 0.7542855739593506
in O 0 0.023544512689113617
colorectal O 1 0.9997122883796692
carcinogenesis O 1 0.9963899254798889
, O 0 2.2219053334993077e-06
we O 0 4.319181101664071e-08
have O 0 1.706405683421508e-08
analyzed O 0 1.053261371453118e-07
a O 0 5.483051523924587e-08
large O 0 3.4090305689460365e-07
cohort O 0 1.438881463400321e-05
of O 0 2.4001704446163785e-07
unselected O 0 0.004003412090241909
Ashkenazi O 0 0.00014642346650362015
Jewish O 0 2.4335361104022013e-06
subjects O 0 1.2572032574098557e-05
with O 0 0.00033006741432473063
adenomatous B-Disease 1 0.998789370059967
polyps I-Disease 1 0.9964296221733093
and O 0 0.00019301119027659297
. O 0 0.005826769862323999
or O 1 0.9417408108711243
colorectal B-Disease 1 0.9999141693115234
cancer I-Disease 1 0.9996863603591919
, I-Disease 0 3.958143224735977e-06
for O 0 5.319263891578885e-07
the O 0 3.621288669819478e-06
APC O 0 0.007373967207968235
I1307K O 0 0.004237627610564232
polymorphism O 0 0.00039204329368658364
. O 0 4.5217522711027414e-05

The O 0 1.9030007024412043e-05
APC O 0 0.0012283104006201029
I1307K O 0 0.0004989898880012333
allele O 0 2.3286620489670895e-05
was O 0 8.776121944720217e-07
identified O 0 4.4391927644937823e-07
in O 0 8.109438454084739e-08
48 O 0 7.021882879598706e-07
( O 0 1.493390158202601e-07
10 O 0 2.1519989346074908e-08
. O 0 9.830344538386271e-09
1 O 0 6.06175660777808e-08
% O 0 9.408297074742222e-08
) O 0 1.968734721913279e-07
of O 0 6.43934185973194e-07
476 O 0 0.04001385718584061
patients O 0 0.12694135308265686
. O 0 5.8176978200208396e-05

Compared O 0 1.0451227353769355e-05
with O 0 1.6706843553038198e-07
the O 0 6.524063422830295e-08
frequency O 0 5.528933755272192e-08
in O 0 1.1536102739739817e-08
two O 0 5.880355313792052e-09
separate O 0 4.628672556350466e-08
population O 0 4.389851682162771e-08
control O 0 1.1918636033669827e-07
groups O 0 1.00868700059209e-08
, O 0 2.1490745183427862e-08
the O 0 6.799368179599696e-08
APC O 0 0.00045205355854704976
I1307K O 0 0.00023085114662535489
allele O 0 3.4678116662689717e-06
is O 0 7.360387144217384e-08
associated O 0 2.2181441750035447e-07
with O 0 3.968889572547596e-08
an O 0 1.764153552130665e-07
estimated O 0 9.611012501409277e-06
relative O 0 2.219833004346583e-05
risk O 0 0.00010598648805171251
of O 0 3.28310676422916e-07
1 O 0 2.4106266209855676e-05
. O 0 1.5536354112555273e-05

5 O 0 0.0004299564170651138
- O 0 0.006454863119870424
1 O 0 0.00011419488146202639
. O 0 7.544227264588699e-05

7 O 0 0.0007158407242968678
for O 0 0.0014670630916953087
colorectal B-Disease 1 0.9983421564102173
neoplasia I-Disease 1 0.9956746697425842
( O 0 7.320631266338751e-05
both O 0 7.538536465290235e-06
P O 0 0.34746772050857544
= O 0 0.007419964298605919
. O 0 7.729030585323926e-06
01 O 0 0.013271388597786427
) O 0 8.865932613844052e-06
. O 0 6.1845380514569115e-06

Furthermore O 0 0.00011383555829524994
, O 0 3.888681021635421e-06
compared O 0 9.250441507901996e-06
with O 0 5.936042271059705e-06
noncarriers O 0 0.025640321895480156
, O 0 1.6154424884007312e-05
APC O 0 0.02266017720103264
I1307K O 0 0.011939826421439648
carriers O 0 0.000156164969666861
had O 0 3.7892004911554977e-07
increased O 0 7.624042268616904e-07
numbers O 0 3.956189118525799e-07
of O 0 1.711865024844883e-06
adenomas B-Disease 1 0.9847299456596375
and O 0 0.0022098938934504986
colorectal B-Disease 1 0.9996325969696045
cancers I-Disease 1 0.9945091605186462
per O 0 6.747252882632893e-06
patient O 0 0.0067009394988417625
( O 0 2.023173146881163e-05
P O 0 0.01776687055826187
= O 0 0.00036822629044763744
. O 0 2.7391365620133e-07
03 O 0 0.00020880500960629433
) O 0 1.0089068069873974e-07
, O 0 9.65305169131625e-09
as O 0 4.542772824578378e-09
well O 0 4.36757519040043e-09
as O 0 1.321450593394502e-08
a O 0 3.823569727501308e-07
younger O 0 3.4095850423909724e-05
age O 0 9.445162868360057e-05
at O 0 8.112320210784674e-05
diagnosis O 1 0.9311624765396118
. O 0 0.00012643610534723848

We O 0 2.182369371439563e-06
conclude O 0 3.959857167501468e-06
that O 0 1.412457777405507e-07
the O 0 6.4074390593305e-07
APC O 0 0.002393142320215702
I1307K O 0 0.002835868624970317
variant O 0 0.0007141882670111954
leads O 0 2.140708420483861e-05
to O 0 2.3488523765990976e-06
increased O 0 0.00236399844288826
adenoma B-Disease 1 0.9988422989845276
formation O 0 2.8186137569718994e-05
and O 0 7.174978122748144e-08
directly O 0 5.8337843000799694e-08
contributes O 0 5.411857841863821e-07
to O 0 8.367543102849595e-09
3 O 0 1.1298616442445564e-07
% O 0 8.50367811722208e-08
- O 0 2.365877662668936e-06
4 O 0 8.828926922888058e-08
% O 0 1.9240127713260335e-08
of O 0 3.165107997915584e-08
all O 0 1.2407143685777555e-06
Ashkenazi O 0 0.04095390439033508
Jewish O 0 0.13115283846855164
colorectal B-Disease 1 0.9995360374450684
cancer I-Disease 1 0.9991418123245239
. O 0 0.0018190848641097546

The O 0 9.463535207032692e-06
estimated O 0 0.0001547300344100222
relative O 0 0.00033456392702646554
risk O 0 0.010137313976883888
for O 0 1.0885520168812945e-05
carriers O 0 0.006031583528965712
may O 0 2.460532596160192e-05
justify O 0 5.861965109943412e-05
specific O 0 8.99263227438496e-07
clinical O 0 7.312266097869724e-05
screening O 0 2.1630953597195912e-06
for O 0 1.7280225250715375e-08
the O 0 3.4943251847607826e-08
360 O 0 1.8411574274068698e-06
, O 0 1.6468483465814643e-07
000 O 0 1.3292450375956832e-06
Americans O 0 1.8645187083166093e-07
expected O 0 9.606731765643417e-08
to O 0 1.6606474417812933e-08
harbor O 0 4.552360678644618e-06
this O 0 1.46129037759124e-08
allele O 0 6.551084652528516e-07
, O 0 2.8852953803948367e-08
and O 0 2.273193722146516e-08
genetic O 0 1.4543605857397779e-06
testing O 0 1.9054100164339616e-07
in O 0 3.3491642792427e-09
the O 0 3.878242615940053e-09
setting O 0 4.003575071465093e-08
of O 0 5.6840661954993266e-08
long O 0 6.692399620078504e-05
- O 0 0.0010650961194187403
term O 0 2.2567557607544586e-05
- O 0 0.00017517390369903296
outcome O 0 1.2362461347947828e-06
studies O 0 1.475400722483755e-06
may O 0 5.045647412771359e-06
impact O 0 0.0002909603645093739
significantly O 0 0.07000728696584702
on O 0 0.23695175349712372
colorectal B-Disease 1 0.9999403953552246
cancer I-Disease 1 0.9998704195022583
prevention O 1 0.9718409180641174
in O 0 4.779986284120241e-06
this O 0 1.3285175555211026e-06
population O 0 7.877992175053805e-06
. O 0 1.3869316717318725e-05

Localization O 0 6.918244616826996e-05
of O 0 2.020272631853004e-06
human O 0 2.4523520551156253e-05
BRCA1 O 0 0.0007538343197666109
and O 0 2.421085980586213e-07
its O 0 3.657526406186662e-07
loss O 0 0.00015259261999744922
in O 0 6.235233058760059e-07
high O 0 0.00010110506264027208
- O 0 0.005298174452036619
grade O 0 0.0005700673209503293
, O 0 1.2583366697072051e-05
non B-Disease 0 0.004094969481229782
- I-Disease 1 0.9933308959007263
inherited I-Disease 1 0.9961971044540405
breast I-Disease 1 0.9984400868415833
carcinomas I-Disease 1 0.9974024891853333
. O 0 0.0007773207616992295

Although O 0 5.018428055336699e-06
the O 0 9.193454957312497e-07
link O 0 7.63633488531923e-06
between O 0 2.5595363695174456e-06
the O 0 5.31899459019769e-05
BRCA1 O 1 0.9685811400413513
tumour B-Disease 1 0.9986526966094971
- O 1 0.6049903631210327
suppressor O 0 0.10706830024719238
gene O 0 0.00032451876904815435
and O 0 0.0001559344818815589
hereditary B-Disease 1 0.998271107673645
breast I-Disease 1 0.9997321963310242
and I-Disease 1 0.9978456497192383
ovarian I-Disease 1 0.9999661445617676
cancer I-Disease 1 0.9999006986618042
is O 0 8.539599548385013e-06
established O 0 1.2082306284355582e-06
, O 0 1.6525561363778252e-07
the O 0 3.356846889346343e-08
role O 0 2.0552079149638303e-07
, O 0 3.058070419115211e-08
if O 0 6.492679283098823e-09
any O 0 4.154815158585734e-09
, O 0 1.4836682993291106e-08
of O 0 7.298345394701755e-08
BRCA1 O 0 0.002048965310677886
in O 0 4.87524812342599e-06
non B-Disease 0 0.0022248723544180393
- I-Disease 1 0.986775279045105
familial I-Disease 1 0.9979686141014099
cancers I-Disease 1 0.9970332384109497
is O 0 1.3256990314403083e-05
unclear O 0 4.429175169207156e-05
. O 0 2.5961637220461853e-05

BRCA1 O 0 0.2097342163324356
mutations O 0 0.00030063092708587646
are O 0 1.0265275705023669e-06
rare O 0 0.00016785348998382688
in O 0 2.6160565539612435e-05
sporadic B-Disease 1 0.5468944907188416
cancers I-Disease 1 0.9990540146827698
, O 0 6.944345386727946e-06
but O 0 1.0660585303412518e-06
loss O 0 0.00012221002543810755
of O 0 8.036105896280787e-07
BRCA1 O 0 0.06687505543231964
resulting O 0 2.9276561690494418e-05
from O 0 7.124799026314577e-07
reduced O 0 4.466550763027044e-06
expression O 0 1.4653714686119201e-07
or O 0 9.155503022384437e-08
incorrect O 0 3.738496161531657e-07
subcellular O 0 4.87104671265115e-06
localization O 0 6.792874501115875e-06
is O 0 4.417232801756654e-08
postulated O 0 4.3679236227944784e-07
to O 0 6.243948469375482e-09
be O 0 4.8526094253986685e-09
important O 0 2.4955578936669554e-08
in O 0 1.460928956475982e-06
non B-Disease 0 0.0009060134761966765
- I-Disease 1 0.9859936237335205
familial I-Disease 1 0.9981902241706848
breast I-Disease 1 0.9995137453079224
and I-Disease 1 0.9597586989402771
ovarian I-Disease 1 0.9997983574867249
cancers I-Disease 1 0.9987635612487793
. O 0 0.0049275606870651245

Epigenetic O 0 0.020315518602728844
loss O 0 0.15343086421489716
, O 0 1.6789925211924128e-05
however O 0 3.016418986589997e-06
, O 0 5.999780796628329e-07
has O 0 1.1174995506735286e-07
not O 0 2.0092571162422246e-08
received O 0 3.5437122392067977e-07
general O 0 7.706133260398929e-07
acceptance O 0 7.723342605459038e-06
due O 0 1.0294116918885265e-06
to O 0 2.4716973356930794e-08
controversy O 0 5.889202157050022e-07
regarding O 0 5.3895060858621946e-08
the O 0 2.0374057996264128e-08
subcellular O 0 1.3566492498284788e-06
localization O 0 1.8725068002822809e-06
of O 0 1.1909319397318541e-07
BRCA1 O 0 0.00035247200867161155
proteins O 0 3.0098505021669553e-07
, O 0 4.59676208208748e-08
reports O 0 2.7866311924640286e-08
of O 0 2.850330638182186e-09
which O 0 6.71411592989557e-09
have O 0 6.812541197831479e-09
ranged O 0 5.896564516660874e-07
from O 0 1.482562250743058e-08
exclusively O 0 3.031096795780286e-08
nuclear O 0 1.7403904166712891e-06
, O 0 1.8030455350981356e-08
to O 0 8.770046022732458e-09
conditionally O 0 4.82435416415683e-06
nuclear O 0 1.6863667724464904e-06
, O 0 1.2476141897366233e-08
to O 0 1.2199226517850548e-08
the O 0 4.0516570720683376e-07
ER O 0 0.170769602060318
/ O 0 0.0013327490305528045
golgi O 0 0.00010874644794967026
, O 0 1.8694823467058086e-08
to O 0 1.245657266224498e-08
cytoplasmic O 0 2.1585206013696734e-06
invaginations O 0 1.8022699805442244e-05
into O 0 7.383868450006048e-08
the O 0 2.8233867510607524e-07
nucleus O 0 2.4527800633222796e-05
. O 0 1.2528048500826117e-05

In O 0 1.6364011798941647e-06
an O 0 6.887564154567372e-07
attempt O 0 3.0911448902770644e-06
to O 0 2.9719268468397786e-07
resolve O 0 1.890328712761402e-05
this O 0 1.418513591033843e-07
issue O 0 9.048135893863218e-07
, O 0 8.050399458170432e-08
we O 0 2.6438151223828754e-08
have O 0 6.937852248256604e-08
comprehensively O 0 0.00018156709847971797
characterized O 0 0.0004242576833348721
19 O 0 7.016147719696164e-05
anti O 0 0.1289062350988388
- O 1 0.7123801112174988
BRCA1 O 0 0.19896309077739716
antibodies O 0 0.0013533281162381172
. O 0 2.6954028726322576e-05

These O 0 2.2106059986981563e-06
reagents O 0 6.736547948094085e-05
detect O 0 3.118938548141159e-05
a O 0 1.0690090448406409e-06
220 O 0 8.313334546983242e-06
- O 0 0.000301635533105582
kD O 0 0.00097713153809309
protein O 0 4.186740909517539e-07
localized O 0 2.6454174530954333e-06
in O 0 3.29487797046113e-08
discrete O 0 4.4843943669548025e-07
nuclear O 0 3.022771306859795e-05
foci O 0 3.594504596549086e-05
in O 0 1.1291678703173602e-07
all O 0 1.1512740627495077e-07
epithelial O 0 0.020509246736764908
cell O 0 0.00010680533887352794
lines O 0 2.783078116408433e-06
, O 0 7.315613714808933e-08
including O 0 1.2943085891947703e-07
those O 0 2.0067146522251278e-07
derived O 0 7.484494290110888e-06
from O 0 0.00021206260134931654
breast B-Disease 1 0.9980220794677734
malignancies I-Disease 1 0.9920547008514404
. O 0 0.0003260189841967076

Immunohistochemical O 0 0.13127180933952332
staining O 0 0.0035980187822133303
of O 0 5.913766653975472e-05
human O 0 0.019566385075449944
breast O 1 0.9966810345649719
specimens O 0 0.0006201397045515478
also O 0 1.1521869964781217e-05
revealed O 0 0.0011035866336897016
BRCA1 O 0 0.10409123450517654
nuclear O 0 0.0024998863227665424
foci O 0 0.020265720784664154
in O 0 0.001310717430897057
benign O 1 0.9985106587409973
breast O 1 0.999426007270813
, O 0 0.17814664542675018
invasive B-Disease 1 0.9983226656913757
lobular I-Disease 1 0.9992056488990784
cancers I-Disease 1 0.9981942772865295
and O 0 0.00022531770810019225
low B-Disease 0 0.3548031151294708
- I-Disease 1 0.9880973696708679
grade I-Disease 1 0.9820398688316345
ductal I-Disease 1 0.9982470273971558
carcinomas I-Disease 1 0.9976904392242432
. O 0 0.0008617615676485002

Conversely O 0 0.0008547238539904356
, O 0 2.0585066522471607e-05
BRCA1 O 0 0.0016467234818264842
expression O 0 5.479075753100915e-06
was O 0 3.685084720927989e-06
reduced O 0 2.101798600051552e-05
or O 0 1.7557943010615418e-06
undetectable O 0 0.00023015536135062575
in O 0 1.991807963008796e-08
the O 0 1.2763189616293857e-08
majority O 0 5.756511356480587e-08
of O 0 1.2006435667899495e-07
high O 0 0.00020875070185866207
- O 0 0.044983040541410446
grade O 0 0.013761891052126884
, O 0 0.0002793672611005604
ductal B-Disease 1 0.9987377524375916
carcinomas I-Disease 1 0.9988917708396912
, O 0 1.9369017536519095e-06
suggesting O 0 4.382800398161635e-06
that O 0 4.778591389253961e-08
absence O 0 2.857724439309095e-06
of O 0 8.958248827184434e-07
BRCA1 O 0 0.13874119520187378
may O 0 4.401129444886465e-06
contribute O 0 5.297742973198183e-07
to O 0 1.7304532917705728e-08
the O 0 5.3314430203954544e-08
pathogenesis O 0 0.00013150557060725987
of O 0 1.1916222675267818e-08
a O 0 3.578515190838516e-07
significant O 0 7.771432137815282e-07
percentage O 0 4.872361841989914e-06
of O 0 6.686553660983918e-06
sporadic B-Disease 1 0.9193639159202576
breast I-Disease 1 0.9994059801101685
cancers I-Disease 1 0.9980886578559875
. O 0 6.703942199237645e-05
. O 0 8.51090153446421e-05

